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ABSTRACT	  
Background	  
The	  central	  hypothesis	  of	  the	  thesis	  is	  that	  the	  neat	  division	  of	  tuberculosis	  (TB)	  into	  states	  
of	  active	  disease	  and	  latent	  infection	  is	  an	  oversimplification	  and	  that	  the	  transition	  between	  
latent	  and	  active	  TB	  involves	  passage	  through	  a	  subclinical	  phase	  of	  disease,	  which	  may	  be	  
prolonged,	  during	  which	  pathology	  evolves.	  	  The	  primary	  aim	  of	  this	  thesis	  is	  to	  utilise	  [18F]-­‐
fluoro-­‐2-­‐deoxy-­‐D-­‐glucose	  positron	  emission	  tomography	  combined	  with	  computed	  
tomography	  (FDG-­‐PET/CT)	  to	  identify	  and	  define	  intra-­‐thoracic	  pathology	  consistent	  with	  
subclinical	  TB	  in	  a	  cohort	  of	  asymptomatic	  adults	  diagnosed	  with	  latent	  TB	  at	  high	  risk	  of	  
developing	  active	  TB	  (due	  to	  HIV	  co-­‐infection)	  and	  then	  to	  identify	  transcriptional	  and	  
immunological	  biomarkers	  that	  distinguish	  those	  with	  radiographic	  evidence	  of	  subclinical	  
pathology.	  	  Such	  biomarkers	  may	  have	  future	  translational	  potential	  as	  tests	  more	  predictive	  
of	  active	  TB	  compared	  to	  the	  currently	  available	  tests (tuberculin	  skin	  testing	  (TST)	  and	  
interferon	  gamma	  release	  assays	  (IGRA))	  and	  may	  also	  aid	  our	  understanding	  of	  the	  biology	  
of	  TB.	  	  
	  
Methodology	  
Healthy	  HIV	  infected,	  ART	  naïve,	  adult	  outpatients	  living	  in	  an	  area	  with	  very	  high	  TB	  burden	  
(Khayelitsha	  township,	  Cape	  Town,	  South	  Africa)	  were	  screened	  to	  identify	  35	  participants	  
that	  were	  asymptomatic,	  with	  CD4	  count	  ≥	  350/mm3,	  evidence	  of	  latent	  TB	  (by	  
QuantiFERON	  Gold	  in	  tube	  (QFGIT))	  and	  with	  no	  history	  of	  previous	  tuberculosis	  or	  evidence	  
of	  current	  active	  TB.	  	  These	  participants	  had	  FDG-­‐PET/CT	  performed	  and	  were	  then	  
commenced	  on	  isoniazid	  preventive	  therapy	  (IPT)	  or	  standard	  TB	  therapy	  if	  clinically	  
indicated	  and	  had	  repeat	  FDG-­‐PET/CT	  following	  treatment.	  	  A	  number	  of	  additional	  groups	  
of	  HIV	  infected	  and	  uninfected	  control	  participants	  with	  and	  without	  active	  TB	  were	  also	  
recruited	  for	  blood	  sampling.	  	  Microarray,	  carried	  out	  on	  RNA	  extracted	  from	  whole	  blood,	  
was	  used	  to	  identify	  differentially	  abundant	  transcripts	  between	  those	  with	  and	  without	  
subclinical	  pathology.	  	  A	  38-­‐plex	  assay	  and	  ELISA	  covering	  a	  total	  of	  45	  analytes	  were	  then	  
used	  to	  identify	  serological	  or	  QFGIT	  plasma	  biomarkers	  that	  distinguish	  those	  with	  and	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Main	  Results	  
Parenchymal	  abnormalities	  in	  the	  35	  participants	  were	  evaluated	  in	  detail	  and	  interpreted	  in	  
relation	  to	  the	  historical	  autopsy	  data	  and	  28.6%	  were	  categorised	  as	  having	  evidence	  of	  
subclinical	  TB	  pathology.	  	  Analysis	  of	  the	  whole	  blood	  microarray	  for	  these	  35	  participants	  
along	  with	  15	  age,	  sex	  and	  CD4	  count	  matched	  controls	  with	  clinical	  active	  TB	  identified	  82	  
transcripts	  that	  clustered	  80%	  of	  those	  with	  subclinical	  TB	  with	  active	  TB.	  	  Those	  with	  more	  
metabolically	  active	  subclinical	  pathology,	  as	  determined	  by	  FDG	  uptake,	  clustered	  more	  
effectively	  with	  clinical	  active	  TB.	  	  This	  signature	  was	  confirmed	  as	  specific	  to	  TB	  in	  HIV	  
uninfected	  controls.	  	  Transcripts	  relating	  to	  the	  classical	  complement	  pathway	  and	  Fcγ	  
receptor	  were	  found	  to	  be	  overabundant	  in	  subclinical	  and	  active	  TB	  in	  relation	  to	  those	  
with	  latent	  TB	  with	  no	  evidence	  of	  subclinical	  pathology.	  	  Neutrophil	  related	  transcripts	  
were	  over	  abundant	  only	  in	  clinical	  active	  TB,	  particularly	  in	  those	  that	  were	  smear	  positive.	  	  
Network	  analysis	  of	  the	  82	  transcript	  signature,	  informed	  the	  selection	  of	  45	  soluble	  protein	  
analytes.	  10	  analytes	  showed	  a	  significant	  difference	  in	  concentration	  between	  the	  3	  groups	  
(active,	  subclinical	  and	  latent	  TB).	  	  IL-­‐1α	  with	  a	  cut-­‐off	  of	  16.9	  pg/mL	  and	  circulating	  immune	  
complex	  (CIC)	  with	  a	  cut-­‐off	  of	  100.9	  µg	  Eq/mL	  individually	  classified	  50%	  and	  together	  70%	  
of	  those	  with	  subclinical	  TB	  as	  active	  TB.	  	  In	  addition	  when	  assessed	  across	  5	  stages	  of	  
increasing	  disease	  activity	  by	  PET	  findings	  and	  smear	  status	  all	  10	  analytes	  showed	  a	  
significant	  increasing	  trend.	  
	  
Conclusion	  
The	  utility	  of	  FDG-­‐PET/CT	  a	  novel	  research	  tool	  in	  the	  study	  of	  latent	  TB	  in	  humans	  has	  been	  
systematically	  evaluated	  for	  the	  first	  time	  in	  this	  thesis.	  	  It	  has	  allowed	  for	  the	  identification	  
of	  pathology	  within	  the	  lungs	  consistent	  with	  subclinical	  TB	  not	  reliably	  identified	  on	  CXR.	  	  
Microarray	  analysis	  of	  whole	  blood	  has	  contributed	  of	  our	  understanding	  of	  which	  biological	  
process	  may	  be	  pertinent	  from	  the	  early	  subclinical	  stages	  of	  disease,	  suggesting	  that	  the	  
classical	  complement	  pathway	  and	  overabundance	  of	  Fcγ	  receptor	  may	  be	  important.	  	  
Furthermore,	  the	  approach	  has	  lead	  to	  the	  identification	  of	  transcriptional	  and	  serological	  
biomarkers	  that	  distinguish	  those	  with	  subclinical	  pathology	  from	  those	  without.	  	  These	  
biomarkers	  may	  have	  translational	  potential	  as	  more	  predictive	  diagnostic	  tests	  for	  active	  
TB.	  	  
	  	   5	  
ACKNOWLEDGEMENTS	  
First	  and	  foremost,	  I	  wish	  to	  thank	  my	  parents	  for	  their	  lifelong	  and	  unquestioning	  support,	  
love	  and	  encouragement.	  	  In	  particular,	  I	  am	  grateful	  for	  the	  sacrifices	  they	  have	  made	  for	  
me	  over	  the	  years.	  	  Their	  own	  academic	  journey	  has	  also	  been	  a	  constant	  source	  of	  
inspiration	  and	  a	  clear	  example	  of	  the	  transformative	  power	  of	  education.	  
	  
This	  thesis	  would	  not	  have	  been	  possible	  without	  the	  help	  and	  support	  of	  numerous	  people.	  	  
I	  am	  particularly	  grateful	  to	  my	  supervisor	  Professor	  Robert	  Wilkinson.	  	  From	  our	  first	  
meeting,	  over	  6	  years	  ago	  to	  discuss	  research	  opportunities	  in	  Cape	  Town,	  he	  has	  been	  a	  
very	  generous	  and	  supportive	  academic	  mentor,	  providing	  me	  with	  numerous	  opportunities,	  
helpful	  advice	  but	  also	  the	  freedom	  to	  develop	  as	  a	  clinical	  researcher.	  	  I	  am	  also	  grateful	  for	  
the	  mentorship	  and	  support	  of	  Professor	  Douglas	  Young	  and	  Dr	  Clifton	  Barry	  3rd	  and	  the	  
exposure	  they	  have	  provided	  me	  to	  a	  global,	  collaborative	  group	  of	  TB	  researchers,	  which	  
has	  been	  both	  exciting	  and	  inspiring.	  	  	  
	  
This	  research	  would	  not	  have	  been	  possible	  without	  the	  group	  of	  participants	  from	  
Khayelitsha,	  to	  whom	  I	  am	  greatly	  indebted	  to	  for	  consenting	  to	  take	  part	  the	  study.	  	  The	  
study	  would	  also	  not	  have	  been	  feasible	  without	  the	  help,	  both	  administratively	  and	  
clinically,	  of	  a	  very	  large	  group	  of	  dedicated	  people,	  in	  the	  Wilkinson	  Group	  at	  the	  University	  
of	  Cape	  Town.	  	  I	  am	  especially	  appreciative	  of	  all	  the	  help	  and	  assistance	  provided	  by	  the	  
clinical	  research	  workers,	  nurses	  and	  drivers	  in	  the	  recruitment	  and	  follow-­‐up	  of	  the	  
participants	  while	  they	  were	  working	  on	  a	  number	  of	  other	  studies.	  	  Particular	  thanks	  go	  to	  
Kathryn	  Wood	  and	  Rene	  Goliath	  who	  have	  always	  readily	  provided	  assistance	  to	  ensure	  the	  
smooth	  running	  of	  the	  study.	  	  	  
	  
A	  number	  of	  people	  have	  assisted	  with	  the	  technical	  aspects	  of	  the	  research	  conducted	  for	  
this	  thesis	  and	  deserve	  acknowledgement.	  	  Dr	  Tolullah	  Oni,	  as	  the	  second	  reader	  of	  
hundreds	  of	  screening	  CXR,	  spent	  many	  Sunday	  evenings	  with	  me	  to	  patiently	  determine	  
consensus	  reports.	  	  Dr	  Qonita	  Said-­‐Hartley,	  a	  consultant	  radiologist	  at	  Groote	  Schuur	  
Hospital,	  in	  her	  spare	  time	  also	  provided	  a	  great	  deal	  of	  assistance	  in	  reading	  CXR	  and	  
helping	  me	  to	  improve	  my	  radiological	  skills.	  	  She	  was	  also	  invaluable	  in	  the	  recruitment	  of	  
her	  consultant	  colleagues,	  Professor	  Hillel	  Goodman,	  Dr	  Sally	  Candy,	  Dr	  Dilesh	  Chhiba,	  Dr	  
Paul	  Scholtz,	  Dr	  Sulaiman	  Moosa	  and	  Dr	  Nazir	  Ahmed	  who	  also	  reported	  the	  CXR	  for	  
	  	   6	  
comparison	  with	  the	  PET/CT	  images.	  	  Professor	  James	  Warwick,	  a	  consultant	  in	  Nuclear	  
Medicine	  at	  Tygerberg	  Hospital,	  was	  incredibly	  helpful	  in	  providing	  advice	  for	  the	  PET/CT	  
component	  of	  the	  study	  and	  recruiting	  his	  colleagues	  to	  help	  report	  the	  images.	  	  He	  also	  
sacrificed	  many	  hours	  going	  through	  numerous	  scans	  in	  great	  detail	  with	  me.	  	  	  	  
	  
On	  the	  laboratory	  side,	  I	  am	  thankful	  to	  Professor	  Katalin	  Wilkinson	  for	  teaching	  a	  clinician	  
to	  perform	  a	  number	  of	  immunological	  assays	  and	  also	  in	  assisting	  me	  with	  the	  MILLPLEX	  
and	  ELISA	  assays	  reported	  in	  the	  thesis.	  	  Fadheela	  Patel	  was	  especially	  helpful	  in	  providing	  
assistance	  with	  processing	  samples	  and	  performed	  the	  screening	  QFGIT	  assays.	  	  Nonzwakazi	  
Bangani	  also	  spent	  many	  late	  evenings	  helping	  me	  to	  extract	  RNA	  to	  send	  to	  London	  in	  time	  
to	  perform	  the	  microarray.	  	  	  
	  
I	  thank	  Professor	  Anne	  O’Garra	  at	  the	  MRC	  National	  Institute	  for	  Medical	  Research	  in	  
London,	  for	  hosting	  me	  for	  3	  months	  to	  conduct	  the	  microarray	  study	  and	  for	  providing	  
valuable	  input	  in	  the	  design	  of	  the	  experiment	  and	  analysis	  of	  the	  data.	  	  At	  the	  NIMR,	  Dr	  
Rachel	  Lai	  was	  not	  only	  very	  welcoming	  but	  also	  an	  indispensible	  help	  in	  processing	  the	  RNA	  
for	  microarray.	  	  Thanks	  also	  go	  to	  Dr	  Christine	  Graham	  for	  providing	  the	  protocols	  for	  RNA	  
processing	  and	  for	  technical	  advice.	  
	  
I	  am	  very	  grateful	  to	  my	  friends	  and	  colleagues,	  Dr	  Suzaan	  Marais,	  Dr	  Jennifer	  Hughes	  and	  Dr	  
Anna	  Coussens	  for	  reading	  various	  chapters	  of	  this	  thesis	  and	  providing	  helpful	  and	  
thoughtful	  comments.	  
	  
Finally	  and	  most	  importantly,	  my	  sincerest	  gratitude	  goes	  to	  my	  wife,	  Naomi,	  who	  over	  the	  
last	  4	  years	  has	  been	  selfless	  in	  her	  support,	  a	  constant	  provider	  of	  encouragement	  and	  
endlessly	  tolerant	  and	  understanding,	  especially	  over	  the	  last	  few	  months	  while	  writing	  up.	  	  	  	  	  	  	  	  	  	  	  	  	  
	  	   7	  
DECLARATION	  
Apart	  from	  the	  assistance	  I	  have	  outlined	  in	  the	  acknowledgement	  section,	  the	  work	  
described	  in	  this	  thesis	  is	  my	  own,	  with	  everything	  else	  being	  appropriately	  referenced.	  	  The	  
work	  in	  this	  thesis	  has	  not	  been	  previously	  submitted	  for	  a	  degree	  or	  qualification	  at	  this	  or	  
any	  other	  university.	  	  	  	  	  	  
	  
The	  copyright	  of	  this	  thesis	  rests	  with	  the	  author	  and	  is	  made	  available	  under	  a	  Creative	  
Commons	  Attribution	  Non-­‐Commercial	  No	  Derivatives	  licence.	  Researchers	  are	  free	  to	  copy,	  
distribute	  or	  transmit	  the	  thesis	  on	  the	  condition	  that	  they	  attribute	  it,	  that	  they	  do	  not	  use	  
it	  for	  commercial	  purposes	  and	  that	  they	  do	  not	  alter,	  transform	  or	  build	  upon	  it.	  For	  any	  
reuse	  or	  redistribution,	  researchers	  must	  make	  clear	  to	  others	  the	  licence	  terms	  of	  this	  
work.	  
	  	   8	  
TABLE	  OF	  CONTENTS	  
ABSTRACT	   3	  
ACKNOWLEDGEMENTS	   5	  
DECLARATION	   7	  
TABLE	  OF	  CONTENTS	   8	  
LIST	  OF	  TABLES	   13	  
LIST	  OF	  FIGURES	   14	  
ABBREVIATIONS	   18	  
CHAPTER	  1:	  INTRODUCTION	   23	  
1.1	   GENERAL	  INTRODUCTION	   23	  
1.2	   LATENT	  TUBERCULOSIS	   25	  1.2.1	   THE	  EVOLUTION	  OF	  LATENCY	  IN	  TUBERCULOSIS	   25	  1.2.2	   OVERVIEW	  OF	  THE	  LIFECYCLE	  OF	  TUBERCULOSIS	   26	  1.2.3	   LATENT	  TUBERCULOSIS	  IN	  THE	  CONTEXT	  OF	  GLOBAL	  TUBERCULOSIS	  CONTROL	   27	  1.2.4	   THE	  CURRENT	  DIAGNOSTIC	  TESTS	  FOR	  LATENT	  TUBERCULOSIS	   28	  1.2.5	   THE	  GLOBAL	  BURDEN	  OF	  LATENT	  TUBERCULOSIS	   32	  1.2.6	   RISK	  OF	  LATENT	  INFECTION	  PROGRESSING	  TO	  ACTIVE	  DISEASE	   34	  1.2.7	   RISK	  FACTORS	  FOR	  DEVELOPING	  ACTIVE	  TUBERCULOSIS	   36	  
1.3	   SUBCLINICAL	  TUBERCULOSIS	   38	  1.3.1	   MASS	  CHEST	  RADIOGRAPH	  SCREENING	  FOR	  SUBCLINICAL	  TUBERCULOSIS	   38	  1.3.2	   LIMITATIONS	  OF	  CHEST	  RADIOGRAPHY	   40	  1.3.3	   ASYMPTOMATIC	  CULTURE	  POSITIVE	  TUBERCULOSIS	  IN	  HIV	   41	  1.3.4	   THE	  SPECTRUM	  OF	  INFECTION	  STATES	  IN	  TUBERCULOSIS	   42	  
1.4	   HIV	  AND	  ITS	  IMPACT	  ON	  TUBERCULOSIS	   43	  1.4.1	   HIV	   43	  1.4.2	   INTERACTION	  OF	  HIV	  AND	  TUBERCULOSIS	   44	  
1.5	   THE	  PATHOLOGY	  OF	  TUBERCULOSIS	   47	  1.5.1	   PRIMARY	  INFECTION	   47	  1.5.2	   POST-­‐PRIMARY	  PULMONARY	  DISEASE	  IN	  HUMANS	   52	  
	  	   9	  
1.5.3	   OTHER	  PATTERNS	  OF	  TUBERCULOSIS	  DISEASE	  THAT	  MAY	  BE	  PRESENT	  WITHIN	  THE	  LUNG	   55	  
1.6	   FDG-­‐PET/CT	  IMAGING	   55	  1.6.1	   FDG-­‐PET/CT	   55	  1.6.2	   CELLULAR	  UPTAKE	  OF	  FDG	  IN	  TUBERCULOSIS	   57	  1.6.3	   FDG-­‐PET/CT	  IN	  CLINICAL	  STUDIES	  OF	  TUBERCULOSIS	   57	  1.6.4	   FDG-­‐PET/CT	  IN	  ANIMAL	  MODELS	   58	  1.6.5	   FDG-­‐PET/CT	  IN	  ASYMPTOMATIC	  HIV	  INFECTED	  AND	  UNINFECTED	  INDIVIDUALS	   59	  
1.7	   IMMUNOLOGICAL	  ASSAYS	  TO	  DISTINGUISH	  ACTIVE	  AND	  LATENT	  TUBERCULOSIS	   60	  
1.8	   HOST	  TRANSCRIPTIONAL	  SIGNATURES	  IN	  TUBERCULOSIS	   63	  
1.9	   SUMMARY	   67	  
1.10	   THESIS	  SCOPE	  AND	  AIMS	   68	  1.10.1	   OVERALL	  HYPOTHESES	  AND	  AIMS	   68	  1.10.2	   GENERAL	  CHAPTER	  AIMS	   68	  
CHAPTER	  2:	  MATERIALS	  AND	  METHODS	   70	  
2.1	   SETTING	   70	  2.1.1	   SOUTH	  AFRICA	   70	  2.1.2	   HIV/AIDS	  AND	  TUBERCULOSIS	  IN	  SOUTH	  AFRICA	   70	  2.1.3	   KHAYELITSHA,	  CAPE	  TOWN	   71	  2.1.4	   UNIVERSITY	  OF	  CAPE	  TOWN	   74	  2.1.5	   MRC	  NATIONAL	  INSTITUTE	  FOR	  MEDICAL	  RESEARCH,	  LONDON	   75	  2.1.6	   PET/CT	  FACILITIES	   75	  2.1.7	   OVERVIEW	  OF	  STUDY	  TIMELINE	   76	  
2.2	   CLINICAL	  RECRUITMENT	   76	  2.2.1	   APPROVALS	  FOR	  STUDY	   76	  2.2.2	   SUMMARY	  OF	  CLINICAL	  STUDY	  DESIGN	   76	  2.2.3	   DIAGNOSTIC	  DEFINITIONS	   78	  2.2.4	   CONSENT	  PROCEDURE	   79	  2.2.5	   OVERVIEW	  OF	  STUDY	  SAMPLING	  AND	  PROCEDURES	   81	  2.2.6	   RECRUITMENT	  OF	  PRIMARY	  GROUP	  OF	  INTEREST	   81	  2.2.7	   RATIONAL	  FOR	  INCLUSION/EXCLUSION	  CRITERIA	   83	  2.2.8	   MODIFICATIONS	  TO	  THE	  STUDY	  DESIGN	   84	  2.2.9	   FOLLOW-­‐UP	  AND	  TREATMENT	   84	  2.2.10	   MATCHING	  STRATEGY	  FOR	  CONTROL	  GROUPS	   85	  2.2.11	   SYMPTOMATIC	  ACTIVE	  TB	  CONTROLS	   85	  2.2.12	   ASYMPTOMATIC	  QFGIT	  NEGATIVE,	  TST	  NEGATIVE	  CONTROLS	   86	  
	  	   10	  
2.2.13	   ASYMPTOMATIC	  HIV	  INFECTED	  ART	  CONTROLS	   87	  
2.3	   DETAILS	  OF	  CLINICAL	  PROCEDURES	  &	  DATA	  COLLECTION	  METHODS	   87	  2.3.1	   HISTORY	  AND	  EXAMINATION	   87	  2.3.2	   SPUTUM	  SAMPLING	  AND	  INDUCTION	   87	  2.3.3	   TUBERCULIN	  SKIN	  TESTING	   88	  2.3.4	   ROUTINE	  LABORATORY	  TESTS	   88	  
2.4	   IMAGING	  METHODS	   89	  2.4.1	   CHEST	  RADIOGRAPHY	   89	  2.4.2	   	  FDG-­‐PET/CT	   91	  
2.5	   PROCESSING	  OF	  RESEARCH	  SAMPLES	   94	  2.5.1	   QUANTIFERON	  GOLD	  IN	  TUBE	  (QFGIT)	   94	  2.5.2	   TEMPUS	  BLOOD	  RNA	  TUBES	  COLLECTION	  AND	  STORAGE	   95	  2.5.3	   SERUM	  STORAGE	   95	  
2.6	   RESEARCH	  LABORATORY	  ASSAYS	  AND	  METHODOLOGY	   95	  2.6.1	   TRANSCRIPTIONAL	  PROFILING	  USING	  MICROARRAY	  (CHAPTER	  5)	   95	  2.6.2	   MUTIPLEX	  ASSAY	  (CHAPTER	  6)	   100	  2.6.3	   ENZYME-­‐LINKED	  IMMUNOSORBENT	  ASSAY	  (ELISA)	  (CHAPTER	  6)	   101	  2.6.4	   LIMUS	  AMEBOCYTE	  LYSATE	  (LAL)	  ASSAY	  (LONZA)	   105	  
2.7	   CHALLENGES	  FACED	  IN	  UNDERTAKING	  STUDY	   105	  
2.8	   CHAPTER	  SUPPLEMENTARY	  INFORMATION	   108	  
CHAPTER	  3	  –	  EVALUATION	  OF	  SCREENING	  TOOLS	  USED	  IN	  PARTICIPANT	  
RECRUITMENT	   110	  
3.1	   CHAPTER	  3	  INTRODUCTION	   110	  
3.2	   CHAPTER	  3	  AIMS	   111	  3.2.1	   SPECIFIC	  CHAPTER	  3	  AIMS	   111	  
3.3	   CHAPTER	  3	  METHODS	   111	  
3.4	   RESULTS	   112	  3.4.1	   SCREENING	  OF	  HIV-­‐INFECTED	  ART	  NAÏVE	  OUTPATIENTS	  FOR	  STUDY	  PARTICIPATION	   112	  3.4.2	   PREVALENCE	  OF	  TUBERCULOSIS	  IN	  SCREENED	  PARTICIPANTS	   113	  3.4.3	   AGREEMENT	  IN	  SCREENING	  CXR	  REPORTS	  BETWEEN	  READERS	   116	  3.4.4	   AGREEMENT	  BETWEEN	  TST	  AND	  IGRA	   117	  3.4.5	   SCREEN	  FAILURES	   117	  3.4.6	   CLINICAL	  FEATURES	  OF	  35	  PARTICIPANTS	  UNDERGOING	  PET/CT	   118	  3.4.7	   SCREENING	  FOR	  TST	  NEGATIVE	  /	  QFGIT	  NEGATIVE	  CONTROLS	   122	  3.4.8	   ACTIVE	  TB	  CONTROLS	   125	  
	  	   11	  
3.4.9	   HIV	  INFECTED	  QFGIT+VE,	  ART	  ESTABLISHED	  CONTROLS	   127	  
3.5	   SUMMARY	  OF	  MAIN	  FINDINGS	   129	  
3.6	   DISCUSSION	   129	  
3.7	   CONCLUSIONS	   133	  
CHAPTER	  4	  –	  FDG-­‐PET/CT	  FINDINGS	   135	  
4.1	   CHAPTER	  4	  INTRODUCTION	   135	  
4.2	   CHAPTER	  4	  HYPOTHESIS	   135	  
4.3	   CHAPTER	  4	  AIM	   135	  4.3.1	   SPECIFIC	  CHAPTER	  4	  AIMS	   136	  
4.4	   CHAPTER	  4	  METHODS	   136	  
4.5	   TREATMENT	  AND	  FOLLOW-­‐UP	  OF	  PARTICIPANTS	   136	  
4.6	   RESULTS	   138	  4.6.1	   PARENCHYMAL	  LESIONS	  ON	  FDG-­‐PET/CT	  SCAN	   138	  4.6.2	   LYMPH	  NODE	  ABNORMALITIES	  ON	  FDG-­‐PET/CT	  SCAN	   147	  4.6.3	   NEW	  ABNORMALITIES	  ON	  FOLLOW-­‐UP	  FDG-­‐PET/CT	  SCAN	   153	  4.6.4	   COMPARISON	  OF	  CXR	  AND	  FDG-­‐PET/CT	   153	  
4.7	   SUMMARY	  OF	  MAIN	  FINDINGS	   157	  
4.8	   DISCUSSION	   157	  
4.9	   CONCLUSION	   166	  
CHAPTER	  5	  –	  TRANSCRIPTIONAL	  PROFILE	   168	  
5.1	   CHAPTER	  5	  INTRODUCTION	   168	  
5.2	   CHAPTER	  5	  HYPOTHESIS	   168	  
5.3	   CHAPTER	  5	  AIMS	   168	  5.3.1	   SPECIFIC	  CHAPTER	  5	  AIMS	   169	  
5.4	   CHAPTER	  5	  METHODS	   169	  5.4.1	   QUALITY	  CONTROL	  AND	  RAW	  DATA	  PROCESSING	   169	  5.4.2	   MICROARRAY	  ANALYSIS	   170	  5.4.3	   CLINICAL	  FEATURES	  OF	  PARTICIPANTS	  USED	  IN	  CHAPTER	  5	   172	  
5.5	   RESULTS	   173	  5.5.1	   DERIVING	  A	  TRANSCRIPTIONAL	  SIGNATURE	  FOR	  SUBCLINICAL	  TB	   173	  5.5.2	   HIV	  TB	  INTERACTION	  IN	  WHOLE	  BLOOD	  GENE	  EXPRESSION	   188	  
5.6	   SUMMARY	  OF	  MAIN	  FINDINGS	   195	  
5.7	   DISCUSSION	   196	  
5.8	   CONCLUSION	   202	  
	  	   12	  
5.9	   CHAPTER	  SUPPLEMENTARY	  FIGURES	   203	  
CHAPTER	  6	  –	  SERUM	  AND	  QUANTIFERON	  PLASMA	  BIOMARKERS	   204	  
6.1	   CHAPTER	  6	  INTRODUCTION	   204	  
6.2	   CHAPTER	  6	  HYPOTHESIS	   204	  
6.3	   CHAPTER	  6	  AIM	   204	  6.3.1	   SPECIFIC	  CHAPTER	  AIMS	   204	  
6.4	   CHAPTER	  6	  METHODS	   205	  6.4.1	   CHOICE	  OF	  CYTOKINES,	  CHEMOKINES	  AND	  SOLUBLE	  PROTEINS	  FOR	  EVALUATION	   205	  6.4.2	   HANDLING	  OF	  OUT	  OF	  RANGE	  VALUES	   207	  6.4.3	   SAMPLES	  USED	  IN	  ANALYSIS	   207	  6.4.4	   STATISTICAL	  METHODS	   208	  
6.5	   RESULTS	   208	  6.5.1	   CONCENTRATION	  OF	  ANALYTES	  IN	  SERUM	   208	  6.5.2	   CONCENTRATION	  OF	  ANALYTES	  IN	  QFGIT	  PLASMA	   215	  
6.6	   SUMMARY	  OF	  MAIN	  FINDINGS	   220	  
6.7	   DISCUSSION	   221	  
6.8	   CONCLUSIONS	   227	  
CHAPTER	  7	  –	  GENERAL	  DISCUSSION	  AND	  CONCLUSIONS	   229	  
7.1	   SCOPE	  OF	  THESIS	   229	  
7.2	   GENERAL	  DISCUSSION	  OF	  FINDINGS	   231	  
7.3	   IMPACT	  OF	  THESIS	  ON	  THE	  FIELD	  OF	  TUBERCULOSIS	  RESEARCH	   238	  
7.4	   FUTURE	  DIRECTION	  FOR	  THE	  FIELD	  AND	  RESEARCH	  PRIORITIES	   244	  
APPENDIX	  A	  –	  BRIEF	  SUMMARY	  OF	  EXPERIMENTS	  NOT	  INCLUDED	  IN	  THESIS	   247	  
APPENDIX	  B	  –	  APPROVALS	  FOR	  STUDY	   249	  
APPENDIX	  C	  –	  CONSENT	  FORMS	   253	  
APPENDIX	  D	  –	  PARTICIPANT	  INFORMATION	  LEAFLETS	   271	  
REFERENCES	   275	  
	  
	  	   13	  
LIST	  OF	  TABLES	  
Table	  1.1	   History	  of	  diagnostic	  tests	  for	  latent	  tuberculosis	  	   29	  
Table	  1.2	   Current	  preventive	  regimens	  for	  latent	  TB	   30	  
Table	  1.3	   Relative	  risk	  for	  active	  TB	  for	  some	  globally	  common	  conditions	   36	  
Table	  1.4	   Comparison	  of	  microarray	  and	  RNA	  sequencing	   63	  
Table	  2.1	   Summary	  of	  participants	  and	  controls	  recruited	  into	  the	  study	   77	  
Table	  2.2	   Overview	  of	  visits	  and	  sampling	   80	  
Table	  2.3	  	   Blood	  sample	  tubes	  and	  volumes	   89	  
Table	  2.4	  	   Definition	  of	  CXR	  abnormalities	   90	  
Table	  2.5	   Protocol	  for	  FDG-­‐PET/CT	  scan	   91	  
Table	  2.6	   Quantiferon	  results	  interpretation	   94	  
Table	  2.7	  	   Steps	  in	  RNA	  preparation	  for	  microarray	   98	  
Table	  3.1	  	   Clinical	  characteristics	  of	  the	  265	  screened	  participants	   112	  
Table	  3.2	  	   Clinical	  characteristics	  of	  10	  prevalent	  TB	  cases	   113	  
Table	  3.3	   Diagnostic	  performance	  of	  screening	  parameters	   114	  
Table	  3.4	  	  	   Agreement	  between	  CXR	  readers	  for	  screening	  CXR	   116	  
Table	  3.5	   Agreement	  between	  TST	  and	  IGRA	  in	  a	  sample	  of	  104	  participant	   117	  
Table	  3.6	   Clinical	  characteristics	  of	  the	  35	  recruited	  participants	  at	  screening	  
118	  
Table	  3.7	   Clinical	  characteristics	  of	  recruited	  participants	  on	  day	  of	  PET/CT	  scan	  
119	  
Table	  4.1	  	   Summary	  of	  FDG-­‐PET/CT	  findings	  in	  the	  35	  participants	   137	  
Table	  4.2	   FDG-­‐PET/CT	  features	  of	  9	  participants	  with	  infiltrates	  and	  scars	   142	  
Table	  4.3	   Comparison	  of	  clinical	  characteristics	  of	  10	  participants	  with	  
infiltrates/scars	  and	  active	  nodules	  with25	  participants	  with	  discrete	  
nodules	   146	  
Table	  4.4	  	   Location	  of	  mineralized	  lymph	  nodes	   148	  
Table	  5.1	   Median	  modular	  transcript	  abundance	  values	  by	  clinical	  group	   188	  
Table	  6.1	   Serum	  concentration	  for	  43	  analytes	  in	  active,	  subclinical	  and	  latent	  TB	  
209	  
	  	   14	  
LIST	  OF	  FIGURES	  
	  
Fig.	  1.1	   Overview	  of	  TB	  lifecycle	  	   26	  
Fig.	  1.2	   Acceptability	  of	  preventive	  therapy	  for	  latent	  TB	  	   31	  
Fig.	  1.3	   Incidence	  of	  TB	  in	  household	  contacts	  over	  time	  	   35	  
Fig.	  1.4	   Graphical	  representation	  of	  screening	  for	  subclinical	  TB	  	  	   39	  
Fig.	  1.5	   Conceptual	  framework	  for	  outcome	  of	  tuberculosis	  infection	  	   42	  
Fig.	  1.6	   TB	  incidence	  by	  CD4	  strata	  and	  ART	  status	  in	  Cape	  Town	  	  	   45	  
Fig.	  1.7	   Location	  of	  mineralized	  primary	  lesions	  	  	   50	  
Fig.	  1.8	   Location	  of	  minimal	  post	  primary	  lesions	  	  	   52	  
Fig.	  2.1	   Map	  of	  South	  Africa	  showing	  major	  cities,	  provinces	  and	  surrounding	  
countries	  	  	   70	  
Fig.	  2.2	   Map	  of	  Cape	  Town	  showing	  location	  of	  study	  site	   71	  
Fig.	  2.3	   Gant	  chart	  showing	  progress	  with	  study	  	  	   76	  
Fig.	  2.4	   Study	  Flow	  	  	   79	  
Fig.	  2.5	   IASLC	  lymph	  node	  map	  	  	   93	  
Fig.	  3.1	   Screening	  CXR	  for	  prevalent	  TB	   115	  
Fig.	  3.2	   Screen	  failures	  	   117	  
Fig.	  3.3	   Change	  in	  QFGIT	  TBAg-­‐NIL	  results	  between	  screening	  and	  day	  of	  
PET/CT	  scan	  	  	   120	  
Fig.	  3.4	   CXR	  for	  2	  participants	  showing	  progression	  over	  screening	  period	  	  	   121	  
Fig.	  3.5	   Distribution	  of	  QFGIT	  TBAg-­‐NIL	  values	  in	  participants	  that	  are	  HIV	  
infected	  QFGIT-­‐ve/TST-­‐ve	  	   122	  
Fig.	  3.6	   ROC	  curve	  showing	  ability	  to	  differentiate	  those	  QFGIT	  conversion	  by	  
baseline	  QFGIT	  TBAg-­‐NIL	   123	  
Fig.	  3.7	   Distribution	  of	  QFGIT	  TBAg-­‐NIL	  values	  in	  participants	  that	  are	  HIV	  
infected	  QFGIT-­‐ve/TST-­‐ve	  	   124	  
Fig.	  3.8	   kdensity	  distribution	  of	  QGFIT	  TBAg-­‐NIL	  values	  for	  QFGIT	  positive	  HIV	  
infected	  and	  uninfected	  participants	  	   125	  
Fig.	  3.9	   Comparison	  of	  clinical	  characteristics	  for	  participants	  and	  controls	  	   128	  
Fig.	  4.1	   Clinical	  features	  of	  20	  participants	  with	  discrete	  nodules	  on	  FDG-­‐
PET/CT	  and	  distribution	  of	  these	  nodules	  in	  participants	  	   139	  
	  	   15	  
Fig.	  4.2	   Histogram	  showing	  distribution	  of	  number	  of	  discrete	  nodules	  found	  
on	  baseline	  FDG-­‐PET/CT	  	   140	  
Fig.	  4.3a	   Distribution	  of	  active	  nodules	  in	  1	  participant	  and	  graph	  showing	  
change	  in	  QFGIT	  response	  over	  screening	  	  	   141	  
Fig.	  4.3b	   Axial	  section	  of	  CT	  scan	  showing	  examples	  of	  discrete	  and	  active	  
nodules	  	   141	  
Fig.	  4.4	   Distribution	  of	  infiltrates	  and	  scars	  in	  9	  participants	   143	  
Fig.	  4.5	   Coronal	  FDG-­‐PET/CT	  images	  showing	  infiltrates	  and	  scars	  in	  all	  9	  
participants	   144	  
Fig.	  4.6	   CT	  scans	  showing	  progression	  of	  infiltration	  and	  early	  cavitation	   145	  
Fig.	  4.7	   Box	  and	  whisker	  plot	  comparing	  distribution	  of	  SUVmax	  in	  cervical,	  
axillary	  and	  mediastinal	  LN	  	  	   149	  
Fig.	  4.8	   Histogram	  showing	  distribution	  of	  SUVmax	  for	  central	  LN	  	  	   150	  
Fig.	  4.9	   Correlation	  of	  SUVmax	  in	  axillary	  and	  mediastinal	  LN	  between	  pre	  and	  
post	  scan	  	   151	  
Fig.	  4.10	   Participant	  showing	  response	  following	  IPT	  as	  well	  as	  new	  
parenchymal	  lesions	  	  	   152	  
Fig.	  4.11	   Comparison	  of	  FDG-­‐PET/CT	  findings	  and	  consensus	  CXR	  read	  of	  pre	  
scan	  CXR	  	  	   154	  
Fig.	  4.12	   Comparison	  of	  7	  consultant	  CXR	  readers	  to	  each	  other	  and	  to	  FDG-­‐
PET/CT.	  	   155	  
Fig.	  4.13	   Sensitivity	  and	  specificity	  of	  7	  consultant	  readers	  compared	  to	  FDG-­‐
PET/CT	   156	  
Fig.	  5.1	   Graphs	  showing	  quality	  of	  extracted	  RNA	   170	  
Fig.	  5.2	   Graphs	  of	  QC	  parameters	  for	  microarray	  	  	   171	  
Fig.	  5.3	   Volcano	  plots	  for	  18919	  transcripts	  demonstrating	  differentially	  
abundant	  transcripts	   173	  
Fig.	  5.4	   Hierarchical	  clustering	  of	  individual	  participants	  for	  the	  893,	  639,	  203	  
and	  82	  transcript	  lists	   175	  
Fig.	  5.5	   PCA	  plots	  showing	  separation	  of	  subclinical	  and	  latent	  TB	  participants	  
for	  the	  893,	  639,	  203	  and	  82	  transcript	  lists	   176	  
Fig.	  5.6	   Hierarchical	  clustering	  and	  PCA	  plot	  for	  82	  transcript	  signature	  by	  
degree	  of	  disease	  activity	   177	  
Fig.	  5.7	   Hierarchical	  clustering	  of	  HIV	  uninfected	  controls	  with	  and	  without	   	  
	  	   16	  
active	  TB	  using	  82	  transcripts	  and	  203	  transcripts	   178	  
Fig.	  5.8	   Hierarchical	  clustering	  using	  the	  82	  transcripts	  and	  203	  transcripts	  on	  a	  
dataset	  participants	  with	  TB	  and	  other	  disease	   178	  
Fig.	  5.9	  	   Common	  transcripts	  between	  the	  203	  and	  82	  transcript	  signatures	  
with	  3	  other	  published	  active	  TB	  signatures	   180	  
Fig.	  5.10	   Module	  map	  showing	  significantly	  over	  and	  underabundant	  transcripts	  
in	  active	  and	  subclinical	  TB	  compared	  to	  latent	  TB	   181	  
Fig.	  5.11a	   IPA	  ingenuity	  pathway	  analysis	  for	  transcripts	  overabundant	  in	  
subclinical	  TB	  compared	  to	  latent	  TB	   183	  
Fig.	  5.11b	   IPA	  ingenuity	  pathway	  analysis	  for	  transcripts	  underabundant	  in	  
subclinical	  TB	  compared	  to	  latent	  TB	   184	  
Fig.	  5.12	  	   Complement	  pathway	  showing	  components	  overabundant	  in	  
subclinical	  and	  active	  compared	  to	  latent	  TB	   185	  
Fig.	  5.13	  	   Expression	  of	  neutrophil	  and	  platelet	  modules	  and	  correlation	  with	  cell	  
counts	   187	  
Fig.	  5.14	   Module	  map	  showing	  significantly	  over	  and	  underabundant	  transcripts	  
in	  HIV,	  TB	  and	  HIV/TB	  participants	   190	  
Fig.	  5.15	   Radar	  plot	  summarizing	  fold	  change	  in	  median	  modular	  transcript	  
abundance	  in	  comparison	  to	  HIV	  uninfected	  controls	   191	  
Fig.	  5.16a	   Box	  plot	  showing	  average	  transcript	  abundance	  in	  inflammation	  
modules	  in	  HIV	  infected	  and	  uninfected	  participants	   192	  
Fig.	  5.16b	   Scatter	  plot	  showing	  correlation	  of	  cell	  cycle	  modules	  and	  VL	   192	  
Fig.	  5.17	   Transcript	  abundance	  In	  the	  3	  interferon	  modules	  in	  TB	  and	  HIV	  	  	   193	  
Fig.	  5.18	   IPA	  interferon	  signalling	  pathway	   194	  
Fig.	  6.1	  	   IPA	  Network	  analysis	  of	  82	  transcript	  list	   206	  
Fig.	  6.2	   Graphs	  showing	  difference	  in	  serum	  concentration	  for	  10	  analytes	   210	  
Fig.	  6.3	   Scatter	  plots	  for	  7	  analytes	  showing	  effect	  of	  VL	  and	  TB	  status	  on	  
serum	  concentration	  of	  analyte	   211	  
Fig.	  6.4	   Correlation	  matrix	  for	  10	  serum	  analytes	  and	  CRP	  	  Chap	  6	  page	  9	   212	  
Fig.	  6.5	   ROC	  analysis	  for	  10	  analytes,	  CRP	  and	  VL	  	   213	  
Fig.	  6.6	   Effect	  of	  disease	  activity	  on	  serum	  concentration	  of	  analytes	   214	  
Fig.	  6.7	   Scatter	  plots	  showing	  correlation	  of	  transcript	  abundance	  against	  
serum	  concentration	  of	  protein	  product	   214	  
	  	   17	  
Fig.	  6.8	   Scatter	  plot	  showing	  correlation	  of	  IFNγ	  concentration	  in	  QFGIT	  plasma	  
as	  measures	  by	  commercial	  and	  multiplex	  assays	   217	  
Fig.	  6.9	   Comparison	  of	  concentration	  of	  analytes	  in	  serum	  and	  QFGIT	  NIL	  
plasma	  	  	   218	  
Fig.	  6.10	   Concentration	  of	  analytes	  in	  QFGIT-­‐NIL	  plasma	   219	  
Fig.	  7.1	   Diagram	  outlining	  the	  principles	  of	  TB	  control	   229	  




























	  	   18	  
ABBREVIATIONS	  
3TC	   Lamivudine	  
AFB	   Acid	  Fast	  Bacilli	  
ANOVA	   Analysis	  of	  Variance	  
ARI	   Annual	  Rate	  of	  Infection	  
ART	   Anti-­‐Retroviral	  Therapy	  
AUC	   Area	  Under	  the	  Curve	  
AZT	   Zidovudine	  
BCG	   Bacille	  Calmette-­‐Guerin	  
BF	   Complement	  factor	  B	  
Bq	   Becquerel	  
C.I	  	   Confidence	  Interval	  
C/EBPβ 	   CCAAT-­‐enhancer-­‐binding	  protein	  β	  	  
CDC	   Centers	  for	  Disease	  Control	  
cDNA	   complementary	  Deoxyribonucleic	  Acid	  
CEQ	   Chromosomal	  Equivalents	  	  
CFP-­‐10	   10	  kDa	  Culture	  Filtrate	  Antigen	  
Cr	   Creatinine	  
CRF	   Clinical	  Record	  Forms	  
CRP	   C-­‐Reactive	  Protein	  
CT	   Computed	  Tomography	  
CXR	   Chest	  radiograph	  
DHEA	   Dehydroepiandrosterone	  
DosR	   Dormancy	  survival	  Regulon	  
EGF	   Epidermal	  Growth	  Factor	  
EHR	   Extended	  Hypoxic	  Response	  	  
ELISA	   Enzyme-­‐Linked	  Immunosorbent	  Assay	  
ELISPOT	   Enzyme-­‐Linked	  ImmunoSpot	  
Eq	   Equivalents	  
ESAT-­‐6	   6	  kDa	  Early	  Secretory	  Antigenic	  Target	  
ESR	   Erythrocyte	  Sedementation	  Rate	  
EU	  	   Endotoxin	  Units	  
	  	   19	  
FBC	   Full	  Blood	  Count	  
FC	   Fold	  Change	  
FCGR1A	   Fcγ	  receptor	  1A	  	  
FDG	   [18F]-­‐fluoro-­‐2-­‐deoxy-­‐D-­‐glucose	  
FDR	   False	  Discovery	  Rate	  
FGF-­‐2	   Fibroblast	  Growth	  Factor	  
Flt-­‐3L	   Fms-­‐related	  tyrosine	  kinase	  3	  ligand	  
FMISO	   Fluoromisonidazole	  
FOV	   Field	  Of	  View	  
G-­‐CSF	   Granulocyte	  Colony	  Stimulating	  Factor	  
Glut-­‐1	  	   Glucose	  transporter	  1	  
GM-­‐CSF	   Granulocyte	  Macrophage	  Colony	  Stimulating	  Factor	  
GRO	   Growth	  Regulated	  Oncogene	  
grRNA	   globin	  mRNA	  depleted	  RNA	  	  
HHC	   Healthy	  Household	  Contacts	  
HIV	   Human	  Immunodeficiency	  Virus	  
HKII	   Hexokinase	  II	  
HLA	   Human	  Leukocyte	  Antigen	  
HRCT	   High	  Resolution	  Computed	  Tomography	  
HRP	   Horseradish	  Peroxidase	  	  
HSD	   Tukey's	  Honest	  Significant	  Difference	  
hspX	   heat	  shock	  protein	  
HU	   Hounsefield	  Units	  
IASLC	   International	  Association	  for	  Study	  of	  Lung	  Cancer	  
ICH-­‐GCP	   International	  Conference	  on	  Harmonization	  of	  Good	  Clinical	  Practice	  
IFN	   Interferon	  
IGRA	   Interferon	  Gamma	  Release	  Assay	  
IL	   Interleukin	  
IL-­‐1RA	   Interleukin	  1	  Receptor	  Antagonist	  
INH/H	   Isoniazid	  
IP	   Interferon-­‐gamma	  inducible	  Protein	  
IPT	   Isonazid	  Preventive	  Therapy	  
IQR	   Inter	  Quartile	  Range	  
ISGF	   Interferon	  Stimulated	  Gene	  Factor	  
	  	   20	  
kV	   kilovoltage	  
LAL	   Limus	  Amebocyte	  Lysate	  	  
LFT	   Liver	  Function	  Test	  
LLL	   Left	  Lower	  Lobe	  
LN	   Lymph	  Node	  
LPS	   Lipopolysaccharide	  
LR-­‐	   negative	  Likelihood	  Ratio	  
LR+	   positive	  Likelihood	  Ratio	  
LTA4H	   Leukotriene	  A4	  hydrolase	  
LUL	   Left	  Upper	  Lobe	  
mAs	   milliampere-­‐second	  
MCP	   Monocyte	  Chemoattactant	  Protein	  
MDC	   Macrophage	  Derived	  Chemokine	  
med	   median	  
MGIT	   Mycobacteria	  Growth	  Indicator	  Tube	  
MHC	   Major	  Histocompatibility	  Complex	  
MIP	   Macrophage	  Inflammatory	  Protein	  
MMP	   Matrix	  Metalloproteinases	  
MRC	   Medical	  Research	  Council	  
Mtb	   Mycobacterium	  tuberculosis	  
NHLS	   National	  Health	  Laboratory	  Services	  
NIAID	   National	  Institute	  of	  Allergy	  and	  Infectious	  Diseases	  
NNRTI	   Non-­‐Nucleotide	  Reverse	  Transcriptase	  Inhibitor	  
NNT	   Number	  Needed	  to	  Treat	  
NPV	   Negative	  Predictive	  Value	  
NRTI	   Nucleotide	  Reverse	  Transcriptase	  Inhibitor	  
OD	   Optical	  Density	  	  
PCA	   Principal	  Component	  Analysis	  
PCR	   Polymerase	  Chain	  Reaction	  
PET	   Positron	  Emission	  Tomography	  
pNPP	   p-­‐Nitrophenyl	  Phosphate	  	  
POC	   Point	  Of	  Care	  
PPD	   Purified	  Protein	  Derivative	  
PPV	   Positive	  Predictive	  Value	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PZA/Z	   Pyrazinamide	  
QA	   Quality	  Assurance	  
QC	   Quality	  Control	  	  
QFGIT	   QuantiFERON	  TB	  Gold	  In-­‐Tube	  
RD	   Regions	  of	  Difference	  
RIF/R	   Rifampicin	  
RIN	   RNA	  Integrity	  Number	  	  
RLL	   Right	  Lower	  Lobe	  
RML	   Right	  Middle	  Lobe	  
ROC	   Receiver	  Operating	  Characteristic	  
RPE	   Rifapentine	  
rpf	   resuscitation-­‐promoting	  factors	  
RT-­‐MLPA	   Reverse	  Transcriptase	  Multiplex	  Ligation	  dependant	  Probe	  Amplification	  
RUL	   Right	  Upper	  Lobe	  
s.d	   standard	  deviation	  
SLE	   Systemic	  Lupus	  Erythematosis	  
Sm	   Smear	  
SOP	   Standard	  Operating	  Procedure	  
ss	   single-­‐stranded	  	  
SUV	   Standardized	  Uptake	  Value	  
Sv	   Sievert	  
TB	   Tuberculosis	  
TBNA	   Transbronchial	  Needle	  Aspirate	  
TCEP	   tris(2-­‐carboxyethyl)phosphine	  
TDF	   Tenofovir	  Disoproxil	  Fumerate	  
TGF	   Transforming	  Growth	  Factor	  
TLR	   Toll-­‐Like	  Receptor	  
TMB	   Tetramethylbenzidine	  
TNF	   Tumour	  Necrosis	  Factor	  	  
TST	   Tuberculin	  Skin	  Test	  
TU	   Tuberculin	  Units	  
tx	   treatment	  
UCT	  	   University	  of	  Cape	  Town	  
USPHS	   United	  States	  Public	  Health	  Service	  
	  	   22	  
USS	   Ultra	  Sound	  Scan	  
VL	   Viral	  Load	  
VS	   Visual	  Score	  
vs.	   versus	  
WHO	   World	  Health	  Organization	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CHAPTER	  1:	  Introduction	  
1.1 General	  introduction	  
Tuberculosis	  (TB)	  is	  a	  disease	  of	  mammals	  caused	  by	  infection	  with	  members	  of	  the	  
Mycobacterium	  tuberculosis-­‐complex.	  	  Mycobacterium	  tuberculosis	  (Mtb)	  sensu	  stricto	  is	  the	  
most	  common	  cause	  of	  tuberculosis	  in	  humans	  and	  is	  only	  occasionally	  isolated	  in	  other	  
animals	  which	  are	  usually	  domesticated	  or	  in	  captivity	  and	  are	  generally	  unable	  to	  transmit	  
Mtb.	  	  The	  organism,	  a	  bacterium	  characterised	  by	  a	  cell	  wall	  rich	  in	  mycolic	  acid,	  is	  a	  slow	  
growing,	  strict	  aerobe	  and	  an	  obligate	  pathogen.	  	  Despite	  its	  adaptability	  within	  the	  host	  
Mtb	  is	  unable	  to	  survive	  for	  long	  periods	  in	  the	  environment	  and	  hence	  humans	  are	  the	  
main	  reservoir.	  	  Infection	  is	  usually	  transmitted	  via	  the	  respiratory	  route	  and	  the	  lungs	  are	  
also	  the	  most	  common	  sites	  of	  disease	  but	  disease	  can	  occur	  in	  any	  part	  of	  the	  body	  and	  
most	  often	  takes	  a	  sub-­‐acute	  course.	  	  Common	  symptoms	  of	  disease	  are	  weight	  loss,	  night	  
sweats,	  fever	  and	  cough	  but	  one	  of	  the	  most	  characteristic	  features	  of	  tuberculosis	  is	  its	  
variable	  and	  often	  prolonged	  incubation	  period	  and	  the	  fact	  that	  only	  a	  small	  proportion	  of	  
those	  infected	  ever	  develop	  symptomatic	  disease.	  	  As	  a	  result	  we	  conceptualise	  a	  non-­‐
infectious	  latent	  stage	  of	  TB	  during	  which	  the	  host	  is	  asymptomatic	  with	  low	  bacillary	  
numbers	  and	  a	  state	  of	  symptomatic	  active	  disease	  with	  significantly	  increased	  bacillary	  
numbers	  when	  there	  is	  potential	  for	  infection	  to	  be	  transmitted.	  	  The	  transition	  between	  
these	  2	  states	  can	  be	  considered	  as	  subclinical	  TB.	  	  	  
	  
Our	  ability	  to	  predict	  in	  whom	  and	  when	  the	  transition	  from	  latent	  infection	  to	  active	  
disease	  will	  occur	  and	  our	  understanding	  of	  the	  mechanisms	  and	  events	  that	  underlie	  this	  
are	  poor.	  	  However,	  there	  are	  a	  number	  of	  risk	  factors	  known	  to	  increase	  the	  likelihood	  of	  
progression	  from	  latent	  to	  active	  TB.	  	  Human	  Immunodeficiency	  Virus	  (HIV)	  infection	  is	  one	  
of	  the	  most	  potent	  and	  important	  of	  these	  risk	  factors	  and	  has	  had	  a	  major	  impact	  on	  the	  
global	  epidemiology	  of	  TB.	  	  Although	  the	  currently	  available	  diagnostic	  tests	  for	  latent	  TB	  
(tuberculin	  skin	  test	  (TST)	  and	  interferon	  gamma	  release	  assays	  (IGRA))	  do	  not	  distinguish	  
and	  are	  poorly	  predictive	  of	  active	  TB,	  recently	  progress	  has	  been	  made	  in	  identifying	  
transcriptional	  and	  immunological	  biomarkers	  that	  can	  distinguish	  latent	  and	  active	  TB.	  	  This	  
raises	  the	  possibility	  of	  developing	  infection	  stage	  specific	  biomarkers	  and	  diagnostic	  tests	  
more	  predictive	  of	  active	  TB.	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A	  central	  aim	  of	  this	  thesis	  is	  to	  contribute	  to	  our	  understanding	  of	  latent	  TB	  infection	  and	  
early	  stages	  of	  its	  transition	  to	  active	  disease,	  particularly	  in	  the	  context	  of	  early	  HIV	  
infection,	  with	  a	  view	  that	  this	  could	  facilitate	  development	  of	  diagnostic	  tests	  better	  able	  to	  
predict	  active	  tuberculosis	  which	  would	  be	  an	  important	  step	  in	  global	  TB	  control.	  	  A	  core	  
hypothesis	  for	  this	  thesis	  is	  that	  this	  definition	  of	  latent	  infection	  encompasses	  a	  spectrum	  
of	  infection	  states.	  
	  
The	  concept	  of	  a	  latent	  phase	  of	  tuberculosis	  even	  predates	  the	  discovery	  of	  Mtb	  by	  Robert	  
Koch,	  though	  understanding	  developed	  in	  the	  early	  part	  of	  the	  20th	  century	  with	  many	  
holding	  quite	  a	  nuanced	  and	  sophisticated	  view	  of	  the	  condition,	  recognising	  that	  the	  
boundary	  between	  latent	  and	  active	  TB	  was	  often	  blurred,	  fluctuated	  and	  was	  influenced	  by	  
available	  diagnostics.	  
	  
“Latent	  tuberculosis	  may	  be	  defined	  for	  convenience	  as	  that	  which	  is	  
unaccompanied	  by	  symptoms	  and	  physical	  signs,	  causes	  no	  obvious	  disturbance	  
and	  is	  not	  recognised	  by	  the	  physician.	  	  There	  is	  no	  sharp	  distinction	  between	  
latent	  and	  manifest	  tuberculosis,	  and	  in	  some	  instances	  latent	  tuberculosis	  is	  
more	  extensive	  than	  that	  which	  is	  recognisable.	  	  Ability	  to	  distinguish	  between	  
latent	  and	  manifest	  disease	  will	  vary	  with	  the	  means	  available	  for	  diagnosis”	  
	  
Opie	  and	  McPhedran	  1926[1]	  
	  
In	  the	  pre-­‐chemotherapy	  era,	  when	  early	  diagnosis	  was	  considered	  crucial	  to	  a	  favourable	  
outcome,	  identifying	  people	  in	  this	  fluctuating	  transition	  between	  latent	  and	  active	  TB	  was	  
appreciated	  with	  mass	  chest	  radiograph	  (CXR)	  screening	  for	  subclinical	  TB	  being	  widely	  
implemented	  globally.	  	  This	  was	  perhaps	  the	  first	  example	  of	  a	  mass	  screening	  programme	  
in	  modern	  medicine.	  	  In	  the	  post-­‐chemotherapy	  era	  a	  more	  rigid	  distinction	  evolved,	  with	  
latent	  and	  active	  TB	  considered	  as	  binary	  outcomes	  in	  a	  diagnostic	  algorithm	  that	  required	  
different	  management	  strategies.	  	  Latent	  TB	  is	  generally	  defined	  as	  having	  evidence	  of	  
immune	  sensitization	  by	  Mtb,	  in	  the	  absence	  of	  symptoms	  or	  signs	  of	  disease	  and	  treatment	  
with	  1	  or	  2	  anti-­‐tuberculous	  agents	  for	  3-­‐9	  months	  has	  been	  shown	  to	  reduce	  risk	  of	  
progression	  to	  active	  TB.	  	  The	  diagnosis	  of	  active	  TB	  is	  made	  following	  identification	  of	  Mtb	  
or	  evidence	  of	  active	  pathology	  caused	  by	  Mtb	  in	  a	  person	  with	  suggestive	  symptoms	  and	  
treatment	  with	  a	  minimum	  of	  3	  effective	  drugs	  for	  a	  minimum	  of	  6	  months	  is	  required.	  	  
However,	  recently	  the	  increasing	  availability	  in	  many	  parts	  of	  the	  world	  of	  advanced	  imaging	  
more	  sensitive	  than	  CXR	  for	  the	  detection	  of	  minimal	  pathology,	  such	  as	  [18F]-­‐fluoro-­‐2-­‐
deoxy-­‐D-­‐glucose	  (FDG)	  positron	  emission	  tomography	  combined	  with	  computed	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tomography	  (PET/CT),	  and	  invasive	  sampling,	  such	  as	  trans-­‐bronchial	  needle	  aspiration	  
(TBNA)	  of	  lymph	  nodes,	  has	  again	  led	  to	  the	  frequent	  identification	  of	  cases	  that	  do	  not	  
neatly	  fit	  into	  this	  simplistic	  binary	  categorisation	  which	  usually	  results	  in	  a	  management	  
dilemma.	  	  	  In	  this	  thesis	  the	  improved	  sensitivity	  of	  PET/CT	  was	  exploited	  to	  detect	  evidence	  
of	  subclinical	  pathology	  in	  asymptomatic	  persons	  otherwise	  considered	  to	  have	  latent	  TB.	  	  
Transcriptional	  and	  immunological	  differences	  were	  then	  evaluated	  in	  those	  with	  and	  
without	  subclinical	  pathology.	  
	  
This	  introductory	  chapter	  will	  outline	  our	  current	  and	  historical	  understanding	  of	  latent	  and	  
subclinical	  tuberculosis,	  the	  natural	  history	  of	  infection	  and	  transition	  to	  active	  TB,	  the	  
impact	  of	  HIV	  on	  progression	  of	  TB,	  the	  pathological	  and	  radiographic	  features	  of	  TB,	  and	  
ability	  of	  biomarkers	  to	  distinguish	  active	  from	  latent	  TB.	  	  
1.2 Latent	  tuberculosis	  
1.2.1 The	  evolution	  of	  latency	  in	  tuberculosis	  
Mtb	  co-­‐evolved	  with	  anatomically	  modern	  humans	  over	  at	  least	  40-­‐70,000	  years,	  originating	  
in	  Africa	  and	  co-­‐migrating	  with	  us	  to	  cover	  every	  corner	  of	  the	  globe.	  	  Humans	  initially	  lived	  
largely	  as	  foragers	  in	  small	  communities	  of	  roaming	  hunter-­‐gatherers.	  	  In	  these	  small	  
isolated	  populations	  infectious	  pathogens	  of	  high	  virulence	  and	  short	  incubation	  periods	  
would	  result	  in	  rapidly	  terminating	  epidemics	  due	  to	  the	  lack	  of	  susceptible	  hosts[2,	  3].	  	  
Persistence	  of	  low	  virulence	  pathogens	  capable	  of	  initiating	  a	  chronic	  and/or	  latent	  infection	  
within	  the	  human	  host	  would	  be	  favoured	  since	  transmission	  to	  susceptible	  new	  birth	  
cohorts	  years	  after	  the	  initial	  infection	  would	  be	  possible.	  	  Our	  natural	  immune	  response	  to	  
TB	  is	  likely	  to	  have	  been	  shaped	  over	  this	  period.	  	  Starting	  with	  the	  Neolithic	  Transition	  
Period	  approximately	  10,000	  years	  ago,	  agricultural	  development	  allowed	  for	  increases	  in	  
population	  density	  and	  the	  development	  of	  permanent	  settlements.	  	  More	  recently	  the	  
urbanization	  following	  the	  Industrial	  revolution	  led	  to	  further	  rapid	  increases	  in	  population	  
density	  especially	  in	  Europe	  and	  Asia[4].	  	  Co-­‐incident	  with	  this	  demographic	  change	  was	  a	  
significant	  expansion	  in	  mycobacterial	  genetic	  diversity	  and	  the	  development	  of	  3	  
evolutionary	  modern	  lineages	  (lineage	  2	  (East	  Asia),	  lineage	  3	  (India/East	  Africa)	  and	  lineage	  
4	  (Europe/America)[5].	  	  It	  might	  be	  expected	  that	  through	  adaptation	  to	  higher	  population	  
densities	  these	  modern	  strains	  may	  be	  more	  virulent	  and	  have	  shorter	  incubation	  periods	  in	  
comparison	  to	  ancient	  strains	  (lineage	  1(Philippines/	  Indian	  Ocean	  rim)	  and	  lineage	  5&6	  –	  
M.africanum	  (West	  Africa)).	  	  This	  would	  certainly	  be	  consistent	  with	  the	  observed	  success	  in	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terms	  of	  global	  spread	  of	  W-­‐Beijing	  stain	  (Lineage	  2)	  and	  is	  supported	  by	  the	  finding	  of	  de	  
Jong	  et	  al	  who	  showed	  fewer	  household	  contacts	  of	  ancient	  strains	  developed	  TB	  over	  a	  2	  
year	  period	  compared	  to	  contacts	  for	  evolutionary	  modern	  strains[5,	  6].	  	  
1.2.2 Overview	  of	  the	  lifecycle	  of	  tuberculosis	  
Figure	  1.1	  –	  Overview	  of	  TB	  lifecycle:	  	  Solid	  lines	  represent	  main	  routes	  of	  progression.	  	  Dashed	  lines	  represent	  less	  common	  or	  
theoretical	  routes	  of	  progression	  	  
	  
The	  general	  outline	  of	  the	  natural	  history	  of	  TB	  in	  humans	  is	  widely	  accepted	  and	  forms	  the	  
basis	  of	  the	  majority	  of	  epidemiological	  models	  (figure	  1.1).	  	  However	  many	  of	  the	  finer	  
details	  and	  biological	  mechanisms	  underlying	  this	  are	  poorly	  understood	  or	  yet	  to	  be	  
established	  and	  will	  be	  explored	  in	  subsequent	  sections	  of	  this	  chapter.	  	  
	  
Although	  TB	  can	  develop	  in	  virtually	  any	  part	  of	  the	  body,	  disease	  involving	  the	  lungs	  (which	  
occurs	  in	  60-­‐75%	  of	  cases)	  is	  necessary	  for	  transmission	  of	  infection;	  in	  particular	  pulmonary	  
cavitation	  facilitates	  efficient	  Mtb	  replication	  and	  transmission.	  	  There	  is	  some	  evidence	  that	  
suggests	  Mtb	  may	  specifically	  exploit	  the	  immune	  response	  through	  conservation	  of	  
immunodominant	  epitopes[7],	  which	  could	  promote	  the	  induction	  of	  immunopathology	  that	  
leads	  to	  lung	  cavitation.	  Immunocompetent	  adults	  contribute	  most	  to	  disease	  transmission.	  	  
Individuals	  who	  are	  most	  effective	  at	  transmitting	  are	  often	  sputum	  smear	  positive	  for	  acid-­‐
fast	  bacilli	  (AFB)	  and	  cough	  spontaneously,	  thereby	  generating	  infectious	  particles.	  	  Infection	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5µm	  in	  size)	  that	  can	  remain	  suspended	  in	  the	  air	  for	  hours	  (if	  not	  disrupted	  by	  turbulence)	  
and	  are	  inhaled	  by	  contacts	  sharing	  the	  same	  environment[8].	  	  	  Following	  an	  initial	  exposure	  
to	  Mtb,	  infection	  may	  fail	  to	  establish	  due	  to	  mechanical	  or	  cellular	  element	  of	  the	  innate	  
immune	  system	  but	  around	  30-­‐50%	  of	  close	  contacts	  will	  develop	  a	  primary	  infection,	  as	  
evidenced	  by	  immune	  sensitization	  (a	  positive	  TST	  or	  IGRA	  -­‐	  see	  below)[9].	  	  In	  a	  small	  
proportion	  (more	  common	  in	  children	  ≤	  2	  years	  and	  immunocompromised)	  primary	  
infection	  may	  progress	  to	  cause	  disease,	  this	  primary	  progressive	  TB	  is	  sometimes	  referred	  
to	  as	  childhood	  disease	  in	  the	  historical	  literature.	  	  In	  the	  remainder	  primary	  infection	  is	  
controlled	  and	  infection	  is	  considered	  latent.	  	  It	  is	  possible	  that	  in	  a	  number	  of	  those	  in	  
whom	  infection	  is	  initially	  established	  Mtb	  is	  eradicated	  through	  the	  acquired	  immune	  
response.	  	  Disease	  that	  subsequently	  develops	  is	  termed	  post-­‐primary	  and	  invariably	  arises	  
at	  a	  site	  distant	  to	  the	  primary	  site	  of	  infection	  in	  the	  lungs.	  	  In	  immunocompetent	  adults	  
this	  is	  commonly	  within	  the	  apical	  or	  sub	  apical	  region	  of	  the	  upper	  lung	  lobes;	  in	  the	  
historical	  literature	  this	  is	  sometimes	  referred	  to	  as	  adult	  disease.	  	  Post-­‐primary	  disease	  
occurs	  in	  around	  10%	  of	  those	  initially	  infected	  (higher	  in	  those	  with	  immunocompromise)	  
and	  at	  least	  half	  of	  which	  occurs	  in	  the	  2-­‐3	  years	  following	  initial	  reactivation	  of	  infection.	  	  	  
Although,	  once	  active	  disease	  is	  initiated	  progression	  of	  symptoms	  and	  pathology	  is	  
common,	  spontaneous	  arrest	  of	  disease	  accompanied	  by	  healing	  of	  pathology	  and	  
resolution	  of	  symptoms	  may	  occur.	  	  Data	  from	  the	  pre-­‐chemotherapy	  era	  for	  HIV	  uninfected	  
persons	  suggest	  that	  if	  left	  untreated,	  case	  fatality	  of	  smear	  positive	  TB	  was	  approximately	  
70%	  and	  smear	  negative	  TB	  approximately	  20%;	  the	  average	  duration	  of	  disease	  from	  
diagnosis	  to	  either	  death	  or	  cure	  was	  approximately	  3	  years	  although	  relapse	  after	  cure	  was	  
common[10].	  	  Re-­‐infection	  can	  occur	  at	  any	  stage	  but	  the	  fate	  of	  the	  bacillus	  and	  outcome	  
of	  reinfection	  will	  depend	  on	  numerous	  factors,	  which	  are	  incompletely	  understood.	  	  	  	  	  
1.2.3 Latent	  tuberculosis	  in	  the	  context	  of	  global	  tuberculosis	  control	  	  
The	  World	  Health	  Organization	  (WHO)	  and	  Stop	  TB	  partnership	  have	  set	  the	  challenge	  to	  
eliminate	  TB	  as	  a	  public	  health	  problem	  by	  2050[11].	  This	  has	  been	  defined	  as	  achieving	  an	  
incidence	  rate	  of	  less	  than	  1	  case	  per	  million	  of	  the	  global	  population).	  	  For	  comparison,	  the	  
2012	  rate	  is	  1220	  cases	  per	  million[12].	  	  In	  addition	  bold	  interim	  targets	  have	  recently	  been	  
set	  for	  2025	  (to	  reduce	  TB	  mortality	  by	  75%	  and	  TB	  incidence	  by	  50%	  compared	  to	  2015	  
levels)	  and	  2035	  (to	  reduce	  TB	  mortality	  by	  95%	  and	  TB	  incidence	  by	  90%	  compared	  to	  2015	  
levels)[13].	  	  In	  the	  20th	  century	  when	  much	  of	  Western	  Europe,	  North	  America	  and	  parts	  of	  
East	  Asia	  saw	  dramatic	  reductions	  in	  TB	  incidence	  through	  major	  socio-­‐economic	  progress	  
and	  implementation	  of	  improved	  TB	  control	  and	  treatment	  programmes;	  peak	  reduction	  in	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TB	  cases	  of	  8.8%/year	  was	  achieved	  in	  these	  regions	  after	  the	  2nd	  world	  war[14].	  	  In	  contrast	  
Sub-­‐Saharan	  Africa	  and	  Eastern	  Europe/Central	  Asia	  in	  particular	  suffered	  a	  steep	  increase	  in	  
TB	  incidence	  during	  the	  1990s	  due	  to	  the	  HIV	  epidemic	  and	  the	  socio-­‐economic	  disruption	  
following	  the	  collapse	  of	  the	  Soviet	  Union	  respectively.	  	  Latest	  estimates	  suggest	  that	  in	  
2012	  there	  were	  8.6	  million	  new	  cases	  of	  tuberculosis	  and	  1.3	  million	  deaths,	  with	  the	  global	  
incidence	  of	  tuberculosis	  falling	  2%/year	  over	  recent	  years[12].	  	  In	  this	  context	  the	  2050	  
elimination	  target	  seems	  particularly	  bold	  requiring	  a	  historically	  unprecedented	  20%/year	  
reduction	  in	  global	  TB	  incidence[14].	  	  Widespread	  implementation	  of	  current	  TB	  control	  
measures	  coupled	  with	  continued	  socio-­‐economic	  development	  particularly	  within	  the	  
BRICS	  (Brazil,	  Russia,	  India,	  China	  and	  South	  Africa)	  countries	  along	  with	  continued	  Anti	  
Retroviral	  Therapy	  (ART)	  roll	  out	  in	  Sub-­‐Saharan	  Africa	  could	  result	  in	  global	  reductions	  in	  TB	  
incidence	  of	  10%/year.	  	  However	  to	  bring	  global	  incidence	  down	  towards	  current	  levels	  seen	  
in	  North	  America	  and	  parts	  of	  Western	  Europe,	  considered	  to	  be	  in	  the	  elimination	  phase	  
(<100	  cases/million/year),	  development	  of	  novel	  technologies	  and	  approaches	  will	  be	  
required	  though	  research	  and	  innovation.	  	  Whereas	  until	  now	  TB	  control	  has	  focused	  on	  
detection	  and	  management	  of	  active	  disease,	  which	  will	  continue	  to	  be	  important,	  a	  
renewed	  focus	  on	  understanding	  and	  managing	  the	  important	  reservoir	  of	  infected	  humans	  
with	  latent	  infection	  will	  be	  critical	  to	  future	  progress.	  	  Modelling	  suggests	  that	  mass	  
treatment	  of	  latent	  TB	  would	  be	  one	  of	  the	  most	  effective	  ways	  to	  reduce	  incidence	  of	  
TB[14,	  15].	  	  However,	  with	  current	  treatment	  and	  diagnostics	  this	  would	  involve	  up	  to	  1/3	  of	  
the	  world’s	  population	  taking	  3-­‐9	  months	  of	  anti-­‐tuberculous	  therapy,	  which	  is	  neither	  
desirable	  nor	  feasible.	  	  The	  need	  for	  novel	  diagnostic	  tests	  for	  latent	  TB	  more	  predictive	  of	  
active	  disease	  and	  shorter	  course	  preventive	  treatments	  are	  clear,	  but	  in	  order	  to	  pursue	  
these	  a	  greater	  understanding	  of	  the	  biology	  of	  latency	  and	  reactivation	  is	  required.	  	  	  
1.2.4 The	  current	  diagnostic	  tests	  for	  latent	  tuberculosis	  
By	  the	  end	  of	  the	  19th	  century	  the	  notion	  that	  a	  latent	  period	  of	  infection	  could	  occur	  in	  
tuberculosis	  was	  widely	  accepted.	  	  Several	  autopsy	  case	  series	  carried	  out	  around	  the	  turn	  
of	  the	  century	  demonstrated	  that	  Mtb	  was	  frequently	  present	  in	  persons	  who	  died	  of	  causes	  
other	  than	  tuberculosis	  by	  inoculating	  material	  from	  cadavers	  into	  rabbits	  or	  guinea	  pigs	  and	  
observing	  secondary	  infection[16,	  17].	  	  Detecting	  the	  presence	  of	  infection	  in	  asymptomatic	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living	  people	  was	  more	  challenging.	  	  Koch’s	  discovery	  and	  development	  of	  tuberculin,	  a	  
heat-­‐killed	  culture	  filtrate	  of	  tuberculosis	  that	  was	  proposed	  unsuccessfully	  as	  a	  cure	  in	  
1890,	  provided	  a	  useful	  diagnostic	  test,	  unmasking	  occult	  infection	  by	  inducing	  systemic	  
reaction	  following	  subcutaneous	  injection[18].	  	  
	  
Over	  a	  period	  of	  65	  years	  tuberculin	  was	  refined	  into	  an	  intradermal	  skin	  test	  using	  a	  
standardised	  purified	  protein	  derivative	  of	  tuberculin	  (PPD)	  and	  measuring	  the	  induration	  
formed	  after	  48-­‐72	  hours	  (table	  1.1).	  	  The	  result,	  expressed	  as	  millimetres	  (mm)	  of	  
induration,	  is	  a	  continuous	  variable	  where	  the	  threshold	  for	  a	  positive	  result	  can	  be	  varied	  to	  
modify	  diagnostic	  sensitivity	  and	  specificity.	  	  The	  dose	  of	  PPD	  was	  optimized	  to	  maximise	  
sensitivity	  in	  distinguishing	  healthy	  close	  contacts	  of	  TB	  from	  healthy	  non-­‐contacts,	  and	  the	  
tuberculin	  skin	  test	  (TST)	  remains	  widely	  used	  globally	  today	  and	  is	  generally	  considered	  to	  
demonstrate	  the	  presence	  of	  infection[19].	  	  In	  general	  different	  cut-­‐offs	  are	  used	  for	  groups	  
depending	  on	  their	  risk	  of	  developing	  TB.	  	  Commonly	  the	  Centers	  for	  Disease	  Control	  and	  
Prevention	  (CDC)	  recommended	  cut-­‐offs	  are	  used;	  ≥5mm	  for	  those	  at	  highest	  risk,	  namely	  
those	  with	  HIV	  co-­‐infection,	  other	  significant	  immunosuppression,	  recent	  close	  contact	  of	  TB	  
or	  fibrotic	  changes	  on	  CXR,	  ≥10mm	  for	  those	  living	  in	  or	  recently	  migrated	  from	  high	  TB	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Table	  1.1	  –	  History	  of	  diagnostic	  tests	  for	  latent	  tuberculosis.	  
TU	  =	  tuberculin	  units,	  ESAT-­‐6	  =	  6	  kDa	  early	  secretory	  antigenic	  target,	  CFP-­‐10	  =	  10	  kDa	  culture	  filtrate	  antigen,	  ELISA	  =	  
enzyme-­‐linked	  immunosorbent	  assay,	  ELISPOT	  =	  enzyme-­‐linked	  immunospot	  assay,	  IFNγ	  =	  interferon	  gamma,	  hrs	  =	  hours	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Those	  with	  positive	  TST	  are	  clearly	  at	  greater	  risk	  of	  developing	  TB	  and	  will	  derive	  greater	  
benefit	  from	  preventive	  therapy	  and	  hence	  one	  can	  reasonably	  conclude	  that	  they	  are	  more	  
likely	  to	  be	  infected	  with	  Mtb.	  	  However,	  to	  what	  extent	  can	  all	  those	  with	  a	  positive	  test	  be	  
presumed	  to	  have	  a	  viable	  mycobacterial	  infection	  with	  the	  absence	  of	  studies	  relating	  pre-­‐
morbid	  TST	  result	  to	  post-­‐mortem	  autopsy	  findings?	  	  The	  guinea	  pig	  “natural	  infection”	  
model,	  initially	  developed	  by	  Riley	  to	  investigated	  airborne	  transmission	  in	  which	  air	  from	  
side	  rooms	  or	  wards	  where	  TB	  infected	  patients	  are	  resident	  is	  vented	  over	  chambered	  
guinea	  pigs,	  can	  provide	  some	  evidence.	  	  In	  these	  studies	  the	  distribution	  and	  magnitude	  of	  
TST	  reactions	  found	  in	  guinea	  pigs	  was	  similar	  to	  humans;	  at	  autopsy	  evidence	  of	  infection	  
was	  found	  in	  0%	  of	  guinea	  pigs	  with	  tuberculin	  reactions	  0-­‐5mm	  (negative	  reaction),	  92%	  of	  
guinea	  pigs	  with	  TST	  >=14mm	  or	  evidence	  of	  necrosis	  but	  only	  in	  25%	  with	  TST	  6-­‐13mm	  [21].	  	  
This	  finding,	  that	  not	  all	  “naturally	  infected”	  guinea	  pigs	  with	  positive	  TST	  have	  evidence	  of	  
infection	  at	  autopsy,	  has	  been	  confirmed	  by	  others	  [22,	  23].	  	  Equally,	  if	  positive	  TST	  indicates	  
presence	  of	  infection	  and	  negative	  TST	  absence	  of	  infection,	  then	  treatment	  of	  latent	  
infection	  might	  be	  expected	  to	  cause	  a	  reversion	  of	  status.	  In	  the	  United	  States	  Public	  Health	  
Service	  (USPHS)	  Trials	  13,176	  household	  contacts	  who	  were	  initially	  TST	  positive	  had	  TST	  
repeated	  at	  12	  months	  after	  placebo	  or	  isoniazid.	  	  6.5%	  of	  contacts	  who	  received	  placebo	  
converted	  to	  negative	  and	  7.9%	  of	  isoniazid	  treated	  contacts	  converted	  to	  negative.	  	  
However,	  isoniazid	  reduced	  the	  10-­‐year	  incidence	  of	  TB	  by	  59%	  in	  those	  who	  remained	  TST	  
positive	  at	  12	  months	  and	  38%	  in	  those	  who	  converted	  at	  12	  months	  indicating	  that	  
isoniazid’s	  efficacy	  to	  prevent	  disease	  was	  not	  associated	  with	  a	  capacity	  to	  induce	  TST	  
reversion[24].	  	  	  From	  this	  we	  can	  conclude	  that	  TST	  provides	  evidence	  of	  immune	  
sensitization	  by	  Mtb	  and	  is	  a	  correlate	  of	  TB	  infection	  but	  not	  all	  those	  with	  a	  positive	  test	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Table	  1.2	  –	  Current	  preventive	  regimens	  for	  latent	  TB.	  
INH	  =	  isoniazid,	  RIF	  =	  rifampicin,	  RPE	  =	  rifapentine,	  PZA	  =	  pyrazinamide	  	  	  
PZA	  =	  Pyrazinamide	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Because	  TST	  can	  render	  low-­‐level	  false	  positive	  results	  due	  to	  sensitisation	  by	  environmental	  
mycobacteria	  and	  Bacillus	  Calmette-­‐Guérin	  (BCG)	  vaccination,	  IGRA	  were	  developed	  to	  
improve	  diagnostic	  specificity.	  	  A	  positive	  TST	  represents	  cell-­‐mediated,	  delayed	  
hypersensitivity	  to	  a	  collection	  of	  secreted	  mycobacterial	  antigens	  (which	  are	  not	  Mtb	  
specific)	  injected	  into	  the	  skin.	  	  Development	  of	  IGRA	  refined	  this	  by	  measuring	  the	  cell	  
mediated	  response	  to	  Mtb	  in	  circulating	  blood	  by	  detection	  of	  interferon	  gamma	  (IFNγ)	  
either	  by	  enzyme-­‐linked	  immunosorbent	  assay	  (ELISA)	  or	  enzyme-­‐linked	  immunospot	  assay	  
(ELISPOT)	  following	  short	  term	  incubation	  of	  either	  whole	  blood	  or	  peripheral	  blood	  
mononuclear	  cells	  (PBMC)	  with	  antigens	  from	  the	  region	  of	  deletion	  (RD)	  1	  locus	  of	  the	  Mtb	  
genome	  (table	  1.1).	  	  The	  RD1	  locus	  of	  Mtb	  encodes	  a	  number	  of	  genes	  essential	  to	  the	  
virulence	  of	  the	  organism	  including	  those	  relating	  the	  ESX-­‐1	  secretory	  system.	  	  6	  kDa	  early	  
secretory	  antigenic	  target	  (ESAT-­‐6)	  and	  10	  kDa	  culture	  filtrate	  antigen	  (CFP-­‐10)	  are	  highly	  
immunogenic	  antigens	  secreted	  by	  this	  system	  and	  are	  the	  stimulatory	  antigens	  used	  in	  
IGRA	  (along	  with	  TB7.7	  in	  QuantiFERON-­‐TB	  Gold-­‐In-­‐Tube	  (QFGIT)).	  	  The	  RD1	  locus	  is	  absent	  
in	  the	  attenuated	  M.	  bovis-­‐BCG	  and	  the	  majority	  of	  environmental	  mycobacteria	  (although	  
notably	  not	  from	  M.	  kansasii	  and	  M.	  marinum[25]).	  	  	  While	  IGRA	  have	  been	  confirmed	  to	  be	  
more	  specific	  than	  TST,	  especially	  in	  populations	  vaccinated	  with	  BCG	  after	  infancy	  and,	  
particularly	  for	  TSPOT-­‐TB,	  remain	  more	  sensitive	  than	  TST	  in	  advanced	  HIV,	  many	  other	  of	  
the	  test	  characteristics	  are	  similar[26].	  In	  particular	  although	  the	  negative	  predictive	  values	  
(NPV)	  for	  both	  tests	  are	  very	  high	  (IGRA	  99.7%,	  TST	  99.4%),	  they	  are	  both	  poorly	  predictive	  
of	  progression	  to	  active	  disease	  (positive	  predictive	  value	  (PPV):	  IGRA	  2.7%,	  TST	  1.5%)[27,	  
28].	  	  As	  a	  result	  when	  these	  immunodiagnostic	  tests	  are	  used	  as	  a	  guide	  for	  administration	  
of	  preventive	  therapy	  (table	  1.2)	  the	  number	  needed	  to	  treat	  (NNT)	  to	  prevent	  one	  case	  of	  
Figure	  1.2	  –	  Acceptability	  of	  preventive	  therapy	  for	  latent	  TB:	  Conceptual	  diagram	  showing	  how	  acceptability	  of	  treatment	  
for	  latent	  TB	  (LTBI	  tx)	  might	  be	  improved	  by	  developing	  more	  tolerable	  drug	  regimens	  or	  diagnostic	  tests	  more	  predictive	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active	  TB	  is	  high.	  	  In	  a	  systematic	  review	  of	  11	  studies	  involving	  73,375	  HIV-­‐uninfected	  
participants	  randomised	  to	  isoniazid	  or	  placebo	  the	  pooled	  NNT	  was	  100,	  ranging	  from	  36	  in	  
recently	  infected	  household	  contacts	  to	  179	  in	  those	  remotely	  infected[29].	  	  This	  poor	  
predictive	  value	  of	  current	  diagnostic	  tests,	  along	  with	  lengthy	  duration	  of	  preventive	  
therapy	  are	  the	  main	  barriers	  to	  implementation	  of	  widespread	  treatment	  for	  latent	  TB	  
(figure	  1.2).	  	  After	  the	  initial	  need	  to	  develop	  sensitive	  and	  then	  specific	  tests	  for	  latent	  TB	  
we	  now	  need	  to	  develop	  tests	  that	  are	  better	  able	  to	  predict	  who	  will	  develop	  active	  TB.	  	  
1.2.5 The	  global	  burden	  of	  latent	  tuberculosis	  
One	  of	  the	  most	  widely	  quoted	  statistics	  is	  that	  1/3	  of	  the	  world’s	  population	  is	  infected	  by	  
Mtb	  emphasising	  the	  huge	  scale	  of	  the	  problem[30].	  	  However,	  aside	  from	  the	  fact	  that	  no	  
test	  accurately	  demonstrates	  the	  presence	  of	  infection,	  it	  is	  useful	  to	  consider	  the	  data	  upon	  
which	  the	  statement	  is	  made.	  	  Prevalence	  of	  infection	  in	  a	  population	  is	  derived	  from	  the	  
Annual	  Rate	  of	  Infection	  (ARI),	  which	  can	  either	  be	  directly	  determined	  from	  focused	  
tuberculin	  surveys	  (usually	  in	  school	  children)	  or	  indirectly	  estimated	  from	  incidence	  of	  
active	  TB	  using	  the	  equation	  ARI	  =	  Incidence/coefficient,	  as	  risk	  of	  infection	  is	  determined	  by	  
contact	  with	  infectious	  cases[31].	  	  Of	  note	  however,	  the	  incidence	  itself	  is	  usually	  estimated	  
from	  case	  notification,	  disease	  prevalence	  or	  mortality	  data.	  	  In	  addition,	  in	  order	  to	  
accurately	  determine	  prevalence	  of	  infection	  the	  change	  in	  ARI	  over	  time	  in	  the	  population	  
should	  ideally	  be	  known.	  	  	  
	  
In	  1999	  WHO	  convened	  a	  consensus	  group	  comprising	  86	  experts	  and	  epidemiologists	  who	  
evaluated	  the	  best	  available	  data	  for	  all	  countries	  up	  to	  1997	  for	  a	  number	  of	  TB	  indicators	  
including	  prevalence	  of	  infection[30].	  	  Recent	  good	  quality	  tuberculin	  surveys	  were	  available	  
for	  only	  24	  countries	  and	  the	  rate	  of	  change	  in	  ARI	  was	  only	  accurately	  known	  in	  a	  minority.	  	  
For	  the	  majority	  of	  countries	  for	  which	  good	  quality	  tuberculin	  surveys	  were	  not	  available	  
(or	  it	  wasn’t	  possible	  to	  confidently	  extrapolate	  from	  countries	  with	  good	  data)	  ARI	  was	  
derived	  from	  the	  incidence	  of	  smear	  positive	  disease	  using	  the	  equation	  above	  with	  the	  
coefficient	  of	  50	  (for	  countries	  where	  HIV	  prevalence	  in	  TB	  cases	  was	  less	  than	  5%)	  coming	  
from	  “Styblo’s	  rule”	  [32]	  (which	  states	  that	  a	  smear	  positive	  pulmonary	  tuberculosis	  
incidence	  of	  50/100,000/year	  corresponds	  to	  ARI	  of	  1%,	  potentially	  an	  overestimate	  –	  see	  
below).	  	  The	  authors	  estimated	  that	  32%	  of	  the	  world’s	  population	  was	  infected	  with	  Mtb	  
but	  acknowledged	  the	  lack	  of	  good	  data	  and	  limitations	  of	  the	  models	  to	  determine	  
prevalence	  of	  infection	  and	  did	  not	  provide	  an	  uncertainty	  estimate.	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Tuberculin	  surveys,	  while	  widely	  performed,	  have	  several	  limitations.	  	  Interpreting	  results	  to	  
determine	  the	  proportion	  that	  are	  immune	  sensitized	  by	  Mtb	  is	  challenging	  as	  the	  specificity	  
of	  the	  test	  varies	  between	  populations,	  depending	  upon	  exposure	  to	  environmental	  
mycobacteria	  and	  BCG	  vaccination.	  	  Analysing	  the	  distribution	  of	  TST	  reactions	  using	  mixture	  
models	  and	  other	  techniques	  to	  identify	  bimodal	  patterns	  (as	  the	  reaction	  to	  TST	  is	  greater	  
following	  immune	  sensitization	  by	  Mtb	  than	  environmental	  mycobacteria	  or	  BCG)	  can	  be	  
performed	  but	  not	  all	  distributions	  lend	  themselves	  to	  this	  form	  of	  analysis[33,	  34].	  	  
Systematic	  surveys	  using	  IGRA	  have	  not	  often	  been	  performed	  and	  the	  need	  for	  
venepuncture,	  specialist	  laboratories	  and	  cost	  may	  limit	  widespread	  use.	  	  In	  addition,	  the	  
dynamics	  of	  IGRA	  conversion	  and	  reversion	  over	  time	  and	  hence	  sensitivity	  to	  detect	  remote	  
infection	  are	  less	  well	  understood,	  although	  data	  from	  IGRA	  surveys	  could	  be	  used	  with	  
tuberculin	  surveys	  to	  refine	  estimates	  of	  LTBI	  prevalence[35].	  	  A	  recombinant	  ESAT-­‐6/CFP-­‐10	  
skin	  test	  is	  currently	  in	  development	  with	  early	  clinical	  studies	  showing	  superior	  specificity	  to	  
TST	  and	  correlation	  with	  whole	  blood	  Quantiferon	  results[36],	  such	  a	  test	  may	  ultimately	  
prove	  particularly	  useful	  for	  surveys	  of	  this	  kind.	  	  	  
	  
Modelling	  the	  risk	  of	  infection	  from	  the	  incidence	  of	  smear	  positive	  active	  disease	  seems	  
appropriate	  but	  “Styblo’s	  rule”	  makes	  some	  key	  assumptions	  informed	  by	  6	  studies	  between	  
1921	  and	  1971.	  	  Namely	  each	  smear	  positive	  incident	  case	  is	  infectious	  for	  2	  years	  
(corresponding	  to	  2	  prevalent	  cases)	  and	  each	  prevalent	  case	  results	  in	  10	  new	  infections	  
per	  year.	  	  Hence	  the	  rule,	  an	  incidence	  of	  50/100,000/year	  results	  in	  infection	  rate	  of	  
1,000/100,000/year.	  	  This	  may	  be	  less	  applicable	  in	  the	  contemporary	  era	  as	  improved	  
diagnosis	  and	  treatment	  may	  have	  reduced	  the	  average	  duration	  of	  infectiousness	  
significantly	  and	  factors	  such	  as	  population	  density,	  success	  of	  TB	  control	  programmes,	  the	  
prevalence	  of	  HIV	  infection,	  and	  the	  prevalence	  of	  drug	  resistant	  TB	  will	  also	  have	  influenced	  
transmission[37].	  	  A	  recent	  analysis	  of	  data	  from	  East	  Asian	  countries	  between	  1975	  and	  
1994	  by	  van	  Leth	  et	  al	  determined	  that	  the	  number	  of	  infections	  per	  prevalent	  smear	  
positive	  prevalent	  case	  was	  2.6-­‐5.9/	  year,	  so	  at	  least	  in	  some	  parts	  of	  the	  world	  “Styblo’s	  
rule”	  overestimates	  infection[37,	  38].	  	  Smear	  positive	  TB	  is	  also	  not	  homogenous.	  Jones-­‐
Lopez	  et	  al	  have	  shown	  in	  only	  45%	  of	  smear	  positive	  cases	  could	  Mtb	  be	  cultured	  from	  
cough	  aerosols	  generated	  though	  10	  minutes	  of	  strong	  coughing.	  In	  addition	  the	  variability	  
in	  colony	  forming	  units	  (cfu)	  generated	  was	  great	  (1-­‐378cfu).	  	  They	  also	  showed	  that	  
infection	  of	  household	  contacts	  was	  significantly	  greater	  when	  the	  index	  cases	  had	  a	  high	  
cough	  aerosol	  cfu	  compared	  to	  low	  or	  no	  cough	  aerosol	  cfu[39].	  	  Confirming	  that	  cases	  of	  TB	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transmit	  variably,	  Escombe	  et	  al	  using	  the	  Riley	  guinea	  pig	  model	  of	  airborne	  infection	  in	  an	  
HIV/TB	  ward	  in	  Peru,	  showed	  8.5%	  of	  admissions	  were	  responsible	  for	  98%	  of	  infections	  in	  
guinea	  pigs[40].	  	  Further	  complicating	  the	  situation	  is	  the	  fact	  that	  Mtb	  strains	  themselves	  
may	  differ	  in	  their	  transmissibility	  and	  nature	  of	  immune	  response	  they	  induce.	  	  Taken	  
together	  using	  a	  general	  rule	  derived	  from	  a	  small	  sample	  of	  cases	  to	  establish	  prevalence	  of	  
infection	  in	  different	  populations	  is	  likely	  to	  be	  extremely	  inaccurate.	  
	  
Accurate	  estimation	  of	  the	  proportion	  of	  the	  world	  that	  is	  infected	  using	  the	  currently	  
available	  tools	  is	  extremely	  difficult.	  	  Better	  data	  and	  a	  better	  understanding	  of	  how	  
parameters	  change	  regionally	  or	  in	  certain	  situations	  (such	  as	  drug	  resistance)	  may	  allow	  for	  
the	  development	  of	  more	  sophisticated	  models[41].	  	  These	  may	  then	  allow	  more	  accurate	  
assessment	  of	  the	  prevalence	  of	  infection	  and	  provide	  estimates	  for	  important	  subgroups	  
such	  as	  the	  prevalence	  of	  drug	  resistant	  latent	  TB	  or	  the	  proportion	  of	  latent	  TB	  related	  to	  a	  
recent	  infection.	  	  However,	  ultimately	  what	  we	  want	  to	  know	  is	  the	  proportion	  that	  is	  highly	  
likely	  to	  develop	  active	  disease.	  
1.2.6 Risk	  of	  latent	  infection	  progressing	  to	  active	  disease	  
The	  lifetime	  age-­‐weighted	  risk	  of	  TB	  following	  infection	  in	  settings	  with	  low	  exogenous	  
reinfection	  is	  estimated	  to	  be	  12%[42].	  	  Careful	  follow-­‐up	  in	  placebo-­‐controlled	  intervention	  
studies	  has	  demonstrated	  that	  disease	  is	  most	  likely	  to	  occur	  in	  the	  first	  year	  following	  
infection,	  with	  stepwise	  reduction	  year	  on	  year	  over	  the	  following	  5-­‐10	  years	  (see	  figure	  1.3)	  
by	  which	  time	  incidence	  approaches	  that	  of	  uninfected	  contacts[24].	  	  The	  different	  
manifestations	  of	  tuberculosis	  occur	  at	  different	  intervals	  following	  infection	  with	  pleural	  TB,	  
TB	  meningitis	  and	  miliary	  TB	  occurring	  after	  a	  shorter	  interval	  than	  pulmonary	  or	  other	  
extra-­‐pulmonary	  sites[43].	  
	  
Reactivation	  several	  decades	  after	  initial	  infection	  occurs[44]	  but	  as	  observational	  studies	  
with	  close	  follow-­‐up	  rarely	  continue	  beyond	  10	  years	  it	  is	  difficult	  to	  assess	  how	  common	  
reactivation	  is	  outside	  this	  timeframe.	  In	  addition,	  conventional	  observational	  studies	  make	  
it	  difficult	  to	  evaluate	  whether	  disease	  relates	  to	  the	  initial	  infection	  event	  or	  subsequent	  
reinfection.	  	  Borgdorff	  et	  al	  applied	  a	  molecular	  epidemiology	  approach	  (using	  Restriction	  
Fragment	  Length	  Polymorphism	  of	  IS6110	  +/-­‐	  Polymorphic	  GC	  Rich	  Sequence)	  to	  12,222	  
cases	  of	  TB	  over	  a	  15-­‐year	  period	  in	  the	  Netherlands	  and	  identified	  1,095	  linked	  secondary	  
cases	  from	  688	  source	  cases.	  	  The	  median	  incubation	  period	  (time	  between	  predicted	  date	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of	  infection	  and	  onset	  of	  symptoms	  in	  the	  secondary	  case)	  was	  calculated	  to	  be	  1.26	  years	  
and	  the	  serial	  interval	  (time	  between	  symptom	  onset	  in	  source	  and	  secondary	  case)	  was	  
found	  to	  be	  1.44	  years	  with	  83%	  of	  secondary	  cases	  occurring	  within	  5	  years	  of	  the	  source	  
case	  and	  >95%	  within	  10	  years[45].	  	  Studies	  of	  immigrants	  from	  high	  burden	  to	  low	  burden	  
countries	  provide	  further	  information.	  McCarthy	  showed	  that	  of	  128	  migrants	  from	  high	  
burden	  countries	  in	  Asia	  diagnosed	  with	  TB	  in	  London	  in	  the	  1980s	  (low	  burden	  setting)	  and	  
who	  had	  neither	  returned	  to	  Asia	  since	  migrating	  nor	  had	  a	  known	  UK	  TB	  contact,	  71.9%	  had	  
arrived	  in	  the	  UK	  0-­‐5	  years	  previously,	  23.4%	  had	  arrived	  6-­‐10	  years	  previously,	  3.9%	  had	  
arrived	  10-­‐15	  years	  previously,	  and	  0.8%	  had	  arrived	  16-­‐20	  years	  previously[46].	  	  	  	  This	  
supports	  the	  assertion	  that	  after	  more	  than	  10	  year	  of	  infection	  reactivation	  of	  disease	  is	  
very	  rare.	  	  However,	  it	  is	  acknowledged	  that	  there	  are	  several	  limitations	  in	  interpretation	  of	  
this	  data	  in	  particular	  relating	  to	  stability	  of	  migration	  rate	  and	  over	  this	  period	  and	  
ascertainment	  of	  all	  cases.	  	  The	  observation	  that	  the	  elderly	  in	  low	  TB	  burden	  settings	  have	  a	  
higher	  incidence	  of	  TB	  is	  often,	  possibly	  incorrectly,	  interpreted	  as	  providing	  evidence	  of	  
prolonged	  latency	  and	  reactivation	  following	  immunosenescence.	  	  However,	  careful	  
evaluation	  of	  birth	  cohorts	  shows	  this	  apparent	  increased	  risk	  is	  an	  artefact	  of	  falling	  
transmission,	  and	  younger	  adults	  are	  still	  invariably	  at	  greater	  risk	  of	  TB	  than	  the	  elderly[47].	  
These	  data	  show	  that	  the	  common	  view	  that	  reactivation	  TB	  disease	  often	  occurs	  decades	  
after	  initial	  infection	  may	  be	  overstated;	  the	  majority	  of	  cases	  occur	  within	  18	  months	  of	  
infection	  and	  disease	  resulting	  from	  reactivation	  more	  than	  10	  years	  after	  infection	  may	  be	  
Figure	  1.3	  –	  Incidence	  of	  TB	  in	  household	  contacts	  over	  time:	  from	  data	  in	  Ferebee	  [24]	  
	  
Chapter	  1	  -­‐	  Introduction	  
	   36	  
rare.	  	  The	  risk	  of	  disease	  is	  also	  not	  constant	  over	  time;	  following	  a	  single	  infection	  the	  risk	  is	  
approximately	  12%	  over	  a	  person’s	  lifetime,	  if	  no	  disease	  develops	  after	  5	  years	  the	  lifetime	  
risk	  might	  only	  be	  2%	  and	  after	  10	  years	  0.5%.	  
1.2.7 Risk	  factors	  for	  developing	  active	  tuberculosis	  
The	  risk	  of	  developing	  active	  TB	  can	  be	  associated	  with	  increased	  risk	  of	  exposure	  to	  Mtb,	  
increased	  risk	  of	  infection	  following	  exposure	  or	  increased	  risk	  of	  reactivation	  (or	  
progression)	  following	  infection.	  	  Many	  conventional	  risk	  factors	  can	  all	  of	  these	  effects	  and	  
in	  epidemiological	  studies	  it	  can	  be	  difficult	  to	  separate	  what	  is	  driving	  the	  increased	  risk	  
[48](table	  1.3).	  	  The	  majority	  of	  these	  common	  risk	  factors	  for	  active	  TB	  have	  complex	  and	  
often	  poorly	  understood	  effects	  on	  the	  host	  response	  to	  Mtb	  (HIV	  will	  be	  discussed	  in	  detail	  
below)	  but	  they	  are	  considered	  to	  be	  either	  generally	  immunosuppressive	  or	  to	  specifically	  
affect	  the	  lung.	  	  	  Anti	  tumour	  necrosis	  factor	  (TNF)	  therapy	  (such	  as	  infliximab)	  by	  contrast	  
has	  a	  very	  specific	  effect	  on	  host	  immunity	  and	  a	  particularly	  striking	  impact	  on	  
development	  of	  active	  TB.	  	  In	  patients	  treated	  with	  infliximab	  the	  risk	  of	  developing	  active	  
TB	  in	  the	  first	  90	  days	  of	  treatment	  is	  almost	  20-­‐times	  that	  of	  the	  background	  population,	  
with	  43%	  of	  total	  TB	  cases	  in	  a	  2	  years	  follow	  up,	  occurring	  within	  90	  days	  of	  administration	  
of	  the	  drug[49].	  	  Reactivation	  is	  thought	  to	  be	  precipitated	  by	  disruption	  of	  the	  granuloma	  
by	  interference	  with	  TNFα	  signalling,	  however	  reactivation	  is	  by	  no	  means	  universal.	  	  In	  an	  
evaluation	  of	  the	  implementation	  of	  latent	  TB	  screening	  prior	  to	  anti-­‐TNF	  therapy	  in	  Spain,	  
56	  patients	  with	  positive	  TST	  (>5mm)	  were	  identified	  who	  did	  not	  receive	  any	  isoniazid	  
prophylaxis	  and	  in	  only	  one	  case	  did	  active	  TB	  occur	  following	  anti-­‐TNF	  treatment[50].	  	  
	  
Rather	  than	  just	  immunosuppression	  alone,	  it	  is	  becoming	  more	  apparent	  that	  the	  extremes	  
of	  the	  immune	  response	  may	  lead	  to	  detrimental	  outcome	  in	  tuberculosis	  with	  a	  more	  
balanced	  response	  being	  optimal	  (the	  so	  called	  “Goldilocks	  effect”).	  	  It	  has	  been	  proposed	  









Table	  1.3	  –	  Relative	  risk	  for	  active	  TB	  for	  some	  globally	  common	  conditions	  -­‐	  Adapted	  from	  Lönnroth	  et	  al	  [48]	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aggressive	  response	  may	  lead	  to	  tissue	  damage	  and	  necrosis,	  which	  may	  provide	  a	  more	  
favourable	  environment	  for	  the	  bacillus.	  	  An	  example	  of	  one	  possible	  mechanism	  for	  this	  
“Goldilocks	  effect”	  has	  been	  recently	  characterised.	  	  Leukotriene	  A4	  hydrolase	  (LTA4H)	  
mediates	  the	  balance	  of	  pro-­‐inflammatory	  eicosanoid	  LTB4	  and	  anti-­‐inflammatory	  lipoxin	  A.	  	  
Zebrafish	  larvae	  in	  which	  LTA4H	  is	  over-­‐	  or	  under-­‐expressed	  are	  made	  hyper-­‐susceptible	  to	  
M.	  marinum	  infection	  compared	  to	  wildtype	  either	  by	  low	  levels	  of	  LTA4H	  resulting	  in	  
increased	  lipoxin	  A	  and	  impaired	  TNFα	  production,	  or	  excessive	  LTA4H	  resulting	  in	  increased	  
LTB4	  and	  increased	  TNFα	  production[51].	  	  Humans	  who	  are	  heterozygous	  for	  a	  single	  
nucleotide	  polymorphism	  of	  LTA4H	  promoter	  rs17525495	  (C/T)	  appear	  to	  have	  the	  best	  
clinical	  outcome	  from	  TB	  meningitis,	  those	  who	  are	  homozygotes	  for	  the	  T	  allele	  (T/T)	  have	  
increased	  LTA4H	  expression	  and	  increased	  inflammatory	  cerebrospinal	  fluid	  but	  derive	  
significantly	  greater	  benefit	  from	  dexamethasone	  therapy	  compared	  to	  those	  with	  the	  C/C	  
genotype[51-­‐53].	  	  	  
	  
A	  further	  intriguing	  and	  poorly	  understood	  risk	  factor	  is	  age.	  	  It	  is	  a	  consistent	  and	  striking	  
feature	  of	  tuberculosis	  that	  the	  age	  at	  which	  infection	  occurs	  affects	  the	  risk	  of	  subsequently	  
developing	  active	  disease[54,	  55].	  	  Infants	  and	  young	  children	  especially	  those	  ≤	  2	  years	  are	  
at	  considerable	  risk	  of	  developing	  disease	  following	  infection.	  Older	  children	  (5-­‐10	  years	  old)	  
have	  consistently	  been	  shown	  to	  be	  at	  the	  lowest	  risk	  of	  active	  TB	  following	  infection,	  
whereas	  in	  comparison	  peri-­‐pubescent	  adolescents	  and	  young	  adults	  are	  at	  much	  greater	  
risk	  of	  developing	  cavitary	  TB[54,	  55].	  	  It	  has	  been	  suggested	  that	  this	  may	  relate	  to	  the	  
immunoendocrine	  effects	  mediated	  by	  the	  balance	  between	  dehydroepiandrosterone	  
(DHEA	  –	  a	  precursor	  of	  sex	  steroids)	  and	  glucocorticoids[56].	  DHEA	  levels	  start	  increasing	  
from	  7	  years	  old,	  peak	  in	  early	  adulthood,	  and	  reduce	  in	  older	  adults[55].	  	  One	  of	  DHEA’s	  
many	  effects	  is	  as	  a	  glucocorticoid	  antagonist	  and	  the	  cortisol:DHEA	  ratio	  has	  important	  
immunological	  consequences.	  	  Recently	  DHEA	  has	  been	  shown	  to	  influence	  dendritic	  cell	  
function	  to	  promote	  TH1	  responses	  by	  increasing	  interleukin	  (IL)-­‐12	  and	  diminishing	  IL-­‐10	  
production	  following	  Mtb	  stimulation,	  with	  increased	  expression	  of	  major	  histocompatibility	  
complex	  (MHC)	  I,	  MHCII	  and	  cluster	  of	  differentiation	  (CD)	  86	  expression	  resulting	  in	  
enhanced	  T-­‐cell	  proliferation	  and	  IFNγ	  production[57].	  	  So	  it	  seems	  plausible	  that	  pro-­‐
inflammatory	  responses	  in	  healthy	  adolescents	  and	  young	  adults	  have	  detrimental	  effects	  
leading	  to	  cavitary	  disease,	  anti-­‐inflammatory	  responses	  in	  infants	  lead	  to	  their	  inability	  to	  
control	  replication	  and	  there	  is	  a	  more	  optimal	  balanced	  response	  in	  older	  children	  leading	  
to	  a	  beneficial	  outcome.	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Another	  interesting	  observation	  is	  the	  seasonality	  of	  active	  TB	  with	  increased	  case	  
notification,	  which	  can	  be	  20-­‐25%	  higher	  in	  spring/summer	  than	  in	  autumn/winter[58-­‐61].	  	  
This	  is	  striking	  for	  an	  infectious	  disease	  with	  relatively	  prolonged	  and	  variable	  incubation.	  	  In	  
common	  with	  other	  respiratory	  pathogens	  one	  explanation	  would	  be	  behavioural,	  with	  
winter	  crowding	  leading	  to	  greater	  transmission,	  but	  modelling	  evidence	  and	  analysis	  of	  
unique	  and	  clustered	  Mtb	  strains	  suggests	  that	  this	  cannot	  fully	  explain	  the	  seasonality	  of	  
TB[43,	  62].	  	  A	  seasonal	  precipitating	  factor	  such	  as	  vitamin	  D	  deficiency	  or	  a	  viral	  respiratory	  
infection	  (e.g.	  influenza)	  is	  an	  alternative	  explanation.	  	  Vitamin	  D,	  synthesised	  within	  the	  skin	  
requiring	  UV	  light,	  acts	  as	  an	  immunomodulatory	  and	  anti-­‐inflammatory	  agent	  primarily	  
exerting	  its	  effect	  on	  macrophages,	  facilitating	  enhanced	  control	  of	  mycobacteria	  through	  
pleiotropic	  mechanisms[63,	  64].	  	  A	  number	  of	  clinical	  observations	  provide	  some	  support	  for	  
the	  role	  of	  vitamin	  D	  deficiency	  in	  inducing	  reactivation.	  	  TB	  patients	  are	  well	  documented	  to	  
have	  significantly	  lower	  vitamin	  D	  levels	  than	  healthy	  household	  controls[65,	  66],	  and	  the	  
spring/summer	  peak	  in	  TB	  notifications	  is	  preceded	  by	  a	  winter	  trough	  in	  vitamin	  D	  levels	  in	  
Cape	  Town[67].	  	  There	  is	  some	  evidence	  to	  suggest	  that	  seasonality	  is	  more	  pronounced	  in	  
foreign	  born	  cases	  (who	  may	  be	  at	  greater	  risk	  of	  vitamin	  D	  deficiency	  due	  to	  skin	  
pigmentation)	  compared	  to	  native	  cases	  in	  Europe[68,	  69].	  	  An	  alternative	  seasonal	  
precipitant	  could	  be	  a	  viral	  infection.	  	  It	  has	  recently	  been	  shown	  that	  the	  type	  2	  interferon	  
(IFNγ)	  response	  critical	  for	  mycobacterial	  control	  can	  be	  impaired	  by	  the	  downstream	  effects	  
of	  type	  1	  interferons	  (IFNα/β)[70].	  	  It	  has	  therefore	  been	  hypothesised	  that	  viral	  respiratory	  
infections	  inducing	  a	  type	  1	  interferon	  response	  could	  lead	  to	  reactivation	  by	  impairment	  of	  
type	  2	  interferon	  facilitated	  control	  of	  Mtb.	  	  In	  the	  mouse	  model,	  mycobacterial	  growth	  is	  
enhanced	  and	  survival	  decreased	  in	  mice	  previously	  exposed	  to	  influenza	  by	  a	  mechanism	  
dependent	  on	  Type	  1	  interferon	  signalling[71].	  	  In	  addition,	  historical	  observations	  and	  
modelling	  of	  the	  1918	  influenza	  pandemic	  suggest	  a	  negative	  impact	  of	  influenza	  on	  TB[72].	  	  
1.3 Subclinical	  tuberculosis	  	  
1.3.1 Mass	  chest	  radiograph	  screening	  for	  subclinical	  tuberculosis	  	  
As	  TB	  is	  in	  general	  a	  relatively	  slowly	  progressive	  condition,	  there	  is	  a	  period	  of	  time	  during	  
the	  transition	  from	  latent	  to	  active	  TB	  when	  a	  person	  may	  be	  asymptomatic	  despite	  
evolution	  of	  the	  disease.	  	  This	  period	  can	  be	  considered	  a	  subclinical	  phase	  of	  TB.	  	  
Subsequently,	  there	  is	  a	  period	  of	  time	  following	  the	  onset	  of	  symptoms	  during	  which	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healthcare	  may	  not	  be	  sought	  and	  this	  can	  be	  considered	  a	  pre-­‐diagnostic	  phase	  of	  TB.	  	  
Screening	  is	  an	  active	  process	  that	  offers	  a	  possibility	  to	  identify	  persons	  in	  the	  subclinical	  or	  
pre-­‐diagnostic	  phase	  of	  TB.	  	  The	  aim	  of	  screening	  is	  to	  identify	  evidence	  of	  pathology	  related	  
to	  the	  disease	  in	  an	  acceptable	  and	  cost	  effective	  way	  such	  that	  treatment	  or	  isolation	  can	  
be	  initiated	  earlier	  than	  would	  otherwise	  have	  been	  the	  case.	  	  This	  could	  potentially	  improve	  
prognosis	  of	  the	  condition	  for	  the	  individual	  and	  reduce	  transmission	  within	  the	  community.	  	  
CXR	  screening	  for	  subclinical	  tuberculosis	  was	  the	  one	  of	  the	  first	  examples	  of	  a	  mass	  
screening	  program	  in	  modern	  medicine	  that	  saw	  millions	  of	  people	  x-­‐rayed	  globally	  between	  
the	  1930s	  and	  1970s[73].	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  
The	  primary	  abnormalities	  of	  interest	  on	  CXR	  at	  screening	  were	  those	  relating	  to	  active	  
tuberculosis	  at	  a	  minimal	  stage	  of	  disease	  (when	  even	  in	  the	  pre-­‐chemotherapeutic	  era	  
isolation,	  sanatoria	  care	  or	  invasive	  intervention	  may	  have	  been	  of	  benefit)	  as	  well	  as	  
evidence	  of	  healed,	  inactive	  tuberculosis,	  particularly	  following	  the	  availability	  of	  drug	  
treatments	  to	  reduce	  risk	  of	  disease	  progression.	  	  Diagnostic	  standards	  for	  these	  
radiographic	  lesions	  were	  established	  early	  on[74].	  	  One	  of	  the	  most	  comprehensive	  
evaluations	  of	  minimal	  lesions	  identified	  through	  a	  mass	  screening	  programme	  was	  the	  
Royal	  College	  of	  Physicians	  Prophit	  survey.	  	  1,213	  adults	  with	  minimal	  TB	  lesions	  were	  
identified	  from	  181,391	  persons	  attending	  2	  mass	  screening	  units	  in	  London	  between	  1946	  
and	  1948,	  99%	  of	  whom	  were	  tuberculin	  positive.	  	  Approximately	  75%	  of	  lesions	  were	  in	  the	  
upper	  zones,	  mainly	  unilateral,	  usually	  comprising	  of	  clusters	  of	  small	  nodules	  covering	  on	  
average	  10cm2.	  	  Although	  almost	  all	  participants	  denied	  symptoms	  and	  reported	  good	  
health,	  on	  direct	  questioning	  approximately	  50%	  admitted	  to	  at	  least	  one	  TB	  symptom.	  	  













Figure	  1.4	  –	  Graphical	  representation	  of	  screening	  for	  subclinical	  TB:	  	  In	  the	  pre-­‐symptomatic	  phase	  of	  TB,	  pathology	  
related	  to	  active	  TB	  might	  be	  detectable	  using	  different	  strategies	  with	  differing	  sensitivity.	  	  Low	  sensitivity	  imaging	  
modalities	  such	  as	  CXR	  are	  most	  acceptable	  a	  have	  been	  widely	  used	  for	  this	  purpose.	  	  High	  sensitivity	  imaging	  modalities	  
such	  as	  FDG-­‐PET/CT	  may	  be	  more	  sensitive	  but	  not	  suitable	  for	  general	  screening.	  	  The	  star	  represents	  the	  point	  at	  which	  
healthcare	  is	  actively	  sought,	  prior	  to	  this	  if	  symptoms	  are	  present	  can	  be	  considered	  a	  pre-­‐diagnostic	  phase	  of	  TB.	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the	  initial	  CXR	  and	  a	  further	  27%	  within	  6-­‐18	  months.	  	  In	  54%	  of	  those	  with	  radiographic	  
deterioration	  Mtb	  was	  isolated,	  but	  Mtb	  was	  also	  isolated	  in	  21%	  without	  radiographic	  
deterioration.	  	  Therefore	  approximately	  44%	  of	  screened	  adults	  with	  minimal	  lesions	  had	  
radiographic	  or	  microbiological	  deterioration	  over	  5	  years[75].	  
	  
Those	  that	  had	  disease	  identified	  at	  a	  minimal	  stage	  on	  CXR	  were	  found	  to	  have	  much	  better	  
prognosis	  than	  those	  with	  moderately	  advanced	  or	  far	  advanced	  TB,	  with	  1	  study	  showing	  
mortality	  in	  these	  3	  groups	  with	  sanatoria	  care	  to	  be	  4.1%,	  9.2%	  and	  46.8%	  respectively,	  
however	  these	  differences	  in	  part	  will	  reflect	  length	  and	  lead	  time	  bias[76].	  	  In	  addition,	  
minimal	  lesions	  were	  more	  likely	  to	  improve	  than	  moderately	  advanced	  lesions.	  	  As	  these	  
lesions	  improved,	  radiographic	  evidence	  of	  activity	  reduced	  and	  fibrosis	  of	  lesions	  was	  
observed,	  however,	  subsequent	  deterioration	  in	  those	  in	  which	  disease	  activity	  had	  
appeared	  to	  arrest	  was	  common.	  	  As	  a	  result	  identifying	  those	  with	  inactive	  (healed	  or	  
fibrotic)	  lesions	  on	  CXR	  became	  increasingly	  important,	  particularly	  with	  the	  availability	  of	  
drug	  treatment.	  	  Those	  with	  inactive	  lesions	  on	  CXR	  fell	  into	  2	  groups	  those	  that	  were	  known	  
to	  have	  had	  previous	  active	  TB,	  which	  subsequently	  healed,	  and	  those	  with	  no	  diagnosis	  of	  
previous	  active	  TB	  in	  which	  subclinical	  TB	  was	  presumed	  to	  have	  spontaneously	  healed.	  	  
Individuals	  with	  fibrotic	  inactive	  lesions	  on	  CXR	  with	  no	  previous	  diagnosis	  of	  TB	  were	  5-­‐15	  
times	  more	  likely	  to	  develop	  TB	  than	  tuberculin	  reactors	  with	  a	  normal	  CXR[24,	  77].	  	  
Isoniazid	  therapy	  was	  also	  found	  to	  significantly	  reduce	  the	  likelihood	  of	  those	  with	  inactive	  
lesions	  progressing	  to	  active	  disease[78].	  	  In	  addition,	  studies	  in	  Europe	  and	  America	  at	  a	  
time	  of	  rapidly	  falling	  TB	  incidence	  showed	  that	  up	  to	  70%	  of	  persons	  developing	  TB	  (with	  no	  
history	  of	  TB	  and	  usually	  no	  clear	  contact	  history)	  had	  evidence	  of	  fibrotic	  scarring	  on	  
previous	  CXR[79,	  80].	  	  	  
	  
Taken	  together	  the	  evidence	  from	  CXR	  evaluation	  of	  TB	  suggests,	  that	  in	  a	  proportion	  of	  
people,	  the	  disease	  may	  follow	  a	  cyclical	  waxing	  and	  waning	  course	  with	  earlier	  reactivation	  
initially	  arrested	  by	  the	  host,	  delaying	  disease	  presentation.	  	  In	  addition,	  it	  is	  clear	  that	  the	  
subclinical	  phase	  of	  active	  disease	  prior	  to	  clinical	  presentation	  may	  be	  several	  months.	  	  
1.3.2 Limitations	  of	  chest	  radiography	  
Mass	  CXR	  screening	  probably	  played	  a	  role	  in	  the	  success	  of	  TB	  control	  in	  Europe	  and	  
America	  over	  the	  twentieth	  century,	  largely	  being	  abandoned	  due	  to	  poor	  cost	  effectiveness	  
particularly	  as	  prevalence	  of	  disease	  fell.	  	  However,	  CXR	  used	  for	  TB	  screening	  has	  a	  number	  
of	  notable	  limitations	  as	  a	  diagnostic	  test,	  summarized	  by	  Koppaka	  and	  Bock[81].	  	  Several	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studies	  demonstrated	  that	  both	  under-­‐detection	  and	  over-­‐detection	  of	  abnormalities	  were	  
common,	  although	  of	  note	  the	  gold	  standards	  used	  in	  such	  studies	  were	  not	  ideal	  (usually	  
panel	  of	  experts	  or	  final	  clinical	  diagnosis).	  	  Experience	  of	  the	  reader	  made	  a	  small	  difference	  
with	  accuracy	  being	  improved	  only	  in	  those	  that	  read	  more	  than	  20,000	  films	  a	  year	  or	  had	  
greater	  than	  10	  years	  experience.	  	  Inter-­‐observer	  variability	  was	  high	  (up	  to	  30%)	  and	  of	  
greater	  concern	  intra-­‐observer	  variability	  (when	  the	  same	  reader	  was	  asked	  to	  interpret	  the	  
film	  months	  apart)	  there	  was	  disagreement	  with	  the	  earlier	  read	  in	  approximately	  20%	  of	  
cases.	  	  Fundamentally	  the	  more	  subtle	  a	  lesion	  the	  greater	  the	  disagreement	  about	  its	  
presence	  is	  as	  “signal	  to	  noise	  ratio”	  is	  high	  as	  overlying	  structures	  impair	  ability	  to	  identify	  
the	  lesion	  of	  interest,	  particularly	  at	  the	  apical	  and	  subapical	  regions	  where	  tuberculous	  
lesions	  are	  most	  frequent.	  
	  
CXR	  screening	  is	  still	  undertaken	  for	  groups	  at	  high	  risk	  of	  tuberculosis	  and	  recently	  a	  
systematic	  review	  evaluating	  CXR	  screening	  compared	  to	  a	  gold	  standard	  of	  sputum	  culture	  
identified	  4	  studies	  in	  which	  any	  CXR	  changes	  of	  TB	  had	  a	  pooled	  sensitivity	  of	  87%	  and	  
specificity	  of	  89%.	  	  However,	  a	  high	  risk	  of	  verification	  bias	  potentially	  overestimating	  
sensitivity	  was	  identified	  in	  all	  studies	  as,	  in	  general,	  sputum	  culture	  examination	  was	  limited	  
to	  those	  that	  also	  had	  symptoms	  or	  abnormal	  CXR[82].	  	  Other	  imaging	  modalities	  such	  as	  CT	  
can	  provide	  considerably	  greater	  detail	  of	  the	  lung	  parenchyma	  and	  would	  be	  expected	  to	  
be	  significantly	  more	  sensitive	  for	  smaller	  parenchymal	  lesion	  but	  its	  application	  in	  this	  
context	  has	  been	  limited	  (discussed	  below).	  	  Although	  CT	  would	  be	  generally	  inappropriate	  
as	  a	  screening	  tool	  it	  may	  have	  considerable	  value	  as	  a	  research	  tool.	  	  Dual	  energy	  CXR	  in	  
which	  a	  soft	  tissue	  image	  and	  bone	  image	  are	  produced	  though	  a	  weighted	  subtraction	  of	  a	  
high	  energy	  and	  low	  energy	  exposure	  could	  be	  of	  interest	  as	  an	  improved	  screening	  tool	  for	  
tuberculosis.	  	  	  	  	  	  	  	  	  	  	  	  	  
1.3.3 Asymptomatic	  culture	  positive	  tuberculosis	  in	  HIV	  
In	  addition	  to	  CXR	  abnormalities	  preceding	  clinical	  TB,	  it	  has	  also	  been	  demonstrated	  that	  
persons	  can	  be	  culture	  positive	  for	  Mtb	  in	  the	  absence	  of	  symptoms.	  	  This	  is	  more	  common	  
in	  the	  context	  of	  HIV	  co-­‐infection	  particularly	  in	  those	  with	  advancing	  immunosuppression.	  	  
Oni	  et	  al	  screened	  213	  asymptomatic	  HIV-­‐1	  infected	  persons	  with	  sputum	  culture,	  17	  (8%)	  
were	  found	  to	  be	  culture	  positive,	  of	  whom	  14	  had	  CXR	  performed	  of	  which	  only	  3	  were	  
abnormal.	  	  Median	  CD4	  count	  of	  those	  with	  asymptomatic	  TB	  was	  249/mm3	  and	  just	  over	  
50%	  developed	  symptoms	  with	  2	  months[83].	  	  Whether	  those	  with	  a	  normal	  CXR	  truly	  had	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an	  absence	  of	  pathology	  within	  the	  lungs	  is	  unknown,	  as	  no	  studies	  have	  performed	  cross-­‐
sectional	  imaging	  in	  such	  patients.	  
1.3.4 The	  spectrum	  of	  infection	  states	  in	  tuberculosis	  	  
It	  is	  becoming	  clearer	  that	  dichotomisation	  of	  tuberculosis	  into	  a	  latent	  and	  active	  stages	  of	  
infection	  is	  an	  oversimplification.	  	  Over	  the	  past	  few	  years	  many	  researchers	  have	  revisited	  
the	  notion	  that	  asymptomatic	  people	  considered	  to	  have	  latent	  tuberculosis	  might	  be	  better	  
considered	  as	  part	  of	  a	  spectrum	  of	  infection	  states	  where	  at	  one	  end	  infection	  may	  have	  
been	  eliminated	  but	  immune	  sensitization	  remains,	  while	  at	  the	  other	  end	  disease	  may	  be	  
active	  but	  in	  a	  subclinical	  form,	  and	  between	  these	  two	  extremes	  infection	  is	  controlled	  in	  a	  
quiescent	  state[84-­‐89].	  	  Considering	  this	  in	  terms	  of	  the	  natural	  history	  of	  infection	  it	  seems	  
plausible	  that	  soon	  after	  initial	  infection	  and	  immune	  sensitization	  there	  are	  3	  main	  possible	  
outcomes	  influenced	  by	  predisposing	  factors,	  which	  determine	  the	  course	  of	  infection	  
during	  this	  critical	  phase	  and	  alter	  the	  proportions	  in	  each	  group.	  	  Some	  may	  initially	  
develop	  primary	  progressive	  disease;	  this	  may	  be	  a	  very	  small	  proportion	  in	  adults	  but	  would	  
likely	  be	  more	  common	  in	  advanced	  immunosuppression	  and	  infants.	  	  A	  second	  group	  (a	  
high	  risk	  group	  -­‐	  the	  main	  group	  from	  which	  reactivation	  disease	  arises)	  may	  enter	  a	  more	  
unstable	  state	  with	  infection	  taking	  a	  waxing-­‐waning	  course	  during	  which,	  periods	  of	  disease	  
progression	  triggered	  by	  precipitating	  factors	  may	  be	  followed	  by	  control	  (which	  may	  lead	  to	  
evidence	  of	  immunopathology)	  or	  the	  development	  of	  clinical	  disease.	  	  Some	  precipitating	  
factors	  may	  be	  more	  potent	  than	  others,	  very	  potent	  precipitating	  factors	  (such	  as	  anti-­‐TNF	  





















Figure	  1.5	  –	  Conceptual	  framework	  for	  outcome	  of	  tuberculosis	  infection:	  from	  Esmail	  et	  al	  [89]	  
Prd	  =	  predisposing	  factors,	  Pre=	  precipitating	  factors	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also	  in	  this	  group	  that	  isoniazid	  preventive	  therapy	  (IPT)	  may	  be	  most	  effective.	  	  A	  third	  
group	  may	  rapidly	  and	  effectively	  control	  infection	  and	  eventually	  may	  even	  sterilize	  the	  
organism	  and	  may	  be	  at	  extremely	  low	  risk	  of	  progressing	  to	  active	  disease	  even	  in	  the	  
presence	  of	  certain	  precipitating	  factors	  (figure	  1.5).	  	  
1.4 HIV	  and	  its	  impact	  on	  Tuberculosis	  
1.4.1 HIV	  
HIV	  is	  single-­‐stranded	  ribonucleic	  acid	  (ssRNA),	  enveloped	  retrovirus	  transmitted	  between	  
humans	  sexually,	  intravenously	  or	  vertically	  via	  infected	  blood,	  breast	  milk,	  seminal	  or	  
vaginal	  fluid.	  	  The	  primary	  cellular	  target	  is	  the	  CD4	  T	  cell	  but	  macrophages	  and	  dendritic	  
cells	  can	  also	  be	  infected.	  	  The	  virus	  enters	  the	  cell	  via	  interaction	  with	  CD4	  receptor	  and	  
chemokine	  receptor	  CXCR4	  or	  CCR5.	  	  Once	  within	  the	  cell	  the	  ssRNA	  viral	  genome	  is	  reverse	  
transcribed	  to	  complementary	  deoxyribonucleic	  acid	  (cDNA)	  and	  integrated	  into	  the	  host	  
genome.	  	  Viral	  replication	  is	  then	  governed	  by	  the	  cell	  cycle	  and	  influenced	  by	  cellular	  
transcription	  factor	  notably	  NF-­‐κB.	  	  	  
	  
Two	  types	  of	  HIV	  virus	  exist,	  HIV-­‐1	  and	  HIV-­‐2.	  	  HIV-­‐2	  has	  a	  limited	  geographic	  distribution	  
confined	  primarily	  to	  West	  Africa	  and	  is	  of	  lower	  virulence	  and	  infectivity.	  	  HIV-­‐1	  is	  
distributed	  globally	  and	  the	  predominant	  virus	  found	  in	  South	  Africa.	  	  HIV	  is	  grouped	  
according	  to	  variation	  in	  the	  envelope	  region	  into	  groups	  M,	  N	  and	  O	  with	  group	  M	  being	  
the	  most	  common,	  this	  then	  sub-­‐grouped	  into	  8	  clades	  with	  clade	  C	  being	  prevalent	  in	  South	  
Africa.	  
	  
The	  initial	  phase	  of	  HIV-­‐1	  infection,	  termed	  acute	  infection,	  which	  is	  non-­‐specifically	  
symptomatic	  in	  a	  proportion,	  is	  accompanied	  by	  a	  rapid	  rise	  in	  viral	  load	  and	  a	  reciprocal	  fall	  
in	  CD4	  count.	  	  This	  is	  followed	  by	  a	  period	  of	  clinical	  latency	  as	  the	  viral	  load	  stabilizes	  and	  
CD4	  count	  recovers.	  	  Over	  a	  period	  of	  time,	  CD4	  count	  slowly	  falls	  and	  the	  individual	  
becomes	  more	  susceptible	  to	  characteristic	  groups	  of	  infections	  and	  malignancies,	  which	  
allow	  HIV	  to	  be	  staged	  clinically	  (commonly	  as	  WHO	  stage	  I-­‐IV).	  	  	  	  Initially	  (often	  while	  CD4	  
count	  is	  ≥	  350/mm3)	  a	  number	  of	  minor	  infections,	  such	  as	  fungal	  nail	  infections,	  shingles,	  
bacterial	  skin	  infection	  are	  more	  common,	  however,	  as	  the	  CD4	  count	  approaches	  200/mm3	  
the	  individual	  become	  susceptible	  to	  a	  number	  of	  more	  unusual	  and	  rare	  opportunistic	  
infections	  such	  as	  toxoplasmosis,	  cryptococcosis	  and	  Pneumocystis	  jirovecii	  either	  following	  
reactivation	  of	  a	  latent	  source	  or	  recent	  infection.	  	  This	  stage	  of	  HIV	  infection	  is	  termed	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acquired	  immune	  deficiency	  syndrome	  (AIDS)	  and	  is	  rapidly	  followed	  by	  death	  in	  the	  
absence	  of	  antiretroviral	  therapy	  (ART).	  	  ART	  suppresses	  the	  virus	  allowing	  recovery	  of	  the	  
CD4	  count	  and	  reconstitution	  of	  the	  immune	  system	  reducing	  the	  risk	  of	  opportunistic	  
infection.	  
1.4.2 Interaction	  of	  HIV	  and	  tuberculosis	  
The	  interaction	  between	  TB	  and	  HIV	  is	  complex	  and	  differs	  in	  some	  key	  respects	  to	  other	  
opportunistic	  infections.	  	  Most	  notably	  risk	  of	  TB	  increases	  soon	  after	  HIV	  infection	  and	  the	  
nature	  of	  TB	  disease	  characteristically	  changes	  with	  advancing	  HIV.	  	  	  
	  
The	  relative	  risk	  of	  active	  tuberculosis	  increases	  within	  the	  first	  year	  of	  HIV	  infection	  and	  
progressively	  increases	  thereafter	  [90,	  91].	  	  In	  a	  lower	  TB	  transmission	  setting	  Selwyn	  et	  al	  
showed	  in	  a	  study	  of	  intravenous	  drug	  users	  in	  1980’s	  New	  York,	  that	  over	  a	  21	  month	  
follow	  up	  of	  217	  HIV	  infected	  patients,	  7	  of	  49	  (14.4%)	  that	  were	  TST	  positive	  at	  entry	  
developed	  TB	  compared	  to	  1	  of	  168	  (0.6%)	  that	  were	  TST	  negative	  (rate	  ratio	  =	  24).	  	  In	  
addition	  none	  of	  the	  303	  HIV	  uninfected	  patients,	  a	  similar	  proportion	  of	  which	  were	  TST	  
positive,	  developed	  active	  TB.	  	  This	  demonstrated	  the	  increased	  pressure	  to	  reactivated	  
latent	  infection	  in	  HIV	  co-­‐infection,	  although	  of	  note	  a	  significant	  number	  of	  TST	  positive	  
people	  with	  HIV	  infection	  did	  not	  develop	  TB	  over	  this	  period.	  	  This	  is	  in	  contrast	  to	  the	  non-­‐
human	  primate	  model	  of	  simian	  immune	  deficiency	  virus	  (SIV)-­‐TB.	  	  In	  macaques	  with	  latent	  
TB	  infection	  (defined	  by	  absence	  of	  disease	  ≥	  6	  months	  after	  TB	  infection),	  subsequently	  
infected	  with	  SIV,	  reactivation	  and	  progression	  of	  TB	  disease	  occurred	  in	  all	  animals	  over	  an	  
11	  month	  period[92].	  	  
	  
In	  high	  TB	  transmission	  settings	  like	  South	  Africa,	  molecular	  epidemiological	  evidence	  
suggests	  that	  in	  HIV	  associated	  TB,	  3	  times	  as	  many	  infecting	  strains	  are	  unique	  in	  early	  
stages	  (within	  2	  years	  of	  seroconversion)	  compared	  with	  later	  stages	  of	  HIV	  infection.	  	  This	  
suggests	  that	  while	  reactivation	  of	  a	  latent	  infection	  is	  an	  important	  factor	  in	  developing	  TB	  
in	  early	  HIV	  infection,	  in	  more	  advanced	  HIV	  in	  regions	  of	  high	  transmission	  active	  TB	  more	  
commonly	  reflects	  a	  rapid	  progression	  to	  disease	  following	  recent	  (re)infection[91].	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The	  impact	  of	  advancing	  immunosuppression	  on	  TB	  incidence	  in	  high	  transmission	  settings	  
like	  Cape	  Town	  is	  striking	  with	  a	  marked	  increase	  in	  those	  with	  CD4	  counts	  less	  than	  
200/mm3	  compared	  to	  those	  with	  CD4	  count	  ≥	  350/mm3	  (figure	  1.6)[93].	  	  In	  a	  recent	  
evaluation	  of	  29,478	  cases	  of	  TB	  in	  Cape	  Town,	  62.1%	  of	  the	  HIV	  associated	  cases	  had	  CD4	  
count	  less	  than	  200/mm3	  and	  82.7%	  had	  CD4	  less	  than	  350/mm3	  with	  the	  proportion	  of	  
those	  with	  extra	  pulmonary	  TB	  increasing	  with	  advancing	  immunosuppression[94].	  	  
Commencement	  of	  ART	  has	  a	  dramatic	  effect	  on	  reduction	  of	  TB	  incidence	  but	  risk	  of	  TB	  is	  
still	  elevated	  compared	  to	  HIV	  uninfected	  persons	  even	  in	  those	  with	  CD4	  counts	  greater	  
than	  500/mm3.	  	  	  	  
	  
Supporting	  this	  notion	  that	  TB	  in	  early	  and	  advanced	  HIV	  have	  differing	  pathogenesis,	  the	  
presentation	  of	  TB	  differs	  with	  CD4	  count.	  	  Chamie	  et	  al	  reviewed	  the	  CXR	  changes	  in	  848	  
HIV	  infected	  and	  1,085	  HIV-­‐uninfected	  persons	  with	  culture	  confirmed	  TB	  presenting	  to	  the	  
National	  TB	  centre	  in	  Uganda	  and	  related	  CXR	  and	  clinical	  findings	  to	  CD4	  count.	  	  They	  found	  
that	  compared	  to	  HIV	  uninfected	  TB	  patients	  there	  was	  no	  difference	  in	  the	  proportion	  of	  
HIV	  infected	  TB	  patients	  with	  cavitation	  or	  disease	  in	  the	  upper	  lung	  fields	  on	  CXR	  if	  CD4	  ≥	  
300/mm3	  and	  no	  difference	  in	  the	  proportion	  of	  smear	  positivity	  if	  CD4	  ≥	  400/mm3.	  	  By	  
comparison	  as	  CD4	  count	  declined,	  adenopathy,	  pleural	  effusion,	  miliary	  pattern	  and	  lower	  
lung	  field	  disease	  became	  more	  common;	  a	  pattern	  that	  is	  more	  closely	  associated	  with	  
progressive	  primary	  disease[95].	  	  Furthermore	  numerous	  studies	  have	  shown	  that	  median	  
CD4	  count	  at	  presentation	  of	  extra-­‐pulmonary	  (137-­‐242/mm3)	  and	  disseminated	  TB	  (40-­‐
79/mm3)	  is	  markedly	  lower	  than	  in	  pulmonary	  TB	  (250-­‐500/mm3)[96].	  



























TB Incidence by CD4 Strata and ART Status
in HIV-1 infected in Cape Town
Figure	  1.6	  	  -­‐	  TB	  incidence	  by	  CD4	  strata	  and	  ART	  status	  in	  Cape	  Town:	  	  Adapted	  from	  Badri	  et	  al	  [93]	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Lucas	  and	  Nelson	  carefully	  reviewing	  the	  histopathological	  appearance	  of	  HIV-­‐associated	  TB	  
identified	  3	  histologic	  stages	  of	  the	  cellular	  immune	  response	  that	  correlated	  well	  with	  stage	  
of	  HIV	  infection.	  	  They	  reported	  that	  in	  early	  HIV	  infection	  a	  typical,	  organized,	  
granulomatous	  response	  was	  still	  observed	  with	  CD4	  T	  cells	  clustered	  closely	  around	  
abundant	  epithelioid	  macrophages	  and	  Langhans	  giant	  cells.	  	  As	  CD4	  count	  decreased	  the	  
histological	  appearance	  became	  increasingly	  hypo-­‐reactive	  with	  fewer	  macrophages	  and	  
CD4	  T	  cells	  and	  increased	  numbers	  of	  AFB	  present	  with	  lesions	  beginning	  to	  coalesce.	  	  In	  the	  
most	  advanced	  stages	  of	  HIV/AIDS	  where	  disseminated	  disease	  was	  often	  present,	  the	  
histological	  picture	  was	  anergic.	  	  The	  characteristic	  granulomatous	  organization	  was	  now	  
absent,	  with	  very	  few	  CD4	  T	  cells,	  epithelioid	  macrophages	  or	  Langhans	  giant	  cells,	  and	  
replaced	  with	  a	  supparitive	  (neutrophil	  rich)	  necrosis	  and	  large	  numbers	  of	  AFB[96].	  	  	  
	  
The	  interaction	  between	  HIV	  and	  Mtb	  at	  a	  cellular	  level	  is	  complex	  and	  remains	  incompletely	  
understood.	  	  HIV	  infection	  leads	  to	  depletion	  of	  CD4	  cells	  however	  it	  preferentially	  infects	  
activated	  and	  memory	  CD4	  cells	  which	  has	  a	  profound	  effect	  on	  Mtb	  specific	  immune	  
responses.	  	  Peripheral	  Mtb	  specific	  CD4	  cells	  in	  individuals	  with	  latent	  TB	  have	  also	  been	  
shown	  to	  be	  selectively	  depleted	  following	  HIV	  infection[97]	  and	  there	  is	  some	  evidence	  to	  
suggest	  that	  this	  may	  be	  due	  to	  selective	  infection	  of	  IL-­‐2	  producing	  cells	  with	  a	  central	  
memory	  phenotype[98].	  	  In	  addition	  HIV	  affects	  the	  functional	  characteristics	  of	  Mtb	  specific	  
T	  cells,	  which	  may	  further	  impair	  host	  control[99].	  	  HIV	  infection	  may	  also	  directly	  impair	  
granuloma	  function;	  activated	  CD4	  cells	  within	  the	  TB	  granuloma	  may	  be	  targeted	  by	  HIV	  
leading	  to	  localized	  increases	  in	  HIV	  replication	  and	  further	  selective	  killing	  of	  T	  cells.	  	  As	  a	  
result	  subsequent	  impairment	  of	  macrophage	  function	  through	  loss	  of	  T	  cell	  help	  may	  lead	  
to	  failure	  of	  mycobacterial	  containment	  by	  the	  granuloma[99].	  	  In	  addition	  to	  the	  effect	  on	  T	  
cell	  function,	  direct	  HIV	  infection	  of	  the	  macrophage	  itself	  results	  in	  a	  dysregulated	  response	  
to	  mycobacterial	  infection	  for	  example	  being	  shown	  to	  attenuate	  the	  IL-­‐10	  response	  to	  Mtb	  
infection	  resulting	  in	  an	  exaggerated	  pro-­‐inflammatory	  response	  [100].	  	  	  
	  
Taken	  together	  we	  can	  infer	  that	  Mtb	  which	  is	  controlled	  within	  granuloma	  at	  a	  time	  of	  
greater	  immunocompetence	  may	  be	  prone	  to	  reactivation	  following	  HIV	  infection	  and	  this	  
may	  occur	  soon	  after	  acquiring	  HIV	  infection.	  	  However,	  if	  Mtb	  was	  sterilised	  at	  a	  time	  of	  
greater	  immunocompetence	  then	  disease	  can	  not	  develop	  because	  of	  reactivation	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secondary	  to	  HIV	  infection	  but	  may	  occur	  following	  reinfection	  and	  primary	  progression	  of	  
infection	  which	  would	  become	  more	  likely	  as	  immunosuppression	  progressed.	  
1.5 The	  pathology	  of	  tuberculosis	  
The	  natural	  history	  of	  TB	  is	  more	  complex	  than	  most	  bacterial	  pathogens.	  The	  incubation	  
period	  is	  prolonged	  and	  the	  outcome	  of	  infection	  variable	  depending	  upon	  both	  host	  and	  
pathogen.	  	  However,	  understanding	  this	  natural	  history	  of	  infection	  is	  critical	  to	  accurate	  
categorisation	  of	  TB	  infected	  persons,	  identification	  of	  correlates	  of	  risk	  and	  protection,	  and	  
development	  of	  novel	  interventions.	  	  In	  addition	  detailed	  knowledge	  of	  how	  infection	  
evolves	  and	  its	  pathological	  correlation	  in	  humans	  will	  assist	  interpretation	  of	  FDG-­‐PET/CT	  
scans.	  	  Much	  of	  our	  current	  understanding	  still	  arises	  from	  piecing	  together	  results	  from	  
historical	  surveys,	  autopsy	  studies	  and	  evidence	  from	  animal	  models.	  	  	  
1.5.1 Primary	  infection	  
1.5.1.1 Dissemination	  following	  primary	  infection	  
Pathological	  descriptions	  from	  autopsies	  in	  humans	  less	  than	  6	  weeks	  following	  infection	  are	  
incredibly	  rare	  and	  hence	  the	  earliest	  stages	  of	  Mtb	  infection	  and	  dissemination	  can	  only	  be	  
understood	  from	  animal	  models,	  particularly	  the	  guniea	  pig,	  rabbit	  and	  mouse	  models.	  	  
More	  recently	  improved	  understanding	  has	  been	  made	  possible	  by	  cross-­‐sectional	  imaging	  
(e.g.	  FDG-­‐PET/CT)	  in	  non-­‐human	  primates,	  which	  has	  allowed	  for	  careful	  follow-­‐up	  of	  
anatomical	  changes	  within	  animals	  over-­‐time	  without	  need	  for	  necropsy.	  	  By	  contrast,	  
events	  that	  occur	  over	  a	  period	  of	  months	  and	  years	  can	  only	  be	  adequately	  addressed	  in	  
studies	  in	  humans.	  
	  
A	  single	  droplet	  nucleus	  (probably	  containing	  1-­‐10	  bacilli)	  is	  thought	  to	  be	  able	  to	  initiate	  
infection.	  	  This	  long	  held	  belief	  has	  been	  supported	  by	  recent	  evidence	  from	  animal	  models.	  	  
Lin	  et	  al	  infecting	  macaques	  with	  34	  colony	  forming	  units	  (cfu)	  of	  Mtb	  comprised	  of	  
organisms	  with	  8	  different	  single	  nucleotide	  polymorphisms	  (SNP)	  (acting	  as	  molecular	  
barcodes)	  determined	  that	  79%	  of	  all	  granuloma	  identified	  at	  4	  weeks	  grew	  Mtb	  of	  only	  a	  
single	  SNP	  suggesting	  initiation	  by	  a	  single	  organism[101].	  	  Animal	  models	  then	  suggest	  that	  
Mtb	  deposited	  at	  the	  alveolus	  is	  initially	  taken	  up	  by	  resident	  alveolar	  macrophages,	  which	  
are	  thought	  to	  be	  maintained	  at	  a	  low	  level	  of	  activation	  non-­‐specifically	  through	  encounter	  
with	  a	  wide	  variety	  of	  inhaled	  particles[102].	  	  If	  these	  fail	  to	  eliminate	  the	  organism,	  bacillary	  
multiplication	  within	  the	  macrophage	  resulting	  in	  chemokine	  and	  cytokine	  release,	  leads	  to	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recruitment	  of	  inflammatory	  cells	  to	  the	  region.	  	  After	  an	  initial	  lag	  of	  approximately	  3	  days,	  
bacillary	  numbers	  increase	  exponentially	  over	  2-­‐3	  weeks	  before	  stabilizing.	  	  At	  this	  stage	  
macrophage	  and	  neutrophils	  are	  the	  predominant	  cell	  types	  at	  the	  site	  of	  infection,	  though	  
poorly	  organized.	  	  Immature	  resident	  dendritic	  cells	  transport	  bacillus	  via	  lymphatics	  to	  
regional	  lymph	  nodes	  and	  between	  14-­‐18	  days	  in	  the	  guinea	  pig	  model	  bacilli	  are	  culturable	  
within	  broncho-­‐tracheal	  lymph	  nodes.	  	  Spread	  into	  the	  blood	  stream,	  probably	  from	  
lymphatics,	  allows	  further	  dissemination	  to	  extra-­‐pulmonary	  sites;	  this	  is	  also	  the	  point	  at	  
which	  the	  lung	  lobes	  not	  initially	  infected	  via	  airways	  and	  distant	  to	  the	  primary	  lesion	  are	  
infected.	  	  Secondary	  lesions	  then	  develop	  at	  these	  locations	  and	  Mtb	  is	  culturable	  at	  these	  
sites	  18-­‐21	  days	  following	  infection.	  	  Around	  this	  time	  the	  animal	  becomes	  tuberculin	  
positive	  as	  a	  result	  of	  developing	  a	  mycobacteria	  specific,	  cell	  mediated	  immune	  response.	  	  
Antigen	  specific	  lymphocytes	  accumulate	  rapidly	  to	  the	  sites	  of	  infection	  while	  neutrophil	  
numbers	  drop,	  with	  CD4	  T	  cells	  playing	  major	  role	  in	  activating	  macrophages	  through	  
release	  of	  IFNγ	  and	  other	  cytokines.	  	  Over	  this	  period	  the	  granuloma	  becomes	  increasingly	  
organized	  and	  bacillary	  numbers	  begin	  to	  fall.	  	  At	  around	  4	  weeks,	  caseation	  is	  visible	  at	  the	  
centre	  of	  the	  granuloma	  and	  the	  characteristic	  architecture	  of	  the	  tuberculous	  granuloma	  is	  
present[103,	  104].	  	  During	  these	  early	  stages	  of	  development	  vascularisation	  of	  the	  
granuloma	  increases,	  mediated	  by	  vascular	  endothelial	  growth	  factor	  (VEGF),	  which	  then	  
facilitates	  cellular	  recruitment[105].	  	  With	  developments	  in	  intra-­‐vital	  microscopy	  it	  has	  now	  
become	  possible	  to	  view	  real-­‐time	  dynamic	  changes	  within	  granuloma	  at	  this	  stage.	  	  Egen	  et	  
al	  showed	  that	  at	  3-­‐4	  weeks	  after	  intravenous	  BCG	  infection,	  granulomas	  within	  the	  mouse	  
liver	  were	  dynamic	  structures	  with	  continuous	  recruitment	  of	  T	  cells,	  which	  displayed	  rapid	  
motility	  interacting	  with	  a	  more	  stable	  macrophage	  core.	  	  They	  also	  showed	  that	  efficient	  T	  
cell	  recruitment	  was	  highly	  dependent	  on	  TNFα[106].	  	  The	  granuloma	  continues	  to	  mature	  
over	  the	  following	  weeks	  with	  macrophages	  evolving	  into	  multi-­‐nucleated	  giant	  cells,	  
epithelioid	  cells	  and	  foamy	  macrophages[105].	  While	  the	  primary	  lesion	  remains	  
macroscopically	  visible,	  the	  majority	  of	  secondary	  lesions	  regress.	  	  
	  
The	  nature	  of	  primary	  lesions	  in	  humans	  has	  been	  carefully	  studied	  in	  numerous	  autopsy	  
series	  starting	  with	  Parrot	  (1876),	  Kuss	  (1898)	  and	  later	  Ghon	  (who	  became	  the	  eponym	  for	  
this	  lesion)	  and	  numerous	  others[107].	  	  Of	  particular	  note	  the	  progression	  and	  healing	  of	  the	  
primary	  lesion	  over	  time	  in	  humans	  both	  at	  autopsy	  and	  radiographically	  was	  carefully	  
documented	  by	  Sweany	  in	  his	  1941	  monograph	  “Age	  Morphology	  of	  Primary	  Tubercules”	  in	  
which	  he	  systematically	  documented	  the	  microscopic	  and	  macroscopic	  evidence	  of	  healing	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of	  the	  primary	  lesion	  in	  relation	  to	  the	  known	  ante-­‐mortem	  TB	  contact	  history	  of	  the	  patient	  
at	  hundreds	  of	  autopsies[108].	  	  The	  earliest	  changes	  described	  are	  from	  around	  6	  weeks	  
after	  infection	  at	  which	  stage	  the	  tubercule	  is	  still	  surrounded	  by	  an	  inflammatory	  exudate	  
resembling	  a	  sub-­‐acute	  bronchopneumonia,	  although	  Cannetti	  suggests	  that	  the	  extent	  of	  
this	  perifocal	  inflammation	  is	  highly	  variable	  and	  is	  sometimes	  not	  present[109].	  	  This	  
infiltration	  may	  be	  visible	  on	  CXR	  and	  is	  termed	  the	  primary	  infiltrate.	  	  This	  inflammation	  
begins	  to	  recede	  over	  a	  period	  of	  months	  and	  is	  followed	  by	  the	  laying	  down	  of	  a	  fibrous	  
capsule	  which	  continues	  to	  thicken	  over	  a	  period	  of	  years.	  	  Calcification	  is	  visible	  after	  about	  
a	  year,	  initially	  as	  a	  ring	  in	  the	  margins	  and	  by	  7	  years	  after	  initial	  infection	  has	  filled	  the	  
core.	  	  Bony	  change	  is	  not	  normally	  seen	  until	  approximately	  10	  years.	  	  At	  the	  same	  time	  
capsule	  begins	  to	  resorb	  and	  has	  all	  but	  disappeared	  by	  20	  years.	  	  	  	  
1.5.1.2 Location	  of	  primary	  site	  of	  infection	  from	  studies	  in	  humans	  
In	  humans	  the	  site	  of	  implantation	  appears	  to	  be	  related	  to	  airflow	  within	  the	  lungs	  and	  
largely	  follows	  a	  chance	  distribution.	  	  Evidence	  for	  this	  comes	  both	  from	  studies	  
documenting	  location	  of	  primary	  infiltrate	  on	  CXR	  in	  recent	  tuberculin	  converters	  and	  from	  
autopsy	  studies	  in	  which	  location	  of	  primary	  complex	  or	  nodules	  are	  documented.	  
How	  commonly	  primary	  infiltration	  is	  identified	  on	  CXR	  (which	  is	  often	  associated	  with	  hilar	  
lymphadenopathy)	  varies	  greatly	  between	  studies	  in	  part	  related	  to	  age	  of	  subjects,	  though	  
the	  caveats	  of	  CXR	  interpretation	  are	  described	  below.	  	  Gedde	  Dahl	  and	  Poulsen	  conducting	  
separate	  studies	  in	  Scandinavia	  in	  the	  1930’s/40’s	  performed	  CXR	  on	  carefully	  defined,	  
recent	  TST	  converters	  (children	  and	  young	  adults)	  and	  characterised	  the	  location	  of	  the	  
primary	  infiltrate.	  	  They	  noted	  that	  its	  location	  was	  relatively	  evenly	  distributed	  with	  a	  slight	  
weighting	  to	  middle	  and	  lower	  lung	  zones	  and	  the	  right	  lung	  (however	  cardiac	  shadow	  may	  
have	  obscured	  some	  infiltrates	  of	  the	  left	  lung)	  [110,	  111].	  	  	  
	  
The	  autopsy	  studies	  in	  which	  the	  location	  of	  primary	  lesions	  has	  been	  carefully	  documented	  
(2	  of	  which	  are	  detailed	  below)	  mirror	  the	  findings	  of	  the	  CXR	  studies	  above.	  	  In	  1917	  Opie	  
evaluated	  the	  pulmonary	  lesions	  that	  were	  present	  at	  autopsy	  in	  93	  children	  and	  in	  50	  
adults.	  	  If	  TB	  was	  identified	  in	  infants	  under	  2	  it	  was	  invariably	  the	  cause	  of	  death,	  frequently	  
massive,	  caseous	  lesions	  were	  identified	  with	  little	  tendency	  to	  heal.	  	  These	  did	  not	  affect	  
the	  apex	  of	  the	  lung	  more	  frequently	  than	  other	  parts	  and	  likely	  represent	  progression	  from	  
the	  primary	  site	  infection.	  	  From	  the	  age	  of	  2	  years	  he	  observed	  well-­‐circumscribed	  lesions	  
between	  1mm	  and	  1cm	  in	  size,	  situated	  in	  any	  part	  of	  the	  lung,	  usually	  solitary	  in	  about	  two-­‐
thirds	  of	  cases,	  and	  with	  about	  50%	  of	  the	  lesions	  in	  contact	  with	  the	  pleural	  surface.	  	  These	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focal	  lesions	  were	  often	  freshly	  caseous	  and	  accompanied	  initially	  by	  tuberculous	  lymphatic	  
lesions	  in	  early	  childhood	  and	  with	  increasing	  age	  the	  proportion	  of	  people	  exhibiting	  these	  
lesions	  increased	  (as	  did	  evidence	  of	  healing	  characterized	  by	  encapsulation,	  fibrosis	  and	  
then	  calcification)	  such	  that	  in	  the	  elderly	  they	  were	  present	  in	  100%.	  	  In	  adults	  the	  lesions	  
were	  distributed	  as	  follows,	  26%	  right	  upper	  lobe	  (RUL),	  8%	  right	  middle	  lobe	  (RML),	  23%	  
right	  lower	  lobe	  (RLL),	  21%	  left	  upper	  lobe	  (LUL),	  23%	  left	  lower	  lobe	  (LLL)	  and	  found	  to	  be	  
calcified	  in	  73%[112].	  	  Medlar	  performed	  1,225	  necropsies	  on	  adults	  who	  died	  unexpectedly	  
(i.e.	  presumed	  not	  to	  be	  as	  a	  result	  of	  TB)	  and	  described	  localisation	  of	  the	  primary	  complex	  
(single	  calcified	  parenchymal	  foci	  ≥	  2mm	  with	  and	  calcified	  lymph	  node)	  and	  lesions	  of	  early	  
disease	  (described	  later).	  	  105	  cases	  had	  evidence	  of	  a	  calcified	  primary	  complex	  and	  104	  
evidence	  of	  early	  disease.	  	  Calcified	  primary	  foci	  had	  a	  scatter	  pattern	  consistent	  with	  
chance	  airborne	  distribution,	  85%	  of	  foci	  were	  within	  1cm	  of	  pleura	  with	  only	  12%	  in	  a	  
supra-­‐clavicular	  location,	  49%	  were	  within	  right	  lung,	  40%	  were	  RUL	  or	  LUL,	  53%	  within	  RLL	  
or	  LLL	  and	  7%	  within	  RML[113]	  (figure	  1.7).	  	  
	  
The	  lobar	  distribution	  of	  primary	  lesions	  appears	  to	  relate	  to	  the	  volume	  of	  the	  lobe	  and	  
there	  is	  some	  suggestion	  that	  the	  lower	  portions	  of	  the	  lobes	  are	  preferentially	  infected;	  
these	  sites	  are	  also	  preferentially	  ventilated	  by	  inspired	  air	  in	  the	  upright	  position.	  	  It	  is	  also	  
a	  consistent	  finding	  that	  the	  primary	  foci	  of	  infection	  are	  frequently	  located	  at	  the	  periphery	  
of	  the	  lung	  most	  commonly	  close	  to	  the	  pleural	  surface.	  	  Murray	  has	  speculated	  that	  this	  
may	  relate	  to	  the	  fact	  that	  the	  peripheral	  locations	  of	  the	  lung	  are	  served	  by	  the	  straightest	  
bronchioles	  with	  the	  largest	  cross-­‐sectional	  area	  (which	  favours	  implantation	  within	  the	  
alveoli	  rather	  than	  the	  wall	  of	  a	  bronchiole)[114].	  
Figure	  1.7	  –	  Location	  of	  mineralized	  primary	  lesions:	  	  Lesions	  from	  105	  autopsy	  spatially	  represented	  on	  a	  chest	  radiograph	  
from	  Medlar	  [113]	  	  open	  circles	  =	  lower,	  closed	  	  circles	  =	  upper	  lobe.	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1.5.1.3 Bacillary	  control	  and	  disease	  progression	  
The	  relationship	  between	  evidence	  of	  tissue	  healing	  and	  presence	  of	  viable	  bacilli	  was	  
determined	  early	  on	  by	  researchers.	  	  Opie	  and	  Aronson	  in	  1927	  performed	  autopsies	  on	  169	  
adults	  (dying	  of	  causes	  other	  than	  tuberculosis)	  and	  examined	  304	  lung	  lesions,	  performing	  
guinea	  pig	  inoculation	  experiments	  on	  the	  majority	  of	  these.	  	  They	  determined	  that	  viable	  
bacilli	  were	  most	  frequent	  in	  lesions	  that	  still	  had	  evidence	  of	  caseation	  and	  became	  
increasingly	  less	  common	  if	  lesions	  had	  evidence	  of	  fibrosis	  or	  calcification[115].	  	  Lin	  et	  al	  
have	  recently	  provided	  further	  insight	  into	  the	  relationship	  between	  granuloma	  and	  bacillary	  
viability.	  	  Infecting	  macaques	  with	  25	  cfu	  of	  Mtb	  bronchoscopically	  the	  animals	  were	  then	  
followed	  up	  with	  FDG-­‐PET/CT	  and	  then	  necropsy	  was	  performed	  at	  either	  4	  weeks,	  11	  weeks	  
or	  after	  6	  months	  when	  animals	  were	  classified	  either	  as	  having	  a	  latent	  infection	  or	  active	  
infection	  on	  the	  basis	  of	  “clinical”	  signs	  (e.g.	  weight	  loss,	  abnormal	  radiography	  or	  positive	  
culture)[101].	  	  Median	  cfu	  per	  granuloma	  at	  4	  weeks	  was	  1.8x104,	  but	  by	  11	  weeks	  (once	  the	  
acquired	  immune	  response	  is	  established)	  median	  cfu	  per	  granuloma	  had	  fallen	  significantly	  
(by	  15	  fold)	  and	  a	  number	  of	  lesions	  were	  already	  sterile.	  	  After	  6	  months	  median	  cfu	  had	  
fallen	  further	  still	  (by	  10-­‐100	  fold)	  in	  both	  active	  and	  latent	  monkeys	  and	  a	  variety	  of	  lesions	  
types	  (including	  those	  that	  were	  completely	  sterile)	  were	  present	  in	  both	  groups.	  	  However,	  
evidence	  of	  TB	  pneumonia	  was	  only	  present	  in	  monkeys	  with	  active	  disease.	  	  The	  authors	  
also	  measured	  chromosomal	  equivalents	  (CEQ)	  within	  the	  granuloma,	  which	  is	  reflective	  of	  
the	  number	  of	  viable	  and	  non-­‐viable	  bacilli,	  and	  found	  this	  to	  be	  relatively	  stable	  at	  around	  
105	  CEQ/granuloma,	  irrespective	  of	  cfu	  or	  time	  since	  infection.	  	  Even	  treatment	  with	  
isoniazid,	  which	  led	  to	  significant	  fall	  in	  cfu/granuloma,	  had	  little	  effect	  on	  CEQ/granuloma.	  	  
By	  creating	  a	  ratio	  of	  cfu/CEQ	  they	  were	  able	  to	  evaluate	  proportion	  of	  viable	  bacilli	  (as	  
determined	  by	  culturability)	  within	  each	  lesion	  type.	  	  Viability	  within	  areas	  of	  TB	  pneumonia	  
was	  found	  to	  be	  maximal	  with	  cfu/CEQ	  approximately	  1,	  whereas	  cfu/CEQ	  ratio	  was	  lower	  
within	  caseous	  lesions	  and	  lowest	  within	  fibrocalcific	  lesions.	  	  	  The	  authors	  concluded	  that	  
granulomas,	  at	  least	  in	  macaques,	  had	  a	  maximum	  “carrying	  capacity”	  of	  organism	  (around	  
105).	  	  They	  also	  speculated	  that	  if	  bacillary	  numbers	  increased	  beyond	  this,	  secondary	  
granulomas	  would	  need	  to	  arise	  to	  contain	  the	  bacilli	  (as	  is	  often	  seen)	  but	  if	  increase	  in	  
numbers	  was	  too	  rapid	  or	  excessive	  that	  this	  may	  result	  in	  progression	  to	  TB	  pneumonia.	  	  
They	  also	  concluded	  that	  this	  failure	  of	  control	  occurred	  at	  a	  granuloma	  level,	  as	  monkeys	  
with	  active	  TB	  had	  a	  distribution	  of	  granuloma	  not	  dissimilar	  to	  that	  found	  in	  the	  latent	  
monkeys.	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1.5.2 Post-­‐primary	  pulmonary	  disease	  in	  humans	  
Understanding	  of	  the	  critical	  events	  that	  lead	  to	  the	  failure	  of	  Mtb	  containment	  following	  
primary	  infection	  and	  the	  progression	  of	  post-­‐primary	  TB	  in	  humans	  is	  very	  limited.	  	  Hunter	  
has	  attempted	  to	  describe	  the	  progressive	  pathological	  changes	  of	  post-­‐primary	  TB	  seen	  at	  
autopsy	  as	  well	  as	  on	  evaluation	  of	  surgical	  specimens	  and	  from	  historical	  pathology	  slides.	  	  
He	  then	  performed	  extensive	  literature	  search	  to	  compare	  and	  validate	  these	  findings	  to	  
that	  of	  earlier	  investigators.	  	  He	  concluded	  that	  one	  of	  the	  earliest	  manifestations	  of	  post-­‐
primary	  disease	  in	  humans	  was	  the	  accumulation	  of	  foamy	  macrophages	  containing	  
numerous	  AFB	  within	  the	  alveolus.	  	  This	  then	  progresses	  endobronchially,	  with	  the	  foamy	  
macrophages,	  the	  recruited	  leukocytes	  and	  the	  fibrin	  and	  lipid-­‐rich,	  cellular	  debris	  
accumulating	  within	  alveoli	  and	  bronchioles.	  	  The	  endobronchial	  spread	  can	  be	  remarkably	  
slow	  and	  often	  halts	  and	  heals	  leaving	  characteristic	  fibrotic	  scaring	  within	  the	  lungs.	  	  In	  
addition,	  Hunter	  identified	  endobronchial	  obstruction	  as	  one	  of	  the	  critical	  points	  in	  the	  
pathogenesis	  of	  disease	  leading	  to	  development	  of	  a	  lipid-­‐rich	  pneumonia	  which	  can	  then	  
progress	  to	  caseous	  pneumonia,	  necrosis	  and	  eventually	  cavitation	  as	  the	  soft	  friable	  lung	  is	  
expectorated.	  	  These	  later	  stages	  are	  accompanied	  by	  large	  increases	  in	  bacillary	  numbers	  as	  
conditions	  for	  growth	  become	  more	  favourable[116].	  	  CT	  imaging	  corroborates	  some	  of	  
these	  findings	  although	  CT	  studies	  are	  usually	  opportunistic,	  related	  to	  clinical	  need	  rather	  
than	  systematic.	  	  The	  earliest	  changes	  on	  CT	  have	  been	  described	  as	  2-­‐4	  mm	  centrilobular	  
nodules,	  which	  pathological	  correlation	  shows	  relates	  to	  caseous	  necrosis	  within	  the	  
bronchioles,	  as	  well	  as	  linear	  branching	  representing	  cellular	  infiltration	  of	  the	  airways	  and	  
endobronchial	  spread	  (giving	  a	  tree-­‐in-­‐bud	  appearance).	  	  These	  smaller	  lesions	  then	  
!"#$# %#
Figure	  1.8	  –	  Location	  of	  minimal	  post-­‐primary	  lesions:	  	  Lesions	  found	  in	  55	  autopsies	  spatially	  represented	  on	  a	  chest	  
radiograph	  from	  Medlar	  [113]	  	  
Reprinted	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coalesce	  to	  form	  larger	  5-­‐8mm	  hazy,	  ill-­‐defined	  nodules	  and	  larger	  areas	  of	  consolidation	  
with	  finally,	  small	  areas	  of	  cavitation	  arising	  at	  the	  centre[117].	  	  	  	  	  	  	  	  	  	  	  	  	  
1.5.2.1 Location	  of	  post-­‐primary	  TB	  within	  the	  lung	  
In	  contrast	  to	  the	  site	  of	  primary	  infection	  it	  has	  been	  understood	  since	  at	  least	  the	  18th	  
century	  from	  autopsy	  studies	  that	  tuberculosis	  disease	  in	  adults	  typically	  presents	  in	  the	  
upper	  parts	  of	  the	  lung[118].	  	  With	  the	  development	  of	  CXR,	  researchers	  and	  clinicians	  were	  
able	  to	  identify	  the	  early	  sites	  of	  TB	  disease	  and	  a	  number	  of	  terms	  were	  used	  to	  describe	  
these;	  Assman	  focus,	  Simon	  focus	  and	  Frühinfiltrat	  (spring	  infiltrates)	  being	  the	  most	  
common.	  	  One	  of	  the	  first	  attempts	  to	  document	  the	  evolution	  of	  disease	  radiographically	  
was	  conducted	  by	  Malmros	  and	  Hedvall	  who	  followed	  up	  3,336	  student	  nurses	  entering	  
clinical	  practice	  into	  a	  hospital	  in	  Sweden	  from	  1930,	  a	  setting	  with	  extremely	  high	  annual	  
rates	  of	  infection	  and	  high	  incidence	  of	  disease.	  	  All	  students	  had	  tuberculin	  testing	  
performed	  at	  entry	  and	  those	  that	  were	  negative	  were	  retested	  annually.	  	  In	  addition,	  all	  
students	  had	  regular	  CXR	  performed	  at	  short	  intervals	  and	  those	  with	  suspected	  
tuberculosis	  had	  close	  follow	  up	  over	  a	  period	  of	  years[119].	  	  From	  this	  cohort	  133	  cases	  of	  
“indisputably	  active	  tuberculosis”	  were	  identified,	  99	  had	  pulmonary	  tuberculosis	  and	  of	  
these	  52	  had	  a	  previously	  normal	  CXR	  available	  allowing	  the	  authors	  to	  give	  an	  account	  of	  
the	  first	  localisation	  of	  disease	  within	  the	  lungs.	  	  In	  those	  that	  were	  tuberculin	  convertors	  
initial	  foci	  appeared	  on	  average	  11.5	  months	  post	  conversion.	  	  The	  initial	  focus	  of	  pulmonary	  
tuberculosis	  was	  found	  to	  begin	  in	  the	  upper	  portion	  of	  the	  lung	  usually	  within	  the	  supra-­‐
clavicular	  region	  (apical)	  or	  infra-­‐clavicularly	  around	  the	  1st	  intercostal	  space	  (subapical)	  
although	  the	  initial	  focus	  of	  disease	  did	  not	  involve	  these	  regions	  in	  11%	  of	  cases.	  	  In	  those	  
that	  had	  an	  initial	  normal	  CXR	  the	  subsequent	  abnormalities	  were	  bilateral	  in	  only	  15%.	  	  
They	  went	  on	  to	  describe	  the	  initial	  abnormalities	  as	  follows:	  
	  
“The	  initial	  changes	  most	  frequently	  consist	  of	  minute	  and	  small	  cloudy	  spots,	  
occurring	  singly	  or	  in	  groups	  (initial	  foci).	  	  These	  spots	  have	  a	  progressive	  tendency	  
and	  in	  general	  spread	  very	  slowly	  in	  an	  apico-­‐caudal	  direction	  ,	  new	  spots	  arising	  
lower	  down	  the	  lung	  or	  in	  the	  other	  lung.	  	  Occasionally,	  however,	  the	  
dissemination	  takes	  place	  more	  rapidly,	  the	  spots	  then	  becoming	  fused	  into	  
infiltrations	  which	  may	  liquefy	  and	  give	  rise	  to	  bronchogenic	  spread”	  	  	  
	  
-­‐	  Malmros	  and	  Hedvall	  1940	  [119]	  	  
	  
The	  distribution	  of	  early	  post-­‐primary	  disease	  has	  been	  carefully	  documented	  at	  autopsy.	  
Medlar	  noted	  this	  minimal	  disease	  was	  evenly	  distributed	  between	  right	  and	  left	  lung	  and	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present	  bilaterally	  in	  19%.	  	  84%	  of	  minimal	  disease	  was	  in	  the	  upper	  lobes	  and	  most	  
commonly	  dorsally	  located	  in	  the	  upper	  half	  of	  the	  lobe	  (figure	  1.8)[113].	  	  Opie	  also	  
described	  post-­‐primary	  lesions	  apically,	  tending	  to	  spread	  diffusely	  and	  noted	  these	  were	  
not	  present	  before	  the	  age	  of	  11	  but	  became	  increasingly	  common	  in	  adolescence	  and	  
adulthood	  and	  often	  had	  evidence	  of	  partial	  or	  complete	  healing[112].	  
1.5.2.2 Apical	  localization	  
The	  apico-­‐dorsal	  localization	  of	  post-­‐primary	  tuberculosis	  is	  one	  of	  the	  most	  intriguing	  and	  
least	  understood	  features	  of	  the	  disease.	  	  As	  described	  above	  the	  primary	  site	  of	  infection	  is	  
no	  more	  likely	  to	  be	  in	  the	  lung	  apices	  than	  anywhere	  else	  within	  the	  lung.	  	  Dissemination	  
throughout	  the	  lungs	  occurs	  via	  haematogenous	  spread	  around	  the	  3rd	  week	  of	  infection	  and	  
unlike	  primary	  lesions	  the	  secondary	  lesions	  that	  arise	  often	  regress	  and	  are	  not	  apparent	  
macroscopically.	  	  Apical	  localization	  of	  disease	  is	  undoubtedly	  reciprocally	  related	  to	  the	  
effect	  of	  gravity	  as	  while	  disease	  in	  humans	  commonly	  initiates	  at	  this	  location,	  in	  cows	  
disease	  is	  most	  common	  at	  the	  highest	  point	  of	  the	  lungs	  dorsally,	  while	  bats	  have	  been	  
have	  been	  shown	  to	  develop	  disease	  at	  the	  bases.	  	  In	  addition	  it	  has	  been	  demonstrated	  
that	  maintaining	  a	  rabbit	  in	  an	  upright	  position	  for	  up	  to	  11	  hours	  a	  day	  causes	  TB	  to	  develop	  
at	  the	  apices	  rather	  than	  dorso-­‐basal	  region,	  as	  usually	  occurs[120,	  121].	  	  	  
	  
The	  2	  most	  striking	  effects	  of	  gravity	  on	  the	  highest	  point	  of	  the	  lung	  are	  elevated	  oxygen	  
tension	  and	  very	  poor	  perfusion	  relative	  to	  the	  rest	  of	  the	  lungs	  (pulmonary	  artery	  pressure	  
is	  only	  one	  fifth	  that	  of	  systemic	  circulation).	  	  This	  has	  led	  to	  competing	  theories	  about	  the	  
explanation	  for	  apical	  localisation,	  however	  it	  is	  possible	  that	  both	  effects	  play	  a	  role.	  	  Peak	  
oxygen	  tension	  is	  a	  commonly	  favoured	  explanation	  and	  certainly	  an	  oxygen	  rich	  
environment	  facilitates	  growth	  of	  Mtb.	  	  However,	  bacilli	  are	  generally	  thought	  to	  be	  
contained	  within	  granuloma,	  which	  are	  known	  to	  be	  profoundly	  hypoxic	  and	  this	  may	  not	  be	  
affected	  by	  alveolar	  oxygen	  tension[122].	  	  In	  addition,	  people	  that	  live	  at	  high	  altitude	  in	  
Peru	  have	  been	  found	  have	  similar	  rates	  of	  TB	  to	  those	  that	  live	  in	  lowland	  regions.	  	  Finally	  
apical	  localization	  is	  observed	  in	  a	  number	  of	  other	  non-­‐infectious	  conditions	  such	  as	  
progressive	  massive	  fibrosis,	  ankylosing	  spondylitis	  where	  a	  role	  for	  oxygen	  tension	  is	  harder	  
to	  understand.	  	  A	  second	  explanation	  relates	  to	  lymphatic	  clearance.	  	  It	  has	  been	  speculated	  
that	  areas	  of	  the	  lung	  where	  this	  is	  poorest	  will	  result	  in	  ineffective	  clearance	  of	  antigen	  
resulting	  in	  more	  robust	  and	  potentially	  more	  pro-­‐inflammatory	  immune	  response	  at	  that	  
site.	  	  Lymphatic	  flow	  is	  proportional	  to	  microvascular	  pressure	  and	  is	  greatly	  reduced	  at	  the	  
apex.	  	  Lymphatic	  flow	  has	  been	  shown	  to	  be	  at	  least	  4	  fold	  slower	  at	  the	  apex	  than	  the	  lung	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base.	  	  In	  addition	  flow	  is	  assisted	  by	  respiration	  with	  the	  movement	  of	  the	  anterior	  chest	  
wall,	  which	  is	  more	  minimal	  apically.	  	  As	  a	  result	  one	  would	  expect	  the	  dorsal	  apical	  region,	  
where	  TB	  most	  commonly	  arises,	  to	  have	  the	  most	  sluggish	  lymphatic	  flow.	  	  This	  argument	  
also	  provides	  better	  explanation	  for	  the	  apical	  localization	  of	  pneumoconiosis	  and	  is	  also	  
said	  to	  support	  the	  anecdotal	  observation	  that	  TB	  is	  more	  common	  in	  those	  with	  pulmonary	  
stenosis	  versus	  mitral	  stenosis	  and	  provides	  physiological	  credence	  to	  the	  suggestion	  that	  
supine	  bed	  rest,	  a	  common	  part	  of	  sanatoria	  care,	  may	  facilitate	  recovery	  from	  TB[114].	  
1.5.3 Other	  patterns	  of	  tuberculosis	  disease	  that	  may	  be	  present	  within	  the	  
lung	  	  
1.5.3.1 Miliary	  tuberculosis	  
A	  miliary	  pattern	  of	  disease	  can	  occur	  following	  massive	  haematogenous	  dissemination	  of	  
Mtb	  and	  most	  likely	  occurs	  when	  a	  source	  of	  infection	  has	  persistent	  access	  to	  the	  
vasculature	  rather	  than	  following	  the	  transient	  bacilaemia	  that	  occurs	  to	  allow	  initial	  
dissemination	  (e.g.	  erosion	  of	  a	  tuberculous	  focus	  into	  the	  blood	  stream	  or	  focus	  of	  infection	  
with	  the	  vasculature).	  	  Miliary	  disease	  may	  occur	  as	  a	  part	  of	  primary	  progressive	  disease	  or	  
later	  as	  a	  part	  of	  post	  primary	  disease.	  	  The	  characteristic	  finding	  on	  imaging	  or	  autopsy	  are	  
of	  numerous	  nodules	  2-­‐3	  mm	  in	  size	  (similar	  to	  millet	  seeds)	  evenly	  distributed	  throughout	  
the	  lung	  fields	  and	  other	  organs,	  especially	  those	  that	  receive	  high	  blood	  flow.	  	  Miliary	  
tuberculosis	  occurs	  in	  approximately	  1-­‐2%	  of	  TB	  cases	  in	  immunocompetent	  adults	  but	  at	  
higher	  frequencies	  in	  children	  and	  the	  immunocompromised[123].	  
1.5.3.2 Tuberculoma	  
Tuberculoma	  describes	  a	  well-­‐circumscribed	  rounded	  lesion	  commonly	  between	  1	  and	  5	  
centimetres	  (cm)	  diameter.	  	  They	  are	  often	  single	  but	  can	  be	  multiple	  and	  are	  usually	  found	  
incidentally	  on	  CXR	  in	  asymptomatic	  persons	  where	  it	  can	  resemble	  a	  tumour.	  	  It	  probably	  
does	  not	  represent	  a	  single	  granuloma	  increasing	  in	  size	  but	  more	  likely	  a	  localised	  area	  of	  
tuberculous	  pneumonia	  that	  has	  ceased	  progression	  and	  encapsulated	  or	  a	  small	  cavitary	  
lesion	  that	  has	  healed	  following	  bronchial	  obstruction[124].	  	  	  	  
1.6 FDG-­‐PET/CT	  imaging	  
1.6.1 FDG-­‐PET/CT	  	  
PET/CT	  is	  a	  non-­‐invasive	  medical	  imaging	  technique	  that	  not	  only	  provides	  detailed	  
anatomical	  information	  but	  also	  allows	  functional	  assessments	  through	  the	  monitoring	  of	  
Chapter	  1	  -­‐	  Introduction	  
	   56	  
the	  distribution	  and	  anatomical	  localisation	  of	  positron-­‐emitting	  radiopharmaceutical	  
tracers.	  	  The	  most	  commonly	  used	  tracer,	  18F-­‐fluoro-­‐2-­‐deoxy-­‐glucose	  (FDG),	  is	  a	  glucose	  
analogue	  with	  the	  oxygen	  molecule	  at	  the	  C-­‐2	  position	  of	  glucose	  (C6H12O6)	  replaced	  with	  
18-­‐Fluorine	  (18F).	  	  18F	  is	  a	  radioisotope	  of	  Fluorine	  and	  is	  unstable	  with	  a	  half-­‐life	  of	  109.8	  
minutes	  and	  decays	  by	  the	  emission	  of	  positrons	  (positively	  charged	  antielectrons	  released	  
from	  protons	  to	  form	  neutrons)	  to	  stable	  18-­‐oxygen.	  	  
	  
FDG	  is	  taken	  up	  by	  cells	  in	  the	  same	  manner	  as	  glucose,	  via	  glucose	  transport	  proteins	  
(GLUT).	  	  Once	  within	  the	  cell	  FDG,	  like	  glucose,	  it	  is	  phosphorylated	  by	  hexakinases	  but	  
unlike	  glucose	  is	  unable	  to	  enter	  the	  glycolysis	  pathway	  and	  is	  effectively	  “trapped”	  within	  
the	  cell.	  	  This	  occurs	  preferentially	  in	  cells	  with	  increased	  metabolic	  activity	  in	  which	  GLUT	  
and	  hexakinases	  have	  been	  up-­‐regulated	  through	  greater	  requirement	  for	  glycolysis.	  	  The	  
positrons	  emitted,	  annihilate	  with	  surrounding	  electrons	  (typically	  only	  having	  travelled	  1-­‐3	  
mm).	  	  A	  single	  annihilation	  event	  results	  in	  the	  emission	  of	  2	  gamma	  ray	  photons	  in	  opposite	  
directions,	  approximately	  180	  degrees	  to	  each	  other.	  	  These	  gamma	  rays	  are	  then	  localised	  
and	  quantified	  by	  PET	  camera	  surrounding	  the	  patient	  circumferentially,	  typically	  1-­‐2	  hours	  
follow	  intravenous	  administration	  of	  FDG.	  	  PET	  imaging	  is	  followed	  in	  quick	  succession	  
(usually	  sequentially)	  by	  CT	  imaging	  which	  allow	  generation	  of	  detailed	  3-­‐dimensional	  (3D)	  
X-­‐ray	  images	  through	  reconstruction	  of	  multiple	  2D	  slices.	  	  Co-­‐registration	  of	  these	  images	  
allows	  anatomical	  localisation	  of	  sites	  of	  metabolic	  activity.	  	  The	  FDG	  activity	  is	  often	  just	  
evaluated	  visually	  in	  comparison	  to	  physiological	  uptake	  of	  surrounding	  organs	  and	  
structures	  but	  can	  then	  be	  converted	  into	  a	  standardized	  uptake	  value	  (SUV)	  for	  objective	  
comparisons	  using	  the	  following	  formula;	  	  
	  
SUV	  =	  Tissue	  radioactivity	  concentration/(Injected	  radioactivity(corrected	  for	  time)/weight)	  
	  
Essentially	  SUV	  represents	  the	  ratio	  of,	  concentration	  of	  radioactivity	  found	  at	  a	  certain	  time	  
point	  in	  a	  selected	  region	  of	  interest	  within	  the	  body	  (derived	  from	  the	  image)	  and	  the	  
injected	  radioactivity	  concentration	  normalised	  for	  body	  weight	  and	  corrected	  for	  time	  since	  
injection.	  	  Maximal	  radioactivity	  in	  the	  region	  of	  interest	  is	  most	  commonly	  used	  and	  termed	  
SUVmax,	  but	  mean	  and	  peak	  values	  can	  also	  be	  used.	  	  The	  sensitivity	  of	  PET	  is	  dependent	  on	  
the	  size	  of	  the	  abnormality	  as	  well	  as	  the	  intensity	  of	  uptake	  of	  the	  tracer.	  	  In	  practice	  lesions	  
less	  than	  1	  cm	  in	  size	  have	  activity	  underestimated	  and	  may	  be	  falsely	  negative	  on	  PET	  scan	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due	  to	  a	  phenomenon	  known	  as	  the	  partial	  volume	  effect,	  although	  it	  is	  possible	  to	  develop	  
algorithms	  to	  correct	  for	  this.	  
	  
1.6.2 Cellular	  uptake	  of	  FDG	  in	  tuberculosis	  
The	  primary	  use	  of	  FDG-­‐PET/CT	  imaging	  is	  in	  oncology	  as	  tumour	  cells	  demonstrate	  increase	  
FDG	  uptake.	  	  However	  inflammatory	  and	  immune	  cells,	  especially	  if	  activated,	  also	  have	  
considerable	  requirement	  for	  glucose.	  	  As	  a	  result	  FDG	  uptake	  is	  also	  elevated	  at	  sites	  of	  
infectious	  and	  non-­‐infectious	  inflammatory	  pathology.	  	  
	  
In	  animal	  models	  specific	  cellular	  localization	  of	  FDG	  can	  be	  determined	  at	  necropsy	  (if	  FDG	  
is	  injected	  into	  the	  animal	  just	  prior	  to	  being	  euthanized)	  by	  a	  process	  of	  autoradiography	  
(as	  β-­‐particles	  (like	  positrons)	  and	  gamma	  rays	  will	  develop	  photographic	  film	  similarly	  to	  X-­‐
Ray).	  	  Kaim	  et	  al	  performing	  this	  technique	  in	  experimental	  soft	  tissue	  abscesses	  in	  rats	  
showed	  that	  in	  acute	  stages	  of	  infection	  considerable	  FDG	  uptake	  was	  found	  within	  the	  
neutrophil	  layer	  of	  the	  abscess	  and	  in	  chronic	  infection	  even	  higher	  uptake	  occurred	  in	  the	  
macrophages	  layer.	  	  Of	  note	  only	  limited	  activity	  (8-­‐fold	  less	  than	  macrophage	  layer)	  was	  
detected	  within	  fibroblast	  enriched	  granulation	  tissue	  [125].	  	  
	  
Evidence	  that	  FDG	  might	  be	  preferentially	  taken	  up	  primarily	  by	  neutrophils	  and	  
macrophages	  in	  humans	  with	  TB	  comes	  from	  Mamede	  et	  al.	  	  In	  this	  study	  patients	  
undergoing	  thoracotomy	  and	  surgical	  resection	  of	  pulmonary	  lesions	  in	  Japan	  had	  prior	  FDG-­‐
PET/CT.	  	  In	  10	  patients,	  lesions	  were	  subsequently	  found	  to	  relate	  to	  TB	  with	  a	  median	  
SUVmax	  of	  6.6.	  	  Immunohistochemical	  staining	  for	  Glucose	  transport	  protein	  -­‐1	  (Glut-­‐1)	  and	  
hexokinase	  II	  (HKII)	  (required	  for	  cellular	  trapping	  to	  FDG)	  was	  performed	  on	  the	  resected	  
lesions.	  	  9/10	  TB	  lesions	  stained	  positive	  for	  Glut-­‐1	  and	  9/10	  for	  HKII	  with	  Glut-­‐1	  and	  HKII	  
staining	  both	  found	  to	  localise	  to	  neutrophils	  and	  macrophages	  within	  necrotizing	  
granuloma[126].	  	  	  	  
1.6.3 FDG-­‐PET/CT	  in	  clinical	  studies	  of	  tuberculosis	  	  
Increased	  FDG	  uptake	  within	  active	  tuberculosis	  lesions	  is	  well	  described	  and	  FDG-­‐PET/CT	  is	  
often	  diagnostically	  useful	  in	  localising	  site	  of	  disease	  [127-­‐129].	  	  As	  lesions	  heal	  (either	  
following	  treatment	  of	  as	  part	  of	  their	  natural	  history),	  their	  cellular	  make-­‐up	  alters	  as	  
activated	  immunoregulatory	  and	  effector	  cells	  are	  replaced	  by	  scar	  tissue.	  As	  a	  result,	  we	  
can	  expect	  that	  the	  metabolic	  activity	  will	  be	  different	  between	  active	  cellular	  lesions	  and	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healed	  lesions	  that	  are	  fibrosed	  or	  mineralized.	  	  Kim	  et	  al	  have	  demonstrated	  differences	  in	  
histology	  and	  FDG	  uptake	  in	  surgically	  excised	  culture	  or	  polymerase	  chain	  reaction	  (PCR)	  
positive	  tuberculoma	  compared	  with	  culture/PCR	  negative	  tuberculoma.	  	  The	  former	  group	  
displayed	  elevated	  FDG	  uptake	  (median	  SUVmax	  =	  2.3)	  and	  histology	  showed	  granuloma	  
with	  numerous	  cells	  in	  the	  lesion	  periphery,	  whereas	  the	  latter	  displayed	  low	  FDG	  uptake	  
(median	  SUV	  max	  =	  0.79)	  and	  histology	  showed	  granuloma	  surrounded	  by	  dense	  fibrous	  
tissue[130].	  
	  
Treatment	  accelerates	  healing	  and	  FDG	  uptake	  has	  been	  shown	  to	  normalize	  by	  the	  end	  of	  
treatment	  in	  a	  number	  of	  case	  series[131-­‐133].	  	  Martinez	  et	  al	  looked	  at	  the	  early	  effects	  of	  
TB	  treatment	  on	  SUV	  uptake	  in	  20	  cases;	  FDG	  uptake	  reduced	  by	  a	  median	  31%	  after	  1	  
month	  TB	  treatment	  the	  one	  patient	  that	  showed	  no	  improvement	  in	  FDG	  uptake	  remained	  
smear	  positive	  at	  3	  months[134].	  	  
	  
Abnormal	  FDG	  uptake	  is	  seen	  within	  anatomically	  normal	  mediastinal	  and	  hilar	  lymph	  nodes	  
in	  individuals	  with	  active	  tuberculosis.	  	  Sathekge	  et	  al	  identified	  18	  lymph	  node	  (LN)	  sites	  in	  9	  
TB	  patients	  demonstrating	  abnormal	  FDG	  accumulation	  -­‐	  mean	  SUVmax	  6.3(range	  3.4-­‐9.2)	  
[135].	  	  In	  5	  of	  these	  patients	  no	  abnormalities	  were	  picked	  up	  on	  CT.	  	  Shora	  et	  al	  identified	  
28	  LN	  sites	  in	  14	  TB	  patients	  that	  demonstrated	  abnormal	  FDG	  accumulation	  (SUVpeak	  
range	  2.7-­‐7.7)[136].	  	  Of	  particular	  interest	  Ghesani	  et	  al	  have	  recently	  shown	  that	  4	  of	  5	  
recent	  contacts	  of	  TB	  with	  positive	  Quantiferon	  or	  TST	  had	  abnormal	  FDG	  uptake	  within	  
mediastinal	  nodes,	  3	  of	  which	  improved	  following	  IPT	  and	  furthermore	  there	  was	  a	  strong	  
positive	  correlation	  with	  between	  Quantiferon	  result	  and	  SUV[137].	  
1.6.4 FDG-­‐PET/CT	  in	  animal	  models	  
PET/CT	  has	  been	  used	  as	  a	  method	  to	  serially	  evaluate	  evolving	  tuberculous	  pathology	  both	  
prior	  to	  and	  during	  treatment	  in	  the	  rabbit,	  marmoset	  and	  macaque	  models[138-­‐140].	  	  In	  
the	  macaque	  model	  granulomas	  (as	  nodules)	  appeared	  on	  PET/CT	  as	  early	  as	  2	  weeks	  
following	  bronchoscopic	  administration	  of	  200-­‐400	  cfu	  of	  Mtb	  with	  99%	  of	  granuloma	  
having	  visible	  FDG	  uptake	  by	  8	  weeks.	  	  The	  authors	  followed	  a	  random	  sample	  of	  
granulomas	  over	  time	  and	  demonstrated	  that	  granulomas	  behaved	  independently	  with	  
disease	  outcome	  dependent	  on	  only	  a	  subset	  of	  lesions.	  	  Areas	  of	  consolidation	  (TB	  
pneumonia)	  could	  either	  arise	  from	  a	  single	  lesion	  or	  from	  the	  coalescence	  of	  multiple	  
lesions,	  corresponding	  to	  histological	  findings,	  and	  appeared	  to	  contribute	  substantially	  to	  
the	  development	  of	  active	  TB.	  	  Areas	  of	  necrosis	  within	  TB	  pneumonia	  or	  granuloma	  were	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evidenced	  by	  a	  characteristic	  pattern	  of	  lack	  of	  central	  FDG	  uptake.	  	  At	  necropsy	  cfu	  within	  a	  
lesion	  correlated	  with	  its	  size	  but	  not	  SUV.	  	  Following	  2	  months	  of	  treatment	  with	  isoniazid	  
(INH),	  rifampicin	  (RIF)	  or	  a	  combination	  of	  isoniazid,	  rifampicin,	  pyrazinamide	  and	  
ethambutol	  (HRZE)	  total	  SUV	  reduced	  influenced	  largely	  by	  reduction	  in	  SUV	  in	  regions	  of	  TB	  
pneumonia.	  	  However,	  at	  the	  level	  of	  individual	  granuloma	  INH	  treated	  animals	  were	  more	  
variable	  with	  some	  granuloma	  increasing	  in	  SUV	  while	  others	  reduced,	  this	  occurred	  to	  a	  
lesser	  extent	  in	  animals	  treated	  with	  RIF	  where	  the	  majority	  of	  granuloma	  reduced	  in	  SUV	  
with	  treatment[140].	  	  	  
	  
These	  findings	  are	  consistent	  with	  the	  interpretation	  that	  SUV	  relates	  to	  presence	  of	  
metabolically	  active	  cells	  and	  may	  reflect	  their	  accumulation	  within	  a	  granuloma	  or	  region	  of	  
consolidation	  as	  bacillary	  numbers	  increase	  or	  reflect	  the	  presence	  of	  cells	  such	  as	  activated	  
macrophages	  that	  are	  able	  to	  adequately	  control	  numbers	  (especially	  if	  scans	  are	  performed	  
in	  the	  early	  stages	  of	  infection).	  	  Treatment	  particularly	  with	  INH	  may	  result	  in	  antigen	  
release,	  which	  may	  result	  in	  inflammation	  and	  cellular	  recruitment	  accounting	  for	  increase	  
SUV	  uptake.	  
1.6.5 FDG-­‐PET/CT	  in	  asymptomatic	  HIV	  infected	  and	  uninfected	  individuals	  	  
The	  degree	  to	  which	  abnormal	  FDG	  uptake	  on	  PET	  is	  present	  in	  an	  asymptomatic	  population	  
both	  HIV	  infected	  and	  uninfected	  individuals	  has	  also	  been	  well	  established.	  	  Over	  40,000	  
healthy	  (HIV	  uninfected)	  individuals	  have	  been	  screened	  in	  Japan	  with	  whole	  body	  FDG-­‐PET	  
[141-­‐144].	  	  Although	  the	  rate	  of	  abnormal	  FDG	  uptake	  anywhere	  in	  the	  body	  is	  
approximately	  10%[141],	  abnormalities	  are	  most	  common	  in	  organs	  outside	  the	  thorax,	  with	  
the	  thyroid	  and	  lower	  gastrointestinal	  tract	  being	  most	  frequently	  affected[141].	  	  In	  a	  study	  
where	  2,911	  asymptomatic	  HIV	  uninfected	  individuals	  40	  years	  and	  older	  were	  screened	  by	  
FDG-­‐PET,	  only	  26	  (0.9%)	  had	  any	  focal	  FDG	  uptake	  within	  the	  lungs	  [144].	  	  Although	  FDG	  
uptake	  within	  hilar	  LN	  is	  not	  uncommon,	  uptake	  greater	  than	  the	  background	  mediastinal	  
blood	  pool	  is	  uncommon.	  	  In	  a	  study	  assessing	  FDG	  uptake	  in	  hilar	  LN	  of	  179	  healthy	  HIV	  
uninfected	  individuals	  only	  1	  (0.6%)	  had	  FDG	  uptake	  within	  hilar	  LN	  greater	  than	  background	  
mediastinal	  blood	  pool[145].	  	  	  	  	  	  	  	  
	  
Several	  studies	  have	  established	  patterns	  of	  FDG	  uptake	  in	  ART	  naive	  and	  treated	  HIV	  
infected	  individuals	  [146-­‐151].	  	  A	  distinct	  pattern	  of	  LN	  activation,	  felt	  to	  represent	  sites	  of	  
viral	  replication,	  have	  been	  identified.	  	  In	  early	  infection	  (off	  ART)	  multiple,	  peripheral	  LN	  
chains	  within	  the	  upper	  and	  lower	  torso	  (cervical,	  axillary,	  inguinal	  and	  iliac	  LN)	  demonstrate	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increased	  FDG	  uptake	  symmetrically.	  	  FDG	  uptake	  is	  correlated	  with	  viral	  load	  and	  the	  
pattern	  of	  LN	  activation	  has	  been	  shown	  not	  to	  change	  at	  repeat	  scanning	  after	  an	  interval	  
of	  4	  months[146].	  	  In	  treated	  HIV	  infected	  individuals	  with	  suppressed	  viral	  load,	  similarly	  to	  
HIV	  uninfected	  individuals,	  very	  little	  FDG	  uptake	  within	  lymph	  nodes	  is	  seen.	  	  However,	  if	  
treatment	  is	  stopped,	  resulting	  in	  increased	  viral	  load,	  FDG	  uptake	  increases	  [148].	  	  In	  
advanced	  HIV	  more	  extensive	  LN	  involvement	  particularly	  of	  mesenteric	  LN	  has	  been	  
demonstrated	  but	  this	  may	  reflect	  opportunistic	  infections	  rather	  than	  as	  a	  result	  if	  HIV	  
infection	  in	  itself.	  	  
1.7 Immunological	  assays	  to	  distinguish	  active	  and	  latent	  
tuberculosis	  
Major	  limitations	  of	  TST	  and	  IGRA	  are	  that	  neither	  are	  able	  to	  distinguish	  active	  from	  latent	  
tuberculosis	  and,	  more	  importantly,	  they	  poorly	  predict	  who	  will	  develop	  active	  disease.	  	  In	  
order	  to	  make	  progress	  in	  this	  regard,	  one	  popular	  approach	  has	  been	  to	  identify	  whether	  
cytokines	  and	  chemokines	  other	  than	  IFNγ	  are	  released	  differentially	  between	  active	  and	  
latent	  tuberculosis	  following	  stimulation	  of	  whole	  blood	  or	  PBMC	  with	  ESAT-­‐6,	  CFP-­‐10	  +/-­‐	  
TB7.7	  (usually	  by	  taking	  supernatants	  from	  QFGIT	  or	  T.SPOT.TB	  and	  detecting	  other	  
cytokines	  by	  ELISA	  or	  multiplex).	  	  	  Chegou	  et	  al	  have	  reviewed	  these	  studies.	  	  Differential	  
release	  of	  cytokines	  between	  active	  and	  latent	  TB	  vary	  between	  studies	  and	  results	  are	  
often	  contradictory.	  	  The	  cytokines/chemokines	  that	  appear	  most	  promising,	  being	  more	  
consistently	  identified	  across	  a	  number	  of	  studies	  and	  induced	  to	  high	  levels,	  are	  IFNγ	  
induced	  protein	  10	  (IP-­‐10	  or	  CXCL10),	  IL-­‐2,	  monocyte	  chemotactic	  protein	  1	  (MCP-­‐1	  or	  
CCL2),	  MCP-­‐2	  (CCL8),	  macrophage	  inflammatory	  protein	  1β	  (MIP1β)	  and	  IL-­‐1	  receptor	  
antagonist	  (IL-­‐1RA)	  although	  even	  for	  these	  biomarkers	  there	  are	  disagreement	  between	  
studies	  and	  no	  large	  confirmatory	  validation	  studies	  have	  been	  published[152].	  	  In	  addition	  it	  
should	  also	  be	  noted	  that	  the	  approach	  to	  selecting	  cytokines	  of	  interest	  for	  these	  studies	  is	  
determined	  to	  a	  great	  extent	  by	  which	  cytokines	  and	  chemokines	  are	  present	  on	  
commercially	  available	  multiplex	  kits	  and	  hence	  there	  are	  numerous	  potential	  
cytokine/chemokines	  yet	  to	  be	  fully	  investigated.	  	  	  
	  
A	  second	  approach	  has	  been	  to	  consider	  the	  differential	  immunogenicity	  of	  antigens	  other	  
than	  ESAT-­‐6,	  CFP-­‐10	  and	  TB7.7	  between	  latent	  and	  active	  tuberculosis.	  	  In	  particular	  there	  
has	  been	  interest	  in	  the	  products	  of	  genes	  induced	  by	  hypoxia	  and	  other	  conditions	  that	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allow	  the	  bacillus	  to	  persist	  in	  a	  non-­‐replicating	  state,	  especially	  those	  that	  form	  part	  of	  the	  
dormancy	  survival	  regulon	  (DosR)	  and	  the	  extended	  hypoxic	  response	  (EHR).	  	  However,	  on	  
the	  whole,	  results	  have	  been	  disappointing	  in	  terms	  of	  degree	  of	  immunogenicity,	  
universality	  of	  response	  and	  consistency	  of	  findings.	  	  In	  addition,	  it	  should	  be	  noted	  that	  in	  
almost	  all	  of	  these	  studies	  the	  read	  out	  has	  been	  restricted	  to	  IFNγ	  production.	  	  Leyten	  et	  al	  
initially	  evaluated	  immunogenicity	  of	  recombinant	  proteins	  derived	  from	  the	  25	  most	  
strongly	  induced	  genes	  from	  the	  DosR	  in	  active	  TB	  patients	  and	  asymptomatic	  TST	  positive	  
controls	  in	  Holland.	  	  	  18	  of	  the	  25	  antigens	  were	  recognised	  in	  at	  least	  10%	  of	  the	  
participants,	  with	  Rv1733c,	  Rv2029c	  and	  RV2627c	  recognised	  in	  greater	  than	  50%	  of	  TST	  
positive	  participants	  (although	  none	  were	  recognised	  in	  greater	  than	  62%).	  	  Only	  Rv2029c	  
was	  recognised	  in	  significantly	  more	  TST	  positive	  than	  active	  TB	  patients,	  whereas	  Rv2031c	  
(heat	  shock	  protein	  -­‐	  hspX)	  was	  recognised	  by	  a	  greater	  proportion	  of	  patients	  with	  active	  
TB[153].	  	  	  Subsequently	  Black	  et	  al,	  using	  a	  7-­‐day	  whole	  blood	  assay,	  evaluated	  IFNγ	  
responses	  by	  ELISA	  to	  51	  antigens	  spanning	  the	  48	  genes	  of	  DosR	  in	  3	  African	  populations	  
with	  LTBI	  in	  South	  Africa,	  Uganda	  and	  The	  Gambia.	  	  Rv0081,	  Rv1733c,	  Rv1735c	  and	  Rv2006	  
were	  in	  the	  top	  10	  most	  frequently	  recognised	  antigens	  for	  all	  3	  sites	  and	  Rv1736c-­‐C,	  
Rv1737c	  and	  Rv1997-­‐C	  were	  in	  the	  top	  10	  at	  South	  African	  and	  Ugandan	  sites.	  	  	  Responses	  
to	  Rv1735c,	  RV1736c-­‐C	  and	  Rv1737c	  appeared	  to	  be	  highly	  correlated[154].	  	  In	  a	  subsequent	  
study	  this	  group	  compared	  IFNγ	  response	  to	  a	  total	  of	  118	  antigens	  (including	  the	  51	  DosR	  
antigens)	  between	  active	  TB	  patients	  and	  healthy	  household	  contacts	  (HHC)	  in	  Cape	  Town.	  	  
For	  8	  DosR	  antigens	  (Rv2032,	  Rv2625c,	  Rv1996,	  Rv0081,	  Rv2624c,	  Rv2006,	  Rv2629	  and	  
Rv2007c)	  IFNγ	  response	  was	  greater	  in	  HHC	  than	  active	  TB	  patients	  with	  an	  area	  under	  the	  
curve	  (AUC)	  >	  0.7	  in	  receiver	  operating	  characteristic	  (ROC)	  analysis.	  	  Of	  the	  other	  antigens,	  
all	  5	  resuscitation	  promotion	  factor	  (rpf)	  antigens	  were	  found	  to	  elicit	  greater	  IFNγ	  
responses	  HHC	  compared	  to	  active	  TB	  patients	  all	  with	  AUC	  >0.7[155].	  	  Taking	  this	  further	  
for	  5	  promising	  DosR	  antigens	  and	  2	  rpf	  antigens	  they	  compared	  responses	  for	  12	  cytokines	  
between	  active	  disease	  and	  HHC.	  IL-­‐12(p40),	  IP-­‐10,	  IL-­‐10	  and	  TNF-­‐α	  responses	  to	  Rv0081	  
were	  most	  promising	  being	  greater	  in	  HHC	  and	  distinguishing	  these	  2	  groups	  with	  an	  
accuracy	  of	  100%[156].	  	  	  
	  
Looking	  beyond	  DosR,	  Gideon	  et	  al	  evaluated	  immugenicity	  of	  antigens	  coded	  by	  genes	  
upregulated	  during	  more	  prolonged	  hypoxia.	  	  They	  specifically	  focused	  on	  genes	  showing	  
the	  greatest	  fold	  change	  over	  a	  7	  day	  hypoxic	  culture	  that	  were	  also	  likely	  to	  demonstrate	  
greater	  Mtb	  specificity	  and	  identified	  Rv2658c	  and	  Rv2659c	  (RD11	  encoded,	  absent	  from	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M.bovis)	  and	  Rv1986c	  (RD2	  encoded,	  absent	  from	  most	  BCG	  strains)	  as	  antigens	  of	  interest.	  	  
Evaluating	  IFNγ	  and	  IL-­‐2	  ex	  vivo	  ELISPOT	  responses	  to	  these	  antigens	  in	  HIV	  uninfected	  
participants	  with	  active	  or	  latent	  infection	  they	  found	  Rv1986	  to	  have	  striking	  
immunodominance	  for	  an	  IL-­‐2	  response.	  	  This	  was	  of	  comparable	  magnitude	  to	  the	  IFNγ	  
response	  to	  ESAT-­‐6/CFP-­‐10,	  with	  a	  greater	  proportion	  of	  those	  with	  latent	  infection	  
recognising	  this	  antigen	  compared	  to	  those	  with	  active	  TB[157].	  	  	  
	  
Most	  of	  these	  approaches	  above	  have	  been	  driven	  by	  the	  hypothesis	  that	  the	  predominant	  
metabolic	  state	  of	  the	  population	  of	  Mtb,	  and	  thus	  the	  antigens	  presented	  to	  the	  immune	  
system,	  may	  vary	  between	  latent	  and	  active	  infection.	  	  However	  recently,	  Lindestam-­‐
Arlehamn	  et	  al	  have	  shown	  the	  value	  of	  a	  more	  unbiased,	  genome-­‐wide	  approach	  to	  identify	  
the	  novel	  immunodominant	  antigens	  (in	  terms	  of	  IFNγ	  response)	  in	  latent	  TB.	  	  The	  authors	  
initially	  predicted	  the	  binding	  potential	  of	  all	  15-­‐mer	  peptides	  derived	  from	  protein	  
sequences	  of	  5	  complete	  Mtb	  genomes	  for	  22	  of	  the	  most	  common	  human	  leukocyte	  
antigen	  (HLA)	  class	  II	  alleles	  and	  then	  synthesised	  the	  20,060	  peptides	  expected	  to	  be	  the	  
most	  promiscuous	  epitopes.	  	  They	  then	  determined	  the	  ex	  vivo	  IFNγ	  response	  to	  these	  
peptides	  using	  PBMC	  from	  28	  donors	  with	  latent	  TB	  and	  identified	  82	  antigens	  that	  
accounted	  for	  over	  80%	  of	  the	  total	  response	  in	  this	  group,	  74%	  of	  these	  antigens	  were	  
novel[158].	  	  The	  differential	  recognition	  of	  many	  of	  these	  antigens	  is	  yet	  to	  be	  evaluated.	  	  
	  
A	  third	  common	  approach	  to	  distinguishing	  active	  and	  latent	  TB	  immunologically	  is	  using	  
flow	  cytometry	  to	  determine	  differences	  in	  the	  phenotype	  of	  Mtb	  specific	  cells	  either	  with	  
regard	  to	  expression	  of	  surface	  markers	  or	  functionality	  in	  terms	  of	  cytokine	  production.	  	  
The	  most	  common	  cell	  types	  to	  focus	  on	  have	  been	  CD4	  and	  CD8	  cells,	  usually	  characterised	  
according	  to	  memory	  phenotype	  or	  activation	  markers	  with	  intracellular	  cytokine	  staining	  
most	  commonly	  performed	  for	  IFNγ,	  IL-­‐2,	  TNFα	  and	  MIP-­‐1β.	  	  Results,	  particularly	  with	  
regard	  to	  polyfunctionality	  of	  Mtb	  specific	  CD4	  cells,	  have	  been	  inconsistent	  between	  
studies	  and	  methodology,	  particularly	  with	  regard	  to	  co-­‐stimulation,	  varies	  greatly.	  	  Pollock	  
et	  al	  evaluating	  differences	  between	  active	  and	  latent	  TB	  in	  those	  with	  and	  without	  HIV	  
demonstrated	  that	  frequency	  of	  PPD	  specific	  CD4+	  cells	  secreting	  IFNγ	  only,	  TNFα	  only	  and	  
IFNγ/TNFα	  were	  greater	  in	  those	  with	  active	  TB	  irrespective	  of	  HIV	  status.	  	  PPD	  and	  RD1	  
specific	  CD4	  cells	  were	  found	  to	  be	  predominantly	  of	  central	  memory	  phenotype	  
(CD45RA+/CCR7+)	  in	  latent	  TB	  and	  effector	  memory	  phenotype	  (CD45RA-­‐/CCR7-­‐)	  in	  active	  
TB,	  in	  addition	  CD127	  expression	  was	  found	  to	  be	  reduced	  in	  active	  TB[159].	  	  Harari	  et	  al	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similarly	  demonstrated	  that	  there	  was	  a	  substantial	  increase	  in	  proportion	  of	  TNFα	  only	  
producing	  RD1	  specific	  CD4	  cells	  in	  active	  compared	  to	  latent	  TB	  where	  as	  polyfunctional	  
IFNγ/TNFα/IL-­‐2	  producing	  cells	  showed	  the	  opposite	  pattern[160].	  	  By	  contrast,	  Caccamo	  et	  
al	  demonstrated	  that	  polyfunctional	  IFNγ/TNFα/IL-­‐2	  producing	  CD4	  cells	  were	  more	  
common	  in	  active	  compared	  to	  latent	  TB,	  being	  detectable	  in	  85-­‐90%	  of	  those	  with	  active	  TB	  
and	  only	  10-­‐15%	  of	  those	  with	  latent	  TB.	  	  This	  is	  in	  keeping	  with	  findings	  by	  Sutherland	  et	  al	  
who	  also	  showed	  that	  these	  polyfunctional	  cells	  were	  more	  common	  in	  active	  TB	  compared	  
to	  healthy	  household	  contacts[161,	  162].	  
1.8 Host	  transcriptional	  signatures	  in	  tuberculosis	  
Profiling	  of	  transcript	  abundance	  (transcriptomics),	  commonly	  in	  whole	  blood,	  aims	  to	  
generate	  a	  global	  picture	  of	  cellular	  function	  by	  simultaneously	  measuring	  the	  expression	  of	  
thousands	  of	  genes	  with	  a	  broad	  coverage	  of	  the	  entire	  genome.	  	  However,	  it	  should	  be	  
noted	  that	  transcript	  abundance	  only	  partially	  predicts	  protein	  abundance	  due	  to	  a	  variety	  
of	  post-­‐transcriptional	  events[163].	  	  These	  studies	  can	  reveal	  biological	  mechanisms	  relevant	  
to	  the	  condition	  of	  interest	  and	  also	  provide	  biomarkers	  of	  disease	  that	  may	  have	  potential	  
utility	  diagnostically.	  	  There	  are	  two	  main	  techniques	  in	  wide	  use	  for	  global	  transcriptional	  
profiling,	  microarray	  and	  RNA	  sequencing,	  each	  with	  their	  own	  advantages	  and	  
disadvantages	  (see	  table	  1.4).	  	  
	  
Several	  studies,	  all	  using	  the	  microarray	  approach,	  have	  recently	  been	  published	  highlighting	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HIV	  negative	  participants,	  Berry	  et	  al	  identified	  a	  393	  transcript	  signature	  that	  distinguished	  
active	  tuberculosis	  from	  latent	  tuberculosis	  and	  healthy	  controls	  on	  a	  training	  cohort	  in	  
London[164].	  	  Applying	  this	  signature	  to	  test	  and	  validation	  cohorts	  in	  London	  and	  Cape	  
Town	  the	  sensitivity	  for	  active	  TB	  was	  61.7%	  and	  94.1%	  and	  specificity	  93.8%	  and	  96.7%	  
respectively	  using	  k-­‐nearest	  neighbour	  class	  prediction.	  	  5	  of	  21	  (24%)	  of	  those	  latently	  
infected	  in	  the	  test	  cohort	  and	  3	  of	  31	  (10%)	  in	  the	  validation	  cohort	  clustered	  with	  active	  
TB.	  	  The	  authors	  hypothesised	  that	  it	  may	  be	  possible	  that	  this	  group	  of	  latently	  infected	  
persons	  that	  were	  misclassified	  as	  active	  TB	  may	  have	  had	  subclinical	  tuberculosis	  or	  
otherwise	  been	  at	  high	  risk	  of	  developing	  TB.	  	  However,	  it	  is	  worth	  noting	  that	  4	  of	  21	  (19%)	  
in	  test	  and	  1	  of	  20	  (5%)	  in	  validation	  with	  active	  TB	  clustered	  with	  latent	  TB	  and	  healthy	  
controls	  so	  misclassification	  could	  be	  related	  to	  chance	  as	  much	  as	  having	  a	  biological	  basis.	  	  
The	  authors	  went	  on	  to	  show	  that	  this	  active	  TB	  signature	  was	  related	  to	  the	  radiographic	  
extent	  of	  disease	  with	  the	  signature	  being	  much	  more	  apparent	  in	  those	  with	  moderate	  and	  
advanced	  disease.	  	  They	  then	  went	  on	  to	  demonstrate	  that	  an	  86	  transcript	  signature	  
distinguished	  active	  tuberculosis	  from	  other	  infectious	  and	  inflammatory	  diseases	  
(streptococcal	  and	  staphylococcal	  infection,	  Still’s	  disease	  and	  systemic	  lupus	  erythromatosis	  
(SLE))	  with	  a	  pooled	  specificity	  of	  83%.	  	  Both	  the	  86	  and	  393	  signature	  diminished	  with	  
treatment.	  	  Analysing	  the	  functional	  components	  of	  the	  host	  response	  by	  modular	  analysis	  
of	  transcripts	  in	  whole	  blood	  and	  separated	  cells	  they	  demonstrated	  that	  the	  TB	  signature	  
revealed	  a	  decreased	  abundance	  of	  B	  cell	  and	  T	  cell	  transcripts	  and	  an	  increased	  abundance	  
of	  myeloid	  transcripts.	  	  Although	  this	  reduction	  in	  T	  cell	  transcripts	  was	  likely	  to	  reflect	  
reduced	  circulating	  T	  cell	  number	  in	  active	  TB,	  the	  increase	  in	  myeloid	  transcripts	  was	  less	  
likely	  to	  relate	  to	  changes	  in	  circulating	  cell	  types.	  	  The	  most	  significantly	  over	  represented	  
pathway	  identified	  in	  active	  TB	  was	  found	  to	  be	  IFN	  (type	  1	  and	  type	  2)	  signalling,	  which	  was	  
particularly	  over-­‐expressed	  on	  neutrophils.	  	  In	  a	  subsequent	  study	  the	  group	  recruiting	  new	  
cohorts	  from	  London	  and	  Cape	  Town	  looked	  further	  into	  the	  effect	  of	  treatment	  response	  
on	  transcriptional	  signature.	  	  They	  derived	  a	  664-­‐transcript	  signature	  from	  differentially	  
expressed	  genes	  between	  pre-­‐treated	  active	  and	  latent	  TB	  in	  Cape	  Town	  and	  showed	  that	  
this	  signature	  significantly	  and	  rapidly	  changed	  after	  2	  weeks	  of	  TB	  treatment[165].	  	  	  
	  
Maertzdorf	  et	  al	  performing	  a	  study	  in	  HIV	  uninfected	  participants	  in	  South	  Africa	  identified	  
2,048	  transcripts	  that	  were	  differentially	  expressed	  between	  TB	  patients	  and	  latently	  
infected	  household	  contacts	  including	  918	  transcripts	  that	  were	  also	  differentially	  expressed	  
with	  non-­‐infected	  donors	  (fold	  change	  (FC)	  cut	  off	  ≥	  0.2	  or	  ≤	  0.2	  (log2scale)	  with	  q=0.01).	  Fcγ	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receptor	  1B	  was	  found	  to	  be	  the	  most	  strongly	  differentially	  expressed	  gene.	  	  Analysing	  the	  
functional	  categorization	  of	  differentially	  expressed	  genes	  they	  determined	  that	  decreased	  
apoptotic	  activity	  and	  increased	  innate	  host	  defence	  response	  were	  apparent	  in	  TB	  patients	  
compared	  to	  latent	  TB	  controls[166].	  	  In	  The	  Gambia	  this	  group	  identified	  1,661	  differentially	  
expressed	  transcripts	  between	  HIV	  uninfected	  TB	  patients	  and	  latently	  infected	  controls	  
(log2-­‐fold	  change	  ≥0.5	  or	  ≤0.5	  significance	  q=0.01).	  	  Using	  signalling	  pathway	  impact	  analysis	  
they	  demonstrated	  that	  genes	  involved	  in	  the	  complement	  and	  coagulation	  cascades,	  toll-­‐
like	  receptor	  (TLR)	  signalling	  and	  SLE	  were	  significantly	  enriched	  with	  significant	  
perturbation	  within	  Fcγ	  receptor	  mediated	  phagocytosis	  pathway.	  	  Comparing	  the	  
signatures	  they	  identified	  in	  The	  Gambia	  and	  South	  Africa	  with	  the	  signature	  identified	  in	  a	  
UK	  cohort	  by	  Berry	  et	  al	  they	  determined	  74%	  of	  genes	  to	  be	  common	  to	  all	  3	  sites	  in	  
particular	  genes	  involved	  in	  IFN	  signalling[167].	  	  In	  a	  larger	  study	  incorporating	  523	  HIV	  
infected	  and	  uninfected	  participants	  from	  sites	  in	  Malawi	  and	  Ethiopia	  as	  well	  as	  The	  
Gambia	  and	  South	  Africa,	  reverse	  transcriptase	  multiplex	  ligation	  dependant	  probe	  
amplification	  (RT-­‐MLPA)	  was	  performed	  to	  evaluate	  expression	  of	  a	  specific	  set	  of	  genes	  
determined	  to	  be	  involved	  in	  TB	  pathogenesis	  from	  previous	  studies.	  	  Fcγ	  receptor	  1A	  
(FCGR1A)	  was	  identified	  as	  the	  most	  consistent	  classifier	  of	  active	  TB	  regardless	  of	  HIV	  
status[168].	  	  	  	  
	  
Cliff	  et	  al	  taking	  a	  different	  analytical	  approach,	  evaluated	  the	  dynamics	  of	  the	  host	  
transcriptional	  response	  during	  treatment	  and	  were	  able	  to	  determine	  which	  genes	  
responded	  within	  1	  week	  of	  TB	  treatment,	  the	  time	  of	  greatest	  killing	  of	  Mtb,	  as	  well	  as	  
which	  gene	  responded	  later	  in	  treatment	  (between	  4	  and	  26	  weeks).	  	  Specific	  components	  
of	  the	  complement	  system	  were	  found	  to	  be	  rapidly	  down-­‐regulated	  after	  1	  week	  of	  
treatment.	  	  In	  particular	  C1q,	  C2,	  SerpinG1	  and	  factor	  B	  (BF)	  with	  C5,	  CD55	  (complement	  
decay	  accelerating	  factor)	  and	  CD59	  (MAC	  inhibitory	  protein)	  down-­‐regulated	  to	  a	  lesser	  
degree.	  	  The	  authors	  speculated	  that	  these	  changes	  were	  as	  a	  result	  of	  rapid	  action	  of	  
isoniazid	  on	  actively	  replicating	  bacilli	  and	  reflected	  the	  reduction	  in	  bacillary	  burden[169].	  	  
	  
In	  order	  to	  identify	  common	  themes	  in	  these	  TB	  transcriptomic	  studies,	  Joosten	  et	  al	  
performed	  an	  analysis	  of	  the	  biological	  pathways	  and	  process	  represented	  by	  genes	  
identified	  in	  8	  recently	  published	  studies	  (the	  majority	  of	  which	  are	  outlined	  above).	  	  A	  total	  
gene	  set	  of	  409	  genes	  was	  identified	  across	  these	  studies	  and	  then	  functional	  analysis	  was	  
undertaken	  using	  3	  platforms	  (Ingenuity	  Pathway	  Analysis	  (IPA),	  Gene	  Set	  Enrichment	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Analysis	  (GSEA)	  and	  	  modular	  analysis).	  	  Their	  analysis	  revealed	  a	  less	  dominant	  role	  for	  
interferon	  related	  genes	  and	  suggested	  an	  important	  role	  of	  myeloid	  cells,	  in	  particular	  
signalling	  through	  Pattern	  Recognition	  Receptors,	  Fc	  receptors,	  fibrosis	  and	  TREM1[170].	  	  	  	  	  	  	  	  
	  
While	  helpful	  to	  interrogate	  biological	  processes	  that	  may	  be	  involved	  in	  a	  disease	  process,	  
large	  transcriptional	  signatures	  are	  less	  useful	  as	  diagnostic	  signatures.	  Kaforou	  et	  al	  
attempting	  to	  define	  the	  minimal	  transcript	  signature	  to	  distinguish	  TB	  from	  latent	  TB	  and	  
other	  diseases	  carried	  out	  a	  study	  in	  HIV	  infected	  and	  uninfected	  participants	  in	  Malawi	  and	  
South	  Africa.	  Using	  variable	  selection	  via	  elastic	  net	  to	  identify	  transcripts,	  they	  identified	  27	  
transcripts	  that	  optimally	  distinguished	  active	  from	  latent	  TB	  and	  44	  transcripts	  
distinguishing	  TB	  from	  other	  diseases.	  	  In	  order	  to	  evaluate	  individual	  risk	  of	  TB	  they	  
developed	  a	  disease	  risk	  score	  (DRS)	  derived	  by	  subtracting	  the	  total	  intensity	  of	  down	  
regulated	  transcripts	  from	  up-­‐regulated	  transcripts	  with	  the	  threshold	  derived	  from	  the	  
weighted	  average	  risk	  score	  for	  a	  group	  of	  patients.	  	  These	  signatures	  were	  found	  to	  have	  
sensitivity	  and	  specificity	  of	  95%	  and	  90%,	  respectively,	  to	  distinguish	  active	  from	  latent	  TB	  
and	  93%	  and	  86%,	  respectively,	  to	  distinguish	  active	  from	  latent	  TB	  in	  a	  test	  cohort	  of	  HIV	  
infected	  and	  uninfected	  participants.	  	  These	  signatures	  performed	  considerably	  better	  in	  HIV	  
uninfected	  than	  HIV	  infected	  participants[171].	  	  
	  
Though	  these	  signatures	  perform	  well	  at	  distinguishing	  active	  from	  latent	  TB	  and	  from	  some	  
other	  diseases,	  they	  have	  been	  less	  discriminatory	  against	  other	  diseases	  most	  notably	  
sarcoidosis	  and	  meliodosis.	  	  Several	  authors	  have	  demonstrated	  that	  apparently	  TB	  specific	  
signatures	  fail	  to	  distinguish	  active	  TB	  from	  sarcoidosis	  and	  that	  the	  IFN	  inducible,	  neutrophil	  
driven	  transcriptional	  signature	  is	  also	  present	  in	  active	  sarcoidosis[172-­‐174].	  	  However,	  
Bloom	  et	  al	  were	  able	  to	  define	  a	  signature	  of	  144	  differentially	  abundant	  transcripts	  
between	  tuberculosis	  and	  sarcoidosis[174].	  	  Koh	  et	  al	  demonstrated	  that	  differentially	  
abundant	  transcripts	  from	  healthy	  controls	  in	  melioidosis	  and	  tuberculosis	  followed	  a	  similar	  
pattern	  with	  IFNγ	  pathway	  being	  most	  prominent	  in	  both	  diseases[175].	  
	  
In	  summary,	  whole	  blood	  transcriptional	  signatures	  for	  active	  tuberculosis	  have	  been	  
demonstrated	  by	  several	  groups	  at	  a	  number	  of	  geographically	  diverse	  location	  
encompassing	  participants	  and	  Mtb	  strains	  of	  varied	  genetic	  background.	  	  Interferon	  
signalling	  is	  a	  dominant	  part	  of	  this	  signature	  but	  transcripts	  involved	  in	  other	  pathways	  are	  
frequently	  over-­‐represented,	  most	  notably	  complement	  pathways	  and	  genes	  relating	  to	  Fcγ	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mediated	  phagocytosis.	  	  Although	  these	  signatures	  are	  distinct	  from	  certain	  infectious	  and	  
inflammatory	  conditions,	  they	  overlap	  to	  a	  large	  extent	  with	  other	  pulmonary	  
granulomatous	  diseases	  and	  diseases	  caused	  by	  other	  intracellular	  bacteria.	  
	  
Work	  is	  now	  beginning	  on	  converting	  these	  signatures	  into	  assays	  that	  may	  prove	  more	  
feasible	  for	  developing	  novel	  diagnostics	  for	  active	  TB.	  	  However,	  it	  is	  not	  clear	  whether	  
these	  signatures	  could	  be	  predictive	  of	  active	  TB,	  which	  is	  potentially	  more	  significant.	  	  It	  
may	  be	  that	  pathways	  that	  dominate	  the	  active	  TB	  signature	  do	  not	  become	  prominent	  until	  
later	  in	  the	  disease	  process	  while	  other	  components	  of	  the	  signature	  appear	  earlier	  in	  
disease.	  	  This	  would	  have	  the	  effect	  of	  persons	  with	  minimal	  or	  subclinical	  pathology	  being	  
misclassified	  because	  they	  lack	  the	  dominant	  component	  of	  the	  transcript	  signature.	  	  In	  
addition	  although	  a	  few	  studies	  have	  included	  HIV	  infected	  individuals	  in	  their	  cohorts	  none	  
have	  looked	  in	  detail	  at	  the	  interaction	  between	  TB	  and	  HIV	  on	  the	  whole	  blood	  
transcriptional	  signature.	  	  	  	  	  	  	  	  	  	  	  	  
1.9 Summary	  
In	  order	  to	  make	  progress	  toward	  elimination	  of	  TB	  as	  a	  public	  health	  problem	  we	  need	  to	  
have	  a	  better	  understanding	  of	  the	  reservoir	  of	  infection,	  persons	  with	  latent	  TB.	  	  Current	  
diagnostic	  tests	  for	  latent	  TB	  poorly	  predict	  active	  disease,	  development	  of	  more	  predictive	  
tests	  will	  allow	  focusing	  of	  resources	  on	  those	  at	  greatest	  risk	  of	  active	  disease	  and	  improve	  
acceptability	  of	  preventive	  therapy	  by	  reducing	  number	  needed	  to	  treat.	  	  From	  early	  in	  the	  
course	  of	  HIV	  infection	  the	  risk	  of	  reactivating	  latent	  infection	  and	  progression	  to	  active	  TB	  is	  
high.	  	  Those	  at	  highest	  risk	  of	  developing	  active	  TB	  may	  have	  evidence	  of	  minimal	  active	  
pathology	  or	  fibrotic	  scarring	  suggestive	  of	  a	  fluctuating	  transition	  from	  latent	  to	  active	  TB.	  
This	  subclinical	  pathology	  historically	  was	  screened	  for	  by	  CXR.	  	  FDG-­‐PET/CT	  is	  a	  more	  
advanced	  imaging	  modality	  that	  provides	  superior	  anatomical	  detail	  with	  CT	  component	  and	  
assessment	  of	  metabolic	  activity	  with	  a	  PET	  component	  and	  should	  result	  in	  much	  greater	  
sensitivity	  for	  detection	  of	  subclinical	  pathology.	  	  Recently	  transcriptional	  assessment	  of	  
whole	  blood,	  as	  well	  as	  immunological	  profiling,	  has	  been	  successful	  in	  distinguishing	  active	  
from	  latent	  tuberculosis,	  not	  possible	  with	  TST	  or	  IGRA.	  	  This	  raises	  the	  possibility	  that	  these	  
modalities	  may	  be	  able	  to	  distinguish	  those	  with	  and	  without	  subclinical	  pathology	  on	  
PET/CT.	  	  This	  may	  provide	  an	  infection	  stage	  specific	  biomarker	  that	  may	  have	  translational	  
potential	  as	  a	  more	  predictive	  diagnostic	  test.	  	  In	  addition,	  this	  would	  provide	  greater	  insight	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into	  the	  early	  stages	  and	  biological	  processes	  that	  occur	  in	  the	  transition	  from	  latent	  to	  
active	  TB.	  
1.10 	  	  	  Thesis	  scope	  and	  aims	  
1.10.1 Overall	  Hypotheses	  and	  Aims	  
The	  overall	  hypotheses	  informing	  this	  thesis	  are	  that:	  
1. The	  transition	  from	  latent	  tuberculosis	  to	  active	  pulmonary	  tuberculosis	  involves	  a	  
subclinical	  phase,	  which	  may	  be	  apparent	  on	  detailed	  imaging	  of	  the	  lungs	  with	  FDG-­‐
PET/CT.	  	  
	  
2. Those	  with	  evidence	  of	  subclinical	  pathology	  will	  have	  similarities	  in	  immune	  response	  
and	  transcriptional	  profile	  to	  people	  with	  active	  tuberculosis	  but	  be	  distinguishable	  from	  
those	  with	  evidence	  of	  latent	  infection	  without	  subclinical	  pathology	  	  
	  
The	  overall	  aims	  and	  scope	  of	  the	  thesis	  is	  to:	  
1. Evaluate	  the	  utility	  of	  FDG-­‐PET/CT	  to	  identify	  intra-­‐thoracic	  pathology	  consistent	  
with	  active	  tuberculosis	  in	  asymptomatic,	  ART	  naïve,	  HIV-­‐1	  infected	  adults	  with	  
evidence	  of	  latent	  tuberculosis	  infection	  by	  QuantiFERON	  Gold-­‐in-­‐tube	  and	  no	  
history	  of	  active	  tuberculosis;	  thereby	  defining	  a	  group	  with	  evidence	  of	  subclinical	  
tuberculosis	  and	  a	  group	  without	  evidence	  of	  subclinical	  tuberculosis.	  	  
	  
2. Determine	  the	  similarities	  and	  differences	  in	  peripheral	  blood	  transcript	  abundance	  
between	  those	  categorized	  with	  and	  without	  subclinical	  tuberculosis	  and	  age,	  sex	  
and	  CD4	  matched	  controls	  with	  symptomatic	  active	  tuberculosis	  
	  
3. Determine	  the	  similarities	  and	  differences	  in	  peripheral	  blood	  immune	  responses	  
between	  those	  categorized	  with	  and	  without	  subclinical	  tuberculosis	  and	  age,	  sex	  
and	  CD4	  matched	  controls	  with	  symptomatic	  active	  tuberculosis	  
1.10.2 General	  Chapter	  aims	  	  
Chapter	  1	  Aim	  
• To	  provide	  an	  extensive	  overview	  and	  analysis	  of	  the	  current	  understanding	  of	  latent	  
and	  subclinical	  TB	  and	  the	  impact	  of	  HIV	  infection	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Chapter	  2	  Aim	  
• To	  describe	  material	  and	  methods	  used	  in	  thesis	  
	  
Chapter	  3	  Aim	  
• To	  describe	  the	  recruitment	  of	  participants	  and	  controls	  in	  the	  study	  and	  to	  explore	  
the	  performance	  of	  the	  current	  tools	  for	  screening	  of	  active	  and	  latent	  TB	  used	  in	  
the	  recruitment	  of	  participants.	  
	  
Chapter	  4	  Aim	  
• To	  evaluate	  the	  utility	  of	  FDG-­‐PET/CT	  to	  identify	  evidence	  of	  subclinical	  pathology	  in	  
asymptomatic,	  ART	  naïve,	  HIV	  infected	  adults	  with	  evidence	  of	  latent	  TB	  and	  no	  
previous	  history	  of	  tuberculosis	  	  
	  
Chapter	  5	  Aim	  
• To	  determine	  the	  differentially	  expressed	  transcripts	  in	  whole	  blood	  in	  those	  with	  
and	  without	  subclinical	  TB	  and	  in	  comparison	  to	  an	  active	  TB	  control	  group	  and	  to	  
evaluate	  the	  effect	  of	  HIV	  on	  the	  transcriptional	  response	  to	  TB	  
	  
Chapter	  6	  Aim	  
• Identify	  serological	  and	  QFGIT	  supernatant	  markers	  that	  distinguish	  those	  without	  
evidence	  of	  subclinical	  pathology	  from	  those	  with	  evidence	  of	  subclinical	  pathology	  
and	  active	  TB	  control	  group	  	  
	  
Chapter	  7	  Aim	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CHAPTER	  2:	  Materials	  and	  Methods	  
2.1 Setting	  
2.1.1 South	  Africa	  
South	  Africa	  lies	  at	  the	  southern	  tip	  of	  Africa	  bordering	  Namibia,	  Botswana	  and	  Zimbabwe	  to	  
the	  north,	  and	  Mozambique	  and	  Swaziland	  to	  the	  east	  (figure	  2.1).	  	  It	  has	  a	  population	  of	  53	  
million	  of	  which	  approximately	  80%	  are	  of	  Black	  African	  ancestry[176].	  	  South	  Africa	  is	  an	  
upper	  middle-­‐income	  country	  and	  has	  the	  largest	  and	  most	  developed	  economy	  in	  Africa	  
with	  a	  Gross	  National	  Income	  (Purchasing	  Power	  Parity)	  per	  capita	  of	  $11010	  (2012)[177].	  
However,	  it	  also	  has	  one	  of	  the	  highest	  levels	  of	  income	  inequality	  in	  the	  world	  (as	  
determined	  by	  the	  Gini	  index)	  and	  as	  a	  result	  has	  relatively	  high	  rates	  of	  poverty	  and	  
unemployment.	  	  
2.1.2 HIV/AIDS	  and	  tuberculosis	  in	  South	  Africa	  
Approximately	  6.1	  million	  people	  (11.5%	  of	  the	  population)	  in	  South	  Africa	  are	  living	  with	  
HIV[178]	  and	  amongst	  antenatal	  women	  approximately	  30%	  are	  HIV	  infected[179].	  	  The	  
national	  rollout	  of	  ART	  commenced	  in	  2004	  and	  by	  2012,	  2.2	  million	  people	  were	  taking	  ART,	  
83%	  of	  those	  eligible[180].	  	  South	  Africa	  has	  both	  the	  highest	  number	  of	  people	  infected	  
with	  HIV	  and	  the	  largest	  ART	  programme	  in	  the	  world.	  	  Patients	  eligible	  to	  commence	  ART	  
under	  South	  African	  guidelines	  (2013)	  include,	  all	  HIV	  infected	  persons	  with	  CD4	  count	  less	  
than	  350/mm3,	  HIV	  infected	  persons	  with	  WHO	  Stage	  III	  or	  IV	  disease	  (including	  all	  forms	  of	  
active	  tuberculosis)	  irrespective	  of	  CD4	  count	  and	  pregnant	  women	  irrespective	  of	  CD4	  
count[179].	  	  	  
Figure	  2.1	  –	  Map	  of	  South	  Africa	  showing	  Cape	  Town,	  provinces	  and	  surrounding	  countries	  
?????????
Chapter	  2	  –	  Material	  and	  Methods	  
	   71	  
	  
In	  2012,	  349,582	  cases	  of	  TB	  were	  reported	  in	  South	  Africa,	  65%	  of	  which	  were	  HIV	  
associated.	  	  Overall	  TB	  case	  detection	  was	  estimated	  to	  be	  62%	  and	  national	  incidence	  of	  TB	  
is	  estimated	  to	  be	  1,003/100000	  (one	  of	  the	  highest	  rates	  in	  the	  world)[12].	  	  Tuberculosis	  is	  
the	  leading	  cause	  of	  death	  in	  South	  Africa	  and	  accounts	  for	  approximately	  12%	  of	  all	  deaths	  
annually[181].	  	  	  
2.1.3 Khayelitsha,	  Cape	  Town	  
	  
All	  participants	  and	  controls	  for	  this	  study	  were	  resident	  in	  Khayelitsha,	  a	  peri-­‐urban	  
township	  approximately	  25	  kilometres	  southeast	  of	  Cape	  Town	  in	  the	  Western	  Cape	  
province.	  	  Khayelitsha	  is	  one	  of	  the	  largest	  and	  fastest	  growing	  townships	  in	  South	  Africa	  
with	  a	  population	  of	  391,749	  living	  in	  118,809	  households	  (2011	  census	  –	  although	  this	  is	  
considered	  to	  be	  an	  underestimate)[182].	  	  The	  population	  is	  predominantly	  Black	  African	  
(99%)	  and	  Xhosa	  speaking	  (>95%)	  with	  the	  majority	  of	  residents	  being	  rural	  to	  urban	  
migrants	  from	  the	  Eastern	  Cape	  province.	  	  Levels	  of	  socio-­‐economic	  deprivation	  are	  high,	  
38%	  of	  the	  adult	  population	  are	  unemployed	  and	  74%	  of	  households	  have	  a	  monthly	  income	  
of	  less	  than	  R3200	  (£250).	  	  Only	  36%	  have	  completed	  high	  school	  education,	  although	  
literacy	  levels	  are	  very	  high	  at	  94%.	  	  55%	  of	  household	  live	  in	  informal	  shack	  
accommodation,	  62%	  have	  access	  to	  piped	  water,	  81%	  electricity	  and	  72%	  access	  to	  a	  flush	  
toilet.	  	  Use	  of	  biomass	  fuel	  for	  cooking	  and	  heating	  is	  uncommon	  and	  reported	  by	  less	  than	  
Figure	  2.2	  –	  Map	  of	  Cape	  Town	  showing	  location	  of	  study	  site.	  	  
Yellow	  star	  =	  Khayelitsha	  Site	  B	  Clinic,	  Red	  star	  =	  Tygerberg	  Hospital,	  Green	  star	  =	  University	  of	  Cape	  Town	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1%	  of	  households[182].	  	  TB	  incidence	  in	  Khayelitsha	  is	  at	  least	  50%	  higher	  that	  the	  national	  
average	  at	  >1,500/100000.	  	  Cure	  rate	  for	  new	  TB	  patient	  is	  approximately	  80%.	  70%	  of	  TB	  
cases	  are	  co-­‐infected	  with	  HIV	  and	  antenatal	  HIV	  prevalence	  approximately	  26%.	  	  Case	  
detection	  rate	  of	  multi-­‐drug	  resistant	  (MDR)-­‐TB	  is	  approximately	  50/100000[183,	  184].	  	  
Tuberculosis	  notifications	  in	  Cape	  Town	  demonstrates	  seasonal	  variation	  with	  case	  
notification	  being	  lowest	  April-­‐June	  and	  highest	  October-­‐December	  and	  vitamin	  D	  deficiency	  
in	  the	  winter	  is	  common[67].	  	  Approximately	  80%	  of	  young	  adults	  in	  this	  environment	  have	  
evidence	  of	  immune	  sensitization	  to	  Mtb	  by	  either	  TST	  or	  IGRA	  and	  force	  of	  TB	  infection	  is	  
approximately	  4-­‐8%/year	  during	  adolescence	  and	  early	  adulthood[185,	  186].	  	  
	  
Routine	  healthcare	  and	  HIV/TB	  management	  in	  Khayelitsha	  is	  becoming	  increasingly	  
decentralized	  and	  nurse-­‐led	  and	  is	  provided	  through	  4	  community	  healthcare	  centres,	  6	  
general	  clinics,	  2	  youth	  clinics,	  1	  male	  clinic	  and	  2	  midwife	  obstetric	  units.	  	  In	  2012	  a	  300-­‐bed	  
district	  hospital	  was	  opened	  in	  Khayelitsha	  to	  provide	  secondary	  care	  and	  referral	  support.	  	  
Tertiary	  level	  care	  is	  provided	  by	  referral	  to	  Tygerberg	  Hospital	  in	  Bellville	  or	  Groote	  Schuur	  
Hospital	  in	  Observatory.	  	  	  
2.1.3.1 Khayelitsha	  Site	  B	  Community	  Health	  Centre	  
The	  site	  of	  recruitment	  and	  clinical	  follow	  up	  of	  the	  participants	  in	  this	  study	  was	  the	  
Khayelitsha	  site	  B	  community	  health	  centre	  (CHC).	  	  On	  this	  site	  there	  are	  several	  healthcare	  
facilities.	  	  A	  day	  hospital	  provides	  outpatient	  services	  for	  the	  day-­‐to-­‐day	  management	  of	  
stable	  chronic	  conditions	  and	  includes	  a	  wellness	  clinic	  for	  the	  management	  and	  regular	  
follow-­‐up	  of	  HIV	  infected	  adults	  that	  are	  not	  eligible	  for	  ART.	  	  Adjoined	  to	  the	  day	  hospital	  is	  
an	  emergency	  and	  trauma	  unit	  for	  the	  stabilisation	  of	  acutely	  unwell	  patients	  that	  may	  need	  
onward	  referral	  to	  hospital.	  	  In	  a	  separate	  building	  health	  services	  for	  HIV	  infected	  persons	  
requiring	  ART	  are	  provided,	  adjoined	  to	  this	  is	  the	  TB	  clinic,	  which	  has	  resulted	  in	  TB/HIV	  
care	  being	  increasingly	  integrated.	  	  Also	  on	  the	  same	  site	  is	  a	  midwife	  obstetric	  unit.	  	  	  
	  
This	  site	  has	  a	  longstanding	  relationship	  with	  the	  medical	  humanitarian,	  non-­‐governmental	  
organisation,	  Médecins	  Sans	  Frontières	  (MSF)	  (who	  started	  the	  first	  programme	  to	  provide	  
ART	  in	  South	  Africa	  at	  this	  site	  in	  2001)	  and	  with	  the	  University	  of	  Cape	  Town.	  	  Several	  
successful	  and	  large	  clinical	  studies	  primarily	  focused	  on	  HIV/TB	  have	  been	  conducted	  at	  this	  
site	  since	  2004.	  	  Over	  this	  time	  research	  infrastructure	  and	  capacity	  has	  been	  expanded	  to	  
provide	  additional	  rooms,	  buildings	  and	  appropriate	  facilities	  as	  well	  as	  a	  core	  of	  
International	  Convention	  on	  Harmonization	  of	  Good	  Clinical	  Practice	  (ICH-­‐GCP)	  trained	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clinical	  research	  staff	  to	  enable	  recruitment	  and	  follow	  up	  of	  participants	  in	  clinical	  studies	  
and	  trials.	  	  
2.1.3.2 Standard	  of	  care	  for	  adult	  HIV/TB	  patients	  in	  Khayelitsha	  
HIV	  counselling	  and	  testing	  (HCT)	  has	  been	  widely	  rolled	  out	  in	  Khayelitsha	  and	  uptake	  and	  
acceptability	  amongst	  the	  population	  has	  rapidly	  increased	  with	  55,000	  being	  tested	  for	  HIV	  
in	  2010	  (20%	  were	  positive)[184].	  	  HIV	  testing	  is	  performed	  by	  trained	  healthcare	  staff	  using	  
a	  point-­‐of-­‐care	  (POC)	  finger	  prick	  test	  for	  antibodies	  to	  HIV	  1/2	  with	  positive	  results	  
confirmed	  by	  a	  second	  (different)	  POC	  test.	  	  Those	  who	  are	  HIV	  positive	  have	  blood	  taken	  
for	  CD4	  count.	  	  Patients	  with	  CD4	  count	  ≤	  350/mm3	  (or	  otherwise	  eligible	  for	  ART	  as	  
mentioned	  above)	  are	  referred	  to	  ART	  clinic	  and	  offered	  treatment.	  	  First	  line	  treatment	  is	  
currently	  a	  fixed	  dose	  combination	  of	  300	  mg	  tenofovir	  (TDF),	  200	  mg	  emtricitabine	  (FTC),	  
600	  mg	  efavirenz	  (EFV)	  taken	  once	  daily.	  	  Those	  not	  eligible	  for	  ART	  are	  referred	  to	  a	  
wellness	  clinic	  where	  they	  are	  reviewed	  every	  1-­‐2	  months	  and	  provided	  with	  healthy	  
lifestyle	  advice	  and	  vitamin	  tablets	  (B/C).	  	  In	  addition,	  specific	  concerns	  of	  the	  patient	  are	  
addressed,	  weight	  and	  blood	  pressure	  is	  measured,	  symptom	  screens	  for	  sexually	  
transmitted	  infection	  and	  TB	  are	  carried	  out	  and	  WHO	  clinical	  stage	  is	  determined.	  	  CD4	  
count	  is	  repeated	  every	  6	  months	  to	  re-­‐evaluate	  for	  ART	  eligibility.	  	  Co-­‐trimoxazole	  
prophylaxis	  is	  commenced	  for	  patients	  with	  a	  WHO	  stage	  II/III/IV	  condition	  or	  CD4	  count	  ≤	  
200/mm3.	  	  In	  adults	  no	  testing	  for	  latent	  TB	  by	  TST	  is	  performed	  and	  currently	  Isoniazid	  
Preventive	  Therapy	  (IPT)	  is	  not	  widely	  provided	  within	  the	  Western	  Cape,	  which	  is	  an	  
anomaly	  nationally[187,	  188].	  	  The	  current	  national	  guidelines	  (2010)	  recommend	  6	  months	  
IPT	  without	  the	  requirement	  for	  TST	  in	  ART	  naïve	  patients[189].	  	  The	  Western	  Cape	  province	  
are	  hoping	  to	  implement	  a	  more	  comprehensive	  approach	  based	  on	  recent	  evidence	  and	  
international	  guidelines	  suggesting	  longer	  duration	  of	  IPT,	  up	  to	  36	  months	  in	  ART	  naïve	  and	  
12	  months	  in	  ART	  established	  patients	  may	  be	  beneficial[190-­‐192].	  	  Patients	  in	  whom	  TB	  
screen	  is	  positive	  (cough	  >	  2	  weeks,	  weight	  loss	  >	  1	  month,	  night	  sweats	  >	  1	  month,	  lymph	  
nodes	  >	  2cm	  palpable)	  are	  referred	  to	  TB	  clinic.	  	  At	  the	  start	  of	  the	  study	  in	  2011	  local	  
guidelines	  for	  TB	  investigation	  in	  HIV	  infected	  persons	  included	  submission	  of	  2	  sputum	  
samples	  for	  direct	  smear	  microscopy	  and	  culture.	  	  In	  2012	  this	  changed	  to	  the	  routine	  
testing	  of	  sputum	  of	  TB	  suspects	  using	  GeneXpert	  MTB/RIF	  (Sunnyvale,	  CA,	  USA),	  a	  nucleic	  
acid	  amplification	  test	  (NAAT).	  	  Culture	  was	  then	  only	  performed	  if	  GeneXpert	  was	  
inconclusive	  or	  suggested	  rifampicin	  resistance	  and	  smear	  microscopy	  only	  performed	  if	  
GeneXpert	  was	  positive.	  	  Anyone	  diagnosed	  with	  TB	  (sensitive	  to	  Rifampicin	  on	  GeneXpert)	  
is	  started	  on	  a	  standard	  regimen	  of	  Isoniazid,	  Rifampicin,	  Pyrazinamide	  and	  Ethambutol	  for	  2	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months	  (2HRZE)	  followed	  by	  Isoniazid	  and	  Rifampicin	  for	  4	  months	  (4HR).	  	  ART	  is	  usually	  
commenced	  usually	  within	  2	  –	  8	  weeks	  of	  starting	  of	  TB	  treatment.	  	  	  	  	  	  	  	  	  	  
2.1.4 University	  of	  Cape	  Town	  
The	  majority	  of	  laboratory	  work	  has	  been	  carried	  out	  within	  the	  Institute	  of	  Infectious	  
Diseases	  and	  Molecular	  Medicine	  (IDM)	  at	  the	  University	  of	  Cape	  Town	  (UCT).	  	  The	  IDM	  is	  a	  
world-­‐class,	  multi-­‐disciplinary,	  postgraduate	  research	  institute	  comprised	  of	  more	  than	  20	  
research	  groupings	  that	  operates	  in	  the	  fields	  of	  infectious	  diseases	  and	  molecular	  medicine	  
with	  a	  strong	  focus	  on	  TB	  and	  HIV	  research.	  	  It	  is	  housed	  at	  the	  Faculty	  of	  Health	  Sciences	  
campus	  of	  the	  University	  of	  Cape	  Town	  in	  close	  proximity	  to	  Groote	  Schuur	  Hospital.	  	  	  
	  
Processing	  of	  blood	  samples	  drawn	  from	  study	  participants	  in	  Khayelitsha,	  was	  performed	  
within	  the	  Wilkinson	  Group	  facilities	  at	  the	  IDM,	  which	  included	  a	  BSL	  2	  laboratory	  with	  4	  x	  
class	  2	  biosafety	  cabinets,	  2	  x	  37oC	  CO2	  incubators,	  4	  x	  centrifuges,	  and	  -­‐20oC,	  -­‐80oC	  and	  
liquid	  nitrogen	  sample	  storage	  facilities.	  	  In	  addition	  there	  was	  a	  dedicated	  RNA	  preparation	  
area.	  Daily	  assessment	  and	  maintenance	  of	  these	  facilities	  was	  carried	  out	  by	  a	  laboratory	  
team.	  	  Freezers	  were	  all	  connected	  to	  back	  up	  emergency	  CO2	  supply	  and	  a	  text	  alert	  
system.	  	  	  	  
2.1.4.1 MVA85A	  Phase	  IIB	  vaccine	  trial	  	  
The	  recruitment	  process	  for	  the	  study	  described	  in	  this	  thesis	  was	  initially	  closely	  associated	  
with	  the	  screening	  process	  for	  the	  MVA85A	  Phase	  IIB	  vaccine	  trial.	  	  MVA85A	  is	  a	  TB	  vaccine	  
candidate	  developed	  at	  University	  of	  Oxford	  that	  has	  been	  evaluated	  in	  clinical	  trials	  in	  
partnership	  with	  AERAS.	  	  A	  two	  centre	  Phase	  IIB	  vaccine	  trial	  of	  MVA85A	  in	  healthy	  HIV	  
infected	  adult	  outpatients	  (ART	  naïve	  CD4≥350/mm3	  and	  ART	  established	  CD4≥300/mm3)	  
commenced	  in	  August	  2011;	  Khayelitsha	  site	  B	  CHC	  was	  one	  of	  the	  clinical	  recruitment	  sites	  
and	  Prof	  R.J.	  Wilkinson	  was	  the	  local	  PI.	  	  A	  dedicated	  building	  was	  constructed	  for	  the	  
purpose	  of	  recruitment	  and	  follow-­‐up	  for	  the	  vaccine	  trial	  as	  well	  as	  other	  associated	  studies	  
and	  contained	  4	  consultation	  rooms,	  office	  space,	  phlebotomy	  area	  and	  pharmacy.	  	  A	  
separate	  container	  housing	  a	  digital	  CXR	  machine	  was	  erected	  close	  by	  with	  an	  adjoining	  
sputum	  induction	  booth.	  	  	  
	  
For	  the	  MVA85A	  vaccine	  trial,	  prior	  to	  randomization	  to	  either	  vaccine	  or	  placebo	  arms,	  
potential	  trial	  participants	  were	  screened	  for	  active	  TB	  with	  symptom	  screen,	  sputum	  
culture	  and	  CXR	  and	  for	  latent	  TB	  with	  QFGIT	  first	  and	  then	  TST.	  	  Participants	  with	  a	  positive	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screen	  for	  active	  TB	  were	  referred	  for	  on-­‐going	  investigation	  and	  excluded	  from	  
participation	  in	  the	  vaccine	  trial.	  	  Those	  with	  a	  negative	  screen	  for	  active	  TB	  and	  latent	  TB	  
were	  immediately	  randomised	  into	  the	  vaccine	  trial.	  	  Those	  that	  had	  a	  negative	  screen	  for	  
active	  TB	  but	  a	  positive	  QFGIT	  were	  considered	  as	  potentially	  eligible	  for	  the	  study	  described	  
in	  this	  thesis	  and	  were	  further	  evaluated	  for	  eligibility	  as	  explained	  below	  (prior	  to	  TST	  
administration).	  	  Participants	  not	  considered	  eligible	  for	  the	  study	  described	  in	  this	  thesis,	  
then	  had	  TST	  performed	  and	  were	  treated	  with	  6	  months	  of	  IPT	  prior	  to	  randomization	  into	  
the	  vaccine	  trial.	  	  From	  April	  2012	  there	  was	  a	  sponsor-­‐initiated	  postponement	  in	  
recruitment	  into	  the	  vaccine	  trial	  followed	  by	  a	  curtailment	  in	  scope	  of	  the	  trial	  following	  
disappointing	  results	  from	  a	  separate	  paediatric	  trial	  of	  MVA85A[193].	  	  Therefore	  from	  
August	  2011	  to	  April	  2012	  participants	  for	  the	  study	  described	  in	  this	  thesis	  were	  recruited	  
within	  screening	  process	  of	  the	  vaccine	  trial	  but	  after	  April	  2012	  it	  was	  necessary	  for	  the	  
screening	  for	  this	  study	  to	  take	  place	  independently	  from	  the	  vaccine	  trial	  but	  using	  a	  similar	  
screening	  approach	  for	  active	  and	  latent	  TB.	  	  	  	  	  	  	  	  	  
2.1.5 MRC	  National	  Institute	  for	  Medical	  Research,	  London	  
The	  laboratory	  work	  for	  whole	  blood	  transcriptomics	  component	  of	  the	  study	  and	  training	  in	  
analysis	  of	  microarray	  data	  was	  carried	  out	  at	  the	  MRC	  National	  Institute	  for	  Medical	  
Research	  in	  London	  over	  a	  3	  month	  period	  between	  August	  and	  November	  2013	  in	  the	  
laboratories	  of	  Dr	  Anne	  O’Garra.	  	  	  	  	  	  	  	  
2.1.6 PET/CT	  facilities	  	  
FDG-­‐PET/CT	  scans	  were	  performed	  at	  2	  different	  sites	  during	  the	  study	  both	  approximately	  
15	  miles	   from	  the	  study	  site	   in	  Khayelitsha	  with	  the	  participants	  transported	  too	  and	  from	  
these	  sites	   for	  scans	   to	  be	  carried	  out.	   	  Those	  performed	  between	  October	  2011	  and	  May	  
2012	  were	  performed	  at	   the	  Cape	  PET-­‐CT	  centre	   in	  Panorama	  Medi-­‐Clinic	  private	  hospital	  
using	  a	  Siemens	  Biograph	  PET/CT	  machine	  as	  this	  was	  at	  the	  time	  the	  only	  PET/CT	  scanner	  in	  
the	   Western	   Cape	   province.	   	   From	   June	   2012	   to	   July	   2013,	   FDG-­‐PET/CT	   scans	   were	  
performed	   at	   the	   newly	   opened	   Western	   Cape	   Academic	   PET-­‐CT	   centre	   at	   Tygerberg	  
provincial	   hospital	  which	  had	   close	   links	   to	   Stellenbosch	  University.	   	   This	   facility	   housed	  a	  
Phillips	   Gemini	   PET/CT	   machine.	   	   The	   transfer	   was	   due	   to	   the	   development	   of	   academic	  
collaboration	  with	  Stellenbosch	  Nuclear	  Medicine	  department	  and	  the	  cost	  effectiveness	  of	  
performing	  imaging	  outside	  of	  a	  private	  hospital.	  	  Imaging	  protocols	  used	  on	  the	  2	  machines	  
were	  similar	  and	  all	  repeat	  imaging	  was	  performed	  on	  the	  same	  machine	  as	  the	  initial	  scan.	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All	   imaging	   carried	  out	  on	   the	  2	   scanners	  was	   reported	  by	   the	   same	  group	  of	   radiologists	  
and	  Nuclear	  Medicine	  physicians	  using	  the	  same	  structured	  report.	  
2.1.7 Overview	  of	  study	  timeline	  
Recruitment	  for	  study	  commenced	  in	  August	  2011	  and	  was	  completed	  in	  January	  2013.	  	  
Follow-­‐up	  of	  patients	  continued	  until	  July	  2013.	  	  Laboratory	  work	  continued	  until	  May	  2014	  
with	  analysis	  and	  write	  up	  completed	  by	  August	  2014	  (figure	  2.3).	  
	  
2.2 Clinical	  Recruitment	  
2.2.1 Approvals	  for	  study	  
Ethical	  approval	  for	  this	  study	  was	  received	  from	  University	  of	  Cape	  Town	  (013/2011)	  and	  
Stellenbosch	  University	  (N12/11/079).	  	  Approval	  to	  conduct	  this	  study	  at	  the	  Khayelitsha	  Site	  
B	  Community	  Health	  Centre	  was	  received	  from	  Western	  Cape	  Government,	  Department	  of	  
Health	  (RP	  23/2012)	  and	  the	  City	  of	  Cape	  Town	  (10286).	  	  
2.2.2 Summary	  of	  Clinical	  Study	  Design	  
This	  was	  an	  observational	  study	  in	  which	  the	  groups	  of	  participants	  and	  controls	  outlined	  in	  
table	  2.1	  were	  recruited,	  to	  test	  the	  principal	  hypotheses	  that:	  
	  
• The	  transition	  from	  latent	  tuberculosis	  to	  active	  pulmonary	  tuberculosis	  involves	  a	  
subclinical	  phase,	  which	  may	  be	  apparent	  on	  detailed	  imaging	  of	  the	  lungs	  using	  FDG-­‐
PET/CT.	  	  
	  
• Those	  with	  radiographic	  evidence	  of	  subclinical	  pathology	  will	  have	  similarities	  in	  
immune	  response	  and	  transcriptional	  profile	  to	  people	  with	  active	  tuberculosis	  but	  be	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Figure	  2.3	  –	  Gant	  chart	  showing	  progress	  with	  study	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distinguishable	  from	  those	  with	  evidence	  of	  latent	  infection	  without	  radiographic	  
evidence	  of	  subclinical	  pathology.	  
	  
As	  the	  primary	  aim	  of	  the	  study	  was	  to	  establish	  whether	  subclinical	  TB	  was	  on	  a	  spectrum	  
between	  latent	  and	  active	  TB	  with	  regard	  transcriptional	  and	  immune	  responses,	  the	  
principal	  control	  group	  used	  was	  HIV	  infected	  persons	  with	  active	  TB	  that	  were	  ART	  naïve	  
but	  matched	  for	  CD4	  count,	  sex	  and	  age.	  	  The	  HIV	  uninfected	  no	  TB,	  HIV	  uninfected	  active	  
TB	  and	  HIV	  infected	  no	  TB	  groups	  were	  used	  to	  establish	  the	  independent	  effects	  of	  active	  
TB	  and	  HIV	  on	  the	  transcriptional	  signature.	  	  It	  is	  acknowledged	  that	  these	  control	  groups	  
may	  also	  have	  also	  been	  of	  value	  in	  exploring	  the	  independent	  effects	  of	  HIV	  and	  TB	  on	  
immune	  responses	  but	  these	  samples	  were	  not	  available.	  	  The	  HIV	  infected	  ART	  established	  
group	  was	  used	  to	  explore	  if	  the	  effect	  of	  HIV	  on	  the	  transcriptional	  signature	  was	  reversible	  
with	  ART.	  	  The	  important	  factor	  therefore	  was	  that	  this	  group	  did	  not	  have	  active	  TB	  
although	  it	  is	  acknowledged	  that	  an	  HIV	  infected,	  ART	  established	  group	  with	  no	  TB	  would	  
have	  been	  a	  preferable	  control	  group	  for	  this	  purpose.	  	  However,	  as	  explained	  recruitment	  
of	  the	  ART	  group	  was	  curtailed	  following	  postponement	  of	  the	  vaccine	  trial.	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Table	  2.1	  –	  Summary	  of	  participants	  and	  controls	  recruited	  into	  the	  study:	  	  Table	  shows	  clinical	  characteristics,	  whether	  
PET/CT	  was	  performed	  and	  whether	  participants	  formed	  part	  of	  transcriptional	  study	  (RNA)	  or	  immunological	  study	  
(Immune)	  
Chapter	  2	  –	  Material	  and	  Methods	  
	   78	  
2.2.3 Diagnostic	  definitions	  
2.2.3.1 HIV-­‐1	  infection	  	  
Participants	  were	  determined	  to	  be	  HIV-­‐1	  infected	  if	  they	  had	  documented	  evidence	  of	  a	  
positive	  point	  of	  care	  (POC)	  test	  for	  HIV	  in	  their	  medical	  notes	  AND,	  either	  a	  positive	  HIV-­‐1	  
viral	  load	  and/or	  a	  positive	  HIV-­‐1	  ELISA.	  	  Participants	  with	  inconsistent	  results	  had	  further	  
testing	  performed	  if	  necessary	  (e.g.	  HIV	  PCR,	  HIV	  Western	  Blot).	  	  	  
	  
A	  participant	  was	  determined	  to	  be	  ART	  naïve	  if	  they	  verbally	  reported	  not	  taking	  ART	  AND	  
no	  evidence	  of	  ART	  prescription	  was	  found	  in	  the	  medical	  notes.	  	  	  
	  
Participants	  were	  determined	  to	  be	  established	  on	  ART	  if	  they	  verbally	  reported	  taking	  ART	  
for	  >	  6	  months	  AND	  had	  evidence	  of	  ART	  prescription	  in	  the	  medical	  notes	  AND	  had	  a	  
suppressed	  viral	  load	  (<40	  copies/mL	  or	  Lower	  than	  detectable	  limit	  (LDL)).	  	  	  
	  
2.2.3.2 Active	  Tuberculosis	  
Participants	  were	  considered	  to	  have	  active	  pulmonary	  tuberculosis	  if	  they	  had	  any	  of	  the	  
following	  symptoms	  consistent	  with	  tuberculosis:	  
• Cough	  ≥	  1week	  
• Haemoptysis	  
• Fever	  –	  documented	  >	  38oC	  or	  reported	  history	  of	  fever	  
• Drenching	  night	  sweats	  
• Weight	  loss	  	  
AND	  sputum	  either	  culturing	  Mtb	  or	  positive	  by	  GeneXpert	  for	  Mtb.	  	  	  
2.2.3.3 Latent	  Tuberculosis	  
Participants	  were	  determined	  to	  have	  latent	  tuberculosis	  if	  at	  initial	  screening	  they	  had	  all	  of	  
the	  following	  features:	  	  
• QFGIT	  positive	  	  
• CXR	  without	  evidence	  of	  active	  tuberculosis	  (see	  below)	  
• Negative	  42-­‐day	  culture	  for	  M.	  tuberculosis	  	  
• No	  symptoms	  suggestive	  of	  active	  TB	  over	  the	  screening	  period	  	  
• No	  previous	  history	  of	  active	  TB	  treatment	  or	  IPT	  
	  
Chapter	  2	  –	  Material	  and	  Methods	  
	   79	  
TST	  was	  not	  used	  to	  confirm	  latent	  tuberculosis	  because	  of	  concern	  over	  Mtb	  antigens	  
within	  PPD	  boosting	  mycobacteria	  specific	  immune	  responses	  and	  affecting	  interpretation	  of	  
any	  subsequent	  immunological	  assays.	  	  This	  has	  previously	  been	  well	  reported[194].	  
	  
Asymptomatic	  HIV	  infected	  ART	  naïve	  participants	  with	  latent	  TB	  were	  then	  sub-­‐classified	  
into	  those	  with	  and	  without	  subclinical	  pathology	  on	  the	  basis	  of	  PET/CT	  findings	  (see	  
chapter	  4)	  prior	  to	  subsequent	  transcriptional	  (chapter	  5)	  and	  immunological	  (chapter	  6)	  
analyses.	  	  	  	  	  
2.2.3.4 No	  evidence	  of	  latent	  TB	  
Participant	  were	  considered	  to	  have	  no	  evidence	  of	  latent	  TB	  if	  they	  had	  the	  following	  
features:	  
• QFGIT	  negative	  
• TST	  <5mm	  if	  HIV	  infected	  or	  <10mm	  if	  HIV	  uninfected	  
For	  HIV	  infected	  control	  in	  addition	  they	  required	  a	  CXR	  with	  no	  evidence	  of	  active	  or	  
inactive	  TB	  and	  a	  negative	  culture	  at	  42	  days.	  
	  
2.2.4 Consent	  procedure	  
All	  consent	  documents	  were	  provided	  to	  potential	  participants	  in	  English	  or	  Xhosa	  and	  read	  
through	  with	  a	  member	  of	  the	  study	  team	  to	  ensure	  full	  understanding	  and	  capacity	  to	  
consent	  before	  signing.	  	  Participants	  recruited	  to	  undergo	  PET/CT	  were	  recruited	  in	  a	  2-­‐stage	  
process.	  	  At	  initial	  screening	  consent	  they	  were	  provided	  with	  an	  information	  leaflet	  in	  
English	  or	  Xhosa	  explaining	  the	  study	  procedures	  and	  the	  risks	  and	  benefits	  of	  study	  
involvement.	  	  At	  the	  end	  of	  the	  screening	  period	  this	  leaflet	  was	  explained	  in	  detail	  with	  
eligible	  participants	  and	  any	  queries	  or	  concerns	  addressed	  prior	  to	  final	  consenting	  for	  
study	  entry.	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Figure	  2.4	  Study	  Flow	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2.2.5 Overview	  of	  study	  sampling	  and	  procedures	  
	  
	  
2.2.6 Recruitment	  of	  primary	  group	  of	  interest	  	  
	  
Healthy	  outpatients	  attending	  the	  pre-­‐ART	  wellness	  clinic	  were	  approached	  for	  screening	  
consent.	  	  At	  the	  initial	  screening	  those	  that	  provided	  consent	  had	  the	  following	  performed:	  
• CXR	  
• QFGIT	  
• CD4	  (if	  very	  recently	  available	  this	  was	  not	  repeated	  at	  screening)	  
• Sputum	  smear	  and	  culture	  x	  2	  
• Screening	  history	  and	  exam	  
	  
This	  screening	  was	  either	  performed	  as	  part	  of	  the	  vaccine	  trial	  screening	  or	  independently	  
as	  explained	  above.	  	  Participants	  were	  reviewed	  after	  1	  week	  with	  results.	  	  Those	  that	  were	  
asymptomatic,	  ART	  naïve,	  CD4	  ≥350mm3,	  QFGIT	  positive,	  with	  no	  previous	  history	  of	  
tuberculosis	  and	  without	  CXR	  evidence	  of	  active	  disease	  had	  a	  detailed	  history	  and	  
Table	  2.2	  –	  Overview	  of	  visits	  and	  sampling:	  Red	  diamond	  =	  primary	  group	  of	  interest;	  Green	  diamond	  =	  controls,	  Black	  
diamond	  =	  samples	  stored	  not	  used	  in	  thesis	  analysis;	  Green	  star	  =	  CXR	  not	  specifically	  performed	  for	  study	  so	  not	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examination	  performed	  and	  were	  asked	  to	  return	  at	  6	  weeks	  for	  results	  of	  sputum	  culture	  
and	  a	  repeat	  CXR	  (figure	  2.4).	  	  At	  6	  weeks	  those	  that	  met	  inclusion/exclusion	  criteria	  were	  
consented	  for	  participation	  in	  the	  study	  and	  had	  PET/CT	  scan	  arranged	  	  	  	  	  	  	  	  
2.2.6.1 Inclusion	  criteria	  
• HIV-­‐1	  infected	  	  
• ART	  naïve	  
• CD4	  ≥	  350/mm3	  at	  initial	  screening	  visit	  
• QFGIT	  positive	  at	  initial	  screening	  visit	  
• CXR	  without	  evidence	  of	  active	  TB	  at	  initial	  screening	  visit	  	  
• Age	  ≥	  18	  years	  
2.2.6.2 Exclusion	  criteria	  
• Screening	  sputum	  culture	  positive	  for	  TB	  
• Symptoms	  or	  signs	  of	  active	  pulmonary	  or	  extra-­‐pulmonary	  TB	  during	  screening	  
period	  
• Evidence	  of	  any	  acute	  or	  unexplained	  chronic	  illness	  
• Previously	  diagnosed	  or	  treated	  TB	  
• Previous	  IPT	  
• Known	  recent	  contact	  of	  MDR	  TB	  
• CXR	  abnormality	  within	  lung	  parenchyma	  or	  lymph	  nodes	  known	  or	  suspected	  to	  
related	  to	  a	  condition	  other	  than	  inactive	  TB	  	  
• Age	  >	  50	  years	  
• Smoker	  of	  >	  30	  pack	  years	  
• History	  of	  working	  in	  the	  mines	  or	  evidence	  of	  silicosis	  
• Previously	  diagnosed	  malignancy	  
• Previously	  diagnosed	  chronic	  lung	  infection	  (NTM,	  Fungal)	  
• Known	  diagnosis	  of	  chronic	  lung	  disease	  (COPD,	  bronchiectasis)	  
• Known	  diagnosis	  of	  chronic	  inflammatory	  condition	  associated	  with	  pulmonary	  
pathology	  (Sarcoid,	  RA,	  Wegeners	  granulomatosis)	  	  
• Current	  steroid	  use	  
• Uncontrolled	  diabetes	  mellitus	  
• Pregnant	  or	  planning	  pregnancy	  
• Breast	  feeding	  or	  unable	  to	  avoid	  very	  close	  contact	  with	  young	  children/pregnant	  
persons	  for	  12	  hours	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• Compelling	  indication	  for	  ART	  despite	  CD4>350/mm3	  
• Inclusion	  in	  study	  to	  result	  in	  annual	  radiation	  exposure	  of	  >	  50mSv	  
• Investigator	  assessment	  of	  lack	  of	  willingness	  or	  inability	  to	  participate	  and	  comply	  
with	  all	  requirements	  of	  the	  protocol	  or	  identification	  of	  any	  factor	  felt	  to	  
significantly	  increase	  the	  participant’s	  risk	  of	  suffering	  an	  adverse	  outcome	  
	  
2.2.7 Rational	  for	  inclusion/exclusion	  criteria	  
In	  the	  extremely	  high	  TB	  burden	  setting	  of	  Khayelitsha	  particularly	  in	  an	  asymptomatic	  HIV	  
infected	  cohort	  with	  evidence	  of	  latent	  tuberculosis	  and	  CD4≥350/mm3,	  the	  pre-­‐test	  
probability	  of	  pulmonary	  lesions	  identified	  on	  FDG-­‐PET/CT	  being	  related	  to	  tuberculosis	  was	  
high.	  	  However,	  inclusion	  and	  exclusion	  criteria	  were	  designed	  to	  ensure	  that	  pulmonary	  
lesions	  related	  to	  alternative	  causes	  were	  minimised	  and	  that	  conditions	  that	  may	  cause	  
false	  negative	  or	  positive	  FDG	  uptake	  were	  excluded.	  Malignancy	  is	  the	  main	  differential	  
diagnosis	  of	  concern.	  	  To	  minimise	  probability	  of	  a	  lesion	  relating	  to	  malignancy,	  those	  aged	  
over	  50	  years	  or	  with	  >	  30	  pack	  years	  of	  smoking	  history	  or	  with	  a	  previous	  history	  of	  
malignancy	  were	  excluded[195].	  
	  	  	  
Alternative	  infections	  similarly	  could	  give	  rise	  to	  abnormalities	  and	  those	  with	  a	  history	  of	  
chronic	  pulmonary	  infection	  were	  excluded.	  	  With	  regard	  to	  undiagnosed	  infection	  other	  
than	  TB,	  those	  with	  bacterial	  pneumonia	  would	  be	  unlikely	  to	  remain	  asymptomatic	  over	  6	  
weeks.	  	  Non-­‐tuberculous	  mycobacteria	  (NTM)	  infection	  usually	  presents	  as	  disseminated	  
disease	  in	  HIV-­‐infected	  persons	  with	  CD4	  <	  100mm3	  (even	  at	  this	  level	  of	  
immunosuppression	  disseminated	  TB	  is	  approximately	  5	  times	  more	  common	  than	  
Mycobacterium	  avium	  and	  intracellulare	  infections	  (MAI)	  in	  South	  Africa[196]),	  however,	  it	  is	  
also	  a	  cause	  of	  pulmonary	  disease	  in	  those	  with	  pre-­‐existing	  lung	  disease.	  	  Silicosis,	  
previously	  treated	  TB	  and	  working	  >	  9	  years	  in	  a	  mine	  were	  exclusion	  criteria	  to	  minimise	  
this[197,	  198].	  	  Other	  chronic	  infections	  considered	  were	  pulmonary	  cryptococcal	  disease	  
which	  is	  uncommon	  in	  those	  with	  CD4	  counts	  greater	  than	  350	  /mm3.	  	  Classical	  
histoplasmosis,	  although	  present	  in	  the	  Western	  Cape	  province	  of	  South	  Africa	  is	  relatively	  
rare	  [199].	  Blastomycosis	  is	  rarer	  still	  with	  only	  81	  cases	  reported	  in	  the	  whole	  of	  Africa	  
between	  1951	  and	  1987[200]	  and	  only	  a	  single	  case	  of	  Paragonimus	  has	  been	  reported	  in	  
South	  Africa[201].	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Inflammatory	  conditions	  such	  as	  rheumatoid	  arthritis,	  ankylosing	  spondylitis	  or	  sarcoidosis	  
can	  cause	  parenchymal	  abnormalities	  and	  those	  with	  history	  of	  such	  chronic	  inflammatory	  
conditions	  were	  excluded.	  	  It	  would	  be	  unlikely	  that	  parenchymal	  abnormalities	  related	  to	  
these	  conditions	  would	  be	  present	  in	  the	  absence	  of	  other	  symptoms.	  	  	  
	  
Uncontrolled	  diabetes	  mellitus	  leading	  to	  chronic	  hyperglycaemia	  can	  lead	  to	  
downregulation	  of	  GLUT	  transporters	  and	  interfere	  with	  FDG	  uptake	  into	  cells	  hence	  was	  an	  
exclusion.	  	  Steroid	  use	  may	  also	  affect	  cellular	  recruitment	  to	  sites	  of	  pathology	  reducing	  
FDG	  uptake	  so	  was	  also	  an	  exclusion.	  
2.2.8 Modifications	  to	  the	  study	  design	  
In	  the	  initial	  study	  design	  it	  was	  intended	  that	  asymptomatic,	  ART	  naïve,	  HIV	  infected	  
participants	  with	  latent	  TB	  recruited	  to	  undergo	  PET/CT	  would	  also	  have	  evidence	  of	  inactive	  
TB	  lesions	  on	  CXR,	  which	  were	  intended	  to	  be	  evaluated	  in	  by	  PET/CT.	  	  Screening	  was	  
therefore	  incorporated	  into	  a	  much	  larger	  study	  (the	  MVA85A	  vaccine	  trial)	  as	  the	  screen	  to	  
recruitment	  ratio	  was	  anticipated	  to	  be	  high.	  	  Following	  postponement	  of	  the	  vaccine	  trial	  in	  
April	  2012	  modifications	  to	  the	  study	  design	  had	  to	  be	  made	  and	  it	  had	  already	  become	  
apparent	  that	  CXR	  was	  not	  an	  effective	  way	  to	  screen	  for	  abnormalities	  on	  PET/CT	  (as	  will	  be	  
discussed	  in	  chapter	  4).	  	  The	  inclusion	  criteria	  were	  modified	  so	  that	  participants	  were	  
required	  to	  have	  no	  evidence	  of	  active	  TB	  (i.e.	  either	  have	  evidence	  of	  inactive	  TB	  lesions	  or	  
considered	  to	  have	  a	  normal	  CXR).	  	  This	  reduced	  the	  screen	  to	  recruitment	  ratio	  and	  allowed	  
for	  the	  study	  to	  continue	  independently	  of	  the	  vaccine	  trial.	  	  In	  all,	  8	  participants	  were	  
recruited	  into	  the	  study	  via	  vaccine	  trial	  screening	  and	  27	  participants	  independently	  from	  it.	  	  	  
2.2.9 Follow-­‐up	  and	  treatment	  
Recruited	  participants	  in	  the	  primary	  group	  of	  interest	  were	  followed	  up	  and	  sampled	  as	  
outlined	  in	  Table	  2.2.	  	  Participants	  were	  seen	  for	  study	  visits	  at	  the	  following	  time	  points	  for	  
assessment	  and	  sampling,	  
• Day	  of	  PET/CT	  scan	  
• 1	  week	  after	  PET/CT	  scan	  
• 1	  month	  after	  PET/CT	  scan	  
• 3	  months	  after	  PET/CT	  scan	  
• 6	  months	  after	  PET/CT	  scan	  for	  repeat	  PET/CT	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In	  terms	  of	  clinical	  management,	  the	  majority	  of	  participants	  were	  commenced	  on	  6	  months	  
isoniazid	  as	  preventive	  therapy.	  	  Any	  participant	  that	  developed	  symptoms,	  radiographic	  
progression	  or	  had	  concerning	  abnormalities	  on	  PET/CT	  was	  further	  investigated	  as	  
appropriate	  with	  participants	  commenced	  on	  full	  active	  TB	  treatment	  if	  TB	  was	  confirmed	  
microbiologically	  or	  suspected	  as	  highly	  probable.	  	  	  	  	  
2.2.10 Matching	  strategy	  for	  control	  groups	  
Control	  participants	  were	  recruited	  primarily	  to	  provide	  positive	  and	  negative	  control	  groups	  
for	  whole	  blood	  transcriptomics	  experiments	  and	  to	  allow	  for	  a	  degree	  of	  validation	  of	  any	  
identified	  transcriptional	  signatures.	  The	  HIV	  infected	  active	  TB	  control	  group	  were	  also	  used	  
to	  provide	  a	  positive	  control	  for	  immunological	  studies.	  
	  
The	  HIV	  infected	  controls	  were	  matched	  with	  participants	  of	  the	  primary	  group	  of	  interest	  
by	  distribution	  of	  age,	  sex	  and	  CD4	  count	  as	  these	  were	  potentially	  confounding	  factors.	  	  
Ethnicity	  in	  Khayelitsha	  is	  almost	  exclusively	  Xhosa	  and	  therefore	  did	  not	  need	  to	  be	  formally	  
matched.	  	  HIV	  infected	  participants	  were	  not	  matched	  for	  viral	  load,	  as	  active	  TB	  infection	  is	  
known	  to	  directly	  increase	  HIV	  viral	  load	  and	  hence	  matching	  by	  this	  variable	  would	  not	  
feasible	  and	  would	  also	  lead	  to	  issues	  of	  overmatching.	  	  The	  effect	  of	  any	  difference	  in	  viral	  
load	  between	  these	  groups	  will	  be	  considered	  in	  analysis.	  	  
	  
Matching	  was	  performed	  such	  that	  the	  distributions	  of	  the	  variables	  (age,	  sex	  and	  CD4	  
count)	  were	  similar	  between	  the	  groups	  and	  so	  that	  the	  median	  values	  didn’t	  vary	  
significantly.	  	  Recruitment	  of	  the	  primary	  group	  and	  the	  HIV	  infected	  control	  groups	  
overlapped	  so	  distribution	  was	  monitored	  in	  real	  time.	  
	  
HIV	  uninfected	  control	  groups	  were	  recruited	  towards	  the	  end	  of	  the	  study	  over	  a	  shorter	  
period	  of	  time,	  after	  the	  majority	  of	  the	  other	  participant	  groups	  had	  been	  recruited.	  
Therefore	  precise	  matching	  of	  age	  and	  sex	  was	  not	  possible.	  
2.2.11 Symptomatic	  active	  TB	  controls	  
HIV	  infected	  active	  TB	  controls	  were	  recruited	  either	  within	  the	  study	  screening	  process,	  as	  
outlined	  above	  in	  figure	  2.4,	  at	  the	  research	  clinic	  in	  Khayelitsha	  Site	  B	  CHC,	  or	  
independently	  through	  the	  TB	  clinic	  at	  the	  same	  site.	  	  HIV	  uninfected	  active	  TB	  controls	  were	  
all	  recruited	  through	  the	  TB	  clinic	  at	  this	  site.	  	  The	  majority	  of	  participants	  recruited	  through	  
the	  TB	  clinic	  already	  had	  a	  confirmed	  diagnosis	  of	  active	  TB,	  either	  by	  GeneXpert	  or	  culture	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and	  were	  often	  co-­‐recruited	  with	  other	  ongoing	  clinical	  studies.	  	  In	  these	  instances	  sputum	  
sampling	  was	  not	  repeated.	  	  In	  some	  cases	  TB	  treatment	  had	  already	  been	  commenced,	  
those	  that	  had	  >	  24	  hours	  treatment	  were	  not	  eligible.	  	  After	  providing	  consent	  eligible	  
active	  control	  participants	  had	  blood	  sampling	  as	  indicated	  in	  table	  2.2	  	  	  	  
2.2.11.1 Inclusion	  criteria	  -­‐	  active	  TB	  controls	  	  
• Sputum	  GeneXpert	  positive	  or	  culture	  positive	  	  
• Symptoms	  consistent	  with	  active	  TB	  
• Age	  ≥	  18	  years	  
	  
For	  HIV	  infected	  active	  controls	  
• HIV-­‐1	  infected	  	  
• ART	  naïve	  	  
• CD4	  ≥	  350/	  mm3	  or	  CD4	  count	  unknown	  if	  newly	  diagnosed	  with	  HIV	  
	  
For	  HIV	  uninfected	  active	  controls	  
• Evidence	  of	  negative	  POC	  HIV	  test	  
2.2.11.2 Exclusion	  criteria	  -­‐	  active	  TB	  Controls	  	  
• On	  TB	  treatment	  for	  more	  than	  24	  hours	  
• Evidence	  of	  acute	  or	  unexplained	  chronic	  illness	  other	  than	  TB	  or	  HIV	  
	  
2.2.12 Asymptomatic	  QFGIT	  negative,	  TST	  negative	  controls	  
HIV	  infected,	  QFGIT	  negative,	  TST	  negative	  control	  subjects	  were	  identified	  through	  the	  
screening	  process	  outlined	  above	  (figure	  2.4).	  	  HIV	  uninfected,	  QFGIT	  negative,	  TST	  negative	  
control	  subjects	  were	  screened	  and	  identified	  separately	  at	  the	  same	  site.	  	  For	  all	  these	  
control	  participants,	  blood	  sampling	  was	  carried	  out	  prior	  to	  TST	  administration.	  	  HIV	  
infected	  controls	  also	  had	  sputum	  culture	  and	  CXR	  performed,	  however,	  HIV	  uninfected	  
controls	  did	  not.	  	  This	  was	  in	  part	  due	  to	  logistics	  but	  also	  because	  asymptomatic,	  HIV	  
uninfected	  persons	  are	  less	  likely	  to	  have	  positive	  sputum	  culture	  even	  in	  this	  setting.	  	  	  
2.2.12.1 Inclusion	  criteria	  –	  QFGIT	  negative,	  TST	  negative	  controls	  
• QFGIT	  negative	  
• TST	  negative	  
• Age	  ≥	  18	  years	  
	  
For	  HIV	  infected	  controls	  
• HIV-­‐1	  infected	  
• ART	  naive	  
• CD4	  ≥	  350/	  mm3	  
• CXR	  no	  evidence	  of	  active	  or	  inactive	  TB	  
• Sputum	  culture	  negative	  for	  Mtb	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For	  HIV	  uninfected	  controls	  	  	  
• Evidence	  of	  negative	  POC	  HIV	  test	  
 
2.2.12.2 Exclusion	  criteria	  -­‐	  QFGIT	  negative,	  TST	  negative	  controls	  
• Symptoms	  or	  signs	  of	  active	  pulmonary	  or	  extra-­‐pulmonary	  TB	  
• Evidence	  of	  acute	  or	  unexplained	  chronic	  illness	  
	  
2.2.13 Asymptomatic	  HIV	  infected	  ART	  controls	  
HIV	  infected,	  QFGIT	  positive	  control	  subjects	  established	  on	  ART	  were	  recruited	  through	  the	  
screening	  process	  of	  the	  vaccine	  trial	  and	  were	  not	  recruited	  following	  postponement	  of	  the	  
vaccine	  trial	  and	  hence	  numbers	  were	  limited	  to	  8.	  	  	  
2.2.13.1 Inclusion	  criteria	  -­‐	  HIV	  infected	  ART	  established,	  QFGIT	  positive	  controls	  	  
• HIV-­‐1	  infected	  
• Established	  on	  ART	  for	  ≥	  6	  months	  with	  suppressed	  viral	  load	  
• CD4	  ≥	  350/	  mm3	  
• QFGIT	  positive	  
• CXR	  without	  evidence	  of	  active	  TB	  
• Age	  ≥	  18	  years	  
 
2.2.13.2 Exclusion	  Criteria	  -­‐	  HIV	  infected	  ART	  established	  QFGIT	  positive	  controls	  	  
• Sputum	  culture	  positive	  for	  Mtb	  
• Symptoms	  or	  signs	  of	  active	  pulmonary	  or	  extra-­‐pulmonary	  TB	  
• Evidence	  of	  acute	  or	  unexplained	  chronic	  illness	  
2.3 Details	  of	  Clinical	  Procedures	  &	  Data	  collection	  Methods	  
2.3.1 History	  and	  Examination	  
Medical	  history	  and	  examination	  was	  recorded	  in	  a	  structured	  format	  directly	  onto	  a	  
dedicated	  clinical	  research	  form	  (CRF)	  with	  ability	  to	  add	  free	  text	  if	  desired.	  	  A	  
comprehensive	  medical	  history	  and	  examination	  was	  recorded	  on	  participants	  recruited	  for	  
PET/CT.	  	  History	  and	  examination	  were	  more	  targeted	  during	  screening	  of	  participants	  and	  
for	  control	  participants.	  	  
2.3.2 Sputum	  sampling	  and	  induction	  
All	  HIV	  infected	  participants	  and	  controls	  regardless	  of	  symptoms	  were	  asked	  to	  provide	  
sputum	  samples	  as	  part	  of	  screening	  for	  active	  TB.	  	  If	  participants	  could	  not	  produce	  
adequate	  sputum	  samples	  spontaneously,	  they	  were	  requested	  to	  undergo	  sputum	  
induction,	  provided	  there	  were	  no	  contraindications	  (primarily	  asthma).	  	  Sputum	  was	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induced	  in	  a	  specially	  designed	  cubicle	  housed	  outdoors	  on	  the	  study	  site	  to	  minimise	  the	  
risk	  of	  aerosol	  transmission.	  	  This	  was	  performed	  with	  the	  assistance	  of	  a	  trained	  research	  
worker	  who	  wore	  an	  N95	  mask	  for	  personal	  protection.	  	  30ml	  of	  3%	  hypertonic	  saline	  was	  
administered	  via	  the	  mouthpiece	  of	  a	  nebuliser	  and	  expectorated	  sputum	  was	  collected	  
over	  a	  1/2hr	  period.	  
2.3.3 Tuberculin	  Skin	  Testing	  
Control	  participants	  with	  a	  negative	  QFGIT	  subsequently	  had	  a	  TST	  administered	  to	  confirm	  
lack	  of	  evidence	  of	  immune	  sensitisation	  by	  Mtb.	  	  As	  explained	  above	  participants	  recruited	  
who	  underwent	  PET/CT	  did	  not	  receive	  TST	  because	  of	  concern	  about	  boosting.	  	  TST	  was	  
carried	  out	  by	  ICH-­‐GCP	  trained	  research	  nurses.	  	  2TU	  (0.1mL)	  of	  PPD	  RT23	  (Statens	  Serum	  
Institut)	  was	  injected	  intradermally	  with	  a	  27G	  needle	  into	  the	  volar	  aspect	  of	  the	  forearm.	  	  
Participants	  returned	  for	  reading	  48-­‐72	  hours	  after	  injection.	  	  The	  edge	  of	  indurated	  margin	  
was	  marked	  using	  a	  ballpoint	  pen	  and	  maximal	  transverse	  induration	  was	  measured.	  	  
Induration	  ≥	  5mm	  was	  considered	  positive	  for	  HIV	  infected	  persons	  and	  ≥	  10mm	  was	  
considered	  positive	  for	  HIV	  uninfected	  persons.	  	  	  	  
2.3.4 Routine	  Laboratory	  Tests	  
2.3.4.1 Microbiology	  test	  
Sputum	  samples	  were	  processed	  in	  the	  accredited	  laboratories	  of	  the	  National	  Health	  
Laboratory	  Services	  (NHLS)	  where	  auramine	  sputum	  smear,	  GeneXpert	  and	  mycobacteria	  
growth	  indicator	  tube	  (MGIT)	  liquid	  TB	  culture	  were	  performed	  according	  to	  local	  standard	  
operating	  procedure	  (SOP).	  	  As	  part	  of	  the	  quality	  control	  (QC)	  for	  the	  vaccine	  trial,	  which	  
sent	  samples	  to	  the	  same	  laboratory,	  sterile	  mock	  sputa	  were	  sent	  weekly	  to	  the	  laboratory.	  	  
In	  all	  209	  mock	  sputa	  were	  sent	  to	  the	  NHLS	  laboratory	  for	  TB	  culture	  between	  August	  2011	  
and	  June	  2014.	  	  None	  of	  these	  were	  found	  to	  be	  positive	  for	  Mtb,	  demonstrating	  that	  cross	  
contamination	  within	  this	  laboratory	  was	  very	  low.	  
2.3.4.2 Blood	  Tests	  
Volume	  of	  blood	  and	  tubes	  used	  for	  each	  test	  is	  outlined	  in	  table	  2.3.	  	  All	  blood	  tests	  were	  
processed	  in	  regional	  haematology,	  biochemistry,	  immunology	  and	  virology	  laboratories	  
with	  nationally	  recognised	  accreditation	  according	  to	  the	  SOP	  employed	  by	  the	  individual	  
laboratories.	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2.3.4.3 HIV	  POC	  tests	  
All	  HIV	  infected	  persons	  had	  a	  diagnosis	  of	  HIV	  prior	  to	  study	  entry	  and	  all	  HIV	  uninfected	  
participants	  had	  a	  confirmed	  negative	  HIV	  test	  using	  the	  testing	  strategy	  adopted	  within	  the	  
Western	  Cape	  province.	  	  This	  involved	  a	  trained	  healthcare	  professional	  first	  counselling	  the	  
patient	  for	  an	  HIV	  test.	  	  A	  rapid	  immunochromatographic	  card	  test	  for	  the	  detection	  of	  
antibodies	  to	  HIV	  1	  and	  2	  was	  then	  performed	  on	  a	  capillary	  blood	  sample	  drawn	  following	  
finger	  prick	  (FIRST	  RESPONSE®,	  Premier	  Medical	  Corporation,	  Nani	  Daman,	  India).	  	  Results	  
were	  interpreted	  after	  5-­‐15	  minutes	  as	  either	  Negative,	  HIV-­‐1	  positive,	  HIV-­‐2	  positive,	  HIV1	  
&	  2	  positive	  or	  invalid.	  	  Those	  with	  a	  positive	  test	  had	  a	  second	  rapid	  
immunochromatographic	  card	  test	  performed	  from	  a	  different	  manufacturer	  (DetermineTM	  
HIV-­‐1/2,	  Alere	  Medical	  Corporation,	  Chiba,	  Japan).	  	  Results	  and	  discussion	  with	  patient	  were	  
recorded	  on	  a	  structured	  reporting	  sheet	  and	  this	  was	  used	  as	  evidence	  of	  HIV	  status.	  	  As	  
mentioned	  in	  2.2.3.1	  additional	  confirmatory	  tests	  for	  HIV	  were	  performed	  within	  the	  study.	  	  	  	  	  	  	  	  	  	  	  	  
2.4 Imaging	  methods	  
2.4.1 Chest	  Radiography	  
Chest	  radiographs	  were	  all	  performed	  using	  a	  digital	  X-­‐Ray	  machine	  and	  captured	  posterior-­‐
anteriorly	  with	  the	  participant	  standing	  in	  full	  expiration	  with	  arms	  pronated	  to	  reduce	  
scapular	  shadow	  over	  the	  lung	  fields.	  	  High	  kV	  (125kV)	  was	  used	  to	  ensure	  optimal	  
visualization	  of	  the	  lung	  fields.	  	  Two	  different	  machines	  were	  used	  during	  the	  study,	  
between	  August	  2011	  and	  February	  2012	  CXR	  were	  performed	  on	  a	  Delft	  Oldeca	  DR	  
machine	  located	  at	  UCT,	  for	  which	  the	  participants	  were	  transported	  to	  and	  from	  
Khayelitsha.	  	  From	  February	  2012	  until	  July	  2013	  CXR	  were	  performed	  on	  a	  dedicated	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repeat	  CXR	  were	  performed	  on	  the	  same	  machine	  as	  the	  initial	  CXR	  though	  the	  imaging	  
protocols	  used	  were	  similar	  	  	  
2.4.1.1 Reporting	  of	  Chest	  Radiographs	  
The	  Digital	  CXR	  images	  were	  viewed	  on	  2	  megapixel	  screens	  in	  low	  ambient	  light	  using	  the	  
OsiriX	  version	  3.8.1	  32-­‐bit	  (Pixemo,	  Geneva,	  Switzerland)	  software	  package	  and	  reported	  
independently	  by	  2	  medically	  qualified	  researchers	  (H	  Esmail	  and	  T	  Oni)	  blinded	  to	  clinical	  
details.	  	  Reading	  of	  the	  CXR	  was	  performed	  in	  a	  structured	  way	  using	  a	  slightly	  modified	  
version	  of	  the	  Chest	  radiograph	  Reading	  and	  Reporting	  System	  (CRRS)	  report	  sheet	  (see	  
chapter	  supplementary	  information).	  	  The	  CRRS	  system	  has	  been	  specifically	  designed	  and	  
validated	  to	  facilitate	  reading	  of	  CXR	  performed	  in	  research	  and	  epidemiological	  studies	  for	  
the	  investigation	  of	  TB	  and	  provides	  a	  structured	  report	  form	  to	  assess	  all	  areas	  of	  the	  CXR	  
for	  the	  presence	  of	  abnormalities	  consistent	  with	  TB[202].	  	  Both	  researchers	  reading	  the	  CXR	  
successfully	  completed	  the	  CRRS	  course	  prior	  to	  commencement	  of	  the	  study.	  	  After	  
structured	  reading,	  the	  CXR	  was	  determined	  to	  be	  consistent	  with	  active	  or	  inactive	  TB	  
according	  to	  modified	  CDC	  criteria	  outlined	  in	  the	  Tuberculosis	  component	  of	  Technical	  
Instructions	  for	  the	  medical	  examination	  of	  Aliens	  in	  the	  USA	  May	  2008	  [203]	  (table	  2.4).	  	  
The	  slight	  modification	  for	  the	  purpose	  of	  this	  study	  being	  that	  discrete	  nodules	  with	  
calcification	  were	  kept	  as	  part	  of	  the	  definition	  for	  inactive	  TB	  and	  the	  other	  category	  for	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The	  CXRs	  were	  then	  categorised	  as:	  
1. Consistent	  with	  Active	  TB	  
2. Consistent	  with	  Inactive	  TB	  
3. Abnormality	  not	  consistent	  with	  TB	  
4. Normal	  
	  
Any	  disagreement	  in	  reporting	  was	  resolved	  by	  consensus	  to	  provide	  final	  categorization	  of	  
CXR.	   	   If	  consensus	  could	  not	  be	  achieved	  CXR	  were	  reported	  by	  a	  consultant	  radiologist	  (Q	  
Said-­‐Hartley)	   using	   a	   similar	   structured	   report	   and	   final	   categorization	   in	   these	   cases	  was	  
determined	  by	  the	  consultant	  radiologist.	  	  
2.4.2 	  FDG-­‐PET/CT	  
Participants	  undergoing	  FDG-­‐PET/CT	  were	  asked	  not	  to	  eat	  for	  6	  hours	  prior	  to	  the	  scan	  and	  
were	  driven	  to	  the	  PET/CT	  centre	  escorted	  by	  a	  research	  worker.	  	  At	  the	  PET/CT	  centre	  a	  
point	  of	  care	  assessment	  of	  blood	  glucose	  measurement	  (BM)	  was	  performed	  to	  ensure	  BM	  
<	  11.1mmol/L	  (hyperglycaemia	  can	  contribute	  to	  false	  negative	  FDG-­‐PET/CT).	  A	  POC	  
pregnancy	  test	  was	  performed	  prior	  to	  scan	  on	  all	  female	  participants	  to	  ensure	  they	  were	  
not	  pregnant.	  	  Participants	  were	  then	  given	  20mg	  of	  propranolol	  orally	  to	  minimize	  brown	  
fat	  uptake	  of	  FDG	  (as	  long	  as	  systolic	  blood	  pressure	  was	  greater	  than	  100mmHg).	  	  Thirty	  
minutes	  later	  4MBq/kg	  of	  the	  radiolabelled	  tracer,	  FDG,	  was	  administered	  via	  a	  22G	  cannula	  
in	  the	  forearm.	  	  Sixty	  minutes	  after	  FDG	  administration	  a	  PET/CT	  scan	  was	  performed	  
according	  to	  the	  protocol	  in	  table	  2.5.	  	  CT	  was	  limited	  to	  the	  chest	  (although	  this	  included	  
neck	  and	  upper	  abdomen	  to	  just	  below	  the	  liver)	  to	  reduce	  radiation	  exposure.	  	  Total	  
effective	  radiation	  dose	  per	  scan	  was	  approximately	  10mSv	  (varying	  with	  body	  weight	  and	  
height).	  	  A	  second	  PET/CT	  was	  performed	  after	  approximately	  6	  months	  towards	  the	  end	  of	  
treatment	  with	  either	  IPT	  or	  2HRZE/4HR	  (as	  indicated).	  	  Every	  effort	  was	  made	  to	  use	  a	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2.4.2.1 Reporting	  of	  PET/CT	  images	  
Images	  were	  reported	  using	  a	  specially	  designed,	  structured	  report	  focusing	  on	  the	  Regions	  
Of	   Interest	   (ROI);	   lung	   parenchyma	   and	   mediastinal	   and	   hilar	   lymph	   nodes	   (see	   chapter	  
supplementary	  information	  for	  copy	  of	  report).	  	  The	  primary	  report	  of	  the	  scan	  was	  provided	  
by	   radiologists	   and	   nuclear	   medicine	   physicians	   at	   the	   Western	   Cape	   Academic	   PET/CT	  
centre.	  	  If	  scans	  were	  performed	  at	  the	  Panorama	  Medi-­‐Clinic	  they	  were	  re-­‐reported	  by	  the	  
team	   at	   Western	   Cape	   Academic	   PET/CT	   centre.	   	   Detailed	   reporting	   instructions	   were	  
provided	   to	   all	   readers.	   	   Parenchymal	   lesions	   were	   categorized	   as	   nodules,	   fibrotic	   scars,	  
infiltrates	   or	   other.	   	   The	   size	   and	   location	   of	   lesion	   (both	   the	   lobe	   lesion	   was	   in	   and	   its	  
relationship	   to	   pleura	   and	   secondary	   lobule)	   were	   described.	   	   The	   lesions	   were	   also	  
evaluated	  for	  radiographic	  signs	  of	  active	  TB	  as	  follows:	  
	  
Consistent	  with	  TB	  with	  signs	  of	  disease	  activity	  (within	  lung	  parenchyma)	  
• Poorly	  defined	  nodule	  or	  infiltrate	  
• Tree	  in	  bud	  appearance	  	  
• Cavitation	  
	  
Consistent	  with	  TB	  but	  without	  signs	  of	  disease	  activity	  (within	  lung	  parenchyma)	  
• Well	  defined	  nodule	  
• Fibrotic	  scar	  
• Mineralization	  
	  
FDG	   uptake	   within	   the	   parenchyma	   lesions	   was	   quantified	   by	   both	   a	   widely	   used	   and	  
accepted	  Visual	  Score	  (VS)	  (see	  below)	  and	  also	  by	  SUVmax.	  	  SUVmax	  is	  the	  most	  commonly	  
used	  measure	   of	   PET	   activity	   and	   provides	   a	   ratio	   of	   the	  maximum	   radioactivity	   (derived	  
from	  image)	  within	  a	  particular	  defined	  ROI	  to	  the	  total	  injected	  radioactivity	  normalised	  to	  
body	  weight	  (taking	  into	  consideration	  radioactive	  decay	  over	  time)	  	  
	  
Visual	  Score	  	  
0. No	  visible	  uptake	  
1. Visible	  uptake	  within	  lesion	  greater	  that	  background	  lung	  parenchyma	  but	  less	  than	  
mediastinal	  blood	  pool	  
2. Visible	  uptake	  within	  lesion	  greater	  than	  mediastinal	  blood	  pool	  but	  less	  that	  liver	  
3. Visible	  uptake	  within	  lesion	  greater	  than	  liver	 	  
	  
Parenchymal	  lesions	  were	  considered	  to	  have	  signs	  of	  activity	  if	  VS	  was	  ≥	  1	  or	  if	  VS	  was	  0	  but	  
the	  lesion	  had	  radiographic	  signs	  of	  activity.	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Mediastinal	   and	   hilar	   lymph	   nodes	   were	   specifically	   focused	   upon	   and	   were	   considered	  
abnormal	  if	  short	  axis	  width	  was	  greater	  than	  1	  cm,	  there	  was	  evidence	  of	  mineralization	  or	  
there	  was	  FDG	  uptake	  above	  that	  of	  the	  mediastinal	  blood	  pool	  (i.e.	  VS	  ≥	  2).	   	  SUVmax	  was	  
also	  recorded	  for	  all	  abnormal	  lymph	  nodes.	  	  Abnormal	  lymph	  nodes	  were	  located	  into	  1	  of	  
the	   following	   lymph	  node	  basins	   following	   convention	  of	   the	   International	  Association	   for	  
Study	  of	  Lung	  Cancer	  (IASLC)	  (figure	  2.5)	  
• R	  or	  L	  Superior	  Mediastinal	  (2	  –	  4)	  
• Aortic	  (5,6)	  
• Inferior	  Mediastinal	  (Subcarinal)	  (7-­‐9)	  
• R	  or	  L	  Hilar	  (10-­‐14)	  
	  
In	  addition	   to	   the	  mediastinal	  and	  hilar	   lymph	  nodes,	  any	  abnormal	  uptake	  within	  cervical	  
LN,	   axillary	   LN	  and	   thymus	  were	  noted	  and	  any	  other	  pathological	   abnormalities	  between	  
mandible	  and	  base	  of	  liver	  were	  commented	  upon.	  	  	  
	  
The	   scans	   were	   reviewed	   by	   a	   researcher	   (H	   Esmail)	   and	   any	   queries	   or	   differences	   of	  
opinion	  with	  the	  primary	  report	  were	  resolved	  by	  a	  3rd	  reader	  (J	  Warwick).	  	  
Figure	  2.5	  –	  IASLC	  lymph	  node	  map	  .	  	  	  
Reproduced	  with	  permission	  of	  Robin	  Smithuis	  and	  Radiology	  Assistant	  website	  (http://www.radiologyassistant.nl)	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2.5 Processing	  of	  research	  samples	  
2.5.1 Quantiferon	  Gold	  in	  tube	  (QFGIT)	  	  
2.5.1.1 Background	  to	  Quantiferon	  Gold	  in	  tube	  
Quantiferon	  (Qiagen;	  Linberg,	  Netherlands)	  is	  one	  of	  two	  commercially	  available	  IGRA	  tests	  
used	  for	  the	  in	  vitro	  diagnosis	  of	  latent	  tuberculosis	  (i.e.	  having	  evidence	  of	  sensitization	  by	  
Mtb).	  	  It	  is	  a	  short	  term,	  whole	  blood	  assay	  in	  which	  IFNγ	  release	  in	  response	  to	  stimulation	  
with	  Mtb	  specific	  antigens	  is	  quantified	  by	  ELISA.	  	  It	  comprises	  3	  heparinized	  tubes;	  NIL	  (used	  
as	  negative	  control	  for	  background	  subtraction),	  ANTIGEN	  (coated	  with	  Mtb	  specific	  
antigens,	  ESAT-­‐6,	  CFP-­‐10	  and	  TB7.7)	  and	  MITOGEN	  (phytohemaglutinin-­‐	  used	  as	  a	  positive	  
control).	  	  IFNγ	  ELISA	  Optical	  Density	  (OD)	  values	  are	  converted	  into	  International	  Units	  and	  
results	  are	  interpreted	  as	  in	  table	  2.6.	  	  	  	  	  
	  
2.5.1.2 Methodology	  for	  QFGIT	  	  
One	  mL	  of	  blood	  was	  drawn	  directly	  into	  each	  of	  the	  3	  QFGIT	  tubes	  (NIL,	  ANTIGEN	  and	  
MITOGEN)	  and	  immediately	  inverted	  10	  times.	  	  Blood	  tubes	  were	  transported	  from	  the	  
clinical	  site	  to	  the	  Wilkinson	  Laboratory	  where	  they	  were	  incubated	  in	  an	  upright	  position	  at	  
37oC	  for	  24	  hours.	  	  After	  incubation	  the	  tubes	  were	  centrifuged	  at	  2200g	  for	  10	  minutes	  and	  
the	  plasma	  supernatant	  was	  removed	  and	  aliquoted	  into	  2	  vials.	  	  100µL	  was	  stored	  at	  -­‐20oC	  
for	  the	  QFGIT	  assay,	  which	  was	  usually	  performed	  within	  1	  week	  of	  collection,	  and	  the	  
remainder	  approximately	  300µL	  was	  stored	  at	  -­‐80oC	  for	  use	  in	  research	  multiplex	  assays	  and	  
ELISA	  described	  below.	  
	  
The	  QuantiFERON	  IFNγ	  ELISA	  assay	  was	  performed	  weekly	  along	  with	  vaccine	  trial	  samples	  
according	  to	  manufacturer	  instructions	  by	  good	  laboratory	  practice	  (GLP)	  trained	  research	  
laboratory	  assistants	  (F	  Patel	  and	  M	  Carr).	  	  They	  also	  had	  regular	  evaluation	  as	  part	  of	  the	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quality	  assurance	  (QA)	  of	  the	  vaccine	  trial.	  	  The	  result	  of	  the	  assay	  was	  determined	  as	  
POSITIVE,	  NEGATIVE	  or	  INDETERMINANTE	  according	  to	  manufacturers	  instructions.	  	  
INDETERMINANT	  results	  were	  repeated	  once.	  	  	  	  
2.5.2 Tempus	  Blood	  RNA	  tubes	  collection	  and	  storage	  	  	  
2.5.2.1 Background	  to	  Tempus	  tubes	  
Tempus	  Blood	  RNA	  tubes	  (Applied	  Biosystems;	  Foster	  City,	  CA,	  USA)	  are	  specifically	  designed	  
to	  stabilise	  and	  isolate	  RNA	  from	  whole	  blood	  for	  transcriptional	  analysis.	  	  Tempus	  tubes	  
contain	  6	  mL	  of	  stabilization	  reagent	  which	  when	  mixed	  with	  blood	  causes	  immediate	  cell	  
lysis,	  inactivation	  of	  cellular	  RNAses	  and	  precipitation	  of	  RNA	  thus	  “freezing”	  the	  global	  gene	  
expression	  profile.	  	  	  	  	  
2.5.2.2 Methodology	  
Three	  mL	  of	  blood	  was	  drawn	  into	  2	  x	  Tempus	  Blood	  RNA	  tubes	  and	  shaken	  vigorously	  for	  
10-­‐15	  seconds	  as	  recommended	  by	  the	  manufacturer.	  	  Tubes	  were	  then	  transported	  to	  the	  
Wilkinson	  laboratory	  and	  kept	  for	  long-­‐term	  storage	  between	  -­‐20oC	  and	  -­‐80oC	  prior	  to	  use.	  	  	  
2.5.3 Serum	  storage	  	  	  	  
Blood	  was	  drawn	  into	  5mL	  SSTTM	  II	  Advance	  tubes	  (BD	  Diagnostics;	  Franklin	  Lakes,	  NJ,	  USA),	  
transported	   to	   the	  Wilkinson	   laboratory,	   centrifuged	   at	   1200g	   for	   10	  minutes	   and	   serum	  
supernatant	  was	  aliquot	  and	  stored	  at	  -­‐80oC	  for	  long-­‐term	  storage	  prior	  to	  use.	  
2.6 Research	  laboratory	  assays	  and	  methodology	  
2.6.1 Transcriptional	  profiling	  using	  microarray	  (Chapter	  5)	  
2.6.1.1 RNA	  Extraction	  	  
Tempus	  tubes	  were	  in	  storage	  between	  -­‐20oC	  and	  -­‐80oC	  for	  no	  longer	  than	  21	  months	  
before	  RNA	  extraction.	  	  RNA	  was	  extracted	  from	  1	  of	  the	  2	  Tempus	  tubes	  available	  using	  the	  
5	  PRIME	  PerfectPure™	  Blood	  RNA	  Kit	  (5	  PRIME;	  Dusseldrof,	  Germany)	  in	  the	  Wilkinson	  
laboratories	  at	  UCT	  in	  a	  dedicated	  RNA	  area	  by	  2	  researchers	  (H	  Esmail	  and	  N	  Bangani).	  	  A	  
modification	  of	  the	  manufacturers	  protocol	  developed	  by	  C	  Graham	  at	  MRC	  National	  
Institute	  for	  Medical	  Research	  London	  was	  followed.	  	  All	  equipment	  and	  laboratory	  surfaces	  
were	  cleaned	  of	  RNase	  with	  RNaseZAPTM	  (Sigma-­‐Aldrich;	  St	  Louis,	  MO,	  USA)	  prior	  to	  
extraction.	  	  Briefly,	  tempus	  tubes	  were	  placed	  on	  ice	  for	  1	  hour	  to	  ensure	  complete	  slow	  
thaw.	  	  The	  blood/reagent	  mixture	  was	  then	  transferred	  into	  a	  50mL	  universal	  falcon	  tube	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containing	  3mL	  of	  cold	  ethanol	  and	  vortexed	  for	  2	  minutes	  of	  to	  ensure	  sample	  
homogenization.	  	  The	  falcon	  tubes	  were	  then	  centrifuged	  at	  4700	  rpm	  for	  60	  minutes	  at	  0oC	  
after	  which	  the	  supernatant	  was	  poured	  off	  and	  the	  tubes	  were	  inverted	  onto	  absorbent	  
paper	  for	  2	  minutes.	  	  The	  RNA	  pellet	  was	  then	  dissolved	  in	  200µL	  of	  1%	  tris(2-­‐
carboxyethyl)phosphine	  (TCEP)	  Lysis	  solution	  and	  transferred	  into	  a	  purification	  column.	  	  
RNA	  was	  then	  isolated	  on	  the	  purification	  column	  filter	  by	  centrifugation	  at	  13000	  rpm	  in	  a	  
microfuge.	  	  The	  RNA	  was	  then	  washed	  with	  400µL	  of	  Wash	  1	  solution	  and	  incubated	  with	  
50µL	  of	  DNase	  at	  room	  temperature	  for	  15	  minutes.	  	  RNA	  was	  then	  washed	  twice	  in	  200µL	  
of	  DNase	  wash	  solution	  followed	  by	  washing	  twice	  in	  200µL	  of	  Wash	  2	  solution.	  	  50µL	  of	  
RNA	  Elution	  Solution	  was	  then	  added	  to	  the	  column	  and	  RNA	  collected	  into	  a	  vial	  by	  
centrifugation.	  	  The	  collected	  solution	  was	  then	  pipetted	  back	  into	  the	  column	  and	  
centrifuged	  again	  to	  maximise	  RNA	  yield.	  	  1.5µL	  was	  aliquoted	  for	  Nanodrop	  evaluation,	  5µL	  
for	  RNA	  integrity	  number	  (RIN)	  evaluation	  and	  20µL	  was	  aliquoted	  into	  2	  cryovials	  and	  
stored	  at	  -­‐80oC.	  	  RNA	  was	  shipped	  on	  dry	  ice	  to	  the	  MRC	  National	  Institute	  for	  Medical	  
Research,	  London	  by	  a	  specialist	  clinical,	  cold-­‐chain	  courier	  (World	  Courier;	  New	  Hyde	  Park,	  
NY,	  USA)	  and	  the	  remainder	  of	  the	  RNA	  processing	  and	  microarray	  set-­‐up	  were	  performed	  
there	  by	  3	  researchers	  (H	  Esmail	  and	  R	  Lai	  with	  assistance	  from	  C	  Graham).	  	  	  	  	  	  	  	  	  
2.6.1.2 Assessment	  of	  RNA	  purity,	  concentration	  and	  quality	  
Nanodrop	  
Nanodrop	  spectrophotometers	  allow	  evaluation	  of	  RNA	  purity	  by	  evaluating	  the	  spectral	  
absorbance	  of	  a	  sample	  at	  230nm,	  260nm	  and	  280nm.	  	  Absorbance	  at	  260nm	  and	  280nm	  is	  
affected	  by	  nucleic	  acids.	  	  As	  thymine	  and	  uracil	  have	  different	  spectral	  absorbance	  the	  
260/280	  ratio	  can	  be	  used	  to	  assess	  degree	  of	  DNA	  contamination.	  	  A	  260/280	  ratio	  of	  
approximately	  2	  reflects	  ”pure”	  RNA	  and	  1.8-­‐2	  was	  considered	  acceptable.	  	  The	  260/230	  
ratio	  reflects	  contamination	  with	  other	  compounds	  and	  solvents	  usually	  from	  involved	  in	  the	  
processing	  of	  RNA.	  	  A	  260/230	  ratio	  of	  >1.5	  was	  considered	  acceptable	  and	  2-­‐2.2	  optimal.	  	  In	  
addition	  to	  purity	  nanodrop	  spectrophotometers	  can	  evaluate	  RNA	  concentration	  (ng/µL).	  	  A	  
total	  yield	  of	  greater	  than	  2000ng	  was	  considered	  acceptable	  for	  subsequent	  processing	  and	  
microarray.	  
	  	  	  	  	  	  	  	  	  
RNA	  purity	  and	  concentration	  were	  determined	  using	  a	  Thermoscientific	  Nanadrop	  ND	  1000	  
spectrophotometer	  (Thermo	  Fisher	  Scientific;	  Waltham,	  MA,	  USA)	  in	  the	  adjacent	  Medical	  
Microbiology	  Research	  Unit	  laboratory	  at	  UCT.	  	  Briefly,	  the	  sample	  pedestal	  was	  cleaned	  
with	  RNase-­‐free	  water	  and	  then	  1.2µL	  of	  elution	  solution	  was	  then	  pipetted	  onto	  the	  sample	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pedestal	  to	  allow	  assessment	  of	  background	  spectral	  distribution.	  	  1.2µL	  of	  the	  RNA	  sample	  
was	  then	  pipetted	  onto	  the	  sample	  pedestal	  and	  the	  spectral	  measurement	  taken.	  	  The	  
pedestal	  was	  wiped	  with	  RNase	  free	  water	  between	  sample	  measurements.	  	  Results	  were	  
provided	  in	  graphical	  and	  tabular	  format	  on	  computer	  connected	  to	  the	  machine.	  	  	  	  	  
	  
RNA	  Integrity	  Number	  (RIN)	  
RIN	  is	  generated	  by	  a	  software	  algorithm	  which	  analyses	  the	  entire	  electrophoretic	  trace	  of	  
the	  RNA	  sample	  for	  the	  detection	  of	  degradation	  products.	  	  It	  provides	  a	  more	  consistent	  
evaluation	  of	  RNA	  integrity	  than	  using	  the	  28S	  to	  18S	  rRNA	  ratio.	  	  A	  RIN	  ≥	  7	  was	  considered	  
good	  quality	  RNA	  acceptable	  for	  use	  in	  the	  microarray	  experiments.	  
	  
RIN	  evaluation	  was	  performed	  by	  the	  Centre	  for	  Proteomic	  and	  Genomic	  Research	  (CPGR)	  
based	  close	  to	  the	  university	  using	  an	  Agilent	  Bioanalyser	  Nano	  Assay	  (Agilent;	  Santa	  Clara,	  
CA,	  USA).	  	  A	  written	  report	  was	  provided	  detailing	  results.	  	  
2.6.1.3 Removal	  of	  Globin	  mRNA	  
Globin	  mRNA	  in	  whole	  blood	  decreases	  transcript	  detection	  sensitivity	  and	  increases	  signal	  
variation	  on	  microarray.	  	  Samples	  therefore	  underwent	  removal	  of	  α	  and	  β	  globin	  mRNA	  
using	  Ambion®	  Human	  GLOBINclear™	  Kit	  (Thermo	  Fisher	  Scientific;	  Waltham,	  MA,	  USA)	  
using	  a	  protocol	  adapted	  by	  C	  Graham.	  	  Briefly,	  first	  RNA	  concentration	  in	  the	  samples	  was	  
normalised	  to	  a	  concentration	  of	  2000ng	  in	  14µL	  using	  RNase	  free	  water	  as	  a	  diluent.	  	  Globin	  
mRNA	  was	  then	  hybridized	  to	  biotinylated	  capture	  oligonucleotides	  by	  addition	  of	  1µL	  of	  
Capture	  Oligomix	  with	  15µL	  of	  2	  x	  Hybridisation	  buffer	  and	  incubation	  at	  50oC	  for	  30	  
minutes.	  	  Streptavidin	  Magnetic	  Beads	  were	  then	  added	  to	  sample	  and	  incubated	  at	  50oC	  for	  
1	  hour	  to	  bind	  the	  Globin	  mRNA.	  	  Globin	  mRNA	  was	  then	  immobilized	  on	  a	  magnetic	  rack	  
and	  the	  supernatant	  containing	  globin	  mRNA	  depleted	  RNA	  (grRNA)	  transferred	  to	  a	  96	  well	  
plate.	  	  RNA	  magnetic	  Binding	  Beads	  were	  then	  added	  to	  capture	  grRNA	  and	  400uL	  of	  80%	  
ethanol	  added	  for	  further	  purification.	  	  grRNA	  was	  immobilized	  on	  a	  magnetic	  rack	  and	  
ethanol	  aspirated.	  	  An	  elution	  buffer	  was	  then	  added	  to	  recover	  grRNA	  from	  magnetic	  
Binding	  Beads.	  	  grRNA	  was	  stored	  at	  -­‐80oC.	  	  Purity,	  concentration	  and	  integrity	  of	  grRNA	  
were	  assessed	  by	  Nanodrop	  and	  RIN	  performed	  at	  NIMR.	  	  
2.6.1.4 RNA	  preparation	  for	  microarray	  
grRNA	  was	  reverse	  transcribed	  to	  cDNA	  and	  then	  in	  vitro	  transcribed	  into	  biotinylated	  cRNA	  
ready	  for	  microarray	  using	  Illumina®	  TotalPrep	  RNA	  Amplification	  Kit	  (Illumina;	  San	  Diego,	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CA,	  USA)	  using	  a	  protocol	  adapted	  by	  C	  Graham.	  	  Briefly,	  the	  concentration	  of	  grRNA	  was	  
normalised	  to	  200ng	  in	  11µl	  using	  RNase	  free	  water	  as	  a	  diluent	  and	  samples	  were	  then	  
transferred	  to	  a	  96	  well	  plate.	  	  Steps	  1,2	  and	  3	  were	  then	  carried	  out	  as	  shown	  in	  table	  2.7	  
by	  the	  addition	  of	  Master	  Mix	  to	  sample	  and	  incubation	  in	  thermo-­‐cycler	  at	  the	  temperature	  
and	  duration	  shown	  followed	  by	  purification.	  	  Purity,	  concentration	  and	  integrity	  of	  cRNA	  
was	  confirmed	  by	  Nanodrop	  and	  RIN	  performed	  at	  NIMR.	  
	  
2.6.1.5 Illumina	  HumanHT-­‐12	  v4	  Expression	  BeadChips	  
Samples	  were	  then	  handed	  over	  to	  the	  MRC	  National	  Institute	  for	  Medical	  Research	  
microarray	  core	  facility	  where	  cRNA	  was	  fragmented	  and	  hybridized	  to	  Illumina	  HumanHT-­‐
12	  v	  4.0	  Expression	  BeadChips	  (Illumina;	  San	  Diego,	  CA,	  USA)	  and	  labelled	  with	  streptavidin-­‐
Cy3.	  	  Samples	  were	  randomly	  distributed	  across	  chips	  along	  with	  control	  samples	  to	  
minimise	  chip	  related	  bias.	  	  Microarray	  chips	  were	  then	  scanned	  on	  Illumina	  HiScan	  machine	  
(Illumina;	  San	  Diego,	  CA,	  USA)	  and	  florescence	  emission	  quantitated	  to	  provide	  raw	  data.	  
	  
Illumina	  HumanHT-­‐12	  v	  4.0	  Expression	  BeadChips	  are	  high	  density	  microarrays	  providing	  
genome	  wide	  transcriptional	  coverage	  of	  well	  characterised	  genes,	  gene	  candidates	  and	  
splice	  variants.	  	  Each	  array	  targets	  more	  than	  47,000	  probes	  derived	  from	  the	  National	  
Center	  for	  Biotechnology	  Information	  Reference	  Sequence	  (NCBI	  RefSeq)	  Release	  38	  
(November	  7,	  2009).	  
	  
Array	  probes	  are	  transcript	  specific	  50-­‐mer	  oligonucleotides,	  most	  genes	  are	  represented	  by	  
a	  single	  probe	  but	  may	  be	  represented	  by	  more	  than	  one	  if	  different	  isoforms	  of	  the	  gene	  
are	  covered.	  	  Hundreds	  of	  thousands	  of	  copies	  of	  each	  probe	  (which	  provides	  dynamic	  range	  
for	  transcript	  abundance)	  are	  bound	  to	  3µm	  silica	  beads,	  which	  are	  then	  randomly	  






















?3F5! >/6R! 'J6R! KA6R!






Table	  2.7	  Steps	  in	  RNA	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allow	  subsequent	  localisation	  of	  probe	  on	  the	  chip.	  Each	  bead	  has	  approximately	  15	  
replicates,	  which	  are	  randomly	  distributed	  across	  the	  array	  to	  provide	  technical	  replicates.	  	  
In	  addition	  some	  beads	  are	  probe	  free	  providing	  assessment	  of	  background	  signal.	  	  Up	  to	  12	  
samples	  can	  arrayed	  on	  a	  single	  chip.	  
2.6.1.6 Microarray	  Quality	  Control	  
To	  ensure	  that	  technical	  factors	  (either	  chip	  differences	  or	  differences	  in	  labelling	  and	  
staining	  procedures)	  didn’t	  affect	  downstream	  analysis	  and	  interpretation,	  5	  QC	  parameters	  
were	  evaluated	  for	  each	  sample	  prior	  to	  analysis.	  	  	  Any	  sample	  falling	  greater	  than	  3	  
standard	  deviations	  from	  the	  mean	  was	  flagged	  as	  an	  outlier	  and	  suggested	  technical	  
concerns.	  	  The	  5	  QC	  parameters	  were:	  
• Intensity	  value	  of	  housekeeping	  genes	  
o Expression	  level	  in	  12	  housekeeping	  transcripts	  was	  recorded.	  	  This	  parameter	  is	  
influenced	  by	  labeling	  and	  staining	  procedures.	  	  
	  
• Intensity	  value	  of	  background	  
o Expression	  levels	  in	  “empty”	  probes	  (beads	  that	  do	  not	  carry	  oligonucleotides)	  
was	  recorded.	  	  This	  parameter	  is	  affected	  by	  blocking	  and	  staining	  and	  should	  be	  
in	  the	  range	  80-­‐120.	  
	  
• Intensity	  value	  of	  pre-­‐labeled	  biotinylated	  probes	  
o Expression	  level	  for	  pre-­‐labeled	  biotinylated	  probes	  is	  affected	  by	  the	  staining	  
procedure	  independently	  of	  labeling.	  	  The	  biotin	  signal	  is	  commonly	  highly	  
variable	  
	  
• Intensity	  of	  the	  95th	  percentile	  
o This	  parameter	  is	  affected	  by	  labeling	  and	  staining	  procedures	  similarly	  to	  
housekeeping	  genes.	  
	  
• Number	  of	  genes	  detected	  (p<0.01)	  
o This	  parameter	  represents	  the	  number	  of	  transcripts	  showing	  expression	  above	  
background	  with	  p	  value	  representing	  confidence	  with	  which	  transcripts	  are	  
detected	  above	  background.	  	  Low	  numbers	  of	  detected	  transcripts	  usually	  relate	  
to	  high	  background	  or	  low	  signal	  intensity.	  
	  
4	  samples	  all	  on	  a	  single	  chip	  failed	  all	  QC	  suggesting	  a	  technical	  problem	  with	  the	  chip	  or	  its	  
processing.	  	  All	  samples	  on	  the	  chip	  of	  concern	  were	  repeated	  randomly	  distributed	  across	  2	  
new	  chips	  along	  with	  a	  selection	  of	  samples	  that	  had	  passed	  QC.	  	  All	  samples	  passed	  QC	  on	  
repeat	  array.	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2.6.2 Mutiplex	  Assay	  (Chapter	  6)	  	  
Quantiferon	  plasma	  supernatants	  and	  serum	  samples	  from	  participants	  that	  underwent	  
PET/CT	  (drawn	  on	  the	  day	  of	  PET/CT)	  and	  HIV	  infected	  controls	  with	  active	  TB	  (drawn	  on	  the	  
day	  of	  recruitment)	  and	  had	  multiplex	  assay	  performed	  to	  determine	  the	  levels	  of	  secreted	  
cytokines	  and	  chemokines.	  
2.6.2.1 Background	  to	  Multiplex	  assay	  	  	  	  	  	  	  
Multiplex	  assays	  are	  particularly	  useful	  in	  allowing	  the	  simultaneous	  evaluation	  of	  multiple	  
(up	  to	  100)	  analytes	  within	  a	  single	  specimen	  using	  a	  small	  volume	  of	  sample.	  	  The	  
technology	  uses	  5.6µm	  polystyrene	  beads.	  	  The	  beads	  are	  internally	  dyed	  with	  a	  specific	  
combination	  of	  red	  and	  infrared	  fluorophores	  which	  provide	  a	  unique	  spectral	  signature	  for	  
each	  bead	  set.	  	  Each	  bead	  set	  is	  coated	  with	  thousands	  of	  capture	  antibodies	  to	  different	  
analytes.	  	  Captured	  analytes	  are	  sandwiched	  by	  biotinylated	  detection	  antibodies	  labelled	  
with	  the	  green	  fluorophore	  streptavidin-­‐PE.	  	  The	  samples	  are	  then	  passed	  through	  Green	  
and	  Red	  lasers	  using	  a	  fluidic	  approach	  similar	  to	  flow	  cytometry.	  	  Bead	  florescence	  is	  
acquired	  with	  bead	  type	  characterised	  by	  red	  florescence	  and	  concentration	  of	  analyte	  
quantitated	  through	  green	  fluorescence.	  	  A	  number	  of	  beads	  (e.g.	  50)	  for	  each	  analyte	  are	  
acquired.	  	  
2.6.2.2 Methodology	  
The	  assay	  used	  was	  the	  standard	  premixed	  42-­‐plex	  MILLIPLEX®	  Map	  Kit	  Human	  
Cytokine/Chemokine	  Magnetic	  Bead	  Panel	  (Millipore;	  Billerica,	  MA,	  USA)	  as	  majority	  of	  the	  
analytes	  of	  interest	  as	  determined	  by	  microarray	  analysis.	  	  Specifically	  it	  allowed	  detection	  
of	  Epidermal	  Growth	  Factor	  (EGF),	  Fibroblast	  Growth	  Factor	  (FGF-­‐2),	  Eotaxin	  (CCL11/24/26),	  
Transforming	  Growth	  Factor	  (TGF)-­‐α,	  Granulocyte	  Colony	  Stimulating	  Factor	  (G-­‐CSF)(CSF-­‐3),	  
Fms-­‐related	  tyrosine	  kinase	  3	  ligand	  (Flt-­‐3L),	  Granulocyte	  Macrophage	  Colony	  Stimulating	  
Factor	  (GM-­‐CSF)(CSF-­‐2),	  Fractalkine	  (CX3CL1),	  Interferon	  (IFN)α2,	  IFNγ,	  Growth	  Regulated	  
Oncogene	  (GRO)(CXCL1),	  Interleukin	  (IL)-­‐10,	  Monocyte	  Chemotactic	  Protein	  (MCP)-­‐3(CCL7),	  
IL-­‐12p40,	  Macrophage	  Derived	  Chemokine	  (MDC)(CCL22),	  IL-­‐12p70,	  IL-­‐13,	  IL-­‐15,	  sCD40L,	  IL-­‐
17A,	  IL-­‐1ra,	  IL-­‐1α,	  IL-­‐9,	  IL-­‐1β,	  IL-­‐2,	  IL-­‐3,	  IL-­‐4,	  IL-­‐5,	  IL-­‐6,	  IL-­‐7,	  IL-­‐8,	  IFNγ	  induced	  protein	  (IP)-­‐
10(CXCL10),	  MCP-­‐1(CCL2),	  Macrophage	  Inflammatory	  Protein	  (MIP)-­‐1α(CCL3),	  MIP1-­‐
β(CCL4),	  Tumour	  Necrosis	  Factor	  (TNF)α,	  TNFβ,	  Vascular	  Endothelial	  Growth	  Factor(VEGF)).	  	  
In	  addition	  RANTES,	  platelet	  derived	  growth	  factor	  (PDGF)-­‐AA	  and	  PGDF-­‐BB	  can	  be	  
quantitated	  but	  separately	  as	  they	  require	  1:100	  dilution	  which	  was	  not	  performed.	  	  
Quantiferon	  supernatants	  of	  the	  NIL	  (unstimulated)	  and	  ANTIGEN	  (ESAT-­‐6,	  CFP-­‐10,	  TB7.7)	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tubes	  were	  assayed	  in	  singlet.	  	  Two	  plates	  were	  required	  and	  participant	  samples	  were	  
randomly	  distributed	  across	  the	  plates	  to	  minimise	  bias,	  however	  NIL	  and	  ANITIGEN	  from	  
the	  same	  participant	  were	  plated	  sequentially	  and	  on	  the	  same	  plate.	  	  Serum	  samples	  were	  
also	  assayed	  separately	  in	  singlet	  on	  a	  single	  plate	  again	  randomly	  distributed	  to	  minimise	  
bias.	  
	  
Assays	  were	  carried	  out	  on	  the	  96	  well	  plate	  supplied	  as	  per	  manufacturers	  protocol	  using	  
the	  2	  hour	  incubation	  method	  by	  2	  researchers	  (H	  Esmail	  and	  K	  Wilkinson).	  	  Briefly,	  samples	  
and	  kit	  were	  brought	  to	  room	  temperature	  prior	  to	  use.	  	  Plates	  were	  washed	  in	  wash	  buffer	  
and	  then	  25µL	  of	  undiluted	  sample	  and	  25µL	  of	  assay	  buffer	  were	  added	  to	  wells	  along	  with	  
required	  standards	  and	  controls.	  	  25µL	  of	  vortexed,	  premixed	  beads	  were	  added	  to	  each	  
well.	  	  Plates	  were	  sealed,	  covered	  and	  placed	  on	  a	  plate	  shaker	  at	  room	  temperature	  for	  2	  
hours.	  	  Plates	  were	  washed	  using	  a	  magnetic	  plate	  washer	  to	  immobilise	  beads	  and	  25µL	  of	  
detection	  antibody	  was	  added	  to	  each	  well	  and	  then	  re-­‐sealed,	  covered	  and	  placed	  on	  a	  
plate	  shaker	  at	  room	  temperature	  for	  1	  hour.	  	  25µL	  of	  Streptavidin-­‐PE	  was	  then	  added	  to	  
each	  well	  and	  plates	  were	  returned	  to	  the	  plate	  shaker	  for	  a	  further	  30	  minutes.	  	  Plates	  were	  
then	  washed	  on	  a	  magnetic	  plate	  washer	  and	  150µL	  of	  sheath	  fluid	  added	  to	  all	  wells.	  	  
Plates	  were	  then	  read	  on	  a	  Bio-­‐plex	  200	  reader	  (Bio-­‐Rad;	  Hercules,	  CA,	  USA)	  ensuring	  at	  
least	  50	  beads	  for	  each	  analyte	  were	  read.	  	  Standard	  curves	  were	  generated	  by	  software	  for	  
each	  analyte	  and	  concentrations	  calculated.	  	  Quality	  control	  samples	  incorporated	  into	  assay	  
were	  all	  in	  the	  expected	  range.	  	  For	  GRO,	  IL-­‐6,	  IL-­‐8,	  MIP-­‐1α	  and	  IP-­‐10	  the	  majority	  of	  values	  
were	  above	  the	  upper	  limit	  of	  detection	  for	  QFGIT	  samples	  and	  assay	  was	  repeated	  at	  a	  1:40	  
dilution.	  	  	  
2.6.3 Enzyme-­‐Linked	  Immunosorbent	  Assay	  (ELISA)	  (Chapter	  6)	  
ELISA	  were	  performed	  on	  serum	  to	  quantify	  circulating	  protein	  informed	  by	  microarray	  
analysis.	  	  Assays	  were	  carried	  out	  by	  2	  researchers	  (H	  Esmail	  and	  K	  Wilkinson)	  in	  the	  
University	  of	  Cape	  Town	  laboratories.	  	  All	  plates	  were	  read	  on	  a	  Bio-­‐Rad	  iMark	  microplate	  
reader	  (Bio-­‐Rad;	  Hercules,	  CA,	  USA)	  with	  final	  concentrations	  calculated	  from	  a	  standard	  
curve	  using	  MPM6	  software	  (Bio-­‐Rad;	  Hercules,	  CA,	  USA).	  
2.6.3.1 CCL23	  sandwich	  ELISA	  (Abcam)	  
CCL23	  (also	  known	  as	  MIP3	  or	  MPIF-­‐1)	  ELISA	  (Abcam;	  Cambridge,	  UK)	  was	  carried	  out	  
according	  to	  manufacturers	  instructions.	  	  Briefly,	  samples	  were	  diluted	  1:2	  in	  supplied	  assay	  
diluent	  and	  standards	  were	  prepared	  by	  serial	  dilution	  1:2	  to	  obtain	  a	  7-­‐point	  standard	  curve	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with	  the	  range	  8.23-­‐6000	  pg/mL.	  	  100µL	  of	  standards	  and	  diluted	  samples	  were	  added	  to	  
appropriate	  wells	  in	  a	  96-­‐well	  ELISA	  plate	  precoated	  with	  CCL23	  specific	  antibody	  and	  
incubated	  for	  2.5	  hours	  at	  room	  temperature	  with	  gentle	  shaking.	  	  Plates	  were	  washed	  4	  
times	  with	  300µL	  of	  supplied	  wash	  solution	  using	  an	  autowasher	  and	  then	  inverted	  onto	  
paper	  towels	  to	  ensure	  removal	  of	  wash	  solution.	  	  100µL	  of	  biotinylated	  CCL23	  detection	  
antibody	  was	  added	  to	  each	  well	  and	  plate	  was	  incubated	  for	  1	  hour	  at	  room	  temperature	  
with	  gentle	  shaking.	  	  The	  wash	  step	  was	  repeated	  as	  previously	  described	  and	  100µL	  of	  
Horseradish	  Peroxidase	  (HRP)-­‐Streptavidin	  was	  added	  as	  enzyme	  conjugate	  followed	  by	  45	  
minutes	  incubation	  at	  room	  temperature	  with	  gentle	  shaking.	  	  The	  wash	  step	  was	  repeated	  
as	  previously	  described	  and	  100µL	  of	  Tetramethylbenzidine	  (TMB)	  substrate	  was	  added	  to	  
each	  well	  and	  incubated	  at	  room	  temperature	  with	  gentle	  shaking	  for	  about	  30	  minutes	  
until	  optimal	  colour	  density	  developed.	  	  Finally	  50µL	  of	  Stop	  Solution	  was	  added	  and	  
absorbance	  was	  read	  immediately	  at	  450nm.	  
2.6.3.2 Haptoglobin	  competitive	  ELISA	  (Abcam)	  	  	  	  	  	  	  	  	  	  	  
Haptoglobin	  competitive	  ELISA	  (Abcam;	  Cambridge,	  UK)	  was	  carried	  out	  according	  to	  
manufacturers	  instructions.	  	  Briefly,	  samples	  were	  diluted	  1:2,000	  in	  supplied	  assay	  diluent	  
and	  standards	  were	  prepared	  by	  serial	  dilution	  1:2	  to	  obtain	  a	  7-­‐point	  standard	  curve	  with	  
the	  range	  0.01-­‐20	  µg/mL.	  	  25µL	  of	  standards	  and	  diluted	  samples	  were	  added	  to	  appropriate	  
wells	  in	  a	  96-­‐well	  ELISA	  plate,	  precoated	  with	  Haptoglobin	  specific	  antibody.	  	  Immediately	  
25µL	  of	  biotinylated	  Haptoglobin	  was	  added	  to	  each	  well	  and	  plate	  was	  incubated	  for	  1	  hour	  
at	  room	  temperature	  with	  gentle	  shaking	  incubated.	  	  Plates	  were	  washed	  5	  times	  with	  
200µL	  supplied	  wash	  solution	  using	  an	  autowasher	  and	  then	  inverted	  onto	  paper	  towels	  to	  
ensure	  removal	  of	  wash	  solution.	  	  50µL	  of	  HRP-­‐Streptavidin	  was	  added	  as	  enzyme	  conjugate	  
followed	  by	  30	  minutes	  incubation	  at	  room	  temperature	  with	  gentle	  shaking.	  	  The	  wash	  step	  
was	  repeated	  as	  previously	  described	  and	  50µL	  of	  TMB	  substrate	  was	  added	  to	  each	  well	  
and	  incubated	  at	  room	  temperature	  with	  gentle	  shaking	  for	  about	  15	  minutes	  until	  optimal	  
colour	  density	  developed.	  	  Finally	  50µL	  of	  Stop	  Solution	  was	  added	  and	  absorbance	  was	  read	  
immediately	  at	  450nm	  in	  a	  plate	  reader.	  
2.6.3.3 C5	  sandwich	  ELISA	  (Abcam)	  
C5	  ELISA	  (Abcam;	  Cambridge,	  UK)	  was	  carried	  out	  according	  to	  manufacturers	  instructions.	  	  
Briefly	  samples	  were	  diluted	  1:20,000	  in	  supplied	  assay	  diluent	  and	  standards	  were	  prepared	  
by	  serial	  dilution	  1:2	  to	  obtain	  a	  7-­‐point	  standard	  curve	  with	  the	  range	  0.313-­‐20	  ng/mL.	  	  
50µL	  of	  standards	  and	  diluted	  samples	  were	  added	  to	  appropriate	  wells	  in	  a	  96-­‐well	  ELISA	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plate	  precoated	  with	  C5	  specific	  antibody	  and	  incubated	  for	  2	  hours	  at	  room	  temperature	  
with	  gentle	  shaking.	  	  Plates	  were	  washed	  5	  times	  with	  200µL	  of	  supplied	  wash	  solution	  using	  
an	  autowasher	  and	  then	  inverted	  onto	  paper	  towels	  to	  ensure	  removal	  of	  wash	  solution.	  	  
50µL	  of	  biotinylated	  C5	  detection	  antibody	  was	  added	  to	  each	  well	  and	  plate	  was	  incubated	  
for	  1	  hour	  at	  room	  temperature	  with	  gentle	  shaking.	  	  The	  wash	  step	  was	  repeated	  as	  
previously	  described	  and	  50µL	  of	  HRP-­‐Streptavidin	  was	  added	  as	  enzyme	  conjugate	  followed	  
by	  30	  minutes	  incubation	  at	  room	  temperature	  with	  gentle	  shaking.	  	  The	  wash	  step	  was	  
repeated	  and	  50µL	  of	  TMB	  substrate	  was	  added	  to	  each	  well	  and	  incubated	  at	  room	  
temperature	  with	  gentle	  shaking	  for	  about	  30	  minutes	  until	  optimal	  colour	  density	  
developed.	  	  Finally	  50µL	  of	  Stop	  Solution	  was	  added	  and	  absorbance	  was	  read	  immediately	  
at	  450nm	  in	  a	  plate	  reader.	  
2.6.3.4 C1q	  sandwich	  ELISA	  (Abcam)	  
C1q	  ELISA	  (Abcam;	  Cambridge,	  UK)	  was	  carried	  out	  according	  to	  manufacturers	  instructions.	  	  
Briefly,	  samples	  were	  diluted	  1:50,000	  in	  supplied	  assay	  diluent	  and	  standards	  were	  
prepared	  by	  serial	  dilution	  1:4	  to	  obtain	  a	  6-­‐point	  standard	  curve	  with	  the	  range	  0.039-­‐40	  
ng/mL.	  	  50µL	  of	  standards	  and	  diluted	  samples	  were	  added	  to	  appropriate	  wells	  in	  a	  96-­‐well	  
ELISA	  plate	  precoated	  with	  C1q	  specific	  antibody	  and	  incubated	  for	  2	  hours	  at	  room	  
temperature	  with	  gentle	  shaking.	  	  Plates	  were	  washed	  6	  times	  with	  300µL	  of	  supplied	  wash	  
solution	  using	  an	  autowasher	  and	  then	  inverted	  onto	  paper	  towels	  to	  ensure	  removal	  of	  
wash	  solution.	  	  50µL	  of	  biotinylated	  C1q	  detection	  antibody	  was	  added	  to	  each	  well	  and	  
plate	  was	  incubated	  for	  1	  hour	  at	  room	  temperature	  with	  gentle	  shaking.	  	  The	  wash	  step	  
was	  repeated	  as	  previously	  described	  and	  50µL	  of	  HRP-­‐Streptavidin	  was	  added	  as	  enzyme	  
conjugate	  followed	  by	  30	  minutes	  incubation	  at	  room	  temperature	  with	  gentle	  shaking.	  	  The	  
wash	  step	  was	  repeated	  and	  50µL	  of	  TMB	  substrate	  was	  added	  to	  each	  well	  and	  incubated	  
at	  room	  temperature	  with	  gentle	  shaking	  for	  about	  15	  minutes	  until	  optimal	  colour	  density	  
developed.	  	  Finally	  50µL	  of	  Stop	  Solution	  was	  added	  and	  absorbance	  was	  read	  immediately	  
at	  450nm.	  
2.6.3.5 CXCL17	  sandwich	  ELISA	  (Cusabio)	  
CXCL17	  ELISA	  (Cusabio;	  Wuhan,	  China)	  was	  carried	  out	  according	  to	  manufacturers	  
instructions.	  	  Briefly,	  samples	  were	  used	  undiluted	  and	  standards	  were	  prepared	  by	  serial	  
dilution	  1:2	  to	  obtain	  a	  6-­‐point	  standard	  curve	  with	  the	  range	  125-­‐8000	  pg/mL.	  	  100µL	  of	  
standards	  and	  undiluted	  samples	  were	  added	  to	  appropriate	  wells	  in	  a	  96-­‐well	  ELISA	  plate	  
precoated	  with	  CXCL17	  specific	  antibody	  and	  incubated	  for	  2	  hours	  at	  37OC	  in	  the	  dark.	  Fluid	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was	  then	  aspirated	  from	  the	  wells	  and	  100µL	  of	  biotinylated	  CXCL17	  detection	  antibody	  was	  
added	  to	  each	  well	  without	  washing	  and	  plate	  was	  incubated	  for	  1	  hour	  at	  37OC	  in	  the	  dark.	  	  
Plates	  were	  washed	  3	  times	  with	  200µL	  of	  supplied	  wash	  solution	  with	  2	  minute	  soak	  in-­‐
between	  each	  wash	  step	  using	  an	  autowasher	  and	  then	  inverted	  onto	  paper	  towels	  to	  
ensure	  removal	  of	  wash	  solution.	  	  100µL	  of	  HRP-­‐Streptavidin	  was	  then	  added	  as	  enzyme	  
conjugate	  followed	  by	  1	  hour	  incubation	  at	  37OC	  in	  the	  dark.	  	  The	  wash	  step	  was	  repeated	  as	  
previously	  described	  5	  times	  and	  90µL	  of	  TMB	  substrate	  was	  added	  to	  each	  well	  and	  
incubated	  at	  37OC	  in	  the	  dark	  for	  about	  30	  minutes	  until	  optimal	  colour	  density	  developed.	  	  
Finally	  50µL	  of	  Stop	  Solution	  was	  added	  and	  absorbance	  was	  read	  immediately	  at	  450nm.	  
	  
2.6.3.6 SERPING1	  competition	  ELISA	  (Cusabio)	  
SERPING1	  (also	  known	  as	  C1	  inhibitor)	  competition	  ELISA	  (Cusabio;	  Wuhan,	  China)	  was	  
carried	  out	  according	  to	  manufacturers	  instructions.	  	  Briefly,	  samples	  were	  diluted	  1:1000	  in	  
supplied	  assay	  diluent	  and	  standards	  were	  prepared	  by	  serial	  dilution	  1:2	  to	  obtain	  a	  6-­‐point	  
standard	  curve	  with	  the	  range	  18.75-­‐1200	  ng/mL.	  	  50µL	  of	  standards	  and	  diluted	  samples	  
were	  added	  to	  appropriate	  wells	  in	  a	  96-­‐well	  ELISA	  plate	  precoated	  with	  SERPING1	  along	  
with	  SERPING1	  specific	  antibody	  conjugated	  to	  HRP	  and	  incubated	  for	  30	  minutes	  at	  37OC	  in	  
the	  dark.	  Plates	  were	  washed	  5	  times	  with	  200µL	  of	  supplied	  wash	  solution	  with	  2	  minute	  
soak	  in-­‐between	  each	  wash	  step	  using	  an	  autowasher	  and	  then	  inverted	  onto	  paper	  towels	  
to	  ensure	  removal	  of	  wash	  solution.	  	  90µL	  of	  TMB	  substrate	  was	  then	  added	  to	  each	  well	  
and	  incubated	  at	  37OC	  in	  the	  dark	  for	  about	  20	  minutes	  until	  optimal	  colour	  density	  
developed.	  	  Finally	  50µL	  of	  Stop	  Solution	  was	  added	  and	  absorbance	  was	  read	  immediately	  
at	  450nm.	  
2.6.3.7 Circulating	  Immune	  Complex	  (CIC)	  ELISA	  (Bühlmann)	  
CIC	  ELISA	  (Bühlmann;	  Schönenbuch,	  Switzerland)	  was	  carried	  out	  according	  to	  
manufacturers	  instructions.	  	  Briefly	  samples	  were	  diluted	  1:50	  in	  supplied	  assay	  diluent.	  	  
Pre-­‐prepared	  standards	  comprising	  7	  known	  calibrating	  concentrations	  of	  aggregated	  IgG	  
were	  supplied.	  	  The	  96-­‐well	  ELISA	  plate	  precoated	  with	  human	  C1q	  (which	  binds	  the	  Fc	  
region	  of	  human	  IgG)	  was	  twice	  using	  300µL	  of	  supplied	  wash	  buffer	  using	  an	  autowasher	  
and	  then	  inverted	  onto	  paper	  towels	  to	  ensure	  removal	  of	  wash	  solution.	  	  100µL	  of	  
standards	  and	  diluted	  samples	  were	  added	  to	  appropriate	  wells	  and	  the	  plate	  was	  incubated	  
for	  1	  hour	  at	  room	  temperature	  with	  gentle	  shaking.	  	  The	  wash	  step	  was	  repeated	  3	  times	  as	  
previously	  described	  and	  100µL	  of	  Enzyme	  Label	  (Protein	  A	  conjugated	  APase)	  was	  added	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followed	  by	  30	  minutes	  incubation	  at	  room	  temperature	  with	  gentle	  shaking.	  	  The	  wash	  step	  
was	  repeated	  3	  times	  and	  100µL	  of	  p-­‐Nitrophenyl	  Phosphate	  (pNPP)	  substrate	  was	  added	  to	  
each	  well	  and	  incubated	  at	  room	  temperature	  with	  gentle	  shaking	  for	  about	  30	  minutes	  
until	  optimal	  colour	  density	  developed.	  	  Finally	  100µL	  of	  Stop	  Solution	  was	  added	  and	  
absorbance	  was	  read	  immediately	  at	  405nm	  in	  a	  plate	  reader.	  
2.6.4 Limus	  Amebocyte	  Lysate	  (LAL)	  assay	  (Lonza)	  
The	  LAL	  assay	  (Lonza;	  Basel,	  Switzerland)	  is	  a	  quantitative	  test	  for	  Gram-­‐negative	  bacterial	  
endotoxin	  (e.g.	  lipopolysaccharide	  (LPS)).	  It	  was	  used	  to	  evaluate	  specimens	  in	  which	  there	  
was	  a	  concern	  over	  LPS	  contamination	  of	  the	  blood	  tubes	  used	  to	  collect	  samples.	  	  The	  assay	  
is	  based	  on	  a	  protein	  found	  in	  the	  horseshoe	  crab,	  Limus	  polyhemus,	  which	  has	  been	  found	  
to	  react	  with	  endotoxin.	  	  Assay	  was	  carried	  out	  according	  to	  a	  slight	  modification	  to	  the	  
manufacturer’s	  protocol.	  	  Briefly,	  samples	  were	  diluted	  1:10	  in	  the	  supplied	  LAL	  Reagent	  
Water,	  and	  then	  heat	  inactivated	  at	  80oC	  for	  15	  minutes	  on	  a	  heating	  block	  and	  allowed	  to	  
cool.	  	  Standards	  were	  prepared	  by	  serial	  dilution	  1:2	  to	  obtain	  a	  7-­‐point	  standard	  curve	  with	  
the	  range	  0.008	  EU/mL-­‐0.5	  EU/mL	  (EU	  =	  endotoxin	  units).	  	  50µL	  of	  standards	  and	  samples	  
were	  then	  loaded	  in	  triplicate	  to	  the	  manufacturer	  supplied	  plate	  (the	  first	  two	  used	  as	  
duplicate	  results	  and	  the	  third	  for	  background	  subtraction).	  	  The	  plate	  was	  equilibrated	  in	  a	  
37oC	  incubator	  for	  5	  minutes	  and	  then	  50µL	  of	  LAL	  was	  added	  to	  the	  first	  two	  wells	  of	  each	  
sample	  and	  standards.	  	  The	  plate	  was	  then	  returned	  to	  the	  incubator	  for	  a	  further	  12	  
minutes.	  	  100µL	  of	  chromogenic	  substrate	  was	  then	  added	  to	  the	  first	  two	  wells	  for	  each	  
sample	  and	  standard	  and	  the	  plate	  was	  then	  returned	  to	  the	  incubator	  for	  7	  minutes.	  	  50µL	  
of	  Stop	  solution	  (25%	  acetic	  acid)	  was	  then	  added	  to	  the	  first	  two	  wells	  of	  each	  sample	  and	  
standard	  and	  absorbance	  was	  read	  immediately	  at	  405nm	  in	  a	  plate	  reader.	  	  Final	  
concentrations	  were	  calculated	  from	  a	  standard	  curve	  using	  Excel	  software.	  	  Samples	  with	  >	  
0.5	  EU/mL	  were	  considered	  contaminated	  with	  endotoxin.	  	  	  	  	  
2.7 Challenges	  faced	  in	  undertaking	  study	  
This	  study	  could	  only	  be	  conducted	  in	  a	  setting	  of	  high	  HIV	  and	  TB	  burden.	  	  However,	  the	  use	  
of	  FDG-­‐PET/CT	  imaging	  as	  well	  as	  laboratory	  requirements	  meant	  the	  study	  needed	  to	  be	  
conducted	  in	  a	  setting	  with	  adequate	  clinical	  and	  research	  infrastructure,	  making	  Cape	  Town	  
an	  ideal	  study	  site.	  	  As	  might	  be	  expected,	  there	  were	  a	  number	  of	  logistical	  and	  technical	  
challenges	  in	  conducting	  a	  complex	  clinical	  and	  laboratory	  study	  in	  this	  setting	  that	  resulted	  
in	  the	  requirement	  for	  additional	  time	  and	  modifications	  to	  the	  study	  design.	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As	  stated	  previously	  the	  study	  was	  initially	  designed	  to	  be	  embedded	  within	  the	  MVA85A	  
vaccine	  trial	  which	  was	  due	  to	  commence	  in	  July	  2010,	  however	  unforeseen	  problems	  with	  
the	  manufacture	  of	  the	  investigational	  product	  resulted	  in	  the	  vaccine	  trial	  start	  being	  
delayed	  until	  August	  2011.	  	  This	  resulted	  in	  a	  6-­‐month	  delay	  to	  the	  start	  of	  the	  recruitment	  
for	  this	  study.	  	  Digital	  chest	  radiography	  was	  a	  vital	  part	  of	  TB	  screening	  for	  this	  study	  and	  
the	  vaccine	  trial,	  however	  the	  machine	  available	  on	  the	  study	  site	  at	  the	  start	  of	  the	  study	  
(Sedecal	  Dragon	  DR)	  was	  not	  deemed	  appropriate	  for	  this	  use	  and	  thus	  was	  not	  given	  
regulatory	  approval.	  	  This	  resulted	  in	  a	  re-­‐tendering	  process	  to	  purchase	  a	  more	  appropriate	  
digital	  X-­‐ray	  machine	  (Phillips	  Essenta	  DR),	  which	  was	  not	  installed	  on	  site	  until	  February	  
2012.	  	  As	  an	  interim	  measure,	  a	  suitable	  digital	  X-­‐Ray	  machine	  (Delft	  Oldeca	  DR)	  was	  
identified	  at	  UCT	  to	  allow	  commencement	  of	  both	  the	  vaccine	  trial	  and	  this	  study	  although	  
this	  required	  participants	  to	  be	  transported	  on	  a	  30	  mile	  round	  trip	  for	  CXR	  screening.	  
	  
In	  the	  initial	  study	  design	  the	  intention	  was	  that	  CXR	  screening	  would	  be	  used	  to	  identify	  
asymptomatic	  participants	  with	  inactive	  TB	  lesions,	  which	  would	  then	  be	  evaluated	  in	  
greater	  metabolic	  and	  anatomical	  detail	  by	  FDG-­‐PET/CT.	  	  Diagnostic	  standards	  for	  such	  
inactive	  TB	  lesions	  on	  CXR	  have	  been	  present	  since	  at	  least	  1940	  and	  identification	  of	  these	  
lesions	  are	  considered	  an	  important	  part	  of	  TB	  screening	  CXR	  as	  they	  are	  associated	  with	  
increase	  risk	  of	  developing	  active	  TB.	  	  However,	  it	  quickly	  became	  clear	  that	  often	  the	  CXR	  
determined	  lesions	  were	  not	  apparent	  on	  CT	  and	  that	  CT	  frequently	  identified	  inactive	  
lesions	  not	  obviously	  visible	  on	  CXR.	  	  	  
	  
The	  vaccine	  trial	  had	  a	  sponsor-­‐initiated	  postponement	  due	  to	  staffing	  and	  investigational	  
product	  issues	  in	  April	  2012,	  this	  resulted	  in	  a	  necessary	  change	  to	  study	  design	  as	  
recruitment	  needed	  to	  be	  conducted	  independently	  of	  the	  vaccine	  trial.	  	  As	  few	  changes	  as	  
possible	  were	  made	  to	  the	  recruitment	  process,	  however,	  because	  of	  the	  need	  to	  improve	  
the	  screen	  to	  recruitment	  ratio	  and	  the	  preliminary	  observations	  regarding	  the	  relationship	  
between	  inactive	  TB	  lesions	  on	  CXR	  and	  CT,	  the	  main	  modification	  was	  to	  extent	  recruitment	  
to	  those	  with	  “normal”	  lung	  parenchyma	  on	  CXR	  while	  still	  excluding	  participants	  with	  active	  
TB	  on	  CXR.	  	  This	  also	  provided	  an	  opportunity	  to	  compare	  TB	  CXR	  screening	  to	  the	  gold	  
standard	  of	  CT	  for	  the	  first	  time	  (see	  chapter	  4).	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FDG-­‐PET/CT	  is	  not	  widely	  available	  in	  South	  Africa	  and	  at	  the	  beginning	  of	  the	  study	  the	  only	  
place	  in	  the	  Western	  Cape	  with	  an	  FDG-­‐PET/CT	  machine	  was	  based	  in	  the	  Panorama	  Medi-­‐
Clinic	  private	  hospital.	  	  Though	  well	  established	  they	  had	  little	  experience	  of	  conducting	  
research	  studies.	  	  Although	  training	  and	  supervision	  meant	  protocol	  adherence	  was	  good,	  
the	  reporting	  of	  images	  was	  not	  adequate	  for	  the	  needs	  of	  a	  research	  study	  and	  there	  was	  
little	  enthusiasm	  to	  address	  this	  at	  the	  Medi-­‐Clinic.	  	  Therefore,	  a	  collaboration	  was	  
developed	  with	  the	  Academic	  Nuclear	  Medicine	  department	  at	  Stellenbosch	  University	  to	  
develop	  a	  structured	  approach	  to	  reporting	  the	  images.	  	  As	  a	  result,	  for	  practical	  and	  
financial	  reasons,	  when	  the	  Western	  Cape	  Academic	  PET-­‐CT	  centre	  at	  Tygerberg	  Hospital	  
(the	  main	  teaching	  hospital	  for	  Stellenbosch	  University)	  opened	  in	  2012	  the	  study	  imaging	  
was	  moved	  to	  the	  new	  facility.	  	  As	  few	  changes	  as	  possible	  were	  made	  to	  the	  imaging	  
protocol	  following	  the	  transfer	  between	  imaging	  facilities.	  
	  
Follow	  up	  of	  the	  participants	  was	  also	  challenging	  and	  only	  27	  of	  the	  35	  participants	  had	  
follow	  up	  PET-­‐CT,	  which	  was	  less	  that	  anticipated.	  	  The	  main	  challenge	  to	  follow-­‐up	  was	  the	  
regular	  movement	  of	  participants	  between	  Khayelitsha	  and	  the	  Eastern	  Cape	  province	  
(where	  most	  of	  the	  Xhosa	  speaking	  community	  living	  in	  Khayelitsha	  originate).	  	  This	  was	  a	  
particular	  issue	  around	  Christmas	  and	  Easter	  time,	  as	  well	  as	  throughout	  the	  year	  for	  
funerals	  and	  weddings.	  	  Also	  because	  unemployment	  was	  very	  high	  in	  Khayelitsha	  if	  job	  
opportunities	  arose	  elsewhere	  during	  the	  study,	  participants	  rightly	  felt	  compelled	  to	  
prioritize	  their	  employment.	  	  Pregnancy	  was	  also	  an	  issue	  particularly	  as	  participants	  were	  
mainly	  women	  aged	  20-­‐40,	  with	  3	  of	  35	  participants	  falling	  pregnant	  during	  the	  study,	  
meaning	  repeat	  PET/CT	  was	  not	  performed.	  	  This	  was	  despite	  planning	  pregnancy	  being	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CHAPTER	  3	  –	  Evaluation	  of	  screening	  
tools	  used	  in	  participant	  recruitment	  
3.1 Chapter	  3	  Introduction	  
In	  this	  chapter	  the	  recruitment	  of	  participants	  and	  controls	  will	  be	  detailed	  and	  their	  clinical	  
features	  presented	  and	  compared.	  	  Each	  of	  the	  participant	  and	  control	  groups	  were	  
distinguished	  by	  the	  presence	  or	  absence	  of	  active	  and/or	  latent	  TB	  and	  by	  HIV	  status.	  	  
Active	  TB	  in	  HIV	  infected	  participants	  was	  excluded	  by	  sputum	  culture,	  TB	  symptom	  
screening	  and	  CXR	  screening.	  	  These	  three	  screening	  investigations	  for	  active	  TB	  were	  
performed	  on	  almost	  all	  potential	  participants.	  	  As	  a	  result	  this	  provided	  an	  opportunity	  for	  
evaluation	  and	  comparison	  of	  the	  performance	  of	  screening	  investigations.	  	  Screening	  was	  
conducted	  in	  healthy	  outpatients	  so	  the	  prevalence	  of	  undiagnosed	  culture	  positive	  TB	  
(prevalent	  TB)	  could	  also	  be	  assessed.	  	  Prevalent	  TB	  is	  either	  pre-­‐diagnostic	  (i.e.	  TB	  
symptoms	  are	  present	  but	  presentation	  to	  healthcare	  services	  for	  diagnosis	  and	  treatment	  
has	  not	  occurred)	  or	  culture	  positive,	  subclinical	  (i.e.	  no	  TB	  symptoms	  are	  present).	  	  This	  
chapter	  therefore	  begins	  to	  provide	  insight	  into	  the	  grey	  area	  between	  latent	  TB	  and	  active	  
TB,	  which	  has	  then	  been	  further	  explored	  in	  subsequent	  chapters.	  	  The	  diagnosis	  of	  latent	  TB	  
was	  made	  by	  QFGIT	  and	  although	  TST	  was	  not	  performed	  on	  everyone	  (as	  previously	  
explained)	  comparison	  of	  the	  2	  tests	  could	  be	  made.	  	  As	  healthy	  HIV	  uninfected	  participants	  
were	  also	  screened	  as	  controls,	  comparison	  of	  the	  performance	  of	  QFGIT	  in	  HIV	  infected	  and	  
HIV	  uninfected	  persons	  living	  in	  the	  same	  community	  could	  be	  made.	  	  	  	  	  
	  
Evaluation	  of	  these	  screening	  tools	  remains	  important	  and	  relevant.	  	  Although	  
indiscriminate	  mass	  TB	  screening,	  widely	  implemented	  in	  the	  mid-­‐20th	  century	  was	  
abandoned	  from	  the	  1970’s	  in	  the	  face	  of	  falling	  TB	  prevalence	  and	  poor	  cost	  effectiveness,	  
in	  recent	  years	  there	  has	  been	  renewed	  interest	  in	  targeted	  screening	  of	  high	  risk	  persons	  
especially	  in	  high	  TB	  burden	  countries[204].	  	  Symptom	  screening	  and	  CXR	  remains	  the	  
mainstay	  of	  for	  active	  TB	  screening	  and	  TST	  remains	  widely	  used	  for	  screening	  of	  latent	  TB	  
although	  in	  some	  contexts	  IGRA	  are	  also	  implemented.	  	  Screening	  for	  active	  and	  latent	  TB	  
are	  both	  important	  in	  the	  context	  of	  IPT	  administration	  especially	  in	  HIV	  infected	  
populations.	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3.2 Chapter	  3	  aims	  
• To	  describe	  and	  compare	  the	  clinical	  features	  of	  the	  main	  cohort	  of	  participants	  and	  
control	  participants	  	  
• To	  evaluate	  the	  performance	  of	  clinical	  screening	  tools	  for	  the	  detection	  of	  active	  TB	  
and	  latent	  TB.	  	  
3.2.1 Specific	  chapter	  3	  aims	  
1. To	  describe	  compare	  the	  clinical	  features	  of	  participants	  of	  controls	  	  
2. To	  determine	  the	  prevalence	  of	  active	  TB	  and	  latent	  TB	  in	  a	  population	  of	  healthy,	  
outpatient	  HIV	  infected	  persons	  that	  are	  ART	  naïve.	  
3. To	  determine	  the	  utility	  of	  symptom	  screen,	  CXR	  and	  QFGIT	  screening	  to	  detect	  
prevalent	  TB	  
4. To	  compare	  QFGIT	  and	  TST	  for	  the	  diagnosis	  of	  latent	  TB	  
5. To	  evaluate	  the	  inter-­‐observer	  variability	  of	  screening	  CXR	  
6. To	  evaluate	  the	  variability	  in	  QFGIT	  diagnosis	  of	  latent	  TB	  in	  HIV	  infected	  and	  
uninfected	  adults	  
3.3 Chapter	  3	  methods	  
Statistical	  analysis	  was	  performed	  using	  Stata	  ver.	  12.1.	  	  Graphs	  and	  figures	  were	  created	  
using	  both	  Stata	  ver.	  12.1	  and	  GraphPad	  Prism	  ver.	  5.0a.	  	  Area	  propionate	  Venn	  diagrams	  
were	  derived	  using	  the	  BioVenn	  application	  (http://www.cmbi.ru.nl/cdd/biovenn/).	  	  CXR	  
images	  were	  assessed	  in	  and	  exported	  from	  OsiriX	  3.8.1	  32-­‐bit.	  	  	  
	  
Non	  paired,	  non-­‐parametric	  data	  was	  compared	  using	  Wilcoxon	  rank	  sum	  (Mann-­‐Whitney	  U	  
test)	  or	  Kruskal	  Wallis	  rank	  test	  and	  parametric	  data	  compared	  using	  t-­‐test	  or	  ANOVA.	  	  
Proportions	  were	  compared	  by	  χ2	  test	  or	  Fisher’s	  exact	  test	  (if	  the	  contingency	  included	  a	  
number	  ≤	  5).	  	  Correlation	  was	  performed	  by	  Pearson	  and	  Spearman	  analysis.	  	  Agreement	  
between	  tests	  was	  determined	  using	  kappa	  statistic	  with	  degree	  of	  agreement	  defined	  as	  
follows[205];	  
κ	  <	  0	  	  	   	   Less	  that	  chance	  agreement	  
κ	  =	  0.01-­‐0.20	  	   Slight	  agreement	  
κ	  =	  0.21-­‐0.40	   Fair	  agreement	  
κ	  =	  0.41-­‐0.60	   Moderate	  agreement	  
κ	  =	  0.61-­‐0.80	   Substantial	  agreement	  
κ	  =	  0.81-­‐0.99	  	   Almost	  perfect	  agreement	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3.4 Results	  
3.4.1 Screening	  of	  HIV-­‐infected	  ART	  naïve	  outpatients	  for	  study	  
participation	  	  
265	  healthy	  HIV	  infected,	  adult	  outpatients	  with	  no	  history	  of	  previous	  TB,	  attending	  pre-­‐
ART	  wellness	  clinics,	  were	  screened	  for	  study	  eligibility	  by	  CXR,	  sputum	  culture	  x	  2	  (induced	  
if	  necessary),	  QFGIT,	  CD4	  count	  and	  a	  short	  structured	  history	  (table	  3.1).	  	  143	  were	  
screened	  within	  the	  vaccine	  study	  between	  August	  2011	  and	  May	  2012	  and	  122	  
independently	  from	  the	  vaccine	  study	  between	  May	  2012	  and	  January	  2013.	  	  A	  similar	  
strategy	  was	  used	  for	  both	  phases	  of	  screening.	  	  The	  potential	  participants	  that	  were	  
screened	  had	  a	  median	  age	  of	  32	  years	  (IQR	  28-­‐38	  years)	  and	  84.5%	  were	  women,	  the	  high	  
proportion	  of	  women	  screened	  reflected	  attendance	  at	  the	  pre-­‐ART	  clinic.	  	  89.2%	  had	  CD4	  
≥350/mm3	  with	  median	  CD4	  520/mm3	  (IQR	  429-­‐673/mm3).	  	  All	  those	  with	  CD4	  <	  350/mm3	  
were	  referred	  for	  ART.	  	  The	  prevalence	  of	  latent	  TB	  as	  determined	  by	  QFGIT	  in	  this	  
population	  was	  64.2%	  (95%	  C.I	  58.3%	  -­‐	  70.0%);	  the	  proportion	  with	  positive	  QFGIT	  did	  not	  
vary	  significantly	  across	  CD4	  quartiles	  (p=0.77).	  	  5.6%	  reported	  previous	  IPT	  and	  had	  mainly	  
received	  this	  through	  previous	  clinical	  studies	  conducted	  at	  the	  site.	  	  Only	  participants	  self-­‐
reporting	  as	  well	  and	  free	  of	  symptoms	  were	  screened,	  however	  on	  direct	  questioning	  about	  
TB	  symptoms	  (cough	  >	  1	  week,	  haemoptysis,	  night	  sweats,	  weight	  loss,	  fever,	  pleuritic	  pain,	  
or	  shortness	  of	  breath)	  8.4%	  reported	  symptoms.	  	  Of	  those	  with	  symptoms,	  weight	  loss	  was	  
most	  commonly	  reported	  by	  73.9%,	  followed	  by	  cough	  and	  fever	  both	  reported	  by	  21.7%,	  
haemoptysis	  13%,	  pleuritic	  pain	  8.7%	  and	  shortness	  of	  breath	  4.3%.	  	  	  
	  
The	  2	  CXR	  readers	  were	  blind	  to	  clinical	  details	  and	  laboratory	  results.	  	  Independent	  
structured	  reports	  were	  provided	  as	  described	  in	  chapter	  2	  with	  final	  report	  determined	  by	  
consensus.	  	  Where	  consensus	  could	  not	  be	  reached	  a	  3rd	  reader	  arbitrated.	  	  12.5%	  of	  the	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Table	  3.1-­‐	  Clinical	  characteristics	  of	  the	  265	  screened	  participants	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screened	  participants	  were	  reported	  to	  have	  CXR	  changes	  consistent	  with	  active	  TB,	  31.7%	  
had	  CXR	  changes	  consistent	  with	  inactive	  TB,	  47.6%	  had	  a	  normal	  CXR	  and	  8.3%	  had	  other	  
abnormalities	  on	  CXR	  unrelated	  to	  TB.	  	  The	  most	  common	  “other	  abnormality”	  on	  CXR	  was	  
cardiomegaly	  (cardio	  thoracic	  ratio	  >	  50%).	  	  Proportion	  of	  CXR	  abnormalities	  did	  not	  vary	  by	  
CD4	  quartile	  (p=0.69)	  or	  with	  QFGIT	  status	  (p=0.54).	  	  Significantly	  more	  participants	  with	  
symptoms	  had	  CXR	  changes	  consistent	  with	  active	  TB	  than	  those	  without	  symptoms	  (30.4%	  
vs.	  10.7%,	  p=0.014)	  but	  there	  was	  no	  significant	  association	  of	  inactive	  changes	  with	  
symptoms	  (39.1%	  vs.	  31.0%	  p=0.48).	  
3.4.2 Prevalence	  of	  tuberculosis	  in	  screened	  participants	  
Of	  the	  265	  participants	  consenting	  for	  screening,	  244	  were	  able	  to	  produce	  sputum	  either	  
spontaneously	  or	  following	  induction	  (unfortunately	  whether	  sputum	  was	  spontaneously	  
produced	  or	  induced	  was	  not	  reliably	  recorded).	  	  The	  21	  participants	  (7.9%)	  in	  whom	  
sputum	  culture	  was	  not	  available	  were	  less	  likely	  to	  have	  TB	  symptoms	  4.7%	  vs.	  9.0%	  or	  CXR	  
changes	  of	  active	  TB	  4.8%	  vs.	  13.2%	  but	  these	  differences	  were	  not	  statistically	  significant.	  	  
Of	  those	  with	  culture	  results,	  10	  participants	  were	  culture	  positive	  for	  Mtb	  (i.e.	  had	  
prevalent	  untreated	  TB)	  (table	  3.2).	  	  All	  were	  smear	  negative	  and	  GeneXpert	  was	  not	  
performed	  on	  any	  samples.	  	  Both	  sputum	  samples	  were	  culture	  positive	  in	  4	  participants,	  
one	  of	  two	  cultures	  positive	  for	  5	  participants	  and	  only	  one	  sputum	  was	  sent	  for	  1	  
participant	  (which	  was	  positive).	  	  Median	  time	  to	  culture	  positivity	  was	  16.5	  days	  (IQR	  14.25-­‐
20	  days)	  (for	  1st	  of	  2	  samples	  if	  both	  positive).	  
	  
The	  prevalence	  of	  undiagnosed	  TB	  in	  healthy	  pre-­‐ART,	  HIV	  infected,	  outpatients	  with	  median	  
CD4	  520/mm3	  and	  no	  prior	  history	  of	  TB	  in	  this	  setting	  was	  therefore	  to	  be	  4.1%	  (95%	  CI	  
1.6%-­‐6.6%).	  	  In	  the	  subgroup	  of	  participants	  that	  were	  QFGIT	  positive	  with	  no	  history	  of	  IPT,	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  3.2	  Clinical	  characteristics	  of	  10	  prevalent	  TB	  cases	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prevalence	  was	  6.1%	  (95%	  C.I.	  2.2%-­‐10%).	  	  Six	  participants	  with	  prevalent	  TB	  were	  
asymptomatic	  and	  culture	  positive	  (i.e.	  culture	  positive	  subclinical	  TB)	  and	  of	  these	  5	  did	  not	  	  
have	  evidence	  of	  active	  TB	  on	  CXR.	  	  The	  prevalence	  of	  culture	  positive	  subclinical	  TB	  in	  
healthy	  pre-­‐ART	  outpatients	  in	  this	  setting	  was	  therefore	  determined	  to	  be	  2.5%	  (95%	  CI	  
0.5%-­‐4.4%).	  	  TB	  prevalence	  was	  only	  determined	  on	  the	  basis	  of	  screening	  cultures	  sent,	  but	  
likely	  underestimated	  the	  true	  prevalence	  as	  a	  number	  of	  participants	  with	  symptoms	  
and/or	  abnormal	  CXR	  that	  were	  culture	  negative	  at	  screen	  were	  referred	  to	  TB	  clinic.	  	  For	  
example	  one	  such	  participant	  was	  found	  to	  have	  inguinal	  LN	  TB.	  	  
	  
There	  was	  no	  significant	  difference	  in	  age,	  sex,	  CD4	  count	  or	  QFGIT	  positivity	  between	  
screened	  participants	  with	  or	  without	  prevalent	  TB.	  	  Those	  with	  prevalent	  TB,	  however,	  
were	  significantly	  more	  likely	  to	  have	  TB	  symptoms	  on	  direct	  questioning	  40%	  vs.	  7.7%	  
(p=0.007)	  and	  have	  evidence	  of	  active	  TB	  on	  CXR	  50%	  vs.	  11.5%	  (p=0.026)	  than	  those	  that	  
were	  culture	  negative.	  	  Of	  the	  specific	  symptoms	  only	  cough	  (p=0.016)	  and	  haemoptysis	  
(p=0.005)	  were	  more	  common	  in	  those	  with	  prevalent	  TB.	  	  In	  participants	  screened	  with	  
evidence	  of	  active	  TB	  on	  CXR	  (33	  in	  total)	  there	  was	  a	  trend	  to	  parenchymal	  opacification	  
without	  evidence	  of	  mineralization	  being	  more	  common	  in	  those	  with	  prevalent	  TB	  	  
(p=0.052).	  	  	  Those	  with	  prevalent	  TB	  and	  symptoms	  were	  more	  likely	  to	  have	  CXR	  suggestive	  
of	  active	  TB.	  	  All	  4	  symptomatic	  participants	  had	  CXR	  evidence	  of	  active	  TB	  compared	  to	  1	  of	  
the	  asymptomatic	  participants	  although	  this	  did	  not	  reach	  statistically	  significance	  (p=0.07).	  	  
All	  of	  the	  parenchymal	  lesions	  were	  of	  minimal	  extent	  and	  2	  participants	  also	  had	  
lymphadenopathy	  (see	  figure	  3.1).	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Figure	  3.1	  –	  TOP	  Area	  proportionate	  Venn	  diagram	  showing	  symptom	  screening	  and	  CXR	  screening	  results	  in	  participants	  
with	  prevalent	  TB	  
BOTTOM	  –	  CXR	  of	  5	  participants	  with	  prevalent	  TB	  and	  active	  TB	  changes	  on	  CXR:	  	  Parenchymal	  abnormalities	  circled	  in	  
green,	  lymphadenopathy	  circled	  in	  red	  and	  pleural	  abnormalities	  in	  yellow.	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The	  negative	  predictive	  value	  (NPV)	  of	  all	  screening	  parameters	  for	  prevalent	  TB	  was	  high	  
which	  would	  be	  expected	  given	  the	  prevalence	  of	  culture	  positive	  TB	  was	  4.1%	  (table	  3.3).	  	  	  
The	  positive	  predictive	  values	  (PPV)	  for,	  positive	  symptom	  screen,	  CXR	  abnormalities	  and	  
QFGIT	  were	  generally	  poor	  especially	  for	  any	  TB	  abnormalities	  on	  CXR	  and	  QFGIT	  however	  
these	  parameters	  had	  high	  sensitivity.	  	  Evaluating	  performance	  of	  specific	  symptoms	  screen	  
questions,	  PPV	  was	  highest	  for	  presence	  of	  cough	  >	  1	  week	  and	  haemoptysis,	  however,	  95%	  
confidence	  limits	  around	  these	  estimates	  were	  very	  large.	  	  Considering	  the	  performance	  of	  
CXR	  in	  those	  with	  and	  without	  symptoms,	  diagnostic	  performance	  was	  markedly	  different.	  	  
Sensitivity	  and	  PPV	  of	  CXR	  was	  good	  in	  those	  with	  TB	  symptoms	  and	  poor	  in	  those	  without	  
TB	  symptoms	  however	  as	  numbers	  were	  small	  95%	  C.I.	  overlapped.	  
3.4.3 Agreement	  in	  screening	  CXR	  reports	  between	  readers	  	  
Given	  that	  CXR	  lesions	  were	  subtle	  and	  usually	  of	  minimal	  extent,	  agreement	  between	  
readers	  was	  further	  evaluated.	  	  The	  independent	  reports	  of	  2	  CXR	  readers	  blind	  to	  clinical	  
details	  are	  cross-­‐tabulated	  in	  table	  3.4	  with	  agreement	  shown	  in	  red.	  	  Categorizing	  CXR	  into	  
those	  consistent	  with	  active	  TB,	  inactive	  TB	  or	  normal/other	  CXR,	  observed	  agreement	  
between	  readers	  was	  57.5%	  against	  an	  expected	  agreement	  of	  43.1%,	  κ=	  0.25	  (95%	  C.I.	  
0.16-­‐0.35).	  	  Therefore	  agreement	  between	  CXR	  readers	  was	  fair.	  	  Difference	  in	  reporting	  
between	  readers	  was	  resolved	  by	  consensus.	  	  Agreement	  between	  individual	  readers	  and	  
the	  consensus	  read	  was	  similar	  for	  readers	  1	  and	  2,	  κ=0.61	  (95%	  C.I.	  0.51-­‐0.70)	  and	  
κ=0.66(95%	  C.I.	  0.56-­‐0.76)	  suggesting	  that	  no	  one	  reader	  influenced	  the	  consensus	  read	  
more	  than	  the	  other.	  	  Approximately	  25%	  of	  images	  were	  read	  independently	  by	  a	  	  
consultant	  radiologist	  to	  validate	  reads	  and	  agreement	  with	  consensus	  read	  was	  moderate,	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3.4.4 Agreement	  between	  TST	  and	  IGRA	  
TST	  was	  performed	  after	  screening	  for	  104	  of	  143	  screened	  within	  the	  vaccine	  study	  
(weighted	  slightly	  towards	  QFGIT	  negative),	  which	  allowed	  comparison	  of	  TST	  for	  a	  sample	  
of	  QFGIT	  results.	  	  Taking	  TST	  ≥	 5mm	  as	  positive,	  agreement	  with	  QFGIT	  was	  moderate.	  	  
Observed	  agreement	  was	  78.9%	  compared	  to	  expected	  agreement	  of	  49.2	  %,	  κ=0.58	  
(95%C.I.	  0.40-­‐0.77)	  (table	  3.5).	  	  
3.4.5 Screen	  failures	  
Of	  the	  265	  healthy,	  HIV	  infected,	  outpatients	  screened,	  101	  participants	  had	  no	  TB	  
symptoms,	  a	  CD4	  count	  >	  350/mm3,	  a	  positive	  QFGIT,	  negative	  TB	  cultures,	  no	  evidence	  of	  
active	  TB	  on	  CXR	  and	  no	  history	  of	  IPT	  and	  were	  considered	  to	  have	  untreated	  latent	  TB.	  	  As	  
described	  previously,	  during	  screening	  within	  vaccine	  study,	  an	  additional	  inclusion	  criterion	  
of	  CXR	  compatible	  with	  inactive	  TB	  applied	  and	  so	  only	  70	  of	  101	  participants	  were	  
considered	  potentially	  eligible,	  of	  these	  55	  had	  more	  extensive	  medical	  history	  and	  clinical	  
assessment	  to	  screen	  for	  eligibility.	  	  35	  participants	  met	  full	  inclusion	  and	  exclusion	  criteria	  
and	  provided	  consent	  for	  PET/CT	  and	  full	  participation	  in	  the	  study.	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3.4.6 Clinical	  features	  of	  35	  participants	  undergoing	  PET/CT	  
3.4.6.1 Clinical	  Features	  at	  screening	  
The	  35	  HIV	  infected	  ART	  naïve	  participants	  that	  underwent	  FDG-­‐PET/CT	  were	  in	  general	  
representative	  of	  the	  screened	  population	  (table	  3.6).	  	  These	  participants	  had	  a	  median	  age	  
of	  31	  years	  (IQR	  27-­‐38	  years),	  91.4%	  were	  female	  and	  the	  median	  CD4	  count	  at	  initial	  
screening	  was	  561/mm3	  (IQR	  505-­‐651/mm3).	  	  The	  median	  time	  since	  HIV	  diagnosis	  was	  2.1	  
years	  (IQR	  0.8-­‐5.2	  years)	  with	  80%	  having	  WHO	  stage	  1	  infection	  and	  20%	  with	  WHO	  stage	  2	  
infection.	  	  Of	  the	  7	  participants	  with	  WHO	  stage	  2	  infection,	  5	  had	  previous	  shingles	  and	  2	  
had	  a	  history	  of	  fungal	  nail	  infection.	  	  Two	  participants	  were	  current	  smokers	  and	  2	  ex-­‐
smokers,	  however,	  none	  had	  smoked	  more	  for	  more	  than	  2	  pack	  years.	  	  Only	  1	  participant	  
had	  current	  biomass	  fuel	  exposure.	  	  Biomass	  fuel	  use	  is	  very	  uncommon	  in	  Khayelitsha	  but	  
more	  common	  in	  rural	  Eastern	  Cape	  province,	  year	  of	  migration	  to	  Khayelitsha	  was	  known	  
for	  13	  participants	  and	  median	  time	  since	  migration	  for	  these	  participants	  was	  10	  years	  (IQR	  
8-­‐15	  years).	  	  45.7%	  of	  participants	  reported	  a	  history	  of	  close	  contact	  with	  someone	  with	  TB	  
(almost	  always	  a	  partner	  or	  first-­‐degree	  relative)	  a	  median	  of	  7	  years	  previously	  (IQR	  2.5-­‐17	  
years).	  	  40%	  had	  CXR	  changes	  consistent	  with	  inactive	  TB	  and	  60%	  CXR	  with	  normal	  
parenchyma,	  therefore	  despite	  the	  screening	  strategy	  that	  focused	  on	  inactive	  TB	  initially	  
the	  final	  proportions	  were	  representative	  of	  the	  265	  screened	  participants.	  	  In	  those	  without	  
active	  TB	  changes	  on	  CXR	  36%	  had	  CXR	  consistent	  with	  inactive	  TB	  and	  64%	  Normal	  CXR	  or	  
other	  non-­‐TB	  abnormalities,	  for	  the	  overall	  screened	  cohort.	  	  	  
	  
!"#$#%&"'!(&)&%*+)#,*#%,'-.'/012!1'3&)*#%#3&$*,'&*',%)++$#$4'
/&)&5+*+)' 6+,7"*' /&)&5+*+)' 6+,7"*'
84+'5+9':';+9'<=>6?' -@'<ABC-D?' E+F+)',5GH+9'C'I'<$2E?' DDJ.I'<-@2-.?'
K+5&"+'C'I'<$2E?' L@JMI'<-A2-.?' E+F+)'01NO'C'I'<$2E?' DPI'<AD2-.?'
!QM',%)++$':'55-';+9'<=>6?' .RM'<.P.CR.R?' !7))+$*'S#G5&,,'+T3G,7)+'C'' AJLI'<@2-M?'
>KU=1'1S84CE#"':'=V25"';+9'<=>6?' AJ@B'<PJLRC-J.M?'' W+&),',#$%+'O=X'9#&4$G,#,'C';+9'<=>6?' AJ@'<PJDC.JA?'
A'T';*Y'!7"*7)+'$+4&*#F+'C'I'<$2E?'' @PPI'<-.2-.?'' ZON'[*&4+'@'<I?\',*&4+''A'<I?' DPI\'API'
Z+#4(*':'H4';+9#&$'<=>6?' B@J.<RMJ.CDMJB?' S!U',%&)'3)+,+$*'C'I'<$2E?' -BJ@I'<@-2-M?'
S;=':'H425A';+9#&$'<=>6?' ADJB'<AMJ.C--J-?' V$+53"G]+9'C'I'<$2E?' RAJLI'<AA2-.?'
8%*#F+'!^6',%)++$'C'I'<$2E?' PI'<P2-.?'' OT'G_'1S'%"G,+'%G$*&%*'C'I'<$2E?' M.JBI'<@R2-.?'
=$&%*#F+'!^62E'!^6' MPI'2'RPI' OT'G_'1S'*T'G)'=/1'C'I'<$2E?' PI'<P2-.?'
'
Table	  3.6	  –	  Clinical	  Characteristics	  of	  the	  35	  recruited	  participants	  at	  screening	  
Chapter	  3	  –	  Screening	  for	  participants	  
	   119	  
3.4.6.2 Stability	  of	  clinical	  features	  over	  screening	  period	  
	  
FDG-­‐PET/CT	  was	  performed	  a	  median	  of	  55	  days	  (IQR	  -­‐	  50-­‐73	  days)	  after	  initial	  screen	  
usually	  in	  the	  1-­‐2	  weeks	  following	  the	  42	  day	  culture	  result.	  	  FDG-­‐PET/CT	  performed	  outside	  
this	  time	  usually	  resulted	  from	  participant	  unavailability	  due	  to	  travel	  to	  the	  Eastern	  Cape	  
province,	  especially	  over	  Christmas	  and	  Easter	  periods.	  	  The	  participants	  were	  evaluated	  for	  
symptoms	  and	  signs	  of	  TB	  or	  acute	  illness	  3-­‐4	  times	  over	  this	  screening	  period	  and	  no	  
patient	  developed	  progressive	  symptoms	  consistent	  with	  active	  TB.	  	  Weight	  did	  not	  change	  
significantly	  between	  screen	  and	  scan	  (median	  weight	  change/28	  days	  -­‐0.6%	  (IQR	  -­‐1.1%	  to	  
+0.4%)	  with	  no	  participant	  losing	  more	  than	  5%	  total	  body	  weight	  over	  the	  screening	  period.	  	  
Any	  symptoms	  or	  conditions	  developing	  over	  this	  period	  were	  appropriately	  addressed	  and	  
all	  participants	  were	  asymptomatic	  at	  time	  of	  PET/CT	  scan.	  	  
	  
On	  the	  day	  of	  the	  scan,	  the	  participants	  had	  a	  symptom	  screen,	  clinical	  examination,	  1	  x	  
sputum	  culture	  sent	  (no	  sputum	  induction)	  and	  clinical	  blood	  tests	  (CD4,	  VL,	  FBC,	  ESR,	  CRP,	  
Cr,	  LFT)	  as	  well	  as	  research	  blood	  tests	  performed	  (table	  3.7).	  	  Median	  ESR	  was	  the	  only	  
parameter	  to	  be	  significantly	  outside	  the	  normal	  range	  (defined	  in	  HIV	  uninfected	  adults).	  
This	  was	  not	  unexpected	  as	  ESR	  is	  frequently	  abnormal	  in	  “healthy”	  HIV	  infected	  
adults[206].	  	  Over	  the	  period	  between	  screen	  and	  scan,	  not	  unexpectedly,	  CD4	  count	  
significantly	  reduced	  to	  a	  median	  of	  517/mm3	  (IQR	  393-­‐658,	  p<0.001)	  and	  CD4	  count	  was	  
≤350/mm3	  in	  4	  participants	  (≥346/mm3	  in	  3	  and	  297/mm3	  in	  the	  fourth).	  	  VL	  was	  not	  
performed	  at	  screening	  but	  on	  day	  of	  PET/CT	  scan,	  median	  VL	  was	  10800	  (IQR	  1982-­‐26052).	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,
Table	  3.7	  –	  Clinical	  characteristics	  of	  recruited	  participants	  on	  day	  of	  PET/CT	  scan	  -­‐	  *ESR	  n=34	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3.4.6.3 Stability	  of	  Quantiferon	  over	  screening	  period	  
Median	  QFGIT	  TBAg-­‐NIL	  on	  the	  day	  of	  PET/CT	  scan	  was	  1.76IU/ml	  (0.59-­‐7.52)	  and	  did	  not	  
differ	  significantly	  from	  screening	  values	  (p=0.42).	  	  QFGIT	  TBAg-­‐NIL	  values	  at	  the	  2	  time-­‐
points	  were	  also	  significantly	  correlated	  (r=	  0.77	  –	  p<0.0001).	  	  However,	  fluctuations	  in	  
QFGIT	  resulted	  in	  reversion	  (from	  TBAg-­‐NIL	  ≥	  0.35IU/mL	  à	  <	  0.35IU/mL)	  in	  20%	  in	  keeping	  
with	  what	  is	  described	  in	  the	  literature[207-­‐209].	  	  Reversion	  rate	  was	  significantly	  different	  
across	  baseline	  QFGIT	  TBAg-­‐NIL	  quintiles	  (p=0.04)	  with	  the	  majority	  of	  reversions	  occurring	  
in	  those	  with	  screening	  QFGIT	  in	  the	  1st	  	  and	  2nd	  quintiles	  as	  shown	  in	  table	  3.8.	  	  There	  was	  
no	  significant	  difference	  in	  CD4	  count	  between	  reverters	  and	  non-­‐reverters	  	  (p=0.76;	  median	  









Figure	  3.3	  –	  Change	  in	  QFGIT	  TBAg-­‐NIL	  results	  between	  screening	  and	  day	  of	  PET/CT	  scan:	  	  	  
TOP	  -­‐	  Scatter	  plot	  of	  QFGIT	  TBAg-­‐Nil	  results	  at	  screening	  and	  on	  day	  of	  scan.	  	  Dotted	  line	  is	  positive	  result	  reference	  
(0.35IU/mL).	  	  BOTTOM	  –	  Table	  showing	  proportion	  of	  reverters	  by	  screening	  QFGIT	  quintile	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3.4.6.4 Stability	  of	  CXR	  and	  sputum	  culture	  over	  screening	  period	  
All	  recruited	  participants	  had	  a	  single	  sputum	  culture	  repeated	  on	  day	  of	  scan.	  	  Two	  of	  35	  
participants	  who	  had	  2	  x	  negative	  Mtb	  culture	  at	  screening	  had	  a	  positive	  Mtb	  culture	  at	  
scan	  despite	  remaining	  asymptomatic	  (days	  to	  culture	  positivity	  being	  33	  and	  12).	  	  All	  
recruits	  also	  had	  a	  repeat	  CXR	  performed	  just	  prior	  to	  scan	  and	  2	  of	  35	  showed	  slight	  
deterioration	  (1	  of	  whom	  was	  also	  culture	  positive)	  though	  remained	  asymptomatic	  (figure	  
3.4).	  	  These	  3	  participants	  all	  developed	  TB	  symptoms	  7,	  30	  and	  34	  days	  after	  PET/CT	  scan	  
while	  awaiting	  culture	  results.	  
	  
	  
+	  47	  days	  
+	  71	  days	  
Figure	  3.4	  –	  CXRs	  for	  2	  participants	  showing	  progression	  from	  day	  of	  screening	  to	  just	  prior	  to	  PET/CT	  scan:	  	  
Screening	  CXR	  alongside	  pre-­‐scan	  CXR	  for	  2	  participants	  both	  showing	  development	  of	  subtle	  infiltrate	  in	  R	  Upper	  
Lobe	  (circles	  in	  green).	  	  Participant	  in	  top	  panel	  also	  was	  culture	  positive	  on	  day	  of	  scan	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3.4.7 Screening	  for	  TST	  negative	  /	  QFGIT	  negative	  controls	  
3.4.7.1 HIV-­‐infected	  TST	  negative	  QFGIT	  negative	  controls	  
From	  the	  screen	  failures,	  15	  HIV-­‐infected	  ART	  naïve	  participants	  that	  were	  TST	  and	  QFGIT	  
negative	  were	  recruited	  to	  provide	  age,	  sex	  and	  CD4	  matched	  (to	  day	  of	  scan)	  controls.	  	  For	  
these	  15	  control	  participants,	  median	  age	  was	  34	  years	  (IQR	  28-­‐37),	  CD4	  count	  453/mm3	  
(IQR	  398-­‐593),	  viral	  load	  7042	  copies/ml	  (IQR	  4937-­‐71100)	  and	  86.7%	  were	  female.	  	  These	  
characteristics	  were	  not	  significantly	  different	  from	  the	  35	  participants	  undergoing	  PET/CT	  
scan	  (p=0.70,	  p=0.39,	  p=0.67and	  p=1.0)	  (figure	  3.9).	  	  None	  of	  the	  controls	  had	  TB	  symptoms	  
or	  any	  CXR	  abnormalities	  consistent	  with	  active	  or	  inactive	  TB.	  	  Of	  the	  15	  participants,	  11	  
had	  sputum	  culture	  performed	  and	  were	  negative	  (4	  were	  unable	  to	  produce	  sputum	  even	  
with	  induction).	  
	  
TST	  was	  0	  mm	  in	  11/15	  participants	  and	  1-­‐4	  mm	  in	  4	  participants.	  	  Median	  QFGIT	  TBAg-­‐NIL	  
was	  0.17IU/ml	  (0.03-­‐0.26).	  	  However,	  the	  distribution	  of	  these	  values	  appeared	  bimodal,	  
raising	  the	  possibility	  that	  those	  at	  the	  higher	  end	  of	  the	  distribution	  may	  represent	  a	  
distinct	  subgroup	  (see	  figure	  3.5).	  	  Those	  with	  QFGIT	  TBAg-­‐NIL	  ≥	  0.17IU/ml	  were	  not	  more	  




Figure	  3.5	  –	  Distribution	  of	  QFGIT	  TBAg-­‐NIL	  values	  in	  HIV	  infected	  participants	  
that	  were	  QFGIT	  and	  TST	  negative	  
Chapter	  3	  –	  Screening	  for	  participants	  
	   123	  
3.4.7.2 Evidence	  of	  QFGIT	  conversion	  following	  TST	  boosting	  in	  HIV-­‐infected	  persons	  
with	  negative	  TST	  and	  negative	  QFGIT	  (in	  separate	  cohort)	  
To	  further	  evaluate	  the	  hypothesis	  that	  there	  may	  be	  different	  subgroups	  within	  HIV	  
infected	  persons	  with	  negative	  QFGIT	  results.	  	  The	  effect	  of	  administering	  TST	  on	  
subsequent	  QFGIT	  results	  was	  investigated	  in	  a	  separate	  group	  (not	  recruited	  as	  controls	  
into	  this	  study	  and	  of	  mixed	  ART	  status,	  but	  recruited	  into	  the	  vaccine	  trial).	  	  The	  
phenomenon	  of	  boosting	  and	  conversion	  of	  QFGIT	  results	  following	  TST	  has	  been	  well	  
described	  especially	  in	  HIV	  uninfected	  individuals[194].	  	  This	  evaluation	  was	  possible	  as	  part	  
of	  the	  vaccine	  trial	  protocol,	  as	  if	  screened	  participants	  that	  were	  TST	  and	  QFGIT	  negative	  
had	  a	  >	  45	  day	  delay	  before	  randomization	  to	  placebo	  or	  vaccine,	  repeat	  TB	  screening	  
including	  a	  QFGIT	  was	  performed.	  	  	  	  
	  
22	  HIV-­‐1-­‐infected,	  TST	  negative	  (all	  0mm),	  QFGIT	  negative	  adults	  (median	  CD4	  477/mm3	  IQR	  
439-­‐621)	  of	  whom	  6	  were	  ART	  naïve	  and	  16	  ART	  established,	  had	  QFGIT	  repeated	  after	  
median	  62	  days	  (IQR	  49-­‐70).	  	  40.9%	  (95%CI	  18.6%-­‐63.2%)	  converted	  from	  negative	  to	  
positive.	  	  In	  those	  who	  converted,	  median	  TBAg-­‐NIL	  increased	  from	  0.21IU/mL	  (IQR	  0.16-­‐
0.28)	  to	  0.84IU/mL	  (IQR	  0.6-­‐1.89)	  compared	  to	  0.02IU/mL	  (IQR	  0-­‐0.07)	  to	  0.06IU/mL	  (IQR	  0-­‐
0.1)	  in	  non-­‐converters.	  	  Both	  baseline	  and	  repeat	  values	  were	  significantly	  different	  p=0.005	  
and	  p	  =	  0.0001	  respectively	  between	  converters	  and	  non-­‐converters.	  	  The	  groups	  did	  not	  
differ	  by	  CD4	  count	  or	  ART	  status.	  	  	  
	  
Figure	  3.6	  –	  ROC	  curve	  showing	  ability	  to	  differentiate	  those	  that	  convert	  QFGIT	  
following	  TST	  from	  those	  that	  don’t	  by	  baseline	  QFGIT	  value	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ROC	  analysis	  showed	  a	  baseline	  cut	  off	  was	  effective	  at	  predicting	  QFGIT	  conversion	  
following	  TST	  with	  AUC	  =	  0.87.	  	  Baseline	  cut	  off	  of	  0.15IU/ml	  and	  0.17IU/ml	  correctly	  
classified	  86%	  of	  converters	  with	  sensitivity/specificity	  of	  89%/85%	  and	  78%/92%	  
respectively.	  	  
3.4.7.3 HIV	  uninfected	  TST-­‐ve	  QFGIT-­‐ve	  controls	  
In	  order	  to	  identify	  HIV	  uninfected,	  TST	  negative/QFGIT	  negative	  controls,	  healthy	  adults	  
living	  in	  the	  Khayelitsha	  site	  B	  area	  were	  screened	  with	  rapid	  POC	  test	  for	  HIV.	  	  90	  
asymptomatic	  participants	  confirmed	  as	  HIV	  uninfected	  underwent	  QFGIT	  and	  TST	  of	  whom	  
five	  did	  not	  return	  for	  TST	  reading.	  	  For	  the	  85	  participants	  with	  complete	  results,	  median	  
age	  was	  22	  years	  (IQR	  20-­‐31)	  and	  57.7%	  were	  female.	  	  In	  line	  with	  CDC	  guidance	  for	  HIV	  
infected	  persons	  from	  high	  TB	  prevalence	  regions,	  TST	  was	  considered	  positive	  if	  
≥10mm[20].	  	  The	  proportion	  of	  HIV	  uninfected	  adults	  with	  a	  positive	  QFGIT	  was	  71.8%	  (95%	  
C.I.	  62.0%	  -­‐	  81.5%)	  and	  64.7%	  (95%C.I.	  54.3%-­‐75.1%)	  had	  a	  TST	  ≥	  10	  mm.	  	  Latent	  TB	  was	  
diagnosed	  by	  either	  test	  in	  82.3%	  (95%	  C.I.	  74.1%-­‐90.6%).	  	  Agreement	  between	  QFGIT	  and	  
TST	  results	  was	  fair	  with	  observed	  agreement	  being	  71.8%	  compared	  to	  expected	  
agreement	  of	  56.4%,	  κ=0.35(95%C.I.	  0.14-­‐0.56).	  	  The	  15	  participants	  that	  were	  TST	  and	  
QFGIT	  negative	  were	  considered	  eligible	  control.	  	  Only	  QFGIT	  results	  could	  be	  compared	  
with	  the	  HIV	  infected	  population	  and	  there	  was	  no	  significant	  difference	  in	  the	  proportion	  
that	  were	  positive	  (p=0.23).	  	  Median	  age	  was	  20	  years	  (IQR	  19-­‐21)	  and	  66.7%	  were	  female,	  
significantly	  different	  from	  the	  35	  participants	  undergoing	  PET/CT	  scan	  (p<0.0001	  and	  
p=0.04	  respectively)	  although	  no	  attempt	  was	  made	  to	  match	  these	  characteristics.	  	  	  
	  
Figure	  3.7	  –	  Distribution	  of	  QFGIT	  TBAg-­‐NIL	  values	  in	  HIV	  uninfected	  
participants	  that	  are	  QFGIT	  and	  TST	  negative	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However,	  in	  contrast	  to	  the	  HIV	  infected,	  TST	  negative,	  QFGIT	  negative	  controls,	  distribution	  
of	  TBAg-­‐NIL	  results	  was	  normally	  distributed	  (Shapiro-­‐Wilk	  test	  for	  normality	  p=0.56)	  around	  
a	  mean	  of	  0.03IU/mL	  (figure	  3.7).	  	  	  	  
	  
The	  distribution	  of	  the	  TBAg-­‐NIL	  values	  in	  HIV	  infected	  and	  uninfected	  persons	  screened	  
with	  positive	  QFGIT	  was	  then	  further	  evaluated.	  	  Median	  TBAg-­‐Nil	  was	  significantly	  higher	  in	  
HIV	  uninfected	  participants	  (4.66IU/mL	  vs.	  2.38IU/mL,	  p=0.015).	  	  The	  distribution	  of	  values	  
for	  both	  HIV	  infected	  and	  uninfected	  persons	  screened	  with	  positive	  QFGIT	  was	  bimodal	  
though	  left-­‐shifted	  in	  HIV	  infected	  participants	  (Figure	  3.8).	  	  
3.4.8 Active	  TB	  controls	  
3.4.8.1 HIV-­‐infected	  ART	  naïve	  active	  TB	  controls	  
21	  HIV	  infected	  ART	  naïve	  participants	  with	  either	  confirmed	  or	  suspected	  TB	  were	  screened	  
at	  the	  TB	  clinic	  at	  the	  Khayelitsha	  Site	  B	  CHC	  to	  provide	  age,	  sex	  and	  CD4	  matched	  (to	  day	  of	  	  
scan)	  controls	  (figure	  3.9).	  	  Two	  participants	  did	  not	  have	  culture	  or	  GeneXpert	  confirmed	  TB	  
and	  3	  participants	  had	  very	  low	  CD4	  counts	  (8,	  18	  and	  154/mm3)	  and	  were	  excluded.	  The	  
remaining	  16	  participants	  were	  considered	  eligible	  controls.	  	  Of	  these	  16	  participants,	  only	  
15	  had	  good	  quality	  RNA	  for	  use	  in	  microarray	  experiment,	  14	  had	  available	  QFGIT	  plasma	  
supernatants	  and	  13	  had	  available	  serum	  samples.	  	  	  
	  
Figure	  3.8	  –	  kdensity	  distribution	  of	  QGFIT	  TBAg-­‐NIL	  values	  for	  QFGIT	  positive	  HIV	  infected	  and	  
uninfected	  participants	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For	  the	  16	  participants	  the	  median	  age	  was	  30.5	  years	  (IQR	  27-­‐36.5),	  median	  CD4	  count	  
447/mm3	  (IQR	  375-­‐538/mm3)	  and	  81.3%	  were	  female.	  	  These	  characteristics	  were	  not	  
significantly	  different	  from	  the	  35	  participants	  undergoing	  PET/CT	  scan	  (p=0.97,	  p=0.12,	  
p=0.36	  respectively).	  	  The	  median	  viral	  load	  was	  69677	  copies/ml	  (IQR	  33184-­‐156096)	  and	  as	  
expected	  this	  was	  significantly	  different	  to	  those	  undergoing	  PET/CT	  scan	  (p=0.0006).	  
	  
All	  participants	  had	  positive	  Mtb	  sputum	  culture	  or	  positive	  sputum	  GeneXpert;	  7	  were	  
diagnosed	  by	  culture	  and	  9	  by	  GeneXpert.	  	  Only	  1	  participant	  had	  a	  history	  of	  previous	  TB	  
and	  she	  was	  diagnosed	  by	  Mtb	  culture.	  	  All	  participants	  had	  sputum	  smear	  microscopy	  
performed	  and	  9	  of	  16	  were	  smear	  positive.	  	  Of	  these	  6	  were	  3+	  smear	  positive	  and	  3	  were	  
scanty	  smear	  positive.	  	  All	  participants	  were	  symptomatic	  at	  diagnosis	  with	  median	  duration	  
of	  symptoms	  being	  3	  weeks	  (IQR	  2-­‐8	  weeks).	  	  Cough	  and	  weight	  loss	  were	  reported	  most	  
commonly,	  each	  by	  10	  of	  the	  16	  participants	  (61.5%)	  while	  haemoptysis,	  fever,	  night	  sweats	  
and	  pleuritic	  pain	  were	  each	  reported	  by	  5	  of	  16	  participants	  (31.25%).	  	  Nine	  participants	  
had	  CXR	  available;	  8	  were	  consistent	  with	  active	  TB	  and	  1	  with	  inactive	  TB.	  	  All	  participants	  
had	  less	  than	  24	  hours	  TB	  treatment	  at	  diagnosis	  with	  most	  participants	  being	  recruited	  on	  
the	  day	  of	  diagnosis.	  	  QFGIT	  was	  positive	  in	  15	  out	  of	  16	  HIV	  infected	  active	  TB	  control	  with	  
median	  TBAg-­‐NIL	  3.46IU/ml	  (0.81-­‐9.71),	  this	  was	  not	  significantly	  different	  from	  either	  
screening	  or	  day-­‐of-­‐scan	  values	  for	  the	  35	  participants	  undergoing	  PET/CT	  (p=0.55	  and	  
p=0.50	  respectively).	  	  	  	  	  	  
3.4.8.2 HIV	  uninfected	  active	  TB	  controls	  
20	  HIV	  uninfected	  participants	  with	  either	  confirmed	  or	  suspected	  TB	  were	  screened	  at	  the	  
TB	  clinic	  at	  the	  Khayelitsha	  Site	  B	  CHC.	  	  Three	  TB	  suspects	  were	  not	  culture	  or	  GeneXpert	  
confirmed	  and	  3	  were	  subsequently	  found	  to	  be	  HIV	  infected	  and	  these	  6	  participants	  were	  
excluded.	  	  The	  remaining	  14	  HIV	  uninfected,	  symptomatic,	  Mtb	  culture	  positive	  participants	  
were	  considered	  eligible	  controls	  of	  which	  11	  were	  smear	  positive	  (4	  were	  smear	  3+,	  4	  were	  
smear	  2+,	  2	  were	  smear	  1+	  and	  1	  scanty).	  	  	  
	  
The	  median	  age	  was	  39	  years	  (IQR	  35-­‐54)	  and	  35.7%	  were	  female,	  significantly	  different	  
from	  the	  35	  participants	  undergoing	  PET/CT	  scan	  (p<0.0001	  and	  p=0.0001	  respectively)	  
although	  no	  attempt	  had	  been	  made	  to	  match	  these	  characteristics	  (figure	  3.9).	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3.4.9 HIV	  infected	  QFGIT+ve,	  ART	  established	  controls	  
From	  within	  the	  screening	  process	  of	  the	  vaccine	  study,	  9	  asymptomatic	  participants	  that	  
were	  HIV-­‐infected,	  QFGIT	  positive	  but	  established	  on	  ART	  were	  consented	  for	  participation.	  	  	  
Of	  these	  1	  participant	  was	  sputum	  culture	  positive	  despite	  being	  asymptomatic	  and	  was	  
excluded.	  	  	  All	  8	  participants	  had	  been	  on	  ART	  for	  >	  24	  weeks	  (median	  2.1	  years	  (1.1-­‐2.8))	  
and	  all	  had	  a	  suppressed	  viral	  load	  (<40	  copies/ml).	  	  All	  participants	  were	  prescribed	  
Lamivudine	  (3TC)	  with	  5	  taking	  Tenofovir	  (TDF)	  and	  3	  taking	  Zidovudine	  (AZT)	  as	  2nd	  
nucleotide	  reverse	  transcriptase	  inhibitor	  (NRTI).	  	  All	  participants	  were	  prescribed	  a	  non-­‐
nucleotide	  reverse	  transcriptase	  inhibitors	  (NNRTI),	  with	  5	  taking	  Efavirenz	  and	  3	  taking	  
Nevirapine.	  	  The	  median	  age	  was	  34.5	  years	  (32-­‐41),	  median	  CD4	  count	  516/mm3	  (IQR	  476-­‐
569)	  and	  87.5%	  were	  female,	  these	  characteristics	  were	  not	  significantly	  different	  from	  the	  
35	  participants	  undergoing	  PET/CT	  scan	  (p=0.20,	  p=0.70,	  p=1.0	  respectively).	  	  All	  8	  
participants	  were	  asymptomatic,	  culture	  negative	  with	  no	  evidence	  of	  active	  or	  inactive	  TB	  
on	  CXR	  and	  QFGIT	  positive	  with	  median	  TBAg-­‐NIL	  7.7	  IU/ml	  (IQR	  1.93-­‐10)	  which	  was	  not	  
significantly	  different	  from	  either	  screening	  or	  day-­‐of-­‐scan	  values	  for	  the	  35	  participants	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Figure	  3.9	  -­‐	  Comparison	  of	  clinical	  characteristics	  for	  participants	  and	  controls:	  	  TOP	  –	  Table	  of	  clinical	  characteristics	  for	  
participants	  and	  controls	  (shaded	  region	  parameters	  that	  were	  matched.	  	  BELOW	  –	  Graphs	  showing	  distribution	  of	  age,	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3.5 Summary	  of	  main	  findings	  
In	  a	  “healthy”	  outpatient	  HIV	  infected	  population	  with	  median	  CD4	  count	  approximately	  
500/mm3	  in	  Khayelitsha,	  the	  prevalence	  of	  un-­‐treated	  culture	  positive	  TB	  was	  4,098/100,000	  
(4.1%).	  	  40%	  of	  these	  cases	  could	  be	  considered	  pre-­‐diagnostic,	  i.e.	  symptoms	  were	  present	  
on	  direct	  questioning	  and	  60%	  were	  subclinical	  i.e.	  participant	  did	  not	  have	  symptoms	  even	  
on	  direct	  questioning.	  	  The	  sensitivity	  and	  specificity	  of	  positive	  symptom	  screen,	  active	  CXR	  
findings	  and	  any	  TB	  CXR	  abnormality	  for	  culture	  positive	  TB	  was	  found	  to	  be	  40%/92.3%,	  
50%/88.5%	  and	  70%/56.8%	  respectively.	  	  Progression	  from	  a	  negative	  to	  a	  positive	  sputum	  
culture	  and/or	  from	  a	  CXR	  without	  active	  TB	  findings	  to	  one	  with	  active	  TB	  findings	  occurred	  
in	  3	  asymptomatic	  participants	  soon	  after	  recruitment.	  	  All	  3	  participants	  developed	  
symptoms	  within	  5	  weeks.	  	  CXR	  lesions	  were	  subtle	  and	  there	  was	  considerable	  inter-­‐
observer	  variability	  in	  CXR	  reporting	  with	  agreement	  being	  fair	  (κ=0.25).	  	  The	  prevalence	  of	  
QFGIT	  positivity	  was	  64.1%	  in	  HIV	  infected	  adults	  and	  71.8%	  in	  HIV	  uninfected	  adults.	  	  
Agreement	  between	  QFGIT	  and	  TST	  was	  fair	  to	  moderate.	  	  Reversion	  of	  QFGIT	  (from	  positive	  
to	  negative)	  occurred	  in	  20%	  of	  recruited	  participants	  over	  a	  median	  of	  55	  days	  and	  was	  
commonest	  in	  those	  in	  the	  lowest	  2	  quintiles	  of	  baseline	  QFGIT	  results.	  	  In	  those	  that	  were	  
TST	  and	  QFGIT	  negative	  the	  distribution	  of	  QFGIT	  results	  was	  different	  for	  HIV	  infected	  
(bimodal)	  and	  HIV	  uninfected	  (normally	  distributed)	  adults.	  	  In	  a	  separate	  cohort	  of	  HIV	  
infected	  adults,	  conversion	  of	  QFGIT	  (from	  negative	  to	  positive)	  following	  boosting	  with	  TST	  
occurred	  in	  40.9%,	  most	  commonly	  in	  those	  with	  a	  baseline	  QFGIT	  TBAg-­‐NIL	  of	  0.15IU/mL.	  	  	  
	  
Compared	  to	  the	  main	  group	  of	  interest,	  asymptomatic	  HIV	  infected	  adults	  with	  positive	  
QFGIT	  undergoing	  PET/CT,	  HIV	  infected	  controls	  were	  all	  well	  matched	  for	  CD4	  count,	  age	  
and	  sex	  as	  planned.	  	  Viral	  load	  was	  significantly	  higher	  in	  those	  with	  active	  TB	  and	  
suppressed	  in	  those	  taking	  ART	  as	  expected.	  	  In	  HIV	  uninfected	  controls	  both	  age	  and	  
proportion	  that	  were	  female	  were	  significantly	  different	  as	  no	  attempt	  was	  made	  to	  match	  
these	  characteristics	  and	  is	  a	  limitation	  of	  the	  study.	  	  All	  participants	  and	  controls	  were	  Black	  
African	  residing	  in	  the	  same	  community	  in	  which	  >	  95%	  of	  people	  are	  of	  Xhosa	  origin.	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
3.6 Discussion	  
The	  point	  prevalence	  of	  sputum	  culture	  positive	  TB	  identified	  in	  this	  study	  is	  in	  line	  with	  
previously	  published	  studies	  in	  this	  setting.	  	  Wood	  et	  al	  reported	  the	  prevalence	  of	  
untreated	  TB	  in	  a	  similar	  community,	  of	  mixed	  HIV	  status,	  in	  Cape	  Town	  to	  be	  1,575/100,000	  
(5,140/100,000	  in	  HIV	  infected	  adults	  and	  514/100,000	  in	  HIV	  un-­‐infected	  adults).	  	  However,	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little	  was	  known	  about	  degree	  of	  immunosuppression	  in	  the	  HIV	  infected	  population.	  	  By	  
comparing	  the	  untreated	  point	  prevalence	  with	  the	  case	  notification	  rate,	  the	  authors	  also	  
calculated	  that	  the	  estimated	  mean	  duration	  of	  untreated	  TB	  disease	  was	  just	  over	  1	  year	  
for	  both	  HIV	  infected	  and	  uninfected	  adults[210].	  	  Oni	  et	  al	  screened	  HIV	  infected	  persons	  
attending	  the	  same	  clinic	  as	  used	  in	  this	  study,	  between	  2008	  and	  2010,	  and	  found	  the	  
prevalence	  of	  subclinical	  TB	  to	  be	  8.5%	  though	  degree	  of	  immunosuppression	  (median	  CD4	  
of	  TB	  cases	  249/mm3)	  was	  greater	  than	  in	  this	  study[83].	  	  	  
	  
Two	  systematic	  reviews	  of	  screening	  strategies	  for	  TB	  have	  recently	  been	  published	  in	  HIV	  
infected	  and	  HIV	  uninfected	  persons[82,	  211].	  	  The	  systematic	  review	  of	  HIV	  infected	  
persons	  incorporated	  12	  studies	  in	  which	  symptom	  screening	  of	  8148	  participants	  was	  
performed	  (6.1%	  had	  TB).	  	  A	  symptom	  screen	  of	  any	  one	  of	  current	  cough,	  haemoptysis,	  
weight	  loss,	  fever	  or	  night	  sweats	  was	  found	  to	  have	  a	  sensitivity	  of	  78.9%	  and	  specificity	  of	  
49.6%	  in	  contrast	  to	  the	  40%	  sensitivity	  and	  92.3%	  specificity	  found	  in	  this	  study.	  	  Several	  
factors	  accounted	  for	  this	  difference.	  	  The	  use	  of	  any	  or	  current	  cough	  rather	  than	  prolonged	  
cough	  (cough	  >	  1week	  was	  used	  in	  this	  study)	  would	  be	  expected	  to	  increase	  sensitivity	  and	  
reduce	  specificity	  of	  a	  symptom	  screen	  as	  a	  greater	  proportion	  of	  the	  population	  will	  be	  
screen	  positive.	  	  Also	  the	  studies	  contributing	  to	  the	  systematic	  review	  were	  heterogeneous,	  
in	  particular	  screening	  studies	  from	  mines	  were	  included	  where	  symptoms	  such	  as	  cough	  
would	  be	  expected	  to	  be	  generally	  more	  common.	  	  This	  again	  would	  lead	  to	  increased	  
sensitivity	  and	  reduced	  specificity	  of	  a	  symptom	  screen.	  	  The	  high	  specificity	  of	  symptom	  
screen	  in	  this	  study	  may	  also	  relate	  to	  recruitment	  strategy,	  which	  was	  biased	  toward	  those	  
self-­‐reporting	  as	  healthy	  and	  so	  less	  likely	  to	  have	  symptoms	  than	  all	  comers.	  	  However,	  of	  
note	  the	  sensitivity	  and	  specificity	  of	  symptom	  screen	  for	  this	  study	  were	  within	  the	  95%	  
confidence	  limits	  calculated	  in	  the	  systematic	  review.	  	  They	  are	  also	  similar	  to	  2	  community	  
based	  TB/HIV	  prevalence	  surveys	  conducted	  in	  Zimbabwe	  by	  Corbett	  et	  al	  which	  were	  
included	  in	  the	  systematic	  review[211-­‐213].	  	  No	  analysis	  of	  CXR	  screening	  in	  HIV	  infected	  
populations	  was	  performed	  in	  this	  systematic	  review	  owing	  to	  limited	  numbers	  of	  studies.	  	  	  
	  
In	  the	  systematic	  review	  of	  TB	  screening	  in	  HIV	  uninfected	  adults,	  pooled	  sensitivity	  and	  
specificity	  in	  for	  prolonged	  cough	  (>2	  weeks)	  was	  35.1%	  and	  94.7%,	  for	  any	  cough	  62.7%	  and	  
77.5%	  respectively	  and	  any	  symptom	  77.0%	  and	  67.7%	  respectively.	  	  Evaluation	  of	  CXR	  
screening	  was	  based	  on	  5	  studies	  with	  pooled	  sensitivity	  and	  specificity	  for	  any	  abnormality	  
suggestive	  of	  TB	  being	  86.8%	  and	  89.4%	  respectively	  and	  any	  CXR	  abnormality	  being	  97.8%	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and	  75.4%	  respectively.	  	  The	  pooled	  sensitivity	  in	  particular	  was	  higher	  than	  reported	  in	  this	  
study	  (50%	  for	  active	  TB,	  70%	  for	  any	  TB	  related	  abnormality)	  and	  this	  likely	  relates	  to	  
methodological	  differences	  in	  the	  studies	  included	  in	  the	  systematic	  review.	  	  In	  4	  of	  the	  5	  
studies,	  CXR	  was	  not	  performed	  in	  parallel	  to	  sputum	  culture	  but	  rather	  sputum	  culture	  was	  
performed	  after	  symptoms	  and	  CXR	  screening	  leading	  to	  verification	  bias	  that	  would	  tend	  to	  
overestimate	  sensitivity[82].	  	  As	  demonstrated	  in	  this	  study	  the	  sensitivity	  of	  CXR	  in	  those	  
with	  symptoms	  (100%)	  was	  considerably	  higher	  than	  in	  those	  without	  symptoms	  (16.7%).	  	  In	  
addition,	  even	  at	  high	  CD4	  counts,	  HIV	  infection	  may	  be	  expected	  to	  affect	  CXR	  findings	  in	  
those	  screened	  with	  positive	  culture.	  	  In	  a	  recent	  screening	  study	  in	  which	  825	  HIV	  infected	  
adults	  in	  South	  Africa	  underwent	  TB	  screening	  with	  symptoms	  screen,	  CXR	  and	  sputum	  
culture	  performed	  in	  parallel.	  	  The	  sensitivity	  of	  any	  CXR	  abnormality	  was	  found	  to	  be	  69.4%	  
and	  specificity	  44.9%,	  similar	  to	  findings	  in	  this	  study[214].	  	  	  
	  
In	  this	  study	  7.9%	  of	  participants	  did	  not	  have	  a	  sputum	  culture	  result	  and	  these	  participants	  
were	  less	  likely	  to	  have	  abnormal	  CXR	  or	  TB	  symptoms.	  	  Therefore	  they	  may	  have	  been	  less	  
likely	  to	  have	  culture	  positive	  TB.	  	  This	  may	  potentially	  have	  lead	  to	  a	  partial	  verification	  bias,	  
however,	  the	  proportion	  without	  sputum	  compares	  favourably	  to	  other	  similar	  studies.	  	  In	  
the	  CXR	  screening	  study	  described	  by	  Ahmad	  Khan	  et	  al,	  10.9%	  of	  participants	  did	  not	  have	  
cultures	  available[214].	  	  Another	  potential	  limitation	  of	  this	  study	  is	  that	  physicians	  (that	  had	  
undergone	  specific	  training	  in	  TB	  screening	  CXR	  reading)	  reported	  films	  rather	  than	  
experienced	  radiologists	  who	  may	  be	  expected	  to	  perform	  better.	  	  
	  
Agreement	  between	  CXR	  readers	  in	  this	  study	  was	  fair	  this	  and	  is	  in	  keeping	  with	  historical	  
studies	  performed	  in	  the	  20th	  century	  which	  highlighted	  the	  significant	  inter	  and	  intra-­‐
observer	  variability	  in	  reporting	  of	  TB	  screening	  CXR[81].	  	  More	  recently	  it	  has	  been	  reported	  
that	  using	  a	  structured	  report,	  for	  example	  the	  CRRS	  system,	  inter-­‐observer	  variability	  can	  
be	  minimised	  and	  agreement	  considerably	  improved[202].	  	  	  However,	  the	  study	  setting	  and	  
aims	  can	  have	  a	  considerable	  influence	  on	  inter-­‐observer	  variability.	  	  Active	  screening	  has	  
been	  shown	  to	  identify	  persons	  at	  earlier	  stages	  of	  disease	  with	  more	  minimal	  CXR	  
pathology[215]	  in	  addition	  HIV	  infection	  may	  result	  in	  more	  subtle	  CXR	  findings.	  	  Subtle	  
lesions	  will	  affect	  the	  signal	  to	  noise	  ratio,	  as	  they	  are	  harder	  to	  distinguish	  from	  overlying	  
bony	  structures,	  and	  hence	  disagreement	  will	  be	  expected	  to	  increase.	  	  The	  aim	  of	  CXR	  
reporting	  in	  a	  study	  may	  also	  influence	  observer	  variability.	  	  Structured	  reporting	  systems	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such	  as	  CRRS	  train	  readers	  to	  report	  abnormalities	  in	  the	  same	  way	  to	  minimize	  variability,	  
however	  this	  does	  necessarily	  mean	  that	  reporting	  will	  be	  more	  accurate[205].	  	  	  	  	  	  
	  
The	  finding	  of	  a	  relationship	  between,	  presence	  of	  TB	  symptoms	  and	  presence	  of	  CXR	  
abnormalities	  suggestive	  of	  active	  TB	  is	  of	  interest.	  	  It	  suggests	  that	  the	  extent	  of	  pathology	  
that	  typically	  causes	  symptoms	  and	  the	  extent	  of	  pathology	  that	  typically	  is	  detectable	  by	  
CXR	  may	  be	  similar.	  	  The	  implication	  being	  that,	  at	  least	  in	  this	  population,	  CXR	  may	  be	  
better	  able	  to	  identify	  TB	  in	  its	  pre-­‐diagnostic	  rather	  than	  truly	  subclinical	  phase.	  	  	  In	  culture	  
positive	  participants	  that	  are	  asymptomatic	  with	  no	  evidence	  of	  active	  TB	  on	  CXR	  it	  could	  be	  
questioned	  as	  to	  whether	  laboratory	  contamination	  had	  occurred	  (i.e.	  potentially	  false	  
positives).	  	  As	  this	  study	  was	  closely	  linked	  to	  a	  TB	  vaccine	  trial	  in	  which	  development	  of	  TB	  
was	  a	  primary	  endpoint,	  anonymous	  sterile	  mock	  sputum	  samples	  were	  sent	  twice	  a	  week	  
to	  the	  laboratory	  over	  the	  course	  of	  this	  study	  as	  QC.	  	  None	  of	  the	  209	  specimens	  sent	  over	  
a	  34	  month	  period	  were	  positive	  for	  Mtb	  suggesting	  laboratory	  contamination	  was	  highly	  
uncommon.	  	  Although	  subclinical	  cases	  were	  not	  systematically	  followed	  up	  after	  referral	  to	  
TB	  clinic,	  in	  the	  previously	  described	  study	  by	  Oni	  et	  al,	  56%	  of	  subclinical	  cases	  developed	  
symptoms	  within	  2	  months[83].	  	  	  
	  
In	  this	  study	  the	  difference	  in	  QGFIT	  positivity	  between	  HIV	  infected	  and	  uninfected	  persons	  
was	  not	  significant.	  	  The	  CD4	  count	  in	  this	  population	  was	  relatively	  well	  preserved	  and	  of	  
note	  the	  HIV	  uninfected	  participants	  were	  significantly	  younger.	  	  However,	  median	  TBAg-­‐NIL	  
was	  significantly	  lower	  and	  the	  distribution	  of	  results	  was	  left-­‐shifted	  in	  HIV	  infected	  
participants	  with	  positive	  QFGIT	  compared	  to	  HIV	  uninfected	  participants.	  	  The	  proportion	  of	  
HIV	  infected	  adults	  with	  a	  positive	  TST	  and	  IGRA	  has	  been	  found	  in	  other	  studies	  to	  reduce	  
as	  CD4	  count	  falls[216].	  	  Due	  to	  the	  study	  design	  TST	  was	  not	  performed	  on	  all	  of	  the	  HIV	  
infected	  participants,	  however,	  in	  line	  with	  most	  studies	  discordance	  between	  TST	  and	  
QFGIT	  result	  was	  common	  in	  both	  HIV	  infected	  and	  uninfected	  participants[217].	  	  As	  
previously	  reported	  reversions	  of	  QFGIT	  were	  found	  to	  be	  common,	  particularly	  in	  those	  
with	  baseline	  results	  just	  above	  the	  cut	  off[218].	  	  Of	  interest,	  the	  distribution	  of	  QFGIT	  TBAg-­‐
NIL	  values	  differed	  between	  HIV	  infected	  and	  uninfected	  participants	  that	  were	  negative	  for	  
both	  TST	  and	  QFGIT,	  with	  the	  bimodal	  distribution	  suggestive	  of	  2	  distinct	  groups	  in	  the	  HIV	  
infected	  population.	  	  In	  a	  separate	  cohort,	  administration	  of	  TST	  resulted	  boosted	  IFNγ	  
release	  with	  conversion	  of	  QFGIT	  in	  40.9%.	  	  89%	  of	  those	  that	  converted	  had	  a	  baseline	  
QFGIT	  TBAg-­‐Nil	  ≥0.15IU/mL.	  	  The	  phenomenon	  of	  boosting	  has	  been	  well	  described	  in	  HIV	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uninfected	  persons	  in	  South	  Africa	  although	  at	  a	  lower	  rate	  than	  observed	  in	  this	  study	  and	  
has	  been	  noted	  to	  persist	  for	  almost	  3	  months	  after	  TST[194,	  219].	  	  Of	  note	  however	  in	  low	  
risk	  populations	  in	  low	  burden	  settings	  boosting	  of	  negative	  QFGIT	  is	  very	  uncommon	  in	  
addition	  in	  these	  populations	  negative	  QFGIT	  tend	  to	  cluster	  close	  to	  zero[220,	  221].	  	  One	  
explanation	  for	  the	  phenomenon	  of	  boosting	  is	  that	  pre-­‐existing	  memory	  responses	  may	  be	  
stimulated	  by	  a	  cocktail	  of	  antigens	  within	  PPD	  (which	  will	  include	  ESAT-­‐6	  and	  CFP-­‐10)	  when	  
TST	  is	  performed.	  	  This	  may	  then	  lead	  to	  proliferation	  of	  antigen	  specific	  effector	  cells	  which	  
may	  then	  be	  present	  in	  greater	  numbers	  when	  peripheral	  blood	  is	  restimulated	  ex	  vivo	  in	  a	  
second	  QFGIT	  performed	  weeks	  later	  leading	  to	  greater	  IFNγ	  release.	  	  This	  is	  also	  the	  
principle	  behind	  the	  2-­‐step	  TST	  strategy	  (where	  an	  initial	  negative	  TST	  is	  repeated	  a	  few	  
weeks	  later	  to	  see	  if	  conversion	  of	  response	  has	  been	  induced	  by	  PPD	  administration)	  which	  
has	  been	  recommended	  to	  confirm	  true	  negative	  in	  high	  risk	  populations[20].	  	  	  
	  
Taken	  together	  this	  suggests	  that	  in	  a	  high	  burden	  setting	  in	  HIV	  infected	  participants,	  it	  may	  
not	  be	  possible	  to	  infer	  that	  those	  with	  a	  negative	  QFGIT	  and	  TST	  have	  no	  evidence	  of	  past	  
or	  current	  TB	  infection.	  	  It	  is	  possible	  that	  some	  of	  those	  with	  negative	  results	  are	  in	  fact	  
falsely	  negative	  as	  a	  result	  of	  impaired	  cell	  mediated	  immune	  responses.	  Given	  the	  left	  
shifted	  distribution	  of	  results	  in	  HIV	  infected	  persons,	  the	  bimodal	  distribution	  of	  negative	  
results	  and	  the	  observed	  high	  rates	  of	  conversion	  following	  boosting	  with	  TST	  especially	  if	  
baseline	  negative	  QGFIT	  was	  above	  0.15IU/mL.	  	  It	  therefore	  seems	  possible	  that	  the	  current	  
cut	  off	  of	  0.35IU/mL	  may	  not	  be	  appropriate	  for	  both	  HIV	  infected	  and	  uninfected	  
individuals.	  	  A	  lower	  cut	  off	  may	  improve	  sensitivity	  in	  HIV	  infected	  persons	  in	  a	  similar	  
fashion	  to	  the	  lower	  cut	  off	  used	  for	  TST.	  	  This	  would	  seem	  appropriate	  for	  an	  
immunodiagnostic	  test	  in	  a	  population	  with	  impaired	  immune	  responses.	  	  Further	  
assessment	  and	  validation	  would	  need	  to	  be	  undertaken	  different	  HIV	  infected	  cohorts	  with	  
different	  levels	  of	  immunosuppression.	  	  	  	  	  	  	  	  	  	  
3.7 Conclusions	  
All	  currently	  available	  screening	  tools	  have	  limitations	  for	  the	  early	  detection	  of	  active	  
tuberculosis.	  	  In	  particular	  while	  symptom	  screen	  and	  CXR	  perform	  well	  in	  the	  detection	  of	  
pre-­‐diagnostic	  cases	  of	  TB	  they	  appear	  less	  well	  suited	  to	  identify	  true	  subclinical	  cases.	  	  
Sputum	  culture	  is	  the	  gold	  standard	  investigation	  but	  even	  this	  has	  limitation	  for	  detection	  
of	  active	  TB	  especially	  if	  disease	  is	  extra-­‐pulmonary,	  sputum	  is	  scarce	  or	  insufficient	  numbers	  
of	  bacilli	  are	  within	  the	  airways.	  	  The	  performance	  of	  CXR	  is	  significantly	  impaired	  as	  lesions	  
become	  more	  subtle	  and	  can	  not	  be	  reliably	  identified	  from	  surrounding	  structures	  which	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leads	  to	  high	  levels	  of	  inter	  observer	  variability.	  	  Novel	  techniques	  are	  therefore	  required	  to	  
further	  interrogate	  the	  earliest	  stages	  of	  disease	  reactivation.	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CHAPTER	  4	  –	  FDG-­‐PET/CT	  findings	  	  
4.1 Chapter	  4	  introduction	  
Active	  pulmonary	  TB	  is	  a	  comparatively	  slowly	  progressive	  condition	  that	  may	  follow	  a	  
fluctuating	  course	  and	  has	  a	  number	  of	  characteristic	  pathological	  features.	  	  In	  particular,	  an	  
apical	  and	  sub-­‐apical	  preponderance,	  tendency	  for	  cavitation	  and	  a	  spontaneous	  healing	  
phase	  that	  is	  characterised	  by	  fibrosis	  and	  calcification.	  	  Numerous	  autopsy	  studies	  from	  the	  
early	  20th	  century	  showed	  that	  early	  stages	  of	  disease	  were	  present	  in	  persons	  dying	  of	  
conditions	  other	  than	  TB	  (i.e.	  sub-­‐clinically)[112,	  113,	  115].	  	  CXR	  screening	  has	  been	  and	  still	  
is	  widely	  used	  identify	  TB	  in	  this	  subclinical	  phase	  but	  is	  has	  considerable	  limitations	  in	  terms	  
of	  sensitivity	  and	  specificity	  as	  described	  in	  the	  previous	  chapter.	  	  The	  more	  sensitive	  
imaging	  modality	  of	  FDG-­‐PET/CT	  may	  be	  able	  to	  identify	  evidence	  of	  subclinical	  pathology	  
that	  may	  not	  be	  reliably	  detected	  by	  conventional	  CXR	  imaging.	  	  This	  could	  then	  allow	  
identification	  of	  a	  group	  a	  higher	  risk	  of	  progression	  to	  active	  TB.	  
	  
While	  other	  subacute	  and	  chronic	  conditions	  can	  cause	  similar	  pathological	  appearances	  to	  
TB	  e.g.	  histoplasmosis,	  atypical	  mycobacteria,	  sarcoidosis	  etc.	  	  In	  settings	  such	  as	  Khayelitsha	  
these	  conditions	  are	  orders	  of	  magnitude	  less	  common	  than	  TB.	  	  	  HIV	  infection	  considerably	  
increases	  the	  risk	  of	  developing	  active	  TB	  and	  while	  CD4	  count	  is	  high	  (≥	  350/mm3)	  the	  
pattern	  of	  disease	  resembles	  that	  in	  the	  immunocompetent	  HIV	  uninfected	  persons.	  	  	  	  
4.2 Chapter	  4	  hypothesis	  	  
FDG-­‐PET/CT	  can	  be	  used	  to	  identify	  evidence	  of	  pathology	  consistent	  with	  TB	  disease	  activity	  
in	  asymptomatic,	  HIV	  infected	  persons	  with	  CD4	  ≥350/mm3	  and	  with	  evidence	  of	  immune	  
sensitization	  by	  Mtb	  (by	  QFGIT).	  
4.3 Chapter	  4	  aim	  
To	  evaluate	  the	  utility	  of	  FDG-­‐PET/CT	  to	  identify	  evidence	  of	  subclinical	  pathology	  in	  
asymptomatic,	  ART	  naïve,	  HIV	  infected	  adults	  with	  evidence	  of	  immune	  sensitization	  by	  Mtb	  
and	  no	  previous	  history	  of	  tuberculosis	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4.3.1 Specific	  chapter	  4	  aims	  
1. To	  describe	  and	  categorise	  baseline	  parenchymal	  abnormalities	  visible	  on	  FDG-­‐PET/CT	  
and	  to	  evaluate	  their	  activity	  radiographically	  (by	  CT)	  and	  metabolically	  (by	  FDG	  uptake).	  	  
2. To	  describe	  baseline	  FDG-­‐PET/CT	  findings	  within	  the	  mediastinal	  LN.	  
3. To	  describe	  baseline	  FDG-­‐PET/CT	  findings	  with	  cervical,	  axillary	  and	  upper	  abdominal	  LN.	  
4. To	  evaluate	  effect	  of	  TB	  treatment	  (IPT	  or	  standard	  TB	  treatment)	  +/-­‐	  ART	  on	  baseline	  
FDG-­‐PET/CT	  abnormalities.	  
5. To	  compare	  the	  reporting	  of	  CXR	  to	  findings	  on	  FDG-­‐PET/CT.	  
6. In	  asymptomatic	  persons	  with	  evidence	  of	  immune	  sensitization	  by	  Mtb	  to	  define	  a	  
group	  with	  evidence	  of	  subclinical	  TB	  and	  a	  group	  without	  evidence	  subclinical	  TB.	  
4.4 Chapter	  4	  methods	  	  
Statistical	  analysis	  was	  performed	  using	  Stata	  ver.	  12.1.	  	  Graphs	  and	  figures	  were	  created	  
using	  both	  Stata	  ver.	  12.1	  and	  GraphPad	  Prism	  ver.	  5.0a.	  	  Primary	  analysis	  of	  PET/CT	  images	  
including	  lesion	  size	  and	  SUV	  was	  performed	  on	  Philips	  Extended	  Brilliance	  Workspace	  
version	  4.5.3.40140.	  	  Additional	  analysis	  was	  carried	  out	  using	  OsiriX	  3.8.1	  32-­‐bit.	  	  All	  fused	  
PET/CT	  images	  are	  shown	  with	  SUV	  scaled	  0-­‐10.	  	  Images	  summarizing	  lesion	  location	  were	  
created	  to	  be	  anatomically	  accurate	  as	  follows.	  	  First	  an	  outline	  of	  the	  lesion	  was	  digitally	  
propagating	  in	  the	  coronal	  plane	  and	  the	  location	  of	  the	  lesion	  captured	  at	  the	  level	  of	  the	  
carina	  in	  the	  coronal	  plane	  using	  OsiriX.	  	  The	  location	  of	  the	  lesion	  was	  then	  digitally	  traced	  
onto	  a	  representative	  CXR	  anchored	  by	  anatomical	  reference	  points.	  	  Non-­‐parametric	  data	  
was	  compared	  using	  Wilcoxon	  rank	  sum	  (Mann-­‐Whitney	  U	  test)	  or	  Kruskal	  Wallis	  rank	  test	  
and	  parametric	  data	  compared	  using	  t-­‐test	  or	  ANOVA.	  	  Proportions	  were	  compared	  by	  χ2	  
test	  or	  Fisher’s	  exact	  test	  (if	  the	  contingency	  included	  a	  number	  ≤	  5).	  	  Correlation	  was	  
performed	  by	  Pearson	  and	  Spearman	  analysis.	  	  Agreement	  between	  tests	  was	  determined	  
using	  kappa	  statistic	  with	  degree	  of	  agreement	  as	  defined	  in	  Chapter	  3.	  
4.5 Treatment	  and	  follow-­‐up	  of	  participants	  
The	  35	  recruited	  asymptomatic	  participants	  underwent	  FDG-­‐PET/CT	  at	  baseline.	  	  Repeat	  
scans	  were	  performed	  in	  27	  out	  of	  35	  participants	  after	  a	  median	  of	  26	  weeks	  (IQR	  25-­‐
26.93).	  	  The	  median	  activity	  of	  FDG	  injected	  at	  the	  1st	  scan	  was	  4.03	  MBq/kg	  (IQR	  3.71-­‐4.17)	  
and	  2nd	  scan	  4.04	  MBq/kg	  (IQR	  3.93-­‐4.12);	  injected	  FDG	  at	  the	  2nd	  scan	  was	  between	  90-­‐
110%	  of	  1st	  scan	  for	  74%	  of	  participants.	  	  The	  time	  between	  FDG	  infusion	  and	  scan	  for	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the	  1st	  scan	  was	  60	  minutes	  (IQR	  58.5-­‐61)	  and	  2nd	  scan	  60	  minutes	  (IQR	  59-­‐65);	  time	  from	  
injection	  to	  scan	  for	  the	  2nd	  scan	  was	  between	  90-­‐110%	  of	  1st	  scan	  for	  89%	  of	  participants.	  	  
As	  calculation	  of	  SUVmax	  factors	  in	  the	  injected	  FDG	  dose	  and	  time	  between	  injection	  and	  
scan,	  slight	  differences	  in	  these	  parameters	  between	  scans	  do	  not	  significantly	  affect	  
interpretation.	  	  Repeat	  FDG-­‐PET/CT	  was	  not	  performed	  in	  8	  participants	  for	  the	  following	  
reasons;	  3	  became	  pregnant,	  2	  withdrew	  consent	  for	  study	  participation,	  2	  migrated	  to	  the	  
Eastern	  Cape	  and	  1	  was	  lost	  to	  follow-­‐up.	  	  Participants	  were	  prescribed	  6	  months	  IPT	  unless	  
there	  was	  a	  clinical	  concern	  regarding	  the	  initial	  FDG-­‐PET/CT.	  	  Four	  participants,	  who	  all	  
subsequently	  developed	  TB	  symptoms	  following	  the	  scan,	  were	  prescribed	  (or	  converted	  to)	  
standard	  TB	  therapy	  between	  7	  and	  90	  days	  of	  the	  baseline	  scan.	  	  Two	  of	  these	  participants	  
also	  had	  a	  positive	  culture	  for	  Mtb	  having	  initially	  been	  culture	  negative	  and	  2	  remained	  
culture	  negative	  but	  had	  evidence	  of	  evolving	  pathology	  on	  repeat	  imaging	  (table	  4.1).	  	  	  
Table	  4.1	  -­‐	  Summary	  of	  FDG-­‐PET/CT	  findings	  in	  the	  35	  participants.	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4.6 Results	  
4.6.1 Parenchymal	  lesions	  on	  FDG-­‐PET/CT	  scan	  
For	  the	  35	  participants	  undergoing	  FDG-­‐PET/CT,	  none	  of	  whom	  had	  previous	  TB,	  71.4%	  had	  
CT	  abnormalities	  within	  the	  lung	  parenchyma	  and	  only	  28.6%	  had	  normal	  lung	  parenchyma.	  	  
All	  abnormalities	  within	  the	  lung	  parenchyma	  could	  be	  categorized	  into	  4	  groups	  	  
1. Discrete	  (inactive)	  nodules	  
2. Active	  nodules	  	  
3. Infiltrates	  	  	  	  
4. Fibrotic	  scars	  	  
4.6.1.1 Discrete	  Nodules	  	  
Discrete	  nodules	  were	  defined	  as	  small,	  spherical	  opacities	  present	  within	  the	  lung	  
parenchyma	  where	  the	  border	  was	  clearly	  defined	  with	  no	  CT	  evidence	  of	  disease	  activity	  
(figure	  4.3b).	  	  Discrete	  nodules	  were	  present	  in	  57.1%	  of	  participants.	  	  In	  those	  with	  discrete	  
nodules	  the	  majority	  had	  only	  1	  present	  and	  only	  4	  participants	  had	  >	  3	  present	  (figure	  4.2).	  	  
The	  median	  size	  of	  nodules	  was	  3.8mm	  (IQR	  3.1-­‐4.5)	  with	  all	  nodules	  being	  sub-­‐centimetre	  
and	  83.3%	  being	  less	  than	  5mm.	  	  18.3%	  of	  nodules	  had	  a	  CT	  appearance	  of	  complete	  
mineralization	  and	  in	  35%	  of	  those	  with	  nodules	  at	  least	  1	  nodule	  was	  calcified.	  	  49.2%	  of	  
nodules	  were	  sub-­‐pleural	  and	  an	  additional	  30.5%	  were	  located	  within	  the	  lobar	  fissures.	  
Hence	  78.3%	  were	  in	  contact	  with	  pleura	  and	  20.3%	  had	  a	  centrilobular	  location.	  	  Of	  the	  
nodules	  not	  associated	  with	  the	  pleura,	  the	  median	  distance	  from	  pleura	  was	  8.8mm	  (IQR	  
5.6-­‐12.4);	  in	  total	  83.3%	  of	  discrete	  nodules	  were	  within	  5mm	  of	  the	  pleura.	  	  	  96.7%	  of	  
nodules	  had	  no	  visible	  uptake	  of	  FDG	  above	  background	  lung	  (VS	  =	  0)	  and	  for	  those	  that	  did	  
FDG	  uptake	  was	  less	  than	  that	  of	  mediastinal	  blood	  pool	  (VS	  =	  1).	  	  The	  median	  SUVmax	  of	  
discrete	  nodules	  was	  0.89	  (0.68-­‐1.14).	  	  The	  discrete	  nodules	  were	  evenly	  distributed	  
between	  the	  lung	  lobes	  with	  the	  observed	  distribution	  not	  being	  significantly	  different	  to	  
that	  expected	  if	  equally	  distributed	  (p=0.19).	  	  In	  general	  a	  slightly	  higher	  percentage	  of	  
nodules	  were	  within	  the	  right	  lung	  (56.6%)	  and	  in	  the	  lower	  half	  of	  the	  lung	  (70%)	  with	  very	  
few	  being	  located	  superior	  to	  the	  clavicles	  (figure	  4.1).	  
	  
Of	  the	  20	  participants	  with	  discrete	  inactive	  nodules,	  14	  had	  a	  repeat	  FDG-­‐PET/CT	  
performed.	  	  Of	  the	  53	  discrete	  nodules	  present	  on	  these	  baseline	  scans,	  96.2%	  were	  visible	  
on	  follow	  up	  scan,	  this	  slight	  differences	  most	  likely	  resulted	  from	  differences	  in	  image	  
acquisition	  between	  the	  studies.	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Figure	  4.1	  –	  Clinical	  features	  of	  20	  participants	  with	  discrete	  nodules	  and	  distribution	  of	  these	  nodules	  in	  participants:	  
	  
TOP	  -­‐	  Table	  showing	  clinical	  characteristics	  of	  participants	  with	  and	  without	  discrete	  nodules;	  	  
MIDDLE	  -­‐	  CT	  location	  of	  discrete	  nodules	  for	  all	  20	  participants	  spatially	  represented	  on	  a	  single	  CXR	  image	  as	  filled	  circles.	  	  
Numbers	  signify	  participant	  study	  number,	  colour	  represents	  lobe;	  BLACK	  =	  upper	  lobe,	  WHITE	  =	  middle	  lobe,	  GREEN	  =	  
Right	  middle	  lobe.	  
BOTTOM	  –	  Tables	  showing	  features	  and	  distribution	  of	  discrete	  nodules.	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The	  presence	  of	  discrete	  nodules	  on	  FDG-­‐PET/CT	  was	  not	  associated	  with	  TB	  household	  
contact	  history,	  duration	  since	  TB	  contact,	  presence	  of	  BCG	  scar,	  WHO	  clinical	  status	  or	  any	  
smoking	  history.	  	  In	  addition	  there	  was	  no	  significant	  difference	  in	  age,	  sex,	  CD4	  count,	  viral	  
load,	  QFGIT	  result	  or	  BMI	  between	  those	  with	  discrete	  nodules	  and	  those	  without.	  
4.6.1.2 Active	  nodules	  
This	  term	  was	  used	  to	  describe	  small,	  spherical	  opacities	  within	  the	  lung	  parenchyma	  with	  
poorly	  defined	  borders	  (figure	  4.4).	  	  These	  were	  present	  only	  in	  a	  single	  participant	  (an	  18	  
year	  old	  female	  with	  CD4	  count	  of	  802/mm3	  and	  VL	  of	  3948	  copies/mL)	  in	  whom	  sputum	  
was	  culture	  negative	  at	  screening	  but	  positive	  48	  days	  later	  on	  the	  day	  of	  scan	  (time	  to	  
sputum	  culture	  positivity	  33	  days).	  	  Symptoms	  of	  cough	  and	  night	  sweats	  developed	  34	  days	  
after	  the	  scan.	  	  Standard	  6	  month	  TB	  therapy	  was	  commenced	  but	  ART	  was	  not	  commenced	  
until	  after	  TB	  therapy	  was	  complete.	  	  26	  nodules	  were	  present	  within	  the	  lung	  parenchyma.	  	  
The	  median	  size	  was	  3.4mm	  (IQR	  3.1-­‐3.9)	  and	  SUVmax	  0.86	  (IQR	  0.71-­‐0.95)	  which	  was	  not	  
significantly	  different	  from	  discrete	  nodules	  (p=0.23	  and	  p=0.78).	  	  	  All	  lesions	  had	  a	  VS	  =	  0	  
and	  none	  had	  evidence	  of	  mineralization.	  	  Nodules	  were	  present	  in	  all	  lung	  lobes	  in	  a	  
random	  distribution	  with	  only	  42.3%	  of	  nodules	  in	  contact	  with	  the	  pleura	  (either	  sub-­‐
pleural	  or	  within	  pleural	  fissure)	  and	  57.7%	  being	  centrilobular.	  	  This	  distribution	  was	  
significantly	  different	  to	  discrete	  nodules	  (p=0.001)	  (figure	  4.3a/b).	  	  Unusually,	  QFGIT	  TBAg-­‐
NIL	  for	  this	  participant	  increased	  from	  2.58IU/mL	  to	  >10IU/mL	  between	  screen	  and	  scan	  
date,	  change	  of	  this	  magnitude	  was	  only	  seen	  in	  one	  other	  participant	  (figure	  4.3a).	  	  
Furthermore	  in	  contrast	  to	  discrete	  nodules,	  following	  treatment	  for	  TB	  all	  but	  1	  of	  the	  
active	  nodules	  disappeared	  on	  follow-­‐up	  FDG-­‐PET/CT.	  
Figure	  4.2	  –	  Histogram	  showing	  distribution	  of	  number	  of	  discrete	  nodules	  
found	  on	  baseline	  FDG-­‐PET/CT	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Figure	  4.3b	  –	  Axial	  section	  of	  CT	  showing	  examples	  of	  discrete	  and	  active	  nodules	  
	  
LEFT	  –	  Example	  of	  sub-­‐pleural,	  non-­‐calcified,	  well-­‐circumscribed,	  discrete	  nodule	  (green	  arrow)	  
RIGHT	  –	  Example	  of	  4	  centrilobular,	  poorly	  circumscribed,	  active	  nodules	  in	  left	  lung	  (green	  arrow)	  and	  1	  sub-­‐pleural	  active	  
nodule	  in	  right	  lung	  (green	  arrow)	  	  	  
Figure	  4.3a	  –	  Distribution	  of	  active	  nodules	  in	  1	  participant	  and	  change	  in	  QFGIT	  response	  
	  
LEFT:	  Graph	  showing	  QFGIT	  TBAg-­‐Nil	  results	  at	  screening	  and	  on	  day	  of	  scan	  (participant	  with	  active	  nodules	  shown	  in	  RED);	  
RIGHT:	  	  CT	  location	  of	  nodules	  in	  1	  participant	  with	  active	  nodules	  spatially	  represented	  on	  a	  CXR	  image	  as	  orange	  filled	  circles.	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4.6.1.3 Infiltrates	  and	  scars	  
In	  total	  9	  participants	  (25.7%)	  had	  infiltrates	  consistent	  with	  active	  TB	  or	  fibrotic	  scars	  
consistent	  with	  “inactive”	  TB	  present	  within	  lung	  parenchyma,	  6	  having	  fibrotic	  scar	  and	  6	  
having	  infiltrates	  (figure	  4.5	  and	  table	  4.2).	  	  Those	  with	  fibrotic	  scarring	  within	  lung	  were	  
significantly	  more	  likely	  to	  have	  infiltrates	  within	  the	  lung	  than	  those	  that	  did	  not	  (p=0.049).	  	  
Of	  the	  3	  participants	  with	  fibrotic	  scars	  who	  did	  not	  have	  infiltrates,	  2	  displayed	  other	  
evidence	  of	  disease	  activity	  responding	  to	  IPT.	  	  One	  had	  considerable	  uptake	  within	  a	  
mediastinal	  LN	  which	  resolved	  with	  IPT	  (fig	  4.5-­‐G2)	  and	  the	  other	  had	  repeat	  scans	  showing	  
reduction	  in	  size	  and	  FDG	  uptake	  within	  mediastinal	  LN	  post	  IPT	  (and	  also	  developed	  
asymptomatic	  sterile	  FDG	  avid	  nodules	  –	  both	  cases	  discussed	  in	  detail	  below).	  	  	  
	  
Scars	  were	  linear	  fibrotic	  or	  fibro-­‐cystic	  abnormalities	  slightly	  distorting	  the	  surrounding	  lung	  
tissue	  with	  no	  radiographic	  signs	  of	  activity,	  all	  had	  a	  VS	  =	  0	  and	  median	  SUVmax	  0.9	  (0.87-­‐
1.0).	  	  50%	  of	  scars	  had	  evidence	  of	  mineralization	  and	  the	  median	  length	  was	  12.2mm	  (IQR	  
7.2-­‐16).	  	  All	  scars	  were	  situated	  within	  the	  upper	  lobes	  (58.3%	  within	  left	  upper	  lobe	  and	  
41.7%	  with	  right	  upper	  lobe)	  with	  83.3%	  being	  located	  within	  the	  S1+2	  (apico-­‐posterior,	  left	  
lung),	  S1	  (apical,	  right	  lung)	  or	  S2	  (posterior,	  right	  lung)	  broncho-­‐pulmonary	  segments	  and	  
16.7%	  within	  the	  S3	  (anterior,	  left	  or	  right	  lung)	  broncho-­‐pulmonary	  segments	  (figure	  4.4).	  	  	  
	  
Infiltrates	  represented	  irregular,	  poorly	  defined,	  airway	  consolidation	  with	  radiographic	  
signs	  of	  activity.	  	  In	  all	  6	  participants	  with	  evidence	  of	  infiltrates,	  only	  a	  single	  infiltrate	  was	  
present.	  	  Median	  SUVmax	  was	  2.4	  (IQR	  0.84-­‐5.1)	  and	  in	  5,	  the	  lesion	  had	  VS	  ≥	  1.	  	  
Mineralization	  was	  not	  present	  in	  any	  lesion	  and	  median	  length	  was	  16.3mm	  (IQR	  5-­‐19.8).	  	  2	  
participants	  with	  largest	  areas	  of	  infiltration	  had	  evidence	  of	  tree-­‐in-­‐bud	  opacification	  and	  a	  
small	  area	  of	  cavitation	  was	  present	  in	  the	  centre	  of	  the	  largest	  infiltrate	  measuring	  
approximately	  3mm	  (fig	  4.6).	  	  Lesions	  were	  within	  the	  upper	  lobe	  in	  5	  of	  6.	  	  However,	  the	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Figure	  4.4	  –	  Distribution	  of	  infiltrates	  and	  scars	  in	  9	  participants.	  
TOP	  –	  CT	  location	  of	  infiltrates	  and	  scars	  from	  9	  participants	  represented	  on	  a	  single	  CXR	  as	  triangles.	  	  Length	  of	  triangle	  
proportional	  to	  length	  of	  lesion.	  	  Colour	  represents	  activity;	  RED	  =	  FDG	  avid	  Infiltrate,	  ORANGE	  =	  Infiltrate	  without	  FDG	  
avidity	  but	  CT	  evidence	  of	  activity,	  BLUE	  =	  fibrocystic	  scar,	  BLUE/BLACK	  =	  mineralized	  fibrocystic	  scar.	  	  Numbers	  represent	  
participant.	  	  	  
BOTTOM	  –	  CT	  location	  of	  infiltrates	  represented	  on	  a	  single	  axial	  section.	  	  Colour	  represents	  broncho-­‐pulmonary	  segment;	  
WHITE	  –	  S1,	  R	  lung,	  GREEN	  –	  S2,	  R	  lung	  and	  S1/2,	  L	  lung,	  YELLOW	  –	  S3	  R/L	  lung,	  BLACK	  –	  lower	  lobe.	  Number	  represents	  
participant	  (blue	  number	  =	  scar,	  red	  number	  =	  infiltrate)	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Figure	  4.5	  -­‐	  Coronal	  sections	  through	  fused	  FDG-­‐PET/CT	  showing	  infiltrates	  and	  scars	  in	  all	  9	  participants.	  	  	  
Letter	  signifies	  individual	  participant	  where	  another	  image	  relates	  to	  same	  participant	  letter	  is	  followed	  by	  “2”,	  post-­‐
treatment	  image	  represented	  by	  ‘.	  	  Pre-­‐treatment	  lesion	  circled	  in	  green	  and	  post-­‐treatment	  in	  red.	  	  Green	  arrow	  in	  “B2”	  
identifies	  LN	  within	  porta	  hepatis	  (confirmed	  on	  USS)	  and	  red	  arrow	  increased	  uptake	  within	  spleen	  with	  spherical	  lesions	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the	  right	  upper	  lobe.	  	  Of	  those	  with	  upper	  lobe	  lesions	  4	  of	  5	  (80%)	  had	  lesions	  within	  the	  S1	  
or	  S2	  broncho-­‐pulmonary	  segment	  and	  1	  (20%)	  within	  the	  S3	  segment.	  	  Of	  those	  with	  	  
infiltrates	  1	  participant	  (with	  small	  cavity)	  was	  culture	  positive	  on	  day	  of	  scan	  (time	  to	  
positivity	  12	  days)	  having	  been	  culture	  negative	  at	  screening	  but	  had	  shown	  progression	  of	  
CXR	  changes	  between	  day	  of	  screening	  and	  day	  of	  scan	  (see	  chapter	  3	  section	  5.3.2).	  	  	  
She	  developed	  symptoms	  of	  fever	  and	  night	  sweats	  approximately	  7	  days	  after	  scan	  and	  was	  
commenced	  on	  quadruple	  therapy.	  	  ART	  was	  commenced	  after	  66	  days	  of	  TB	  therapy.	  	  
Repeat	  FDG-­‐PET/CT	  was	  performed	  22	  days	  after	  completing	  TB	  therapy	  and	  lesion	  showed	  
substantial	  improvement	  in	  FDG	  uptake	  (SUVmax	  6.31à	  1.59)	  (Fig	  4.5	  –F/F’).	  	  	  
	  
Two	  additional	  participants	  with	  infiltrates	  developed	  TB	  symptoms	  after	  90	  and	  30	  days,	  
and	  were	  commenced	  on	  TB	  therapy	  though	  TB	  culture	  was	  negative.	  	  The	  former	  had	  a	  
small	  lung	  infiltrate	  which	  was	  not	  FDG	  avid	  but	  had	  enlarged	  FDG	  avid	  lymph	  nodes	  within	  
the	  porta-­‐hepatis	  and	  increase	  patchy	  uptake	  within	  the	  spleen	  (splenic	  FDG	  uptake	  being	  
greater	  than	  liver	  uptake).	  	  Splenic	  micro-­‐abscesses	  and	  LN	  were	  confirmed	  by	  abdominal	  
ultrasound	  scan	  (USS)	  and	  were	  suggestive	  of	  abdominal	  TB.	  	  Symptoms	  of	  malaise	  and	  left	  
upper	  quadrant	  pain	  resolved	  after	  TB	  therapy	  but	  FDG-­‐PET/CT	  was	  not	  repeated.	  	  The	  other	  
had	  a	  clinically	  indicated	  contrast	  CT	  scan	  of	  the	  chest	  performed	  approximately	  4	  weeks	  
after	  initial	  scan	  while	  awaiting	  results	  of	  TB	  culture	  which	  showed	  evidence	  of	  
bronchogenic	  progression	  of	  infiltrate	  down	  an	  adjacent	  lobule,	  which	  may	  represent	  how	  
TB	  progresses	  in	  the	  early	  stages	  (figure	  4.6).	  	  She	  developed	  symptoms	  of	  night	  sweats	  30	  
days	  after	  scan,	  which	  responded	  to	  TB	  therapy.	  	  ART	  in	  this	  participant	  was	  commenced	  
after	  18	  days	  of	  TB	  treatment.	  	  FDG-­‐PET/CT	  was	  repeated	  71	  days	  into	  TB	  treatment	  showed	  
improvement	  in	  FDG	  uptake	  (fig	  4.5	  –	  E/E’).	  	  The	  remaining	  participants	  with	  infiltrates	  
continued	  on	  IPT.	  	  
	  
Figure	  4.6	  –	  CT	  scans	  showing	  progression	  of	  infiltration	  and	  early	  cavitation.	  
Left	  panels	  (A+B)	  CT	  scan	  multi-­‐planar	  reconstruction	  (MPR)	  of	  same	  participant	  4	  weeks	  apart	  (second	  CT	  clinically	  
indicated	  contrast	  scan)	  green	  arrow	  showing	  initial	  infiltrate	  with	  red	  arrow	  showing	  progression	  down	  adjacent	  lobule	  (B)	  
in	  an	  area	  with	  evidence	  of	  tree-­‐in-­‐bud	  opacification	  on	  initial	  scan	  (A).	  	  Right	  panel	  (C)	  showing	  different	  participant	  with	  
small	  area	  of	  cavitation	  within	  dense	  consolidation	  (green	  arrow)	  and	  surrounding	  area	  of	  tree-­‐in-­‐bud	  opacification.	  	  	  	  
A	   B	   C	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Of	  the	  3	  participants	  with	  infiltrates	  who	  also	  had	  scars,	  the	  infiltrates	  did	  not	  develop	  
directly	  from	  or	  adjacent	  to	  scars	  in	  any	  case.	  	  Furthermore,	  in	  2	  participants	  the	  scars	  and	  
infiltrates	  were	  in	  different	  broncho-­‐pulmonary	  segments.	  	  One	  participant	  had	  multiple	  
distinct	  fibrocystic	  scars	  within	  both	  lungs	  (figure	  4.5	  –	  G	  only	  1	  cluster	  of	  scars	  shown).	  	  
Three	  scars	  were	  closely	  clustered	  peripherally	  within	  the	  S1/2	  broncho-­‐pulmonary	  segment	  
in	  the	  left	  lung	  and	  showed	  significant	  calcification	  with	  a	  4th	  non-­‐calcified	  scar	  more	  apically	  
located	  within	  the	  same	  broncho-­‐pulmonary	  segment.	  	  Two	  further	  non-­‐calcified	  scars	  were	  
clustered	  within	  the	  S2	  broncho-­‐pulmonary	  right	  lung.	  	  If	  scars	  represented	  prior	  
spontaneous	  healing	  of	  sites	  of	  active	  infection.	  	  This	  could	  suggest	  episodes	  of	  reactivation	  
in	  this	  participant	  on	  2	  or	  3	  separate	  occasions	  with	  the	  clustered	  scars	  relating	  to	  
bronchogenic	  spread	  down	  adjacent	  lobules	  followed	  by	  healing.	  	  
	  
The	  10	  participants	  with	  evidence	  of	  upper	  lobe	  infiltration	  and	  scarring	  and	  the	  participant	  
with	  the	  active	  nodular	  pattern	  were	  grouped	  together	  as	  having	  evidence	  of	  current	  or	  
previous	  disease	  activity.	  	  Their	  clinical	  characteristics	  were	  compared	  with	  the	  25	  
participants	  that	  had	  either	  no	  parenchymal	  abnormalities	  or	  only	  discrete	  nodules	  (table	  
4.3).	  	  There	  were	  no	  statistically	  significant	  differences	  between	  the	  groups.	  	  However,	  in	  
those	  with	  evidence	  of	  disease	  activity	  there	  was	  a	  suggestion	  of	  slightly	  more	  advanced	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  4.3	  –	  Comparison	  of	  clinical	  characteristics	  of	  10	  participants	  with	  infiltrates/scars	  and	  active	  
nodules	  and	  25	  participants	  with	  normal	  parenchyma	  of	  discrete	  nodules	  only	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viral	  load	  of	  18949	  and	  30%	  being	  WHO	  stage	  2.	  	  In	  comparison,	  the	  25	  participants	  without	  
evidence	  of	  activity	  were	  a	  median	  of	  1.7	  years	  from	  HIV	  diagnosis	  with	  a	  median	  CD4	  count	  
of	  517/mm3	  and	  viral	  load	  of	  9958	  with	  16%	  being	  WHO	  stage	  2.	  	  In	  addition,	  those	  with	  
evidence	  of	  disease	  activity	  had	  a	  non-­‐significant	  trend	  towards	  a	  lower	  median	  BMI	  (24.8	  
vs.	  28.8	  –	  p=0.09)	  and	  a	  greater	  change	  in	  weight	  over	  the	  screening	  period	  (-­‐0.84%/28	  days	  
vs.	  -­‐0.24%	  /28	  days	  –	  p=0.10)	  compared	  to	  participants	  without	  these	  changes.	  	  Otherwise	  
there	  were	  no	  differences	  between	  the	  groups	  particularly	  with	  regard	  to	  inflammatory	  
markers,	  history	  of	  household	  TB	  contact	  or	  presence	  of	  BCG	  scar.	  	  	  	  
	  
There	  was	  no	  apparent	  relationship	  between	  discrete	  nodules	  and	  presence	  of	  infiltrates,	  
scars	  and	  active	  nodules	  and	  no	  evidence	  that	  such	  lesions	  arose	  from	  or	  in	  relation	  to	  
discrete	  nodules.	  	  	  
4.6.2 Lymph	  node	  abnormalities	  on	  FDG-­‐PET/CT	  scan	  
Mediastinal	  lymph	  nodes	  (LN)	  were	  categorized	  into	  the	  following	  LN	  basins.	  	  R	  and	  L	  
superior	  mediastinal,	  aortic,	  R	  and	  L	  hilar	  and	  subcarinal/inferior	  mediastinal	  and	  were	  
considered	  abnormal	  if	  any	  of	  the	  following	  were	  present:	  	  	  
1. Mineralization	  
2. Enlargement	  ≥	  10mm	  in	  short	  axis	  
3. Increased	  FDG	  uptake	  greater	  than	  mediastinal	  blood	  pool	  	  
	  
At	  repeat	  scan	  any	  changes	  in	  specific	  LN	  identified	  on	  initial	  scan	  were	  evaluated.	  	  In	  
addition	  maximal	  FDG	  uptake	  was	  defined	  in	  visible	  cervical	  and	  axillary	  peripheral	  LN	  chains	  
and	  within	  LN	  in	  the	  upper	  abdomen	  abnormal	  FDG	  uptake	  within	  lymph	  nodes	  was	  
recorded.	  
4.6.2.1 Lymph	  node	  mineralization	  	  
Mineralized	  LN	  were	  identified	  in	  11	  participants	  (31.4%)	  with	  3	  participants	  having	  greater	  
than	  1	  mineralized	  LN	  basin	  resulting	  in	  a	  total	  of	  15	  mineralized	  LN	  basins	  being	  identified	  
(table	  4.4).	  	  Hilar	  and	  subcarinal	  LN	  were	  most	  commonly	  mineralized.	  	  Discrete	  
parenchymal	  nodules	  were	  present	  in	  7	  participants	  with	  mineralized	  LN	  (63.6%),	  of	  which	  in	  
only	  1	  was	  the	  parenchymal	  nodule	  also	  mineralized.	  	  This	  distribution	  was	  not	  significantly	  
different	  from	  participants	  without	  mineralized	  lymph	  nodes	  (p=0.40).	  	  A	  consistent	  
relationship	  between	  location	  of	  parenchymal	  nodules	  and	  location	  of	  mineralized	  lymph	  
nodes	  was	  not	  easily	  discerned,	  however,	  lymphatic	  drainage	  of	  lungs	  though	  well	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characterised	  is	  complex	  and	  variable.	  	  In	  total	  17	  participants	  (48.6%)	  had	  evidence	  of	  
mineralized	  parenchymal	  nodules	  or	  LN.	  	  Any	  mineralization	  within	  lung	  parenchyma	  or	  LN	  
was	  not	  associated	  with	  history	  of	  TB	  contact,	  BCG	  scar,	  QFGIT	  result,	  employment	  history	  
or	  HIV	  indices.	  	  
4.6.2.2 Lymph	  node	  enlargement	  and	  FDG	  uptake	  
Both	  HIV	  and	  TB	  infection	  are	  known	  to	  lead	  to	  enlargement	  and	  increased	  metabolic	  
activity	  of	  LN.	  	  Abnormal	  FDG	  uptake	  was	  present	  in	  the	  cervical	  LN	  in	  70.6%,	  axillary	  LN	  in	  
97.1%	  and	  mediastinal	  LN	  in	  45.7%.	  	  One	  participant	  had	  significant	  FDG	  uptake	  within	  
upper	  abdominal	  lymph	  nodes	  (2.9%).	  	  The	  presence	  of	  FDG	  avid	  cervical,	  axillary	  or	  
mediastinal	  lymph	  nodes	  was	  not	  associated	  with	  significant	  differences	  in	  viral	  load,	  CD4	  
count	  or	  number	  of	  days	  since	  HIV	  diagnosis	  and	  there	  was	  no	  significant	  correlation	  of	  
SUVmax	  with	  VL,	  CD4	  or	  baseline	  QFGIT	  for	  any	  of	  the	  3	  groups	  of	  LN.	  	  However,	  abnormal	  
axillary	  lymph	  nodes	  had	  significantly	  greater	  SUVmax	  than	  either	  cervical	  or	  mediastinal	  
nodes	  (see	  figure	  4.7).	  	  	  
	  
The	  10	  participants	  with	  infiltrates,	  scars	  or	  active	  nodules	  were	  no	  more	  likely	  to	  have	  
abnormal	  uptake	  within	  cervical	  or	  axillary	  nodes	  compared	  to	  those	  without	  these	  
parenchymal	  features	  of	  activity	  (p=0.68	  and	  p=1.0	  respectively)	  and	  the	  median	  SUVmax	  
for	  cervical	  and	  axillary	  nodes	  was	  also	  not	  significantly	  different.	  	  However,	  they	  were	  
significantly	  more	  likely	  to	  have	  abnormal	  uptake	  within	  mediastinal	  lymph	  nodes	  (p=0.022),	  
although	  for	  those	  with	  abnormal	  LN	  median	  SUV	  was	  not	  significantly	  different	  (p=0.75).	  	  In	  
addition	  the	  only	  participant	  with	  abnormal	  FDG	  uptake	  within	  abdominal	  LN	  had	  an	  
infiltrate	  within	  the	  lung	  parenchyma.	  	  The	  distribution	  of	  SUVmax	  within	  abnormal	  central	  
LN	  (mediastinal	  LN	  and	  abdominal	  LN)	  appeared	  bimodal	  (figure	  4.8).	  	  A	  significantly	  greater	  
proportion	  of	  those	  with	  infiltrates,	  scars	  or	  active	  nodules	  had	  a	  central	  lymph	  nodes	  with	  
SUVmax	  ≥	  5	  compared	  to	  those	  without	  parenchymal	  evidence	  of	  activity	  (40%	  vs.	  4%;	  









Table	  4.4	  -­‐	  Location	  of	  mineralized	  lymph	  nodes	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abnormal	  FDG	  uptake	  within	  all	  visible	  LN	  basins.	  	  For	  this	  participant	  there	  was	  initial	  
concern	  regarding	  ground	  glass	  opacification	  of	  lung	  parenchyma	  but	  this	  was	  dismissed	  at	  
review	  of	  follow	  up	  scan.	  	  Bronchoscopy	  and	  transbronchial	  needle	  aspirate	  (TBNA)	  were	  
performed	  with	  samples	  sent	  for	  cytology	  and	  culture	  not	  revealing	  a	  cause	  for	  the	  
abnormalities.	  	  The	  participant	  did	  complain	  of	  intermittent	  cough	  post	  bronchoscopy	  but	  
these	  symptoms	  resolved	  without	  treatment	  there	  was	  no	  weight	  loss	  by	  the	  time	  of	  second	  
scan	  she	  remained	  asymptomatic	  and	  all	  cultures	  were	  negative	  for	  TB.	  	  LN	  abnormalities	  
remained	  present	  at	  the	  second	  scan.	  	  However,	  it	  is	  possible	  that	  there	  was	  an	  undiagnosed	  
pathology	  other	  than	  HIV	  responsible	  for	  these	  abnormalities.	  
	  
Enlarged	  central	  lymph	  nodes	  (>10mm)	  were	  present	  in	  14	  (40%)	  of	  participants.	  	  There	  was	  
no	  significant	  correlation	  between	  size	  of	  enlarged	  lymph	  node	  and	  its	  SUVmax	  (r	  =	  0.2,	  
p=0.24).	  	  Median	  VL	  and	  CD4	  were	  not	  significantly	  different	  to	  those	  without	  enlarged	  
lymph	  nodes	  (p=0.17	  and	  0.62	  respectively).	  	  Enlarged	  central	  lymph	  nodes	  were	  present	  in	  
6	  of	  10	  participants	  (60%)	  with	  infiltrates,	  scars	  or	  active	  nodules	  compared	  to	  8	  of	  25	  (32%)	  
with	  no	  evidence	  of	  TB	  disease	  activity	  (p=0.151).	  
	  	  	  	  	  	  	  	  	  
Of	  the	  27	  participants	  who	  had	  a	  repeat	  scan,	  the	  majority	  of	  were	  treated	  with	  IPT	  and	  not	  
commenced	  on	  ART	  prior	  to	  repeat	  scan	  at	  6	  months.	  	  For	  these	  participants	  there	  was	  a	  
significant	  correlation	  of	  SUVmax,	  between	  initial	  and	  repeat	  scan	  for	  cervical,	  axillary	  and	  
mediastinal	  LN.	  	  This	  relationship	  was	  particularly	  strong	  for	  axillary	  LN	  (r	  =	  0.89,	  p<0.0001)	  
and	  mediastinal	  LN	  (r	  =	  0.87,	  p<0.0001)	  compared	  to	  cervical	  LN	  	  (r	  =	  0.51,	  p=0.02).	  	  One	  






















Figure	  4.7	  –	  Box	  and	  whisker	  plot	  comparing	  distribution	  of	  SUVmax	  in	  cervical,	  
axillary	  and	  mediastinal	  LN.	  **	  =	  p≤0.01,	  ***	  =	  p≤0.001	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participant	  was	  commenced	  on	  standard	  TB	  therapy	  but	  not	  ART,	  1	  participant	  commenced	  
on	  ART	  and	  remained	  on	  IPT	  and	  2	  participants	  were	  commenced	  on	  standard	  TB	  therapy	  
and	  ART.	  	  This	  therefore	  allowed	  some	  assessment	  of	  the	  effect	  of	  TB	  therapy	  and	  ART	  on	  
FDG	  uptake	  particularly	  within	  axillary	  and	  mediastinal	  LN.	  	  For	  axillary	  LN,	  neither	  IPT	  nor	  TB	  
treatment	  alone	  had	  a	  significant	  impact	  on	  FDG	  uptake	  suggesting	  that	  TB	  infection	  or	  
disease	  may	  not	  contribute	  significantly	  to	  metabolic	  activity	  of	  axillary	  LN	  (closed	  symbols	  
figure	  4.9	  (TOP)).	  	  ART	  initiation,	  however	  did	  appear	  to	  result	  in	  a	  reduction	  in	  FDG	  uptake	  
irrespective	  of	  whether	  IPT	  or	  standard	  TB	  therapy	  was	  prescribed	  (open	  symbols	  figure	  4.9	  
(TOP))	  with	  reduction	  in	  FDG	  uptake	  being	  greatest	  in	  participants	  that	  had	  a	  longer	  duration	  
of	  ART.	  	  All	  participants	  that	  commenced	  ART	  also	  had	  marked	  improvement	  in	  FDG	  uptake	  
within	  the	  cervical	  LN.	  	  	  
	  
For	  FDG	  avid	  mediastinal	  LN,	  the	  impact	  of	  ART	  initiation	  on	  FDG	  uptake	  for	  the	  participant	  
on	  IPT	  was	  less	  dramatic.	  	  Abnormal	  mediastinal	  LN	  showed	  a	  median	  reduction	  in	  SUVmax	  
of	  12%	  after	  126	  days	  of	  ART	  in	  comparison	  to	  a	  median	  7%	  reduction	  for	  all	  those	  on	  IPT	  
alone.	  	  Four	  participants	  were	  reported	  to	  have	  a	  significant	  reduction	  in	  SUVmax	  of	  
mediastinal	  LN	  on	  repeat	  scan,	  3	  of	  whom	  were	  treated	  with	  IPT	  alone	  (2	  of	  whom	  also	  had	  
fibrotic	  scarring)	  and	  1	  that	  was	  treated	  with	  standard	  TB	  therapy	  and	  ART	  (Fig	  4.5	  E/E’,	  Fig	  
4.9	  (BOTTOM)	  labelled	  “B”).	  	  For	  all	  these	  cases	  there	  were	  no	  technical	  differences	  between	  
the	  1st	  and	  2nd	  scans;	  administered	  FDG	  and	  time	  between	  injection	  and	  scan	  for	  pre	  and	  
post	  scans	  were	  within	  90-­‐110%	  in	  all	  cases.	  	  One	  of	  the	  participants	  with	  fibrotic	  scarring	  
treated	  with	  IPT	  alone	  had	  an	  especially	  dramatic	  improvement	  with	  a	  59%	  reduction	  in	  
SUVmax	  (SUVmax	  6.1	  à	  2.5)	  and	  almost	  total	  Improvement	  in	  visual	  score	  within	  a	  very	  	  
Figure	  4.8	  –	  Histogram	  showing	  distribution	  of	  SUVmax	  for	  central	  
(mediastinal	  and	  abdominal)	  LN	  
Chapter	  4	  –	  FDG-­‐PET/CT	  




Figure	  4.9	  –	  Correlation	  of	  SUVmax	  in	  axillary	  and	  mediastinal	  LN	  between	  pre	  and	  post	  scan.	  	  
TOP	  –	  Scatter-­‐plot	  showing	  correlation	  of	  SUVmax	  in	  axillary	  LN	  on	  pre	  and	  post	  FDG-­‐PET/CT	  scan	  
BOTTOM	  –	  Scatter-­‐plot	  showing	  correlation	  of	  SUVmax	  in	  mediastinal	  LN	  on	  pre	  and	  post	  FDG-­‐PET/CT	  scan.	  
Effect	  of	  different	  IPT,	  standard	  TB	  therapy	  and	  ART	  is	  shown	  (see	  text	  for	  reference	  to	  “A”	  and	  “B”)	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enlarged	  (19.4mm),	  R	  superior	  mediastinal	  LN	  which	  also	  reduced	  in	  size.	  	  There	  was	  very	  
little	  change	  within	  other	  mediastinal	  LN	  (6%	  reduction)	  or	  axillary	  LN	  (11%	  reduction).	  	  
Hence,	  this	  was	  consistent	  with	  tuberculous	  lymphadenitis	  responding	  to	  isoniazid	  (fig	  4.5	  
G2/G2’,	  fig	  4.9	  BOTTOM	  labelled	  “A”).	  	  The	  other	  participant	  with	  fibrotic	  scarring	  had	  a	  
median	  20%	  reduction	  in	  SUV	  following	  IPT	  within	  a	  significantly	  enlarged	  mediastinal	  LN	  (up	  
to	  20mm)	  accompanied	  by	  reduction	  in	  size	  of	  LN	  and	  development	  of	  mineralization.	  	  This	  
was	  accompanied	  by	  a	  1%	  increase	  in	  axillary	  SUV	  and	  therefore	  suggested	  a	  response	  to	  IPT	  
(figure	  4.10	  –	  TOP)	  .	  	  In	  the	  final	  participant	  on	  IPT	  who	  was	  reported	  as	  showing	  a	  visual	  
improvement	  within	  mediastinal	  LN,	  had	  no	  fibrotic	  scaring.	  	  The	  median	  SUVmax	  with	  
mediastinal	  LN	  (which	  were	  not	  enlarged)	  reduced	  38.5%	  but	  there	  was	  also	  a	  23%	  
reduction	  within	  axillary	  LN.	  	  The	  interpretation	  therefore	  was	  less	  clear	  but	  may	  have	  
represented	  a	  response	  to	  IPT.	  	  Of	  note	  in	  only	  2	  of	  the	  4	  participants	  with	  improvement	  in	  
FDG	  uptake	  within	  mediastinal	  LN	  was	  the	  baseline	  SUVmax	  >	  5	  (median	  SUVmax	  4.4	  range	  
2.4-­‐6.47)	  suggesting	  that	  there	  may	  be	  considerable	  overlap	  in	  SUVmax	  for	  resulting	  directly	  
from	  HIV	  infection	  alone	  and	  that	  related	  to	  TB	  infection.	  	  Of	  interest	  for	  these	  4	  participants	  
in	  whom	  there	  was	  a	  response	  within	  the	  mediastinal	  LN	  to	  TB	  therapy	  there	  was	  a	  strong	  





Figure	  4.10	  –	  Participant	  showing	  response	  following	  IPT	  within	  mediastinal	  LN	  as	  well	  as	  new	  parenchymal	  lesions.	  
TOP:	  Coronal	  fused	  FDG-­‐PET/CT	  images	  showing	  a	  reported	  significant	  improvement	  in	  FDG	  uptake	  within	  hilar	  and	  
subcarinal	  LN	  following	  IPT.	  
BOTTOM:	  Same	  participant	  showing	  development	  of	  new	  FDG	  avid	  lymph	  nodes	  within	  apex	  of	  R	  lower	  lobe	  (2	  of	  3	  
nodules	  shown).	  	  	  
Participant	  also	  had	  fibrotic	  scarring	  shown	  (Fig	  4.5	  –	  H)	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LN	  (r=0.84,	  p=0.16),	  however	  this	  was	  not	  significant	  due	  to	  small	  sample	  size,	  but	  reflects	  
findings	  by	  Ghesani	  et	  al[137].	  
	  
Of	  note	  all	  6	  participants	  with	  infiltrates,	  scars	  or	  active	  nodules	  that	  had	  a	  repeat	  scan	  had	  a	  
significant	  improvement	  in	  baseline	  abnormalities	  reported,	  either	  within	  lung	  parenchyma	  
or	  mediastinal	  LN,	  compared	  to	  only	  1	  of	  21	  participants	  without	  evidence	  of	  TB	  disease	  
activity	  who	  had	  a	  repeat	  scan	  (p<0.0001).	  	  	  
4.6.3 New	  abnormalities	  on	  follow-­‐up	  FDG-­‐PET/CT	  scan	  	  
Of	  the	  27	  participants	  that	  had	  a	  follow-­‐up	  scan	  only	  3	  showed	  significant	  new	  findings	  on	  
repeat	  scan.	  	  One	  participant	  had	  a	  R	  lower	  lobe	  infiltrate	  and	  developed	  a	  productive	  cough	  
and	  pleuritic	  pain	  within	  1	  week,	  which	  resolved	  following	  a	  short	  course	  of	  amoxicillin.	  	  This	  
deterioration	  was	  attributed	  to	  a	  bacterial	  bronchopneumonia.	  	  The	  other	  2	  participants	  
developed	  new	  FDG	  avid,	  poorly	  defined	  nodules.	  	  One	  of	  these	  participants	  had	  fibrotic	  scar	  
visible	  on	  the	  initial	  scan,	  which	  had	  not	  changed,	  but	  an	  improvement	  was	  reported	  within	  
the	  mediastinal	  LN	  (reduction	  in	  size	  and	  FDG	  uptake,	  as	  well	  as	  increased	  mineralization	  (as	  
described	  above))	  (figure	  4.10).	  	  In	  addition	  to	  this,	  3	  distinct,	  large	  (>1cm),	  FDG	  avid,	  
nodules	  (SUVmax	  2.86-­‐2.96)	  appeared	  within	  the	  apex	  of	  the	  RLL.	  	  Compliance	  with	  IPT	  
appeared	  good	  as	  judged	  by	  pill	  count.	  	  These	  lesions	  did	  not	  appear	  similar	  to	  type	  of	  
lesions	  described	  on	  the	  initial	  scans,	  appearing	  as	  distinct	  lesions	  with	  little	  evidence	  of	  
endobronchial	  spread	  (unlike	  infiltrates)	  and	  larger	  and	  less	  numerous	  than	  the	  active	  
nodules	  described.	  	  The	  second	  participant,	  similarly,	  had	  a	  single	  large	  FDG	  avid	  nodule	  
appear	  within	  the	  R	  lower	  lobe.	  Compliance	  with	  IPT	  in	  this	  case	  was	  difficult	  to	  assess	  as	  
pills	  were	  rarely	  returned	  for	  counting.	  Neither	  of	  these	  2	  participants	  developed	  any	  TB	  
symptoms	  and	  sputum	  cultures	  were	  negative.	  	  Lesions	  were	  not	  visible	  on	  CXR	  and	  repeat	  
CXR	  did	  not	  show	  any	  further	  deterioration.	  	  Both	  participants	  underwent	  bronchoalveolar	  
lavage	  (BAL)	  and	  BAL	  cultures	  were	  also	  negative	  for	  Mtb	  and	  bacteria	  with	  unremarkable	  
cytology.	  	  	  
4.6.4 Comparison	  of	  CXR	  and	  FDG-­‐PET/CT	  	  
Consensus	  reading	  of	  screening	  CXR	  was	  used	  to	  exclude	  active	  TB	  and	  categorize	  
participants	  as	  having	  either	  normal	  CXR	  or	  evidence	  of	  inactive	  TB.	  	  As	  described	  2	  
participants	  had	  evidence	  of	  progressive	  abnormalities	  at	  repeat	  CXR	  performed	  just	  prior	  to	  
the	  initial	  scan	  consistent	  with	  active	  TB	  and	  33	  had	  no	  evidence	  of	  progression	  on	  CXR.	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Comparison	  between	  the	  CT	  findings	  and	  the	  consensus	  CXR	  diagnosis	  for	  the	  CXR	  
performed	  just	  prior	  to	  the	  initial	  scan	  is	  shown	  in	  figure	  4.11.	  	  	  
	  
To	  allow	  for	  broad	  comparison	  between	  FDG-­‐PET/CT	  and	  CXR,	  FDG-­‐PET/CT	  parenchymal	  
lesions	  were	  classified	  as	  follow	  
• Normal	  	  
o No	  parenchymal	  abnormalities	  
o Discrete	  non-­‐calcified	  nodules	  (as	  these	  were	  commonly	  <5mm	  and	  when	  
present	  usually	  <3	  per	  patient	  these	  would	  not	  be	  expected	  to	  be	  detectable	  
on	  CXR)	  	  
• Inactive	  
o Fibrotic	  scar	  
o Discrete	  calcified	  nodules	  (these	  were	  included	  in	  CXR	  definition	  of	  inactive	  
TB	  hence	  to	  allow	  for	  fair	  comparison)	  
• Active	  	  
o Infiltrate	  
o Active	  nodules	  	  
	  
Using	  these	  criteria,	  agreement	  between	  the	  consensus	  report	  and	  the	  FDG-­‐PET/CT	  scan	  
was	  moderate.	  	  The	  observed	  agreement	  was	  68.6%	  against	  an	  expected	  agreement	  of	  
42.3%,	  κ=0.46	  (95%C.I.	  0.24-­‐0.70	  –	  p=0.0001).	  	  Of	  note	  only	  2	  out	  of	  7	  (28.5%)	  of	  those	  with	  
active	  changes	  on	  FDG-­‐PET/CT	  were	  identified	  by	  CXR	  and	  there	  was	  tendency	  to	  over	  
estimate	  inactive	  TB	  abnormalities.	  	  The	  sensitivity	  and	  specificity	  of	  the	  consensus	  CXR	  
report	  compared	  to	  the	  FDG-­‐PET/CT	  scan	  (for	  ant	  TB	  changes	  (active/inactive)	  vs.	  normal)	  
was	  73.3%	  and	  80%	  respectively.	  	  	  	  
	  
These	  CXR	  diagnoses	  were	  as	  reported	  by	  consensus	  of	  medical	  officers	  following	  viewing	  of	  
2	  CXR	  for	  each	  participant	  (screening	  and	  pre-­‐scan	  CXR).	  	  In	  order	  to	  get	  a	  more	  realistic	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Figure	  4.11	  –	  Comparison	  of	  FDG-­‐PET/CT	  findings	  and	  consensus	  CXR	  read	  of	  pre	  scan	  CXR	  
Chapter	  4	  –	  FDG-­‐PET/CT	  
	   155	  
comparison	  of	  CXR	  screening	  and	  FDG-­‐PET/CT,	  7	  consultant	  radiologists	  with	  median	  
experience	  of	  8	  years	  (IQR	  5.5-­‐11)	  were	  shown	  the	  single	  CXR	  for	  each	  participant	  taken	  
closest	  to	  FDG-­‐PET/CT	  (median	  9	  days	  apart	  (IQR	  7-­‐14	  days).	  	  The	  consultant	  readers	  were	  
given	  minimal	  clinical	  information	  (asymptomatic,	  HIV	  infected	  from	  Khayelitsha,	  screening	  
CXR	  for	  TB).	  	  However,	  they	  were	  given	  detailed	  written	  and	  verbal	  reading	  instructions	  
including	  CXR	  definitions	  of	  active	  TB	  and	  inactive	  TB	  to	  be	  used.	  	  All	  readers	  had	  experience	  
in	  the	  reporting	  of	  TB	  screening	  CXR	  for	  migration	  purposes	  and	  were	  familiar	  with	  the	  
definitions	  provided,	  they	  all	  reported	  between	  100-­‐5000	  CXR/year.	  	  The	  CXR	  were	  reported	  
by	  these	  readers	  independently,	  on	  medical	  diagnostic	  monitors,	  in	  a	  hospital	  reporting	  
room	  with	  low	  ambient	  lighting.	  	  A	  structured	  reporting	  sheet	  was	  used	  to	  ensure	  all	  
sections	  of	  the	  CXR	  were	  focused	  on.	  	  All	  readers	  reported	  images	  in	  a	  different	  random	  
order	  to	  minimize	  reading	  bias.	  	  
	  
Individual	  reader	  agreement	  with	  FDG-­‐PET/CT	  (for	  the	  3	  categories	  active	  TB,	  inactive	  TB	  
and	  normal/no	  TB)	  was	  slight	  to	  fair	  for	  all	  readers	  as	  measured	  by	  kappa	  statistic	  (figure	  	  




































































Figure	  4.12	  –	  Comparison	  of	  7	  consultant	  CXR	  readers	  to	  each	  other	  and	  to	  FDG-­‐PET/CT.	  
A	  –	  (Left)	  Comparison	  of	  each	  CXR	  report	  for	  each	  reader	  (R1-­‐7)	  to	  FDG-­‐PET/CT	  (CT)	  and	  each	  other;	  each	  read	  is	  a	  single	  
bar	  (Black	  –	  reported	  as	  Active	  TB,	  Dappled	  Grey	  -­‐	  reported	  as	  Inactive	  TB,	  White	  –	  reported	  as	  Normal).	  	  
B	  –	  (Top	  Right)	  Distribution	  of	  reports	  for	  each	  reader.	  	  
C	  –	  (Bottom	  Right)	  Kappa	  statistic	  for	  each	  reader	  in	  comparison	  to	  FDG-­‐PET/CT	  	  	  	  	  	  
A	   B	  
C	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4.12	  -­‐	  C).	  	  There	  was	  no	  significant	  correlation	  of	  accuracy	  of	  CXR	  reporting	  with	  years	  of	  
experience	  as	  a	  radiologist	  (r	  =	  0.22,	  p=0.63)	  and	  no	  significant	  effect	  of	  number	  of	  CXR	  
reported/year	  on	  accuracy	  (p=0.86).	  	  None	  of	  the	  readers	  reported	  the	  culture	  positive	  
participant	  with	  active	  nodules	  on	  FDG-­‐PET/CT	  as	  active.	  	  6/7	  reported	  the	  second	  culture	  
positive	  participant	  with	  CXR	  infiltrate	  as	  active.	  	  Reader	  6	  was	  an	  outlier	  with	  regard	  to	  
distribution	  of	  reports.	  	  Excluding	  reader	  6,	  the	  overall	  agreement	  between	  the	  remaining	  6	  
readers	  with	  each	  other	  was	  still	  only	  slight	  κ=0.15,	  with	  agreement	  being	  better	  for	  active	  
TB	  (κ=0.28)	  and	  worse	  for	  inactive	  TB	  (κ=0.10).	  	  In	  general	  there	  was	  a	  tendency	  to	  over	  
report	  inactive	  TB	  changes.	  	  Evaluating	  the	  CXR	  report	  as	  a	  binary	  outcome	  of	  TB	  related	  
changes	  or	  no	  TB	  related	  changes,	  sensitivity	  of	  CXR	  readers	  varied	  considerably	  from	  
33.3%-­‐100%	  (median	  86.7%)	  as	  did	  specificity	  25%-­‐94.7%	  (median	  45%).	  	  A	  reciprocal	  
relationship	  for	  these	  parameters	  was	  apparent	  for	  each	  reader	  (figure	  4.13),	  with	  5	  readers	  
(1,2,4,6,7)	  having	  high	  sensitivity	  and	  low	  specificity	  (over-­‐reading)	  and	  2	  readers	  (3	  and	  5)	  
having	  low	  sensitivity	  and	  high	  specificity	  (under-­‐reading).	  	  The	  positive	  predictive	  value	  of	  
CXR	  readers	  varied	  from	  50%-­‐83.3%	  and	  negative	  predictive	  value	  from	  66.7%-­‐100%.	  	  In	  
contrast	  readers	  in	  general	  had	  poor	  sensitivity	  for	  changes	  consistent	  with	  active	  TB	  
(median	  28.6%)	  but	  specificity	  was	  generally	  good	  (median	  92.6%)	  again	  suggesting	  the	  main	  
tendency	  was	  to	  over	  call	  inactive	  TB	  changes.	  	  
	  
	  









































































Figure	  4.13	  –	  Sensitivity	  and	  specificity	  of	  7	  consultant	  CXR	  readers	  compared	  to	  FDG-­‐PET/CT	  	  
Sensitivity	  (solid	  line)	  and	  specificity	  (dashed	  line)	  for	  any	  TB	  changes	  (left)	  and	  active	  TB	  changes(right)	  for	  the	  7	  readers	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4.7 Summary	  of	  main	  findings	  
Amongst	  a	  cohort	  of	  35	  asymptomatic,	  ART	  naïve,	  HIV	  infected	  adults	  with	  a	  median	  CD4	  
count	  of	  517/mm3,	  recent	  evidence	  of	  a	  positive	  QFGIT	  and	  no	  history	  of	  previous	  TB	  
treatment,	  71.4%	  had	  anatomical	  abnormalities	  within	  the	  lung	  parenchyma	  and	  45.7%	  had	  
abnormal	  FDG	  uptake	  with	  central	  LN	  (mediastinal	  and	  upper	  abdominal).	  	  Four	  patterns	  of	  
parenchymal	  abnormality	  were	  observed,	  potentially	  representing	  different	  stages	  of	  TB	  
infection;	  discrete	  nodules,	  active	  nodules,	  infiltrates	  and	  scars.	  	  Those	  with	  fibrotic	  scars	  
were	  significantly	  more	  likely	  to	  have	  infiltrates	  or	  other	  signs	  of	  disease	  activity	  and	  hence	  
were	  grouped	  with	  those	  with	  infiltrates	  and	  active	  nodules	  as	  having	  some	  evidence	  of	  
current	  or	  prior	  TB	  disease	  activity.	  	  There	  was	  no	  significant	  difference	  in	  clinical	  
characteristics	  between	  these	  10	  participants	  and	  the	  25	  without	  evidence	  of	  disease	  
activity,	  although	  there	  was	  a	  tendency	  towards	  more	  advanced	  HIV	  infection.	  	  The	  10	  
participants	  with	  parenchymal	  evidence	  of	  disease	  activity	  were	  more	  likely	  to	  have	  
abnormal	  uptake	  within	  central	  LN	  (mediastinal	  and	  abdominal),	  in	  particular	  SUVmax	  >	  5,	  
but	  not	  within	  peripheral	  LN	  (cervical	  and	  axillary).	  	  These	  10	  participants	  were	  also	  
significantly	  more	  likely	  to	  have	  improvement	  in	  baseline	  abnormalities	  following	  IPT	  or	  TB	  
treatment.	  	  Two	  participants	  developed	  unexplained	  new	  FDG	  avid	  nodules	  though	  
remained	  asymptomatic	  and	  had	  negative	  culture	  at	  bronchoscopy.	  	  	  
	  
Agreement	  between	  FDG-­‐PET/CT	  and	  CXR	  for	  each	  of	  the	  7	  consultant	  radiologists	  was	  slight	  
to	  fair	  and	  agreement	  between	  the	  radiologists	  was	  again	  only	  slight.	  	  Radiologists	  identified	  
abnormalities	  consistent	  with	  TB	  with	  either	  high	  sensitivity/low	  specificity	  or	  high	  
specificity/low	  sensitivity	  suggesting	  that	  some	  had	  a	  tendency	  to	  over-­‐read	  and	  others	  
under-­‐read	  screening	  CXR.	  	  	  	  	  	  	  	  	  	  
4.8 Discussion	  
Discrete,	  well-­‐circumscribed,	  nodules	  on	  CT	  scan	  were	  identified	  in	  57.1	  %	  of	  participants.	  	  
These	  nodules	  were	  less	  than	  10mm	  in	  size,	  solid	  in	  appearance,	  generally	  spherical	  with	  no	  
evidence	  of	  spiculation	  or	  characteristics	  suspicious	  of	  malignancy.	  	  When	  present,	  nodules	  
were	  most	  commonly	  single,	  sub-­‐pleurally	  located	  with	  no	  lobar	  preference	  (though	  more	  
commonly	  found	  in	  the	  lower	  half	  of	  the	  lung	  field)	  and	  18.3%	  were	  calcified.	  	  	  Smoking,	  
biomass	  fuel	  exposure	  and	  traditional	  risk	  factors	  for	  cancer	  in	  this	  population	  were	  very	  low	  
and	  all	  participants	  were	  under	  50	  years	  with	  only	  14%	  (5	  of	  35)	  being	  over	  40	  years	  old.	  	  No	  
Chapter	  4	  –	  FDG-­‐PET/CT	  
	   158	  
CT	  screening	  studies	  have	  been	  performed	  in	  this	  specific	  population	  to	  compare	  this	  result,	  
although	  numerous	  CT	  screening	  studies	  for	  lung	  cancer	  have	  been	  performed.	  	  The	  majority	  
of	  these	  studies	  focus	  on	  groups	  that	  are	  at	  high	  risk	  of	  lung	  cancer,	  usually	  age	  >	  50	  years	  
with	  at	  least	  a	  15	  pack	  year	  smoking	  history,	  living	  in	  high	  income	  countries[222].	  	  In	  these	  
high-­‐risk	  populations,	  lung	  nodules	  are	  common	  being	  present	  in	  up	  to	  51%	  of	  smokers	  over	  
the	  age	  of	  50[223,	  224].	  	  The	  vast	  majority	  of	  nodules	  in	  smokers	  are	  benign	  and	  are	  likely	  
represent	  reactions	  to	  inhaled	  irritants	  and	  particles.	  	  In	  smokers	  that	  have	  nodules,	  the	  
median	  number	  is	  5-­‐7[225]	  in	  comparison	  to	  the	  median	  of	  2	  in	  those	  with	  nodules	  in	  this	  
study.	  	  The	  prevalence	  of	  lung	  nodules	  is	  likely	  to	  be	  considerably	  lower	  in	  non-­‐smokers.	  	  
Only	  a	  single	  large	  screening	  study	  has	  included	  non-­‐smokers	  and	  these	  participants	  were	  all	  
>	  40	  years	  old.	  	  Sone	  et	  al	  conducted	  a	  population	  lung	  cancer	  screening	  trial	  using	  low	  dose	  
spiral	  CT	  in	  Japan	  involving	  5,483	  participants	  with	  a	  median	  age	  of	  64	  years,	  of	  whom	  
approximately	  50%	  had	  never	  smoked.	  	  The	  results	  were	  not	  reported	  by	  smoking	  status	  but	  
in	  the	  study	  as	  a	  whole	  only	  7.2%	  had	  benign	  lesions	  and	  5.1%	  suspicious	  lung	  lesions,	  
substantially	  fewer	  abnormalities	  than	  in	  screening	  studies	  of	  higher	  risk	  participants[226].	  	  
Hence	  it	  appears	  that	  lung	  nodules	  are	  much	  more	  common	  in	  our	  population	  than	  would	  
be	  expected	  in	  non-­‐smokers	  from	  high-­‐income	  countries	  and	  also	  follow	  a	  different	  pattern	  
to	  that	  found	  in	  smokers.	  
	  
Pathogens	  that	  cause	  granulomas	  are	  a	  common	  cause	  of	  pulmonary	  nodules	  with	  M.	  
tuberculosis,	  Cryptococcus	  neoformans	  and	  Histoplasma	  capsulatum	  being	  amongst	  the	  
most	  common	  causes	  globally.	  	  Histoplasmosis	  is	  a	  relatively	  uncommon	  condition	  in	  South	  
Africa	  although	  outbreaks	  have	  historically	  been	  associated	  with	  a	  history	  of	  cave	  
exploration[227].	  	  In	  recent	  times	  disseminated	  histoplasmosis	  has	  been	  shown	  to	  occur	  in	  
advanced	  HIV	  but	  in	  a	  retrospective,	  8	  year	  review	  of	  histological	  samples	  of	  deep	  fungal	  
infections	  at	  a	  teaching	  hospital	  in	  Cape	  Town,	  histoplasmosis	  was	  only	  confirmed	  in	  only	  a	  
single	  case[228].	  	  Cryptococcosis	  is	  a	  well-­‐known	  cause	  of	  incidental	  pulmonary	  nodules	  but	  
the	  literature	  is	  generally	  limited	  to	  case	  reports	  and	  series.	  	  Two	  case	  series	  have	  reported	  
CT	  findings	  of	  pulmonary	  cryptococcosis,	  suggesting	  that	  nodules	  are	  frequently	  6-­‐20mm	  in	  
size	  and	  more	  often	  multiple	  than	  single	  which	  does	  not	  correspond	  to	  the	  pattern	  found	  in	  
this	  study[229,	  230].	  	  In	  addition	  Cryptococcus	  is	  environmentally	  ubiquitous	  globally,	  not	  
limited	  to	  low-­‐middle	  income	  countries,	  with	  positive	  antibodies	  detectable	  in	  the	  majority	  
of	  children	  by	  the	  age	  of	  5.	  	  A	  study	  from	  New	  York	  has	  shown	  that	  70%	  of	  children	  >	  5	  years	  
had	  detectable	  cryptococcal	  antibodies[231].	  	  Disseminated	  cryptococcal	  disease	  is	  a	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common	  presentation	  in	  advanced	  HIV	  (CD4<100/mm3)	  in	  South	  Africa	  but	  increased	  
identification	  of	  pulmonary	  lesions	  has	  not	  been	  reported	  in	  HIV	  infected	  persons	  with	  
higher	  CD4	  counts.	  	  Environmental	  outbreaks	  of	  Cryptococcus	  sp.	  may	  lead	  in	  increases	  in	  
pulmonary	  nodules	  relating	  to	  the	  organism	  but	  even	  in	  the	  well	  characterised	  outbreak	  of	  
Cryptococcus	  gatti	  on	  Vancouver	  Island	  overall	  numbers	  of	  pulmonary	  cryptococcosis	  	  	  were	  
low[232].	  	  	  	  	  
	  
It	  is	  more	  likely	  that	  these	  nodules	  relate	  to	  mycobacterial	  infection	  with	  Mtb	  infection	  
being	  the	  most	  likely.	  	  While	  non-­‐tuberculous	  mycobacteria	  can	  also	  cause	  lung	  granulomas,	  
Mtb	  is	  the	  most	  commonly	  sensitizing	  mycobacteria	  in	  this	  setting	  with	  >75%	  having	  a	  
positive	  Mtb	  IGRA.	  	  Furthermore	  in	  this	  study	  100%	  of	  recruited	  participants	  had	  recent	  
evidence	  of	  immune	  sensitization	  by	  Mtb	  (positive	  QFGIT).	  	  Those	  with	  advanced	  HIV	  are	  
highly	  susceptible	  to	  both	  Mtb	  and	  Mycobacterium	  avium	  intracellulare	  (MAI)	  (one	  of	  the	  
commonest	  non-­‐tuberculous	  mycobacterial	  infecting	  causing	  disease).	  	  However,	  prevalence	  
surveys	  in	  these	  populations	  in	  South	  Africa	  have	  shown	  Mtb	  to	  be	  at	  least	  5	  times	  more	  
common	  than	  MAI[196].	  	  	  
	  
The	  distribution	  of	  discrete	  nodules	  found	  on	  CT	  in	  this	  study	  is	  remarkably	  similar	  to	  
descriptions	  of	  the	  primary	  site	  of	  initial	  TB	  infection	  (Ghon	  focus)	  reported	  in	  numerous	  
autopsy	  studies.	  	  Although	  most	  autopsy	  studies	  were	  carried	  out	  in	  America	  and	  Europe	  in	  
the	  early	  20th	  century.	  	  This	  was	  at	  a	  period	  when	  prevalence	  of	  TB	  would	  have	  been	  similar	  
to	  what	  is	  seen	  in	  Cape	  Town	  currently	  and	  hence	  they	  provide	  a	  valid	  source	  for	  
comparison.	  	  In	  Ghon’s	  original	  monograph	  “The	  primary	  lung	  focus	  of	  tuberculosis	  in	  
children”	  he	  reported	  on	  the	  presumed	  primary	  foci	  identified	  in	  26%	  of	  children	  undergoing	  
autopsy	  in	  a	  Vienna	  hospital	  between	  1902	  and	  1910.	  	  Of	  these	  the	  majority	  had	  a	  single	  
focus	  and	  only	  6.4%	  had	  4	  or	  more	  foci	  visible.	  	  These	  lesions	  were	  most	  commonly	  “pea	  
sized”	  (approx.	  5mm),	  calcified	  in	  37%	  and	  located	  peripherally	  in	  in	  94%;	  specifically	  sub-­‐
pleural	  in	  40.5%	  and	  within	  the	  lobar	  fissures	  in	  21.5%.	  	  Lesions	  were	  identified	  within	  the	  
right	  lobe	  more	  commonly	  than	  the	  left	  (55:45)	  with	  lobar	  distribution	  being	  as	  follows:	  RUL-­‐
28.5%,	  RML-­‐7%,	  RLL	  19.5%,	  LUL	  25.0%,	  LLL	  20.0%[107].	  	  In	  a	  survey	  of	  1225	  necropsies,	  
Medlar	  described	  to	  location	  of	  calcified	  primary	  foci	  as	  being	  within	  1	  cm	  of	  pleura	  in	  85%	  
and	  in	  the	  lower	  half	  of	  lungs	  in	  two-­‐thirds	  of	  cases	  with	  only	  12%	  being	  supra-­‐clavicular	  (as	  
described	  in	  greater	  detail	  in	  chapter	  1)[113].	  	  This	  distribution	  of	  presumed	  primary	  TB	  foci;	  
peripheral	  location,	  slight	  right	  lung	  dominance	  with	  no	  lobar	  preference	  but	  greater	  in	  the	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lower	  half	  of	  the	  lung	  is	  repeatedly	  described	  in	  the	  literature.	  	  This	  likely	  reflects	  
preferential	  airflow	  within	  the	  lungs	  related	  to	  airway	  size	  suggesting	  that	  implantation	  of	  
the	  TB	  bacillus	  is	  a	  random	  event[114].	  	  In	  this	  study	  a	  greater	  proportion	  of	  lesions	  were	  
within	  the	  R	  middle	  lobe	  than	  previously	  described.	  	  One	  possible	  explanation	  for	  this	  is	  that	  
a	  number	  of	  lesions	  that	  were	  identified	  within	  the	  inter-­‐lobar	  fissures	  between	  R	  upper	  and	  
middle	  lobes	  and	  R	  middle	  and	  lower	  lobes	  could	  have	  been	  misallocated.	  	  In	  addition	  
although	  17	  nodules	  were	  situated	  within	  the	  RML	  these	  related	  to	  8	  participants	  which	  may	  
have	  slightly	  skewed	  results.	  	  In	  autopsy	  studies	  of	  adults	  a	  greater	  proportion	  have	  been	  
found	  to	  have	  primary	  lesions	  as	  reported	  in	  this	  study	  and	  this	  will	  also	  relate	  to	  force	  of	  
infection[112].	  	  In	  addition	  a	  greater	  proportion	  of	  these	  lesions	  are	  described	  as	  
mineralized.	  The	  finding	  in	  this	  study	  that	  18.3%	  of	  nodules	  are	  mineralized	  is	  likely	  to	  be	  an	  
underestimate	  in	  comparison	  to	  autopsy	  studies.	  	  Entirely	  mineralised	  nodules	  are	  easily	  
detectable	  on	  CT	  as	  such	  lesions	  typically	  will	  have	  a	  density	  of	  >	  100	  Hounsfield	  unit	  (HU).	  	  
However,	  Sweany	  in	  his	  monograph	  “The	  age	  morphology	  of	  primary	  tubercule”	  has	  
described	  that	  calcification	  of	  tubercles	  occurs	  in	  layers	  and	  that	  full	  calcification	  takes	  place	  
over	  a	  period	  of	  years[108].	  	  Partial	  calcification	  of	  this	  nature	  in	  small	  nodules	  would	  be	  
difficult	  to	  detect	  by	  CT	  but	  would	  be	  easily	  detectable	  at	  autopsy	  as	  it	  is	  readily	  palpated.	  	  It	  
is	  also	  likely	  that	  nodules	  smaller	  than	  3mm	  would	  not	  be	  identified	  with	  the	  CT	  imaging	  
protocol	  used	  and	  that	  micronodules	  (<3mm)	  may	  have	  been	  present	  in	  some	  of	  those	  
labelled	  as	  having	  normal	  scans.	  	  It	  is	  also	  very	  difficult	  to	  accurately	  evaluate	  the	  metabolic	  
activity	  of	  sub-­‐centimetre	  nodules;	  only	  3.3%	  of	  discrete	  nodules	  were	  described	  as	  having	  
visible	  FDG	  uptake	  above	  background	  lung	  parenchyma.	  	  However,	  this	  could	  be	  an	  
underestimate	  due	  to	  the	  partial	  volume	  effect	  which	  results	  in	  loss	  of	  apparent	  activity	  in	  
objects	  less	  that	  1cm	  due	  to	  the	  poor	  spatial	  resolution	  of	  the	  FDG-­‐PET	  scan	  and	  spill-­‐over	  of	  
activity	  into	  the	  surrounding	  background	  regions.	  	  Equally,	  activity	  is	  sometimes	  
overestimated	  when	  activity	  form	  surrounding	  structures	  overlay	  the	  region	  of	  interest.	  	  	  
	  
In	  comparison	  to	  the	  discrete	  nodules	  described	  above,	  active	  nodules	  were	  identified	  in	  a	  
single	  participant.	  	  Of	  note	  this	  participant	  was	  Mtb	  culture	  negative	  at	  screening	  and	  Mtb	  
culture	  positive	  (although	  remained	  asymptomatic)	  on	  day	  of	  scan	  48	  days	  later.	  	  The	  time	  
to	  culture	  positivity	  was	  prolonged	  at	  33	  days,	  suggesting	  a	  low	  number	  of	  bacilli	  were	  
transmitted	  from	  airways	  into	  the	  sputum.	  	  The	  nodules	  were	  far	  more	  numerous	  than	  
discrete	  nodules	  described	  above.	  	  Twenty-­‐six	  nodules	  were	  easily	  visible	  on	  the	  scan	  
although	  it	  is	  likely	  that	  total	  number	  was	  in	  excess	  of	  this.	  	  These	  nodules,	  which	  were	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present	  in	  all	  the	  lung	  lobes,	  were	  poorly	  defined	  in	  contrast	  to	  discrete	  nodules	  and	  were	  
significantly	  more	  likely	  to	  have	  a	  centrilobular	  location	  (57.7%	  vs.	  20.3%).	  	  In	  addition,	  all	  
but	  1	  active	  nodule	  disappeared	  following	  TB	  treatment	  in	  contrast	  to	  discrete	  nodules.	  	  The	  
fact	  that	  these	  lesions	  did	  not	  demonstrate	  increased	  FDG	  uptake	  is	  again	  not	  surprising	  due	  
to	  the	  factors	  described	  above.	  	  No	  lesions	  were	  easily	  visible	  within	  liver	  or	  spleen	  in	  this	  
participant,	  which	  may	  be	  due	  to	  the	  limitations	  of	  a	  non-­‐contrast	  CT	  scan.	  	  This	  anatomic	  
distribution	  is	  suggestive	  of	  a	  haematogenous	  dissemination	  of	  TB	  and	  supported	  by	  the	  
observation	  that	  IFNγ	  release	  in	  QFGIT	  increased	  from	  2.58	  to	  >10IU/mL	  between	  screen	  
and	  scan.	  	  It	  is	  therefore	  possible	  that	  this	  participant	  was	  in	  an	  early	  stage	  of	  miliary	  TB.	  	  
Pathology	  would	  have	  been	  likely	  to	  be	  considerably	  more	  advanced	  by	  the	  time	  symptoms	  
appeared	  which	  occurred	  34	  days	  after	  the	  culture	  was	  taken.	  	  It	  is	  not	  immediately	  
apparent	  from	  the	  FDG-­‐PET/CT	  scan	  if	  such	  a	  miliary	  presentation	  was	  as	  a	  result	  of	  recent	  
(re)infection	  or	  following	  focal	  reactivation	  and	  haematogenous	  dissemination.	  	  Of	  note	  
there	  were	  no	  sites	  of	  more	  extensive	  disease	  to	  suggest	  an	  initial	  focal	  site	  of	  reactivation.	  	  
Furthermore	  there	  was	  no	  significant	  mediastinal	  LN	  enlargement/FDG	  avidity,	  which	  might	  
be	  expected	  during	  primary	  dissemination	  of	  infection.	  	  However,	  the	  participant	  did	  report	  
potential	  close	  contact	  with	  TB	  within	  the	  year	  prior	  to	  recruitment.	  	  It	  is	  possible	  there	  may	  
have	  been	  a	  tuberculous	  focus	  with	  the	  vascular	  intima	  as	  the	  source	  of	  haematogenous	  
spread	  which	  may	  not	  have	  been	  easily	  visible	  on	  FDG-­‐PET/CT	  scan	  which	  has	  been	  
suggested	  in	  the	  pathogenesis	  of	  miliary	  TB[123].	  	  	  	  	  	  	  
	  	  
Two	  large	  autopsy	  studies,	  the	  first	  involving	  8800	  consecutive	  autopsies	  conducted	  at	  Cook	  
County	  Hospital,	  USA	  between	  1917	  and	  1928	  and	  a	  second	  involving	  4066	  consecutive	  
autopsies	  conducted	  at	  Boston	  City	  Hospital	  between	  1937	  and	  1941,	  reported	  acute	  miliary	  
tuberculosis	  in	  1.09%	  and	  1.55%	  autopsies	  respectively	  and	  would	  be	  in	  keeping	  with	  the	  
single	  case	  (2.86%)	  found	  in	  this	  study[123,	  233,	  234].	  	  In	  advanced	  HIV	  (especially	  if	  CD4	  
count	  <50/mm3),	  in	  high	  burden	  TB	  settings	  disseminated	  miliary	  TB	  is	  far	  more	  common,	  
however,	  this	  participant’s	  CD4	  count	  was	  802/mm3	  when	  such	  a	  presentation	  would	  be	  no	  
more	  common	  than	  in	  HIV	  uninfected	  persons.	  	  	  	  	  	  	  
	  	  	  	  	  	  	  	  	  
Fibrotic	  scarring	  was	  present	  in	  6	  of	  35	  (20%)	  participants,	  exclusively	  in	  the	  upper	  lobes	  and	  
lung	  infiltration	  in	  6	  of	  35	  participants,	  of	  which	  5	  of	  6	  were	  in	  the	  upper	  lobes.	  	  The	  
presence	  of	  scarring	  was	  significantly	  associated	  with	  a	  concurrent	  active	  disease	  process,	  
which	  was	  present	  in	  4	  of	  6	  participants	  (3	  with	  lung	  infiltration	  and	  1	  with	  mediastinal	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lymphadenitis	  responding	  to	  isoniazid).	  	  In	  all	  9	  of	  35	  participants	  had	  evidence	  of	  upper	  
lobe	  fibrosis	  or	  infiltration	  which	  was	  mainly	  apico-­‐dorsally	  located.	  	  A	  number	  of	  conditions	  
can	  cause	  upper	  lobe	  predominant	  infiltrates	  and	  fibrosis	  globally,	  the	  most	  common	  being	  
tuberculosis,	  sarcoidosis	  and	  histoplasmosis.	  	  As	  stated	  histoplasmosis	  is	  rare	  in	  South	  Africa.	  	  
Sarcoidosis	  commonly	  presents	  with	  bilateral	  disease	  and	  fibrosis	  is	  associated	  with	  late	  
(stage	  IV)	  disease	  by	  which	  time	  symptoms	  are	  invariably	  present.	  	  In	  addition,	  in	  this	  setting	  
sarcoidosis	  is	  very	  much	  less	  common	  than	  TB;	  although	  good	  data	  is	  scarce	  incidence	  may	  
be	  50x	  less	  than	  tuberculosis[235].	  	  This	  pattern	  of	  disease	  arising	  predominantly	  in	  the	  
apico-­‐dorsal	  sections	  of	  the	  lobes	  (upper	  >	  lower)	  is	  characteristic	  for	  tuberculosis	  described	  
in	  both	  autopsy	  and	  imaging	  studies.	  	  Medlar	  described	  findings	  of	  minimal	  tuberculosis	  
suggesting	  that	  they	  were	  apico-­‐dorsal	  located	  in	  75%[113].	  	  Sweany	  reported	  in	  detail	  the	  
location	  of	  primary	  cavities	  in	  204	  patients	  with	  pulmonary	  tuberculosis	  using	  stereoscopic	  
X-­‐ray	  imaging.	  	  He	  concluded	  that	  initial	  cavities	  were	  most	  commonly	  in	  the	  posterior,	  
outer	  parts	  of	  the	  upper	  lobes	  usually	  subapical	  or	  within	  the	  apical	  part	  of	  the	  lower	  
lobe[236].	  	  More	  recently	  Yeh	  et	  al	  performing	  high	  resolution	  (HR)	  CT	  in	  279	  TB	  patients	  at	  
presentation	  to	  hospital	  identified	  that	  consolidation	  was	  most	  common	  in	  the	  s1,	  s2,	  s1/s2	  
and	  s6	  bronchopulmonary	  segments	  and	  cavitation	  in	  the	  s1,	  s2,	  and	  s1/s2	  
bronchopulmonary	  segments.	  	  Furthermore	  they	  showed	  that	  pathology	  located	  in	  these	  
regions	  was	  highly	  predictive	  of	  pulmonary	  TB[237].	  
	  
Infiltrates	  are	  likely	  to	  represent	  endobronchial	  spread	  of	  tuberculosis.	  	  The	  most	  advanced	  
infiltrates	  in	  this	  study	  showed	  evidence	  of	  tree-­‐in-­‐bud	  opacification,	  which	  results	  from	  
bronchioles	  filling	  with	  inflammatory	  exudate.	  	  In	  one	  participant	  a	  clinically	  indicated	  repeat	  
scan	  performed	  1	  month	  after	  the	  initial	  scan	  showed	  retrograde	  endobronchial	  spread	  
down	  what	  was	  likely	  to	  be	  an	  adjacent	  pulmonary	  lobule.	  	  This	  may	  be	  how	  denser	  regions	  
infiltration	  eventually	  arise.	  	  	  	  
	  
Fibrocystic	  scarring	  is	  a	  characteristic	  pathological	  finding	  within	  lung	  tissue	  as	  infiltrates	  and	  
cavities	  related	  to	  active	  tuberculosis	  heal.	  	  This	  occurs	  following	  treatment	  but	  is	  also	  
thought	  to	  occur	  spontaneously	  and	  is	  presumed	  to	  result	  from	  reactivation	  being	  arrested	  
and	  reversed	  following	  a	  shift	  towards	  a	  more	  beneficial	  host	  response	  to	  mycobacterial	  
infection.	  	  Such	  upper	  lobe	  scaring	  in	  persons	  with	  no	  history	  of	  TB	  is	  a	  common	  finding	  in	  
both	  autopsy	  and	  imaging	  studies.	  	  In	  addition,	  in	  the	  pre-­‐chemotherapy	  era	  improvement	  in	  
infiltrates	  was	  commonly	  described	  (as	  outlined	  in	  detail	  in	  chapter	  1).	  	  The	  presence	  of	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fibrotic	  scarring,	  however,	  is	  well	  known	  to	  be	  a	  risk	  factor	  for	  developing	  TB,	  increasing	  risk	  
up	  to	  15	  fold[77].	  	  Stead	  and	  other	  have	  also	  described	  that	  those	  with	  sporadic	  TB	  (i.e.	  not	  a	  
part	  of	  a	  cluster	  or	  outbreak)	  frequently	  had	  evidence	  of	  fibrotic	  apical	  scarring	  within	  the	  
lungs	  on	  previous	  CXR,	  although	  these	  authors	  did	  not	  systematically	  report	  the	  spatial	  
relationship	  of	  old	  scars	  to	  disease	  at	  presentation[79,	  80,	  238].	  	  Results	  in	  this	  study	  
support	  these	  findings	  as	  those	  with	  fibrotic	  scars	  were	  significantly	  more	  likely	  to	  have	  
infiltrates	  and	  more	  likely	  to	  have	  evidence	  of	  active	  disease.	  	  However,	  the	  results	  also	  
show	  that	  disease	  reactivation	  does	  not	  necessarily	  occur	  at	  the	  site	  of	  old	  fibrotic	  scarring	  
as	  has	  previously	  be	  thought	  to	  be	  most	  likely.	  	  This	  idea	  that	  multiple	  independent	  
reactivation	  events	  can	  occur	  is	  also	  supported	  by	  findings	  in	  1	  participant	  who	  had	  3	  
separate	  clusters	  of	  fibrotic	  scars	  within	  both	  the	  right	  and	  left	  upper	  lobe	  showing	  different	  
degrees	  of	  calcification.	  	  This	  is	  also	  supported	  by	  autopsy	  studies	  most	  notably	  in	  Opie	  and	  
Aronson’s	  series	  of	  persons	  dying	  of	  causes	  other	  than	  TB	  where	  fibrotic	  apical	  scarring	  was	  
not	  uncommonly	  bilateral[115].	  	  These	  finding	  suggest	  that	  although	  recrudescence	  at	  the	  
site	  of	  fibrotic	  scarring	  may	  occur,	  a	  proportion	  of	  those	  that	  are	  latently	  infected	  may	  
undergo	  sporadic	  reactivation	  and	  healing	  initiated	  at	  different	  sites	  and	  may	  be	  at	  higher	  
risk	  of	  disease	  occurring	  when	  reactivation	  can	  not	  be	  controlled.	  	  
	  
Those	  with	  upper	  lobe	  infiltration	  were	  significantly	  more	  likely	  to	  have	  abnormal	  FDG	  
uptake	  with	  the	  mediastinal	  nodes.	  	  In	  some	  instances	  this	  may	  have	  been	  a	  manifestation	  
of	  disease	  but	  this	  relationship	  was	  not	  consistent	  as	  neither	  of	  the	  2	  culture	  positive	  
participants	  had	  abnormal	  mediastinal	  lymph	  nodes	  present	  and	  the	  largest	  mediastinal	  
lymph	  nodes	  were	  identified	  in	  2	  participants	  with	  scars	  and	  no	  infiltrates.	  	  It	  is	  possible	  that	  
in	  latently	  infected	  participants	  at	  risk	  of	  reactivation	  Mtb	  is	  more	  regularly	  trafficked	  
between	  the	  site	  of	  reactivation	  and	  regional	  lymph	  nodes	  resulting	  in	  pathological	  
abnormalities	  at	  these	  sites.	  	  	  
	  
Almost	  all	  participants	  had	  abnormal	  FDG	  uptake	  within	  peripheral	  (axillary	  and	  cervical)	  
lymph	  node	  chains	  and	  45.7%	  had	  abnormal	  uptake	  within	  mediastinal	  lymph	  nodes	  and	  a	  
single	  participant	  had	  abnormal	  uptake	  within	  abdominal	  lymph	  nodes.	  	  Uptake,	  at	  least	  
within	  axillary	  lymph	  nodes	  appeared	  to	  reduce	  rapidly	  following	  ART,	  however	  response	  did	  
appear	  to	  lag	  behind	  suppression	  of	  viral	  load.	  	  In	  this	  study	  no	  significant	  relationship	  
between	  lymph	  node	  SUVmax	  and	  viral	  load	  or	  CD4	  count	  was	  identified	  in	  contrast	  to	  
previous	  reports[146],	  but	  in	  keeping	  with	  findings	  by	  Brust	  et	  al[148].	  	  Lelievre	  et	  al	  have	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recently	  shown	  that	  SUVmax	  in	  lymph	  nodes	  of	  HIV	  infected	  persons	  is	  highly	  correlated	  
with	  percentage	  of	  CD4	  and	  CD8	  cells	  expressing	  the	  T	  cell	  activation	  markers	  HLA-­‐DR	  and	  
CD38[239].	  	  Although	  abnormal	  uptake	  within	  central	  lymph	  nodes	  was	  not	  uncommon,	  
uptake	  was	  rarely	  intense	  in	  participants	  without	  scars	  and	  infiltrates	  with	  only	  a	  single	  
participant	  with	  SUVmax	  >	  5.	  	  In	  contrast,	  in	  the	  10	  participants	  with	  evidence	  of	  
reactivation,	  40%	  had	  a	  central	  lymph	  node	  with	  SUVmax	  >	  5.	  	  However,	  it	  is	  unlikely	  that	  a	  
cut	  off	  of	  this	  nature	  would	  entirely	  accurately	  distinguish	  HIV	  related	  uptake	  from	  uptake	  
relating	  to	  TB	  or	  other	  opportunistic	  infections	  as	  2	  of	  the	  4	  participants	  that	  has	  
improvement	  in	  uptake	  within	  the	  mediastinal	  LN	  on	  IPT	  had	  SUV	  max	  <	  5.	  	  This	  suggest	  that	  
although	  TB	  related	  LN	  abnormalities	  may	  be	  more	  likely	  than	  HIV	  related	  LN	  abnormalities	  
to	  result	  in	  high	  FDG	  avidity	  there	  may	  be	  significant	  overlap	  in	  SUVmax.	  
	  
Only	  one	  other	  study	  has	  systematically	  performed	  FDG-­‐PET/CT	  in	  persons	  with	  latent	  TB,	  
though	  the	  scale	  and	  setting	  of	  the	  study	  differed	  (5	  HIV	  uninfected	  participants	  that	  were	  
recent	  contacts	  of	  TB	  in	  USA)[137].	  	  In	  their	  study	  4/5	  participants	  were	  shown	  to	  have	  FDG	  
uptake	  within	  the	  lymph	  node	  of	  which	  3	  responded	  to	  IPT.	  	  Lung	  parenchyma	  was	  not	  
evaluated	  in	  detail	  as	  a	  low	  dose	  CT	  protocol	  was	  used[137].	  	  They	  also	  showed	  a	  very	  strong	  
positive	  correlation	  between	  QFGIT	  TBAg-­‐NIL	  and	  SUVmax.	  	  In	  this	  study	  despite	  HIV	  
infection	  as	  a	  considerable	  confounder,	  the	  proportion	  of	  those	  with	  abnormal	  uptake	  
within	  mediastinal	  LN	  was	  less	  than	  50%	  and	  only	  4/27	  (14.8%)	  showed	  response	  to	  TB	  
treatment	  or	  IPT	  (and	  of	  interest	  there	  was	  a	  strong	  but	  non-­‐significant	  correlation	  of	  QFGIT	  
with	  SUVmax	  in	  LN	  for	  these	  participants).	  	  This	  difference	  between	  the	  studies	  is	  likely	  to	  be	  
due	  to	  the	  recency	  of	  (likely	  primary)	  infection	  in	  the	  study	  by	  Ghesani	  et	  al	  compared	  to	  the	  
remote	  infection	  of	  participants	  in	  this	  study.	  	  In	  the	  early	  stages	  of	  infection,	  trafficking	  to	  
regional	  LN	  is	  clearly	  important	  and	  lymphadenopathy	  visible	  on	  CXR	  is	  common	  in	  children.	  	  
Furthermore	  in	  non-­‐human	  primate	  studies	  there	  is	  often	  considerable	  FDG	  uptake	  within	  
mediastinal	  LN	  following	  infection[240].	  	  As	  infection	  stabilizes,	  activity	  within	  LN	  may	  
reduce.	  	  	  	  
	  
Two	  participants	  had	  deterioration	  following	  IPT	  not	  easily	  attributable	  to	  alternative	  
pathology.	  	  Large	  FDG	  avid	  nodules	  that	  developed	  were	  similar	  in	  both	  participant	  but	  
different	  to	  the	  pattern	  of	  lesions	  seen	  in	  the	  initial	  scans.	  	  In	  one	  participant	  this	  was	  
accompanied	  by	  evidence	  of	  a	  treatment	  response	  within	  the	  mediastinal	  lymph	  nodes.	  	  
Neither	  of	  the	  participants	  developed	  symptoms	  or	  evidence	  of	  progression	  of	  these	  lesions.	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One	  possible	  explanation	  for	  these	  lesions	  would	  be	  that	  they	  represent	  expansion	  and	  
increased	  metabolic	  activity	  in	  micronodules	  not	  visible	  on	  the	  initial	  FDG-­‐PET/CT	  following	  
isoniazid	  monotherapy.	  	  Lin	  et	  al	  have	  used	  FDG-­‐PET/CT	  to	  monitor	  lesion	  dynamics	  in	  
response	  to	  INH,	  RIF	  or	  HRZE	  in	  non-­‐human	  primates	  and	  showed	  that	  treatment	  with	  INH	  in	  
contrast	  to	  other	  regimens	  frequently	  lead	  to	  increases	  in	  FDG	  uptake	  within	  lesions	  after	  2	  
months	  treatment	  even	  within	  lesions	  that	  were	  sterile[140].	  	  This	  may	  be	  due	  to	  an	  INH	  
specific	  effect	  relating	  to	  its	  mechanism	  of	  action.	  	  Disruption	  of	  the	  cell	  wall	  with	  isoniazid	  
has	  been	  shown	  to	  result	  in	  the	  release	  of	  antigenic	  material	  and	  isoniazid	  in	  contrast	  to	  
rifampicin	  containing	  regimen	  leads	  to	  a	  boosting	  of	  mycobacteria	  specific	  immune	  
responses	  during	  treatment,	  which	  may	  result	  in	  increased	  inflammation	  within	  a	  
lesion[241,	  242].	  
	  
Evaluation	  of	  radiologist	  reads	  compared	  to	  CT	  as	  a	  gold	  standard	  were	  revealing.	  	  
Agreement	  between	  the	  radiologists	  categorizing	  images	  into	  active	  TB,	  inactive	  TB	  and	  not	  
consistent	  with	  TB	  was	  slight	  (κ=0.15)	  and	  this	  was	  particularly	  poor	  for	  inactive	  TB	  changes.	  	  
There	  appeared	  to	  be	  2	  patterns	  of	  reading;	  over-­‐reading	  of	  TB	  related	  abnormalities	  
resulting	  in	  a	  high	  sensitivity/low	  specificity	  and	  under-­‐reading	  of	  TB	  related	  abnormalities	  
resulting	  in	  low	  sensitivity/high	  specificity.	  	  With	  regard	  to	  active	  TB	  abnormalities,	  
sensitivity	  was	  generally	  poor	  while	  specificity	  was	  generally	  very	  good	  suggesting	  that	  
readers	  in	  general	  under-­‐read	  for	  active	  TB	  and	  over-­‐read	  for	  inactive	  TB.	  	  Poor	  inter	  and	  
intra	  observer	  variability	  had	  been	  described	  before,	  however,	  this	  is	  the	  first	  study	  in	  which	  
reading	  of	  screening	  CXR	  have	  been	  compared	  to	  a	  gold	  standard	  of	  CT.	  	  Previous	  studies	  
have	  show	  high	  levels	  of	  over	  reading	  and	  under	  reading	  when	  compared	  to	  other	  gold	  
standards	  such	  as	  expert	  consensus	  or	  final	  clinical	  diagnosis[81].	  	  	  	  
	  
One	  of	  the	  limitations	  of	  the	  approach	  taken	  in	  this	  study	  is	  that	  lesions	  considered	  to	  
demonstrate	  evidence	  of	  activity	  relating	  to	  TB	  could	  not	  be	  confirmed	  as	  such.	  	  Observing	  
progression	  to	  disease	  in	  participants	  with	  evidence	  of	  latent	  TB	  infection,	  known	  to	  be	  at	  
high	  risk	  due	  to	  HIV	  infection	  would	  be	  ethically	  inappropriate	  especially	  as	  IPT	  is	  a	  
recommended	  intervention.	  	  In	  this	  study	  repeat	  FDG-­‐PET/CT	  at	  the	  end	  of	  treatment	  was	  
used	  to	  demonstrate	  that	  lesions	  considered	  to	  relate	  to	  TB	  responded	  to	  treatment.	  	  
However,	  loss	  to	  follow-­‐up	  meant	  not	  all	  participants	  received	  a	  repeat	  scan	  (although	  
treatment	  response	  was	  demonstrated	  in	  the	  6/10	  that	  had	  a	  repeat	  scan).	  	  In	  addition,	  as	  
decisions	  on	  clinical	  management	  were	  often	  made	  independent	  of	  the	  study	  and	  in	  the	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participant’s	  best	  interests,	  the	  administered	  interventions	  differed	  with	  regard	  to	  
commencement	  of	  ART	  and	  standard	  TB	  therapy.	  	  Furthermore	  compliance	  with	  medication	  
especially	  IPT	  could	  not	  be	  confirmed	  beyond	  questioning	  and	  pill	  count.	  	  An	  alternative	  
approach	  would	  have	  been	  to	  focus	  on	  participants	  that	  were	  contacts	  of	  DR-­‐TB	  where	  
national	  and	  international	  recommendations	  are	  to	  observe	  rather	  than	  provide	  preventive	  
treatment,	  however	  recruitment	  of	  such	  a	  cohort	  in	  the	  available	  timeframe	  would	  have	  
presented	  challenges	  in	  our	  setting	  where	  case	  notification	  of	  DR-­‐TB	  is	  approximately	  
50/100,000.	  	  Further	  microbiological	  proof	  of	  TB	  could	  have	  been	  sought	  by	  routine	  BAL	  of	  
lesions	  but	  benefit	  to	  participants,	  when	  IPT	  was	  available,	  would	  have	  been	  minimal.	  	  
Confirming	  pathological	  cause	  of	  discrete	  nodules	  is	  essentially	  not	  possible	  as	  invasive	  
biopsy	  in	  this	  context	  is	  not	  appropriate	  or	  ethically	  justifiable	  hence	  aetiology	  can	  only	  be	  
speculative.	  
	  
It	  is	  clear	  that	  HIV	  itself	  can	  cause	  FDG	  uptake	  within	  the	  mediastinal	  LN,	  which	  has	  made	  
interpretation	  activity	  relating	  to	  TB	  within	  the	  mediastinal	  LN	  more	  challenging.	  	  Performing	  
such	  a	  study	  in	  HIV	  uninfected	  persons	  may	  have	  simplified	  interpretation	  however	  it	  is	  
likely	  that	  sample	  size	  to	  identify	  adequate	  numbers	  with	  evidence	  of	  TB	  activity	  would	  have	  
been	  considerably	  larger.	  	  
4.9 Conclusion	  
In	  this	  study	  for	  the	  first	  time	  FDG-­‐PET/CT	  has	  been	  used	  to	  characterise	  pathological	  
changes	  within	  the	  lungs	  in	  asymptomatic	  persons	  with	  evidence	  of	  sensitization	  by	  Mtb	  
living	  in	  a	  setting	  of	  extremely	  high	  burden	  and	  with	  the	  additional	  risk	  factor	  of	  HIV.	  	  A	  
group	  of	  10	  participants	  (28.6%)	  were	  identified	  that	  had	  evidence	  of	  reactivation	  and	  either	  
bronchogenic	  spread	  (in	  the	  form	  of	  infiltrates	  and	  scars)	  or	  haematogenous	  spread	  in	  the	  
form	  of	  active	  nodules.	  	  From	  within	  this	  group	  of	  10	  participants,	  2	  participants	  converted	  
to	  culture	  positive,	  a	  further	  2	  developed	  TB	  symptoms	  and	  a	  further	  3	  had	  a	  pathological	  
response	  to	  IPT	  on	  FDG-­‐PET/CT.	  	  It	  seems	  reasonable	  to	  classify	  this	  group	  of	  participants	  as	  
a	  high-­‐risk	  group	  with	  subclinical	  disease	  in	  contrast	  to	  those	  without	  evidence	  of	  activity	  on	  
FDG-­‐PET/CT	  who	  may	  be	  considered	  at	  lower	  risk	  of	  progression.	  	  In	  subsequent	  chapters	  
this	  categorisation	  of	  subclinical	  TB	  and	  low	  risk	  latent	  TB	  will	  be	  used	  to	  evaluate	  
transcriptional	  and	  immunological	  biomarkers.	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In	  addition	  this	  study	  has	  directly	  compared	  a	  screening	  CXR	  for	  TB	  to	  an	  imaging	  gold	  
standard	  and	  demonstrated	  the	  extent	  of	  reader	  variability	  and	  the	  natural	  tendency	  of	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CHAPTER	  5	  –	  Transcriptional	  profile	  
5.1 Chapter	  5	  introduction	  
The	  host	  response	  to	  active	  pulmonary	  tuberculosis	  has	  local	  as	  well	  as	  systemic	  
manifestations.	  	  This	  response	  is	  influenced	  by	  cytokine	  and	  chemokine	  signals	  generated	  at	  
the	  site	  of	  disease,	  which	  amongst	  other	  things	  lead	  to	  recruitment	  of	  cells	  from	  circulating	  
blood	  into	  the	  lungs.	  	  Several	  studies	  have	  shown	  that	  the	  host	  response	  to	  active	  
pulmonary	  tuberculosis	  results	  in	  a	  distinct	  pattern	  of	  transcript	  abundance	  within	  whole	  
blood[243].	  	  This	  is	  driven	  by	  altered	  gene	  expression	  within	  particular	  cell	  types	  but	  also	  in	  
part	  reflects	  altered	  cellular	  proportions	  in	  circulating	  blood[164].	  	  Components	  of	  this	  active	  
pulmonary	  TB	  transcriptional	  signature	  overlap	  with	  other	  diseases	  while	  other	  components	  
may	  be	  more	  disease	  specific[174].	  	  The	  host	  response,	  and	  thus	  the	  transcriptional	  profile,	  
might	  be	  expected	  to	  evolve	  as	  disease	  progresses	  and	  different	  pathological	  processes	  
become	  prominent.	  	  For	  instance	  tissue	  destruction	  and	  repair	  may	  be	  a	  more	  prominent	  
feature	  later	  in	  the	  disease	  process.	  	  As	  a	  result	  elements	  of	  the	  TB	  transcriptional	  profile	  
maybe	  absent	  during	  the	  early,	  subclinical	  stages	  of	  disease.	  	  In	  addition	  the	  more	  minimal	  
extent	  of	  pathology	  in	  subclinical	  disease	  might	  be	  expected	  to	  register	  a	  “weaker”	  blood	  
transcriptional	  signature	  than	  advanced	  disease.	  	  In	  Southern	  Africa,	  the	  majority	  of	  TB	  
disease	  is	  HIV	  associated	  and	  HIV	  co-­‐infection	  might	  also	  be	  expected	  to	  affect	  the	  blood	  
transcriptional	  profile.	  	  However,	  the	  effect	  of	  HIV	  on	  the	  TB	  transcriptional	  signature	  has	  
not	  been	  closely	  investigated.	  	  
5.2 Chapter	  5	  hypothesis	  
HIV	  infected	  persons	  with	  evidence	  of	  subclinical	  tuberculosis	  on	  FDG-­‐PET/CT	  will	  have	  
components	  of	  an	  active	  TB	  transcriptional	  signature	  not	  present	  in	  those	  without	  evidence	  
of	  subclinical	  tuberculosis	  on	  FDG-­‐PET/CT.	  
5.3 Chapter	  5	  aims	  
To	  determine	  the	  differentially	  expressed	  transcripts	  in	  whole	  blood	  in	  those	  with	  and	  
without	  subclinical	  TB	  and	  in	  comparison	  to	  an	  active	  TB	  control	  group	  and	  to	  evaluate	  the	  
effects	  of	  HIV	  on	  the	  transcriptional	  response	  to	  TB.	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5.3.1 Specific	  chapter	  5	  aims	  
1. To	  characterise	  a	  whole	  blood	  transcriptional	  signature	  for	  HIV	  associated	  active	  TB.	  
2. To	  explore	  the	  similarities	  and	  differences	  in	  the	  transcriptional	  signature	  of	  subclinical	  
and	  active	  TB	  and	  to	  identify	  a	  list	  of	  transcripts	  that	  can	  distinguish	  those	  with	  and	  
without	  subclinical	  TB	  (a	  subclinical	  TB	  signature).	  
3. To	  validate	  this	  subclinical	  TB	  signature	  in	  other	  groups	  of	  patients.	  
4. To	  determine	  the	  biological	  significance	  of	  the	  transcriptional	  signatures	  using	  pathway	  
and	  modular	  analysis.	  
5. To	  determine	  the	  similarities	  and	  differences	  in	  transcriptional	  response	  between	  HIV	  
infection,	  active	  TB	  and	  HIV	  associated	  active	  TB.	  	  
5.4 Chapter	  5	  methods	  
5.4.1 Quality	  control	  and	  raw	  data	  processing	  
The	  quality	  of	  extracted	  RNA	  was	  high	  both	  in	  terms	  of	  purity,	  as	  determined	  by	  260/280	  
ratio	  and	  260/230	  ratio,	  and	  integrity	  as	  determined	  by	  RIN	  (see	  chapter	  2	  methods).	  	  
Sample	  yield	  was	  suboptimal	  for	  only	  one	  sample	  (an	  active	  TB	  control),	  which	  was	  not	  
included	  on	  the	  microarray	  (see	  figure	  5.1).	  	  Primary	  analysis	  to	  evaluate	  the	  transcriptional	  
response	  in	  subclinical	  TB	  was	  carried	  out	  on	  50	  samples,	  the	  35	  participants	  that	  underwent	  
PET/CT	  and	  15	  age,	  sex	  and	  CD4	  matched	  participants	  with	  active	  pulmonary	  tuberculosis.	  	  
Additional	  analysis	  to	  evaluate	  the	  interaction	  of	  TB	  and	  HIV	  on	  the	  whole	  blood	  
transcriptional	  response	  was	  carried	  out	  on	  92	  samples	  (using	  the	  additional	  participants	  
outlined	  in	  section	  5.5).	  	  	  
	  
All	  samples	  fell	  within	  3	  s.d.	  of	  the	  mean	  for	  QC	  parameters	  (see	  chapter	  2	  methods	  and	  
figure	  5.2).	  	  	  Raw	  background	  subtracted	  expression	  data	  was	  pre-­‐processed	  using	  
GeneSpring	  GX	  version	  12.6	  (Agilent).	  	  For	  each	  sample,	  probes	  were	  assigned	  a	  signal	  
intensity	  detection	  p-­‐value	  in	  comparison	  to	  background	  hybridization	  and	  probes	  were	  
assigned	  a	  “present”	  flag	  using	  a	  0.99	  cut	  off.	  	  Raw	  signal	  value	  <1	  were	  then	  set	  to	  a	  
threshold	  of	  1	  and	  all	  values	  were	  Log2	  transformed.	  	  To	  minimise	  technical	  variation,	  each	  
sample	  was	  then	  normalised	  using	  a	  75th	  percentile	  shift	  algorithm	  in	  which	  the	  Log2	  
transformed	  intensity	  value	  corresponding	  to	  the	  75th	  percentile	  was	  subtracted	  from	  Log2	  
transformed	  intensity	  value	  for	  each	  probe	  within	  a	  sample.	  	  Baseline	  transformation	  was	  
then	  carried	  out	  to	  rescale	  intensity	  values	  to	  the	  median	  of	  all	  samples.	  	  Samples	  were	  
visualised	  using	  a	  principal	  component	  analysis	  (PCA)	  plot	  to	  confirm	  no	  outliers.	  	  Five	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samples	  fell	  between	  2	  s.d.	  and	  3	  s.d.	  from	  the	  mean	  for	  at	  least	  1	  QC	  parameter	  and	  these	  
were	  also	  visualised	  on	  PCA	  plot	  to	  ensure	  they	  were	  not	  clustered.	  	  Following	  this	  probes	  
that	  were	  not	  “present”	  in	  at	  least	  10%	  of	  samples	  were	  then	  filtered	  out	  before	  further	  
analysis.	  	  Of	  47231	  transcripts,	  18919	  transcripts	  remained	  after	  filtering	  for	  the	  50	  samples	  
in	  the	  primary	  analysis	  and	  18751	  transcripts	  for	  the	  92	  samples	  in	  the	  additional	  analysis.	  	  
5.4.2 Microarray	  analysis	  
Statistical	  analysis	  of	  microarray	  and	  data	  visualisation	  were	  carried	  out	  in	  GeneSpring	  GX	  
ver.	  12.6	  (Agilent).	  	  For	  supervised	  analysis	  statistical	  filtering	  was	  carried	  out	  by	  moderated	  
t-­‐test	  (for	  pairwise	  comparisons)	  and	  ANOVA	  with	  a	  posthoc	  Tukey	  honest	  significant	  
difference	  (HSD)	  test	  (for	  group	  comparisons).	  	  Benjamini	  Hochberg	  false	  discovery	  rate	  
(FDR)	  multiple	  testing	  correction	  was	  applied	  with	  a	  p(corr)	  cut-­‐off=0.05.	  	  Where	  hierarchical	  
clustering	  was	  used	  to	  visualise	  data,	  Pearson	  Uncentered	  (cosine)	  distance	  metric	  and	  
average	  linkage	  rule	  was	  used.	  	  Pathway	  analysis	  was	  performed	  using	  Ingenuity	  Pathway	  

































































Figure	  5.1	  –	  Graphs	  showing	  quality	  of	  extracted	  RNA:	  RNA	  purity	  was	  determined	  by	  260nm/280nm	  spectral	  absorbance	  
ratio	  (>1.8	  acceptable),	  contamination	  was	  determined	  by	  260nm/230nm	  spectral	  absorbance	  ratio	  (>1.5	  acceptable;	  2-­‐2.2	  
optimal),	  RNA	  integrity	  was	  determined	  by	  RIN	  (>7.0	  acceptable).	  	  For	  RNA	  yield	  >2000mg	  was	  acceptable.	  
Chapter	  5	  –	  Transcriptional	  Profile	  
	   171	  
	  
Figure	  5.2	  –	  Graphs	  of	  QC	  parameters	  for	  microarray.	  	  	  
Showing	  Intensity	  of	  biotinalyted	  probes	  (top),	  Intensity	  of	  house	  keeping	  genes	  (2nd	  graph),	  Intensity	  of	  the	  95th	  percentile	  
(3rd	  graph),	  Intensity	  of	  background	  “empty”	  probes	  (bottom)	  for	  all	  processed	  samples	  
Chapter	  5	  –	  Transcriptional	  Profile	  
	   172	  
Modular	  analysis	  and	  visualisation	  was	  performed	  using	  a	  Module	  Analysis	  Tools	  (for	  
Illumina	  V2,	  V3	  and	  V4)	  program	  (version	  1/6/2011)	  provided	  by	  Damien	  Chaussabel	  at	  the	  
Baylor	  Institute	  for	  Immunological	  Research.	  	  Modules,	  which	  are	  groups	  of	  co-­‐regulated	  	  
transcripts	  derived	  from	  multiple	  datasets	  whose	  function	  is	  inferred	  from	  unbiased	  
literature	  search,	  were	  an	  updated	  version	  of	  those	  that	  have	  been	  used	  in	  a	  number	  of	  
recent	  publications[164,	  174,	  244].	  	  This	  program	  was	  used	  to	  generate	  module	  maps	  which	  
allowed	  for	  visualization	  of	  the	  proportion	  of	  transcripts	  within	  a	  module	  that	  were	  
significantly	  under	  or	  over	  abundant	  in	  comparison	  to	  a	  control	  group.	  	  The	  program	  was	  
also	  used	  generate	  average	  transcript	  abundance	  values	  for	  modules	  which	  were	  then	  
further	  analysed	  using	  Stata	  ver.	  12.1.	  	  From	  the	  260	  modules	  included	  in	  the	  program,	  
analysis	  was	  conducted	  on	  the	  39	  modules	  with	  an	  assigned	  function	  (which	  could	  be	  
grouped	  into	  18	  functional	  categories).	  	  Data	  was	  log	  transformed	  where	  this	  facilitated	  the	  
use	  of	  parametric	  tests	  or	  regression	  analysis	  and	  Bonferroni	  multiple	  testing	  correction	  was	  
used	  to	  adjust	  p-­‐value	  cut	  off	  to	  take	  into	  consideration	  the	  18	  functional	  categories	  in	  the	  
analysis.	  	  	  	  	  	  	  	  	  	  	  	  	  	  
5.4.3 Clinical	  features	  of	  participants	  used	  in	  chapter	  5	  
Of	  the	  35	  asymptomatic,	  ART	  naïve,	  HIV	  infected	  participants	  that	  underwent	  FDG-­‐PET/CT	  
the	  10	  participants	  considered	  to	  have	  evidence	  of	  disease	  activity	  on	  FDG-­‐PET/CT	  
(subclinical	  TB	  –	  see	  chapter	  4)	  were	  the	  primary	  group	  of	  interest.	  	  The	  group	  of	  25	  
participants	  with	  no	  evidence	  of	  disease	  activity	  on	  FDG-­‐PET/CT	  (classified	  as	  “low-­‐risk”	  
latent	  TB	  –	  in	  this	  chapter	  they	  will	  be	  termed	  latent	  TB	  group)	  were	  considered	  as	  TB	  
exposed,	  but	  disease	  free	  controls.	  	  The	  categorization	  of	  participants	  into	  a	  group	  with	  
subclinical	  and	  latent	  TB	  was	  finalised	  prior	  to	  the	  analysis	  of	  microarray	  data.	  	  As	  a	  positive	  
control,	  15	  HIV	  infected,	  ART	  naïve	  patients	  with	  culture	  or	  GeneXpert	  confirmed	  active	  
pulmonary	  TB	  who	  were	  age,	  sex	  and	  CD4	  count	  matched	  were	  included.	  	  Of	  the	  active	  TB	  
controls	  9/15	  were	  sputum	  smear	  positive	  (3+;	  n=	  6,	  scanty	  positive;	  n=3).	  	  
In	  order	  to	  interrogate	  the	  transcriptional	  differences	  between	  HIV	  infection	  and	  active	  TB	  
more	  generally,	  samples	  from	  further	  control	  participants	  were	  included.	  	  
• 15	  HIV	  uninfected	  participants	  with	  no	  symptoms	  of	  TB	  who	  were	  TST	  and	  QFGIT-­‐ve	  
• 14	  HIV	  uninfected	  participants	  with	  TB	  symptoms	  who	  were	  sputum	  culture	  or	  
GeneXpert	  positive	  (10/14	  smear	  positive	  (3+;	  n=4,	  2+;	  n=3,	  1+;	  n=2,	  scanty	  
positive;	  n=1)	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• 15	  HIV	  infected,	  ART	  naïve	  participants	  with	  no	  symptoms	  of	  TB,	  who	  had	  no	  
evidence	  of	  active	  TB	  on	  CXR	  and	  were	  Mtb	  culture	  negative	  if	  able	  to	  produce	  
sputum	  sample	  and	  were	  TST	  and	  QFGIT-­‐ve.	  
• 8	  HIV	  infected	  participants,	  established	  on	  ART	  with	  a	  suppressed	  viral	  load	  and	  no	  
TB	  symptoms,	  who	  had	  no	  evidence	  of	  active	  TB	  on	  CXR	  and	  were	  Mtb	  sputum	  
culture	  negative	  but	  were	  QFGIT	  +ve.	  	  	  
It	  is	  acknowledged	  that	  the	  asymptomatic	  control	  groups	  differ	  by	  QFGIT	  status	  but	  for	  this	  
analysis	  the	  comparison	  of	  active	  TB	  and	  HIV	  was	  of	  primary	  interest.	  In	  addition	  HIV	  
uninfected	  participants	  were	  not	  matched	  for	  sex	  and	  age	  (although	  of	  similar	  ethnicity),	  this	  
is	  acknowledged	  as	  a	  limitation	  (Chapter	  3	  -­‐	  figure	  3.9).	  
5.5 Results	  
5.5.1 Deriving	  a	  transcriptional	  signature	  for	  subclinical	  TB	  
Initially	  unbiased	  hierarchical	  clustering	  without	  statistical	  filtering	  was	  carried	  out	  on	  the	  
18919	  transcripts	  to	  identify	  any	  strong	  patterns	  in	  the	  data	  but	  clustering	  of	  the	  
participants	  by	  TB	  status	  was	  limited.	  	  Volcano	  plots	  of	  the	  18919	  transcripts	  were	  then	  used	  
to	  visualise	  the	  differential	  abundant	  transcripts	  (in	  terms	  of	  significance	  and	  fold	  change	  
(FC))	  using	  a	  moderated	  t-­‐test	  to	  make	  pairwise	  comparisons	  of	  active,	  subclinical	  and	  latent	  
TB	  groups	  (figure	  5.3).	  	  This	  demonstrated	  that	  a	  larger	  number	  of	  transcripts	  were	  
differentially	  abundant	  between	  active	  and	  latent	  TB	  than	  active	  and	  subclinical	  TB	  and	  that	  
a	  smaller	  number	  of	  transcripts	  were	  differentially	  abundant	  between	  subclinical	  and	  latent	  
TB.	  	  Using	  Benjamini	  Hochberg	  FDR	  correction	  to	  control	  for	  potential	  false	  discoveries	  this	  
pattern	  was	  maintained.	  	  However,	  this	  resulted	  in	  no	  transcripts	  being	  identified	  that	  were	  
significantly	  differentially	  abundant	  (p(corr)	  <0.05)	  between	  subclinical	  and	  latent	  TB,	  
although	  2469	  transcripts	  had	  ≥1.25	  fold	  and	  675	  transcripts	  had	  ≥1.5	  fold	  difference	  in	  
expression	  values	  between	  subclinical	  and	  latent	  TB.	  	  	  
	  
In	  order	  to	  identify	  biologically	  relevant	  transcripts	  that	  were	  unlikely	  to	  be	  false	  discoveries	  
that	  differentiated	  subclinical	  and	  latent	  TB,	  and	  to	  identify	  the	  biological	  processes	  that	  
were	  similar	  between	  active	  and	  subclinical	  tuberculosis	  the	  3	  groups	  were	  analysed	  
together.	  	  	  The	  aim	  of	  the	  analysis	  was	  to	  identify	  transcripts	  that	  clustered	  participants	  with	  
active	  and	  subclinical	  TB	  but	  differentiated	  these	  2	  groups	  from	  participants	  with	  latent	  TB.	  	  
First,	  transcripts	  that	  were	  differentially	  abundant	  between	  the	  different	  stages	  of	  TB	  were	  
defined	  by	  statistically	  filtering	  of	  the	  18919	  transcripts	  by	  ANOVA	  using	  Benjamini	  Hochberg	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FDR	  multiple	  testing	  correction	  with	  p(corr)=0.05	  as	  a	  cut	  off.	  	  This	  generated	  2274	  
transcripts	  if	  3	  groups	  (active,	  subclinical	  and	  latent)	  were	  defined	  and	  2573	  transcripts	  if	  4	  
groups	  were	  defined	  (smear	  positive	  active,	  smear	  negative	  active,	  subclinical	  and	  latent).	  	  	  
The	  larger	  group	  of	  transcripts	  was	  favoured,	  as	  it	  may	  have	  contained	  biologically	  important	  
transcripts	  distinguishing	  different	  stages	  of	  disease.	  	  The	  2573	  transcripts	  were	  then	  filtered	  
for	  those	  with	  at	  least	  a	  1.5	  fold	  difference	  in	  expression	  between	  active	  and	  latent	  TB	  to	  
define	  a	  list	  of	  893	  transcripts	  considered	  biologically	  relevant	  to	  active	  TB.	  	  Performing	  
hierarchical	  clustering	  on	  this	  group	  of	  893	  transcripts	  demonstrated	  complete	  clustering	  of	  
active	  TB	  away	  from	  latent	  TB	  and	  2/10	  with	  subclinical	  TB	  clustering	  with	  active	  TB	  (figure	  
5.4).	  	  	  
	  
Clustering	  of	  subclinical	  TB	  with	  active	  TB	  may	  have	  been	  prevented	  by	  transcripts	  related	  to	  
later	  stages	  of	  disease	  and	  that	  expression	  of	  genes	  relevant	  to	  both	  active	  and	  subclinical	  
TB	  may	  be	  expressed	  in	  blood	  at	  a	  lower	  level	  in	  the	  early	  stages	  of	  disease.	  	  Therefore,	  the	  
893	  transcripts	  were	  then	  filtered	  to	  identify	  which	  transcripts	  were	  also	  concordantly	  
differentially	  abundant	  between	  subclinical	  and	  latent	  TB	  using	  increasingly	  stringent	  fold	  
change	  cut	  offs.	  	  This	  was	  achieved	  by	  first	  filtering	  the	  2573	  transcripts	  to	  define	  transcripts	  	  
Active	  vs.	  Latent	   Active	  vs.	  Subclinical	   Subclinical	  vs.	  Latent	  
p	  value	  not	  corrected	  
	  
p	  value	  corrected	  for	  
multiple	  comparisons	  
	  
Figure	  5.3	  –	  Volcano	  plots	  for	  18919	  transcripts	  demonstrating	  differentially	  abundant	  transcripts:	  
Differentially	  abundant	  transcripts	  are	  shown	  in	  red	  as	  having	  p	  value	  ≤0.05	  and	  fold	  change	  ≥	  1.5	  between	  active	  TB	  vs.	  
“low	  risk”	  latent	  TB	  (left	  column),	  active	  TB	  vs.	  subclinical	  TB	  (middle	  column)	  and	  subclinical	  TB	  vs.	  “low	  risk”	  latent	  TB.	  	  In	  
the	  top	  row.	  p-­‐value	  is	  uncorrected	  and	  in	  the	  bottom	  row	  p-­‐value	  is	  corrected	  by	  Benjamini	  Hochberg	  (FDR).	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893	  transcripts	  –	  Active	  vs.	  Latent	  ≥	  1.5	  F.C.	  
	  
	  
2/10	  Subclinical	  cluster	  with	  Active	  
0/25	  Latent	  cluster	  with	  Active	  
	  
639	  transcripts	  -­‐	  Active	  vs.	  Latent	  ≥	  1.5	  F.C.	  	  +	  
Subclinical	  vs.	  Latent	  ≥	  1	  
	  
4/10	  Subclinical	  cluster	  with	  Active	  
0/25	  Latent	  cluster	  with	  Active	  
	  
203	  transcripts	  -­‐	  Active	  vs.	  Latent	  ≥	  1.5	  F.C.	  	  +	  
Subclinical	  vs.	  Latent	  ≥	  1.25	  F.C.	  
	  
6/10	  Subclinical	  cluster	  with	  Active	  
3/25	  Latent	  cluster	  with	  Active	  
	  
82	  transcripts	  -­‐	  Active	  vs.	  Latent	  ≥	  1.5	  F.C.	  	  +	  
Subclinical	  vs.	  Latent	  ≥	  1.5	  F.C.	  
	  
8/10	  Subclinical	  cluster	  with	  Active	  
4/25	  Latent	  cluster	  with	  Active	  
	  
Figure	  	  5.4	  –	  Heatmaps	  showing	  hierarchical	  clustering	  of	  individual	  participants	  for	  the	  893,	  639,	  203	  and	  82	  transcript	  lists.	  	  
	  Active	  TB	  (Red),	  Latent	  TB	  (Blue),	  Subclinical	  TB	  (Orange	  –	  Upper	  lobe	  reactivation,	  Pink	  –	  miliary	  pattern)	  	  
Normalised	  values	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that	  were	  at	  least	  1	  fold,	  1.25	  fold	  or	  1.5	  fold	  over	  and	  under	  abundant	  between	  subclinical	  
and	  latent	  TB	  and	  then	  identifying	  the	  common	  over	  and	  under	  abundant	  transcripts	  in	  the	  
893	  transcripts	  list.	  	  Filtering	  the	  893	  transcripts,	  which	  differentiated	  active	  and	  latent	  TB,	  in	  
this	  sequential	  manner,	  resulted	  in	  stepwise	  improvement	  in	  clustering	  of	  subclinical	  with	  
active	  TB	  while	  maintaining	  good	  differentiation	  from	  latent	  TB	  (figures	  5.4	  and	  5.5).	  	  
Filtering	  at	  ≥1	  FC	  reduced	  transcripts	  to	  639	  and	  increased	  clustering	  of	  subclinical	  TB	  with	  
active	  TB	  to	  4	  out	  of	  10.	  	  Further	  filtering	  at	  ≥1.25	  FC	  reduced	  transcripts	  to	  203	  and	  
improved	  clustering	  of	  subclinical	  with	  active	  TB	  to	  6	  of	  10	  and	  3	  of	  25	  with	  latent	  clustered	  
with	  active	  TB.	  	  Finally	  filtering	  at	  ≥1.5	  FC	  differential	  abundance	  between	  subclinical	  and	  
latent	  TB	  reduced	  transcripts	  to	  82	  and	  increased	  clustering	  of	  subclinical	  with	  active	  TB	  to	  
8/10	  and	  latent	  with	  active	  TB	  to	  4/25	  (figure	  5.4).	  	  Of	  note	  the	  participant	  with	  the	  miliary	  
pattern	  of	  disease	  did	  not	  cluster	  with	  active	  TB	  and	  the	  only	  participant	  with	  an	  upper	  lobe	  
reactivation	  pattern	  not	  to	  cluster	  with	  active	  TB	  had	  the	  smallest	  infiltrate	  with	  only	  slight	  
20.86%	   22.08%	  
203	  Transcripts	   82	  Transcripts	  
14.93%	   17.73%	  
893	  Transcripts	   639	  Transcripts	  
Figure	  5.5	  –	  PCA	  plots	  showing	  separation	  of	  subclinical	  and	  latent	  TB	  participants	  for	  the	  893,	  639,	  203	  and	  82	  transcript	  lists.	  	  	  
Subclinical	  (orange)	  Latent	  (blue)	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FDG	  uptake	  (Chapter	  4-­‐	  figure	  4.5D).	  	  The	  4	  participants	  categorized	  as	  latent	  but	  clustering	  
with	  active,	  were	  not	  distinguished	  by	  in	  any	  way	  with	  regard	  to	  HIV	  VL,	  CD4	  count,	  QFGIT	  or	  
lung	  or	  mediastinal	  LN	  abnormalities.	  	  One	  of	  the	  4	  had	  an	  FDG	  avid	  breast	  lesion,	  which	  at	  
biopsy	  was	  determined	  to	  be	  benign,	  xanthalamatous,	  granulomatous	  inflammation.	  	  	  	  
Next,	  in	  order	  to	  confirm	  that	  these	  transcripts	  effectively	  distinguished	  subclinical	  and	  
latent	  tuberculosis	  in	  the	  absence	  of	  active	  TB	  influencing	  hierarchical	  clustering,	  PCA	  was	  
performed	  on	  the	  subclinical	  and	  latent	  group	  alone	  using	  the	  893,	  639,	  203	  and	  82-­‐
transcripts.	  	  Even	  with	  the	  893	  transcripts,	  derived	  as	  a	  signature	  of	  active	  TB,	  the	  tendency	  
for	  subclinical	  and	  latent	  TB	  to	  cluster	  separately	  was	  apparent,	  albeit	  with	  considerable	  
overlap.	  	  Clustering	  improved	  as	  transcript	  numbers	  reduced	  and	  separation	  of	  subclinical	  
and	  latent	  was	  very	  clear	  using	  the	  82-­‐transcripts	  (figure	  5.5).	  	  	  	  	  	  
	  
To	  further	  investigate	  the	  effect	  of	  FDG	  uptake	  on	  this	  signature,	  participants	  with	  
subclinical	  TB	  were	  classified	  into	  5	  participants	  showing	  intense	  FDG	  uptake	  (VS	  >3)	  within	  
lung	  parenchyma	  or	  lymph	  nodes	  considered	  to	  be	  related	  to	  TB	  and	  5	  participants	  who	  did	  
not	  show	  intense	  FDG	  uptake	  on	  PET/CT	  (Visual	  score	  0-­‐2)	  (chapter	  4	  -­‐	  table	  4.2).	  	  
Performing	  group-­‐wise	  hierarchical	  clustering	  using	  the	  82-­‐transcripts	  for	  these	  4	  groups	  of	  
participants	  (latent,	  active,	  subclinical	  (low	  FDG	  uptake)	  and	  subclinical	  (high	  FDG	  uptake))	  
demonstrated	  that	  the	  group	  of	  subclinical	  participants	  with	  high	  uptake	  clustered	  more	  
closely	  with	  active	  TB	  participants	  than	  those	  with	  low	  FDG	  uptake.	  	  PCA	  analysis	  also	  
confirmed	  that	  those	  with	  greater	  metabolic	  activity	  within	  regions	  of	  interest	  were	  more	  
distinct	  from	  those	  with	  latent	  TB	  (figure	  5.6)	  
32.45%	  
Figure	  5.6	  –	  Hierarchical	  clustering	  and	  PCA	  plot	  for	  82	  transcript	  signature	  by	  degree	  of	  disease	  activity.	  
	  Left:	  Hierarchical	  clustering	  of	  groups	  of	  participants	  with	  subclinical	  group	  separated	  by	  visual	  score	  intensity	  of	  FDG	  
uptake.	  	  Right:	  PCA	  plot	  for	  82	  transcripts	  showing	  individual	  participants.	  Active	  (red),	  Subclinical	  VS	  =	  3	  (orange),	  
Subclinical	  VS	  0-­‐2	  (yellow),	  Latent	  (blue)	  	  	  	  
82	  Transcripts	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Figure	  5.7	  –	  Hierarchical	  clustering	  of	  HIV	  uninfected	  controls	  with	  and	  without	  active	  TB	  using	  82	  transcripts	  (left)	  and	  203	  
transcripts	  (right):	  	  





Figure	  5.8	  –	  Hierarchical	  clustering	  using	  the	  82	  transcripts	  and	  203	  transcripts	  on	  a	  dataset	  participants	  with	  TB	  and	  other	  
diseases	  from	  Bloom	  et	  al	  [	  	  ].	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5.5.1.1 Validation	  of	  signature	  in	  other	  participants	  
The	  82-­‐transcripts,	  and	  to	  a	  lesser	  extent	  203-­‐transcripts,	  derived	  from	  the	  893	  transcript	  
signature	  for	  active	  TB	  were	  effective	  at	  distinguishing	  subclinical	  TB	  particularly	  in	  those	  
with	  evidence	  of	  upper	  lobe	  reactivation.	  	  To	  confirm	  that	  these	  transcripts	  were	  able	  to	  
identify	  TB	  independently	  of	  HIV	  they	  were	  applied	  to	  the	  14	  HIV	  uninfected	  controls	  with	  
active	  pulmonary	  TB	  and	  the	  15	  that	  were	  HIV	  uninfected	  and	  TST/IGRA	  negative.	  	  
Hierarchical	  clustering	  demonstrated	  that	  both	  the	  82	  and	  203	  transcript	  signatures	  were	  
effective	  at	  distinguishing	  HIV	  uninfected	  persons	  with	  and	  without	  TB.	  	  Only	  1	  participant	  
with	  active	  TB	  and	  1	  with	  no	  TB	  clustering	  incorrectly	  with	  the	  82	  transcripts	  and	  2	  
participants	  with	  active	  TB	  and	  1	  with	  no	  TB	  clustering	  incorrectly	  with	  the	  203	  transcripts	  
(figure	  5.7).	  	  To	  establish	  if	  these	  transcripts	  were	  specific	  to	  TB	  in	  comparison	  with	  other	  
diseases.	  	  A	  dataset	  of	  normalised	  expression	  values	  from	  HIV	  uninfected	  participants	  with	  
TB	  and	  a	  number	  of	  control	  diseases	  from	  the	  Bloom	  et	  al	  study	  (2013)	  was	  downloaded	  
from	  Gene	  Expression	  Omnibus	  (GEO	  -­‐	  http://www.ncbi.nlm.nih.gov/geo/)	  [174].	  	  The	  
participant	  diagnoses	  in	  this	  dataset	  were	  active	  TB	  (n=11),	  pneumonia	  (n=6),	  lung	  cancer	  
(n=8),	  inactive	  sarcoid	  (n=9),	  active	  sarcoid	  (n=16)	  and	  healthy	  controls	  (n=52).	  	  Performing	  
hierarchical	  clustering	  with	  the	  82	  and	  203	  transcripts,	  both	  were	  effective	  at	  clustering	  TB	  
from	  other	  diseases,	  although	  active	  sarcoidosis	  had	  a	  tendency	  to	  cluster	  with	  active	  TB	  
particularly	  with	  the	  82	  transcripts	  (figure	  5.8).	  	  The	  203	  transcripts	  performed	  particularly	  
well	  with	  10/11	  participants	  with	  active	  TB	  clustering	  together	  with	  only	  3/16	  with	  active	  
sarcoid	  and	  1/8	  with	  lung	  cancer.	  	  
5.5.1.2 Comparison	  to	  other	  signatures	  
The	  203	  and	  82	  transcript	  signatures	  that	  were	  found	  to	  be	  more	  specific	  to	  subclinical	  TB	  
were	  compared	  to	  3	  other	  available	  active	  TB	  transcript	  signatures	  to	  assess	  the	  proportion	  
of	  transcripts	  that	  were	  in	  common	  (393	  transcript	  signature	  from	  Berry	  et	  al	  2010[164],	  664	  
transcript	  signature	  from	  Bloom	  et	  al	  2012[165],	  1446	  transcript	  signature	  from	  Bloom	  et	  al	  
2013[174]).	  	  34%	  of	  transcripts	  from	  the	  203	  transcript	  list	  and	  27%	  of	  transcripts	  from	  the	  
82	  transcript	  list	  were	  present	  in	  at	  least	  one	  of	  the	  other	  published	  TB	  signature	  (figure	  5.9).	  	  
14%	  of	  transcripts	  in	  the	  203	  transcript	  list	  and	  10%	  of	  transcripts	  in	  the	  82	  transcript	  list	  
were	  present	  in	  all	  of	  the	  TB	  signatures.	  	  Kaforou	  et	  al	  have	  recently	  derived	  a	  considerably	  
smaller	  list	  of	  27	  transcripts	  sensitive	  for	  the	  detection	  of	  TB	  in	  a	  diverse	  population	  of	  mixed	  
HIV	  status[171].	  37%	  of	  these	  transcripts	  were	  present	  in	  the	  203	  transcript	  list	  and	  7%	  in	  
the	  82	  transcript	  list.	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Berry	  et	  al	  Nature	  2010	  
393	  signature	  (387)	  
Bloom	  et	  al	  PLOS	  ONE	  2012	  
664	  signature	  
Bloom	  et	  al	  PLOS	  ONE	  2013	  
1446	  signature	  
203	  transcripts	  
Berry	  et	  al	  Nature	  2010	  
393	  signature	  (387)	  
Bloom	  et	  al	  PLOS	  ONE	  2012	  
664	  signature	  
Bloom	  et	  al	  PLOS	  ONE	  2013	  
1446	  signature	  
82	  transcripts	  
Fig	  5.9	  –	  Common	  transcripts	  between	  the	  203	  and	  82	  transcript	  signatures	  with	  3	  other	  published	  active	  TB	  signatures.	  
	  Berry	  et	  al	  (Nature	  2010)	  393	  transcript	  signature	  (only	  387	  transcripts	  compared	  due	  to	  microarray	  platform	  differences),	  Bloom	  
et	  al	  (PLOSONE	  2012)	  664	  transcript	  signature,	  Bloom	  et	  al	  (PLOSONE	  2013)	  1446	  transcript.	  	  Common	  transcripts	  outlined	  in	  
yellow	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Percentage	  of	  transcripts	  in	  modules	  significantly	  overexpressed	  (p<0.05)	  
Percentage	  of	  transcripts	  in	  modules	  significantly	  underexpressed	  (p<0.05)	  
	  Figure	  5.10	  –	  Module	  map	  showing	  significantly	  over	  and	  underabundant	  transcripts	  in	  active	  and	  subclinical	  TB	  
compared	  to	  latent	  TB.	  	  
Red	  dots	  represent	  significant	  overexpression	  of	  module	  and	  blue	  dots	  represent	  significant	  underexpression	  of	  module	  
compared	  to	  control	  group	  (latent	  TB).	  	  Intensity	  corresponds	  to	  percentage	  of	  transcripts	  significantly	  under	  or	  over	  
expressed	  within	  a	  module	  compared	  to	  control	  group.	  	  	  
Chapter	  5	  –	  Transcriptional	  Profile	  
	   182	  
5.5.1.3 Biological	  processes	  represented	  in	  the	  subclinical	  TB	  signature	  
First,	  in	  order	  to	  gain	  an	  visual	  overview	  of	  how	  the	  functional	  components	  of	  the	  
transcriptional	  response	  varied	  at	  the	  different	  stages	  of	  HIV	  associated	  tuberculosis,	  a	  
modular	  analysis	  of	  the	  18919	  transcripts	  (significantly	  detected	  compared	  to	  background	  
hybridization	  in	  at	  least	  10%	  of	  the	  50	  samples)	  was	  undertaken	  using	  the	  “low	  risk”	  latent	  
TB	  as	  the	  control	  group.	  	  Those	  with	  3+	  smear	  positive	  active	  TB	  had	  the	  most	  significant	  
differences	  in	  modular	  expression	  when	  compared	  to	  latent	  TB.	  	  A	  significant	  decrease	  in	  
abundance	  of	  B	  cell	  and	  T	  cell	  transcripts	  was	  apparent	  as	  well	  as	  increased	  abundance	  of	  
transcripts	  in	  interferon,	  inflammation,	  cytotoxic,	  cell	  death,	  dendritic	  cells/apoptosis	  and	  
neutrophil	  modules.	  	  This	  pattern	  of	  modular	  response	  is	  very	  similar	  to	  that	  previously	  
described	  in	  tuberculosis[174].	  	  This	  modular	  signature	  was	  much	  less	  obvious	  in	  
participants	  with	  scanty	  smear	  positive	  and	  smear	  negative	  tuberculosis	  and	  in	  subclinical	  
TB,	  few	  modules	  had	  significant	  differences	  in	  modular	  expression	  when	  compared	  to	  the	  
latent	  TB	  controls	  (figure	  5.10).	  	  	  
	  
IPA	  Ingenuity	  software	  was	  then	  used	  to	  further	  explore	  which	  biological	  processes	  were	  
common	  to	  and	  which	  distinguished	  between	  subclinical	  TB	  and	  later	  stages	  of	  tuberculosis.	  
Analysis	  was	  performed	  on	  the	  4	  transcript	  signatures	  (893,	  639,	  203	  and	  82),	  which	  were	  
progressively	  more	  specific	  to	  subclinical	  TB,	  to	  identify	  pathways	  which	  were	  significantly	  
over	  represented	  in	  these	  transcripts.	  	  The	  complement	  system	  was	  the	  most	  significantly	  
over	  represent	  pathway	  for	  over	  abundant	  transcripts	  all	  4	  signature	  (figure	  5.11a).	  	  The	  
components	  of	  the	  complement	  system	  showing	  overabundance	  related	  to	  the	  classical	  
pathway,	  which	  is	  most	  commonly	  initiated	  by	  C1q	  binding	  of	  the	  Fc	  portion	  of	  antibodies	  in	  
immune	  complexes.	  	  Complement	  component	  1,	  q	  subcomponent,	  B	  chain	  (C1QB),	  
complement	  component	  2	  (C2),	  complement	  component	  5	  (C5)	  and	  serpin	  peptidase	  
inhibitor,	  clade	  G	  (C1	  inhibitor),	  member	  1	  (SERPING1)	  all	  showed	  increased	  expression	  in	  
those	  with	  subclinical	  TB	  and	  active	  TB	  compared	  with	  latent	  TB	  (figure	  5.12).	  	  Acute	  phase	  
response	  signalling	  also	  remained	  prominent	  but	  represented	  a	  number	  of	  pathways	  with	  
complement	  components	  also	  forming	  part	  of	  this.	  	  Of	  note	  transcripts	  relating	  to	  the	  Fc	  
fragment	  of	  IgG,	  high	  affinity	  Ia/b/c	  receptor	  (CD64)	  (FCGR1A/B/C)	  were	  also	  over	  abundant	  
in	  subclinical	  and	  later	  stages	  of	  disease	  compared	  with	  latent	  TB,	  being	  present	  on	  all	  4	  
transcript	  lists.	  	  FCGR1A,	  FCGR1B	  and	  FCGR1C	  were	  all	  over	  abundant	  in	  subclinical	  
compared	  to	  latent	  TB	  (+1.36FC,	  +1.38FC	  and	  +1.58FC	  respectively)	  and	  in	  active	  compared	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Figure	  5.11a	  –	  IPA	  ingenuity	  pathway	  analysis	  for	  transcripts	  overabundant	  in	  subclinical	  TB	  compared	  to	  latent	  TB.	  	  	  
Maximum	  of	  top	  6	  pathways	  showing	  significance	  (p≤0.05	  (log(p-­‐value)>1.30)	  ,	  Fisher’s	  exact)	  with	  at	  least	  2	  transcripts	  in	  
pathway.	  	  Blue	  bar	  =	  –log(p-­‐value),	  yellow	  squares	  =	  ratio	  (proportion	  of	  pathway	  overabundant)	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Figure	  5.11b	  –	  IPA	  ingenuity	  pathway	  analysis	  for	  transcripts	  underabundant	  in	  subclinical	  TB	  compared	  to	  latent	  TB.	  
	  	  Maximum	  of	  top	  6	  pathways	  showing	  significance	  (p≤0.05	  (log(p-­‐value)>1.30)	  ,	  Fisher’s	  exact)	  with	  at	  least	  2	  transcripts	  
in	  pathway.	  	  Blue	  bar	  =	  –log(p-­‐value),	  yellow	  squares	  =	  ratio	  (proportion	  of	  pathway	  underabundant).	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Figure	  5.12	  –	  Complement	  pathway	  showing	  components	  overabundant	  in	  subclinical	  and	  active	  compared	  to	  latent	  TB.	  
Overabundant	  components	  (pink),	  FC	  active	  vs.	  latent	  (red	  text)	  and	  FC	  subclinical	  vs.	  latent	  (brown	  text)	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to	  latent	  TB	  (+2.66FC,	  +2.32FC	  and	  +2.67FC	  respectively).	  	  As	  Fcγ	  receptor	  1	  is	  found	  on	  the	  
surface	  of	  cells	  and	  binds	  the	  Fc	  portion	  of	  antibodies	  in	  immune	  complexes	  this	  again	  
suggested	  the	  potential	  significance	  of	  immune	  complexes	  in	  subclinical	  and	  active	  TB.	  	  The	  
only	  cytokines	  and	  chemokines	  that	  were	  overabundant	  in	  subclinical	  and	  active	  TB	  were	  
CXCL17	  and	  CCL23,	  which	  are	  both	  known	  to	  relate	  to	  pulmonary	  pathology.	  	  Interferon	  
signalling	  pathways	  were	  prominent	  in	  the	  893	  and	  639	  transcript	  lists	  but	  not	  in	  the	  203	  list	  
of	  transcripts	  which	  showed	  at	  least	  1.25	  fold	  change	  between	  latent	  and	  subclinical	  TB.	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
To	  evaluate	  the	  biological	  processes	  that	  may	  have	  been	  more	  specific	  to	  later	  stages	  of	  
disease	  and	  less	  relevant	  in	  subclinical	  TB,	  the	  254	  transcripts	  that	  were	  initially	  filtered	  from	  
the	  893	  TB	  signature	  were	  examined	  in	  greater	  detail.	  	  The	  6	  filtered	  transcripts	  with	  the	  
greatest	  overabundance	  in	  active	  TB	  all	  related	  to	  neutrophils;	  human	  neutrophil	  peptide	  4	  
(α-­‐defensin	  4(DEFA4)),	  DEFA1,	  neutrophil	  expressed	  elastase	  (ELANE),	  cathepsin	  G	  (CSTG),	  
carcinoembryonic	  antigen-­‐related	  cell	  adhesion	  molecule	  6	  (CEACAM6)	  and	  CEACAM8.	  	  To	  
further	  evaluate	  this,	  the	  modular	  composition	  of	  the	  893	  and	  639	  transcripts	  was	  assessed.	  	  
Although	  the	  latter	  list	  of	  transcripts	  represented	  71.5%	  of	  the	  former,	  the	  reduction	  was	  
not	  equal	  across	  the	  modules	  (figure	  5.13).	  	  A	  significantly	  smaller	  proportion	  of	  transcripts	  
in	  the	  639	  list	  were	  neutrophil	  and	  platelet	  related	  compared	  to	  the	  893	  list	  	  (p=0.011	  and	  
p=0.0001	  respectively).	  	  54%	  of	  transcripts	  in	  the	  neutrophil	  related	  module	  (M5.15)	  and	  
24%	  in	  the	  platelet	  related	  module	  were	  present	  in	  the	  893	  transcript	  list	  whereas	  in	  the	  639	  
transcript	  list	  only	  4%	  and	  1%	  respectively	  were	  present.	  	  
	  
To	  evaluate	  whether	  the	  difference	  in	  neutrophil	  and	  platelet	  modules	  could	  have	  related	  to	  
differences	  in	  cell	  counts	  between	  the	  groups,	  the	  relationship	  between	  cell	  counts	  and	  
modular	  expression	  values	  was	  explored	  for	  participants	  and	  controls	  where	  these	  results	  
were	  available	  (platelet	  count	  n=38,	  neutrophil	  count	  n=26).	  	  There	  was	  a	  highly	  significant	  
positive	  correlation	  between	  platelet	  count	  and	  expression	  of	  the	  platelet	  module	  (M1.1),	  r	  
=	  0.51	  (p=0.0009)	  suggesting	  that	  in	  part	  differences	  in	  platelet	  module	  expression	  between	  
active	  and	  subclinical	  TB	  might	  be	  explained	  by	  differences	  in	  platelet	  count.	  	  However,	  
there	  was	  no	  significant	  correlation	  between	  percentage	  of	  white	  blood	  cells	  that	  were	  
neutrophils	  (nor	  for	  absolute	  neutrophil	  count)	  and	  expression	  of	  the	  neutrophil	  module,	  r	  =	  
0.11	  (p=0.6),	  suggesting	  that	  differences	  in	  neutrophil	  module	  expression	  between	  active	  
and	  subclinical	  TB	  were	  unlikely	  to	  be	  relate	  to	  simple	  differences	  in	  neutrophil	  count	  but	  
rather	  genes	  being	  expressed	  by	  these	  cells.	  	  In	  order	  to	  further	  evaluate	  if	  the	  abundance	  of	  
neutrophil	  related	  transcripts	  related	  to	  the	  stage	  of	  disease,	  the	  expression	  of	  the	  21	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Modular	  distribution	  of	  893	  and	  639	  transcript	  signatures	  	  
Correlation	  of	  neutrophil	  proportion	  in	  WBC	  with	  expression	  in	  	  
neutrophil	  module	  	  
Correlation	  of	  platelet	  count	  with	  expression	  in	  platelet	  module	  	  
Fig	  5.13	  –	  Expression	  of	  neutrophil	  and	  platelet	  modules	  and	  correlation	  with	  cell	  counts.	  
	  
(Top)	  Graph	  showing	  the	  difference	  in	  modular	  distribution	  for	  the	  839	  and	  639	  transcript	  lists.	  
(Middle)	  Showing	  correlation	  of	  proportion	  of	  neutrophils	  in	  white	  blood	  cells	  (WCC)	  with	  expression	  in	  neutrophil	  module	  
(n=26).	  
(Bottom)	  Showing	  correlation	  of	  platelets	  count	  with	  expression	  in	  platelet	  module	  (n=38).	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transcripts	  of	  the	  neutrophil	  module	  (M5.15)	  that	  were	  present	  in	  the	  18919	  transcript	  list	  
was	  compared	  for	  different	  stages	  of	  TB	  disease.	  	  Expression	  in	  the	  neutrophil	  module	  was	  
significantly	  higher	  in	  smear	  positive	  compared	  to	  smear	  negative	  TB	  (p≤0.001)	  (with	  
expression	  of	  all	  21	  transcripts	  being	  greater	  in	  smear	  positive	  disease)	  and	  also	  smear	  
negative	  compared	  to	  subclinical	  TB	  (p≤0.001).	  	  However,	  there	  was	  no	  significant	  difference	  
in	  expression	  of	  the	  neutrophil	  module	  between	  subclinical	  TB	  and	  latent	  TB.	  	  
	  
IPA	  Pathway	  analysis	  of	  the	  436	  transcripts	  filtered	  from	  the	  639	  transcripts	  to	  generate	  the	  
203	  transcript	  list	  demonstrated	  that	  the	  most	  prominent	  pathway	  lost	  related	  to	  Interferon	  
signalling.	  	  However,	  expression	  within	  the	  interferon	  modules	  was	  still	  present	  in	  the	  203	  
list	  of	  transcripts	  with	  8.3%	  of	  transcripts	  forming	  part	  of	  one	  of	  the	  3	  interferon	  modules.	  	  	  
This	  suggested	  that	  while	  there	  was	  differential	  expression	  in	  interferon	  induced	  transcripts	  
between	  subclinical	  and	  latent	  TB	  it	  may	  not	  have	  been	  a	  may	  contribute	  to	  discriminating	  
these	  conditions.	  	  	  	  	  	  	  
5.5.2 HIV	  TB	  interaction	  in	  whole	  blood	  gene	  expression	  	  
Genes	  related	  to	  interferon	  signalling	  have	  previously	  been	  demonstrated	  to	  be	  prominently	  
overabundant	  in	  active	  TB.	  However,	  being	  an	  intracellular	  viral	  infection,	  HIV	  also	  induces	  
an	  interferon	  response	  and	  so	  interaction	  between	  TB	  and	  HIV	  on	  the	  whole	  blood	  
transcriptional	  signature	  was	  further	  assessed.	  	  A	  modular	  analysis	  was	  performed	  on	  92	  HIV	  
infected	  and	  uninfected	  participants	  with	  and	  without	  active	  TB.	  	  Participants	  with	  
subclinical	  TB	  were	  excluded	  from	  the	  analysis	  so	  the	  independent	  effects	  of	  HIV	  and	  TB	  on	  
transcriptional	  response	  could	  be	  assessed.	  	  HIV	  uninfected	  participants	  with	  no	  evidence	  of	  
active	  TB	  were	  used	  as	  the	  control	  group.	  	  The	  18751	  transcripts	  that	  were	  significantly	  
detected	  compared	  to	  background	  hybridization	  in	  at	  least	  10%	  of	  the	  92	  samples	  were	  used	  
for	  the	  modular	  analysis	  (table	  5.1,	  fig	  5.14,	  fig	  5.15).	  	  In	  comparison	  to	  healthy	  HIV	  
uninfected	  controls	  (n=15)	  those	  with	  HIV	  but	  no	  evidence	  of	  TB	  disease	  activity	  (n=40),	  
exhibited	  significantly	  lower	  abundance	  in	  the	  T	  cell	  related	  module	  after	  Bonferroni	  
correction	  for	  multiple	  comparisons	  (p=0.0019).	  	  This	  may	  have	  in	  part	  related	  to	  the	  
reduced	  circulating	  CD4	  cells	  in	  the	  HIV	  infected	  participants.	  	  However	  they	  had	  significantly	  
higher	  abundance	  in	  transcripts	  of	  interferon	  related	  modules	  (p≤0.0002)	  as	  well	  as	  modules	  
relating	  to	  cell	  cycle	  (p=0.0021),	  cytotoxic/NK	  cells	  (p=0.0022)	  and	  immune	  responses	  
(p=0.0001).	  	  Transcript	  abundance	  in	  all	  these	  modules	  normalised	  in	  HIV	  infected	  
participants	  taking	  ART	  (n=8)	  with	  suppressed	  viral	  load	  but	  comparable	  CD4	  count.	  	  HIV	  
infected	  participants	  on	  ART	  only	  had	  reduced	  abundance	  in	  a	  mitochondrial	  respiration	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   Table	  5.1.	  Median	  modular	  abundance	  values	  by	  clinical	  group:	  	  Values	  significantly	  different	  from	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Figure	  5.14.	  	  	  Module	  map	  showing	  significantly	  over	  and	  underabundant	  transcripts	  in	  HIV,	  TB	  and	  HIV/TB	  participants	  
compared	  to	  health	  HIV	  uninfected	  controls.	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module	  in	  comparison	  to	  HIV	  uninfected	  controls	  (p=0.0019),	  although	  sample	  size	  was	  
small	  for	  this	  group.	  	  Those	  that	  were	  HIV	  uninfected	  with	  active	  TB	  (n=14)	  also	  had	  
significantly	  lower	  transcript	  abundance	  in	  the	  T	  cell	  related	  module	  in	  comparison	  to	  
healthy	  HIV	  uninfected	  controls	  (p=0.0009)	  and	  also	  had	  reduced	  abundance	  of	  transcripts	  
in	  B	  cell	  related	  modules	  (p≤0.0002)	  and	  lymphocyte	  activation	  (p=0.0026).	  	  Transcript	  
abundance	  in	  the	  interferon	  related	  modules	  (M3.4	  and	  M5.12)	  were	  also	  significantly	  
increased	  (p≤0.0009),	  as	  were	  transcripts	  in	  modules	  relating	  to	  inflammation	  (M4.2,	  M5.1	  
and	  M7.22)	  (p≤0.002),	  neutrophils	  (p=0.0019),	  dendritic	  cells/apoptosis	  (p=0.0009)	  and	  cell	  
death	  (p=0.0012).	  	  In	  HIV	  infected	  participants	  with	  TB,	  the	  modular	  pattern	  had	  features	  of	  
both	  HIV	  infection	  and	  TB	  infection	  alone.	  	  Notably	  transcript	  abundance	  in	  the	  interferon	  
modules	  was	  greater	  than	  in	  TB	  or	  HIV	  alone	  but	  lower	  in	  inflammation	  and	  neutrophil	  
modules	  in	  comparison	  to	  TB	  alone	  and	  not	  significantly	  different	  to	  abundance	  HIV	  
uninfected	  controls	  without	  active	  TB.	  	  However,	  transcript	  abundance	  in	  cell	  cycle	  related	  
modules	  was	  greater	  in	  HIV	  associated	  TB	  than	  HIV	  alone.	  	  These	  differences	  in	  patterns	  of	  
modular	  transcript	  abundance	  are	  summarised	  for	  individual	  participants	  in	  a	  module	  map	  
(figure	  5.14)	  and	  for	  the	  key	  modules	  in	  the	  main	  participant	  groups	  in	  a	  radar	  plot	  (figure	  
5.15)	  	  	  	  	  	  
Figure	  5.15.	  Radar	  plot	  summarizing	  fold	  change	  in	  median	  modular	  abundance	  in	  comparison	  to	  HIV	  uninfected,	  no	  
active	  TB	  controls	  for	  HIV	  uninfected,	  active	  TB	  (red),	  HIV	  infected,	  no	  active	  TB	  (green),	  HIV	  infected,	  active	  TB	  (lilac)	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Expression	  in	  interferon,	  inflammation	  and	  cell	  cycle	  modules	  was	  more	  closely	  evaluated	  to	  
gain	  greater	  insight	  into	  of	  TB/HIV	  interaction.	  	  To	  explore	  the	  effect	  of	  TB	  and	  HIV	  on	  
inflammation	  modules,	  2-­‐way	  ANOVA	  was	  performed	  on	  the	  average	  expression	  of	  
inflammation	  modules	  (log	  transformed	  to	  normalise).	  	  Inflammation	  was	  significantly	  
increased	  by	  active	  TB	  (p<0.0001)	  but	  significantly	  reduced	  by	  HIV	  infection	  (p=0.03),	  there	  
was	  no	  significant	  interaction	  between	  HIV	  and	  TB.	  	  The	  distribution	  of	  smear	  status	  differed	  
between	  HIV	  infected	  and	  uninfected	  participants	  with	  a	  greater	  degree	  of	  smear	  positivity	  
in	  HIV	  uninfected	  participants	  (see	  section	  5.5).	  	  Average	  transcript	  abundance	  in	  the	  
inflammation	  modules	  was	  significantly	  affected	  by	  smear	  status	  (p=0.01),	  however,	  
stratifying	  by	  smear	  status	  showed	  that	  the	  average	  expression	  in	  the	  inflammation	  modules	  
was	  consistently	  lower	  in	  HIV-­‐associated	  TB	  irrespective	  of	  smear	  status	  (figure	  5.16	  -­‐	  A).	  	  
Therefore,	  inflammation	  in	  HIV	  associated	  TB	  was	  affected	  by	  the	  distribution	  of	  smear	  
status	  and	  by	  HIV	  infection	  itself.	  	  
	  
Transcript	  abundance	  in	  cell	  cycle	  modules	  was	  higher	  in	  HIV	  associated	  TB	  than	  HIV	  alone,	  
however,	  viral	  load	  was	  also	  elevated	  in	  active	  TB	  (as	  expected	  despite	  CD4	  being	  well-­‐
matched).	  	  Analysing	  the	  correlation	  between	  viral	  load	  and	  cell	  cycle	  expression,	  a	  single	  
point	  was	  >	  3	  s.d.	  from	  the	  mean	  and	  considered	  a	  potential	  outlier,	  correlation	  (log	  
transformed	  average	  cell	  cycle	  expression)	  with	  outlier	  was	  r=0.35	  (p=0.009)	  and	  without	  
r=0.53	  (p<0.0001)	  (fig.	  5.16	  -­‐	  B).	  	  Linear	  regression	  gave	  an	  adjusted	  r2=0.27	  suggesting	  27%	  
of	  variance	  in	  expression	  being	  explained	  by	  viral	  load.	  	  Adding	  TB	  to	  this	  regression	  model	  
showed	  there	  was	  no	  independent	  effect	  of	  TB	  (p=0.20)	  and	  this	  had	  little	  impact	  on	  the	  
adjusted	  r2	  (r2	  =0.28)	  confirming	  that	  the	  increased	  cell	  cycle	  modular	  abundance	  in	  HIV	  
associated	  TB	  appear	  to	  relate	  to	  increased	  viral	  load.	  
	  
Figure	  5.16	  (A)	  -­‐	  Box	  plot	  showing	  average	  transcript	  abundance	  in	  inflammation	  modules	  in	  HIV	  infected	  and	  uninfected	  
participants	  with	  active	  TB	  by	  smear	  status.	  (B)	  Correlation	  of	  log10	  average	  abundance	  in	  cell	  cycle	  modules	  against	  log10	  VL.	  	  
A	   B	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Fig	  5.17.	  Expression	  In	  3	  interferon	  modules	  in	  TB	  and	  HIV:	  (left	  column)	  box	  plot	  showing	  expression	  in	  those	  with	  
active	  TB	  and	  those	  without	  active	  TB	  by	  HIV	  status.	  (right	  column)	  scatter	  plot	  of	  expression	  in	  module	  against	  
Log10	  VL.	  	  	  
Interferon	  module	  M1.2	  
Interferon	  module	  M3.4	  
Interferon	  module	  M5.12	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Transcript	  abundance	  in	  the	  3	  interferon	  modules	  (M1.2,	  M3.4	  and	  M5.12)	  was	  more	  
complex	  in	  HIV	  associated	  TB.	  	  Both	  HIV	  and	  TB	  were	  independently	  associated	  with	  
increased	  interferon	  expression	  and	  HIV	  associated	  TB	  had	  the	  highest	  expression	  in	  all	  
modules	  (table	  5.1,	  figure	  5.15).	  	  To	  establish	  if	  active	  TB	  itself	  or	  increased	  viral	  load	  as	  a	  
result	  of	  active	  TB	  was	  responsible	  for	  elevated	  transcript	  abundance,	  multiple	  regression	  	  
was	  carried	  out	  with	  Log10	  HIV	  VL	  and	  the	  presence	  of	  active	  TB	  as	  the	  explanatory	  variable	  
for	  Log10	  expression	  in	  the	  3	  interferon	  modules.	  	  For	  module	  M1.2,	  HIV	  VL	  alone	  accounted	  
for	  32%	  of	  variance	  in	  expression	  (adjusted	  r2=0.317)	  and	  addition	  of	  TB	  into	  the	  multiple	  
regression	  model	  had	  minimal	  effect,	  adjusted	  r2	  to	  0.314,	  the	  regression	  model	  showed	  the	  
effect	  of	  viral	  load	  on	  expression	  was	  significant	  (p<0.0001)	  whereas	  the	  effect	  of	  TB	  was	  not	  
(p=0.393).	  	  By	  contrast	  for	  the	  M5.12	  interferon	  module,	  HIV	  VL	  alone	  accounted	  for	  18%	  of	  
variance	  in	  expression	  (adjusted	  r2=0.178)	  whereas	  the	  addition	  of	  TB	  to	  the	  multiple	  
regression	  model	  had	  a	  large	  effect,	  increasing	  the	  adjusted	  r2	  to	  0.392,	  the	  regression	  
model	  showed	  the	  effect	  of	  viral	  load	  on	  M5.12	  expression	  was	  not	  significant	  	  (p=0.054)	  
while	  effect	  of	  TB	  was	  highly	  significant	  (p<0.0001).	  	  For	  module	  M3.4,	  HIV	  VL	  alone	  
accounted	  for	  26%	  of	  variance	  in	  expression	  in	  M3.4	  (adjusted	  r2=0.262)	  whereas	  the	  
addition	  of	  TB	  to	  the	  multiple	  regression	  model	  had	  a	  large	  effect,	  increasing	  adjusted	  r2	  to	  
0.453.	  	  In	  the	  multiple	  regression	  model	  the	  effect	  of	  both	  viral	  load	  and	  TB	  on	  M3.4	  
modular	  expression	  was	  significant	  (p=0.005	  and	  p<0.0001,	  respectively).	  	  This	  analysis	  
Fig	  5.18.	  	  IPA	  interferon	  signalling	  pathway.	  	  Transcripts	  in	  the	  different	  interferon	  modules	  highlighted	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suggested	  that	  in	  HIV	  associated	  TB,	  HIV	  may	  have	  a	  stronger	  effect	  on	  transcript	  abundance	  
in	  interferon	  module	  M1.2	  where	  as	  TB	  may	  have	  a	  stronger	  effect	  on	  transcripts	  in	  modules	  
M3.4	  and	  M5.12.	  	  Although,	  there	  is	  known	  to	  be	  considerable	  overlap	  of	  genes	  induced	  by	  
type	  1	  and	  type	  2	  interferon,	  IPA	  Pathway	  analysis	  of	  the	  transcripts	  in	  the	  3	  interferon	  
modules	  revealed	  that	  while	  genes	  represented	  in	  M3.4	  and	  M5.12	  modules	  formed	  a	  part	  
of	  both	  type	  1	  (interferon	  α/β)	  and	  type	  2	  interferon	  (interferon	  γ)	  signalling	  genes,	  
transcripts	  in	  the	  M1.2	  module	  appeared	  more	  associated	  with	  type	  1	  interferon	  signalling	  
(figure	  5.18).	  	  To	  further	  evaluate	  if	  the	  M1.2	  module	  was	  more	  comprised	  of	  transcripts	  
related	  to	  type	  1	  interferon	  stimulation,	  transcripts	  from	  the	  3	  interferon	  modules	  were	  
compared	  a	  published	  list	  of	  transcripts	  found	  to	  be	  more	  specifically	  induced	  by	  IFNα	  than	  
IFNγ	  (genes	  that	  were	  induced	  by	  IFNα	  at	  least	  3-­‐fold	  over	  IFNγ	  after	  2.5	  hour	  stimulation	  of	  
bone	  marrow	  derived	  macrophages	  in	  Liu	  et	  al	  [245]).	  	  This	  also	  demonstrated	  that	  
significantly	  more	  transcripts	  in	  the	  M1.2	  list	  were	  more	  specifically	  induced	  by	  IFNα	  in	  
comparison	  to	  M3.4	  (p<0.0005)	  and	  M5.12	  (p<0.0005).	  	  This	  suggests	  that	  in	  the	  context	  of	  
HIV	  associated	  TB	  disease,	  HIV	  replication	  contributes	  more	  specifically	  to	  the	  type	  1	  
interferon	  response	  where	  as	  active	  TB	  may	  induce	  both	  type	  2	  and	  type	  1	  interferon	  
responses.	  	  
5.6 Summary	  of	  main	  findings	  
This	  chapter	  demonstrates	  that	  a	  proportion	  of	  transcripts	  that	  form	  part	  of	  an	  active	  TB	  
whole	  blood	  signature	  can	  effectively	  distinguish	  HIV	  infected	  persons	  with	  and	  without	  
subclinical	  TB	  pathology	  determined	  by	  FDG-­‐PET/CT.	  	  Using	  82	  transcripts,	  8	  of	  9	  persons	  
with	  an	  evidence	  of	  an	  upper	  lobe	  reactivation	  pattern	  of	  subclinical	  disease	  cluster	  with	  
active	  TB.	  	  Those	  with	  regions	  of	  presumed	  tuberculous	  pathology	  showing	  greater	  
metabolic	  activity	  by	  FDG	  uptake	  cluster	  more	  strongly	  with	  active	  TB.	  	  The	  transcript	  
signature	  for	  subclinical	  TB	  remains	  discriminatory	  for	  active	  TB,	  even	  in	  HIV	  uninfected	  
participants	  and	  is	  relatively	  specific	  for	  TB	  in	  comparison	  to	  pneumonia,	  lung	  cancer,	  
inactive	  sarcoidosis	  and	  to	  a	  lesser	  extent	  active	  sarcoidosis.	  
	  
Overabundance	  of	  components	  of	  the	  classical	  complement	  pathway	  compared	  to	  latent	  TB	  
remains	  prominent	  in	  subclinical	  disease	  however	  an	  overabundance	  of	  neutrophil	  related	  
transcripts	  appears	  to	  relate	  more	  to	  later	  stages	  of	  active	  TB.	  	  Interferon	  induced	  
transcripts	  are	  overabundant	  in	  TB	  alone	  and	  HIV	  alone	  with	  further	  increased	  expression	  in	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HIV	  associated	  TB	  although	  the	  effect	  of	  HIV	  may	  be	  more	  prominent	  on	  type	  1	  interferon	  
induce	  transcripts.	  
5.7 Discussion	  
Analysis	  in	  this	  chapter	  has	  shown	  that	  a	  proportion	  of	  transcripts	  within	  a	  whole	  blood	  gene	  
expression	  signature	  for	  active	  TB	  can	  be	  used	  to	  distinguish	  groups	  of	  asymptomatic	  HIV	  
infected	  individuals	  with	  and	  without	  parenchymal	  pathology	  consistent	  with	  subclinical	  TB.	  	  
If	  generalizable	  and	  validated	  such	  a	  signature	  might	  identify	  those	  with	  at	  higher	  risk	  of	  
developing	  TB.	  	  In	  addition	  the	  data	  presented	  has	  shown	  that	  there	  are	  common	  features	  of	  
the	  independent	  effects	  of	  HIV	  infection	  and	  TB	  disease	  on	  whole	  blood	  transcript	  
abundance	  and	  that	  in	  co-­‐disease	  and	  these	  pathogens	  have	  an	  interactive	  effect	  on	  whole	  
blood	  transcript	  abundance.	  	  	  	  	  	  	  	  
	  
The	  639,	  203	  and	  82	  signatures	  identified	  transcripts	  from	  the	  893-­‐transcript	  active	  TB	  
signature	  that	  were	  also	  concordantly	  differently	  abundant	  in	  those	  with	  subclinical	  
pathology	  compared	  to	  those	  without	  subclinical	  pathology,	  with	  stepwise	  increasing	  fold	  
change.	  	  As	  they	  were	  derived	  from	  an	  active	  TB	  signature	  and	  those	  with	  subclinical	  
pathology	  clustered	  with	  active	  TB	  they	  were	  unlikely	  to	  be	  “falsely	  discovered”.	  	  The	  82	  
transcripts	  most	  effectively	  distinguished	  those	  with	  latent	  TB	  with	  and	  without	  subclinical	  
pathology.	  	  Of	  the	  2	  participants	  with	  subclinical	  pathology	  that	  did	  not	  cluster	  with	  active	  
TB,	  1	  participant	  had	  a	  miliary	  pattern	  of	  haematogenous	  disease	  spread	  and	  the	  other	  had	  
the	  smallest	  of	  the	  infiltrates,	  with	  minimal	  FDG	  uptake.	  	  All	  8	  participants	  that	  clustered	  
with	  active	  TB	  had	  evidence	  of	  upper	  lobe	  reactivation.	  	  Of	  note	  all	  3	  participants	  with	  
fibrotic	  scarring	  without	  pulmonary	  infiltrates	  clustered	  with	  active	  TB.	  	  It	  is	  possible	  
therefore	  that	  these	  82	  transcripts	  relate	  to	  a	  particular	  disease	  presentation	  that	  reflects	  
risk	  of	  bronchogenic	  reactivation	  and	  may	  be	  insensitive	  to	  haematogenous	  spread	  of	  
disease	  although	  a	  much	  larger	  study	  would	  be	  needed	  to	  investigate	  this	  hypothesis.	  	  No	  
previous	  study	  has	  investigated	  differences	  in	  the	  transcriptional	  response	  between	  
pulmonary	  and	  miliary	  TB.	  	  Of	  note	  those	  with	  greater	  FDG	  uptake	  at	  sites	  of	  pathology	  
consistent	  with	  TB	  clustered	  more	  strongly	  with	  active	  TB	  than	  those	  with	  lower	  FDG	  uptake,	  
demonstrating	  a	  positive	  association	  between	  transcript	  abundance	  and	  the	  extent	  of	  
disease	  activity.	  	  The	  4	  of	  25	  participants	  with	  latent	  TB	  who	  clustered	  with	  active	  disease	  
did	  not	  retrospectively	  have	  any	  unusual	  features	  and	  may	  reflect	  either	  participants	  at	  risk	  
of	  progression	  (and	  since	  IPT	  was	  administered	  this	  would	  be	  less	  likely	  to	  develop	  in	  follow-­‐
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up)	  or	  could	  just	  reflect	  a	  reduced	  specificity	  of	  the	  signature.	  	  However,	  in	  the	  context	  of	  a	  
diagnostic	  signature	  that	  might	  categorise	  a	  high	  risk	  group	  of	  latent	  TB	  for	  prioritized	  
treatment,	  such	  a	  degree	  of	  misclassification	  would	  still	  substantially	  improve	  the	  numbers	  
needed	  to	  treat	  to	  prevent	  a	  case	  of	  symptomatic	  active	  TB.	  	  	  	  
	  
Applying	  these	  transcripts	  to	  existing	  cohorts	  of	  participants	  with	  a	  number	  of	  other	  
diseases,	  the	  82-­‐transcipts	  performed	  well	  at	  clustering	  active	  TB	  from	  other	  diseases	  except	  
active	  sarcoidosis.	  	  This	  is	  unsurprising	  given	  the	  known	  biological	  similarities	  between	  these	  
granulomatous	  diseases	  and	  has	  been	  noted	  in	  a	  number	  of	  previous	  studies[172,	  174].	  	  The	  
implication	  of	  this	  in	  terms	  any	  diagnostic	  potential	  for	  such	  a	  signature	  will	  relate	  to	  the	  
pre-­‐test	  probability	  of	  TB	  and	  sacroidosis	  in	  the	  population	  of	  interest.	  	  If	  used	  specifically	  in	  
those	  at	  high	  risk	  of	  TB	  as	  would	  be	  likely,	  the	  impact	  of	  a	  rare	  disease	  such	  as	  sarcoidosis	  on	  
positive	  predictive	  value	  would	  be	  minimal.	  
	  
In	  terms	  of	  biological	  processes	  represented	  by	  a	  whole	  blood	  transcriptional	  signature,	  it	  
must	  be	  acknowledged	  that	  the	  impact	  of	  a	  localised	  disease	  process	  on	  whole	  blood	  
transcript	  abundance	  is	  complex.	  	  The	  collection	  of	  cells	  at	  the	  site	  of	  disease	  release	  
cytokines	  and	  chemokines,	  which	  can	  alter	  gene	  expression	  in	  circulating	  cells	  within	  the	  
pulmonary	  vasculature.	  	  These	  cells	  may	  then	  be	  return	  to	  the	  systemic	  circulation	  following	  
recirculation	  via	  the	  left	  atrium	  and	  alter	  the	  whole	  blood	  transcriptional	  profile.	  	  However,	  
these	  soluble	  factors	  may	  also	  lead	  to	  the	  recruitment	  of	  leukocytes	  and	  their	  depletion	  
from	  the	  circulation	  might	  reflect	  as	  an	  under	  abundance	  of	  certain	  transcripts	  in	  a	  whole	  
blood	  transcript	  signature.	  	  In	  addition	  some	  cells	  may	  be	  able	  to	  recirculate	  from	  the	  site	  of	  
disease	  back	  into	  the	  systemic	  circulation	  either	  via	  the	  lymphatic	  system	  or	  reverse	  
transmigration.	  	  	  
	  
The	  complement	  pathway	  was	  the	  dominant	  pathway	  for	  overabundant	  transcripts	  in	  the	  
893,	  693,	  203	  and	  82	  transcript	  list	  suggesting	  activation	  of	  this	  pathway	  may	  occur	  from	  the	  
earliest	  subclinical	  stages	  of	  TB.	  	  In	  particular,	  complement	  factors	  relating	  to	  the	  classical	  
complement	  pathway	  were	  differentially	  overabundant	  abundant	  in	  those	  with	  subclinical	  
pathology	  in	  comparison	  to	  those	  without	  (SERPING1	  (+1.89FC),	  C1q(+1.54FC),	  C2(+1.30FC),	  
C5(+1.28FC)).	  	  Transcripts	  relating	  to	  classical	  complement	  pathways	  have	  consistently	  been	  
identified	  as	  overabundant	  in	  active	  compared	  to	  latent	  TB	  in	  a	  number	  of	  studies[164,	  165,	  
171,	  174,	  246].	  	  In	  addition	  recently	  Cliff	  et	  al	  have	  showed	  that	  a	  number	  of	  transcripts	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related	  to	  complement	  pathway	  are	  substantially	  down	  regulated	  within	  the	  first	  week	  of	  
treatment	  for	  active	  TB[169].	  	  This	  suggests	  that	  the	  abundance	  of	  transcripts	  relating	  
complement	  pathway	  may	  be	  a	  marker	  of	  bacillary	  load	  rising	  early	  in	  disease	  and	  this	  falling	  
rapidly	  with	  treatment.	  	  The	  classical	  complement	  pathway	  is	  initiated	  most	  commonly	  by	  
binding	  of	  C1q	  to	  the	  Fcγ	  component	  of	  immunoglobulin	  on	  immune	  complexes	  (although	  
direct	  binding	  of	  C1q	  by	  mycobacteria	  has	  been	  reported[247]).	  	  This	  results	  in	  activation	  of	  
the	  complement	  cascade,	  which	  then	  promotes	  opsonisation	  (through	  C3b	  binding	  to	  
microbial	  surface),	  acute	  inflammatory	  response	  and	  neutrophil	  recruitment	  (through	  C3a	  
and	  C5a	  production)	  and	  cytolysis	  (via	  formation	  of	  the	  membrane	  attack	  complex).	  	  Ex	  vivo	  
studies	  have	  shown	  that	  while	  Mtb	  predominantly	  activates	  complement	  via	  the	  alternative	  
pathway	  in	  serum	  (binding	  C3b	  following	  spontaneously	  hydrolysis	  of	  C3),	  in	  lung	  BAL	  fluid,	  
where	  the	  concentration	  of	  complement	  components	  is	  lower,	  activation	  via	  the	  classical	  
pathway	  predominates[248].	  	  
	  
Although	  the	  majority	  of	  complement	  factors	  are	  produced	  by	  hepatocytes	  within	  the	  liver,	  
myeloid	  cells,	  such	  as,	  tissue-­‐resident	  macrophages	  and	  dendritic	  cells	  are	  major	  extra-­‐
hepatic	  producers	  of	  complement,	  in	  particular	  C1q[249].	  	  It	  has	  been	  demonstrated	  that	  
while	  monocytes	  express	  C1q	  mRNA,	  the	  protein	  in	  not	  present	  until	  differentiation	  into	  a	  
macrophage[250].	  	  This	  extra-­‐hepatic	  production	  is	  thought	  to	  allow	  rapid,	  localised	  
complement	  synthesis	  and	  activation	  following	  myeloid	  cells	  recruitment	  to	  infected	  tissue	  
where	  concentration	  of	  complement	  proteins	  might	  otherwise	  be	  low.	  	  Expression	  of	  C1q	  
has	  been	  shown	  to	  be	  induced	  by	  IFNγ[250].	  	  In	  addition	  to	  secreting	  C1q,	  macrophages	  
have	  been	  shown	  to	  have	  membrane	  bound	  C1q	  (mC1q),	  which	  may	  directly	  facilitate	  
phagocytosis[250].	  
	  
The	  complement	  system	  is	  a	  central	  pillar	  of	  the	  innate	  immune	  response.	  	  However,	  
recently	  its	  role	  in	  modulating	  the	  adaptive	  immune	  response	  has	  been	  increasingly	  
recognised.	  	  Recently	  C1q	  has	  been	  shown	  to	  be	  deposited	  by	  cells	  in	  the	  surrounding	  
extracellular	  matrix[251].	  	  The	  implications	  of	  this	  are	  still	  being	  established	  but	  in	  in	  vitro	  
studies,	  immobilized	  C1q	  has	  been	  demonstrated	  promote	  maturation	  of	  dendritic	  cells	  
enhancing	  their	  production	  of	  IL-­‐12	  and	  TNFα	  and	  their	  capacity	  to	  stimulate	  T	  cells[252].	  	  
Other	  studies	  have	  shown	  that	  immobilized	  C1q	  can	  have	  an	  immunomodulatory	  effect	  on	  T	  
cells	  by	  reducing	  their	  IL-­‐4	  production	  and	  enhancing	  IL-­‐10	  production[251].	  	  Further	  more	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C1q	  plays	  a	  role	  in	  the	  removal	  of	  apoptotic	  cells	  by	  direct	  binding	  to	  cells	  and	  promotion	  of	  
C3	  binding	  to	  cells	  both	  of	  which	  facilitate	  opsonisation[251].	  	  	  
The	  pro-­‐inflammatory	  effects	  of	  complement	  activation	  can	  lead	  to	  significant	  tissue	  
damage	  and	  hence	  it	  is	  regulated	  by	  a	  number	  of	  inhibitors.	  	  SERPING1	  is	  one	  such	  protease	  
inhibitor	  that	  prevents	  activation	  of	  complement	  by	  irreversibly	  binding	  to	  and	  inactivating	  
the	  C1r	  and	  C1s	  proteases	  of	  the	  C1	  complex.	  	  SERPING1	  expression	  is	  also	  induced	  by	  IFNγ	  
and	  has	  frequently	  been	  shown	  to	  be	  overabundant	  in	  active	  TB[164,	  165,	  174].	  	  Recently	  it	  
has	  been	  speculated	  that	  dysregulation	  of	  complement	  activation	  and	  altered	  balance	  of	  
SERPING1	  and	  C1q	  expression	  plays	  a	  part	  in	  pathogenesis	  of	  TB-­‐IRIS[253].	  	  	  	  	  	  	  
	  	  	  	  	  
Consistent	  with	  the	  significance	  of	  the	  classical	  complement	  pathway,	  stimulatory	  FcγR1	  was	  
also	  overabundant	  in	  those	  with	  subclinical	  pathology	  compared	  to	  those	  without	  (FCGR1C	  
(+1.58FC),	  FCGR1B(+1.38FC),	  FCGR1A(+1.36FC))	  again	  suggesting	  that	  immune	  complex	  
formation	  may	  occur	  in	  the	  earliest	  subclinical	  stages	  of	  tuberculosis.	  	  Transcripts	  relating	  to	  
FCγR1	  have	  been	  shown	  to	  be	  overabundant	  in	  TB	  in	  a	  number	  of	  studies[164,	  165,	  168,	  
171,	  174].	  	  In	  addition	  numerous	  studies	  report	  increased	  circulating	  immune	  complexes	  in	  
active	  TB[254].	  	  	  	  	  	  	  
	  
Whereas	  complement	  activation	  appeared	  to	  occur	  from	  the	  early	  stages	  of	  disease	  
reactivation,	  neutrophil	  activation	  appears	  to	  be	  specific	  to	  later	  stages	  of	  disease	  with	  
expression	  increasing	  as	  disease	  advances.	  	  While	  there	  was	  no	  significant	  difference	  in	  
abundance	  of	  transcripts	  in	  the	  neutrophil	  module	  between	  latent	  TB	  and	  subclinical	  TB,	  
abundance	  was	  significantly	  greater	  between	  subclinical	  TB	  and	  smear	  negative	  active	  TB,	  
and	  between	  those	  with	  smear	  negative	  and	  smear	  positive	  disease.	  	  The	  overabundance	  of	  
neutrophil	  related	  transcripts	  seemed	  unlikely	  to	  relate	  to	  differences	  in	  neutrophil	  count	  as	  
there	  was	  poor	  correlation	  between	  proportion	  of	  WBC	  that	  were	  neutrophils	  and	  
expression	  of	  neutrophil	  module.	  	  Although	  characteristically	  tuberculous	  granuloma	  are	  
composed	  primarily	  of	  macrophages	  and	  lymphocytes,	  neutrophils	  appear	  to	  increase	  in	  
abundance	  locally	  as	  disease	  progresses.	  	  Eum	  et	  al	  have	  shown	  that	  neutrophils	  were	  more	  
abundant	  than	  macrophages	  within	  the	  sputum,	  BAL	  fluid	  and	  cavities	  (removed	  at	  surgery)	  
of	  predominantly	  smear	  positive	  patients[255].	  	  While	  Condos	  et	  al	  and	  Dhand	  et	  al	  have	  
shown	  that	  the	  proportion	  of	  neutrophils	  in	  BAL	  is	  greater	  in	  more	  advanced	  TB[256,	  257].	  	  
A	  critical	  stage	  in	  reactivation	  and	  progression	  of	  tuberculosis	  appears	  to	  be	  failure	  of	  the	  
granuloma	  to	  contain	  Mtb,	  which	  leads	  to	  the	  development	  of	  TB	  pneumonia[101].	  	  It	  has	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been	  suggested	  that	  the	  failure	  of	  T	  cell	  immunity	  or	  loss	  of	  responsiveness	  to	  IFNγ	  may	  lead	  
to	  increased	  neutrophil	  recruitment	  to	  the	  site	  of	  disease[258].	  	  Once	  at	  the	  site	  of	  disease,	  
activated	  neutrophils	  are	  thought	  to	  be	  relatively	  short	  lived	  and	  may	  contribute	  to	  further	  
inflammation,	  tissue	  damage	  and	  ongoing	  neutrophil	  recruitment	  especially	  if	  apoptotic	  
neutrophils	  are	  not	  removed	  by	  macrophages	  and	  their	  secondary	  necrosis	  leads	  to	  release	  
of	  cytotoxic	  contents.	  	  Neutrophils	  within	  the	  blood	  may	  be	  particularly	  susceptible	  to	  
having	  their	  gene	  expression	  altered	  by	  locally	  secreted	  cytokines	  from	  the	  sites	  of	  disease	  
within	  the	  lung.	  	  The	  lung	  vasculature	  has	  been	  shown	  to	  be	  enriched	  for	  mature	  neutrophils	  
even	  in	  the	  absence	  of	  disease	  and	  intravascular	  transit	  time	  for	  neutrophils	  within	  the	  lung	  
is	  much	  greater	  than	  for	  other	  organs.	  	  Direct	  observation	  of	  neutrophil	  trafficking	  has	  
shown	  that	  neutrophils	  appear	  to	  be	  “crawling”	  round	  the	  pulmonary	  vasculature	  even	  in	  
the	  normal	  state[259].	  	  In	  addition	  it	  has	  been	  shown	  that	  it	  is	  possible	  for	  recruited	  
neutrophils	  to	  reverse	  transmigrate	  back	  to	  the	  blood	  further	  contributing	  to	  the	  whole	  
blood	  signature[259].	  
	  
Transcripts	  induced	  by	  interferon	  were	  shown	  to	  be	  overabundant	  independently	  in	  active	  
TB	  and	  HIV	  infection.	  	  Abundance	  in	  HIV-­‐associated	  active	  TB	  was	  greater	  than	  in	  either	  
disease	  individually.	  	  This	  was	  in	  part	  contributed	  to	  by	  the	  increased	  HIV	  viral	  load	  seen	  in	  
active	  TB.	  	  Of	  interest,	  the	  analysis	  showed	  that	  the	  dominant	  effect	  of	  HIV	  and	  TB	  appears	  
to	  be	  on	  different	  modules	  of	  co-­‐regulated	  interferon	  related	  transcripts	  with	  HIV	  having	  a	  
more	  prominent	  effect	  on	  type	  1	  interferon	  specific	  transcripts.	  	  While	  the	  prominence	  of	  
interferon	  induced	  genes	  in	  the	  transcriptional	  response	  in	  blood	  to	  TB	  and	  HIV	  
independently	  has	  been	  demonstrated	  previously,	  this	  is	  the	  first	  study	  to	  look	  at	  the	  effect	  
of	  co-­‐infection	  on	  expression	  of	  interferon	  stimulated	  genes[101,	  260].	  	  	  
	  
Although	  type	  2	  interferon	  (IFNγ)	  is	  critical	  to	  the	  host	  response	  to	  Mtb	  the	  role	  and	  
induction	  of	  type	  1	  interferon	  in	  Mtb	  infection	  is	  less	  well	  understood.	  	  Mtb	  clearly	  induce	  a	  
type	  1	  interferon	  response,	  this	  is	  thought	  to	  be	  via	  the	  secretory	  system	  ESX-­‐1,	  a	  key	  
virulence	  factor	  for	  the	  phagolysosome	  bound	  Mtb,	  which	  allows	  bacterial	  products	  into	  the	  
cytosol[261].	  	  There	  is	  some	  evidence	  that	  mycobacterial	  peptidoglycan	  secreted	  into	  the	  
cytosol	  interact	  with	  NOD2	  (an	  intracellular	  pattern	  recognition	  receptor)	  to	  induce	  a	  type	  1	  
interferon	  response[262].	  	  However,	  the	  type	  1	  interferon	  response	  following	  TB	  infection,	  
rather	  than	  being	  protective,	  has	  been	  shown	  to	  result	  in	  a	  deleterious	  outcome	  in	  
mice[263].	  	  It	  has	  been	  demonstrated	  that	  this	  negative	  impact	  of	  type	  1	  IFN	  on	  control	  of	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Mtb	  may	  in	  part	  relate	  to	  suppression	  of	  the	  pro-­‐inflammatory	  cytokines	  IL-­‐1α	  and	  IL-­‐1β	  
which	  may	  be	  in	  part	  mediated	  by	  the	  induction	  of	  IL-­‐10	  by	  type	  1	  interferon[264].	  	  Recently	  
this	  group	  has	  also	  shown	  that	  IL-­‐1	  induction	  of	  eicosanoids	  may	  limit	  excessive	  type	  I	  IFN	  
production,	  promoting	  containment	  of	  Mtb	  by	  the	  host[265].	  	  In	  addition,	  it	  has	  been	  shown	  
that	  the	  observed	  detrimental	  effect	  of	  prior	  infection	  with	  influenza	  A	  on	  control	  of	  Mtb	  in	  
mice,	  is	  dependent	  on	  a	  type	  1	  interferon	  response[71].	  	  	  
	  
The	  type	  1	  interferon	  response	  is	  a	  key	  part	  of	  the	  host	  antiviral	  response	  and	  acute	  and	  
chronic	  HIV	  infection	  have	  been	  demonstrated	  to	  induce	  a	  type	  1	  interferon	  response[266].	  	  
Plasmacytoid	  dendritic	  cells	  have	  been	  shown	  to	  be	  the	  major	  source	  of	  interferon	  α/β	  
production	  in	  HIV,	  despite	  forming	  a	  small	  proportion	  of	  circulating	  blood	  cells[266].	  	  In	  
addition	  overabundance	  of	  interferon	  stimulated	  genes	  has	  been	  shown	  to	  be	  positively	  
correlated	  with	  plasma	  viral	  load,	  as	  has	  been	  confirmed	  in	  this	  study[260].	  	  While	  type	  1	  
interferon	  has	  been	  shown	  to	  restrict	  viral	  replication	  it	  is	  also	  thought	  to	  promote	  CD4	  cell	  
depletion	  and	  chronic	  immune	  activation	  both	  of	  which	  may	  contribute	  to	  progressive	  
immune	  suppression[267].	  	  In	  addition	  HIV	  has	  developed	  ways	  to	  both	  evade	  the	  anti-­‐viral	  
effects	  of	  interferon	  in	  some	  cell	  types	  and	  developed	  mechanisms	  to	  suppress	  the	  
induction	  of	  interferon	  in	  other	  cell	  types	  notably	  macrophages[266].	  	  Recently	  HIV-­‐1	  has	  
been	  show	  to	  evade	  induction	  of	  type	  1	  interferon	  in	  primary	  macrophages	  by	  minimising	  
exposure	  of	  viral	  DNA	  following	  reverse	  transcription	  to	  cytosolic	  pattern	  recognition	  
receptors,	  but	  overcoming	  this	  leads	  to	  increase	  interferon	  production	  and	  promote	  
restriction	  of	  viral	  replication[268].	  	  Of	  note	  it	  has	  also	  been	  demonstrated	  that	  Mtb	  can	  
suppress	  HIV	  replication	  within	  macrophages	  but	  not	  monocytes	  through	  triggering	  an	  
interferon	  response	  through	  production	  of	  interferon-­‐stimulated	  gene	  factor	  3	  (ISGF-­‐3)	  and	  
induction	  of	  inhibitory	  CCAAT-­‐enhancer-­‐binding	  protein	  β	  (C/EBPβ)	  transcription	  
factor[269].	  	  Although	  this	  observation	  is	  of	  interest,	  it	  is	  likely	  that	  this	  suppressive	  effect	  of	  
Mtb	  on	  HIV	  replication	  is	  not	  of	  major	  importance	  given	  a	  number	  of	  other	  mechanisms	  by	  
which	  TB	  increases	  HIV	  replication.	  	  	  	  	  
	  
Interaction	  of	  HIV	  and	  TB	  is	  complex;	  HIV	  infection	  increases	  risk	  of	  active	  TB	  primarily	  
through	  depletion	  of	  CD4	  T	  cells	  but	  active	  TB	  increases	  HIV	  replication	  primarily	  through	  
immune	  activation	  and	  co-­‐localization	  of	  HIV	  infected	  and	  susceptible	  cells	  at	  the	  site	  of	  TB	  
disease.	  	  However,	  it	  is	  possible	  that	  induction	  of	  type	  1	  interferon	  by	  HIV	  may	  further	  affect	  
complexity	  of	  HIV	  TB	  interaction.	  	  Similarly	  to	  influenza,	  HIV	  induction	  of	  type	  1	  interferon	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may	  impair	  host	  control	  of	  Mtb	  by	  suppression	  of	  inflammatory	  cytokines.	  	  In	  keeping	  with	  
this	  the	  analysis	  has	  demonstrated	  that	  while	  TB	  is	  associated	  with	  increase	  in	  expression	  of	  
inflammation	  modules,	  HIV	  is	  associated	  with	  reduced	  expression	  with	  these	  modules.	  
There	  are	  several	  limitations	  in	  study	  design.	  	  In	  particular	  the	  transcriptional	  signatures	  
have	  not	  been	  validated	  in	  a	  separate	  cohort	  either	  to	  demonstrate	  specificity	  to	  subclinical	  
TB	  or	  prediction	  of	  active	  TB,	  which	  would	  increase	  confidence	  in	  their	  potential.	  	  Further	  
more	  confirming	  that	  these	  transcripts	  are	  differentially	  expressed	  on	  a	  different	  platform	  
e.g.	  multiplex	  RT-­‐PCR,	  would	  be	  important.	  	  	  	  	  	  
	  
As	  stated	  making	  inferences	  about	  biology	  from	  a	  whole	  blood	  signature	  is	  not	  without	  
caveats.	  	  Separating	  whole	  blood	  into	  cell	  type	  and	  individually	  interrogating	  transcript	  
abundance	  in	  different	  groups	  of	  white	  blood	  cells	  would	  have	  minimised	  uncertainty	  about	  
whether	  over/under	  abundance	  of	  transcripts	  related	  to	  alteration	  in	  circulating	  numbers	  or	  
true	  differences	  in	  gene	  expression.	  	  Ultimately	  cells	  from	  the	  site	  of	  disease	  may	  be	  more	  
useful	  in	  informing	  about	  biology.	  	  Direct	  sampling	  of	  cells	  is	  only	  possible	  in	  surgically	  or	  
biopsy	  obtained	  samples	  which	  due	  to	  there	  invasive	  nature	  are	  only	  opportunistically	  
available.	  	  However,	  BAL	  samples	  can	  provide	  cells	  from	  closer	  to	  the	  site	  of	  disease.	  
5.8 	  	  Conclusion	  
There	  is	  a	  clear	  need	  to	  develop	  diagnostic	  tests	  that	  are	  more	  predictive	  of	  active	  TB.	  	  In	  
this	  chapter	  proof	  of	  concept	  has	  been	  demonstrated	  that	  a	  transcriptional	  signature	  could	  
be	  used	  to	  identify	  a	  group	  of	  people	  with	  pathology	  in	  lung	  that	  may	  place	  them	  at	  higher	  
risk	  of	  developing	  TB.	  	  However,	  even	  if	  validated	  there	  are	  numerous	  technical	  hurdles	  in	  
translating	  a	  transcriptional	  signature	  into	  a	  low	  cost	  diagnostic	  test.	  	  If	  expressed	  proteins	  
could	  be	  detected	  in	  serum	  or	  plasma	  that	  could	  similarly	  identify	  a	  high-­‐risk	  group	  this	  may	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CHAPTER	  6	  –	  Serum	  and	  QuantiFERON	  
plasma	  biomarkers	  	  
6.1 Chapter	  6	  Introduction	  
In	  the	  previous	  chapter	  transcripts	  that	  related	  to	  different	  stages	  of	  TB	  infection	  and	  
disease	  were	  identified.	  	  Transcriptomics	  can	  inform	  about	  the	  biology	  and	  be	  useful	  for	  the	  
generation	  hypothesis	  regarding	  biological	  mechanisms	  in	  a	  condition	  of	  interest.	  	  A	  key	  
biological	  purpose	  of	  transcribed	  mRNA	  is	  to	  serve	  as	  a	  template	  for	  translation	  of	  proteins,	  
which	  are	  in	  general	  the	  primary	  mediators	  of	  biological	  function	  condition.	  	  Therefore	  
measuring	  levels	  of	  protein	  predicted	  by	  transcriptional	  data	  may	  help	  to	  validate	  and	  
provide	  support	  for	  hypotheses	  generated	  by	  this	  data.	  	  	  Transcriptional	  signatures	  also	  have	  
a	  potential	  role	  as	  diagnostic	  biomarkers.	  	  However,	  translating	  these	  signatures	  to	  into	  low	  
cost	  diagnostics	  remains	  a	  significant	  challenge.	  	  Identification	  of	  serum	  and	  plasma	  
biomarkers	  that	  can	  discriminate	  those	  with	  subclinical	  and	  active	  TB	  from	  those	  with	  latent	  
TB	  would	  provide	  an	  alternative	  and	  simple	  route	  for	  diagnostic	  development.	  	  As	  individual	  
serum	  biomarkers	  are	  often	  not	  specific	  to	  a	  single	  disease,	  the	  use	  of	  mycobacterial	  
antigens	  to	  first	  stimulate	  the	  blood	  is	  one	  approach	  to	  improving	  specificity	  of	  diagnostic	  
tests	  and	  is	  the	  principle	  behind	  QFGIT.	  	  As	  a	  result	  screening	  the	  supernatant	  of	  this	  
commercially	  available	  assay	  is	  an	  attractive	  approach	  to	  TB	  biomarker	  discovery.	  	  
6.2 Chapter	  6	  hypothesis	  
HIV	  infected	  persons	  with	  subclinical	  TB	  (as	  defined	  on	  PET/CT)	  and	  active	  TB	  will	  have	  
differences	  in	  concentration	  of	  cytokines,	  chemokines	  and	  soluble	  proteins	  (informed	  by	  
transcriptional	  analysis)	  within	  serum	  and/or	  QFGIT	  plasma	  compared	  to	  those	  with	  latent	  
TB.	  
6.3 Chapter	  6	  aim	  
To	  identify	  differences	  in	  cytokines,	  chemokines	  and	  soluble	  proteins	  between	  different	  
stages	  of	  HIV	  associated	  TB	  infection	  and	  disease,	  both	  in	  serum	  and	  in	  QFGIT	  supernatants.	  
6.3.1 Specific	  chapter	  aims	  
1. To	  determine	  differences	  in	  median	  serum	  concentration	  of	  cytokines,	  chemokines	  
and	  soluble	  proteins	  determined	  by	  multiplex	  assay	  (MILLIPLEX)	  or	  ELISA	  method	  
for	  different	  stages	  of	  TB	  infection	  and	  TB	  disease.	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2. To	  explore	  the	  relationship	  between	  HIV	  viral	  load	  on	  concentration	  of	  cytokines,	  
chemokines	  and	  soluble	  proteins.	  
3. To	  determine	  optimal	  cut	  off	  for	  cytokines,	  chemokines	  or	  soluble	  proteins	  to	  
distinguish	  active,	  subclinical	  and	  latent	  TB	  
4. To	  compare	  concentration	  of	  cytokines	  and	  chemokines	  in	  serum	  with	  plasma	  from	  
QFGIT	  NIL	  tube	  by	  MILLIPLEX	  assay.	  
5. To	  evaluate	  differences	  in	  plasma	  cytokines	  and	  chemokines,	  detected	  by	  the	  
Luminex	  method,	  following	  stimulation	  of	  whole	  blood	  by	  Mtb	  specific	  antigens	  (in	  
QFGIT	  assay)	  for	  different	  stages	  of	  TB	  infection	  and	  disease.	  	  	  	  	  	  
6.4 Chapter	  6	  methods	  
6.4.1 Choice	  of	  cytokines,	  chemokines	  and	  soluble	  proteins	  for	  evaluation	  
The	  choice	  of	  cytokines,	  chemokines	  and	  soluble	  proteins	  was	  informed	  by	  the	  
transcriptional	  analysis.	  	  Unbiased	  network	  analysis	  was	  performed	  on	  the	  82	  transcripts	  in	  
Ingenuity	  Pathway	  Analysis	  (IPA)	  software.	  	  The	  networks	  around	  transcripts	  of	  interest	  are	  
determined	  by	  algorithm	  using	  the	  Ingenuity	  Knowledgebase,	  which	  is	  a	  curated	  database	  of	  
experimentally	  demonstrated	  relationships	  between	  molecules	  based	  on	  extensive	  review	  
of	  literature	  conducted	  by	  developers	  of	  IPA.	  	  Of	  the	  82	  transcripts,	  30	  were	  identified	  to	  
form	  part	  of	  a	  network	  of	  140	  molecules	  involved	  in	  the	  inflammatory	  response,	  cell	  death	  
and	  survival	  and	  cellular	  movement,	  with	  a	  network	  score	  of	  49	  (p=1x10-­‐49	  that	  these	  
transcripts	  would	  be	  grouped	  together	  by	  chance).	  	  A	  number	  of	  cytokines	  and	  chemokines	  
formed	  part	  of	  this	  network	  suggesting	  that	  their	  abundance	  may	  differ	  in	  subclinical	  and	  
latent	  TB	  (see	  figure	  6.1).	  	  It	  was	  not	  possible	  to	  create	  a	  customised	  multiplex	  assay	  to	  
include	  all	  these	  predicted	  cytokines	  and	  chemokines	  and	  so	  a	  commercially	  available	  38-­‐
plex	  MILLIPLEX	  assay	  covering	  the	  majority	  of	  these	  cytokines	  and	  chemokines	  was	  used	  
(Epidermal	  Growth	  Factor	  (EGF),	  Fibroblast	  Growth	  Factor	  (FGF-­‐2),	  Eotaxin(CCL11/24/26),	  
Transforming	  Growth	  Factor	  (TGF)-­‐α,	  Granulocyte	  Colony	  Stimulating	  Factor	  (G-­‐CSF)(CSF-­‐3),	  
Fms-­‐related	  tyrosine	  kinase	  3	  ligand	  (Flt-­‐3L),	  Granulocyte	  Macrophage	  Colony	  Stimulating	  
Factor	  (GM-­‐CSF)(CSF-­‐2),	  Fractalkine(CX3CL1),	  Interferon	  (IFN)α2,	  IFNγ,	  Growth	  Regulated	  
Oncogene	  (GRO)(CXCL1),	  Interleukin	  (IL)-­‐10,	  Monocyte	  Chemotactic	  Protein	  (MCP)-­‐3(CCL7),	  
IL-­‐12p40,	  Macrophage	  Derived	  Chemokine	  (MDC)(CCL22),	  IL-­‐12p70,	  IL-­‐13,	  IL-­‐15,	  sCD40L,	  	  	  	  
IL-­‐17A,	  IL-­‐1ra,	  IL-­‐1α,	  IL-­‐9,	  IL-­‐1β,	  IL-­‐2,	  IL-­‐3,	  IL-­‐4,	  IL-­‐5,	  IL-­‐6,	  IL-­‐7,	  IL-­‐8,	  IFNγ	  induced	  protein	  (IP)-­‐
10(CXCL10),	  MCP-­‐1(CCL2),	  Macrophage	  Inflammatory	  Protein	  (MIP)-­‐1α(CCL3),	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MIP1-­‐β(CCL4),	  Tumour	  Necrosis	  Factor	  (TNF)α,	  TNFβ,	  Vascular	  Endothelial	  Growth	  
Factor(VEGF)).	  	  This	  38-­‐plex	  assay	  was	  performed	  on	  both	  serum	  and	  QFGIT	  NIL	  and	  Ag	  
plasma.	  	  Specific	  ELISA	  for	  CCL23	  and	  CXCL17	  were	  also	  performed	  on	  serum	  and	  QFGIT	  
plasma	  as	  transcripts	  for	  these	  cytokines	  formed	  part	  of	  the	  differentially	  expressed	  82	  
transcripts.	  	  In	  addition	  to	  these	  cytokines,	  ELISA	  were	  performed	  on	  serum	  for	  the	  acute	  
phase	  and	  complement	  proteins	  Haptoglobin,	  SERPING1	  and	  C1q,	  as	  these	  formed	  part	  of	  
the	  82	  transcript	  signature,	  and	  additionally	  C5,	  which	  formed	  part	  of	  the	  203	  transcript	  
signature.	  	  Due	  to	  the	  prominence	  of	  C1q	  and	  Fcγ	  receptor	  in	  the	  82	  transcript	  signature	  
both	  of	  which	  bind	  immune	  complex,	  Circulating	  Immune	  Complexes	  (CIC)	  in	  serum	  were	  
also	  quantified	  by	  ELISA	  using	  immobilised	  C1q	  to	  bind	  CIC.	  	  	  	  
Fig	  6.1	  –	  The	  most	  significant	  network	  of	  related	  transcripts	  derived	  from	  82	  transcripts	  identified	  by	  IPA	  network	  
analysis:	  	  Of	  the	  140	  transcripts	  shown,	  the	  30	  shown	  in	  colour	  form	  part	  of	  the	  82	  transcripts.	  	  Green	  signifies	  
underabundant	  subclinical	  TB	  vs.	  latent	  TB,	  red	  signifies	  overabundant	  subclinical	  TB	  vs.	  latent	  TB.	  	  Soluble	  protein	  in	  
this	  network	  as	  shown	  in	  the	  “extracellular	  space”	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6.4.2 Handling	  of	  out	  of	  range	  values	  
Standard	  curves	  for	  MILLIPLEX	  assay	  were	  derived	  using	  Bio-­‐Plex	  Manager	  software	  6.1.	  	  
Points	  in	  the	  standard	  curve	  for	  which	  calculated/actual	  concentrations	  were	  <70%	  or	  
>130%,	  were	  invalidated	  and	  curve	  fit	  was	  made	  using	  a	  5-­‐parameter	  logistic	  method	  as	  
recommended	  by	  the	  manufacturer.	  	  For	  the	  MILLIPLEX	  assay,	  QC	  samples	  were	  run	  on	  
every	  plate	  and	  for	  each	  cytokine	  and	  chemokine,	  calculated	  concentrations	  were	  within	  the	  
acceptable	  limits	  provided	  by	  the	  manufacturer.	  	  The	  software	  interpolated	  values	  that	  were	  
within	  the	  minimum	  and	  maximum	  standard	  concentrations	  and	  extrapolated	  values	  that	  
were	  above	  the	  highest	  standard	  concentration	  but	  within	  the	  maximum	  asymptote	  or	  
below	  the	  minimum	  standard	  concentration	  but	  within	  the	  minimum	  asymptote.	  	  
Extrapolated	  values	  were	  accepted	  unless	  the	  value	  was	  less	  than	  the	  manufacturer	  defined	  
minimal	  detectable	  limit	  in	  which	  case	  values	  were	  assigned	  0.	  	  Values	  that	  were	  below	  the	  
minimum	  asymptote	  were	  also	  assigned	  0.	  	  Values	  that	  were	  above	  the	  maximum	  
asymptote,	  if	  this	  applied	  to	  a	  small	  number	  of	  values	  for	  an	  analyte,	  were	  assigned	  either	  
the	  observed	  concentration	  of	  the	  highest	  standard	  or	  the	  highest	  extrapolated	  value	  (if	  
extrapolated	  values	  were	  present).	  Large	  numbers	  of	  values	  were	  out	  of	  maximum	  range	  in	  
QFGIT	  plasma	  for	  GRO,	  MCP-­‐3,	  IL-­‐6,	  IL-­‐8,	  IP-­‐10,	  MCP-­‐1,	  MIP-­‐1α	  and	  MIP-­‐1β.	  	  The	  specimens	  
were	  diluted	  40-­‐fold	  and	  repeated,	  and	  for	  these	  analytes	  the	  diluted	  results	  were	  used.	  	  
Serum	  sCD40L	  was	  completely	  out	  of	  upper	  range	  and	  was	  not	  able	  to	  be	  repeated,	  this	  
analyte	  was	  omitted	  from	  analysis.	  	  ELISA	  standards	  failed	  for	  the	  CXCL17	  assay	  twice	  and	  
therefore	  this	  analyte	  was	  also	  not	  included	  in	  analysis.	  	  Although	  as	  no	  colour	  change	  was	  
visible	  in	  samples	  for	  this	  assay	  it	  is	  likely	  that	  this	  was	  undetectable	  in	  all	  samples.	  	  When	  
data	  required	  Log10	  transformation	  or	  evaluation	  of	  fold	  change,	  0.1	  was	  added	  to	  all	  values	  
to	  ensure	  no	  0	  values	  were	  present.	  	  	  	  	  	  	  
6.4.3 Samples	  used	  in	  analysis	  
All	  35	  participants	  undergoing	  FDG-­‐PET/CT	  had	  both	  serum	  and	  QFGIT	  plasma	  samples	  
available.	  	  Participants	  were	  classified	  into	  10	  with	  evidence	  of	  subclinical	  pathology	  on	  FDG-­‐
PET/CT	  (referred	  to	  as	  “subclinical”	  in	  this	  chapter)	  and	  25	  without	  subclinical	  pathology	  
(referred	  to	  as	  “latent”	  in	  this	  chapter)	  as	  described	  in	  chapter	  4.	  	  Of	  the	  16	  participants	  with	  
active	  TB,	  13	  had	  serum	  samples	  available	  and	  of	  those	  11	  had	  QFGIT	  plasma	  available	  
(Table	  6.1).	  	  Samples	  had	  all	  been	  handled	  in	  the	  same	  manner	  prior	  to	  storage	  at	  -­‐80oC	  for	  a	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minimum	  of	  1	  year	  and	  a	  maximum	  of	  2.5	  years	  and	  were	  then	  aliquoted	  for	  the	  required	  
number	  of	  tests	  on	  a	  single	  occasion	  to	  keep	  freeze	  thaw	  cycles	  to	  a	  minimum.	  	  	  	  
6.4.4 Statistical	  methods	  
Statistical	  analysis	  was	  performed	  using	  Stata	  ver.	  12.1.	  	  Graphs	  and	  figures	  were	  created	  
using	  both	  Stata	  ver.	  12.1	  and	  GraphPad	  Prism	  ver.	  5.0a.	  	  A	  number	  of	  analytes	  were	  non-­‐
normally	  distributed	  even	  following	  log	  transformation	  so	  non-­‐parametric	  statistics	  were	  
used	  for	  main	  analysis.	  	  Comparisons	  between	  non-­‐paired	  data	  were	  compared	  using	  
Wilcoxon	  rank	  sum	  (Mann-­‐Whitney	  U	  test)	  or	  Kruskal	  Wallis	  rank	  test.	  	  Dunns	  post-­‐hoc	  test	  
was	  used	  following	  Kruskal	  Wallis	  test	  to	  determine	  significance	  of	  individual	  comparisons.	  	  
Paired	  data	  was	  compared	  using	  Wilcoxon	  matched	  pairs	  sign	  rank	  test.	  	  Correlation	  was	  
performed	  by	  Spearman	  analysis	  if	  the	  majority	  of	  analytes	  were	  non-­‐normally	  distributed,	  
Pearson’s	  correlation	  was	  also	  used	  if	  the	  analytes	  were	  normally	  distributed.	  	  Bonferroni	  
correction	  was	  used	  to	  account	  for	  number	  of	  analytes	  in	  analysis.	  	  Trend	  analysis	  was	  
performed	  using	  Cuzick	  non-­‐parametric	  test	  for	  trend.	  	  Non-­‐parametric	  Receiver	  Operating	  
Characteristic	  (ROC)	  analysis	  was	  also	  performed	  in	  Stata	  ver.	  12.1	  	  	  	  	  	  
6.5 Results	  
6.5.1 Concentration	  of	  analytes	  in	  serum	  
Of	  the	  43	  analytes	  analysed	  (not	  including	  CXCL17	  and	  sCD40L),	  9	  were	  undetectable	  in	  
serum	  in	  at	  least	  75%	  of	  participants	  in	  each	  of	  the	  3	  groups	  (Fractalkine,	  IL-­‐12p40,	  IL-­‐13,	  IL-­‐
9,	  IL-­‐1β,	  IL-­‐2,	  IL-­‐3,	  IL-­‐4	  and	  TNFβ).	  	  Twenty-­‐four	  analytes	  had	  significantly	  different	  
concentrations	  across	  the	  3	  groups	  (p≤0.05)	  of	  which	  10	  remained	  significant	  after	  
Bonferroni	  multiple	  testing	  correction	  (p≤0.0012)	  (IFNγ,	  IL-­‐15,	  IL-­‐1α,	  IL-­‐5,	  IL-­‐6,	  IL-­‐7,	  IP-­‐10,	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TNFα,	  CIC	  and	  CCL23).	  	  Dunns	  post	  hoc	  test	  demonstrated	  that	  IL-­‐5	  was	  significantly	  
elevated	  in	  serum	  of	  those	  with	  subclinical	  pathology	  compared	  to	  latent	  TB	  and	  that	  all	  10	  	  
analytes	  were	  significantly	  elevated	  in	  serum	  of	  active	  TB	  participants	  compared	  to	  latent	  TB	  
(table	  6.1	  &	  figure.	  6.2).	  	  Of	  note	  MCP-­‐3	  was	  also	  significantly	  elevated	  in	  subclinical	  TB	  and	  
active	  TB	  compared	  to	  latent	  TB	  although	  not	  after	  correcting	  for	  multiple	  comparisons.	  	  As	  
participants	  with	  active	  TB	  also	  had	  significantly	  greater	  HIV	  VL,	  which	  may	  have	  contributed	  
to	  differences	  in	  serum	  concentration	  of	  analytes,	  this	  was	  further	  explored.	  	  Linear	  
regression	  analysis	  was	  not	  appropriate	  for	  the	  majority	  of	  analytes	  due	  to	  non-­‐normality	  
despite	  log	  transformation.	  	  Unsurprisingly,	  6	  of	  the	  10	  analytes	  (IFNγ,	  IL-­‐1α,	  IP-­‐10,	  TNF-­‐α,	  
circulating	  immune	  complex	  and	  CCL23)	  that	  were	  significantly	  different	  between	  active	  and	  
latent	  TB	  also	  had	  a	  significant	  positive	  correlation	  (Spearman)	  with	  HIV	  VL	  when	  all	  
participants	  were	  considered.	  	  Only	  IP-­‐10	  remained	  significant	  after	  correction	  for	  multiple	  
comparisons.	  	  In	  order	  to	  evaluate	  the	  effect	  of	  VL	  independently	  of	  active	  TB,	  correlation	  of	  
VL	  with	  analytes	  for	  those	  with	  latent	  TB	  only	  was	  performed.	  	  EGF,	  MDC	  and	  C5	  were	  found	  
to	  have	  a	  significant	  negative	  correlation	  with	  VL,	  and	  IL-­‐17A,	  IP-­‐10	  and	  SERPING1	  a	  	  
Table	  6.1	  –	  Serum	  concentration	  for	  43	  analytes	  in	  active,	  subclinical	  and	  latent	  TB:	  p-­‐values	  shown	  for	  comparison	  with	  
latent	  TB.	  	  Final	  2	  columns	  show	  correlation	  of	  VL	  with	  analytes	  for	  all	  participants	  and	  for	  latent	  TB	  only.	  	  p-­‐values	  <0.05	  
are	  shown	  in	  red	  and	  those	  remaining	  significant	  after	  Bonferroni	  correction	  are	  starred	  (p≤0.0012).	  
**	  =conc	  for	  SERPING1,	  Haptoglobin,	  C5,	  C1q	  =	  µg/mL,	  CIC	  -­‐	  µg	  Eq/mL	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Figure	  6.2	  –	  Graphs	  showing	  difference	  in	  serum	  concentration	  for	  10	  analytes,	  significant	  after	  multiple	  testing	  correction	  (p≤0.0012)	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significant	  positive	  correlation	  with	  VL	  although	  none	  of	  these	  remained	  significant	  after	  
multiple	  testing	  corrections.	  	  Interaction	  between	  VL	  and	  TB	  was	  further	  visualised	  on	  
scatter	  plots	  (figure	  6.3)	  with	  the	  independent	  effect	  of	  TB	  on	  serum	  concentration	  being	  
apparent	  for	  the	  analytes.	  	  As	  IP-­‐10	  appeared	  to	  be	  independently	  affected	  by	  VL	  this	  was	  
further	  explored	  by	  linear	  regression	  (using	  Log10	  values)	  acknowledging	  that	  data	  was	  
slightly	  heteroscedastic	  and	  that	  distribution	  of	  residuals	  were	  slightly	  skewed	  (although	  
data	  were	  better	  suited	  to	  linear	  regression	  than	  other	  analytes).	  	  This	  analysis	  confirmed	  
that	  VL	  had	  a	  significant	  effect	  on	  IP-­‐10	  accounting	  for	  14%	  of	  variance	  in	  serum	  
concentration	  (adjusted	  r2=0.136,	  p=0.005).	  	  However,	  when	  TB	  status	  was	  added	  to	  the	  
model	  the	  2	  factors	  accounted	  for	  32%	  of	  variance	  in	  serum	  IP-­‐10	  concentration	  (adjusted	  
Figure	  6.3	  –	  Scatter	  plots	  showing	  relationship	  of	  VL	  with	  analytes	  and	  the	  effect	  of	  TB	  status	  for	  the	  7	  analytes	  in	  which	  
there	  was	  a	  significant	  relationship	  of	  serum	  concentration	  with	  VL	  (log	  scale)	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r2=0.329,	  p<0.001)	  with	  TB	  having	  a	  stronger	  independent	  effect	  on	  IP-­‐10	  concentration	  
than	  VL	  (p<0.001	  and	  p=0.01	  respectively).	  
	  
To	  further	  evaluate	  the	  relationship	  between	  these	  10	  variables	  and	  CRP,	  a	  correlation	  
matrix	  was	  created.	  	  This	  demonstrated	  a	  significant	  positive	  correlation	  between	  the	  11	  
analytes	  with	  correlation	  of	  IP-­‐10	  and	  IL-­‐1α	  being	  particularly	  strong	  (Spearman	  rho	  =	  0.90).	  	  
In	  addition	  all	  analytes	  were	  positively	  correlated	  with	  serum	  CRP.	  	  	  
6.5.1.1 ROC	  analysis	  to	  identify	  optimal	  cut	  off	  values	  
ROC	  analysis	  was	  then	  undertaken	  to	  establish	  which	  of	  the	  10	  analytes	  had	  the	  greatest	  
potential	  to	  distinguish	  active	  TB	  from	  latent	  TB	  with	  CRP	  and	  VL	  as	  comparators.	  	  All	  
analytes	  had	  AUC	  ≥0.731	  with	  3	  analytes	  being	  more	  discriminatory	  than	  CRP	  (AUC=0.928),	  
IP-­‐10	  (AUC	  0.982),	  IL-­‐1α	  (AUC=0.942)	  and	  IFNγ	  (AUC=0.934).	  	  Two	  optimal	  cut	  offs	  were	  then	  
derived	  to	  establish	  what	  proportion	  of	  those	  with	  subclinical	  disease	  would	  be	  classified	  as	  
active.	  	  The	  first	  cut	  off	  value	  was	  the	  one	  which	  best	  classified	  those	  with	  active	  and	  latent	  
TB	  (tending	  to	  have	  a	  higher	  specificity).	  	  The	  second	  cut	  off	  value	  considered	  was	  the	  one	  
with	  the	  lowest	  negative	  likelihood	  ratio	  (i.e.	  a	  cut	  off	  below	  which	  active	  TB	  was	  best	  ruled	  
out),	  	  
Figure	  6.4	  –	  Correlation	  matrix	  for	  10	  serum	  analytes	  and	  CRP.	  	  Scatter	  plots	  bottom,	  Spearman	  correlation	  coefficient	  
top.	  Red	  values	  significant	  (p<0.05)	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Figure	  6.5	  –ROC	  analysis	  for	  10	  analytes,	  CRP	  and	  VL:	  	  (TOP)	  Table	  defining	  optimal	  cut	  offs	  for	  optimal	  correct	  classification	  
of	  active	  and	  latent	  TB	  (correct	  class)	  and	  optimal	  negative	  likelihood	  ratio	  (LR-­‐).	  	  %	  of	  subclinical	  TB	  categorized	  as	  active	  
TB	  in	  final	  column.	  	  (CENTRE)	  ROC	  curves	  for	  4	  most	  discriminatory	  analytes	  by	  AUC	  (IP-­‐10,	  IL-­‐1α,	  IFNγ	  &	  CIC).	  	  (BOTTOM)	  	  
Graph	  showing	  discriminatory	  ability	  of	  CIC	  (≥100.9µg	  Eq/mL)	  and	  IL1α	  (≥16.9pg/mL).	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which	  tended	  to	  have	  a	  higher	  sensitivity	  and	  lower	  specificity	  (the	  2	  cut	  offs	  were	  the	  same	  
for	  5	  analytes).	  	  Neither	  of	  the	  cut	  off	  values	  for	  CRP	  classified	  any	  of	  those	  with	  subclinical	  
TB	  as	  active	  TB.	  	  The	  best	  performing	  analytes	  in	  this	  regard	  were	  IL-­‐1α	  with	  cut	  off	  of	  16.9	  
pg/mL	  (which	  had	  a	  sensitivity	  of	  92.3%	  for	  active	  TB,	  classified	  50%	  of	  subclinical	  TB	  as	  
active	  and	  only	  7.9%	  of	  latent	  TB	  as	  false	  positive)	  and	  CIC	  with	  cut	  off	  100.9	  µg	  Eq/mL	  
(which	  had	  a	  sensitivity	  of	  84.6%	  for	  active	  TB,	  classified	  50%	  of	  subclinical	  TB	  as	  active	  and	  
only	  12%	  of	  latent	  TB	  as	  false	  positive).	  	  If	  either	  CIC	  or	  IL-­‐1α	  were	  above	  these	  cut	  offs,	  
sensitivity	  for	  active	  TB	  was	  92.3%,	  70%	  of	  subclinical	  TB	  was	  classified	  as	  active	  and	  20%	  of	  
latent	  TB	  were	  false	  positive	  (figure	  6.5).	  
	  
	  
Figure	  6.6	  –	  Effect	  of	  disease	  activity	  on	  serum	  concentration	  of	  analytes:	  (TOP)	  –	  Table	  showing	  serum	  concentration	  of	  10	  
analytes,	  CRP	  and	  VL	  in	  participants	  stratified	  into	  5	  groups	  by	  increasing	  activity	  of	  disease	  (Latent,	  Subclinical	  VS	  0-­‐2,	  
Subclinical	  VS	  3,	  Active	  Sm	  neg,	  Active	  Sm	  pos)	  with	  analysis	  for	  trend	  in	  far	  column.	  	  BELOW	  –	  Box	  plots	  showing	  serum	  
concentration	  for	  4	  most	  discriminatory	  analytes	  (IP-­‐10,	  IL-­‐1α,	  IFNγ	  and	  CIC)	  by	  disease	  activity.	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6.5.1.2 Relationship	  between	  disease	  activity	  and	  serum	  concentration	  of	  analytes	  
To	  further	  investigate	  whether	  levels	  of	  these	  analytes	  increased	  as	  TB	  progressed,	  
participants	  with	  active	  TB	  were	  divided	  into,	  7	  participants	  that	  were	  smear	  positive	  and	  6	  
participants	  that	  were	  smear	  negative	  and	  those	  with	  subclinical	  TB	  were	  divided	  into,	  5	  
participants	  with	  evidence	  of	  increased	  metabolic	  activity	  considered	  to	  be	  TB	  related	  on	  
PET	  (VS=3	  within	  lung	  parenchyma	  or	  central	  LN)	  and	  5	  within	  lower	  activity	  (VS=0-­‐2)	  (The	  
same	  groupings	  as	  used	  in	  for	  Chapter	  5	  –	  Fig	  5.6).	  	  Non-­‐parametric	  trend	  analysis	  was	  then	  
performed	  to	  establish	  if	  concentration	  of	  analytes	  rose	  with	  increasing	  disease	  activity.	  	  
Significant	  trends	  were	  determined	  for	  all	  10	  analytes	  as	  well	  as	  CRP	  and	  VL.	  	  These	  trends	  
were	  also	  apparent	  graphically	  (figure	  6.6).	  	  
6.5.1.3 Correlation	  of	  transcript	  abundance	  with	  serum	  concentration	  of	  analytes	  
Transcripts	  for	  Haptoglobin,	  C1q,	  SERPING1,	  C5	  and	  CCL23	  formed	  part	  of	  the	  82	  transcript	  
signature	  and	  for	  these	  analytes	  expression	  values	  were	  compared	  with	  serum	  
concentrations	  of	  protein	  measured	  by	  ELISA.	  	  There	  was	  no	  significant	  correlation	  of	  
expression	  data	  with	  serum	  protein	  concentration	  for	  any	  of	  the	  analytes	  apart	  from	  
Haptoglobin,	  which	  showed	  significant	  positive	  correlation	  (r=0.39,	  p=0.006).	  	  As	  C1q	  binds	  
Fcγ	  on	  immune	  complexes,	  the	  correlation	  of	  C1q	  expression	  with	  CIC	  was	  assessed	  and	  
found	  to	  be	  significant	  (r=0.38,	  p=0.007)	  suggesting	  that	  a	  high	  proportion	  of	  serum	  C1q	  may	  
be	  bound	  in	  CIC	  (fig	  6.7).	  	  CIC	  was	  then	  correlated	  with	  other	  complement	  components	  and	  
also	  found	  to	  be	  significantly	  correlated	  with	  SERPING1	  expression	  (C1	  esterase	  inhibitor	  –	  
which	  irreversibly	  binds	  C1r	  and	  C1s)	  (r=0.40,	  p=0.005)	  but	  not	  with	  C5	  levels	  (r=0.19,	  
p=0.20)	  suggesting	  a	  high	  proportion	  of	  SERPING1	  may	  also	  be	  bound	  to	  CIC.	  
6.5.2 Concentration	  of	  analytes	  in	  QFGIT	  Plasma	  	  
First,	  concentration	  of	  IFNγ	  as	  detected	  by	  MILLIPLEX	  assay	  in	  plasma	  from	  QFGIT	  NIL	  and	  Ag	  
tubes	  was	  compared	  with	  initial	  values	  obtained	  from	  the	  commercial	  QFGIT	  assay,	  which	  
had	  been	  performed	  within	  1-­‐2	  weeks	  of	  initial	  sample	  collection.	  	  Values	  were	  highly	  
correlated	  in	  both	  NIL	  and	  Ag	  tube	  (Spearman	  rho	  0.71	  and	  0.84	  respectively	  (p<0.0001	  for	  
both)).	  	  This	  provided	  reassurance	  that	  despite	  prolonged	  storage	  cytokine	  concentration	  
remained	  stable	  and	  that	  errors	  in	  plate	  set	  up	  had	  been	  avoided.	  	  Concentrations	  of	  
cytokine	  and	  chemokines	  were	  then	  compared	  between	  QFGIT	  NIL	  plasma	  and	  serum.	  	  
Correlation	  of	  serum	  and	  plasma	  values	  was	  very	  poor	  for	  the	  37	  analytes.	  	  Only	  11	  analytes	  
showed	  a	  significant	  correlation,	  of	  which	  only	  4	  analytes	  remained	  significantly	  correlated	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Figure	  6.7–	  Scatter	  plots	  showing	  correlation	  of	  transcript	  abundance	  against	  serum	  concentration	  of	  protein	  product.	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after	  multiple	  testing	  correction	  (EGF,	  Eotaxin,	  MDC	  and	  IL-­‐2)	  and	  of	  these	  only	  EGF,	  Eotaxin	  
and	  MDC	  had	  QFGIT	  NIL	  plasma	  values	  similar	  to	  serum	  concentration.	  	  For	  most	  analytes	  
there	  was	  a	  highly	  significant	  difference	  between	  concentration	  in	  QFGIT	  NIL	  plasma	  and	  
serum.	  	  Only	  IL-­‐3	  and	  IL-­‐4	  had	  undetectable	  values	  for	  >	  75%	  in	  each	  group	  in	  comparison	  to	  
the	  9	  analytes	  in	  serum.	  	  For	  several	  of	  the	  analytes,	  notably	  MIP1α,	  IL-­‐6,	  IL-­‐8,	  IL-­‐1β,	  MCP-­‐3	  
and	  GCSF	  concentration	  was	  often	  3	  or	  4	  orders	  of	  magitude	  higher	  in	  QFGIT	  NIL	  plasma	  in	  
comparison	  to	  serum.	  	  Increase	  in	  analyte	  concentration	  was	  not	  proportionate	  across	  the	  3	  
groups	  with	  ratio	  of	  plasma	  to	  serum	  concentration	  being	  significantly	  higher	  (after	  multiple	  
testing	  correction)	  in	  latent	  TB	  for	  TNFα,	  IP-­‐10,	  IL-­‐1α,	  IL-­‐6,	  IFNγ	  and	  IFNα2.	  	  As	  a	  result	  a	  
similar	  pattern	  of	  cytokine	  concentration	  was	  not	  seen	  in	  QFGIT	  NIL	  plasma	  and	  serum.	  	  
	  
Given	  the	  significant	  differences	  in	  serum	  and	  QFGIT	  NIL	  plasma	  concentrations	  of	  cytokines,	  
the	  possibility	  of	  contamination	  of	  QFGIT	  tubes	  was	  further	  evaluated.	  	  QFGIT	  tubes	  are	  
heparin	  coated	  which	  raised	  the	  possibilty	  of	  endotoxin	  contamination.	  	  Twenty-­‐four	  QFGIT	  
NIL	  tubes	  were	  assessed	  for	  endotoxin	  level	  by	  Limulus	  Amebocyte	  Lysate	  Assay.	  	  None	  of	  
the	  tubes	  had	  endotoxin	  level	  >	  0.2	  EU/mL	  making	  endotoxin	  contamination	  unlikely.	  	  QFGIT	  
samples	  are	  incubated	  for	  24	  hours	  at	  37oC	  and	  another	  possibility	  was	  that	  HIV	  infection	  
itself	  might	  have	  led	  to	  further	  cytokine	  release.	  	  Correlation	  of	  VL	  with	  level	  of	  cytokines	  
and	  chemokines	  was	  therefore	  evaluated.	  	  EGF	  had	  a	  significant	  negative	  correlation	  
(p<0.05)	  similarly	  to	  serum	  EGF	  and	  no	  analytes	  showed	  significant	  positive	  correlation	  
suggesting	  that	  HIV	  infection	  itself	  was	  unlikely	  to	  be	  responsible	  for	  difference	  between	  
serum	  and	  QFGIT	  plasma	  values.	  	  Concentration	  of	  cytokine	  and	  chemokines	  was	  then	  
compared	  to	  Ag	  stimulated	  tube.	  	  For	  the	  majority	  of	  analytes	  levels	  were	  higher	  in	  the	  
background	  than	  in	  the	  antigen	  stimulated	  tube	  and	  hence	  Ag-­‐NIL	  concentration	  were	  often	  
negative.	  	  Only	  IFNγ,	  IP-­‐10	  and	  IL-­‐2	  had	  higher	  levels	  in	  Ag	  tube	  for	  almost	  all	  participant	  	  
Figure	  6.8	  –	  Scatter	  plot	  showing	  correlation	  of	  IFNγ	  concentration	  on	  QFGIT	  plasma	  as	  measured	  by	  commercial	  QFGIT	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Figure	  6.9	  –	  Comparison	  of	  concentration	  of	  analytes	  in	  serum	  and	  QFGIT	  NIL	  plasma:	  	  (TOP)	  Table	  comparing	  serum	  and	  
plasma	  concentration	  for	  37	  analytes	  in	  MILLIPLEX	  assay	  with	  right	  column	  showing	  median	  fold	  change	  between	  serum	  and	  
plasma	  (0.1	  added	  to	  all	  values).	  	  BOTTOM	  Showing	  difference	  between	  serum	  and	  QFGIT	  plasma	  for	  6	  analytes	  by	  TB	  status.	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Figure	  6.10	  –	  QFGIT	  Ag-­‐NIL	  concentration	  of	  analytes:	  (TOP)	  -­‐	  Table	  comparing	  Ag-­‐NIL	  values	  by	  disease	  status	  for	  37	  
analytes.	  	  (BOTTOM)	  -­‐	  	  Graphs	  showing	  distribution	  of	  values	  for	  IP-­‐10,	  IFNγ,	  IL-­‐2,	  IL-­‐1RA,	  IL-­‐10.	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samples	  as	  would	  be	  expected	  for	  those	  considered	  to	  have	  evidence	  of	  immune	  
sensitization	  by	  TB	  and	  provided	  further	  reassurance	  that	  no	  errors	  in	  tube	  labelling	  or	  
mixing	  up	  of	  NIL	  and	  Ag	  tubes	  had	  occurred.	  	  Although	  8	  analytes	  showed	  significant	  
differences	  (p≤0.05)	  across	  the	  latent,	  subclinical	  and	  active	  TB	  none	  of	  these	  remained	  
significant	  after	  Bonferroni	  correction	  for	  multiple	  comparisons.	  	  	  IL-­‐10	  and	  IL-­‐1RA	  showed	  
the	  most	  significant	  differences	  across	  the	  groups,	  however	  this	  largely	  related	  to	  Ag-­‐NIL	  
values	  being	  more	  negative	  in	  the	  latent	  TB	  group	  (Fig	  6.10).	  
6.6 Summary	  of	  main	  findings	  
Analysis	  in	  this	  chapter	  has	  shown	  that	  from	  a	  group	  of	  43	  analytes	  derived	  from	  analysis	  of	  
the	  82	  transcript	  signature,	  serum	  concentration	  of	  10	  (IFNγ,	  IP-­‐10,	  TNFα,	  IL-­‐6,	  IL-­‐1α,	  IL-­‐7,	  IL-­‐
15,	  IL-­‐5,	  CCL23	  and	  CIC)	  was	  significantly	  greater	  in	  active	  TB	  compared	  to	  latent	  TB	  and	  
concentration	  of	  IL-­‐5	  was	  also	  significantly	  greater	  in	  subclinical	  compared	  to	  latent	  TB	  (after	  
multiple	  testing	  corrections).	  	  Of	  the	  10	  analytes	  only	  IP-­‐10	  was	  significantly	  correlated	  with	  
VL	  independently	  of	  active	  TB.	  However,	  the	  effect	  of	  active	  TB	  on	  IP-­‐10	  serum	  
concentration	  appeared	  stronger	  than	  VL.	  	  All	  10	  analytes	  were	  positively	  correlated	  with	  
each	  other	  and	  CRP.	  	  ROC	  analysis	  determined	  that	  serum	  IP-­‐10,	  IL-­‐1α	  and	  IFNγ	  were	  all	  
more	  discriminatory	  than	  CRP	  in	  distinguishing	  active	  and	  latent	  TB	  and	  that	  IL-­‐1α	  
(≥16.9pg/mL)	  and	  CIC	  (≥100.9	  µg	  Eq/mL)	  individually	  classified	  50%	  and	  in	  combination	  70%	  
of	  subclinical	  TB	  as	  active	  TB.	  	  In	  addition	  when	  assessed	  across	  5	  stages	  of	  increasing	  
disease	  activity	  by	  PET	  findings	  and	  smear	  status,	  all	  10	  analytes	  showed	  a	  significant	  
increasing	  trend	  in	  serum	  concentration.	  	  Correlation	  of	  transcript	  abundance	  with	  serum	  
concentration	  of	  the	  protein	  product	  was	  very	  poor	  for	  all	  transcripts	  other	  than	  
haptoglobin.	  	  However	  C1q	  and	  SERPING1	  levels	  were	  highly	  correlated	  with	  CIC,	  suggesting	  
that	  a	  high	  proportion	  of	  these	  proteins	  may	  be	  bound	  to	  CIC.	  	  The	  majority	  of	  cytokines	  and	  
chemokines	  were	  present	  in	  significantly	  greater	  concentrations	  in	  QFGIT	  NIL	  plasma	  
compared	  to	  serum.	  	  This	  did	  not	  appear	  to	  represent	  endotoxin	  contamination	  of	  tubes	  or	  
be	  related	  to	  viral	  load.	  	  For	  the	  majority	  of	  cytokines,	  with	  the	  notable	  exception	  of	  IP-­‐10,	  
IFNγ	  and	  IL-­‐2	  cytokine	  and	  chemokine	  concentrations	  were	  lower	  in	  the	  Ag	  stimulated	  tube	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6.7 Discussion	  
A	  number	  of	  studies	  have	  explored	  differences	  in	  the	  serum	  concentration	  of	  cytokines,	  
chemokines	  and	  other	  soluble	  factors	  between	  active	  and	  latent	  tuberculosis	  using	  multiplex	  
assays	  and	  ELISA[270].	  	  These	  studies	  vary	  considerably	  in	  methodology,	  in	  particular	  the	  
analytes	  measured.	  	  Several	  features	  are	  notable	  about	  this	  study;	  firstly	  the	  selection	  of	  the	  
analytes	  was	  informed	  by	  analysis	  of	  a	  whole	  blood	  transcriptional	  signature	  and	  therefore	  
included	  analytes	  not	  included	  in	  commercial	  multiplex	  assays.	  	  Secondly	  imaging	  was	  used	  
to	  characterise	  evidence	  of	  subclinical	  pathology	  in	  a	  population	  that	  would	  ordinarily	  be	  
considered	  as	  “healthy	  latent	  infection”	  allowing	  for	  comparison	  of	  a	  potentially	  lower	  risk	  
group	  of	  latent	  TB	  with	  subclinical	  and	  active	  TB.	  	  Furthermore,	  not	  only	  were	  the	  groups	  in	  
this	  study	  matched	  for	  age	  and	  sex,	  almost	  all	  participants	  were	  of	  Xhosa	  ancestry.	  	  This	  is	  
particularly	  important	  as	  ethnic	  variations	  in	  the	  inflammatory	  response	  to	  Mtb	  are	  
becoming	  increasingly	  apparent[271,	  272].	  	  In	  addition	  this	  is	  one	  of	  the	  few	  studies	  to	  have	  
focused	  on	  HIV	  associated	  TB.	  	  
	  
Some	  common	  themes	  have	  emerged	  from	  this	  and	  previous	  studies	  (although	  often	  
findings	  are	  study	  specific	  and	  occasionally	  contradictory)[270].	  	  As	  part	  of	  a	  more	  extensive	  
metabolomic	  profiling	  of	  active	  and	  latent	  TB,	  Weiner	  3rd	  et	  al	  performed	  a	  similar	  MILLIPLEX	  
assay	  as	  used	  in	  this	  study,	  in	  HIV	  uninfected	  South	  African	  adults.	  	  Of	  the	  35	  analytes	  
evaluated,	  they	  identified	  IFNγ,	  IP-­‐10,	  IL-­‐6,	  G-­‐CSF,	  VEGF	  and	  sIL2ra	  as	  being	  elevated	  in	  
active	  TB	  compared	  to	  latent	  TB	  or	  healthy	  controls[273].	  	  Several	  previous	  studies	  have	  also	  
found	  TH1	  cytokines,	  in	  particular,	  IFNγ,	  IP-­‐10	  and	  TNFα	  to	  be	  elevated	  in	  the	  serum	  and	  
plasma	  of	  active	  TB	  patient	  compared	  to	  healthy	  controls	  with	  latent	  TB[274,	  275].	  	  This	  is	  
unsurprising	  given	  their	  role	  in	  the	  immune	  response	  to	  Mtb.	  	  Similarly	  IL-­‐6,	  a	  pro-­‐
inflammatory	  cytokine,	  has	  been	  previously	  found	  to	  be	  elevated	  in	  the	  serum	  in	  active	  
tuberculosis	  and	  is	  associated	  with	  presence	  of	  systemic	  symptoms	  and	  fever[276].	  	  Data	  for	  
IL-­‐1,	  another	  pro-­‐inflammatory	  cytokine	  and	  an	  important	  component	  in	  host	  control	  of	  
Mtb,	  are	  more	  contradictory.	  	  Although	  previous	  studies	  have	  reported	  that	  IL-­‐1	  levels	  are	  
elevated	  in	  the	  serum	  of	  HIV	  uninfected	  persons	  with	  active	  TB[277].	  	  Recently,	  Mayer-­‐Baber	  
et	  al	  have	  demonstrated	  in	  2	  separate	  cohorts,	  in	  India	  and	  China,	  that	  IL-­‐1	  levels	  were	  
reduced	  in	  HIV	  uninfected	  patients	  with	  active	  TB	  compared	  to	  latent	  TB[265].	  	  In	  addition,	  
IL-­‐10,	  an	  immunoregulatory	  cytokine	  that	  modulates	  the	  TH1	  response	  is	  frequently	  reported	  
to	  be	  elevated	  in	  the	  serum	  of	  active	  TB	  patients[274,	  278].	  	  This	  is	  in	  contrast	  to	  findings	  in	  
this	  study	  where	  IL-­‐10	  was	  not	  found	  to	  be	  elevated	  in	  serum	  of	  HIV	  infected	  active	  TB	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patients	  whereas	  IL-­‐1α	  was.	  	  It	  is	  possible	  that	  this	  relates	  to	  the	  HIV	  status	  of	  participants	  in	  
this	  study.	  	  Recently,	  Tomlinson	  et	  al	  showed	  that	  in	  vitro,	  HIV	  co-­‐infection	  of	  macrophages	  
resulted	  in	  a	  diminished	  IL-­‐10	  response	  and	  an	  enhanced	  pro-­‐inflammatory	  response	  to	  Mtb	  
and	  that	  this	  was	  mirrored	  in	  the	  airway	  samples	  of	  HIV	  infected	  TB	  patients	  who	  had	  low	  
levels	  of	  IL-­‐10	  and	  high	  levels	  of	  IL-­‐1β[100].	  	  
	  
In	  this	  study	  we	  were	  not	  able	  to	  compare	  HIV	  infected	  and	  uninfected	  participants,	  
although,	  recently	  Mihret	  et	  al	  have	  investigated	  the	  effect	  of	  HIV	  on	  circulating	  cytokine	  
levels	  in	  TB.	  	  Using	  a	  17-­‐plex	  assay	  (EGF,	  Fractalkine,	  IFNγ,	  GM-­‐	  CSF,	  IL-­‐1,	  IL-­‐10,	  IL-­‐12,	  IL-­‐17,	  
IL-­‐4,	  IL-­‐7,	  IL-­‐9,	  IP-­‐10,	  MCP-­‐1,	  MCP-­‐3,	  MIP-­‐1β,	  TNFα	  and	  VEGF)	  to	  compare	  plasma	  cytokine	  
levels	  in	  HIV	  infected	  ART	  naïve	  persons	  with	  active	  TB	  (mean	  CD4	  310/mm3)	  with	  HIV	  
uninfected	  adults	  they	  found	  that	  the	  cytokines	  and	  chemokines	  measured	  were	  not	  
affected	  by	  HIV	  status[279].	  	  Few	  studies	  have	  investigated	  the	  effect	  of	  HIV	  infection	  alone	  
on	  circulating	  cytokines,	  Keating	  et	  al	  using	  a	  similar	  MILLIPLEX	  assay	  to	  this	  study,	  measured	  
32	  analytes	  in	  serum	  of	  predominantly	  African	  American	  women	  that	  were	  either	  HIV	  
infected	  ART	  naïve,	  HIV	  infected	  established	  on	  ART,	  or	  HIV	  uninfected.	  	  Serum	  levels	  of	  
TNFα	  and	  IP-­‐10	  were	  found	  to	  be	  significantly	  higher	  and	  IL-­‐12(p40),	  IL-­‐15	  and	  FGF-­‐2	  levels	  
significantly	  lower	  in	  HIV	  infected	  ART	  naïve	  women	  compared	  to	  HIV	  uninfected	  women.	  	  
Of	  these	  5	  analytes	  only	  IP-­‐10	  was	  significantly	  affected	  by	  viral	  load	  in	  keeping	  with	  the	  
findings	  in	  this	  study[280].	  	  In	  other	  studies	  elevated	  levels	  of	  IL-­‐7	  (involved	  in	  lymphocyte	  
maturation	  and	  differentiation)	  have	  been	  reported	  in	  HIV	  infected	  persons	  (as	  well	  as	  other	  
lymphopenic	  states)	  showing	  inverse	  correlation	  with	  CD4	  count	  and	  reducing	  with	  ART	  
initiation.	  	  It	  is	  thought	  this	  may	  represent	  a	  compensatory	  homeostatic	  mechanism	  to	  
lymphopenia[281,	  282].	  	  It	  is	  likely	  therefore	  that	  the	  elevated	  IL-­‐7	  found	  in	  this	  study	  
relates	  more	  to	  HIV	  infection	  than	  active	  TB.	  	  
	  
In	  addition	  to	  the	  TH1	  and	  pro-­‐inflammatory	  cytokines,	  in	  this	  study	  IL-­‐15,	  IL-­‐5,	  CCL23	  and	  
CIC	  were	  also	  found	  to	  be	  elevated	  in	  active	  TB.	  	  IL-­‐15	  has	  not	  previously	  been	  reported	  to	  
be	  elevated	  in	  the	  serum	  of	  active	  TB	  patients,	  however,	  in	  a	  study	  by	  Frahm	  et	  al	  in	  which	  
25	  analytes	  were	  evaluated	  by	  multiplex	  assay	  in	  QFGIT	  supernatants	  and	  Ag-­‐NIL	  values	  
compared	  between	  active	  and	  latent	  TB,	  IL-­‐15	  was	  found	  to	  be	  the	  most	  discriminatory	  
cytokine[283].	  	  IL-­‐5	  has	  also	  not	  been	  reported	  to	  be	  elevated	  in	  serum	  of	  HIV	  uninfected	  
active	  TB	  patients,	  however,	  recently	  a	  role	  for	  IL-­‐5	  has	  been	  suggested	  in	  the	  pathogenesis	  
of	  HIV	  associated	  TB	  in	  an	  SIV/TB	  macaque	  model.	  	  This	  has	  shown	  that	  SIV	  induces	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production	  of	  IL-­‐5	  in	  monocytes	  which	  in	  turn	  inhibits	  T-­‐cell	  production	  of	  TH1	  cytokine	  
which	  would	  be	  expected	  to	  impair	  host	  control	  of	  Mtb	  leading	  to	  progression	  of	  
disease[284]	  (of	  note	  IL-­‐5	  levels	  were	  not	  measured	  in	  the	  study	  by	  Mihret	  et	  al	  discussed	  
above).	  	  
	  
CCL23	  (also	  known	  as	  MIP-­‐3	  and	  MPIF-­‐1)	  was	  differentially	  expressed	  between	  
active/subclinical	  and	  latent	  TB	  and	  was	  part	  of	  the	  82	  transcript	  list.	  	  The	  serum	  
concentration	  of	  CCL23	  was	  also	  significantly	  elevated	  in	  active	  TB	  despite	  being	  poorly	  
correlated	  with	  transcript	  abundance.	  	  CCL23	  is	  expressed	  in	  lung	  tissue,	  liver	  as	  well	  as	  cells	  
of	  myeloid	  origin	  and	  has	  been	  shown	  to	  display	  chemotactic	  activity	  for	  T	  cells	  and	  
monocytes[285].	  	  It	  is	  has	  rarely	  been	  studied	  in	  TB	  and	  does	  not	  form	  part	  of	  most	  
commercially	  available	  multiplex	  assay.	  	  It	  has	  been	  shown	  to	  be	  elevated	  in	  serum	  of	  
patients	  with	  systemic	  sclerosis,	  particularly	  in	  those	  with	  pulmonary	  hypertension[286].	  	  Of	  
note	  however	  in	  a	  microarray	  study	  of	  Mtb	  and	  M.bovis	  infection	  of	  bovine	  alveolar	  
macrophages	  (b.a.mϕ).	  	  CCL23	  was	  found	  to	  be	  the	  most	  overabundant	  transcript	  in	  M.bovis	  
(more	  virulent	  in	  cows)	  compared	  to	  Mtb	  infected	  bovine	  alveolar	  macrophages[287].	  	  This	  
suggests	  the	  possibility	  that	  in	  humans,	  infection	  of	  alveolar	  macrophages	  with	  virulent	  Mtb	  
may	  result	  in	  CCL23	  release	  and	  this	  cytokine	  merits	  further	  investigation	  in	  TB.	  
	  
Circulating	  immune	  complexes	  were	  investigated	  because	  of	  the	  findings	  from	  the	  
microarray	  demonstrating	  an	  over	  abundance	  of	  transcripts	  for	  Fcγ	  receptor	  and	  C1q,	  which	  
typically	  bind	  immune	  complexes.	  The	  ELISA	  assay	  used,	  measured	  binding	  of	  immune	  
complex	  to	  immobilised	  C1q.	  	  	  Circulating	  immune	  complex	  have	  frequently	  been	  reported	  
to	  be	  elevated	  in	  active	  tuberculosis	  and	  are	  increased	  in	  smear	  positive	  compared	  to	  smear	  
negative	  disease	  and	  reduce	  with	  treatment[288,	  289].	  	  They	  have	  been	  found	  to	  be	  
composed	  of	  mycobacterial	  antigens,	  IgG	  and	  IgM	  antibodies	  and	  complement	  components	  
such	  as	  C1q,	  C3	  and	  C4	  [289,	  290].	  	  In	  particular	  these	  antibodies	  have	  been	  shown	  to	  be	  
specific	  for	  mycobacterial	  glycolipids	  such	  as	  LAM	  although	  it	  is	  likely	  that	  antibodies	  to	  
soluble	  proteins	  and	  other	  mycobacterial	  cell	  surface	  components	  are	  also	  present[291,	  
292].	  	  However,	  circulating	  immune	  complexes	  are	  not	  unique	  to	  TB	  and	  are	  reported	  in	  a	  
number	  of	  chronic	  inflammatory,	  autoimmune	  and	  neoplastic	  conditions	  and	  also	  in	  HIV	  
infection.	  	  However,	  at	  least	  in	  acute	  HIV	  infection	  it	  has	  been	  show	  that	  HIV	  VL	  and	  levels	  of	  
circulating	  immune	  complex	  are	  not	  correlated[293].	  	  In	  this	  study	  although	  there	  was	  a	  
positive	  correlation	  of	  VL	  with	  CIC	  in	  those	  with	  latent	  TB	  (Spearman	  rho	  =	  0.32)	  it	  was	  not	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significant	  even	  before	  correction	  for	  multiple	  comparisons.	  	  Using	  linear	  regression	  to	  
distinguish	  effect	  of	  VL	  and	  TB	  was	  not	  considered	  appropriate,	  as	  residuals	  were	  not	  
normally	  distributed.	  	  However,	  there	  was	  a	  significant	  trend	  for	  increasing	  CIC	  levels	  with	  
disease	  activity.	  	  Of	  note	  CIC	  levels	  were	  significantly	  elevated	  in	  those	  with	  subclinical	  TB	  
with	  greater	  evidence	  of	  activity	  on	  PET	  compared	  paired	  to	  those	  with	  latent	  TB	  despite	  no	  
significant	  difference	  in	  viral	  load.	  	  It	  is	  therefore	  likely	  that	  the	  increased	  levels	  of	  CIC	  
observed	  in	  subclinical	  and	  active	  TB	  relate	  more	  to	  progression	  of	  TB	  rather	  than	  increasing	  
HIV	  VL	  that	  accompanies	  active	  TB.	  	  However,	  further	  characterisation	  of	  circulating	  immune	  
complexes	  in	  HIV	  associated	  TB	  would	  be	  required	  to	  determine	  this.	  	  
	  
The	  ability	  to	  distinguish	  active	  from	  latent	  TB	  for	  the	  10	  analytes	  particularly	  IP-­‐10,	  IL-­‐1α	  
and	  IFNγ	  was	  extremely	  good	  and	  superior	  to	  that	  reported	  previously	  in	  a	  number	  of	  
studies[294,	  295].	  	  The	  reason	  for	  this	  is	  likely	  two-­‐fold.	  	  The	  use	  of	  FDG-­‐PET/CT	  allowed	  the	  
identification	  of	  those	  with	  evidence	  of	  subclinical	  TB	  and	  thus	  allowed	  comparison	  of	  active	  
TB	  directly	  to	  those	  with	  latent	  TB	  and	  no	  evidence	  of	  active	  pathology.	  	  Comparison	  of	  
active	  TB	  with	  those	  clinically	  determined	  to	  have	  latent	  TB	  (i.e.	  combining	  the	  latent	  and	  
subclinical	  groups)	  would	  result	  in	  inferior	  performance	  characteristics	  of	  the	  analytes.	  	  
Additionally	  as	  discussed	  above,	  and	  notably	  for	  IP-­‐10	  but	  possibly	  CIC	  and	  other	  analytes,	  
the	  increased	  serum	  levels	  in	  active	  TB	  would	  result	  from	  both	  TB	  disease	  and	  increased	  HIV	  
viral	  load	  accompanying	  it.	  	  This	  would	  be	  expected	  to	  enhance	  the	  discriminatory	  ability	  of	  
these	  analytes.	  	  However,	  this	  is	  not	  of	  major	  concern,	  the	  fact	  that	  active	  TB	  results	  in	  
increasing	  HIV	  VL	  for	  a	  given	  CD4	  count	  means	  that	  HIV	  VL	  itself	  has	  a	  reasonable	  ability	  to	  
discriminate	  active	  from	  latent	  TB.	  	  Increases	  in	  viral	  load	  as	  well	  as	  the	  identified	  serum	  
markers	  are	  likely	  to	  be	  part	  of	  the	  natural	  progression	  of	  HIV	  associated	  TB.	  
	  
Of	  major	  significance	  is	  the	  ability	  of	  the	  analytes,	  in	  particular	  CIC	  and	  IL1α,	  to	  classify	  those	  
with	  subclinical	  TB	  as	  active	  TB	  (70%	  if	  CIC	  ≥100.9µg	  Eq/mL	  and/or	  IL1α	  ≥	  16.9pg/mL)	  and	  
the	  clear	  trend	  of	  increasing	  serum	  concentration	  of	  analytes	  with	  increasing	  disease	  
activity.	  	  The	  implications	  of	  this	  are	  that	  these	  serum	  markers	  may	  be	  to	  an	  extent	  
predictive	  of	  active	  TB	  and	  could	  be	  used	  a	  screening	  tool	  for	  those	  at	  high	  risk	  of	  active	  TB	  
in	  HIV	  co-­‐infected	  populations.	  	  It	  is	  clear	  that	  these	  markers	  need	  validation	  not	  only	  to	  
confirm	  findings	  in	  this	  population	  (HIV	  infected,	  ART	  naïve,	  CD4≥350/mm3)	  but	  also	  in	  other	  
HIV	  infected	  population	  (low	  CD4	  count,	  established	  on	  ART	  and	  other	  ethic	  groups)	  and	  HIV	  
uninfected	  populations	  to	  determine	  generalizability.	  	  Although	  as	  discussed	  above	  it	  is	  likely	  
Chapter	  6	  –	  Serum	  and	  QFGIT	  biomarkers	  
	   225	  
that	  these	  markers	  may	  be	  better	  suited	  to	  HIV	  associated	  TB.	  	  In	  addition,	  the	  specificity	  of	  
these	  analytes	  needs	  to	  be	  further	  explored	  especially	  in	  diseases	  also	  common	  in	  the	  
Southern	  African	  setting.	  
	  
Of	  note	  transcriptional	  abundance	  in	  whole	  blood	  was	  poorly	  correlated	  with	  serum	  levels	  of	  
protein.	  	  Although	  haptoglobin	  expression	  level	  was	  significantly	  correlated	  with	  serum	  
levels,	  transcript	  abundance	  only	  accounted	  for	  15%	  of	  the	  variance	  in	  serum	  levels.	  	  There	  
are	  several	  explanations	  for	  this.	  	  The	  central	  dogma	  of	  molecular	  biology	  (DNAà	  RNAà	  
protein)	  is	  now	  considered	  an	  over-­‐simplification	  and	  there	  are	  several	  reasons	  why	  
transcript	  abundance	  may	  not	  accurately	  reflect	  protein	  abundance,	  as	  has	  often	  been	  
observed.	  	  In	  particular	  post-­‐transcriptional	  processes,	  regulation	  of	  translation	  and	  protein	  
degradation	  may	  have	  a	  significant	  impact	  on	  protein	  concentration[163].	  	  However,	  if	  a	  
high	  proportion	  of	  a	  protein	  is	  bound,	  assays	  measuring	  free	  protein	  levels	  may	  not	  
accurately	  represent	  total	  protein	  concentration.	  	  Both	  SERPING1	  and	  C1q	  expression	  were	  
highly	  correlated	  with	  CIC	  levels	  rather	  than	  the	  free	  serum	  levels	  detected	  by	  ELISA,	  
suggesting	  that	  a	  high	  proportion	  may	  be	  bound	  to	  CIC.	  	  Furthermore	  whole	  blood	  
transcriptomics	  only	  reflects	  transcript	  abundance	  of	  circulating	  cells,	  however,	  other	  cells	  
not	  present	  in	  blood	  may	  contribute	  significantly	  to	  serum	  abundance	  of	  a	  protein.	  	  Notably	  
complement	  factors	  such	  as	  C5	  are	  produced	  in	  significant	  quantities	  by	  hepatocytes	  and	  
CCL23	  is	  also	  produced	  by	  lung	  and	  liver	  tissue.	  	  	  However	  of	  note	  despite	  being	  poorly	  
correlated	  with	  transcript	  abundance,	  serum	  levels	  of	  CCL23	  remained	  significantly	  elevated	  
in	  those	  with	  active	  TB.	  
	  
As	  levels	  of	  individual	  proteins	  are	  rarely	  specific	  to	  a	  single	  disease	  process,	  various	  
strategies	  can	  be	  used	  to	  improve	  specificity	  of	  protein	  biomarkers.	  	  The	  identification	  of	  
multiple	  factors	  in	  serum	  or	  plasma	  using	  proteomics	  to	  give	  a	  disease	  signature	  is	  one	  
approach	  but	  translation	  into	  low	  cost	  diagnostic	  tools	  is	  a	  challenge.	  	  Hence,	  using	  Mtb	  
specific	  antigens	  to	  stimulate	  blood	  prior	  to	  detecting	  cytokines	  and	  chemokines	  is	  an	  
attractive	  strategy,	  particularly,	  as	  QFGIT	  provides	  a	  commercially	  available,	  validated	  
platform	  for	  this.	  	  As	  a	  result	  numerous	  studies	  have	  utilised	  this	  methodology.	  	  	  	  	  
	  
The	  difference	  in	  levels	  of	  cytokines	  in	  serum	  and	  plasma	  from	  the	  QFGIT	  NIL	  tube	  was	  
striking,	  with	  several	  of	  the	  cytokines	  3	  or	  4	  orders	  of	  magnitude	  higher	  in	  QFGIT	  plasma	  
compared	  to	  serum.	  	  Not	  all	  cytokines	  were	  affected	  with	  the	  effect	  being	  greatest	  on	  pro-­‐
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inflammatory	  cytokines.	  	  The	  main	  consequence	  of	  this	  was	  that	  the	  cytokine	  patterns	  
observed	  in	  the	  serum	  were	  not	  observed	  in	  the	  QFGIT	  NIL	  plasma.	  	  Of	  note,	  the	  levels	  of	  
IFNγ	  were	  well	  correlated	  with	  the	  commercial	  assay	  performed	  within	  1-­‐2	  weeks	  of	  initial	  
sampling.	  	  In	  addition,	  stimulation	  with	  Mtb	  specific	  antigens	  resulted	  in	  increases	  in	  IFNγ	  
(again	  well	  correlated	  with	  commercial	  assay),	  IP10	  and	  IL2	  as	  expected	  (but	  reduction	  in	  
may	  other	  cytokines).	  	  This	  suggests	  that	  technical	  or	  set-­‐up	  errors	  in	  the	  multiplex	  assay	  
were	  not	  responsible	  for	  this	  finding.	  	  Other	  studies	  have	  shown	  QFGIT	  NIL	  levels	  to	  be	  
higher	  than	  would	  be	  expected	  in	  the	  serum	  and	  have	  observed	  the	  similar	  pattern	  of	  
reduction	  in	  cytokine	  levels	  with	  stimulation[296].	  	  Little	  explanation	  has	  been	  offered	  for	  
these	  findings,	  although,	  the	  effects	  were	  less	  marked	  than	  for	  this	  study.	  	  The	  tubes	  were	  
confirmed	  not	  to	  be	  LPS	  contaminated	  and	  the	  manufacturer	  states	  tubes	  are	  tested	  for	  
endotoxin	  before	  dispatch.	  	  	  	  	  	  	  	  	  	  	  	  	  
	  
De	  Jager	  et	  al	  using	  a	  multiplex	  assay	  have	  shown	  that	  there	  is	  very	  little	  difference	  between	  
cytokine	  and	  chemokine	  levels	  in	  plasma	  and	  serum,	  when	  isolated	  soon	  after	  blood	  
draw[297].	  	  However	  a	  key	  difference	  between	  the	  serum	  samples	  and	  plasma	  samples	  from	  
QFGIT	  is	  that	  the	  latter	  have	  been	  incubated	  at	  37oC	  for	  24	  hours.	  	  It	  is	  clear	  from	  the	  
literature	  on	  blood	  transfusion	  that	  storage	  of	  whole	  blood	  products	  leads	  to	  increases	  in	  
pro-­‐inflammatory	  cytokines	  and	  that	  this	  can	  be	  mitigated	  by	  the	  depletion	  of	  white	  blood	  
cells[298].	  	  L.	  Beer	  (in	  an	  unpublished	  thesis)	  has	  recently	  systematically	  explored	  the	  effect	  
of	  time	  and	  temperature	  on	  plasma	  and	  serum	  cytokine	  concentrations	  in	  whole	  blood	  
assays[299].	  	  He	  confirmed	  little	  difference	  in	  cytokine	  or	  chemokine	  concentration	  in	  serum	  
and	  plasma	  with	  no	  incubation.	  	  However,	  incubating	  the	  whole	  blood	  of	  healthy	  volunteers	  
at	  37oC	  for	  24	  hours	  (without	  stimulation)	  resulted	  in	  massive	  increases	  in	  cytokines	  and	  
chemokines	  (IL6,	  IL8,	  GRO	  and	  MCP-­‐1)	  in	  the	  serum	  tube	  but	  also	  large	  increases	  in	  levels	  in	  
plasma	  particularly	  in	  heparinised	  tube	  compared	  to	  EDTA	  tube.	  	  He	  then	  demonstrated	  that	  
24	  hour,	  37oC	  incubation	  of	  PBMC	  with	  the	  addition	  of	  serum	  or	  fibrin	  resulted	  in	  similar	  
large	  increases	  cytokine	  compared	  to	  medium	  alone	  and	  concluded	  that	  coagulation	  
products	  were	  likely	  to	  be	  responsible	  for	  these	  observed	  increases.	  	  Furthermore,	  
fibrinogen	  has	  been	  shown	  result	  in	  a	  similar	  pattern	  of	  cytokine	  release	  to	  LPS	  in	  
monocytes,	  mediated	  by	  TLR-­‐4	  stimulation	  leading	  to	  up-­‐regulation	  of	  pro-­‐inflammatory	  
cytokines	  such	  as	  MIP1α,	  MIP1β,	  MIP2	  and	  MCP1[300].	  	  Heparin	  should	  prevent	  clotting	  of	  
blood	  however	  it	  is	  likely	  that	  a	  degree	  of	  clotting	  does	  occurs	  after	  24	  hours	  of	  incubation.	  	  
HIV	  infected	  individuals	  have	  been	  shown	  to	  have	  higher	  circulating	  levels	  of	  both	  fibrinogen	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and	  fibrin	  degradation	  products,	  such	  as	  d-­‐dimer,	  and	  this	  may	  be	  an	  explanation	  to	  why	  
certain	  cytokine	  and	  chemokines	  were	  elevated	  in	  this	  study[301].	  	  An	  alternative	  
hypothesis	  is	  that	  cells	  such	  as	  neutrophils	  may	  undergo	  necrosis	  during	  the	  24	  hour	  
incubation	  leading	  to	  the	  release	  of	  contents	  that	  may	  be	  pro-­‐inflammatory.	  	  Again	  this	  may	  
be	  more	  likely	  to	  occur	  in	  the	  context	  of	  HIV	  infection.	  	  The	  fall	  in	  cytokine	  levels	  following	  
Ag	  stimulation	  that	  was	  observed	  for	  many	  cytokines	  is	  harder	  to	  explain.	  	  To	  speculate	  Ag	  
stimulation	  may	  either	  promote	  the	  consumption	  of	  certain	  cytokines,	  reduce	  the	  tendency	  
of	  blood	  to	  coagulate	  or	  stabilise	  cells	  preventing	  necrosis.	  	  
	  
QFGIT	  tubes	  have	  been	  specifically	  optimized	  for	  use	  as	  an	  interferon	  gamma	  release	  assay.	  	  
If	  a	  similar	  strategy	  is	  to	  be	  used	  for	  other	  cytokines,	  a	  more	  systematic	  evaluation	  of	  the	  
optimal	  tubes	  to	  be	  used,	  incubation	  times	  and	  the	  effect	  of	  HIV	  on	  assays	  is	  warranted.	  	  It	  is	  
clear	  from	  this	  study	  that	  using	  the	  existing	  QFGIT	  platform	  may	  not	  be	  the	  best	  way	  to	  
approach	  novel	  biomarker	  discovery.	  
	  
There	  are	  several	  limitations	  to	  the	  study	  outlined	  in	  this	  chapter.	  	  Firstly,	  the	  commercial	  
multiplex	  assay	  used	  did	  not	  cover	  all	  the	  cytokines	  and	  chemokines	  predicted	  by	  analysis	  of	  
the	  transcriptomic	  data.	  	  Hence,	  there	  may	  be	  additional	  biomarkers	  that	  perform	  well	  and	  
distinguish	  different	  stages	  of	  TB	  infection.	  	  Secondly,	  distinguishing	  the	  effect	  of	  HIV	  from	  
TB	  was	  challenging.	  	  The	  inclusion	  of	  controls	  that	  were	  HIV	  infected	  on	  ART	  and	  HIV	  
uninfected	  (with	  and	  without	  active	  TB)	  may	  have	  helped	  to	  better	  differentiate	  the	  effects	  
of	  TB	  and	  HIV.	  	  However,	  in	  high	  burden	  settings	  such	  as	  South	  Africa	  the	  exclusion	  of	  
subclinical	  TB	  in	  these	  control	  groups	  would	  still	  be	  required.	  	  Control	  groups	  without	  TB	  but	  
with	  other	  diseases	  such	  as	  pneumonia	  may	  have	  also	  allowed	  evaluation	  of	  the	  specificity	  
of	  these	  biomarkers.	  	  Furthermore	  validation	  of	  the	  promising	  biomarkers	  identified	  in	  a	  
additional	  cohorts	  would	  have	  helped	  to	  confirm	  findings	  and	  improve	  generalizability.	  	  	  
	  
6.8 Conclusions	  
The	  use	  of	  FDG-­‐PET/CT	  to	  distinguish	  those	  with	  evidence	  of	  subclinical	  pathology	  within	  the	  
lungs	  has	  facilitated	  identification	  of	  biomarkers	  that	  distinguish	  active	  from	  latent	  TB.	  	  
Furthermore,	  some	  of	  these	  serological	  biomarkers	  show	  promise	  in	  the	  identification	  of	  
those	  with	  subclinical	  TB	  especially	  those	  at	  the	  more	  active	  end	  of	  the	  spectrum.	  	  In	  
addition,	  the	  value	  of	  using	  transcriptional	  data	  to	  inform	  the	  selection	  of	  analytes	  has	  been	  
shown	  and	  in	  particular,	  further	  study	  of	  CCL23	  and	  circulating	  immune	  complexes	  seems	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warranted.	  	  Finally	  the	  data	  has	  highlighted	  some	  key	  concerns	  regarding	  the	  use	  of	  QFGIT	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CHAPTER	  7	  –	  General	  Discussion	  and	  
Conclusions	  
	  
7.1 Scope	  of	  Thesis	  
Mycobacterium	  tuberculosis	  is	  primarily	  a	  disease	  of	  humans	  and	  as	  such	  those	  that	  are	  
infected	  by	  Mtb	  form	  the	  principal	  reservoir	  of	  the	  disease.	  	  	  Transmission,	  via	  the	  
respiratory	  route	  occurs	  when	  infection	  progresses	  accompanied	  by	  bacterial	  replication	  and	  
lung	  damage	  allowing	  aerosolisation	  of	  the	  organism.	  	  The	  later	  stages	  of	  disease	  are	  usually	  
accompanied	  by	  symptoms	  and	  at	  this	  stage	  an	  individual	  is	  considered	  as	  having	  active	  
clinical	  disease	  and	  may	  self-­‐present	  to	  the	  health	  care	  system	  for	  treatment,	  it	  is	  also	  when	  
the	  individual	  is	  most	  infectious.	  	  The	  core	  principles	  of	  TB	  control	  strategies	  are	  (outlined	  in	  
figure	  7.1):	  
	  
1. Preventing	  those	  with	  active	  disease	  transmitting	  to	  susceptible	  individuals	  by	  early	  









Intensive Case finding 
Infection Control 
Isoniazid Preventive Therapy 
Figure	  7.1	  –	  Diagram	  outlining	  the	  principles	  of	  TB	  control:	  	  3I’s	  –	  Infection	  control,	  Intensified	  case	  finding	  and	  Isoniazid	  
preventive	  therapy.	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2. Preventing	  progression	  to	  active	  disease	  in	  those	  with	  latent	  infection	  by	  
administration	  of	  preventive	  therapy	  (usually	  with	  isoniazid).	  
	  
Although	  this	  appears	  a	  conceptually	  attractive	  approach	  to	  TB	  control,	  there	  are	  practical	  
challenges.	  	  Current	  diagnostic	  tests	  for	  latent	  TB	  do	  not	  stratify	  risk	  of	  disease	  progression,	  
classify	  a	  very	  large	  proportion	  of	  the	  population	  as	  having	  evidence	  of	  latent	  infection	  and	  
are	  poorly	  predictive	  of	  active	  TB.	  	  As	  a	  result	  when	  used	  as	  a	  guide	  to	  preventive	  treatment	  
the	  number	  needed	  to	  treat	  to	  prevent	  a	  case	  of	  active	  TB	  is	  very	  high,	  even	  when	  
incorporating	  additional	  epidemiological	  risk	  factors	  such	  as	  recent	  contact	  and	  
immunocompromise.	  	  The	  tests	  also	  have	  the	  effect	  of	  simultaneously	  exaggerating	  the	  
scale	  of	  the	  problem	  and	  reducing	  the	  perception	  of	  risk	  of	  latent	  TB	  (1/3	  of	  the	  world	  
population	  are	  infected	  but	  have	  only	  a	  5-­‐10%	  life	  time	  risk	  of	  active	  disease),	  leading	  to	  
inaction	  on	  effectively	  tackling	  the	  reservoir	  of	  disease,	  which	  is	  a	  necessary	  step	  to	  TB	  
elimination.	  	  	  
	  
On	  the	  other	  hand	  active	  case	  finding	  using	  symptom	  screening,	  although	  a	  simple	  and	  
effective	  way	  to	  identify	  TB	  cases	  with	  symptoms	  yet	  to	  present	  to	  the	  healthcare	  system	  
(pre-­‐diagnostic	  TB),	  may	  miss	  a	  number	  of	  truly	  asymptomatic	  cases	  (subclinical	  TB)	  who	  
may	  be	  culture	  positive	  or	  culture	  negative	  but	  in	  the	  early	  stages	  of	  reactivation.	  	  This	  is	  a	  
particular	  issue	  in	  high	  HIV	  burden,	  high	  transmission	  settings	  such	  as	  Khayelitsha	  and	  
presents	  a	  further	  logistical	  challenge	  for	  the	  implementation	  of	  IPT,	  due	  to	  the	  concern	  of	  
inappropriate	  treatment	  leading	  to	  increased	  drug	  resistance.	  	  CXR	  has	  been	  widely	  used	  for	  
decades	  as	  a	  screening	  tool	  to	  identify	  people	  with	  subclinical	  or	  pre-­‐diagnostic	  TB	  but	  it	  has	  
a	  number	  of	  limitations	  as	  has	  been	  discussed	  in	  previous	  chapters.	  	  There	  is	  a	  clear	  need	  for	  
a	  diagnostic	  test	  to	  fill	  this	  gap,	  that	  can	  identify	  asymptomatic	  persons	  at	  high	  risk	  of	  
developing	  active	  TB	  which	  would	  facilitate	  TB	  control.	  	  However,	  a	  greater	  understanding	  of	  
latent	  TB	  and	  its	  transition	  to	  active	  TB	  is	  required	  which	  is	  the	  area	  in	  which	  this	  thesis	  
aimed	  to	  further	  knowledge.	  	  	  	  	  	  	  	  	  	  	  	  	  
	  
The	  population	  of	  interest	  were	  healthy	  HIV	  infected	  outpatients,	  CD4	  count	  ≥	  350/mm3,	  
ART	  naïve	  living	  in	  Khayelitsha	  and	  the	  scope	  of	  this	  thesis	  was	  to:	  
	  	  	  
1. Explore	  the	  performance	  of	  the	  current	  tools	  for	  screening	  of	  active	  and	  latent	  TB	  
used	  in	  the	  recruitment	  of	  participants	  for	  the	  study	  (Chapter	  3).	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2. Evaluate	  the	  utility	  of	  FDG-­‐PET/CT	  to	  identify	  evidence	  of	  subclinical	  pathology	  in	  
asymptomatic,	  ART	  naïve,	  HIV	  infected	  adults	  with	  evidence	  of	  latent	  TB	  and	  no	  
previous	  history	  of	  tuberculosis	  (Chapter	  4).	  	  
3. Determine	  the	  differentially	  expressed	  transcripts	  in	  whole	  blood	  in	  those	  with	  and	  
without	  subclinical	  TB	  and	  in	  comparison	  to	  an	  active	  TB	  control	  group	  and	  to	  
evaluate	  the	  effect	  of	  HIV	  on	  the	  transcriptional	  response	  to	  TB	  (Chapter	  5)	  	  
4. Identify	  serological	  and	  QFGIT	  supernatant	  markers	  that	  distinguish	  those	  without	  
evidence	  of	  subclinical	  pathology	  from	  those	  with	  evidence	  of	  subclinical	  pathology	  
and	  active	  TB	  control	  group	  (Chapter	  6).	  
	  
7.2 General	  discussion	  of	  findings	  
The	  data	  outlined	  in	  Chapter	  3	  demonstrate	  the	  scale	  of	  the	  problem	  of	  latent	  TB	  in	  this	  
community	  but	  also	  highlighted	  the	  limitations	  of	  the	  current	  diagnostic	  tests.	  	  Of	  235	  
healthy,	  outpatient,	  HIV-­‐infected,	  ART	  naïve	  persons	  with	  median	  CD4	  count	  of	  520/mm3,	  
64.2%	  of	  the	  population	  had	  a	  positive	  QFGIT.	  	  This	  was	  less	  than	  the	  71.8%	  of	  (younger)	  HIV	  
uninfected	  persons	  from	  the	  same	  community	  that	  were	  QFGIT	  positive.	  	  Although	  not	  a	  
significant	  difference,	  this	  highlights	  that	  current	  immunodiagnositic	  tests	  for	  latent	  TB	  may	  
perform	  less	  well	  in	  HIV	  infected	  persons.	  	  In	  addition,	  the	  median	  value	  of	  a	  positive	  QFGIT	  
was	  significantly	  less	  in	  HIV	  infected	  persons	  (2.38IU/mL	  vs.	  4.66IU/mL)	  and	  the	  distribution	  
of	  positive	  results	  was	  clearly	  left-­‐shifted.	  	  This	  is	  unsurprising	  given	  the	  depletion	  of	  CD4	  
cells	  in	  HIV	  infection,	  which	  are	  the	  main	  contributors	  to	  IFNγ	  release.	  	  The	  distribution	  of	  TB	  
Ag-­‐NIL	  values	  in	  those	  with	  a	  negative	  QFGIT	  and	  TST	  was	  similarly	  different	  between	  HIV	  
infected	  and	  uninfected	  persons.	  	  While	  in	  HIV	  uninfected	  persons	  the	  negative	  results	  were	  
normally	  distributed	  around	  a	  mean	  TbAg-­‐NIL	  of	  0.03	  IU/mL,	  the	  HIV	  infected	  participants	  by	  
contrast	  had	  a	  bimodal	  distribution	  of	  TbAg-­‐NIL	  with	  half	  clustered	  around	  0	  IU/mL	  and	  half	  
clustered	  around	  the	  cut-­‐off	  value	  of	  0.35	  IU/mL.	  	  During	  the	  screening	  period	  for	  the	  study,	  
participants	  were	  observed	  for	  a	  6	  week	  period	  and	  during	  this	  time	  20%	  of	  participants	  with	  
a	  positive	  QFGIT	  reverted	  to	  negative	  particularly	  those	  with	  initial	  results	  in	  the	  bottom	  2	  
quintiles,	  in	  keeping	  with	  what	  has	  been	  described	  previously[209].	  	  In	  a	  similar	  population	  
of	  22	  HIV	  infected	  persons	  screened	  for	  the	  vaccine	  study	  (of	  mixed	  ART	  status)	  with	  an	  
initially	  negative	  QFGIT	  and	  TST,	  40.9%	  converted	  from	  QFGIT	  negative	  to	  positive	  following	  
administration	  of	  TST.	  	  A	  QFGIT	  cut-­‐off	  ≥0.15	  IU/mL	  correctly	  classifying	  86%	  of	  those	  
converting	  following	  TST	  boosting.	  	  Taken	  together	  this	  suggests	  that	  the	  universal	  cut	  off	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used	  for	  QFGIT	  of	  0.35IU/mL	  may	  be	  less	  appropriate	  for	  HIV	  infected	  individuals	  to	  detect	  
all	  those	  immune	  sensitized	  by	  Mtb	  and	  in	  a	  similar	  manor	  to	  TST,	  a	  lower	  cut	  off	  possibly	  
around	  0.15-­‐0.17	  IU/mL	  may	  improve	  sensitivity	  of	  the	  test.	  	  This	  will	  need	  validation	  in	  
other	  cohorts	  with	  differing	  CD4	  counts	  and	  on	  and	  off	  ART	  and	  will	  need	  to	  be	  evaluated	  
against	  a	  clinically	  relevant	  endpoint.	  	  Clearly	  the	  effect	  of	  this	  may	  be	  to	  further	  reduce	  the	  
already	  poor	  positive	  predictive	  value	  of	  QFGIT,	  however	  the	  main	  value	  of	  the	  current	  test	  
for	  latent	  tuberculosis	  is	  as	  a	  marker	  of	  exposure	  and	  immune	  sensitization	  by	  Mtb.	  	  
Ensuring	  that	  the	  test	  has	  maximal	  sensitivity	  for	  this	  will	  in	  fact	  improve	  its	  utility	  
epidemiologically	  when	  evaluating	  transmission	  and	  long-­‐term	  impact	  of	  TB	  control	  
programs.	  
	  
The	  high	  burden	  of	  undiagnosed,	  untreated	  culture	  positive	  TB	  (or	  prevalent	  TB)	  in	  this	  
population	  was	  also	  demonstrated	  in	  Chapter	  3.	  	  Prevalence	  was	  estimated	  at	  
4,098/100,000	  highlighting	  the	  importance	  of	  active	  case	  finding.	  	  However,	  only	  40%	  were	  
identified	  by	  symptom	  screening	  (although	  the	  screen	  used	  did	  differ	  from	  the	  WHO	  
symptom	  screen	  with	  cough	  for	  1	  week	  rather	  than	  any	  cough	  being	  used)	  and	  50%	  by	  CXR	  
screening.	  	  Of	  note	  there	  was	  considerable	  overlap	  between	  those	  with	  CXR	  abnormalities	  
and	  those	  with	  symptoms.	  	  The	  sensitivity	  of	  CXR	  screening	  for	  culture	  positive	  TB	  in	  those	  
without	  symptoms	  was	  particularly	  poor	  (16.7%).	  	  In	  addition,	  the	  CXR	  abnormalities	  in	  
persons	  at	  the	  earliest	  stages	  of	  clinical	  TB	  were	  minimal	  in	  extent	  and	  in	  general	  all	  CXR	  
abnormalities	  were	  subtle.	  	  In	  keeping	  with	  previous	  studies,	  there	  was	  poor	  intra-­‐observer	  
agreement	  (κ=0.25)	  in	  reporting[81].	  	  Recent	  evaluations	  of	  CXR	  as	  a	  screening	  tool	  for	  TB	  
that	  report	  better	  sensitivity	  have	  been	  noted	  to	  have	  study	  designs	  resulting	  in	  verification	  
bias	  in	  a	  systematic	  review[82].	  	  The	  data	  presented	  in	  this	  thesis	  suggest	  that	  CXR	  may	  be	  
best	  suited	  to	  identifying	  pre-­‐diagnostic	  TB	  rather	  than	  true	  subclinical	  TB,	  especially	  in	  HIV	  
infected	  persons	  in	  high	  burden	  settings.	  	  This	  warrants	  further	  evaluation	  in	  larger	  studies	  
but	  also	  confirms	  the	  need	  for	  novel	  screening	  tools.	  	  
	  
Although	  CXR	  appears	  useful	  to	  detect	  pathology	  around	  the	  stage	  at	  which	  symptoms	  
commence,	  it	  was	  hypothesised	  that	  those	  in	  the	  early	  stages	  of	  reactivation	  might	  have	  
evidence	  of	  pathology	  within	  lung	  and	  lymph	  nodes	  that	  might	  be	  visible	  using	  a	  more	  
sensitive	  imaging	  technique	  such	  as	  FDG-­‐PET/CT.	  	  In	  Chapter	  4	  asymptomatic	  participants	  
with	  a	  clinical	  diagnosis	  of	  latent	  TB	  (evidence	  of	  immune	  sensitization	  by	  Mtb	  (positive	  
QFGIT)	  but	  no	  evidence	  of	  active	  TB	  following	  screening)	  and	  no	  previous	  history	  of	  TB,	  had	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FDG-­‐PET/CT	  performed.	  	  The	  anatomical	  and	  metabolic	  abnormalities	  within	  the	  lung	  and	  
lymph	  nodes	  in	  this	  population,	  at	  high	  risk	  of	  active	  TB,	  were	  then	  defined.	  	  This	  was	  a	  
novel	  approach,	  which	  has	  not	  previously	  been	  performed	  systematically	  on	  this	  scale.	  	  
Acknowledging	  that	  FDG-­‐PET/CT	  changes	  (like	  CXR	  abnormalities	  and	  macroscopic	  
abnormalities	  defined	  at	  autopsy)	  are	  not	  specific	  for	  but	  consistent	  with	  TB,	  4	  broad	  
categories	  of	  parenchymal	  abnormality	  were	  defined.	  	  Only	  28.6%	  of	  participants	  had	  
normal	  lung	  parenchyma	  on	  PET/CT.	  	  Discrete	  nodules	  were	  found	  in	  57%,	  a	  rate	  far	  higher	  
than	  would	  be	  expected	  in	  a	  relatively	  young	  population	  with	  little	  smoking	  history,	  
although	  few	  suitable	  studies	  are	  available	  for	  comparison.	  	  The	  anatomical	  nature	  and	  
distribution	  of	  these	  lesions	  was	  highly	  suggestive	  of	  the	  Ghon	  focus	  of	  primary	  infecton.	  	  
One	  participant	  had	  active	  nodules	  accompanied	  by	  positive	  culture	  for	  MTB	  in	  a	  pattern	  
suggestive	  of	  haematogenous	  rather	  than	  bronchogenic	  spread	  of	  TB.	  	  28.6%	  of	  persons	  had	  
infiltrates	  and	  scars	  with	  only	  a	  single	  lesion	  not	  located	  within	  the	  upper	  lobe	  (although	  this	  
participant	  did	  have	  a	  second	  lesion	  within	  the	  upper	  lobe).	  	  Infiltrates	  were	  suggestive	  of	  
active	  bronchogenic	  spread	  of	  TB	  and	  scarring	  suggestive	  of	  spontaneous	  healing.	  	  Of	  
significant	  interest	  was	  that	  those	  with	  scaring	  of	  the	  lungs	  were	  significantly	  more	  likely	  to	  
have	  infiltrates	  of	  the	  lungs	  (and	  also	  other	  evidence	  of	  disease	  activity)	  than	  those	  without	  
scars.	  	  This	  supports	  the	  epidemiological	  observations	  that	  those	  with	  inactive	  lesions	  on	  
CXR	  (notwithstanding	  the	  limitations	  of	  CXR)	  are	  more	  likely	  to	  develop	  disease.	  	  However,	  
the	  active	  lesions	  on	  FDG-­‐PET/CT	  were	  not	  within	  scars	  but	  often	  in	  unrelated	  areas	  of	  the	  
lungs.	  	  The	  implication	  of	  this,	  although	  speculative	  given	  the	  limited	  numbers,	  is	  that	  those	  
with	  inactive	  lesions	  are	  at	  high	  risk	  not	  necessarily	  because	  residual	  organisms	  within	  these	  
lesions	  recrudesce	  (although	  this	  may	  still	  happen	  as	  certainly	  viable	  bacilli	  can	  be	  present	  
within	  fibrotic	  scars)	  but	  because	  they	  are	  more	  likely	  to	  have	  repeated	  episodes	  of	  
reactivation.	  	  This	  also	  explains	  the	  findings	  of	  at	  least	  3	  distinct	  clusters	  of	  fibrotic	  scaring	  at	  
different	  stages	  of	  healing	  in	  1	  participant.	  	  	  
	  
Lymph	  node	  abnormalities	  were	  more	  difficult	  to	  evaluate	  because	  of	  the	  presence	  of	  HIV	  
co-­‐infection.	  	  Supporting	  previous	  findings	  in	  the	  ART	  naïve	  population,	  FDG	  uptake	  within	  
peripheral	  lymph	  nodes	  was	  common[146].	  	  Almost	  all	  participants	  had	  abnormal	  axillary	  
lymph	  nodes	  and	  over	  70%	  had	  abnormal	  uptake	  in	  the	  cervical	  lymph	  nodes.	  	  Activity	  in	  the	  
axillary	  lymph	  nodes	  in	  particular	  remained	  stable	  over	  time,	  however,	  initiating	  ART	  
resulted	  in	  a	  reduction	  in	  FDG	  uptake,	  as	  previously	  reported[148].	  	  Activity	  within	  central	  
nodes	  (mediastinal	  and	  upper	  abdominal)	  was	  more	  complex	  and	  appeared	  to	  have	  a	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bimodal	  distribution.	  	  Those	  with	  infiltrates/scars	  and	  active	  nodules	  within	  the	  lungs	  were	  
significantly	  more	  likely	  to	  have	  highly	  avid	  central	  LN	  (SUVmax	  >	  5).	  	  Furthermore	  the	  
reduction	  in	  FDG	  activity	  in	  central	  LN	  appeared	  to	  relate	  more	  to	  treatment	  of	  TB	  than	  to	  
HIV.	  	  This	  suggests	  that	  during	  reactivation	  involvement	  of	  regional	  lymph	  nodes	  occurs,	  this	  
may	  simply	  reflect	  increased	  trafficking	  of	  cells	  or	  may	  reflect	  active	  infection	  of	  the	  regional	  
lymph	  nodes	  (in	  which	  case	  granulomatous	  inflammation	  would	  be	  expected	  histologically).	  	  
However,	  not	  all	  those	  with	  such	  parenchymal	  abnormalities	  had	  central	  lymph	  node	  uptake	  
to	  this	  degree,	  notably	  the	  2	  participants	  that	  that	  were	  asymptomatic	  and	  culture	  positive	  
had	  SUVmax	  <	  5	  within	  the	  central	  lymph	  nodes.	  	  Consideration	  of	  the	  observed	  
abnormalities	  on	  FDG-­‐PET/CT,	  in	  relation	  to	  literature	  from	  historical	  autopsy	  and	  imaging	  
studies,	  allowed	  categorization	  of	  this	  group	  of	  35	  asymptomatic	  persons	  with	  evidence	  of	  
immune	  sensitization	  but	  with	  negative	  symptom	  screen	  into	  a	  group	  of	  10	  with	  evidence	  of	  
reactivation	  of	  latent	  infection	  potentially	  at	  higher	  risk	  of	  progression	  (termed	  subclinical	  
TB)	  and	  25	  without	  evidence	  of	  reactivation	  considered	  to	  be	  a	  lower	  risk	  of	  reactivation.	  	  Of	  
note,	  programmatically	  they	  would	  all	  have	  been	  eligible	  for	  IPT,	  but	  in	  practise	  just	  received	  
2	  month	  follow	  up	  at	  the	  pre-­‐ART	  clinic.	  	  
	  
The	  design	  of	  this	  study	  allowed,	  for	  the	  first	  time,	  comparison	  of	  abnormalities	  reported	  on	  
screening	  CXR	  to	  a	  gold	  standard	  test	  of	  FDG-­‐PET/CT;	  reported	  in	  Chapter	  4.	  	  The	  data	  
highlighted	  that	  for	  7	  consultant	  radiologists,	  individual	  agreement	  with	  FDG-­‐PET/CT,	  for	  the	  
diagnosis	  of	  active,	  inactive	  and	  no	  TB	  was	  fair	  at	  best	  and	  agreement	  between	  readers	  was	  
slight	  (based	  on	  κ-­‐statistic).	  	  Of	  greater	  interest	  was	  the	  observation	  that	  when	  classifying	  
screening	  CXR	  as	  having	  evidence	  of	  TB,	  readers	  either	  had	  a	  tendency	  to	  over-­‐read	  (high	  
sensitivity/low	  specificity)	  or	  under-­‐read	  (low	  sensitivity/high	  specificity)	  which	  may	  reflect	  
an	  inherent	  bias	  in	  individual	  readers.	  	  In	  general	  the	  data	  suggested	  that	  the	  utility	  of	  
screening	  CXR	  for	  the	  identification	  of	  inactive	  TB	  changes	  was	  particularly	  poor,	  with	  high	  
variability	  between	  readers.	  	  It	  is	  worth	  noting	  however	  that	  the	  task	  presented	  to	  the	  
readers	  was	  particularly	  challenging.	  	  The	  participants	  had	  all	  been	  pre-­‐screened	  
approximately	  6	  weeks	  prior	  to	  FDG-­‐PET/CT	  and	  repeat	  CXR,	  to	  ensure	  that	  they	  were	  
symptom	  free,	  culture	  negative,	  had	  no	  history	  of	  previous	  TB	  and	  no	  evidence	  of	  active	  TB	  
on	  an	  initial	  CXR	  (as	  determined	  by	  2	  medical	  officers).	  	  The	  careful	  anatomical	  description	  of	  
parenchymal	  abnormalities	  on	  FDG-­‐PET/CT	  and	  their	  comparison	  to	  CXR,	  may	  help	  in	  the	  
training	  of	  readers,	  as	  improved	  understanding	  of	  the	  expected	  location	  and	  nature	  of	  early	  
Chapter	  7	  –	  General	  discussion	  and	  conclusions	  
	   235	  
TB	  related	  changes	  on	  CXR	  could	  lead	  to	  greater	  consistency	  and	  accuracy	  in	  the	  reporting	  of	  
screening	  CXR.	  	  	  	  	  	  
	  	  
If	  those	  with	  abnormalities	  consistent	  with	  subclinical	  TB	  represented	  a	  group	  in	  the	  early	  
stages	  of	  reactivation,	  at	  higher	  risk	  of	  progressing	  to	  clinical	  active	  TB,	  then	  it	  was	  
hypothesised	  that	  they	  may	  have	  similarities	  in	  transcriptional	  response	  with	  active	  TB	  that	  
distinguished	  them	  from	  those	  with	  latent	  TB	  and	  no	  evidence	  of	  subclinical	  pathology.	  	  In	  
Chapter	  5,	  893	  transcripts	  were	  identified	  that	  were	  differentially	  abundant	  between	  an	  age,	  
sex	  and	  CD4	  matched	  group	  with	  active	  TB	  and	  those	  with	  “low	  risk”	  latent	  TB	  (no	  subclinical	  
pathology)	  using	  statistical	  and	  fold	  change	  filtering.	  	  These	  transcripts	  were	  then	  analysed	  
by	  sequential,	  stepwise	  fold	  change	  filtering	  to	  explore	  which	  were	  differentially	  expressed	  
between	  subclinical	  and	  latent	  TB	  and	  which	  were	  more	  specific	  to	  the	  later	  stages	  of	  clinical	  
TB.	  	  A	  transcriptional	  signature	  of	  82	  transcripts	  was	  defined	  which	  clustered	  8	  of	  10	  
participants	  with	  subclinical	  TB	  with	  active	  TB.	  	  Of	  the	  2	  participants	  that	  did	  not	  cluster,	  1	  
had	  active	  nodules	  suggesting	  haematogenous	  spread	  of	  disease	  and	  the	  other	  the	  most	  
minimal	  of	  the	  bronchogenic	  infiltrates.	  	  Although	  speculative	  given	  the	  small	  numbers,	  it	  is	  
possible	  that	  the	  biological	  differences	  between	  disease	  that	  spreads	  bronchogenically	  and	  
that	  which	  spreads	  haematogenously	  also	  results	  in	  differences	  in	  transcriptional	  response.	  	  
Furthermore,	  those	  with	  subclinical	  pathology	  showing	  greater	  metabolic	  activity	  within	  
lung	  parenchyma	  or	  central	  lymph	  nodes	  clustered	  more	  strongly	  with	  active	  TB	  in	  
comparison	  to	  those	  with	  less	  metabolic	  activity,	  raising	  the	  possibility	  that	  metabolic	  
activity	  in	  part	  reflects	  disease	  activity.	  	  22	  of	  82	  transcripts	  were	  common	  to	  at	  least	  1	  of	  
the	  3	  published	  active	  TB	  transcriptional	  signatures	  defined	  in	  HIV	  uninfected	  persons	  and	  
when	  applied	  to	  a	  cohort	  HIV	  uninfected	  persons,	  these	  82	  transcripts	  effectively	  identified	  
those	  with	  active	  TB	  from	  healthy	  controls	  with	  no	  evidence	  of	  TB.	  	  In	  addition,	  when	  
applied	  to	  an	  existing	  dataset,	  which	  included	  participants	  with	  lung	  cancer,	  pneumonia,	  
inactive	  sarcoidosis,	  active	  sarcoidosis	  and	  healthy	  controls,	  active	  tuberculosis	  effectively	  
clustered	  from	  other	  diseases,	  although	  to	  a	  lesser	  extent	  from	  active	  sarcoidosis.	  	  This	  
suggests	  that	  the	  signature	  relates	  to	  tuberculosis	  (and	  not	  HIV)	  and	  is	  specific	  for	  
granulomatous	  inflammation.	  	  However,	  what	  sets	  it	  apart	  as	  novel	  is	  the	  ability	  to	  identify	  
subclinical	  TB	  and	  hence	  the	  potential	  that	  it	  is	  more	  predictive	  for	  active	  TB,	  although	  it	  is	  
clear	  that	  further	  validation	  is	  required	  to	  confirm	  this.	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As	  well	  as	  providing	  a	  biomarker,	  the	  transcriptional	  signature	  allowed	  evaluation	  of	  the	  
biological	  processes	  (albeit	  those	  represented	  in	  whole	  blood)	  that	  are	  associated	  with	  the	  
subclinical	  stages	  of	  disease	  and	  those	  that	  are	  more	  specific	  to	  later	  stages	  of	  clinical	  
disease.	  	  The	  complement	  system	  was	  consistently	  the	  most	  overabundant	  pathway	  at	  each	  
stage	  of	  signature	  characterization	  and	  in	  particular	  transcripts	  relating	  to	  the	  classical	  
complement	  pathway	  were	  overabundant	  in	  both	  subclinical	  and	  active	  TB	  in	  comparison	  to	  
latent	  TB.	  	  Of	  note,	  SERPING1,	  C1q	  and	  C5	  were	  common	  to	  all	  3	  of	  the	  other	  published	  
active	  TB	  transcriptional	  signatures	  assessed[164,	  165,	  174].	  	  Classical	  complement	  pathway	  
is	  initiated	  by	  C1q	  binding	  to	  Fcγ	  component	  of	  immune	  complexes	  (most	  commonly)	  and	  so	  
the	  over	  abundance	  of	  Fcγ	  receptor	  1	  also	  suggested	  that	  increased	  immune	  complex	  
formation	  maybe	  playing	  a	  role	  early	  in	  disease.	  	  Similarly	  to	  the	  complement	  system,	  
transcripts	  for	  Fcγ	  receptor	  1	  are	  commonly	  identified	  as	  over	  abundant	  in	  active	  TB[243].	  	  
By	  contrast	  over	  abundance	  of	  neutrophil	  related	  transcripts	  appeared	  to	  occur	  in	  the	  later	  
stages	  of	  clinical	  disease.	  	  In	  keeping	  with	  this,	  abundance	  of	  neutrophil	  related	  transcripts	  
was	  greater	  in	  smear	  positive	  compared	  to	  smear	  negative	  TB	  and	  supported	  findings	  that	  
proportion	  of	  neutrophils	  in	  BAL	  is	  greater	  in	  more	  advanced	  TB[256,	  257].	  	  
	  
As	  no	  previous	  study	  has	  addressed	  in	  depth	  the	  impact	  of	  HIV	  on	  the	  TB	  transcriptional	  
signature	  this	  was	  further	  evaluated	  in	  Chapter	  5.	  	  The	  data	  showed	  that	  both	  HIV	  and	  TB	  
individually	  resulted	  in	  a	  significant	  overabundance	  of	  transcripts	  within	  interferon	  related	  
modules	  and	  in	  HIV	  associated	  TB	  this	  overabundance	  was	  further	  increased	  in	  part	  by	  
increasing	  viral	  load.	  	  However,	  it	  was	  notable	  that	  the	  effect	  of	  TB	  and	  HIV	  was	  greatest	  on	  
different	  interferon	  modules,	  which	  may	  reflect	  a	  greater	  impact	  on	  type	  1	  interferon	  for	  
HIV	  and	  type	  2	  interferon	  for	  TB.	  	  Of	  practical	  importance	  this	  prominent	  overabundance	  of	  
interferon	  modules	  in	  HIV	  may	  be	  why	  interferon	  signalling	  transcripts	  were	  less	  prominent	  
in	  the	  subclinical	  signature	  as	  they	  would	  be	  expected	  to	  be	  less	  discriminatory.	  	  	  	  	  
	  
Following	  on	  from	  this	  in	  Chapter	  6,	  it	  was	  reasoned	  that	  if	  transcriptional	  differences	  were	  
present	  between	  these	  different	  stages	  of	  TB	  infection	  and	  disease	  then	  differences	  in	  the	  
concentration	  of	  proteins	  in	  either	  serum	  or	  QFGIT	  supernatant	  may	  also	  be	  present.	  	  The	  
selection	  of	  45	  analytes	  was	  informed	  by	  network	  analysis	  of	  the	  82	  transcriptional	  signature	  
and	  in	  addition,	  concentration	  of	  circulating	  immune	  complexes	  were	  determined	  to	  further	  
investigate	  the	  biological	  hypothesis	  posed	  above.	  	  Ten	  analytes	  were	  found	  to	  have	  a	  
significantly	  increased	  concentration	  in	  serum	  in	  those	  with	  active	  compared	  to	  latent	  TB	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after	  multiple	  testing	  corrections	  and	  1	  analyte,	  IL-­‐5,	  was	  also	  significantly	  higher	  in	  
subclinical	  compared	  to	  latent	  TB.	  	  The	  ability	  of	  these	  10	  analytes	  to	  distinguish	  active	  from	  
latent	  TB	  as	  determined	  by	  ROC	  analysis	  was	  generally	  very	  good	  and	  3	  analytes	  were	  more	  
discriminatory	  than	  CRP	  (which	  has	  been	  suggested	  as	  a	  screening	  tool	  in	  HIV	  associated	  
TB[302,	  303]);	  IP-­‐10,	  IL-­‐1α	  and	  IFNγ.	  	  IL-­‐1α	  with	  a	  cut-­‐off	  of	  16.9	  pg/mL	  and	  CIC	  with	  a	  cut-­‐
off	  of	  100.9	  µg	  Eq/mL	  individually	  classified	  50%	  and	  together	  70%	  of	  those	  with	  subclinical	  
TB	  as	  active	  TB.	  	  In	  addition	  when	  assessed	  across	  5	  stages	  of	  increasing	  disease	  activity	  by	  
PET	  findings	  and	  smear	  status	  all	  10	  analytes	  showed	  a	  significant	  increasing	  trend.	  	  Serum	  
analytes	  are	  attractive	  biomarkers	  as	  unlike	  transcriptional	  biomarkers	  they	  can	  easily	  be	  
developed	  into	  low	  cost	  diagnostic	  tests	  using	  existing	  technologies.	  	  These	  biomarkers	  
require	  validation	  in	  other	  cohorts.	  	  However	  these	  analytes	  could	  be	  particularly	  well	  suited	  
to	  HIV	  associated	  TB	  as	  levels	  of	  these	  analytes,	  in	  particular	  IP-­‐10,	  may	  be	  increased	  both	  by	  
TB	  disease	  itself	  and	  the	  accompanying	  increase	  in	  HIV	  VL.	  	  	  
	  
Of	  particular	  note	  the	  data	  highlighted	  CCL23	  as	  having	  a	  potential	  role	  in	  HIV	  associated	  TB	  
as	  both	  transcript	  abundance	  and	  serum	  levels	  were	  both	  elevated	  in	  active	  TB.	  	  	  However,	  
this	  chemokine	  has	  received	  little	  attention	  previously	  and	  warrants	  further	  study.	  	  In	  
general	  transcript	  abundance	  did	  not	  appear	  to	  correlate	  well	  with	  free	  serum	  levels	  of	  the	  
corresponding	  protein	  other	  than	  for	  haptoglobin.	  	  However,	  both	  C1QB	  expression	  and	  
SERPING1	  expression	  correlated	  well	  with	  CIC	  suggesting	  that	  in	  serum	  most	  of	  these	  
proteins	  may	  be	  bound	  to	  CIC.	  	  Both	  the	  transcriptomics	  and	  serological	  studies	  suggest	  that	  
increases	  in	  immune	  complex	  formation	  may	  occur	  from	  the	  early	  stages	  of	  reactivation	  but	  
little	  is	  known	  of	  the	  antibody	  specificity	  of	  these	  complexes	  particularly	  in	  the	  context	  of	  
HIV	  associated	  TB	  or	  to	  what	  extent	  they	  also	  occur	  at	  the	  disease	  site,	  which	  would	  be	  an	  
interesting	  area	  for	  further	  study.	  	  	  	  	  	  	  
	  
The	  use	  of	  QFGIT	  supernatant	  in	  biomarker	  discovery	  is	  attractive	  as	  it	  provides	  a	  
standardized	  commercial	  method	  of	  stimulating	  whole	  blood	  with	  mycobacteria	  specific	  
antigens.	  	  However,	  the	  data	  presented	  in	  Chapter	  6	  highlight	  that	  levels	  of	  pro-­‐
inflammatory	  cytokines	  are	  orders	  of	  magnitude	  higher	  in	  plasma	  from	  the	  QFGIT	  NIL	  tube	  
compared	  to	  serum	  in	  the	  population	  studied.	  	  This	  may	  result	  in	  masking	  of	  potentially	  
important	  findings.	  	  This	  effect	  may	  be	  exaggerated	  for	  HIV	  infected	  samples	  and	  potential	  
explanations	  may	  be,	  high	  circulating	  levels	  of	  fibrinogen	  or	  fibrin	  degradation	  products	  that	  
can	  activate	  TLR-­‐4	  or	  neutrophil	  necrosis	  leading	  to	  release	  of	  pro-­‐inflammatory	  contents.	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The	  results	  highlight	  the	  need	  to	  systematically	  investigate	  the	  utility	  of	  the	  QFGIT	  assay	  in	  
broader	  biomarker	  discovery	  especially	  in	  HIV	  infected	  individuals	  and	  consideration	  of	  ways	  
to	  optimize	  a	  whole	  blood	  assay	  so	  that	  potentially	  valuable	  cytokine	  and	  chemokines	  are	  
not	  overlooked.	  
	  
7.3 Impact	  of	  thesis	  on	  the	  field	  of	  tuberculosis	  research	  
Latent	  tuberculosis	  is	  a	  challenging	  field	  of	  study.	  	  Asymptomatic	  infection	  is	  defined	  only	  
through	  demonstration	  of	  immune	  sensitization	  by	  Mtb,	  the	  vast	  majority	  of	  those	  immune-­‐
sensitized	  do	  not	  go	  on	  to	  develop	  disease	  and	  in	  those	  that	  do,	  duration	  between	  infection	  
and	  disease	  presentation	  is	  variable	  and	  sometimes	  prolonged.	  	  Despite	  the	  need	  to	  have	  a	  
greater	  understanding	  of	  how	  and	  why	  persons	  with	  latent	  infection	  develop	  active	  TB	  to	  
facilitate	  both	  novel	  diagnostic	  and	  vaccine	  development,	  studying	  the	  natural	  history	  of	  
latent	  TB	  has	  clear	  ethical	  tensions	  given	  the	  availability	  of	  effective,	  though	  sub-­‐optimal,	  
preventive	  treatments.	  	  Another	  significant	  challenge	  is	  that	  no	  animal	  model	  of	  tuberculosis	  
accurately	  and	  completely	  represents	  human	  disease	  (especially	  not	  disease	  seen	  in	  adults)	  
and	  therefore	  much	  of	  our	  understanding	  of	  the	  natural	  history	  of	  latent	  tuberculosis	  
infection	  has	  come	  from	  historical	  autopsy	  studies	  and	  observational	  studies	  from	  the	  pre-­‐
chemotherapeutic	  era.	  	  	  
	  
The	  use	  of	  FDG-­‐PET/CT	  described	  in	  this	  thesis,	  therefore	  provides	  a	  novel	  research	  tool	  to	  
facilitate	  greater	  understanding	  of	  latent	  TB	  and	  is	  the	  first	  study	  to	  systematically	  utilise	  it	  
in	  this	  way.	  	  Its	  utility	  has	  already	  been	  demonstrated	  in	  non-­‐human	  primate	  models	  of	  TB	  
were	  it	  has	  been	  used	  to	  track	  evolution	  of	  granuloma	  over	  time	  in	  vivo	  without	  the	  need	  for	  
necropsy	  and	  it	  is	  being	  used	  in	  a	  number	  of	  studies	  of	  active	  TB	  to	  evaluate	  the	  response	  to	  
treatment[139,	  240].	  	  It	  has	  a	  number	  of	  strengths	  and	  weaknesses	  as	  a	  research	  tool	  in	  this	  
field.	  	  Firstly,	  it	  is	  comprised	  of	  2	  separate	  imaging	  modalities	  that	  independently	  and	  when	  
combined	  provide	  valuable	  information	  on	  underlying	  pathology.	  	  The	  CT	  provides	  
anatomically	  detailed	  information	  of	  normal	  and	  abnormal	  structures	  and	  pathology	  to	  a	  
resolution	  of	  1-­‐3mm	  (depending	  on	  protocols	  used),	  which	  in	  this	  study	  was	  utilised	  as	  the	  
primary	  means	  to	  define	  pathology	  to	  categorise	  participants.	  	  The	  FDG-­‐PET	  component	  
provides	  a	  tool	  to	  evaluate	  metabolic	  activity	  by	  providing	  a	  semi-­‐quantitative	  marker	  of	  
glucose	  uptake	  within	  structures	  that	  can	  be	  anatomically	  defined	  on	  CT.	  	  In	  the	  thesis	  this	  
was	  valuable	  in	  categorising	  participants	  with	  subclinical	  TB	  into	  those	  with	  high	  and	  low	  
Chapter	  7	  –	  General	  discussion	  and	  conclusions	  
	   239	  
metabolic	  activity	  in	  order	  to	  relate	  to	  transcript	  abundance	  and	  concentration	  of	  serological	  
markers.	  	  The	  FDG-­‐PET	  component	  is	  particularly	  useful	  in	  characterising	  lymph	  node	  
abnormalities	  especially	  when	  the	  CT	  is	  non-­‐contrasted.	  	  However,	  PET	  tends	  to	  
underestimate	  activity	  of	  lesions	  smaller	  than	  1	  cm	  although	  partial	  volume	  correction	  can	  
mitigate	  this	  to	  a	  certain	  degree.	  	  This	  underestimation	  was	  apparent	  in	  this	  study	  as	  active	  
nodules,	  which	  were	  likely	  to	  contain	  numerous	  metabolically	  active	  cells,	  being	  <5mm	  in	  
size	  did	  not	  display	  increased	  FDG	  activity.	  	  Furthermore,	  FDG	  is	  a	  non	  specific	  marker	  of	  
activity	  as	  was	  clear	  in	  this	  study	  as	  lymph	  node	  activity,	  likely	  relating	  to	  HIV	  infection,	  
displayed	  considerable	  FDG	  uptake	  especially	  within	  axillary	  lymph	  nodes.	  	  A	  setting	  where	  
FDG-­‐PET/CT	  may	  be	  particularly	  well	  suited	  is	  in	  the	  evaluation	  of	  recent	  HIV	  uninfected	  
household	  contacts	  of	  TB,	  in	  a	  recent	  case	  series	  of	  5	  household	  contacts	  reported	  by	  
Ghesani	  et	  al	  4	  had	  evidence	  of	  increased	  metabolic	  activity	  within	  mediastinal	  lymph	  nodes,	  
3	  of	  which	  showed	  improvement	  following	  IPT[137].	  	  FDG	  is	  the	  most	  commonly	  used	  tracer	  
used	  both	  in	  clinical	  practice	  and	  research	  and	  in	  the	  context	  of	  TB	  is	  primary	  taken	  up	  by	  
neutrophils	  and	  macrophages.	  	  However,	  there	  are	  numerous	  other	  markers	  that	  can	  be	  
used	  for	  the	  in	  vivo	  study	  of	  inflammatory	  processes	  as	  recently	  outlined	  in	  a	  review	  by	  Wu	  
et	  al[304].	  	  Of	  particular	  interest	  to	  TB	  research	  is	  the	  prospect	  of	  using	  radiolabeled	  matrix	  
metalloproteinases	  (MMP),	  IL-­‐2	  and	  TNFα	  which	  are	  currently	  being	  evaluated	  in	  pilot	  
studies[304].	  	  	  18[F]-­‐fluoromisonidazole	  (FMISO)	  is	  another	  marker	  that	  has	  been	  utilised	  in	  
TB	  research	  to	  evaluate	  hypoxia	  within	  TB	  lesions[305].	  	  TB	  specific	  tracers	  are	  also	  in	  
development	  with	  a	  radiolabelled	  analogue	  of	  trehalose	  (two	  1-­‐1	  α,	  α-­‐linked	  glucose	  
monomers	  that	  are	  incorporated	  into	  the	  mycobacterial	  cell	  wall	  by	  antigen	  85A	  enzymes)	  
being	  developed	  by	  the	  Barry	  laboratory	  at	  the	  National	  Institute	  of	  Allergy	  and	  Infectious	  
Diseases	  (NIAID).	  	  Although	  a	  promising	  tool	  in	  TB	  research,	  one	  of	  the	  ethical	  considerations	  
around	  its	  use	  is	  the	  ionizing	  radiation	  accompanying	  the	  scan	  (in	  this	  study	  effective	  
radiation	  dose	  per	  scan	  was	  approximately	  10mSv),	  which	  is	  a	  particular	  factor	  when	  
performing	  follow-­‐up	  imaging.	  	  	  
	  
A	  major	  contribution	  of	  this	  thesis	  has	  also	  been	  to	  demonstrate	  that	  the	  neat	  division	  of	  
tuberculosis	  into	  active	  and	  latent	  infection	  states	  is	  an	  oversimplification	  and	  supports	  the	  
idea	  of	  latent	  tuberculosis	  as	  a	  spectrum	  of	  infection	  states	  as	  has	  been	  proposed	  in	  a	  
number	  of	  recent	  studies[84-­‐86,	  89].	  	  The	  careful	  phenotyping	  of	  latent	  TB	  into	  potentially	  
lower	  and	  higher	  risk	  groups	  may	  facilitate	  biomarker	  discovery	  and	  genetic	  markers	  of	  risk	  
previously	  impeded	  by	  unrecognized	  heterogeneity	  in	  latent	  TB.	  	  Risk	  stratification	  of	  latent	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TB	  is	  currently	  most	  commonly	  performed	  on	  epidemiological	  grounds	  e.g.	  HIV	  infection,	  
recent	  migration	  from	  high	  burden	  setting	  etc.	  and	  is	  used	  to	  help	  make	  decisions	  on	  the	  
appropriateness	  of	  investigation	  for	  active	  TB	  and	  the	  administration	  of	  preventive	  therapy.	  	  
This	  strategy	  has	  limitations	  in	  that	  the	  majority	  of	  those	  with	  epidemiological	  risk	  factors	  
are	  still	  unlikely	  to	  develop	  disease	  and	  those	  considered	  at	  low	  risk	  that	  eventually	  develop	  
disease	  may	  have	  benefitted	  from	  receiving	  preventive	  therapy.	  	  The	  approach	  taken	  in	  this	  
thesis	  may	  lead	  to	  the	  development	  of	  biological	  markers	  of	  risk,	  to	  give	  an	  individual	  risk	  of	  
disease	  development	  rather	  than	  population	  risk	  of	  disease	  development.	  	  One	  
consideration	  is	  over	  what	  timeframe	  would	  such	  as	  biomarker	  be	  predictive;	  as	  it	  is	  likely	  
that	  these	  makers	  may	  perform	  better	  the	  in	  more	  advanced	  subclinical	  TB	  (as	  has	  been	  
suggested	  by	  data	  presented	  in	  this	  thesis).	  	  As	  a	  result	  they	  may	  be	  predictive	  over	  a	  
relatively	  short	  period	  of	  time	  –	  e.g.	  risk	  of	  TB	  over	  6	  -­‐	  12	  months	  rather	  than	  predictive	  of	  
life	  time	  risk	  	  
	  
The	  implications	  of	  the	  data	  presented	  in	  this	  thesis	  could	  have	  a	  significant	  effect	  on	  our	  
approach	  to	  managing	  latent	  TB,	  particularly	  in	  the	  setting	  of	  HIV	  infection.	  	  A	  proportion	  of	  
HIV	  infected	  persons	  considered	  to	  have	  a	  latent	  tuberculosis	  infection	  but	  no	  evidence	  of	  
active	  disease	  by	  the	  current	  diagnostic	  definitions	  (and	  hence	  eligible	  for	  IPT),	  have	  been	  
shown	  to	  have	  evidence	  of	  subclinical	  disease	  activity	  by	  FDG-­‐PET/CT.	  	  This	  subclinical	  group	  
have	  transcriptional	  and	  serological	  similarities	  with	  active	  TB	  and	  are	  likely	  to	  be	  at	  greater	  
risk	  of	  progressing	  to	  clinical	  disease.	  	  Four	  out	  of	  10	  with	  subclinical	  TB	  developed	  
symptoms	  and	  were	  commenced	  on	  standard	  TB	  treatment	  over	  the	  follow-­‐up	  period	  in	  this	  
study.	  	  This	  suggests	  HIV	  infected	  persons	  with	  latent	  TB	  infection	  do	  not	  represent	  a	  
homogenous	  group	  but	  contain	  a	  biologically	  distinct	  and	  identifiable	  group	  at	  greater	  risk	  of	  
disease.	  	  An	  immediate	  concern	  would	  be	  that	  6	  months	  IPT,	  the	  most	  common	  intervention	  
and	  recommended	  in	  the	  current	  South	  African	  guidelines,	  might	  be	  an	  inappropriate	  
therapy	  in	  this	  subclinical	  group.	  	  This	  is	  suggested	  by	  a	  recent	  study	  conducted	  by	  
Samandari	  et	  al	  in	  Botswana.	  	  HIV	  infected	  persons	  were	  randomised	  to	  6	  or	  36	  months	  IPT	  
irrespective	  of	  TST	  status,	  tuberculosis	  incidence	  began	  to	  increase	  in	  the	  group	  randomised	  
to	  6	  months	  IPT	  within	  6-­‐12	  months	  of	  stopping	  therapy[191].	  	  However,	  this	  increased	  TB	  
incidence	  was	  only	  seen	  in	  the	  TST	  positive	  group	  making	  reinfection	  after	  cure	  of	  latent	  TB	  
an	  unlikely	  explanation.	  	  A	  more	  plausible	  explanation	  of	  these	  findings	  would	  be	  
recrudescence	  of	  sub-­‐optimally	  treated	  subclinical	  disease.	  	  As	  a	  result	  of	  this	  and	  other	  
trials,	  36	  months	  IPT	  in	  HIV	  infected	  persons	  with	  latent	  TB	  infection	  has	  become	  a	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conditional	  recommendation	  of	  the	  WHO.	  	  36	  months	  IPT	  may	  effectively	  treat	  subclinical	  
TB,	  however,	  optimal	  treatment	  is	  unknown	  and	  may	  fall	  between	  the	  current	  3-­‐6	  month	  
preventive	  therapy	  and	  6	  month	  standard	  therapy	  regimens	  (if	  drug	  sensitive).	  	  
Furthermore,	  similarly	  to	  active	  TB,	  co-­‐administration	  of	  ART	  may	  be	  appropriate	  to	  
effectively	  manage	  subclinical	  TB.	  	  An	  obvious	  concern	  of	  sub-­‐optimally	  treated	  subclinical	  
TB	  by	  isoniazid	  monotherapy	  is	  the	  potential	  for	  acquired	  drug	  resistance.	  
	  
The	  concept	  of	  subclinical	  TB	  also	  has	  implications	  for	  screening	  for	  active	  TB.	  	  Currently	  in	  
HIV	  clinics	  in	  South	  Africa,	  patients	  undergo	  a	  symptom	  screen	  for	  active	  TB	  at	  each	  
appointment.	  	  If	  the	  screen	  is	  positive,	  patients	  are	  referred	  to	  the	  TB	  clinic	  for	  sputum	  
investigation	  (currently	  with	  GeneXpert)	  and	  commenced	  on	  TB	  therapy	  if	  TB	  is	  confirmed.	  	  
The	  aim	  of	  this	  approach	  is	  to	  identify	  cases	  of	  pre-­‐diagnostic	  TB	  (symptomatic	  but	  yet	  to	  
present	  clinically).	  	  If	  a	  low	  cost	  diagnostic	  test	  could	  be	  developed	  for	  subclinical	  TB	  which	  
was	  found	  to	  be	  predicative	  of	  risk	  of	  tuberculosis	  over	  the	  subsequent	  6-­‐12	  months	  this	  
could	  transform	  our	  approach	  to	  TB	  screening.	  	  This	  might	  allow	  for	  all	  patients	  to	  be	  
screened	  annually	  in	  the	  clinic	  irrespective	  of	  symptoms	  and	  then	  treated	  appropriately	  
before	  symptoms	  develop.	  	  The	  ability	  to	  detect	  subclinical	  TB	  also	  has	  implications	  for	  mass	  
screening	  and	  treatment	  strategies	  more	  generally.	  	  Recently,	  the	  theoretical	  benefits	  of	  5-­‐
year	  cycles	  of	  mass	  treatment	  of	  an	  entire	  population	  with	  standard	  TB	  therapy	  in	  order	  to	  
achieve	  TB	  elimination	  have	  been	  explored[306].	  	  Although	  modelling	  shows	  such	  an	  
approach	  could	  be	  highly	  effective	  at	  rapidly	  reducing	  TB	  incidence	  there	  are	  numerous	  
ethical	  and	  practical	  barriers	  to	  implementation.	  	  The	  approach	  of	  regular	  mass	  screening	  for	  
subclinical	  disease	  and	  targeting	  treatment	  at	  this	  population	  may	  prove	  a	  similarly	  effective	  
strategy	  that	  may	  be	  more	  easily	  accepted	  and	  implemented.	  	  	  	  	  	  
	  
A	  fundamental	  question	  is	  whether	  those	  with	  evidence	  of	  reactivation	  on	  PET/CT	  will	  
inevitably	  go	  on	  to	  develop	  disease	  given	  that	  spontaneous	  healing	  can	  occur.	  	  However,	  
even	  if	  spontaneous	  healing	  was	  to	  occur,	  data	  presented	  in	  this	  thesis	  and	  previous	  
epidemiological	  studies	  suggest	  that	  subsequent	  reactivation	  would	  be	  more	  likely.	  	  It	  may	  
be	  that	  such	  a	  group	  have	  a	  relatively	  unstable	  form	  of	  latent	  TB	  that	  follows	  a	  waxing	  and	  
waning	  course	  during	  which	  periods	  of	  progression	  triggered	  by	  precipitating	  factors	  may	  be	  
followed	  by	  control	  or	  the	  development	  of	  clinical	  disease.	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Several	  studies	  over	  the	  past	  few	  years	  have	  utilized	  whole	  blood	  transcriptomics	  both	  to	  
develop	  signatures	  that	  distinguish	  active	  from	  latent	  TB	  but	  also	  to	  gain	  insight	  into	  the	  
biology	  of	  the	  disease.	  	  A	  number	  of	  common	  biological	  themes	  have	  been	  identified	  
including	  interferon	  signalling,	  complement	  system,	  Fcγ	  receptor	  mediated	  phagocytosis	  and	  
the	  role	  of	  neutrophils	  [243].	  	  This	  thesis	  has	  contributed	  to	  the	  understanding	  of	  which	  of	  
these	  biological	  pathways	  are	  pertinent	  in	  early	  disease	  and	  which	  relate	  to	  more	  advanced	  
disease	  and	  what	  the	  effect	  of	  HIV	  infection	  is.	  	  The	  data	  show	  that	  abundance	  of	  neutrophil	  
related	  transcripts	  may	  be	  a	  feature	  of	  more	  advanced	  disease	  and	  increased	  complement	  
system	  and	  Fcγ	  receptor	  related	  transcripts	  and	  immune	  complex	  formation	  may	  occur	  from	  
early	  on	  in	  disease.	  	  Overabundance	  of	  interferon	  related	  transcripts	  are	  a	  feature	  of	  both	  
HIV	  and	  TB.	  	  This	  suggests	  that	  renewed	  focus	  on	  the	  role	  of	  B-­‐cells	  and	  immune	  complex	  
formation	  in	  TB	  may	  be	  required	  and	  that	  further	  investigation	  into	  the	  interaction	  of	  HIV	  
and	  TB	  through	  their	  mutual	  induction	  of	  type	  1	  interferon	  would	  be	  of	  great	  interest.	  	  Some	  
of	  the	  hypotheses	  generated	  by	  the	  transcriptomics	  data	  were	  then	  validated	  in	  serum	  in	  
particular	  the	  observation	  that	  CIC	  were	  elevated	  in	  serum	  in	  both	  active	  and	  advanced	  
subclinical	  TB	  in	  comparison	  to	  latent	  TB.	  	  	  	  
	  
Serum	  biomarkers	  that	  reliably	  identify	  subclinical	  TB	  would	  clearly	  have	  significant	  
translational	  potential	  diagnostically.	  	  Furthermore	  the	  possibility	  of	  a	  low	  cost	  POC	  test	  
would	  be	  feasible,	  as	  the	  lateral	  flow	  immunochomatographic	  platform	  has	  been	  widely	  
used	  for	  this	  purpose.	  	  The	  analysis	  described	  in	  this	  thesis	  was	  limited	  to	  the	  evaluation	  of	  
individual	  analytes	  to	  discriminate	  active	  and	  subclinical	  TB	  from	  latent	  TB	  using	  ROC	  
analysis.	  	  Although	  several	  individual	  analytes	  discriminated	  active	  and	  latent	  TB	  effectively,	  
the	  performance	  of	  individual	  analytes	  to	  distinguish	  latent	  and	  subclinical	  TB	  was	  relatively	  
poor.	  	  This	  analysis	  could	  be	  taken	  forward	  to	  attempt	  to	  identify	  a	  panel	  of	  biomarkers	  that	  
could	  be	  used	  distinguish	  these	  2	  groups	  more	  effectively.	  	  Classification	  and	  regression	  tree	  
(CART)	  analysis	  would	  be	  one	  approach	  to	  create	  a	  decision	  tree	  of	  the	  smallest	  number	  of	  
analyte	  cut-­‐offs	  that	  effectively	  separated	  those	  with	  subclinical	  and	  active	  TB	  from	  those	  
with	  latent	  TB.	  	  A	  panel	  of	  3-­‐6	  serum	  analytes	  could	  be	  easily	  developed	  initially	  into	  a	  
multiplex	  assay	  and	  taken	  forward	  for	  further	  validation	  in	  a	  new	  cohort	  to	  determine	  the	  
sensitivity	  and	  specificity	  of	  such	  a	  decision	  tree.	  	  These	  potential	  biomarkers	  could	  either	  be	  
evaluated	  in	  a	  similar	  cohort	  where	  PET/CT	  imaging	  is	  used	  to	  define	  subclinical	  pathology	  or	  
ideally	  in	  a	  natural	  history	  cohort	  or	  the	  placebo	  arm	  of	  a	  vaccine	  or	  preventive	  therapy	  trial	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where	  the	  predictive	  potential	  of	  the	  biomarkers	  for	  clinically	  active	  TB	  could	  be	  better	  
determined.	  	  	  	  	  	  	  	  	  	  	  	  	  
	  
While	  CXR	  screening	  may	  be	  reasonably	  effective	  at	  identifying	  pre-­‐diagnostic	  cases	  of	  TB,	  
the	  data	  presented	  in	  this	  thesis	  show	  that	  CXR	  performs	  poorly	  at	  detecting	  truly	  subclinical	  
cases	  of	  TB	  whether	  culture	  positive	  or	  culture	  negative.	  	  In	  these	  cases	  where	  pathology	  is	  
subtle	  even	  highly	  experienced	  radiologists	  disagree	  on	  findings	  and	  perform	  poorly	  against	  
a	  gold	  standard	  imaging	  modality.	  	  Furthermore,	  the	  data	  highlight	  that	  the	  performance	  of	  
CXR	  as	  a	  screening	  “test”	  in	  terms	  of	  sensitivity	  and	  specificity	  can	  vary	  considerably	  from	  
radiologist	  to	  radiologist.	  	  Unlike	  laboratory	  tests,	  there	  is	  no	  “limit	  of	  detection”	  for	  CXR	  
reporting,	  however,	  there	  comes	  a	  point	  at	  which	  the	  “noise”	  from	  overlying	  bony	  
structures	  prevents	  reliable	  detection	  of	  more	  subtle	  lesions.	  	  Advances	  in	  digital	  CXR	  
technology	  may	  help	  improve	  reliability	  of	  TB	  CXR	  screening.	  	  Dual	  energy	  subtraction	  
radiography	  (GE	  Healthcare)	  and	  ClearRead	  bone	  suppression	  software	  (Riverain	  
technologies)	  are	  2	  techniques	  that	  can	  digitally	  remove	  overlying	  bony	  structure.	  	  With	  dual	  
energy	  subtraction	  radiography	  2	  exposures	  of	  different	  energy	  are	  acquired	  and	  then	  bony	  
structures	  are	  digitally	  removed	  to	  create	  soft	  tissue	  only	  and	  bone	  only	  images	  in	  addition	  
to	  the	  standard	  image.	  	  ClearRead	  bone	  suppression	  is	  a	  software	  package	  that	  digitally	  
suppresses	  bony	  structure	  on	  the	  image	  viewer	  i.e.	  not	  requiring	  special	  imaging	  equipment	  
and	  not	  providing	  increased	  radiation	  exposure.	  	  These	  technologies	  have	  been	  shown	  to	  
improve	  detection	  of	  pulmonary	  nodules[307].	  	  In	  addition	  computer	  aided	  detection	  has	  
also	  been	  shown	  to	  further	  enhance	  detection	  of	  nodules	  alone	  and	  when	  combined	  with	  
these	  technologies[308].	  	  	  
	  
Finally,	  two	  potential	  limitations	  of	  the	  QFGIT	  assay	  have	  been	  highlighted,	  firstly	  the	  data	  
have	  questioned	  whether	  it	  is	  appropriate	  to	  have	  the	  same	  cut	  off	  for	  HIV	  infected	  and	  HIV	  
uninfected	  populations.	  	  Secondly,	  although	  the	  QFGIT	  platform	  is	  well	  suited	  to	  detect	  
interferon	  gamma	  release	  in	  whole	  blood	  following	  stimulation	  with	  mycobacterial	  antigens,	  
the	  platform	  may	  not	  be	  the	  ideal	  assay	  for	  biomarker	  discovery	  for	  other	  potentially	  
discriminatory	  biomarkers.	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7.4 Future	  direction	  for	  the	  field	  and	  research	  priorities	  
The	  challenge	  set	  to	  eliminate	  TB	  as	  a	  public	  heath	  problem	  by	  2050	  is	  undeniably	  ambitious	  
but	  one	  that	  if	  successful	  will	  have	  a	  profound	  impact	  on	  human	  health[11].	  	  TB	  is	  estimated	  
to	  have	  been	  responsible	  for	  1	  billion	  deaths	  globally	  between	  1700	  and	  1900,	  is	  currently	  
responsible	  for	  1.4	  million	  deaths	  annually	  and	  is	  still	  the	  leading	  cause	  of	  death	  in	  South	  
Africa.	  	  The	  WHO	  has	  recently	  approved	  a	  road	  map,	  which	  sets	  out	  a	  strategy	  and	  interim	  
targets	  to	  achieve	  this	  goal[13].	  	  A	  core	  part	  of	  this	  strategy	  is	  a	  commitment	  to	  TB	  research	  
and	  development	  as	  it	  is	  recognized	  that	  without	  novel	  vaccines,	  drugs	  and	  diagnostic	  tests	  
that	  the	  2050	  target	  is	  not	  feasible.	  
	  
How	  then	  should	  we	  move	  forward	  in	  the	  field	  of	  latent	  TB,	  recognizing	  that	  the	  effective	  
management	  of	  this	  reservoir	  of	  TB	  will	  become	  increasingly	  important	  as	  progress	  in	  TB	  
control	  is	  made?	  	  This	  thesis	  has	  highlighted	  that	  a	  proportion	  of	  those	  labelled	  as	  having	  
latent	  TB	  have	  evidence	  of	  reactivation	  and	  subclinical	  disease	  which	  may	  put	  them	  at	  
higher	  risk	  of	  disease	  progression.	  	  However,	  little	  is	  known	  about	  the	  precipitants	  for	  
reactivation	  and	  the	  critical	  events	  that	  lead	  to	  loss	  of	  host	  control	  or	  indeed	  the	  subsequent	  










Figure	  7.2	  –	  Knowns	  and	  unknowns	  in	  latent	  TB:	  -­‐	  We	  currently	  have	  estimates	  for	  proportion	  of	  population	  that	  are	  
immune	  sensitized	  (large	  circle)	  and	  number	  of	  cases	  of	  active	  TB	  annually	  (small	  filled	  circle).	  As	  TST	  and	  IGRA	  reversion	  
can	  occur,	  total	  number	  of	  exposed	  persons	  may	  be	  greater	  than	  this	  (larger	  dashed	  circle),	  in	  addition	  TST	  and	  IGRA	  are	  
only	  moderately	  sensitive	  for	  active	  TB.	  A	  much	  smaller	  pool	  of	  people	  may	  be	  at	  much	  higher	  risk	  of	  TB	  (bottom	  small	  
dashed	  circle)	  and	  also	  a	  proportion	  of	  people	  may	  receive	  considerable	  protection	  against	  reinfection	  (top	  small	  dashed	  
circle).	  Identifying	  these	  additional	  populations	  may	  be	  very	  valuable.	  From	  Esmail	  et	  al	  [88]	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all	  those	  that	  show	  evidence	  of	  immune	  sensitization,	  hence	  labelled	  as	  having	  latent	  TB,	  are	  
all	  infected	  with	  viable	  bacilli.	  	  It	  may	  be	  that	  some	  individuals	  have	  succeeded	  in	  eliminating	  
the	  organism,	  while	  maintaining	  immune	  sensitization,	  and	  are	  thus	  at	  no	  risk	  at	  all	  of	  
reactivation.	  	  In	  addition,	  and	  perhaps	  most	  intriguingly,	  the	  epidemiological	  data	  suggest	  
that	  those	  that	  are	  considered	  latently	  infected,	  may	  be	  at	  reduced	  risk	  of	  disease	  following	  
reinfection[42,	  309-­‐311].	  	  This	  suggests	  that	  for	  some,	  there	  maybe	  a	  protective	  effect	  from	  
natural	  infection	  supported	  by	  animal	  studies[312].	  	  Embracing	  and	  trying	  to	  understand	  this	  
heterogeneity	  within	  the	  spectrum	  of	  latent	  TB	  may	  give	  important	  insight	  into	  desirable	  
and	  undesirable	  immune	  responses,	  markers	  of	  protection	  and	  risk,	  that	  will	  be	  of	  value	  in	  
the	  future	  development	  of	  both	  vaccines	  and	  diagnostics	  (figure	  7.2).	  	  	  
	  
In	  addition	  to	  defining	  markers	  of	  risk	  and	  protection,	  developing	  an	  optimal	  marker	  of	  
exposure	  may	  also	  be	  of	  value.	  	  Although	  TST	  and	  IGRA	  are	  recognised	  to	  be	  poorly	  
predictive,	  they	  are	  also	  suboptimal	  markers	  of	  exposure	  as	  they	  both	  undergo	  spontaneous	  
reversion	  and	  sensitivity	  in	  those	  with	  active	  tuberculosis	  (hence	  undeniably	  exposed)	  is	  at	  
best	  85-­‐90%.	  	  A	  more	  sensitive	  marker	  of	  Mtb	  exposure	  would	  give	  a	  better	  understanding	  
of	  TB	  transmission	  dynamics.	  	  Ultimately,	  it	  is	  worth	  recognizing	  that	  one	  test	  can’t	  do	  it	  all,	  
as	  a	  single	  test	  cannot	  be	  both	  highly	  predictive	  for	  active	  TB	  and	  a	  sensitive	  marker	  of	  
exposure,	  as	  these	  test	  characteristics	  are	  to	  a	  degree	  a	  mutually	  exclusive.	  
	  
Finally,	  diagnostics	  are	  only	  one	  side	  of	  the	  coin	  to	  latent	  TB.	  	  If	  preventive	  treatment	  is	  
prolonged	  or	  has	  unacceptable	  side	  effects,	  widespread	  implementation	  in	  an	  asymptomatic	  
population	  is	  challenging.	  	  Isoniazid,	  in	  many	  ways,	  is	  an	  unusual	  drug	  of	  choice	  for	  
treatment	  of	  latent	  TB	  given	  its	  main	  effect	  on	  actively	  replicating	  organisms	  and	  poor	  
sterilizing	  ability.	  	  Several	  novel	  agents	  are	  coming	  through	  the	  TB	  drug	  discovery	  pipeline	  
which	  may	  be	  promising	  candidates	  for	  preventive	  therapy	  either	  alone	  or	  in	  combination	  
(not	  with	  standing	  toxicity	  issues),	  such	  as	  bedaquiline,	  delamanid,	  sutezolid	  and	  
moxifloxacin.	  	  However,	  a	  critical	  issue	  is	  also	  how	  best	  to	  evaluate	  these	  new	  drug	  
regimens.	  	  Phase	  3	  studies	  for	  novel	  preventive	  treatments	  in	  latent	  TB	  will	  require	  
thousands	  of	  participants	  to	  be	  followed	  up	  for	  several	  years	  in	  multisite	  studies	  as	  the	  
outcome	  of	  active	  TB	  is	  comparatively	  rare.	  	  Validated	  biomarkers	  of	  risk	  would	  greatly	  
facilitate	  these	  studies	  by	  potentially	  reducing	  the	  sample	  sizes	  required	  by	  concentrating	  
the	  study	  on	  a	  population	  at	  greater	  risk	  of	  disease.	  	  In	  addition	  validated	  surrogate	  end	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points	  that	  related	  to	  successful	  treatment	  of	  latent	  TB	  could	  help	  in	  selection	  of	  promising	  
candidates	  in	  Phase	  2	  studies,	  this	  could	  take	  the	  form	  of	  blood,	  urine	  or	  imaging	  biomarker.	  	  
	  
Our	  approach	  to	  latent	  tuberculosis	  and	  TB	  control	  would	  be	  transformed	  by,	  an	  inexpensive	  
point	  of	  care	  diagnostic	  that	  provided	  an	  accurate	  assessment	  of	  likelihood	  of	  progression,	  
coupled	  with	  a	  single	  dose	  preventive	  treatment.	  	  This	  would	  enable	  roll	  out	  of	  mass	  testing	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APPENDIX	  A	  –	  Brief	  summary	  of	  PBMC	  
experiments	  not	  included	  in	  thesis	  
Blood	  was	  collected	  at	  each	  time	  point	  in	  NaHep	  tubes	  for	  the	  isolation	  of	  PBMC	  (see	  Table	  
2.2).	  	  PBMC	  were	  then	  cryopreserved	  and	  experiments	  performed	  after	  the	  completion	  of	  
follow-­‐up.	  	  The	  PBMC	  experiments	  were	  not	  included	  in	  this	  thesis	  for	  the	  reasons	  explained	  
below.	  	  The	  primary	  purpose	  of	  PBMC	  isolation	  was	  to	  perform	  a	  longitudinal	  ELISPOT	  
experiment	  to	  address	  the	  hypothesis	  that	  isoniazid	  therapy	  would	  result	  in	  a	  greater	  
increase	  in	  T	  cell	  responses	  to	  TB	  antigens	  during	  treatment	  in	  those	  with	  subclinical	  TB	  
compared	  to	  those	  with	  latent	  TB	  and	  no	  evidence	  of	  subclinical	  pathology.	  	  The	  rationale	  
for	  this	  was	  that,	  isoniazid	  is	  rapidly	  bactericidal	  against	  actively	  replicating	  bacilli	  (a	  greater	  
number	  of	  which	  would	  be	  expected	  in	  subclinical	  TB)	  by	  means	  of	  cell	  wall	  damage.	  	  A	  20-­‐
fold	  increase	  in	  secretion	  of	  mycobacterial	  proteins	  has	  been	  demonstrated	  to	  occur	  shortly	  
after	  isoniazid	  administration	  in	  vitro	  and	  in	  clinical	  studies	  in	  HIV	  uninfected	  persons,	  
preventive	  treatment	  of	  latent	  TB	  resulted	  in	  a	  1.8	  fold	  increase	  in	  IFNγ	  production	  by	  T	  cells	  
to	  TB	  antigens	  [241,	  242].	  	  	  
	  
T	  cell	  responses	  were	  measured	  by	  IFN-­‐γ	  and	  IL-­‐2	  ELISPOT	  at	  screening	  (-­‐6	  weeks),	  baseline	  
(day	  of	  PET/CT),	  1	  week,	  1	  month,	  3	  months	  and	  6	  month	  to	  the	  antigens	  outlined	  in	  Table	  
A1.	  	  	  Samples	  were	  collected	  over	  a	  period	  of	  24	  months,	  during	  this	  period	  2	  batches	  of	  
NaHep	  tubes	  were	  subsequently	  found	  to	  have	  been	  contaminated	  by	  LPS.	  	  This	  had	  the	  
effect	  of	  increasing	  the	  background	  number	  of	  spot	  forming	  cells	  in	  the	  ELISPOT	  assay	  
resulting	  in	  indeterminate/invalid	  results	  for	  a	  number	  of	  the	  follow-­‐up	  samples.	  	  Most	  
Table	  A1	  –	  TB	  antigens	  used	  in	  ELISPOT	  experiment	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participants	  were	  affected	  for	  at	  least	  1	  follow-­‐up	  time	  point.	  	  In	  addition,	  because	  
participants	  were	  managed	  as	  clinically	  indicated	  during	  follow-­‐up,	  4	  participants	  (all	  in	  the	  
subclinical	  group)	  were	  commenced	  on	  standard	  TB	  therapy	  with	  2	  of	  these	  participants	  and	  
an	  additional	  participant	  commenced	  on	  ART.	  	  This	  created	  confounding	  factors	  not	  initially	  
anticipated.	  	  Furthermore,	  the	  difficulties	  in	  follow-­‐up	  described	  previously	  (section	  2.7)	  
resulted	  in	  only	  89.4%	  of	  samples	  required	  being	  available.	  	  Taken	  together	  this	  meant	  that	  
meaningful	  analysis	  to	  address	  the	  hypothesis	  posed	  was	  not	  possible	  and	  hence	  data	  was	  
not	  included	  as	  part	  of	  the	  thesis.	  	  	  
	  
PBMC	  samples	  from	  the	  day	  of	  PET/CT	  scan	  were	  also	  used	  for	  a	  smaller	  flow	  cytometry	  
experiment	  to	  address	  the	  hypothesis	  that	  functionality	  (in	  terms	  of	  IFN-­‐γ,	  IL-­‐2	  and	  TNF-­‐α	  
production)	  and	  memory/senescence	  phenotype	  (in	  terms	  of	  CD45RA/CD27/CD57	  
expression)	  of	  ESAT-­‐6/CFP-­‐10	  specific	  CD4	  T	  cells	  would	  differ	  between	  those	  with	  
subclinical	  TB	  and	  those	  with	  latent	  TB	  and	  no	  evidence	  of	  subclinical	  pathology.	  	  The	  
rationale	  being	  that	  chronic	  antigen	  exposure	  in	  subclinical	  TB	  may	  lead	  to	  terminal	  
differentiation	  and	  senescence	  of	  antigen	  specific	  T	  cells	  with	  accompanying	  change	  in	  
functionality	  as	  has	  been	  described	  in	  chronic	  viral	  infection.	  	  Though	  the	  samples	  taken	  on	  
the	  day	  of	  PET/CT	  scan	  were	  less	  affected	  by	  LPS	  contamination	  the	  results	  were	  not	  
considered	  substantial	  enough	  to	  form	  a	  chapter	  of	  the	  thesis	  and	  were	  not	  related	  to	  work	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APPENDIX	  B	  –	  Approvals	  for	  Study	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APPENDIX	  C	  –	  Consent	  forms	  
Screening	  Consent	  Form	  
	  









How inactive is “inactive” Tuberculosis?  
PET/CT Benchmarking of Latent Tuberculosis Infection 
 
	  
SCREENING	  CONSENT	  FORM	  
	  
My	  name	  is	  _______________________	  
	  
We	  would	  like	  to	  SCREEN	  you	  to	  see	  if	  you	  can	  participate	  in	  our	  study.	  	  
	  
Tuberculosis	  infection	  is	  very	  common	  in	  Khayelitsha	  where	  60-­‐70%	  of	  are	  infected	  with	  tuberculosis	  
but	  are	  well	  and	  can’t	  pass	  the	  infection	  on,	  this	  condition	  is	  known	  as	  latent	  tuberculosis	  infection.	  	  
Some	   people	   with	   latent	   tuberculosis	   especially	   if	   they	   have	   HIV	   as	   well	   will	   become	   sick	   from	  
tuberculosis.	  	  The	  purpose	  of	  our	  study	  is	  to	  see	  if	  everyone	  living	  with	  HIV	  that	  is	  infected	  with	  TB	  is	  
at	   the	   same	   risk	   of	   becoming	   sick	   from	   tuberculosis.	   	   This	  will	   help	   us	   to	   develop	   tests	   to	   identify	  
those	  who	  most	  and	  least	  need	  treatment	  for	  TB	  and	  will	  help	  us	  make	  progress	  toward	  getting	  rid	  of	  
TB	  as	  a	  major	  health	  problem	   in	   the	   long	  run.	   	  This	  study	   is	  being	  run	  by	  the	   Institute	  of	   Infectious	  
Diseases	   and	   Molecular	   Medicine	   at	   the	   University	   of	   Cape	   Town	   and	   has	   been	   funded	   by	   the	  
Wellcome	   Trust.	   Prof	   Robert	   J	   Wilkinson	   is	   the	   Principal	   Investigator.	   	   This	   study	   has	   also	   been	  
approved	  by	  the	  Human	  Research	  Ethics	  Committees	  of	  the	  University	  of	  Cape	  Town	  and	  Stellenbosch	  
University	   and	   will	   be	   conducted	   according	   to	   international	   standards	   of	   Good	   Clinical	   Practice,	  
applicable	  South	  African	  government	  regulations,	  and	  Institutional	  research	  policies	  and	  procedures.	  
	  
You	  will	  receive	  a	  Subject	  Information	  Sheet	  which	  explains	  the	  study	  and	  the	  risks	  and	  benefits	  of	  
taking	  part	  in	  more	  detail.	  
	  	  
Before	  you	  can	  participate	  fully	  in	  the	  study	  we	  need	  to	  make	  sure	  that	  there	  are	  no	  reasons	  why	  you	  
wouldn’t	  be	  able	  to	  take	  part.	  	   IT	  IS	  ENTIRELY	  UP	  TO	  YOU	  TO	  DECIDE	  WHETHER	  OR	  NOT	  YOU	  WHAT	  
TO	  ALLOW	  US	  TO	  SCREEN	  YOU	  FOR	  THIS	  STUDY.	  	  If	  you	  agree	  we	  would	  like	  to	  ask	  you	  permission	  to	  
allow	  a	  doctor	  working	  with	  the	  study	  to	  ask	  you	  some	  questions	  and	  examine	  you.	  Also	  we	  would	  
like	   to	   take	   8	   -­‐11	   tea-­‐spoons	   of	   blood	   to	   check	   that	   you	   have	   TB	   infection	   and	   to	   check	   your	   CD4	  
count,	  a	  urine	  sample	  to	  make	  sure	  that	  women	  are	  not	  pregnant,	  we	  would	   like	  you	  to	  produce	  a	  
cough	  sample	  for	  us	  which	  might	  involve	  breathing	  in	  a	  fine	  mist	  of	  salty	  water	  (called	  a	  nebuliser)	  to	  
see	  if	  we	  can	  grow	  any	  TB,	  this	  will	  cause	  you	  to	  cough	  but	  is	  generally	  well	  tolerated,	  please	  inform	  
study	  staff	   if	   you	  have	  asthma	   in	  which	  case	  you	  should	  not	  have	  sputum	   induced.	   	   In	  addition	  we	  
would	  like	  to	  take	  a	  CXR.	  	  Some	  of	  these	  tests	  may	  have	  already	  been	  done	  as	  part	  of	  your	  screening	  
Principal Investigator 
Prof. Robert J. Wilkinson MA, PhD, FRCP 
Wellcome Trust Senior Research Fellow 
Honorary Professor (IIDMM) 
r.j.wilkinson@imperial.ac.uk 
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Wellcome Trust Clinical Research Training 
Fellow 
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for	  other	  studies	  in	  which	  case	  they	  will	  not	  be	  repeated.	  	  We	  would	  then	  like	  to	  see	  you	  in	  6	  weeks	  to	  
repeat	   your	   chest	   X-­‐Ray	   and	   go	   through	   you	   test	   results	   with	   you.	   	   You	  will	   not	   be	   liable	   for	   any	  
expense	   relating	   to	   these	   investigations	   and	  will	   be	   reimbursed	  R30	   as	   compensation	   for	   time	  and	  
travel.	  	  
	  
Please	  note	  that	  with	  your	  consent	  some	  of	  your	  blood	  and	  urine	  that	  you	  provide	  will	  be	  stored	  
safely	  at	  the	  IIDMM	  for	  use	  in	  this	  research	  study	  or	  future	  studies	  related	  to	  this	  project.	  
	  
Although	   these	   tests	   very	   rarely	   causes	   problems,	   if	   anything	   goes	   wrong	   the	   University	   provides	  
insurance	   to	   cover	   this	   possibility.	   	   If	   you	   have	   any	   concerns	   regarding	   following	   any	   procedure	  
performed	  as	  part	  of	  the	  study	  you	  may	  contact	  the	  study	  doctor.	  	  	  
	  
Please	   take	   time	   to	   read	   through	   the	  Subject	   information	   sheet	  before	  your	  next	  appointment	  and	  
make	  a	  note	  of	  any	  questions	   that	  you	  might	   like	   to	  discuss	   further.	   	  We	  will	  answer	   these	   for	  you	  
when	  we	  go	  over	  your	  results	  with	  you.	  	  	  
	  
Today	  you	  are	  only	  being	  asked	  to	  give	  consent	  to	  be	  screened	  to	  see	  if	  you	  have	  the	  right	  features	  
for	  this	  study,	  you	  are	  not	  agreeing	  at	  this	  stage	  to	  take	  part	  formally	  in	  the	  study.	  	  We	  will	  ask	  for	  you	  
consent	  again	  at	  the	  next	  visit	  if	  you	  wish	  to	  take	  part,	  but	  the	  decision	  to	  participate	  is	  entirely	  your	  
own.	  IF	  YOU	  DECIDE	  NOT	  TO	  PARTICIPATE,	  YOUR	  TREATMENT	  WILL	  NOT	  BE	  DIASDVANTAGED	  IN	  ANY	  
WAY.	  In	  addition,	  at	  any	  point	  during	  the	  trial	  you	  are	  free	  to	  withdraw	  without	  telling	  us	  why.	   	  We	  
are	  aiming	  to	  recruit	  56	  participants	  from	  Cape	  Town.	  
	  
Since	  this	  is	  a	  research	  test,	  the	  results	  will	  not	  be	  made	  available	  to	  the	  participants	  however	  you	  will	  
be	   informed	  of	  any	  new	  relevant	   information	   that	  arises	  during	   the	  course	  of	   the	   trial.	  Throughout	  
the	  trial	  your	  privacy	  will	  be	  maintained	  and	  nobody	  other	  than	  the	  doctors	  and	  nurses	  looking	  after	  
you	  will	  know	  that	  you	  are	  participating.	  Samples	  will	  be	  labelled	  with	  code	  numbers	  and	  hence	  the	  
laboratory	  staff	  will	  not	  know	  your	  identity.	  When	  the	  results	  of	  the	  study	  become	  available,	  names	  
of	   the	  participating	  patients	  will	  not	  be	   included.	   	  The	  Research	  Ethics	  Committees	  may	   inspect	  the	  
research	  records	  if	  required.	  	  	  You	  may	  inform	  your	  general	  practitioner	  of	  involvement	  in	  the	  study.	  	  
	  
Do	  you	  have	  any	  questions?	  You	  may	  contact	  either	   the	  UCT	  Research	   Ethics	   Committee	   (021	  406	  
6492)	  Prof Robert Wilkinson (021 406 6084) or Dr Hanif Esmail (021 406 6389)	  if	  you	  have	  further	  
questions.	   Please	   remember	   that	   Prof	  Wilkinson	   and	   Dr	   Esmail	   will	   not	   be	   directly	   responsible	   for	  
your	  medical	  care	  which	  will	  be	  conducted	  by	  your	  regular	  doctors	  and	  nurses.	  
	  
	  
Consent	  to	  be	  SCREENED	  to	  participate	  in	  the	  study:	  
	  
I	  have	  read	  the	  above	  /	  the	  above	  has	  been	  read	  to	  me	  and	  I	  have	  had	  the	  opportunity	  to	  discuss	  the	  	  


















	   255	  
Study	  Consent	  Form	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INFORMED	  CONSENT	  FORM	  FOR	  STUDY	  ENTRY	  
	  
My	  name	  is	  _______________________	  
	  
We	  are	  asking	  you	  to	  take	  part	  in	  our	  study.	  You	  were	  found	  to	  have	  latent	  tuberculosis	  infection	  as	  
part	  of	  screening	  for	  the	  vaccine	  study.	  	  We	  have	  seen	  you	  on	  2	  occasions	  over	  the	  last	  few	  weeks	  and	  
have	  made	  sure	  that	  your	  X-­‐Ray	  has	  not	  got	  any	  worse,	  that	  you	  remain	  free	  of	  symptoms	  and	  that	  
you	  meet	  all	  the	  criteria	  for	  our	  study.	  
	  
You	  should	  have	  received	  a	  Study	  Information	  Sheet,	  which	  explains	  in	  detail	  the	  risks	  and	  benefits	  
of	  the	  study	  as	  well	  as	  what	  to	  expect	  once	  you	  join,	  and	  had	  plenty	  of	  time	  to	  read	  it	  and	  go	  
through	  any	  questions	  you	  have	  with	  a	  study	  staff	  member.	  	  If	  there	  are	  any	  outstanding	  questions	  
feel	  free	  to	  ask	  now.	  
	  
The	  purpose	  of	  our	  study	  is	  to	  see	  if	  everyone	  that	  is	  infected	  with	  TB	  is	  at	  the	  same	  risk	  of	  becoming	  
unwell.	   	  This	  will	  help	  us	  to	  develop	  tests	   identify	  those	  who	  most	  and	   least	  need	  treatment	  for	  TB	  
and	  will	  help	  us	  make	  progress	   toward	  getting	   rid	  of	   tuberculosis	  as	  a	  major	  health	  problem	   in	   the	  
long	  run.	  	  This	  study	  is	  being	  run	  by	  the	  Institute	  of	  Infectious	  Diseases	  and	  Molecular	  Medicine	  at	  the	  
University	  of	  Cape	  Town	  and	  has	  been	  funded	  by	  the	  Wellcome	  Trust.	  Prof	  Robert	  J	  Wilkinson	  is	  the	  
Principal	  Investigator.	  	  This	  study	  has	  also	  been	  approved	  by	  the	  Human	  Research	  Ethics	  Committees	  
of	   the	   University	   of	   Cape	   Town	   and	   Stellenbosch	   University	   and	   will	   be	   conducted	   according	   to	  
international	   standards	   of	   Good	   Clinical	   Practice,	   applicable	   South	   African	   government	   regulations,	  
and	  Institutional	  research	  policies	  and	  procedures.	  	  56	  participants	  from	  Cape	  Town	  are	  planned	  to	  be	  
recruited	  into	  this	  study	  
	  
If	  you	  agree	  we	  will	  start	  you	  on	  9	  months	  of	  standard	  treatment	  for	  inactive	  TB	  after	  you	  have	  had	  a	  
PET/CT	  scan.	  This	  will	  occur	  at	  some	  point	  in	  the	  next	  week.	  	  After	  starting	  treatment	  you	  will	  be	  seen	  
after	  a	  week	  and	  then	  monthly	  until	  you	  complete	  treatment.	  	  You	  will	  receive	  a	  repeat	  PET/CT	  after	  6	  
months	  of	   treatment.	  At	   5	   of	   the	   visits	  we	  will	   take	  between	  8	   and	  11	   teaspoons	  of	   blood	   for	   the	  
study	  and	  a	  urine	   sample.	   	   You	  will	   receive	  a	   total	   of	  R400	   spread	  over	   the	   course	  of	   the	   study	   to	  
compensate	  you	  for	  time	  and	   loss	  of	  earnings.	   	  Please	  note	  that	  once	  you	  start	  your	  treatment	   it	   is	  
extremely	  important	  that	  you	  continue	  to	  take	  it	  until	  the	  end	  of	  the	  study.	  	  If	  there	  are	  any	  problems	  
with	  taking	  the	  medicine	  you	  must	  inform	  the	  study	  staff.	  	  Prior	  to	  the	  PET/CT	  scan	  we	  may	  give	  you	  a	  
single	  oral	  dose	  of	  propranolol	   (up	   to	  40mg)	  which	   is	  commonly	  used	  to	   reduce	  activity	  of	  your	   fat	  
deposits	  to	  improve	  the	  quality	  of	  the	  PET/CT	  scan,	  we	  do	  not	  expect	  you	  experience	  any	  side	  effects	  
from	  this	  tablet	  but	   if	  you	  suffer	   from	  asthma	  you	  will	  not	  receive	   it.	   	  You	  will	  not	  be	   liable	   for	  any	  
expense	  relating	  to	  these	  investigations.	  	  	  	  	  	  
Study Doctor 
Dr Hanif Esmail MA, MRCP, FRCPath 
Wellcome Trust Clinical Research Training 
Fellow 




Prof. Robert J. Wilkinson MA, PhD, FRCP 
Wellcome Trust Senior Research Fellow 
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One	   of	   the	   blood	   samples	   will	   be	   stored	   for	   genetic	   tests.	   	   Genes	   are	   codes	   in	   you	   body	   that	  
determine	  your	   individual	   characteristics,	   including	  how	  your	   immune	  system	   (your	  body’s	  defence	  
system)	   functions.	   	  The	  only	  genetic	   tests	   that	  would	  be	  done	  on	  your	  sample	  would	  be	   to	   test	   for	  
genes	  involved	  in	  you	  body’s	  response	  to	  tuberculosis.	  	  No	  tests	  will	  be	  done	  for	  genetic	  diseases	  or	  
any	  other	  conditions	  not	  related	  to	  tuberculosis.	  	  
	  
Although	   the	   tests	   in	   the	   study	   very	   rarely	   causes	  problems,	   if	   anything	   goes	  wrong	   the	  University	  
provides	   insurance	   to	   cover	   this	   possibility.	   	   If	   you	   have	   any	   concerns	   regarding	   following	   any	  
procedure	  performed	  as	  part	  of	  the	  study	  you	  may	  contact	  the	  study	  doctor.	  	  	  
	  
The	   decision	   to	   participate	   is	   entirely	   your	   own.	   IF	   YOU	   DECIDE	   NOT	   TO	   PARTICIPATE,	   YOUR	  
TREATMENT	  WILL	  NOT	  BE	  DIASDVANTAGED	  IN	  ANY	  WAY.	  In	  addition,	  at	  any	  point	  during	  the	  trial	  you	  
are	  free	  to	  withdraw	  without	  telling	  us	  why.	  
	  
Since	  these	  are	  research	  tests,	  the	  results	  will	  not	  be	  made	  available	  to	  the	  participants,	  however	  you	  
will	   be	   informed	   of	   any	   new	   relevant	   information	   that	   arises	   during	   the	   course	   of	   the	   trial.	  
Throughout	  the	  trial	  your	  privacy	  will	  be	  maintained	  and	  nobody	  other	  than	  the	  doctors	  and	  nurses	  
looking	  after	   you	  will	   know	   that	   you	  are	  participating.	   Samples	  will	   be	   labelled	  with	   code	  numbers	  
and	  hence	   the	   laboratory	   staff	  will	   not	   know	   your	   identity.	  When	   the	   results	   of	   the	   study	   become	  
available,	  names	  of	  the	  participating	  patients	  will	  not	  be	  included.	   	  The	  Research	  Ethics	  Committees	  
may	   inspect	   the	   research	   records	   if	   required.	   	   	   You	   may	   inform	   your	   general	   practitioner	   of	  
involvement	  in	  the	  study	  
	  
Please	  note	  that	  with	  your	  consent	  some	  of	  your	  blood	  and	  urine	  that	  you	  provide	  will	  be	  stored	  
safely	  at	  the	  IIDMM	  for	  use	  in	  this	  research	  study	  or	  future	  studies	  related	  to	  this	  project.	  
	  
	  
You	  may	  contact	  either	  the	  UCT	  Research	  Ethics	  Committee	  (021	  406	  6492)	  Prof Robert Wilkinson 
(021 406 6084) or Dr Hanif Esmail (021 406 6389)	  if	  you	  have	  further	  questions	  at	  any	  point	  during	  
the	  study.	  Please	  remember	  that	  Prof	  Wilkinson	  and	  Dr	  Esmail	  will	  not	  be	  directly	  responsible	  for	  your	  
medical	  care	  which	  will	  be	  conducted	  by	  your	  regular	  doctors	  and	  nurses.	  
	  
	  
Consent	  to	  participate	  in	  the	  study:	  
	  
I	  have	  read	  the	  above	  /	  the	  above	  has	  been	  read	  to	  me	  and	  I	  have	  had	  the	  opportunity	  to	  discuss	  the	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Normal	  CXR,	  LTBI	  Control	  Consent	  Form	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LTBI	  CONTROL	  CONSENT	  FORM	  
	  
My	  name	  is	  _______________________	  
	  
The	  purpose	  of	  our	  study	  is	  to	  see	  if	  in	  some	  people	  with	  “silent”	  or	  latent	  TB,	  we	  can	  find	  differences	  
that	  mean	  they	  might	  be	  more	  likely	  to	  become	  unwell.	  	  This	  will	  help	  us	  to	  develop	  tests	  to	  identify	  
those	  who	  most	  and	  least	  need	  treatment	  for	  latent	  TB	  and	  will	  help	  us	  make	  progress	  toward	  getting	  
rid	   of	   TB	   as	   a	  major	   health	   problem	   in	   the	   long	   run.	   	   The	  main	   part	   of	   the	   study	   involves	   using	   a	  
PET/CT	  scan	  to	  assess	  the	  activity	  of	  scars	  caused	  by	  tuberculosis	  that	  can	  be	  seen	  on	  a	  chest	  x-­‐ray.	  	  
This	   study	   is	   being	   run	   by	   the	   Institute	   of	   Infectious	   Diseases	   and	   Molecular	   Medicine	   at	   the	  
University	  of	  Cape	  Town	  and	  has	  been	  funded	  by	  the	  Wellcome	  Trust.	  Prof	  Robert	  J	  Wilkinson	  is	  the	  
Principal	  Investigator.	  	  This	  study	  has	  also	  been	  approved	  by	  the	  Human	  Research	  Ethics	  Committees	  
of	   the	   University	   of	   Cape	   Town	   and	   Stellenbosch	   University	   and	   will	   be	   conducted	   according	   to	  
international	   standards	   of	   Good	   Clinical	   Practice,	   applicable	   South	   African	   government	   regulations,	  
and	  Institutional	  research	  policies	  and	  procedures.	  	  .	  	  	  
	  
Your	  chest	  x-­‐ray	  is	  normal.	  however,	  we	  have	  found	  that	  you	  have	  latent	  tuberculosis	   infection	  that	  
requires	  treatment	  with	  isoniazid	  (INH).	  	  We	  do	  not	  need	  to	  perform	  a	  PET/CT	  scan.	  	  	  
	  
We	  would	  like	  to	  ask	  you	  to	  be	  a	  control	  subject	  for	  our	  study,	  to	  see	  if	  you	  respond	  to	  INH	  treatment	  
in	   the	   same	   way	   as	   people	   with	   scars	   on	   there	   chest	   x-­‐ray.	   	   20	   control	   participants	   with	   latent	  
tuberculosis	  from	  Cape	  Town	  are	  planned	  to	  be	  recruited	  into	  this	  study.	  	  This	  will	  involve	  taking	  8-­‐11	  
teaspoons	  of	  blood	  and	  a	  urine	  sample,	  5	  times	  during	  the	  course	  of	  your	  INH	  treatment	  (at	  the	  start	  
of	  treatment,	  then	  after	  1	  week,	  1	  month.	  3	  months	  and	  finally	  at	  the	  end	  of	  treatment).	  	  You	  will	  not	  
be	  liable	  for	  any	  expense	  relating	  to	  these	  investigations	  and	  will	  be	  reimbursed	  up	  to	  R30	  per	  visit	  as	  
compensation	  for	  time	  and	  travel.	  
	  
One	   of	   the	   blood	   samples	   will	   be	   stored	   for	   genetic	   tests.	   	   Genes	   are	   codes	   in	   you	   body	   that	  
determine	  your	   individual	   characteristics,	   including	  how	  your	   immune	  system	   (your	  body’s	  defence	  
system)	   functions.	   	  The	  only	  genetic	   tests	   that	  would	  be	  done	  on	  your	  sample	  would	  be	   to	   test	   for	  
genes	  involved	  in	  you	  body’s	  response	  to	  tuberculosis.	  	  No	  tests	  will	  be	  done	  for	  genetic	  diseases	  or	  
any	  other	  conditions	  not	  related	  to	  tuberculosis.	  	  
	  
Although	   the	   tests	   in	   the	   study	   very	   rarely	   causes	  problems,	   if	   anything	   goes	  wrong	   the	  University	  
provides	   insurance	   to	   cover	   this	   possibility.	   	   If	   you	   have	   any	   concerns	   regarding	   following	   any	  
procedure	  performed	  as	  part	  of	  the	  study	  you	  may	  contact	  the	  study	  doctor	  
	  
Principal Investigator 
Prof. Robert J. Wilkinson MA, PhD, FRCP 
Wellcome Trust Senior Research Fellow 
Honorary Professor (IIDMM) 
r.j.wilkinson@imperial.ac.uk 
Study Doctor 
Dr Hanif Esmail MA, MRCP, FRCPath 
Wellcome Trust Clinical Research Training 
Fellow 
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The	   decision	   to	   participate	   is	   entirely	   your	   own.	   IF	   YOU	   DECIDE	   NOT	   TO	   PARTICIPATE,	   YOUR	  
TREATMENT	  WILL	  NOT	  BE	  DIASDVANTAGED	  IN	  ANY	  WAY.	  In	  addition,	  at	  any	  point	  during	  the	  trial	  you	  
are	  free	  to	  withdraw	  without	  telling	  us	  why.	  
	  
Since	  these	  are	  research	  tests,	  the	  results	  will	  not	  be	  made	  available	  to	  the	  participants,	  however	  you	  
will	   be	   informed	   of	   any	   new	   relevant	   information	   that	   arises	   during	   the	   course	   of	   the	   trial.	  	  
Throughout	  the	  trial	  your	  privacy	  will	  be	  maintained	  and	  nobody	  other	  than	  the	  doctors	  and	  nurses	  
looking	  after	   you	  will	   know	   that	   you	  are	  participating.	   Samples	  will	   be	   labelled	  with	   code	  numbers	  
and	  hence	   the	   laboratory	   staff	  will	   not	   know	   your	   identity.	  When	   the	   results	   of	   the	   study	   become	  
available,	  names	  of	  the	  participating	  patients	  will	  not	  be	  included.	  	  The	  Research	  Ethics	  Committees	  
may	   inspect	   the	   research	   records	   if	   required.	   	   	   You	   may	   inform	   your	   general	   practitioner	   of	  
involvement	  in	  the	  study	  
	  
Please	  note	  that	  with	  your	  consent	  some	  of	  your	  blood	  and	  urine	  that	  you	  provide	  will	  be	  stored	  
safely	  at	  the	  IIDMM	  for	  use	  in	  this	  research	  study	  or	  future	  studies	  related	  to	  this	  project.	  
	  
	  
You	  may	  contact	  either	  the	  UCT	  Research	  Ethics	  Committee	  (021	  406	  6492)	  Prof Robert Wilkinson 
(021 406 6084) or Dr Hanif Esmail (021 406 6389)	  if	  you	  have	  further	  questions	  at	  any	  point	  during	  
the	  study.	  Please	  remember	  that	  Prof	  Wilkinson	  and	  Dr	  Esmail	  will	  not	  be	  directly	  responsible	  for	  your	  






Consent	  to	  participate	  in	  the	  study:	  
	  
I	  have	  read	  the	  above	  /	  the	  above	  has	  been	  read	  to	  me	  and	  I	  have	  had	  the	  opportunity	  to	  discuss	  the	  	  
	  



























	   259	  
Active	  TB	  Control	  Consent	  Form	  
	  









How inactive is “inactive” Tuberculosis?  
PET/CT Benchmarking of Latent Tuberculosis Infection 
 
	  
ACTIVE	  TB	  CONTROL	  CONSENT	  FORM	  
	  
My	  name	  is	  _______________________	  
	  
The	  purpose	  of	  our	  study	  is	  to	  see	  if	  in	  some	  people	  with	  “silent”	  or	  latent	  TB,	  we	  can	  find	  differences	  
that	  mean	  they	  might	  be	  more	  likely	  to	  become	  unwell.	  	  This	  will	  help	  us	  to	  develop	  tests	  to	  identify	  
those	  who	  most	  and	  least	  need	  treatment	  for	  latent	  TB	  and	  will	  help	  us	  make	  progress	  toward	  getting	  
rid	   of	   TB	   as	   a	  major	   health	   problem	   in	   the	   long	   run.	   	   The	  main	   part	   of	   the	   study	   involves	   using	   a	  
PET/CT	  scan	  to	  assess	  the	  activity	  of	  scars	  caused	  by	  tuberculosis	  that	  can	  be	  seen	  on	  a	  chest	  x-­‐ray.	  	  
This	   study	   is	   being	   run	   by	   the	   Institute	   of	   Infectious	   Diseases	   and	   Molecular	   Medicine	   at	   the	  
University	  of	  Cape	  Town	  and	  has	  been	  funded	  by	  the	  Wellcome	  Trust.	  Prof	  Robert	  J	  Wilkinson	  is	  the	  
Principal	  Investigator.	  	  This	  study	  has	  also	  been	  approved	  by	  the	  Human	  Research	  Ethics	  Committees	  
of	   the	   University	   of	   Cape	   Town	   and	   Stellenbosch	   University	   and	   will	   be	   conducted	   according	   to	  
international	   standards	   of	   Good	   Clinical	   Practice,	   applicable	   South	   African	   government	   regulations,	  
and	  Institutional	  research	  policies	  and	  procedures.	  	  	  
You	  have	  been	  found	  to	  have	  active	  TB	  and	  will	  be	  started	  on	  TB	  treatment.	  	  
	  
We	  would	   like	  to	  ask	  you	  to	  be	  a	  control	  subject	  for	  our	  study,	  to	  see	  what	  differences	  we	  can	  find	  
between	  you	  and	  people	  with	   latent	  TB.	   	  We	  plan	   to	   recruit	  15	  control	  participants	  with	  active	  TB.	  	  
This	  will	  involve	  taking	  just	  up	  to	  9	  teaspoon	  of	  blood	  before	  and	  at	  the	  end	  of	  TB	  treatment,	  most	  of	  
this	  will	   be	   for	   research	   tests	   but	  we	  will	   also	   check	   your	   CD4	   count	   and	   viral	   load	   as	   needed.	   	   In	  
addition	  we	  may	  request	  2	  sputum	  samples	  from	  you	  and	  a	  Chest	  X-­‐Ray	  if	  not	  available.	   	  We	  would	  
also	  like	  to	  check	  your	  laboratory	  results	  and	  medical	  notes	  during	  treatment.	  	  You	  will	  not	  undergo	  
PET/CT	   scan.	   	   You	   will	   not	   be	   liable	   for	   any	   expense	   relating	   to	   these	   investigations	   and	   will	   be	  
reimbursed	  R30	  as	  compensation	  for	  time	  and	  travel	  
	  
Although	   the	   tests	   in	   the	   study	   very	   rarely	   causes	  problems,	   if	   anything	   goes	  wrong	   the	  University	  
provides	   insurance	   to	   cover	   this	   possibility.	   	   If	   you	   have	   any	   concerns	   regarding	   following	   any	  
procedure	  performed	  as	  part	  of	  the	  study	  you	  may	  contact	  the	  study	  doctor	  
	  
The	   decision	   to	   participate	   is	   entirely	   your	   own.	   IF	   YOU	   DECIDE	   NOT	   TO	   PARTICIPATE,	   YOUR	  
TREATMENT	  WILL	  NOT	  BE	  DIASDVANTAGED	  IN	  ANY	  WAY.	  In	  addition,	  at	  any	  point	  during	  the	  trial	  you	  
are	  free	  to	  withdraw	  without	  telling	  us	  why.	  
	  
Since	  these	  are	  research	  tests,	  the	  results	  will	  not	  be	  made	  available	  to	  the	  participants,	  however	  you	  
will	   be	   informed	   of	   any	   new	   relevant	   information	   that	   arises	   during	   the	   course	   of	   the	   trial.	  	  
Throughout	  the	  trial	  your	  privacy	  will	  be	  maintained	  and	  nobody	  other	  than	  the	  doctors	  and	  nurses	  
Principal Investigator 
Prof. Robert J. Wilkinson MA, PhD, FRCP 
Wellcome Trust Senior Research Fellow 
Honorary Professor (IIDMM) 
r.j.wilkinson@imperial.ac.uk 
Study Doctor 
Dr Hanif Esmail MA, MRCP, FRCPath 
Wellcome Trust Clinical Research Training 
Fellow 
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looking	  after	   you	  will	   know	   that	   you	  are	  participating.	   Samples	  will	   be	   labelled	  with	   code	  numbers	  
and	  hence	   the	   laboratory	   staff	  will	   not	   know	   your	   identity.	  When	   the	   results	   of	   the	   study	   become	  
available,	  names	  of	  the	  participating	  patients	  will	  not	  be	  included.	   	  The	  Research	  Ethics	  Committees	  
may	  inspect	  the	  research	  records	  if	  required	  
	  
Please	  note	  that	  with	  your	  consent	  some	  of	  your	  blood	  and	  sputum	  will	  be	  stored	  safely	  at	  the	  
IIDMM	  for	  use	  in	  this	  research	  study	  or	  future	  studies	  related	  to	  this	  project.	  
	  
	  
You	  may	  contact	  either	  the	  UCT	  Research	  Ethics	  Committee	  (021	  406	  6492)	  Prof Robert Wilkinson 
(021 406 6084) or Dr Hanif Esmail (021 406 6389)	  if	  you	  have	  further	  questions	  at	  any	  point	  during	  
the	  study.	  Please	  remember	  that	  Prof	  Wilkinson	  and	  Dr	  Esmail	  will	  not	  be	  directly	  responsible	  for	  your	  






Consent	  to	  participate	  in	  the	  study:	  
	  
I	  have	  read	  the	  above	  /	  the	  above	  has	  been	  read	  to	  me	  and	  I	  have	  had	  the	  opportunity	  to	  discuss	  the	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TST-­‐	  IGRA-­‐	  Control	  Consent	  Form	  
	  









How inactive is “inactive” Tuberculosis?  
PET/CT Benchmarking of Latent Tuberculosis Infection 
 
	  
TST-­‐	  IGRA-­‐	  CONTROL	  CONSENT	  FORM	  
	  
My	  name	  is	  _______________________	  
	  
The	  purpose	  of	  our	  study	  is	  to	  see	  if	  in	  some	  people	  with	  “silent”	  or	  latent	  TB,	  we	  can	  find	  differences	  
that	  mean	  they	  might	  be	  more	  likely	  to	  become	  unwell.	  	  This	  will	  help	  us	  to	  develop	  tests	  to	  identify	  
those	  who	  most	  and	  least	  need	  treatment	  for	  latent	  TB	  and	  will	  help	  us	  make	  progress	  toward	  getting	  
rid	   of	   TB	   as	   a	  major	   health	   problem	   in	   the	   long	   run.	   	   The	  main	   part	   of	   the	   study	   involves	   using	   a	  
PET/CT	  scan	  to	  assess	  the	  activity	  of	  scars	  caused	  by	  tuberculosis	  that	  can	  be	  seen	  on	  a	  chest	  x-­‐ray.	  	  
This	   study	   is	   being	   run	   by	   the	   Institute	   of	   Infectious	   Diseases	   and	   Molecular	   Medicine	   at	   the	  
University	  of	  Cape	  Town	  and	  has	  been	  funded	  by	  the	  Wellcome	  Trust.	  Prof	  Robert	  J	  Wilkinson	  is	  the	  
Principal	  Investigator.	  	  This	  study	  has	  also	  been	  approved	  by	  the	  Human	  Research	  Ethics	  Committees	  
of	   the	   University	   of	   Cape	   Town	   and	   Stellenbosch	   University	   and	   will	   be	   conducted	   according	   to	  
international	   standards	   of	   Good	   Clinical	   Practice,	   applicable	   South	   African	   government	   regulations,	  
and	  Institutional	  research	  policies	  and	  procedures.	  	  	  	  
	  
You	   have	  NOT	   been	   found	   to	   have	   latent	   TB.	   	   However,	  we	  would	   like	   to	   ask	   you	   to	   be	   a	   control	  
subject	   for	  our	  study,	   to	  see	  what	  differences	  we	  can	   find	  between	  you	  and	  people	  with	   latent	  TB.	  	  
We	  plan	  to	  recruit	  15	  control	  participants	  with	  no	  evidence	  of	  latent	  TB.	  	  This	  will	  involve	  taking	  just	  
over	  7	  teaspoon	  of	  blood	  on	  a	  single	  occasion.	   	  You	  will	  NOT	  undergo	  PET/CT	  scan.	   	  You	  will	  not	  be	  
liable	  for	  any	  expense	  relating	  to	  these	  investigations	  and	  will	  be	  reimbursed	  R30	  as	  compensation	  for	  
time	  and	  travel.	  
	  
Although	   the	   tests	   in	   the	   study	   very	   rarely	   causes	  problems,	   if	   anything	   goes	  wrong	   the	  University	  
provides	   insurance	   to	   cover	   this	   possibility.	   If	   you	   have	   any	   concerns	   regarding	   following	   any	  
procedure	  performed	  as	  part	  of	  the	  study	  you	  may	  contact	  the	  study	  doctor.	  
	  
The	   decision	   to	   participate	   is	   entirely	   your	   own.	   IF	   YOU	   DECIDE	   NOT	   TO	   PARTICIPATE,	   YOUR	  
TREATMENT	  WILL	  NOT	  BE	  DIASDVANTAGED	  IN	  ANY	  WAY.	  In	  addition,	  at	  any	  point	  during	  the	  trial	  you	  
are	  free	  to	  withdraw	  without	  telling	  us	  why.	  
	  
Since	  these	  are	  research	  tests,	  the	  results	  will	  not	  be	  made	  available	  to	  the	  participants,	  however,	  you	  
will	   be	   informed	   of	   any	   new	   relevant	   information	   that	   arises	   during	   the	   course	   of	   the	   trial.	  	  
Throughout	  the	  trial	  your	  privacy	  will	  be	  maintained	  and	  nobody	  other	  than	  the	  doctors	  and	  nurses	  
looking	  after	   you	  will	   know	   that	   you	  are	  participating.	   Samples	  will	   be	   labelled	  with	   code	  numbers	  
and	  hence	   the	   laboratory	   staff	  will	   not	   know	   your	   identity.	  When	   the	   results	   of	   the	   study	   become	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available,	  names	  of	  the	  participating	  patients	  will	  not	  be	  included.	   	  The	  Research	  Ethics	  Committees	  
may	  inspect	  the	  research	  records	  if	  required.	  
	  
Please	  note	  that	  with	  your	  consent	  some	  of	  your	  blood	  will	  be	  stored	  safely	  at	  the	  IIDMM	  for	  use	  in	  
this	  research	  study	  or	  future	  studies	  related	  to	  this	  project.	  
	  
	  
You	  may	  contact	  either	  the	  UCT	  Research	  Ethics	  Committee	  (021	  406	  6492)	  Prof Robert Wilkinson 
(021 406 6084) or Dr Hanif Esmail (021 406 6389)	  if	  you	  have	  further	  questions	  at	  any	  point	  during	  
the	  study.	  Please	  remember	  that	  Prof	  Wilkinson	  and	  Dr	  Esmail	  will	  not	  be	  directly	  responsible	  for	  your	  






Consent	  to	  participate	  in	  the	  study:	  
	  
I	  have	  read	  the	  above	  /	  the	  above	  has	  been	  read	  to	  me	  and	  I	  have	  had	  the	  opportunity	  to	  discuss	  the	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Bronchoscopy	  Consent	  Form	  
	  









How inactive is “inactive” Tuberculosis?  
PET/CT Benchmarking of Latent Tuberculosis Infection 
 
	  
BRONCHOSCOPY	  INFORMED	  CONSENT	  FORM	  AND	  INFORMATION	  SHEET	  
	  
My	  name	  is	  _______________________	  
	  
Thank	  you	  for	  agreeing	  to	  take	  part	  in	  the	  study.	  	  This	  consent	  form	  relates	  to	  an	  additional	  procedure	  
that	  we	  would	   like	   to	  perform.	   	  The	  decision	   to	  participate	   in	   this	  part	  of	   the	  study	   is	  entirely	  your	  
own.	  IF	  YOU	  DECIDE	  NOT	  TO	  PARTICIPATE,	  YOUR	  TREATMENT	  WILL	  NOT	  BE	  DIASDVANTAGED	  IN	  ANY	  
WAY.	  In	  addition,	  at	  any	  point	  you	  can	  change	  your	  mind.	  
	  
This	  part	  of	  the	  study	  is	  also	  being	  run	  by	  the	  Institute	  of	  Infectious	  Diseases	  and	  Molecular	  Medicine	  
at	  the	  University	  of	  Cape	  Town	  and	  has	  been	  funded	  by	  the	  Wellcome	  Trust.	  Prof	  Robert	  J	  Wilkinson	  
is	   the	   Principal	   Investigator.	   	   This	   study	   has	   also	   been	   approved	   by	   the	   Human	   Research	   Ethics	  
Committees	   of	   the	   University	   of	   Cape	   Town	   and	   Stellenbosch	   University	   and	   will	   be	   conducted	  
according	   to	   international	   standards	  of	  Good	  Clinical	  Practice,	  applicable	  South	  African	  government	  
regulations,	  and	  Institutional	  research	  policies	  and	  procedures.	  	  	  
	  
You	  will	  have	  an	  FDG-­‐PET/CT	  scan	  in	  the	  next	  few	  days.	  	  We	  have	  found	  these	  scans	  to	  be	  frequently	  
abnormal	  in	  persons	  with	  HIV	  and	  latent	  TB.	  	  This	  is	  likely	  to	  relate	  to	  both	  the	  HIV	  infection	  and	  the	  
latent	  TB	  infection.	  	  By	  repeating	  the	  scan	  after	  treating	  your	  latent	  TB	  we	  will	  be	  able	  to	  see	  which	  
abnormalities	  relate	  to	  TB.	  	  However	  there	  may	  be	  other	  reasons	  for	  these	  abnormalities	  (active	  TB,	  
other	   infections	   or	   cancer),	   the	   scan	  will	   not	   be	   able	   to	   tell	   these	   apart.	   	   The	   only	  way	   to	   be	   sure	  
about	   what	   is	   causing	   the	   abnormality	   is	   to	   take	   a	   sample.	   	   	   If	   your	   scan	   is	   abnormal	   and	   the	  
abnormality	   is	   easy	   to	   get	   to	  we	   would	   like	   to	   perform	   a	   routine	   medical	   procedure	   called	   a	  
bronchoscopy	  and	  transbronchial	  biopsy	   to	  sample	  the	  abnormality	  to	  find	  out	  what	  it	   is.	   	  This	   is	  a	  
very	  common	  procedure	  that	  is	  performed	  when	  people	  have	  abnormal	  FDG-­‐PET/CT	  scans.	  
	  
If	  you	  agree,	  after	  the	  scan	  you	  will	  not	  be	  started	  on	  the	  treatment	  for	  latent	  TB	  straight	  away	  but	  
this	  may	  be	  delayed	  by	  up	  to	  2	  weeks,	  we	  do	  not	  expect	  this	  to	  have	  any	  negative	  impact	  for	  you.	  	  We	  
will	  get	  your	  scan	  reviewed	  as	  quickly	  as	  possible	  by	  a	  specialist.	   	   If	  he	  thinks	  your	  scan	  is	  abnormal	  
and	  the	  abnormality	  can	  be	  reached	  easily	  we	  will	  arrange	  a	  bronchoscopy	  for	  you.	  	  You	  will	  have	  an	  
additional	  blood	  test	  to	  make	  sure	  your	  blood	  clots	  normally.	  	  The	  bronchoscopy	  will	  be	  performed	  at	  
the	  Pulmonology	  unit	  at	  Tygerberg	  Hospital	  and	  will	  be	  performed	  by	  an	  experienced	  senior	  doctor.	  	  	  
	  
This	  is	  what	  will	  happen	  during	  the	  procedure,	  which	  will	  take	  around	  30-­‐45	  minutes.	  	  Firstly	  the	  nose	  
and	  back	  of	  your	  throat	  will	  be	  sprayed	  with	  anaesthetic	  fluid,	  which	  will	  numb	  any	  discomfort	  that	  
might	  be	  caused.	  	  A	  sedative	  drug	  (midazolam	  and/or	  propofol)	  may	  be	  given	  through	  a	  drip	  to	  make	  
you	  sleepy	  before	  the	  procedure,	  you	  will	  also	  be	  given	  fluids	  through	  a	  drip,	  given	  oxygen	  to	  breathe	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and	  be	  monitored	  during	  the	  procedure.	  	  The	  bronchoscope	  is	  a	  thin	  flexible	  tube	  about	  as	  wide	  as	  a	  
little	  finger	  with	  a	  camera	  on	  the	  end.	  	  It	  will	  be	  inserted	  via	  the	  nose	  or	  mouth,	  pass	  the	  vocal	  cords	  
and	  into	  the	  windpipe	  and	  air	  tubes	  of	  the	  lung.	  	  The	  abnormality	  on	  the	  scan	  will	  be	  located	  just	  the	  
other	  side	  of	  these	  air	  tubes.	  	  Using	  the	  scan	  to	  guide	  him	  the	  doctor	  will	  place	  a	  thin	  needle	  into	  the	  
abnormality	   after	   first	   making	   it	   numb	   with	   anaesthetic.	   	   The	   sample	   will	   be	   checked	   by	   another	  
doctor	   to	   make	   sure	   it	   is	   in	   the	   right	   place	   and	   then	   up	   to	   5	   samples	   will	   be	   taken.	   	   After	   the	  
procedure	  you	  will	  sleep	  for	  a	  period	  at	  the	  clinic.	  	  The	  doctor	  will	  see	  you	  to	  check	  everything	  is	  fine	  
and	  tell	  you	  when	  you	  can	  eat	  or	  drink	  again.	  
	  
Usually	   the	  procedures	  do	  not	   cause	  any	  problems.	   	   The	  bronchoscope	  may	  be	  uncomfortable	  and	  
can	  cause	  coughing	  during	  and	  immediately	  after	  the	  procedure.	  	  Rarely	  (in	  less	  than	  1%)	  a	  small	  hole	  
in	  the	  lung	  might	  cause	  air	  to	  get	  trapped	  outside	  the	  lungs,	  very	  rarely	  this	  might	  require	  you	  to	  stay	  
in	  hospital	  for	  a	  chest	  tube	  to	  be	  inserted.	  	  Slight	  coughing	  of	  blood	  can	  arise	  in	  3%	  of	  cases	  but	  the	  
risk	  of	  severe	  bleeding	  is	  very	  low	  (<1/1000).	  	  If	  you	  take	  blood-­‐thinning	  tablets	  (warfarin	  or	  aspirin)	  
or	  have	  a	  personal	  or	  family	  history	  of	  abnormal	  bleeding	  you	  should	  tell	  the	  doctor	  and	  nurse.	  
	  
There	  is	  no	  cost	  to	  you	  for	  having	  this	  procedure	  done	  and	  because	  of	  the	  inconvenience	  we	  will	  offer	  
you	  an	  additional	  R350	  compensation.	  	  The	  acceptance	  of	  this	  payment	  in	  no	  way	  affects	  your	  rights	  
should	  anything	  go	  wrong.	  	  In	  the	  event	  that	  anything	  does	  go	  wrong	  we	  will	  arrange	  full	  treatment	  
through	  the	  public	  health	  service.	  	  If	  you	  do	  not	  feel	  well	  after	  the	  bronchoscopy,	  you	  can	  call	  Dr	  Hanif	  
Esmail	  on	  (0820592465)	  	  	  	  	  
	  	  	  
The	  samples	  will	  be	  sent	  to	  a	  laboratory	  to	  try	  and	  find	  out	  what	  the	  reason	  for	  the	  abnormality	  is	  and	  
you	  will	   be	   informed	  of	   any	   significant	   findings	   that	   impact	   your	  health.	   	  However,	   as	   some	  of	   the	  
tests	   are	   research	   tests	   the	   results	  will	   not	   all	   be	  made	  available	   to	   you.	   Throughout	   the	   trial	   your	  
privacy	  will	  be	  maintained	  and	  nobody	  other	  than	  the	  doctors	  and	  nurses	  looking	  after	  you	  will	  know	  
that	  you	  are	  participating.	  Samples	  will	  be	  labelled	  with	  code	  numbers	  and	  hence	  the	  laboratory	  staff	  
will	   not	   know	   your	   identity.	   When	   the	   results	   of	   the	   study	   become	   available,	   names	   of	   the	  
participating	  patients	  will	  not	  be	  included.	  
	  
Please	  note	  that	  with	  your	  consent	  some	  of	  your	  blood	  will	  be	  stored	  safely	  at	  the	  IIDMM	  for	  use	  in	  
this	  research	  study	  or	  future	  studies	  related	  to	  this	  project.	  
	  
You	  may	  contact	  either	  the	  Research	  Ethics	  Committee	  (021	  406	  6492)	  Prof Robert Wilkinson (021 
406 6084) or Dr Hanif Esmail (021 406 6389)	  if	  you	  have	  further	  questions	  at	  any	  point	  during	  the	  
study.	  Please	   remember	   that	  Prof	  Wilkinson	  and	  Dr	  Esmail	  will	  not	  be	  directly	   responsible	   for	   your	  
medical	  care	  that	  will	  be	  provided	  by	  your	  regular	  doctors	  and	  nurses.	  
	  
Consent	  to	  participate	  in	  the	  study:	  
	  
I	  have	  read	  the	  above	  /	  the	  above	  has	  been	  read	  to	  me	  and	  I	  have	  had	  the	  opportunity	  to	  discuss	  the	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How inactive is “inactive” Tuberculosis?  
PET/CT Benchmarking of Latent Tuberculosis Infection 
 
	  
HIV	  –VE	  ACTIVE	  TB	  CONSENT	  FORM	  
	  
Thank	  you	  for	  agreeing	  to	  take	  part	   in	  the	  study.	   	  This	  consent	  form	  relates	  to	  a	  blood	  test	  that	  we	  
would	   like	   to	  perform.	   	  The	  decision	   to	  participate	   in	   this	  part	  of	   the	   study	   is	  entirely	  your	  own.	   IF	  
YOU	  DECIDE	  NOT	  TO	  PARTICIPATE,	  YOUR	  TREATMENT	  WILL	  NOT	  BE	  DIASDVANTAGED	  IN	  ANY	  WAY.	  	  
	  
The	  main	  purpose	  of	  our	  study	  is	  to	  see	  if	  some	  people	  with	  “silent”	  or	  latent	  TB	  have	  similar	  features	  
to	  those	  with	  active	  TB	  in	  the	  context	  of	  HIV	  infection.	   	  This	  will	  help	  us	  to	  develop	  tests	  to	  identify	  
those	  who	  most	  and	  least	  need	  treatment	  for	  latent	  TB	  and	  will	  help	  us	  make	  progress	  toward	  getting	  
rid	   of	   TB	   as	   a	   major	   health	   problem	   in	   the	   long	   run.	   	   This	   study	   is	   being	   run	   by	   the	   Institute	   of	  
Infectious	  Diseases	  and	  Molecular	  Medicine	  at	  the	  University	  of	  Cape	  Town	  and	  has	  been	  funded	  by	  
the	  Wellcome	  Trust.	  Prof	  Robert	   J	  Wilkinson	   is	   the	  Principal	   Investigator.	   	   This	   study	  has	  also	  been	  
approved	   by	   the	   Human	   Research	   Ethics	   Committees	   of	   the	   University	   of	   Cape	   Town	   and	   will	   be	  
conducted	   according	   to	   international	   standards	   of	   Good	   Clinical	   Practice,	   applicable	   South	   African	  
government	  regulations,	  and	  Institutional	  research	  policies	  and	  procedures.	  	  	  
	  
You	  have	  been	  found	  to	  have	  active	  tuberculosis	  and	  we	  would	  like	  to	  ask	  you	  to	  be	  a	  control	  subject	  
for	  our	  study	  so	  that	  we	  can	  compare	  how	  your	  blood	  is	  responding	  to	  those	  with	  HIV	  and	  latent	  TB.	  	  
We	  plan	  to	  recruit	  15	  control	  participants	  with	  active	  TB	  but	  no	  evidence	  of	  HIV	  infection.	  	  In	  addition	  
to	  tests	  and	  investigations	  that	  you	  are	  already	  receiving	  we	  would	  like	  to	  take	  an	  additional	  3mL	  of	  
blood.	  	  You	  may	  have	  been	  recruited	  into	  other	  research	  studies	  if	  so	  we	  would	  like	  to	  use	  the	  results	  
of	  additional	  investigations	  or	  other	  assessments	  you	  are	  having.	  	  We	  may	  also	  use	  results	  that	  have	  
been	  performed	  as	  part	  of	  routine	  medical	  care	  so	  that	  they	  are	  not	  repeated	  unnecessarily.	   	   If	  you	  
have	  not	  had	  these	  additional	  test	  we	  would	  like	  to	  perform	  them,	  these	  might	  include	  Chest	  X-­‐Ray,	  
HIV	  test,	  sputum	  culture,	  full	  blood	  count,	  medical	  history	  and	  examination..	  	  You	  will	  not	  be	  liable	  for	  
any	  expense	  relating	  to	  these	  investigations.	  
	  
Although	   the	   tests	   in	   the	   study	   very	   rarely	   causes	  problems,	   if	   anything	   goes	  wrong	   the	  University	  
provides	   insurance	   to	   cover	   this	   possibility.	   	   If	   you	   have	   any	   concerns	   regarding	   following	   any	  
procedure	  performed	  as	  part	  of	  the	  study	  you	  may	  contact	  the	  study	  doctor	  
	  
The	   decision	   to	   participate	   is	   entirely	   your	   own.	   IF	   YOU	   DECIDE	   NOT	   TO	   PARTICIPATE,	   YOUR	  
TREATMENT	  WILL	  NOT	  BE	  DIASDVANTAGED	  IN	  ANY	  WAY.	  In	  addition,	  at	  any	  point	  during	  the	  trial	  you	  
are	  free	  to	  withdraw	  without	  telling	  us	  why.	  
	  
Since	  these	  are	  research	  tests,	  the	  results	  will	  not	  be	  made	  available	  to	  the	  participants,	  however	  you	  
will	   be	   informed	   of	   any	   new	   relevant	   information	   that	   arises	   during	   the	   course	   of	   the	   trial.	  	  
Throughout	  the	  trial	  your	  privacy	  will	  be	  maintained	  and	  nobody	  other	  than	  the	  doctors	  and	  nurses	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looking	  after	   you	  will	   know	   that	   you	  are	  participating.	   Samples	  will	   be	   labelled	  with	   code	  numbers	  
and	  hence	   the	   laboratory	   staff	  will	   not	   know	   your	   identity.	  When	   the	   results	   of	   the	   study	   become	  
available,	  names	  of	  the	  participating	  patients	  will	  not	  be	  included.	   	  The	  Research	  Ethics	  Committees	  
may	  inspect	  the	  research	  records	  if	  required	  
	  
Please	  note	  that	  with	  your	  consent	  some	  of	  your	  blood	  will	  be	  stored	  safely	  at	  the	  IIDMM	  for	  use	  in	  
this	  research	  study	  or	  future	  studies	  related	  to	  this	  project.	  
	  
You	  may	  contact	  either	  the	  UCT	  Research	  Ethics	  Committee	  (021	  406	  6492)	  Prof Robert Wilkinson 
(021 406 6084) or Dr Hanif Esmail (021 406 6389)	  if	  you	  have	  further	  questions	  at	  any	  point	  during	  
the	  study.	  Please	  remember	  that	  Prof	  Wilkinson	  and	  Dr	  Esmail	  will	  not	  be	  directly	  responsible	  for	  your	  
medical	  care	  which	  will	  be	  conducted	  by	  your	  regular	  doctors	  and	  nurses.	  
	  
Consent	  to	  participate	  in	  the	  study:	  
	  
I	  have	  read	  the	  above	  /	  the	  above	  has	  been	  read	  to	  me	  and	  I	  have	  had	  the	  opportunity	  to	  discuss	  the	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HIV-­‐ve	  Asymptomatic	  Consent	  Form	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ASYMPTOMATIC	  HIV	  –VE	  CONSENT	  FORM	  
	  
Thank	  you	  for	  agreeing	  to	  take	  part	  in	  the	  study.	  	  This	  consent	  form	  relates	  to	  an	  additional	  blood	  and	  
skin	  test	  that	  we	  would	  like	  to	  perform.	  	  The	  decision	  to	  participate	  in	  this	  part	  of	  the	  study	  is	  entirely	  
your	  own.	  IF	  YOU	  DECIDE	  NOT	  TO	  PARTICIPATE,	  YOUR	  TREATMENT	  WILL	  NOT	  BE	  DIASDVANTAGED	  IN	  
ANY	  WAY.	  	  
	  
The	  main	  purpose	  of	  our	  study	  is	  to	  see	  if	  some	  people	  with	  “silent”	  or	  latent	  TB	  have	  similar	  features	  
to	  those	  with	  active	  TB.	  	  This	  will	  help	  us	  to	  develop	  tests	  to	  identify	  those	  who	  most	  and	  least	  need	  
treatment	   for	   latent	   TB	   and	  will	   help	   us	  make	  progress	   toward	   getting	   rid	   of	   TB	   as	   a	  major	   health	  
problem	  in	  the	  long	  run.	  	  This	  study	  is	  being	  run	  by	  the	  Institute	  of	  Infectious	  Diseases	  and	  Molecular	  
Medicine	  at	  the	  University	  of	  Cape	  Town	  and	  has	  been	  funded	  by	  the	  Wellcome	  Trust.	  Prof	  Robert	  J	  
Wilkinson	   is	   the	  Principal	   Investigator.	   	   This	   study	  has	  also	  been	  approved	  by	   the	  Human	  Research	  
Ethics	  Committees	  of	  the	  University	  of	  Cape	  Town	  and	  will	  be	  conducted	  according	  to	   international	  
standards	   of	   Good	   Clinical	   Practice,	   applicable	   South	   African	   government	   regulations,	   and	  
Institutional	  research	  policies	  and	  procedures.	  	  	  
	  
You	  do	  not	  have	  any	  symptoms	  and	  are	  being	  recruited	  for	  participation	  in	  the	  “Tissue	  destruction	  in	  
TB”	  study	  we	  would	  also	  like	  to	  ask	  you	  to	  be	  a	  control	  subject	  for	  our	  study	  so	  that	  we	  can	  compare	  
how	   your	   blood	   is	   responding	   to	   those	   with	   HIV	   and	   latent	   TB.	   	   We	   plan	   to	   recruit	   30	   control	  
participants	  that	  are	  asymptomatic	  and	  have	  no	  evidence	  of	  HIV	  infection.	   	   In	  addition	  to	  the	  blood	  
tests	  and	  investigation	  that	  you	  are	  already	  receiving	  (one	  of	  which	  will	  confirm	  your	  HIV	  status)	  we	  
would	  like	  to	  take	  an	  additional	  6mL	  of	  blood	  and	  perform	  a	  skin	  test.	  	  Some	  of	  the	  blood	  and	  the	  skin	  
test	  will	  be	  used	  to	  establish	  if	  you	  have	  evidence	  of	  latent	  TB.	  	  We	  would	  like	  to	  use	  the	  results	  of	  the	  
other	  investigation	  you	  are	  having	  for	  the	  “Tissue	  destruction	  in	  TB”	  study.	  	  You	  will	  not	  be	  liable	  for	  
any	  expense	  relating	  to	  these	  investigations.	  
 
Although	   the	   tests	   in	   the	   study	   very	   rarely	   causes	  problems,	   if	   anything	   goes	  wrong	   the	  University	  
provides	   insurance	   to	   cover	   this	   possibility.	   	   If	   you	   have	   any	   concerns	   regarding	   following	   any	  
procedure	  performed	  as	  part	  of	  the	  study	  you	  may	  contact	  the	  study	  doctor	  
	  
The	   decision	   to	   participate	   is	   entirely	   your	   own.	   IF	   YOU	   DECIDE	   NOT	   TO	   PARTICIPATE,	   YOUR	  
TREATMENT	  WILL	  NOT	  BE	  DIASDVANTAGED	  IN	  ANY	  WAY.	  In	  addition,	  at	  any	  point	  during	  the	  trial	  you	  
are	  free	  to	  withdraw	  without	  telling	  us	  why.	  
	  
Since	  these	  are	  research	  tests,	  the	  results	  will	  not	  be	  made	  available	  to	  the	  participants,	  however	  you	  
will	  be	  informed	  of	  any	  new	  relevant	  information	  that	  arises	  during	  the	  course	  of	  the	  trial.	  	  Even	  if	  you	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are	  found	  to	  have	  latent	  TB	  no	  treatment	  is	  recommended	  for	  this	  if	  you	  are	  HIV-­‐ve.	  	  Throughout	  the	  
trial	  your	  privacy	  will	  be	  maintained	  and	  nobody	  other	  than	  the	  doctors	  and	  nurses	  looking	  after	  you	  
will	   know	   that	   you	   are	   participating.	   Samples	   will	   be	   labelled	   with	   code	   numbers	   and	   hence	   the	  
laboratory	  staff	  will	  not	  know	  your	  identity.	  When	  the	  results	  of	  the	  study	  become	  available,	  names	  
of	   the	  participating	  patients	  will	  not	  be	   included.	   	  The	  Research	  Ethics	  Committees	  may	   inspect	  the	  
research	  records	  if	  required	  
	  
Please	  note	  that	  with	  your	  consent	  some	  of	  your	  blood	  will	  be	  stored	  safely	  at	  the	  IIDMM	  for	  use	  in	  
this	  research	  study	  or	  future	  studies	  related	  to	  this	  project.	  
	  
You	  may	  contact	  either	  the	  UCT	  Research	  Ethics	  Committee	  (021	  406	  6492)	  Prof Robert Wilkinson 
(021 406 6084) or Dr Hanif Esmail (021 406 6389)	  if	  you	  have	  further	  questions	  at	  any	  point	  during	  
the	  study.	  Please	  remember	  that	  Prof	  Wilkinson	  and	  Dr	  Esmail	  will	  not	  be	  directly	  responsible	  for	  your	  
medical	  care	  which	  will	  be	  conducted	  by	  your	  regular	  doctors	  and	  nurses.	  
	  
Consent	  to	  participate	  in	  the	  study:	  
	  
I	  have	  read	  the	  above	  /	  the	  above	  has	  been	  read	  to	  me	  and	  I	  have	  had	  the	  opportunity	  to	  discuss	  the	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ASYMPTOMATIC	  HIV	  –VE	  CONSENT	  FORM	  -­‐	  	  Repeat	  Blood	  test	  
	  
Thank	  you	  for	  agreeing	  to	  have	  an	  additional	  blood	  test	  for	  our	  study.	  	  This	  consent	  form	  relates	  to	  an	  
additional	  blood	  test	  that	  we	  would	  like	  to	  perform.	  	  The	  decision	  to	  participate	  in	  this	  part	  is	  entirely	  
your	  own.	  IF	  YOU	  DECIDE	  NOT	  TO	  PARTICIPATE,	  YOUR	  TREATMENT	  WILL	  NOT	  BE	  DIASDVANTAGED	  IN	  
ANY	  WAY.	  	  
	  
You	  were	   seen	   a	   few	  weeks	   ago	   and	  had	   tests	   for	   latent	   tuberculosis	   (a	   tuberculin	   skin	   test	   and	   a	  
quantiferon	   blood	   test)	   and	   an	   HIV	   test.	   	   The	   quantiferon	   blood	   test	   for	   latent	   tuberculosis	   was	  
negative	  and	   the	  HIV	   test	  was	  negative.	   	  We	  have	  discovered	   that	   It	  HIV	   infected	  persons	   that	   the	  
quantiferon	  blood	  test	  for	  latent	  tuberculosis	  can	  change	  from	  negative	  to	  postitive	  when	  performed	  
6	  weeks	   following	   the	   tuberculin	  skin	   test	   in	  as	  many	  as	  40%.	   	  We	  would	   like	   to	  compare	   this	  with	  
what	  occur	  in	  HIV	  uninfected	  persons.	  	  This	  will	  help	  us	  to	  understand	  what	  the	  best	  way	  to	  diagnose	  
latent	  tuberculosis	  is.	  
	  
This	   study	   is	   being	   run	   by	   the	   Institute	   of	   Infectious	   Diseases	   and	   Molecular	   Medicine	   at	   the	  
University	  of	  Cape	  Town	  and	  has	  been	  funded	  by	  the	  Wellcome	  Trust.	  Prof	  Robert	  J	  Wilkinson	  is	  the	  
Principal	  Investigator.	  	  This	  study	  has	  also	  been	  approved	  by	  the	  Human	  Research	  Ethics	  Committees	  
of	  the	  University	  of	  Cape	  Town	  and	  will	  be	  conducted	  according	  to	   international	  standards	  of	  Good	  
Clinical	  Practice,	  applicable	  South	  African	  government	  regulations,	  and	  Institutional	  research	  policies	  
and	  procedures	  
	  
We	  would	  like	  to	  perform	  the	  quantiferon	  blood	  test	  again	  which	  will	   involve	  taking	  3	  mL	  (less	  than	  
one	   teaspoon)	   of	   blood	   and	   ask	   you	   a	   few	   further	   questions.	   	   You	  will	   not	   need	   to	   return	   for	   the	  
results	  and	  will	  not	  require	  any	  treatment	  even	  if	  the	  result	  has	  changed.	  	  
	  
Although	   the	   tests	   in	   the	   study	   very	   rarely	   causes	  problems,	   if	   anything	   goes	  wrong	   the	  University	  
provides	   insurance	   to	   cover	   this	   possibility.	   	   If	   you	   have	   any	   concerns	   regarding	   following	   any	  
procedure	  performed	  as	  part	  of	  the	  study	  you	  may	  contact	  the	  study	  doctor	  
	  
The	   decision	   to	   participate	   is	   entirely	   your	   own.	   IF	   YOU	   DECIDE	   NOT	   TO	   PARTICIPATE,	   YOUR	  
TREATMENT	  WILL	  NOT	  BE	  DIASDVANTAGED	  IN	  ANY	  WAY.	  In	  addition,	  at	  any	  point	  during	  the	  trial	  you	  
are	  free	  to	  withdraw	  without	  telling	  us	  why.	  
	  
Since	  these	  are	  research	  tests,	  the	  results	  will	  not	  be	  made	  available	  to	  the	  participants,	  however	  you	  
will	  be	  informed	  of	  any	  new	  relevant	  information	  that	  arises	  during	  the	  course	  of	  the	  trial.	  	  Even	  if	  you	  
are	  found	  to	  have	  latent	  TB	  no	  treatment	  is	  recommended	  for	  this	  if	  you	  are	  HIV-­‐ve.	  	  Throughout	  the	  
trial	  your	  privacy	  will	  be	  maintained	  and	  nobody	  other	  than	  the	  doctors	  and	  nurses	  looking	  after	  you	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will	   know	   that	   you	   are	   participating.	   Samples	   will	   be	   labelled	   with	   code	   numbers	   and	   hence	   the	  
laboratory	  staff	  will	  not	  know	  your	  identity.	  When	  the	  results	  of	  the	  study	  become	  available,	  names	  
of	   the	  participating	  patients	  will	  not	  be	   included.	   	  The	  Research	  Ethics	  Committees	  may	   inspect	  the	  
research	  records	  if	  required	  
	  
Please	  note	  that	  with	  your	  consent	  some	  of	  your	  blood	  will	  be	  stored	  safely	  at	  the	  IIDMM	  for	  use	  in	  
this	  research	  study	  or	  future	  studies	  related	  to	  this	  project.	  
	  
You	  may	  contact	  either	  the	  UCT	  Research	  Ethics	  Committee	  (021	  406	  6492)	  Prof Robert Wilkinson 
(021 406 6084) or Dr Hanif Esmail (021 406 6389)	  if	  you	  have	  further	  questions	  at	  any	  point	  during	  
the	  study.	  Please	  remember	  that	  Prof	  Wilkinson	  and	  Dr	  Esmail	  will	  not	  be	  directly	  responsible	  for	  your	  
medical	  care	  which	  will	  be	  conducted	  by	  your	  regular	  doctors	  and	  nurses.	  
	  
Consent	  to	  participate	  in	  the	  study:	  
	  
I	  have	  read	  the	  above	  /	  the	  above	  has	  been	  read	  to	  me	  and	  I	  have	  had	  the	  opportunity	  to	  discuss	  the	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